

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 January 2023 (12.01.2023)



(10) International Publication Number
WO 2023/283615 A8



(51) International Patent Classification:

A61K 47/68 (2017.01) *A61K 31/7125* (2006.01)
C12N 15/113 (2010.01) *C07K 16/28* (2006.01)
A61K 31/712 (2006.01)

(21) International Application Number:

PCT/US2022/073529

(22) International Filing Date:

08 July 2022 (08.07.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/220,108 09 July 2021 (09.07.2021) US

(71) Applicant: **DYNE THERAPEUTICS, INC.** [US/US];
1560 Trapelo Road, Waltham, MA 02451 (US).

(72) Inventors: **DESJARDINS, Cody, A.**; 1560 Trapelo Road,
Waltham, MA 02451 (US). **TANG, Kim**; 1560 Trapelo
Road, Waltham, MA 02451 (US). **MCSWIGGEN, James**;
19395 W. 94th Avenue, Arvada, CO 80007 (US). **SUBRA-
MANIAN, Romesh, R.**; 9 Alan Street, Framingham, MA
01701 (US). **WEEDEN, Timothy**; 1560 Trapelo Road,

Waltham, MA 02451 (US). **QATANANI, Mohammed, T.**;
1560 Trapelo Road, Waltham, MA 02451 (US). **QUINN,
Brendan**; 45 East Newton Street #320, Boston, MA 02118
(US). **NAJIM, John**; 1560 Trapelo Road, Waltham, MA
02451 (US).

(74) Agent: **BUSS, Colin, G.** et al.; Wolf, Greenfield & Sacks,
P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

(54) Title: MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES




FIG. 1

(57) Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

16 November 2023 (16.11.2023)

(15) Information about Correction:

see Notice of 16 November 2023 (16.11.2023)

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES

RELATED APPLICATIONS

[0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Serial No. 63/220108, entitled “MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES”, filed on July 9, 2021, the contents of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

[0002] The present application relates to targeting complexes for delivering molecular payloads (e.g., oligonucleotides) to cells and uses thereof, particularly uses relating to treatment of disease.

REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0003] The contents of the electronic sequence listing (D082470063WO00-SEQ-COB.xml; Size: 729,857 bytes; and Date of Creation: July 7, 2022) are herein incorporated by reference in their entirety.

BACKGROUND OF INVENTION

[0004] Dystrophinopathies are a group of distinct neuromuscular diseases that result from mutations in the gene encoding dystrophin. Dystrophinopathies include Duchenne muscular dystrophy, Becker muscular dystrophy, and X-linked dilated cardiomyopathy. The DMD gene (“DMD”), which encodes dystrophin, is a large gene, containing 79 exons and about 2.6 million total base pairs. Numerous mutations in DMD, including exonic frameshift, deletion, substitution, and duplicative mutations, are able to diminish the expression of functional dystrophin, leading to dystrophinopathies. Several agents that target exons of human DMD have been approved by the U.S. Food and Drug Administration (FDA), including casimersen, viltolarsen, golodirsen, and eteplirsen.

SUMMARY OF INVENTION

[0005] According to some aspects, the disclosure provides complexes that target muscle cells for purposes of delivering molecular payloads to those cells, as well as molecular payloads that can be used therein. In some embodiments, complexes provided herein are particularly useful for delivering molecular payloads that increase or restore expression or activity of functional

dystrophin protein. In some embodiments, complexes comprise oligonucleotide based molecular payloads that promote expression of functional dystrophin protein through an in-frame exon skipping mechanism or suppression of stop codons, such as by facilitating skipping of DMD exon 44. In some embodiments, molecular payloads provided herein are useful for facilitating exon skipping in a DMD sequence, such as skipping of DMD exon 44. Accordingly, in some embodiments, complexes provided herein comprise muscle-targeting agents (e.g., muscle targeting antibodies) that specifically bind to receptors on the surface of muscle cells for purposes of delivering molecular payloads to the muscle cells. In some embodiments, the complexes are taken up into the cells via a receptor mediated internalization, following which the molecular payload may be released to perform a function inside the cells. For example, complexes engineered to deliver oligonucleotides may release the oligonucleotides such that the oligonucleotides can promote expression of functional dystrophin protein (e.g., through an exon skipping mechanism, such as by facilitating skipping of DMD exon 44) in the muscle cells. In some embodiments, the oligonucleotides are released by endosomal cleavage of covalent linkers connecting oligonucleotides and muscle-targeting agents of the complexes. Complexes and molecular payloads provided herein can be used for treating subjects having a mutated DMD gene, such as a mutated DMD gene that is amenable to exon 44 skipping.

[0006] According to some aspects, complexes comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 44 in a DMD pre-mRNA are provided herein, wherein the oligonucleotide comprises a region of complementarity that is complementary with at least 8 consecutive nucleotides of any one of SEQ ID NOs: 160-195.

[0007] In some embodiments, the anti-TfR1 antibody comprises:

(i) a heavy chain complementarity determining region 1 (CDR-H1) of SEQ ID NO: 33, a heavy chain complementarity determining region 2 (CDR-H2) of SEQ ID NO: 34, a heavy chain complementarity determining region 3 (CDR-H3) of SEQ ID NO: 35, a light chain complementarity determining region 1 (CDR-L1) of SEQ ID NO: 36, a light chain complementarity determining region 2 (CDR-L2) of SEQ ID NO: 37, and a light chain complementarity determining region 3 (CDR-L3) of SEQ ID NO: 32;

(ii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 8, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(iii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 20, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(iv) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 24, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(v) a CDR-H1 of SEQ ID NO: 51, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50;

(vi) a CDR-H1 of SEQ ID NO: 64, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50; or

(vii) a CDR-H1 of SEQ ID NO: 67, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50.

[0008] In some embodiments, the anti-TfR1 antibody comprises:

(i) a heavy chain variable region (VH) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a light chain variable region (VL) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(ii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 69; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 71; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iv) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 72; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(v) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(vi) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(vii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(viii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 78;

(ix) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 79; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80; or

(x) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80.

[0009] In some embodiments, the anti-TfR1 antibody comprises:

- (i) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
- (ii) a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (iii) a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (iv) a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (v) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
- (vi) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
- (vii) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
- (viii) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78;
- (ix) a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80; or
- (x) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

[00010] In some embodiments, the anti-TfR1 antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, an scFv, an Fv, or a full-length IgG. In some embodiments, the anti-TfR1 antibody is a Fab fragment.

[00011] In some embodiments, the anti-TfR1 antibody comprises:

- (i) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;
- (ii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 97; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
- (iii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 98; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
- (iv) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID

NO: 99; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

(v) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(vi) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;

(vii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(viii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 93;

(ix) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 103; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95; or

(x) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95.

[00012] In some embodiments, the anti-TfR1 antibody comprises:

(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 97; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 98; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 99; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 93;

(ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 103; and a light chain comprising the amino acid sequence of SEQ ID NO: 95; or

(x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[00013] In some embodiments, the anti-TfR1 antibody does not specifically bind to the transferrin binding site of the transferrin receptor 1 and/or the anti-TfR1 antibody does not inhibit binding of transferrin to the transferrin receptor 1.

[00014] In some embodiments, the oligonucleotide comprises a region of complementarity to at least 4 consecutive nucleotides of a splicing feature of the DMD pre-mRNA.

[00015] In some embodiments, the splicing feature is an exonic splicing enhancer (ESE) in exon 44 of the DMD pre-mRNA, optionally wherein the ESE comprises a sequence of any one of SEQ ID NOs: 286-296.

[00016] In some embodiments, the splicing feature is a branch point, a splice donor site, or a splice acceptor site, optionally wherein the splicing feature is across the junction of exon 43 and intron 43, in intron 43, across the junction of intron 43 and exon 44, across the junction of exon 44 and intron 44, in intron 44, or across the junction of intron 44 and exon 45 of the DMD pre-mRNA, and further optionally wherein the splicing feature comprises a sequence of any one of SEQ ID NOs: 282-285 and 297-301.

[00017] In some embodiments, the oligonucleotide comprises a sequence complementary to any one of SEQ ID NOs: 160-195 or comprises a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.

[00018] In some embodiments, the oligonucleotide comprises one or more phosphorodiamidate morpholinos, optionally wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).

[00019] In some embodiments, the anti-TfR1 antibody is covalently linked to the oligonucleotide via a cleavable linker, optionally wherein the cleavable linker comprises a valine-citrulline sequence.

[00020] In some embodiments, the anti-TfR1 antibody is covalently linked to the oligonucleotide via conjugation to a lysine residue or a cysteine residue of the antibody.

[00021] According to some aspects, oligonucleotides that target DMD are provided herein, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ

ID NOs: 160-195, optionally wherein the region of complementarity comprises at least 15 consecutive nucleosides complementary to any one of SEQ ID NOs: 160-195.

[00022] In some embodiments, the oligonucleotide comprises at least 15 consecutive nucleosides of any one of SEQ ID NOs: 196-267, optionally wherein the oligonucleotide comprises a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.

[00023] According to some aspects, methods of delivering an oligonucleotide to a cell are provided herein, wherein the method comprises contacting the cell with a complex disclosed herein or with an oligonucleotide disclosed herein.

[00024] According to some aspects, methods of promoting the expression or activity of a dystrophin protein in a cell are provided herein, wherein the method comprises contacting the cell with a complex disclosed or with an oligonucleotide disclosed herein in an amount effective for promoting internalization of the oligonucleotide to the cell, optionally wherein the cell is a muscle cell.

[00025] In some embodiments, the cell comprises a DMD gene that is amenable to skipping of exon 44.

[00026] In some embodiments, the dystrophin protein is a truncated dystrophin protein.

BRIEF DESCRIPTION OF THE DRAWINGS

[00027] **FIG. 1** shows data illustrating that conjugates containing anti-TfR1 Fab (3M12 VH4/Vκ3) conjugated to a DMD exon-skipping oligonucleotide resulted in enhanced exon skipping compared to the naked DMD exon skipping oligo in Duchenne muscular dystrophy patient myotubes.

DETAILED DESCRIPTION OF INVENTION

[00028] Aspects of the disclosure relate to a recognition that while certain molecular payloads (*e.g.*, oligonucleotides, peptides, small molecules) can have beneficial effects in muscle cells, it has proven challenging to effectively target such cells. Accordingly, as described herein, the present disclosure provides complexes comprising muscle-targeting agents covalently linked to molecular payloads in order to overcome such challenges. In some embodiments, the complexes are particularly useful for delivering molecular payloads that modulate (*e.g.*, promote) the expression or activity of dystrophin protein (*e.g.*, a truncated dystrophin protein) or DMD (*e.g.*, a mutated DMD allele). In some embodiments, complexes provided herein may

comprise oligonucleotides that promote expression and activity of dystrophin protein or DMD, such as by facilitating in-frame exon skipping and/or suppression of premature stop codons. For example, complexes may comprise oligonucleotides that induce skipping of exon(s) of DMD RNA (*e.g.*, pre-mRNA), such as oligonucleotides that induce skipping of exon 44. In some embodiments, synthetic nucleic acid payloads (*e.g.*, DNA or RNA payloads) may be used that express one or more proteins that promote normal expression and activity of dystrophin protein or DMD.

[00029] Duchenne muscular dystrophy is an X-linked muscular disorder caused by one or more mutations in the DMD gene located on Xp21. Dystrophin protein typically forms the dystrophin-associated glycoprotein complex (DGC) at the sarcolemma, which links the muscle sarcomeric structure to the extracellular matrix and protects the sarcolemma from contraction-induced injury. In patients with Duchenne muscular dystrophy, the dystrophin protein is generally absent and muscle fibers typically become damaged due to mechanical overextension. Mutations in the DMD gene are associated with two types of muscular dystrophy, Duchenne muscular dystrophy and Becker muscular dystrophy, depending on whether the translational reading frame is lost or maintained. Becker muscular dystrophy is a clinically milder form of Duchenne muscular dystrophy, and is characterized by features similar to Duchenne muscular dystrophy. In some embodiments, exon skipping induced by oligonucleotides (*e.g.*, delivered using complexes provided herein) can be used to restore the reading frame of a mutated DMD allele resulting in production of a truncated dystrophin protein that is sufficiently functional to improve muscle function. In some embodiments, such exon skipping converts a Duchenne muscular dystrophy phenotype into a milder Becker muscular dystrophy phenotype.

[00030] Further aspects of the disclosure, including a description of defined terms, are provided below.

I. Definitions

[00031] **Administering:** As used herein, the terms “administering” or “administration” means to provide a complex to a subject in a manner that is physiologically and/or (*e.g.*, and) pharmacologically useful (*e.g.*, to treat a condition in the subject).

[00032] **Approximately:** As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

[00033] Antibody: As used herein, the term “antibody” refers to a polypeptide that includes at least one immunoglobulin variable domain or at least one antigenic determinant, e.g., paratope that specifically binds to an antigen. In some embodiments, an antibody is a full-length antibody. In some embodiments, an antibody is a chimeric antibody. In some embodiments, an antibody is a humanized antibody. However, in some embodiments, an antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, a Fv fragment or a scFv fragment. In some embodiments, an antibody is a nanobody derived from a camelid antibody or a nanobody derived from shark antibody. In some embodiments, an antibody is a diabody. In some embodiments, an antibody comprises a framework having a human germline sequence. In another embodiment, an antibody comprises a heavy chain constant domain selected from the group consisting of IgG, IgG1, IgG2, IgG2A, IgG2B, IgG2C, IgG3, IgG4, IgA1, IgA2, IgD, IgM, and IgE constant domains. In some embodiments, an antibody comprises a heavy (H) chain variable region (abbreviated herein as VH), and/or (e.g., and) a light (L) chain variable region (abbreviated herein as VL). In some embodiments, an antibody comprises a constant domain, e.g., an Fc region. An immunoglobulin constant domain refers to a heavy or light chain constant domain. Human IgG heavy chain and light chain constant domain amino acid sequences and their functional variations are known. With respect to the heavy chain, in some embodiments, the heavy chain of an antibody described herein can be an alpha (α), delta (Δ), epsilon (ε), gamma (γ) or mu (μ) heavy chain. In some embodiments, the heavy chain of an antibody described herein can comprise a human alpha (α), delta (Δ), epsilon (ε), gamma (γ) or mu (μ) heavy chain. In a particular embodiment, an antibody described herein comprises a human gamma 1 CH1, CH2, and/or (e.g., and) CH3 domain. In some embodiments, the amino acid sequence of the VH domain comprises the amino acid sequence of a human gamma (γ) heavy chain constant region, such as any known in the art. Non-limiting examples of human constant region sequences have been described in the art, e.g., see U.S. Pat. No. 5,693,780 and Kabat E A et al., (1991) supra. In some embodiments, the VH domain comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or at least 99% identical to any of the variable chain constant regions provided herein. In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and/or (e.g., and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and/or (e.g., and) phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecule are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or

carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, an antibody is a construct that comprises a polypeptide comprising one or more antigen binding fragments of the disclosure linked to a linker polypeptide or an immunoglobulin constant domain. Linker polypeptides comprise two or more amino acid residues joined by peptide bonds and are used to link one or more antigen binding portions. Examples of linker polypeptides have been reported (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2:1121-1123). Still further, an antibody may be part of a larger immunoadhesion molecule, formed by covalent or noncovalent association of the antibody or antibody portion with one or more other proteins or peptides. Examples of such immunoadhesion molecules include use of the streptavidin core region to make a tetrameric scFv molecule (Kipriyanov, S. M., et al. (1995) Human Antibodies and Hybridomas 6:93-101) and use of a cysteine residue, a marker peptide and a C-terminal polyhistidine tag to make bivalent and biotinylated scFv molecules (Kipriyanov, S. M., et al. (1994) Mol. Immunol. 31:1047-1058).

[00034] Branch point: As used herein, the term “branch point” or “branch site” refers to a nucleic acid sequence motif within an intron of a gene or pre-mRNA that is involved in splicing of pre-mRNA into mRNA (*i.e.*, removing introns from the pre-mRNA), and can be referred to as a splicing feature. A branch point is typically located 18 to 40 nucleotides from the 3' end of an intron, and contains an adenine but is otherwise relatively unrestricted in sequence. Common sequence motifs for branch points are YNYRAY, YTRAC, and YNYTRAY, where Y is a pyrimidine, N is any nucleotide, R is any purine, and A is adenine. During splicing, the pre-mRNA is cleaved at the 5' end of the intron, which then attaches to the branch point region downstream through transesterification bonding between guanines and adenines from the 5' end and the branch point, respectively, to form a looped lariat structure.

[00035] CDR: As used herein, the term "CDR" refers to the complementarity determining region within antibody variable sequences. A typical antibody molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL), which are usually involved in antigen binding. The VH and VL regions can be further subdivided into regions of hypervariability, also known as “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, which are known as “framework regions” (“FR”). Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The extent of the framework region and CDRs can be precisely identified using methodology known

in the art, for example, by the Kabat definition, the IMGT definition, the Chothia definition, the AbM definition, and/or (e.g., and) the contact definition, all of which are well known in the art. See, e.g., Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; IMGT®, the international ImMunoGeneTics information system® www.imgt.org, Lefranc, M.-P. et al., Nucleic Acids Res., 27:209-212 (1999); Ruiz, M. et al., Nucleic Acids Res., 28:219-221 (2000); Lefranc, M.-P., Nucleic Acids Res., 29:207-209 (2001); Lefranc, M.-P., Nucleic Acids Res., 31:307-310 (2003); Lefranc, M.-P. et al., In Silico Biol., 5, 0006 (2004) [Epub], 5:45-60 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 33:D593-597 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 37:D1006-1012 (2009); Lefranc, M.-P. et al., Nucleic Acids Res., 43:D413-422 (2015); Chothia et al., (1989) Nature 342:877; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, Al-lazikani et al (1997) J. Molec. Biol. 273:927-948; and Almagro, J. Mol. Recognit. 17:132-143 (2004). See also bioinf.org.uk/abs. As used herein, a CDR may refer to the CDR defined by any method known in the art. Two antibodies having the same CDR means that the two antibodies have the same amino acid sequence of that CDR as determined by the same method, for example, the IMGT definition.

[00036] There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1, CDR2 and CDR3, for each of the variable regions. The term "CDR set" as used herein refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat *et al.*, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Sub-portions of CDRs may be designated as L1, L2 and L3 or H1, H2 and H3 where the "L" and the "H" designates the light chain and the heavy chains regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan (FASEB J. 9:133-139 (1995)) and MacCallum (J Mol Biol 262(5):732-45 (1996)). Still other CDR boundary definitions may not strictly follow one of the above systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. The methods used herein may utilize CDRs defined according to any of these systems. Examples of CDR definition systems are provided in Table 1.

Table 1. CDR Definitions

	IMGT¹	Kabat²	Chothia³
CDR-H1	27-38	31-35	26-32
CDR-H2	56-65	50-65	53-55
CDR-H3	105-116/117	95-102	96-101
CDR-L1	27-38	24-34	26-32
CDR-L2	56-65	50-56	50-52
CDR-L3	105-116/117	89-97	91-96

¹ IMGT®, the international ImMunoGeneTics information system®, imgt.org, Lefranc, M.-P. et al., Nucleic Acids Res., 27:209-212 (1999)

² Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242

³ Chothia et al., J. Mol. Biol. 196:901-917 (1987))

[00037] CDR-grafted antibody: The term "CDR-grafted antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species but in which the sequences of one or more of the CDR regions of VH and/or (e.g., and) VL are replaced with CDR sequences of another species, such as antibodies having murine heavy and light chain variable regions in which one or more of the murine CDRs (*e.g.*, CDR3) has been replaced with human CDR sequences.

[00038] Chimeric antibody: The term "chimeric antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species and constant region sequences from another species, such as antibodies having murine heavy and light chain variable regions linked to human constant regions.

[00039] Complementary: As used herein, the term "complementary" refers to the capacity for precise pairing between two nucleosides or two sets of nucleosides. In particular, complementary is a term that characterizes an extent of hydrogen bond pairing that brings about binding between two nucleosides or two sets of nucleosides. For example, if a base at one position of an oligonucleotide is capable of hydrogen bonding with a base at the corresponding position of a target nucleic acid (*e.g.*, an mRNA), then the bases are considered to be complementary to each other at that position. Base pairings may include both canonical Watson-Crick base pairing and non-Watson-Crick base pairing (*e.g.*, Wobble base pairing and Hoogsteen base pairing). For example, in some embodiments, for complementary base pairings, adenosine-type bases (A) are complementary to thymidine-type bases (T) or uracil-type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as 3-nitropyrrole or 5-nitroindole can hybridize to and are considered complementary to any A, C, U, or T. Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U or T.

[00040] Conservative amino acid substitution: As used herein, a "conservative amino acid substitution" refers to an amino acid substitution that does not alter the relative charge or

size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Fourth Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2012, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

[00041] Covalently linked: As used herein, the term “covalently linked” refers to a characteristic of two or more molecules being linked together via at least one covalent bond. In some embodiments, two molecules can be covalently linked together by a single bond, e.g., a disulfide bond or disulfide bridge, that serves as a linker between the molecules. However, in some embodiments, two or more molecules can be covalently linked together via a molecule that serves as a linker that joins the two or more molecules together through multiple covalent bonds. In some embodiments, a linker may be a cleavable linker. However, in some embodiments, a linker may be a non-cleavable linker.

[00042] Cross-reactive: As used herein and in the context of a targeting agent (e.g., antibody), the term “cross-reactive,” refers to a property of the agent being capable of specifically binding to more than one antigen of a similar type or class (e.g., antigens of multiple homologs, paralogs, or orthologs) with similar affinity or avidity. For example, in some embodiments, an antibody that is cross-reactive against human and non-human primate antigens of a similar type or class (e.g., a human transferrin receptor and non-human primate transferrin receptor) is capable of binding to the human antigen and non-human primate antigens with a similar affinity or avidity. In some embodiments, an antibody is cross-reactive against a human antigen and a rodent antigen of a similar type or class. In some embodiments, an antibody is cross-reactive against a rodent antigen and a non-human primate antigen of a similar type or class. In some embodiments, an antibody is cross-reactive against a human antigen, a non-human primate antigen, and a rodent antigen of a similar type or class.

[00043] DMD: As used herein, the term “DMD” refers to a gene that encodes dystrophin protein, a key component of the dystrophin-glycoprotein complex, which bridges the inner cytoskeleton and the extracellular matrix in muscle cells, particularly muscle fibers. Deletions, duplications, and point mutations in DMD may cause dystrophinopathies, such as Duchenne muscular dystrophy, Becker muscular dystrophy, or cardiomyopathy. Alternative promoter usage and alternative splicing result in numerous distinct transcript variants and protein isoforms for this gene. In some embodiments, a dystrophin gene (DMD or DMD gene) may be a human

(Gene ID: 1756), non-human primate (e.g., Gene ID: 465559), or rodent gene (e.g., Gene ID: 13405; Gene ID: 24907). In addition, multiple human transcript variants (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_000109.3, NM_004006.2, NM_004009.3, NM_004010.3 and NM_004011.3) have been characterized that encode different protein isoforms.

[00044] DMD allele: As used herein, the term “DMD allele” refers to any one of alternative forms (e.g., wild-type or mutant forms) of a DMD gene. In some embodiments, a DMD allele may encode for dystrophin that retains its normal and typical functions. In some embodiments, a DMD allele may comprise one or more mutations that results in muscular dystrophy. Common mutations that lead to Duchenne muscular dystrophy involve frameshift, deletion, substitution, and duplicative mutations of one or more of 79 exons present in a dystrophin allele, e.g., exon 8, exon 23, exon 41, exon 44, exon 45, exon 50, exon 51, exon 52, exon 53, or exon 55. Further examples of DMD mutations are disclosed, for example, in Flanigan KM, et al., *Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort*. Hum Mutat. 2009 Dec; 30 (12):1657-66, the contents of which are incorporated herein by reference in its entirety.

[00045] Dystrophinopathy: As used herein, the term “dystrophinopathy” refers to a muscle disease results from one or more mutated DMD alleles. Dystrophinopathies include a spectrum of conditions (ranging from mild to severe) that includes Duchenne muscular dystrophy, Becker muscular dystrophy, and DMD-associated dilated cardiomyopathy (DCM). In some embodiments, at one end of the spectrum, dystrophinopathy is phenotypically associated with an asymptomatic increase in serum concentration of creatine phosphokinase (CK) and/or (e.g., and) muscle cramps with myoglobinuria. In some embodiments, at the other end of the spectrum, dystrophinopathy is phenotypically associated with progressive muscle diseases that are generally classified as Duchenne or Becker muscular dystrophy when skeletal muscle is primarily affected and as DMD-associated dilated cardiomyopathy (DCM) when the heart is primarily affected. Symptoms of Duchenne muscular dystrophy include muscle loss or degeneration, diminished muscle function, pseudohypertrophy of the tongue and calf muscles, higher risk of neurological abnormalities, and a shortened lifespan. Duchenne muscular dystrophy is associated with Online Mendelian Inheritance in Man (OMIM) Entry # 310200. Becker muscular dystrophy is associated with OMIM Entry # 300376. Dilated cardiomyopathy is associated with OMIM Entry X# 302045.

[00046] Exonic splicing enhancer (ESE): As used herein, the term “exonic splicing enhancer” or “ESE” refers to a nucleic acid sequence motif within an exon of a gene, pre-mRNA, or mRNA that directs or enhances splicing of pre-mRNA into mRNA, e.g., as described

in Blencowe et al., Trends Biochem Sci 25, 106-10. (2000), incorporated herein by reference. ESEs can be referred to as splicing features. ESEs may direct or enhance splicing, for example, to remove one or more introns and/or one or more exons from a gene transcript. ESE motifs are typically 6-8 nucleobases in length. SR proteins (e.g., proteins encoded by the gene SRSF1, SRSF2, SRSF3, SRSF4, SRSF5, SRSF6, SRSF7, SRSF8, SRSF9, SRSF10, SRSF11, SRSF12, TRA2A or TRA2B) bind to ESEs through their RNA recognition motif region to facilitate splicing. ESE motifs can be identified through a number of methods, including those described in Cartegni et al., Nucleic Acids Research, 2003, Vol. 31, No. 13, 3568–3571, incorporated herein by reference.

[00047] Framework: As used herein, the term "framework" or "framework sequence" refers to the remaining sequences of a variable region minus the CDRs. Because the exact definition of a CDR sequence can be determined by different systems, the meaning of a framework sequence is subject to correspondingly different interpretations. The six CDRs (CDR-L1, CDR-L2, and CDR-L3 of light chain and CDR-H1, CDR-H2, and CDR-H3 of heavy chain) also divide the framework regions on the light chain and the heavy chain into four sub-regions (FR1, FR2, FR3 and FR4) on each chain, in which CDR1 is positioned between FR1 and FR2, CDR2 between FR2 and FR3, and CDR3 between FR3 and FR4. Without specifying the particular sub-regions as FR1, FR2, FR3 or FR4, a framework region, as referred by others, represents the combined FRs within the variable region of a single, naturally occurring immunoglobulin chain. As used herein, a FR represents one of the four sub-regions, and FRs represents two or more of the four sub-regions constituting a framework region. Human heavy chain and light chain acceptor sequences are known in the art. In one embodiment, the acceptor sequences known in the art may be used in the antibodies disclosed herein.

[00048] Human antibody: The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the disclosure may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*), for example in the CDRs and in particular CDR3. However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[00049] Humanized antibody: The term "humanized antibody" refers to antibodies which comprise heavy and light chain variable region sequences from a non-human species (e.g., a mouse) but in which at least a portion of the VH and/or (e.g., and) VL sequence has been altered to be more "human-like", *i.e.*, more similar to human germline variable sequences. One

type of humanized antibody is a CDR-grafted antibody, in which human CDR sequences are introduced into non-human VH and VL sequences to replace the corresponding non-human CDR sequences. In one embodiment, humanized anti-TfR1 antibodies and antigen binding portions are provided. Such antibodies may be generated by obtaining murine anti-TfR1 monoclonal antibodies using traditional hybridoma technology followed by humanization using *in vitro* genetic engineering, such as those disclosed in Kasaian et al PCT publication No. WO 2005/123126 A2.

[00050] Internalizing cell surface receptor: As used herein, the term, "internalizing cell surface receptor" refers to a cell surface receptor that is internalized by cells, e.g., upon external stimulation, e.g., ligand binding to the receptor. In some embodiments, an internalizing cell surface receptor is internalized by endocytosis. In some embodiments, an internalizing cell surface receptor is internalized by clathrin-mediated endocytosis. However, in some embodiments, an internalizing cell surface receptor is internalized by a clathrin-independent pathway, such as, for example, phagocytosis, macropinocytosis, caveolae- and raft-mediated uptake or constitutive clathrin-independent endocytosis. In some embodiments, the internalizing cell surface receptor comprises an intracellular domain, a transmembrane domain, and/or (e.g., and) an extracellular domain, which may optionally further comprise a ligand-binding domain. In some embodiments, a cell surface receptor becomes internalized by a cell after ligand binding. In some embodiments, a ligand may be a muscle-targeting agent or a muscle-targeting antibody. In some embodiments, an internalizing cell surface receptor is a transferrin receptor.

[00051] Isolated antibody: An "isolated antibody", as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds transferrin receptor is substantially free of antibodies that specifically bind antigens other than transferrin receptor). An isolated antibody that specifically binds transferrin receptor complex may, however, have cross-reactivity to other antigens, such as transferrin receptor molecules from other species. Moreover, an isolated antibody may be substantially free of other cellular material and/or (e.g., and) chemicals.

[00052] Kabat numbering: The terms "Kabat numbering", "Kabat definitions and "Kabat labeling" are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (i.e. hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof (Kabat et al. (1971) Ann. NY Acad. Sci. 190:382-391 and, Kabat, E. A., *et al.* (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable region ranges from amino acid positions 31 to 35 for CDR1,

amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3. For the light chain variable region, the hypervariable region ranges from amino acid positions 24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3.

[00053] Molecular payload: As used herein, the term “molecular payload” refers to a molecule or species that functions to modulate a biological outcome. In some embodiments, a molecular payload is linked to, or otherwise associated with a muscle-targeting agent. In some embodiments, the molecular payload is a small molecule, a protein, a peptide, a nucleic acid, or an oligonucleotide. In some embodiments, the molecular payload functions to modulate the transcription of a DNA sequence, to modulate the expression of a protein, or to modulate the activity of a protein. In some embodiments, the molecular payload is an oligonucleotide that comprises a strand having a region of complementarity to a target gene.

[00054] Muscle-targeting agent: As used herein, the term, “muscle-targeting agent,” refers to a molecule that specifically binds to an antigen expressed on muscle cells. The antigen in or on muscle cells may be a membrane protein, for example an integral membrane protein or a peripheral membrane protein. Typically, a muscle-targeting agent specifically binds to an antigen on muscle cells that facilitates internalization of the muscle-targeting agent (and any associated molecular payload) into the muscle cells. In some embodiments, a muscle-targeting agent specifically binds to an internalizing, cell surface receptor on muscles and is capable of being internalized into muscle cells through receptor mediated internalization. In some embodiments, the muscle-targeting agent is a small molecule, a protein, a peptide, a nucleic acid (*e.g.*, an aptamer), or an antibody. In some embodiments, the muscle-targeting agent is linked to a molecular payload.

[00055] Muscle-targeting antibody: As used herein, the term, “muscle-targeting antibody,” refers to a muscle-targeting agent that is an antibody that specifically binds to an antigen found in or on muscle cells. In some embodiments, a muscle-targeting antibody specifically binds to an antigen on muscle cells that facilitates internalization of the muscle-targeting antibody (and any associated molecular payment) into the muscle cells. In some embodiments, the muscle-targeting antibody specifically binds to an internalizing, cell surface receptor present on muscle cells. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds to a transferrin receptor.

[00056] Oligonucleotide: As used herein, the term “oligonucleotide” refers to an oligomeric nucleic acid compound of up to 200 nucleotides in length. Examples of oligonucleotides include, but are not limited to, RNAi oligonucleotides (*e.g.*, siRNAs, shRNAs), microRNAs, gapmers, mixmers, phosphorodiamidate morpholinos, peptide nucleic acids,

aptamers, guide nucleic acids (e.g., Cas9 guide RNAs), etc. Oligonucleotides may be single-stranded or double-stranded. In some embodiments, an oligonucleotide may comprise one or more modified nucleosides (e.g., 2'-O-methyl sugar modifications, purine or pyrimidine modifications). In some embodiments, an oligonucleotide may comprise one or more modified internucleoside linkages. In some embodiments, an oligonucleotide may comprise one or more phosphorothioate linkages, which may be in the Rp or Sp stereochemical conformation.

[00057] Recombinant antibody: The term "recombinant human antibody", as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described in more details in this disclosure), antibodies isolated from a recombinant, combinatorial human antibody library (Hoogenboom H. R., (1997) TIB Tech. 15:62-70; Azzazy H., and Highsmith W. E., (2002) Clin. Biochem. 35:425-445; Gavilondo J. V., and Larrick J. W. (2002) BioTechniques 29:128-145; Hoogenboom H., and Chames P. (2000) Immunology Today 21:371-378), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L. D., et al. (1992) Nucl. Acids Res. 20:6287-6295; Kellermann S-A., and Green L. L. (2002) Current Opinion in Biotechnology 13:593-597; Little M. et al (2000) Immunology Today 21:364-370) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to *in vitro* mutagenesis (or, when an animal transgenic for human Ig sequences is used, *in vivo* somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire *in vivo*. One embodiment of the disclosure provides fully human antibodies capable of binding human transferrin receptor which can be generated using techniques well known in the art, such as, but not limited to, using human Ig phage libraries such as those disclosed in Jermutus et al., PCT publication No. WO 2005/007699 A2.

[00058] Region of complementarity: As used herein, the term "region of complementarity" refers to a nucleotide sequence, e.g., of an oligonucleotide, that is sufficiently complementary to a cognate nucleotide sequence, e.g., of a target nucleic acid, such that the two nucleotide sequences are capable of annealing to one another under physiological conditions (e.g., in a cell). In some embodiments, a region of complementarity is fully complementary to a cognate nucleotide sequence of target nucleic acid. However, in some embodiments, a region of

complementarity is partially complementary to a cognate nucleotide sequence of target nucleic acid (e.g., at least 80%, 90%, 95% or 99% complementarity). In some embodiments, a region of complementarity contains 1, 2, 3, or 4 mismatches compared with a cognate nucleotide sequence of a target nucleic acid.

[00059] Specifically binds: As used herein, the term “specifically binds” refers to the ability of a molecule to bind to a binding partner with a degree of affinity or avidity that enables the molecule to be used to distinguish the binding partner from an appropriate control in a binding assay or other binding context. With respect to an antibody, the term, “specifically binds”, refers to the ability of the antibody to bind to a specific antigen with a degree of affinity or avidity, compared with an appropriate reference antigen or antigens, that enables the antibody to be used to distinguish the specific antigen from others, e.g., to an extent that permits preferential targeting to certain cells, e.g., muscle cells, through binding to the antigen, as described herein. In some embodiments, an antibody specifically binds to a target if the antibody has a K_D for binding the target of at least about 10^{-4} M, 10^{-5} M, 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M, 10^{-10} M, 10^{-11} M, 10^{-12} M, 10^{-13} M, or less. In some embodiments, an antibody specifically binds to the transferrin receptor, e.g., an epitope of the apical domain of transferrin receptor.

[00060] Splice acceptor site: As used herein, the term “splice acceptor site” or “splice acceptor” refers to a nucleic acid sequence motif at the 3' end of an intron or across an intron/exon junction of a gene or pre-mRNA that is involved in splicing of pre-mRNA into mRNA (*i.e.*, removing introns from the pre-mRNA), and can be referred to as a splicing feature. A splice acceptor site includes a terminal AG sequence at the 3' end of an intron, which is typically preceded (5'-ward) by a region high in pyrimidines (C/U). Upstream from the splice acceptor site is the branch point. Formation of a lariat loop intermediate structure by a transesterification reaction between the branch point and the splice donor site releases a 3'-OH of the 5' exon, which subsequently reacts with the first nucleotide of the 3' exon, thereby joining the exons and releasing the intron lariat. The AG sequence at the 3' end of the intron in the splice acceptor site is known to be critical for proper splicing, as changing one of these nucleotides results in inhibition of splicing. Rarely, alternative splice acceptor sites have an AC at the 3' end of the intron, instead of the more common AG. A common splice acceptor site motif has a sequence of or similar to [Y-rich region]-NCAGG or Y_xNYAGG , in which Y represents a pyrimidine, N represents any nucleotide, and x is a number from 4 to 20. The cut site follows the AG, which represent the 3'-terminal nucleotides of the excised intron.

[00061] Splice donor site: As used herein, the term “splice donor site” or “splice donor” refers to a nucleic acid sequence motif at the 5' end of an intron or across an exon/intron


junction of a gene or pre-mRNA that is involved in splicing of pre-mRNA into mRNA (*i.e.*, removing introns from the pre-mRNA), and can be referred to as a splicing feature. A splice donor site includes a terminal GU sequence at the 5' end of the intron, within a larger and fairly unconstrained sequence. During splicing, the 2'-OH of a nucleotide within the branch point initiates a transesterification reaction via a nucleophilic attack on the 5' G of the intron within the splice donor site. The G is thereby cleaved from the pre-mRNA and bonds instead to the branch point nucleotide, forming a loop lariat structure. The 3' nucleotide of the upstream exon subsequently binds the splice acceptor site, joining the exons and excising the intron. A typical splice donor site has a sequence of or similar to GGGURAGU or AGGURNNG, in which R represents a purine and N represents any nucleotide. The cut site precedes the first GU (*i.e.*, GG/GURAGU or AG/GURNNG), which represent the 5'-terminal nucleotides of the excised intron.

[00062] Subject: As used herein, the term “subject” refers to a mammal. In some embodiments, a subject is non-human primate, or rodent. In some embodiments, a subject is a human. In some embodiments, a subject is a patient, *e.g.*, a human patient that has or is suspected of having a disease. In some embodiments, the subject is a human patient who has or is suspected of having a disease resulting from a mutated DMD gene sequence, *e.g.*, a mutation in an exon of a DMD gene sequence. In some embodiments, a subject has a dystrophinopathy, *e.g.*, Duchenne muscular dystrophy. In some embodiments, a subject is a patient that has a mutation of the DMD gene that is amenable to exon 44 skipping.

[00063] Transferrin receptor: As used herein, the term, “transferrin receptor” (also known as TFRC, CD71, p90, or TFR1) refers to an internalizing cell surface receptor that binds transferrin to facilitate iron uptake by endocytosis. In some embodiments, a transferrin receptor may be of human (NCBI Gene ID 7037), non-human primate (*e.g.*, NCBI Gene ID 711568 or NCBI Gene ID 102136007), or rodent (*e.g.*, NCBI Gene ID 22042) origin. In addition, multiple human transcript variants have been characterized that encoded different isoforms of the receptor (*e.g.*, as annotated under GenBank RefSeq Accession Numbers: NP_001121620.1, NP_003225.2, NP_001300894.1, and NP_001300895.1).

[00064] 2'-modified nucleoside: As used herein, the terms “2'-modified nucleoside” and “2'-modified ribonucleoside” are used interchangeably and refer to a nucleoside having a sugar moiety modified at the 2' position. In some embodiments, the 2'-modified nucleoside is a 2'-4' bicyclic nucleoside, where the 2' and 4' positions of the sugar are bridged (*e.g.*, via a methylene, an ethylene, or a (S)-constrained ethyl bridge). In some embodiments, the 2'-modified nucleoside is a non-bicyclic 2'-modified nucleoside, *e.g.*, where the 2' position of the sugar moiety is substituted. Non-limiting examples of 2'-modified nucleosides include: 2'-deoxy, 2'-

fluoro (2'-F), 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2'-O-dimethylaminoethoxyethyl (2'-O-DMAEOE), 2'-O-N-methylacetamido (2'-O-NMA), locked nucleic acid (LNA, methylene-bridged nucleic acid), ethylene-bridged nucleic acid (ENA), and (S)-constrained ethyl-bridged nucleic acid (cEt). In some embodiments, the 2'-modified nucleosides described herein are high-affinity modified nucleosides and oligonucleotides comprising the 2'-modified nucleosides have increased affinity to a target sequences, relative to an unmodified oligonucleotide. Examples of structures of 2'-modified nucleosides are provided below:



These examples are shown with phosphate groups, but any internucleoside linkages are contemplated between 2'-modified nucleosides.

II. Complexes

[00065] Provided herein are complexes that comprise a targeting agent, e.g. an antibody, covalently linked to a molecular payload. In some embodiments, a complex comprises a muscle-targeting antibody covalently linked to an oligonucleotide. A complex may comprise an antibody that specifically binds a single antigenic site or that binds to at least two antigenic sites that may exist on the same or different antigens.

[00066] A complex may be used to modulate the activity or function of at least one gene, protein, and/or (e.g., and) nucleic acid. In some embodiments, the molecular payload present within a complex is responsible for the modulation of a gene, protein, and/or (e.g., and) nucleic acids. A molecular payload may be a small molecule, protein, nucleic acid, oligonucleotide, or

any molecular entity capable of modulating the activity or function of a gene, protein, and/or (e.g., and) nucleic acid in a cell.

[00067] In some embodiments, a complex comprises a muscle-targeting agent, *e.g.*, an anti-transferrin receptor antibody, covalently linked to a molecular payload, *e.g.*, an antisense oligonucleotide that targets DMD to promote exon skipping, *e.g.*, in a transcript encoded from a mutated DMD allele. In some embodiments, the complex targets a DMD pre-mRNA to promote skipping of exon 44 in the DMD pre-mRNA.

A. Muscle-Targeting Agents

[00068] Some aspects of the disclosure provide muscle-targeting agents, *e.g.*, for delivering a molecular payload to a muscle cell. In some embodiments, such muscle-targeting agents are capable of binding to a muscle cell, *e.g.*, via specifically binding to an antigen on the muscle cell, and delivering an associated molecular payload to the muscle cell. In some embodiments, the molecular payload is bound (*e.g.*, covalently bound) to the muscle targeting agent and is internalized into the muscle cell upon binding of the muscle targeting agent to an antigen on the muscle cell, *e.g.*, via endocytosis. It should be appreciated that various types of muscle-targeting agents may be used in accordance with the disclosure, and that any muscle targets (*e.g.*, muscle surface proteins) can be targeted by any type of muscle-targeting agent described herein. For example, the muscle-targeting agent may comprise, or consist of, a small molecule, a nucleic acid (*e.g.*, DNA or RNA), a peptide (*e.g.*, an antibody), a lipid (*e.g.*, a microvesicle), or a sugar moiety (*e.g.*, a polysaccharide). Exemplary muscle-targeting agents are described in further detail herein, however, it should be appreciated that the exemplary muscle-targeting agents provided herein are not meant to be limiting.

[00069] Some aspects of the disclosure provide muscle-targeting agents that specifically bind to an antigen on muscle, such as skeletal muscle, smooth muscle, or cardiac muscle. In some embodiments, any of the muscle-targeting agents provided herein bind to (*e.g.*, specifically bind to) an antigen on a skeletal muscle cell, a smooth muscle cell, and/or (*e.g.*, and) a cardiac muscle cell.

[00070] By interacting with muscle-specific cell surface recognition elements (*e.g.*, cell membrane proteins), both tissue localization and selective uptake into muscle cells can be achieved. In some embodiments, molecules that are substrates for muscle uptake transporters are useful for delivering a molecular payload into muscle tissue. Binding to muscle surface recognition elements followed by endocytosis can allow even large molecules such as antibodies to enter muscle cells. As another example molecular payloads conjugated to transferrin or anti-TfR1 antibodies can be taken up by muscle cells via binding to transferrin receptor, which may then be endocytosed, *e.g.*, via clathrin-mediated endocytosis.

[00071] The use of muscle-targeting agents may be useful for concentrating a molecular payload (*e.g.*, oligonucleotide) in muscle while reducing toxicity associated with effects in other tissues. In some embodiments, the muscle-targeting agent concentrates a bound molecular payload in muscle cells as compared to another cell type within a subject. In some embodiments, the muscle-targeting agent concentrates a bound molecular payload in muscle cells (*e.g.*, skeletal, smooth, or cardiac muscle cells) in an amount that is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 times greater than an amount in non-muscle cells (*e.g.*, liver, neuronal, blood, or fat cells). In some embodiments, a toxicity of the molecular payload in a subject is reduced by at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, or 95% when it is delivered to the subject when bound to the muscle-targeting agent.

[00072] In some embodiments, to achieve muscle selectivity, a muscle recognition element (*e.g.*, a muscle cell antigen) may be required. As one example, a muscle-targeting agent may be a small molecule that is a substrate for a muscle-specific uptake transporter. As another example, a muscle-targeting agent may be an antibody that enters a muscle cell via transporter-mediated endocytosis. As another example, a muscle targeting agent may be a ligand that binds to cell surface receptor on a muscle cell. It should be appreciated that while transporter-based approaches provide a direct path for cellular entry, receptor-based targeting may involve stimulated endocytosis to reach the desired site of action.

i. Muscle-Targeting Antibodies

[00073] In some embodiments, the muscle-targeting agent is an antibody. Generally, the high specificity of antibodies for their target antigen provides the potential for selectively targeting muscle cells (*e.g.*, skeletal, smooth, and/or (*e.g.*, and) cardiac muscle cells). This specificity may also limit off-target toxicity. Examples of antibodies that are capable of targeting a surface antigen of muscle cells have been reported and are within the scope of the disclosure. For example, antibodies that target the surface of muscle cells are described in Arahata K., et al. “Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide” *Nature* 1988; 333: 861-3; Song K.S., et al. “Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins” *J Biol Chem* 1996; 271: 15160-5; and Weisbart R.H. et al., “Cell type specific targeted intracellular delivery into muscle of a monoclonal antibody that binds myosin IIB” *Mol Immunol.* 2003 Mar, 39(13):78309; the entire contents of each of which are incorporated herein by reference.

a. Anti-Transferrin Receptor (TfR) Antibodies

[00074] Some aspects of the disclosure are based on the recognition that agents binding to transferrin receptor, e.g., anti-transferrin-receptor antibodies, are capable of targeting muscle cell. Transferrin receptors are internalizing cell surface receptors that transport transferrin across the cellular membrane and participate in the regulation and homeostasis of intracellular iron levels. Some aspects of the disclosure provide transferrin receptor binding proteins, which are capable of binding to transferrin receptor. Accordingly, aspects of the disclosure provide binding proteins (e.g., antibodies) that bind to transferrin receptor. In some embodiments, binding proteins that bind to transferrin receptor are internalized, along with any bound molecular payload, into a muscle cell. As used herein, an antibody that binds to a transferrin receptor may be referred to interchangeably as an, transferrin receptor antibody, an anti-transferrin receptor antibody, or an anti-TfR1 antibody. Antibodies that bind, e.g. specifically bind, to a transferrin receptor may be internalized into the cell, e.g. through receptor-mediated endocytosis, upon binding to a transferrin receptor.

[00075] It should be appreciated that anti-TfR1 antibodies may be produced, synthesized, and/or (e.g., and) derivatized using several known methodologies, e.g. library design using phage display. Exemplary methodologies have been characterized in the art and are incorporated by reference (Díez, P. et al. “High-throughput phage-display screening in array format”, Enzyme and microbial technology, 2015, 79, 34-41.; Christoph M. H. and Stanley, J.R. “Antibody Phage Display: Technique and Applications” J Invest Dermatol. 2014, 134:2.; Engleman, Edgar (Ed.) “Human Hybridomas and Monoclonal Antibodies.” 1985, Springer.). In other embodiments, an anti-TfR1 antibody has been previously characterized or disclosed. Antibodies that specifically bind to transferrin receptor are known in the art (see, e.g. US Patent No. 4,364,934, filed 12/4/1979, “Monoclonal antibody to a human early thymocyte antigen and methods for preparing same”; US Patent No. 8,409,573, filed 6/14/2006, “Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells”; US Patent No. 9,708,406, filed 5/20/2014, “Anti-transferrin receptor antibodies and methods of use”; US 9,611,323, filed 12/19/2014, “Low affinity blood brain barrier receptor antibodies and uses therefor”; WO 2015/098989, filed 12/24/2014, “Novel anti-Transferrin receptor antibody that passes through blood-brain barrier”; Schneider C. et al. “Structural features of the cell surface receptor for transferrin that is recognized by the monoclonal antibody OKT9.” J Biol Chem. 1982, 257:14, 8516-8522.; Lee et al. “Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse” 2000, J Pharmacol. Exp. Ther., 292: 1048-1052.).

[00076] In some embodiments, the anti-TfR1 antibody described herein binds to transferrin receptor with high specificity and affinity. In some embodiments, the anti-TfR1

antibody described herein specifically binds to any extracellular epitope of a transferrin receptor or an epitope that becomes exposed to an antibody. In some embodiments, anti-TfR1 antibodies provided herein bind specifically to transferrin receptor from human, non-human primates, mouse, rat, *etc.* In some embodiments, anti-TfR1 antibodies provided herein bind to human transferrin receptor. In some embodiments, the anti-TfR1 antibody described herein binds to an amino acid segment of a human or non-human primate transferrin receptor, as provided in SEQ ID NOs: 105-108. In some embodiments, the anti-TfR1 antibody described herein binds to an amino acid segment corresponding to amino acids 90-96 of a human transferrin receptor as set forth in SEQ ID NO: 105, which is not in the apical domain of the transferrin receptor.

[00077] In some embodiments, the anti-TfR1 antibodies described herein (e.g., Anti-TfR clone 8 in Table 2 below) bind an epitope in TfR1, wherein the epitope comprises residues in amino acids 214-241 and/or amino acids 354-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein bind an epitope comprising residues in amino acids 214-241 and amino acids 354-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein bind an epitope comprising one or more of residues Y222, T227, K231, H234, T367, S368, S370, T376, and S378 of human TfR1 as set forth in SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein bind an epitope comprising residues Y222, T227, K231, H234, T367, S368, S370, T376, and S378 of human TfR1 as set forth in SEQ ID NO: 105.

[00078] In some embodiments, the anti-TfR1 antibody described herein (e.g., 3M12 in Table 2 below and its variants) bind an epitope in TfR1, wherein the epitope comprises residues in amino acids 258-291 and/or amino acids 358-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies (e.g., 3M12 in Table 2 below and its variants) described herein bind an epitope comprising residues in amino acids amino acids 258-291 and amino acids 358-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein (e.g., 3M12 in Table 2 below and its variants) bind an epitope comprising one or more of residues K261, S273, Y282, T362, S368, S370, and K371 of human TfR1 as set forth in SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein (e.g., 3M12 in Table 2 below and its variants) bind an epitope comprising residues K261, S273, Y282, T362, S368, S370, and K371 of human TfR1 as set forth in SEQ ID NO: 105.

[00079] An example human transferrin receptor amino acid sequence, corresponding to NCBI sequence NP_003225.2 (transferrin receptor protein 1 isoform 1, homo sapiens) is as follows:

MMDQARSFAFSNLFGEPLSYTRFSLARQVDGDNHVMKLAVDDEENADNNTKANVT
KPKRCSGSICYGTIAVIVFFLIGFMIGYLG YCKGV EPKTECERLAGTESPVREEPGEDFPA

ARRLYWDDLKRKLSEKLDSTDFTGTIKLLNENSYPREAGSQKDENLALYVENQFREF
 KLSKVWRDQHFVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLV
 HANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNA
 ELFFGHHAHLGTGDPYTPGFPSFNHTQFPPSRSSGLPNIPVQTISRAAAEKLFNGMEGDCP
 SDWKTDSTCRMVTSSESKNVKLTVSNVLKEIKILNIFGVIKGFVEPDHYVVVGAQRDAW
 GPAAKSGVGTALLLKLQMFSDMVLKDGFPQRSIIFASWSAGDFGSGVATEWLEGY
 LSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNWA
 SKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELIERIPELNKVARA
 AAEEVAGQFVIKLTHDVELNLDYERYNSQLLSFVRDLNQYRADIKEMGLSLQWLYSARG
 DFFRATSRLTTDFGNAEKTDRFVMKKLNDRVMRVEYHFLSPYVSPKESPFRRHVFWGSG
 SHTLPALLENLKLRRQNNGAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF
 (SEQ ID NO: 105).

[00080] An example non-human primate transferrin receptor amino acid sequence, corresponding to NCBI sequence NP_001244232.1(transferrin receptor protein 1, *Macaca mulatta*) is as follows:

MMDQARSASFNSLFGGEPLSYTRFSLARQVDGDNHVMKLGVDDEEENTDNNTKPNGT
 KPKRCGGNICYGTIAVIIFFLIGFMIGYLG YCKGVEPKTECERLAGTESPAREEPEEDFPA
 APRLYWDDLKRKLSEKLDTTDFTSTIKLLNENLYVPREAGSQKDENLALYIENQFREFK
 LSKVWRDQHFVKIQVKDSAQNSVIIVDKNGGLVYLVENPGGYVAYSKAATVTGKLVH
 ANFGTKKDFEDLDSPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVKAD
 LSFFGHHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISRAAAEKLFNGMEGDCPS
 DWKTDSTCKMVTSENKSVKLTVSNVLKETKILNIFGVIKGFVEPDHYVVVGAQRDAW
 GPAAKSSVGTALLLKLQMFSDMVLKDGFPQRSIIFASWSAGDFGSGVATEWLEGY
 LSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQDVKHPVTGRSLYQDSNWA
 SKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELVERIPELNKVAR
 AAAEEVAGQFVIKLTHDTELNLDYERYNSQLLLFLRDLNQYRADVKEMGLSLQWLYSA
 RGDFFRATSRLTTDFRNAEKRDKFVMKKLNDRVMRVEYYFLSPYVSPKESPFRRHVFWG
 SGSHTLSALLESLKLRRQNNSAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF
 (SEQ ID NO: 106)

[00081] An example non-human primate transferrin receptor amino acid sequence, corresponding to NCBI sequence XP_005545315.1 (transferrin receptor protein 1, *Macaca fascicularis*) is as follows:

MMDQARSASFNSLFGGEPLSYTRFSLARQVDGDNHVMKLGVDDEEENTDNNTKANGT
 KPKRCGGNICYGTIAVIIFFLIGFMIGYLG YCKGVEPKTECERLAGTESPAREEPEEDFPA
 APRLYWDDLKRKLSEKLDTTDFTSTIKLLNENLYVPREAGSQKDENLALYIENQFREFK

LSKVWRDQHFKVQKDSAQNSVIIVDKNGGLVYLVENPGGYVAYSKAATVTGKLVH
 ANFGTKKDFEDLDSPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVKAD
 LSFFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISRAAAEKLFGNMEGDCPS
 DWKTDSTCKMVTSENKSVKLTVSNVLKETKILNIFGVIKGFVEPDHYVVVGAQRDAW
 GPGAAKSSVGTALLKLAQMFSDMVLDGFGQPSRSIIFASWSAGDFGSGATEWLEGY
 LSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQDVKHPVTGRSLYQDSNWA
 SKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELVERIPELNKVAR
 AA AEVAGQFVIKLTHTDELNDYERYNSQLLLFLRDLNQYRADVKEMGLSLQWL YSA
 RGDFFRATSRLTTDFRNAEKRDKFVMKKLNDRVMRVEYYFLSPYVSPKESPFRHVFWG
 SGSHTLSALLESLKLRQNNSAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF
 (SEQ ID NO: 107).

[00082] An example mouse transferrin receptor amino acid sequence, corresponding to NCBI sequence NP_001344227.1 (transferrin receptor protein 1, mus musculus) is as follows:
 MMDQARSASFNLFGGEPLSYTRFSLARQVDGDN SHVEMKLA ADEEENADNNMKASV
 RPKRFNGRLCFAAIALVIFFLIGMSGYLG YCKRVEQKEECVKLAETEETDKSETMETE
 DVPTSSRLYWADLKTLLSEKLSNIEFADTIKQLSQNTYTPREAGSQKDESLAYYIENQFH
 EFKFSKVWRDEHYVKIQVKSSIGQNMVTIVQSNGNLDPVESPEGYVAFSKPTEVSGKLV
 HANFGTKKDFEELSYSVNGSLVIVRAGEITFAEKVANAQSFNAIGVLIYMDKNKFPVVE
 ADLALFGHAHLGTGDPYTPGFPSFNHTQFPPSQSSGLPNIPVQTISRAAAEKLF GKMEGS
 CPARWNIDSSCKLELSQNQNVKLIVKNVLKERRILNIFGVIKGYEEPDRYVVVGAQRDA
 LGAGVAAKSSVGTGLLLKLAQVFSDMISKDGRPSRSIIFASWTAGDFGAVGATEWLEG
 YLSSLHLKAFTYINLDKVVLTGTSNFKVSASPLLYTLMGKIMQDVKHPVDGKSLYRDSN
 WISKVEKLSFDNAAYPFLAYSGIPAVSFCFCEDADYPYLGTRLDTYEALTQKVPQLNQM
 VRTAAEVAGQLIKLTHTDVELNDYEMYSKLLSFMKDLNQFKTDIRDMGLSLQWL YS
 ARGDYFRATSRLTTDFHNAEKTNR FVMREINDRIMKVEYHFLSPYVSPRESPFRHIFWG
 SGSHTLSALVENLKL RQKNITAFNETLFRNQLALATWTIQGVANALSGDIWNIDNEF
 (SEQ ID NO: 108)

[00083] In some embodiments, an anti-TfR1 antibody binds to an amino acid segment of the receptor as follows:

FVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLVHANFGTKKDFE
 DLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFFGHAHLG
 TGDYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFFGHAHLG
 TGDYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFFGHAHLG
 MVTSESKNVKLTVSNVLKE (SEQ ID NO: 109) and does not inhibit the binding interactions
 between transferrin receptors and transferrin and/or (e.g., and) human hemochromatosis protein

(also known as HFE). In some embodiments, the anti-TfR1 antibody described herein does not bind an epitope in SEQ ID NO: 109.

[00084] Appropriate methodologies may be used to obtain and/or (e.g., and) produce antibodies, antibody fragments, or antigen-binding agents, e.g., through the use of recombinant DNA protocols. In some embodiments, an antibody may also be produced through the generation of hybridomas (see, e.g., Kohler, G and Milstein, C. “Continuous cultures of fused cells secreting antibody of predefined specificity” *Nature*, 1975, 256: 495-497). The antigen-of-interest may be used as the immunogen in any form or entity, e.g., recombinant or a naturally occurring form or entity. Hybridomas are screened using standard methods, e.g. ELISA screening, to find at least one hybridoma that produces an antibody that targets a particular antigen. Antibodies may also be produced through screening of protein expression libraries that express antibodies, e.g., phage display libraries. Phage display library design may also be used, in some embodiments, (see, e.g. U.S. Patent No 5,223,409, filed 3/1/1991, “Directed evolution of novel binding proteins”; WO 1992/18619, filed 4/10/1992, “Heterodimeric receptor libraries using phagemids”; WO 1991/17271, filed 5/1/1991, “Recombinant library screening methods”; WO 1992/20791, filed 5/15/1992, “Methods for producing members of specific binding pairs”; WO 1992/15679, filed 2/28/1992, and “Improved epitope displaying phage”). In some embodiments, an antigen-of-interest may be used to immunize a non-human animal, e.g., a rodent or a goat. In some embodiments, an antibody is then obtained from the non-human animal, and may be optionally modified using a number of methodologies, e.g., using recombinant DNA techniques. Additional examples of antibody production and methodologies are known in the art (see, e.g. Harlow et al. “Antibodies: A Laboratory Manual”, Cold Spring Harbor Laboratory, 1988.).

[00085] In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and/or (e.g., and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and/or (e.g., and) phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecules are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, there are about 1-10, about 1-5, about 5-10, about 1-4,

about 1-3, or about 2 sugar molecules. In some embodiments, a glycosylated antibody is fully or partially glycosylated. In some embodiments, an antibody is glycosylated by chemical reactions or by enzymatic means. In some embodiments, an antibody is glycosylated in vitro or inside a cell, which may optionally be deficient in an enzyme in the N- or O- glycosylation pathway, e.g. a glycosyltransferase. In some embodiments, an antibody is functionalized with sugar or carbohydrate molecules as described in International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, “*Modified antibody, antibody-conjugate and process for the preparation thereof*”.

[00086] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VL domain and/or (e.g., and) a VH domain of any one of the anti-TfR1 antibodies selected from any one of Tables 2-7, and comprises a constant region comprising the amino acid sequences of the constant regions of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule, any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), or any subclass (e.g., IgG2a and IgG2b) of immunoglobulin molecule. Non-limiting examples of human constant regions are described in the art, e.g., see Kabat E A et al., (1991) supra.

[00087] In some embodiments, agents binding to transferrin receptor, e.g., anti-TfR1 antibodies, are capable of targeting muscle cell and/or (e.g., and) mediate the transportation of an agent across the blood brain barrier. Transferrin receptors are internalizing cell surface receptors that transport transferrin across the cellular membrane and participate in the regulation and homeostasis of intracellular iron levels. Some aspects of the disclosure provide transferrin receptor binding proteins, which are capable of binding to transferrin receptor. Antibodies that bind, e.g. specifically bind, to a transferrin receptor may be internalized into the cell, e.g. through receptor-mediated endocytosis, upon binding to a transferrin receptor.

[00088] Provided herein, in some aspects, are humanized antibodies that bind to transferrin receptor with high specificity and affinity. In some embodiments, the humanized anti-TfR1 antibody described herein specifically binds to any extracellular epitope of a transferrin receptor or an epitope that becomes exposed to an antibody. In some embodiments, the humanized anti-TfR1 antibodies provided herein bind specifically to transferrin receptor from human, non-human primates, mouse, rat, *etc.* In some embodiments, the humanized anti-TfR1 antibodies provided herein bind to human transferrin receptor. In some embodiments, the humanized anti-TfR1 antibody described herein binds to an amino acid segment of a human or non-human primate transferrin receptor, as provided in SEQ ID NOs: 105-108. In some embodiments, the humanized anti-TfR1 antibody described herein binds to an amino acid segment corresponding to amino acids 90-96 of a human transferrin receptor as set forth in SEQ ID NO: 105, which is not in the apical domain of the transferrin receptor. In some

embodiments, the humanized anti-TfR1 antibodies described herein binds to TfR1 but does not bind to TfR2.

[00089] In some embodiments, an anti-TFR1 antibody specifically binds a TfR1 (e.g., a human or non-human primate TfR1) with binding affinity (e.g., as indicated by K_d) of at least about 10^{-4} M, 10^{-5} M, 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M, 10^{-10} M, 10^{-11} M, 10^{-12} M, 10^{-13} M, or less. In some embodiments, the anti-TfR1 antibodies described herein bind to TfR1 with a K_D of sub-nanomolar range. In some embodiments, the anti-TfR1 antibodies described herein selectively bind to transferrin receptor 1 (TfR1) but do not bind to transferrin receptor 2 (TfR2). In some embodiments, the anti-TfR1 antibodies described herein bind to human TfR1 and cyno TfR1 (e.g., with a K_d of 10^{-7} M, 10^{-8} M, 10^{-9} M, 10^{-10} M, 10^{-11} M, 10^{-12} M, 10^{-13} M, or less), but do not bind to a mouse TfR1. The affinity and binding kinetics of the anti-TfR1 antibody can be tested using any suitable method including but not limited to biosensor technology (e.g., OCTET or BIACORE). In some embodiments, binding of any one of the anti-TfR1 antibodies described herein does not complete with or inhibit transferrin binding to the TfR1. In some embodiments, binding of any one of the anti-TfR1 antibodies described herein does not complete with or inhibit HFE-beta-2-microglobulin binding to the TfR1.

[00090] Non-limiting examples of anti-TfR1 antibodies are provided in Table 2.

Table 2. Examples of Anti-TfR1 Antibodies

Ab	No. system	IMGT	Kabat	Chothia
3-A4	CDR-H1	GFNIKDDY (SEQ ID NO: 1)	DDYMY (SEQ ID NO: 7)	GFNIKDD (SEQ ID NO: 12)
	CDR-H2	IDPENGDT (SEQ ID NO: 2)	WIDPENGDT EYASKFQD (SEQ ID NO: 8)	ENG (SEQ ID NO: 13)
	CDR-H3	TLWLRRGLDY (SEQ ID NO: 3)	WLRRGLDY (SEQ ID NO: 9)	LRRGLD (SEQ ID NO: 14)
	CDR-L1	KSLHNSGYTY (SEQ ID NO: 4)	RSSKSLHNSGYTYLF (SEQ ID NO: 10)	SKSLHNSGYTY (SEQ ID NO: 15)
	CDR-L2	RMS (SEQ ID NO: 5)	RMSNLAS (SEQ ID NO: 11)	RMS (SEQ ID NO: 5)
	CDR-L3	MQHLEYPFT (SEQ ID NO: 6)	MQHLEYPFT (SEQ ID NO: 6)	HLEYPF (SEQ ID NO: 16)
	VH	EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPENGDT EYASKFQDKATVTADTSSNTAYLQLSSLTSED TAVYYCTLWLRRGLDYWGQGTSVTVS (SEQ ID NO: 17)		
	VL	DIVMTQAAPSVPVTPGESVSISCRSSKSLHNSGYTYLFWFLQRPQGSPQLLIYRMSNLA SGVPDRFSGSGGTAF TLRISRVEAEDVGVYYCMQHLEYPFTFGGGTKLEIK (SEQ ID NO: 18)		
3-A4 N54T*	CDR-H1	GFNIKDDY (SEQ ID NO: 1)	DDYMY (SEQ ID NO: 7)	GFNIKDD (SEQ ID NO: 12)
	CDR-H2	IDPETGDT (SEQ ID NO: 19)	WIDPETGDT EYASKFQD (SEQ ID NO: 20)	ETG (SEQ ID NO: 21)
	CDR-H3	TLWLRRGLDY (SEQ ID NO: 3)	WLRRGLDY (SEQ ID NO: 9)	LRRGLD (SEQ ID NO: 14)
	CDR-L1	KSLHNSGYTY (SEQ ID NO: 4)	RSSKSLHNSGYTYLF (SEQ ID NO: 10)	SKSLHNSGYTY (SEQ ID NO: 15)
	CDR-L2	RMS (SEQ ID NO: 5)	RMSNLAS (SEQ ID NO: 11)	RMS (SEQ ID NO: 5)

Ab	No. system	IMGT	Kabat	Chothia
	CDR-L3	MQHLEYPFT (SEQ ID NO: 6)	MQHLEYPFT (SEQ ID NO: 6)	HLEYPF (SEQ ID NO: 16)
	VH	EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPETGDT EYASKFQDKATVTADTSSNTAYLQLSSLTSED TAVYYCTLWLRRGLDYWGQGTSTVTS S (SEQ ID NO: 22)		
	VL	DIVMTQAAPSVPVTPGESVSISCRSSKSLLSNGYTYLFWFLQRPQGSPQLLIYRMSNLA SGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPFTFGGGTKLEIK (SEQ ID NO: 18)		
3-A4 N54S*	CDR-H1	GFNIKDDY (SEQ ID NO: 1)	DDYMY (SEQ ID NO: 7)	GFNIKDD (SEQ ID NO: 12)
	CDR-H2	IDPESGDT (SEQ ID NO: 23)	WIDPESGDTEYASKFQD (SEQ ID NO: 24)	ESG (SEQ ID NO: 25)
	CDR-H3	TLWLRRGLDY (SEQ ID NO: 3)	WLRRGLDY (SEQ ID NO: 9)	LRRGLD (SEQ ID NO: 14)
	CDR-L1	KSLLSNGYTY (SEQ ID NO: 4)	RSSKSLLSNGYTYLF (SEQ ID NO: 10)	SKSLLSNGYTY (SEQ ID NO: 15)
	CDR-L2	RMS (SEQ ID NO: 5)	RMSNLAS (SEQ ID NO: 11)	RMS (SEQ ID NO: 5)
	CDR-L3	MQHLEYPFT (SEQ ID NO: 6)	MQHLEYPFT (SEQ ID NO: 6)	HLEYPF (SEQ ID NO: 16)
	VH	EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPESGDT EYASKFQDKATVTADTSSNTAYLQLSSLTSED TAVYYCTLWLRRGLDYWGQGTSTVTS S (SEQ ID NO: 26)		
	VL	DIVMTQAAPSVPVTPGESVSISCRSSKSLLSNGYTYLFWFLQRPQGSPQLLIYRMSNLA SGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPFTFGGGTKLEIK (SEQ ID NO: 18)		
3-M12	CDR-H1	GYSITSGYY (SEQ ID NO: 27)	SGYYWN (SEQ ID NO: 33)	GYSITSGY (SEQ ID NO: 38)
	CDR-H2	ITFDGAN (SEQ ID NO: 28)	YITFDGANNYNPSLKN (SEQ ID NO: 34)	FDG (SEQ ID NO: 39)
	CDR-H3	TRSSYDYDVL DY (SEQ ID NO: 29)	SSYDYDVL DY (SEQ ID NO: 35)	SYDYDVL D (SEQ ID NO: 40)
	CDR-L1	QDISNF (SEQ ID NO: 30)	RASQDISNFLN (SEQ ID NO: 36)	SQDISNF (SEQ ID NO: 41)
	CDR-L2	YTS (SEQ ID NO: 31)	YTSRLHS (SEQ ID NO: 37)	YTS (SEQ ID NO: 31)
	CDR-L3	QQGHTLPYT (SEQ ID NO: 32)	QQGHTLPYT (SEQ ID NO: 32)	GHTLPY (SEQ ID NO: 42)
	VH	DVQLQESGPGLVKPSQSLSLTCSVTGYISITSGYYWNWIRQFPGNKLEWMGYITFDGAN NYNPSLKNRISITRDTSKNQFFLKLTSVTTEDTATY YCTRSSYDYDVL DYWGQGTTLTV SS (SEQ ID NO: 43)		
	VL	DIQMTQTSSLSASLGDRVTISCRASQDISNFLN WYQRPDGT VKLLIYYTSRLHSGVPS RFSGSGSGTDFSLTVSNLEQEDIATYFCQQGHTLPYTFGGG TKLEIK (SEQ ID NO: 44)		
5-H12	CDR-H1	GYSFTDYC (SEQ ID NO: 45)	DYCIN (SEQ ID NO: 51)	GYSFTDY (SEQ ID NO: 56)
	CDR-H2	IYPGSGNT (SEQ ID NO: 46)	WIYPGSGNTRYSERFKG (SEQ ID NO: 52)	GSG (SEQ ID NO: 57)
	CDR-H3	AREDYYPYHGMDY (SEQ ID NO: 47)	EDYYPYHGMDY (SEQ ID NO: 53)	DYYPYHGMD (SEQ ID NO: 58)
	CDR-L1	ESVDGYDNSF (SEQ ID NO: 48)	RASESVDGYDNSFMH (SEQ ID NO: 54)	SESVDGYDNSF (SEQ ID NO: 59)
	CDR-L2	RAS (SEQ ID NO: 49)	RASNLES (SEQ ID NO: 55)	RAS (SEQ ID NO: 49)
	CDR-L3	QQSSED PWT (SEQ ID NO: 50)	QQSSED PWT (SEQ ID NO: 50)	SSED PW (SEQ ID NO: 60)
	VH	QIQLQQSGPELVRPGASVKISCKASGYSFTDYCINWVNQRPGQGLEWIGWIYPGSGNTRYSERFKGKATLTVD TSSNTAYMQLSSLTSEDSAVYFCAREDYYPYHGMDYWGQGTSTVTVSS (SEQ ID NO: 61)		

Ab	No. system	IMGT	Kabat	Chothia
	VL	DIVLTQSPTSLAVSLGQRATISCRASESVDGYDNSFMHWYQQKPGQPPLKLLIFRASNLES GIPARFSGSGSRTDFTLTINPVEAADVATYYCQQSSEDPWTFGGGKLEIK (SEQ ID NO: 62)		
5-H12 C33Y*	CDR-H1	GYSFTDYY (SEQ ID NO: 63)	DYYIN (SEQ ID NO: 64)	GYSFTDY (SEQ ID NO: 56)
	CDR-H2	IYPGSGNT (SEQ ID NO: 46)	WIYPGSGNTRYSERFKG (SEQ ID NO: 52)	GSG (SEQ ID NO: 57)
	CDR-H3	AREDYYPYHGMDY (SEQ ID NO: 47)	EDYYPYHGMDY (SEQ ID NO: 53)	DYYPYHGMD (SEQ ID NO: 58)
	CDR-L1	ESVDGYDNSF (SEQ ID NO: 48)	RASESVDGYDNSFMH (SEQ ID NO: 54)	SESVDGYDNSF (SEQ ID NO: 59)
	CDR-L2	RAS (SEQ ID NO: 49)	RASNLES (SEQ ID NO: 55)	RAS (SEQ ID NO: 49)
	CDR-L3	QQSSEDPWT (SEQ ID NO: 50)	QQSSEDPWT (SEQ ID NO: 50)	SSEDPW (SEQ ID NO: 60)
	VH	QIQLQQSGPELVRPGASVKISCKASGYSFTDYYINWVNQRPGQGLEWIGWIYPGSGNTRY YSERFKGKATLTVDTSNTAYMQLSSLTSEDSAVYFCAREDYYPYHGMDYWGQGTSTV TVSS (SEQ ID NO: 65)		
	VL	DIVLTQSPTSLAVSLGQRATISCRASESVDGYDNSFMHWYQQKPGQPPLKLLIFRASNLES GIPARFSGSGSRTDFTLTINPVEAADVATYYCQQSSEDPWTFGGGKLEIK (SEQ ID NO: 62)		
5-H12 C33D*	CDR-H1	GYSFTDYD (SEQ ID NO: 66)	DYDIN (SEQ ID NO: 67)	GYSFTDY (SEQ ID NO: 56)
	CDR-H2	IYPGSGNT (SEQ ID NO: 46)	WIYPGSGNTRYSERFKG (SEQ ID NO: 52)	GSG (SEQ ID NO: 57)
	CDR-H3	AREDYYPYHGMDY (SEQ ID NO: 47)	EDYYPYHGMDY (SEQ ID NO: 53)	DYYPYHGMD (SEQ ID NO: 58)
	CDR-L1	ESVDGYDNSF (SEQ ID NO: 48)	RASESVDGYDNSFMH (SEQ ID NO: 54)	SESVDGYDNSF (SEQ ID NO: 59)
	CDR-L2	RAS (SEQ ID NO: 49)	RASNLES (SEQ ID NO: 55)	RAS (SEQ ID NO: 49)
	CDR-L3	QQSSEDPWT (SEQ ID NO: 50)	QQSSEDPWT (SEQ ID NO: 50)	SSEDPW (SEQ ID NO: 60)
	VH	QIQLQQSGPELVRPGASVKISCKASGYSFTDYDINWVNQRPGQGLEWIGWIYPGSGNTRY SERFKGKATLTVDTSNTAYMQLSSLTSEDSAVYFCAREDYYPYHGMDYWGQGTSTV SS (SEQ ID NO: 68)		
	VL	DIVLTQSPTSLAVSLGQRATISCRASESVDGYDNSFMHWYQQKPGQPPLKLLIFRASNLES GIPARFSGSGSRTDFTLTINPVEAADVATYYCQQSSEDPWTFGGGKLEIK (SEQ ID NO: 62)		
Anti-TfR clone 8	CDR-H1	GYSFTSYW (SEQ ID NO: 138)	SYWIG (SEQ ID NO: 144)	GYSFTSY (SEQ ID NO: 149)
	CDR-H2	IYPGDSDT (SEQ ID NO: 139)	IIYPGDSDTTRYSPSFQQG (SEQ ID NO: 145)	GDS (SEQ ID NO: 150)
	CDR-H3	ARFPYDSSGYYSFDY (SEQ ID NO: 140)	FPYDSSGYYSFDY (SEQ ID NO: 146)	PYDSSGYYSFD (SEQ ID NO: 151)
	CDR-L1	QSISSY (SEQ ID NO: 141)	RASQSISSYLN (SEQ ID NO: 147)	SQSISSY (SEQ ID NO: 152)
	CDR-L2	AAS (SEQ ID NO: 142)	AASSLQS (SEQ ID NO: 148)	AAS (SEQ ID NO: 142)
	CDR-L3	QQSYSTPLT (SEQ ID NO: 143)	QQSYSTPLT (SEQ ID NO: 143)	SYSTPL (SEQ ID NO: 153)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

[00091] In some embodiments, the anti-TfR1 antibody of the present disclosure is a humanized variant of any one of the anti-TfR1 antibodies provided in Table 2. In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-H1, a CDR-

H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 that are the same as the CDR-H1, CDR-H2, and CDR-H3 in any one of the anti-TfR1 antibodies provided in Table 2, and comprises a humanized heavy chain variable region and/or (e.g., and) a humanized light chain variable region.

[00092] Examples of amino acid sequences of anti-TfR1 antibodies described herein are provided in Table 3.

Table 3. Variable Regions of Anti-TfR1 Antibodies

Antibody	Variable Region Amino Acid Sequence**
3A4 VH3 (N54T*)/Vκ4	V _H : EVQLVQSGSELKKPGASVKVSTASGFNIK DDYMYWVRQPPGKGLEWIGWIDP ETGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSED TAVYYCTL WLRRGLD YWGQGTLLTVSS (SEQ ID NO: 69)
	V _L : DIVMTQSPLSLPVTTPGEPASISCRSSK SLLSNGYTYLFWFQQRPGQSPRLLIYR MSNLASGV PDRFSGSGSGTDFTLKISRVEAEDVGVYYCM QHLEY PFTFGGGTK VEIK (SEQ ID NO: 70)
3A4 VH3 (N54S*)/Vκ4	V _H : EVQLVQSGSELKKPGASVKVSTASGFNIK DDYMYWVRQPPGKGLEWIGWIDP ESGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSED TAVYYCTL WLRRGLD YWGQGTLLTVSS (SEQ ID NO: 71)
	V _L : DIVMTQSPLSLPVTTPGEPASISCRSSK SLLSNGYTYLFWFQQRPGQSPRLLIYR MSNLASGV PDRFSGSGSGTDFTLKISRVEAEDVGVYYCM QHLEY PFTFGGGTK VEIK (SEQ ID NO: 70)
3A4 VH3 /Vκ4	V _H : EVQLVQSGSELKKPGASVKVSTASGFNIK DDYMYWVRQPPGKGLEWIGWIDP ENG DTEYASKFQDRVTVTADTSTNTAYMELSSLRSED TAVYYCTLWLRRGLD YWGQGTLLTVSS (SEQ ID NO: 72)
	V _L : DIVMTQSPLSLPVTTPGEPASISCRSSK SLLSNGYTYLFWFQQRPGQSPRLLIYR MSNLASGV PDRFSGSGSGTDFTLKISRVEAEDVGVYYCM QHLEY PFTFGGGTK VEIK (SEQ ID NO: 70)
3M12 VH3/Vκ2	V _H : QVQLQESGPGLVKPSQTLSTCSVTGYSIT SGYYWNWIRQPPGKGLEWMGYITF DGANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAED TATYYCTR SSYDYDVLDY WGQGTITVTVSS (SEQ ID NO: 73)
	V _L : DIQMTQSPSSLSASVGDRVITITCRASQ DISNFLN WYQQKPGQPVKLLIY YTSRLH SGVPSRFSGSGSGTDFTLTISLQPEDFATYYFC QQGHTLPY TFGQGTKLEIK (SEQ ID NO: 74)
3M12 VH3/Vκ3	V _H : QVQLQESGPGLVKPSQTLSTCSVTGYSIT SGYYWNWIRQPPGKGLEWMGYITF DGANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAED TATYYCTR SSYDYDVLDY WGQGTITVTVSS (SEQ ID NO: 73)
	V _L : DIQMTQSPSSLSASVGDRVITITCRASQ DISNFLN WYQQKPGQPVKLLIY YTSRLH SGVPSRFSGSGSGTDFTLTISLQPEDFATYYC QQGHTLPY TFGQGTKLEIK (SEQ ID NO: 75)
3M12 VH4/Vκ2	V _H : QVQLQESGPGLVKPSQTLSTCTVTGYSIT SGYYWNWIRQPPGKGLEWIGYITFD GANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAED TATYYCTR SSYDYDVLDY WGQGTITVTVSS (SEQ ID NO: 76)
	V _L : DIQMTQSPSSLSASVGDRVITITCRASQ DISNFLN WYQQKPGQPVKLLIY YTSRLH SGVPSRFSGSGSGTDFTLTISLQPEDFATYYFC QQGHTLPY TFGQGTKLEIK (SEQ ID NO: 74)

Antibody	Variable Region Amino Acid Sequence**
3M12 VH4/Vκ3	VH: QVQLQESGPGLVKPSQTLSTCTVTGYSTIT SGYYWNWIRQPPGKGLEWIGYITFD GANNYNPSLKNRV SISRDTSKNQFSLKLSSVTAEDTATYYCTR SSYDYDVL DYWGQGTTVTVSS (SEQ ID NO: 76)
	VL: DIQMTQSPSSLSASVGDRVITITCRAS QDISN FLNWyQQKPGQPVKLLIY YTSRLH SGVPSRFSGSGSGTDFTLTISLQPEDFATYYC QQGHTLPYTF GQGGTKLEIK (SEQ ID NO: 75)
5H12 VH5 (C33Y*)/Vκ3	VH: QVQLVQSGAEVKKPGASVKVSCKASGYST DYYINWVRQAPGQGLEWMGWIY PGSGNTRYSERFKGRVTITRDTSASTAYMELSSLRSED AVYYCARE DYYPYH GMDYWGQGLTVTVSS (SEQ ID NO: 77)
	VL: DIVLTQSPDSLAVSLGERATINCR ASESVDGYDNS FMHWYQQKPGQPPKLLIFR ASNLESGVPDRFSGSGSGTDFTLTISLQAEDVAVYYC QQSSEDPWTF GQGGTKLEIK (SEQ ID NO: 78)
5H12 VH5 (C33D*)/Vκ4	VH: QVQLVQSGAEVKKPGASVKVSCKASGYST DYDINWVRQAPGQGLEWMGWIY PGSGNTRYSERFKGRVTITRDTSASTAYMELSSLRSED AVYYCARE DYYPYH GMDYWGQGLTVTVSS (SEQ ID NO: 79)
	VL: DIVMTQSPDSLAVSLGERATINCR ASESVDGYDNS FMHWYQQKPGQPPKLLIFR ASNLESGVPDRFSGSGSGTDFTLTISLQAEDVAVYYC QQSSEDPWTF GQGGTKLEIK (SEQ ID NO: 80)
5H12 VH5 (C33Y*)/Vκ4	VH: QVQLVQSGAEVKKPGASVKVSCKASGYST DYYINWVRQAPGQGLEWMGWIY PGSGNTRYSERFKGRVTITRDTSASTAYMELSSLRSED AVYYCARE DYYPYH GMDYWGQGLTVTVSS (SEQ ID NO: 77)
	VL: DIVMTQSPDSLAVSLGERATINCR ASESVDGYDNS FMHWYQQKPGQPPKLLIFR ASNLESGVPDRFSGSGSGTDFTLTISLQAEDVAVYYC QQSSEDPWTF GQGGTKLEIK (SEQ ID NO: 80)
Anti-TfR clone 8	VH: QVQLVQSGAEVKKPGESLKISCKGSGYSFT SYWIGWVRQMPGKGLEWMGIIYP GDS DT RYSPSFQ QGV TISADKSISTAYLQWSSLKASDTAMYYCARFPYDSSGY SFDYWGQGLTVTVSS (SEQ ID NO: 154)
	VL: DIQMTQSPSSLSASVGDRVITITCRAS QSISSY LNWyQQKPGKAPKLLIY AASSLQ SGVPSRFSGSGSGTDFTLTISLQPEDFATYYC QQSYSTPLTF GGGKVEIK (SEQ ID NO: 155)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

** CDRs according to the Kabat numbering system are bolded

[00093] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the CDR-H1, CDR-H2, and CDR-H3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid variations in the framework regions as compared with the respective VH provided in Table 3. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the CDR-L1, CDR-L2, and CDR-L3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid variations in the framework regions as compared with the respective VL provided in Table 3. In some embodiments, the VH of the anti-TfR1 antibody is a humanized VH, and/or the VL of the anti-TfR1 antibody is a humanized VL.

[00094] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the CDR-H1, CDR-H2, and CDR-H3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprising an amino acid sequence that is at least 70% (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%) identical in the framework regions as compared with the respective VH provided in Table 3.

Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the CDR-L1, CDR-L2, and CDR-L3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprising an amino acid sequence that is at least 70% (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%) identical in the framework regions as compared with the respective VL provided in Table 3. In some embodiments, the VH of the anti-TfR1 antibody is a humanized VH, and/or the VL of the anti-TfR1 antibody is a humanized VL.

[00095] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70.

[00096] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70.

[00097] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70.

[00098] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74.

[00099] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75.

[00100] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74.

[00101] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75.

[000102] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78.

[000103] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

[000104] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

[000105] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 154 and a VL comprising the amino acid sequence of SEQ ID NO: 155.

[000106] In some embodiments, the anti-TfR1 antibody described herein is a full-length IgG, which can include a heavy constant region and a light constant region from a human antibody. In some embodiments, the heavy chain of any of the anti-TfR1 antibodies as described herein may comprise a heavy chain constant region (CH) or a portion thereof (e.g., CH1, CH2, CH3, or a combination thereof). The heavy chain constant region can be of any suitable origin, e.g., human, mouse, rat, or rabbit. In one specific example, the heavy chain constant region is from a human IgG (a gamma heavy chain), e.g., IgG1, IgG2, or IgG4. An example of a human IgG1 constant region is given below:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 81)

[000107] In some embodiments, the heavy chain of any of the anti-TfR1 antibodies described herein comprises a mutant human IgG1 constant region. For example, the introduction of LALA mutations (a mutant derived from mAb b12 that has been mutated to replace the lower hinge residues Leu234 Leu235 with Ala234 and Ala235) in the CH2 domain of human IgG1 is known to reduce Fcγ receptor binding (Bruhns, P., et al. (2009) and Xu, D. et al. (2000)). The mutant human IgG1 constant region is provided below (mutations bonded and underlined):

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAA

GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE
EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLT
VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 82)

[000108] In some embodiments, the light chain of any of the anti-TfR1 antibodies described herein may further comprise a light chain constant region (CL), which can be any CL known in the art. In some examples, the CL is a kappa light chain. In other examples, the CL is a lambda light chain. In some embodiments, the CL is a kappa light chain, the sequence of which is provided below:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKDYSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 83)

[000109] Other antibody heavy and light chain constant regions are well known in the art, e.g., those provided in the IMGT database (www.imgt.org) or at www.vbase2.org/vbstat.php, both of which are incorporated by reference herein.

[000110] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 81 or SEQ ID NO: 82. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with SEQ ID NO: 81 or SEQ ID NO: 82. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region as set forth in SEQ ID NO: 81. In some embodiments, the anti-TfR1 antibody described herein comprises heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region as set forth in SEQ ID NO: 82.

[000111] In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 83. In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with SEQ ID NO: 83. In some embodiments, the anti-TfR1

antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region set forth in SEQ ID NO: 83.

[000112] Examples of IgG heavy chain and light chain amino acid sequences of the anti-TfR1 antibodies described are provided in Table 4 below.

Table 4. Heavy chain and light chain sequences of examples of anti-TfR1 IgGs

Antibody	IgG Heavy Chain/Light Chain Sequences**
3A4 VH3 (N54T*)/Vκ4	Heavy Chain (with wild type human IgG1 constant region) <u>EVQLVQSGSELKPGASVKVSC</u>TASGFNIKDDYMYWVRPPGKGLEWIGWIDPE <u>TGDTEYASKFQDRVT</u>VTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYW <u>GQGT</u>LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSL SLSPGK (SEQ ID NO: 84) Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVT</u>PGEPASISCRSSKSLLHSNGYTYLFWFOORPGQSPRLLIYRMS <u>NLASGVPDRFSGSG</u>SGTDFTLKISRVEAEDVGVYYCMOHLEYPFTFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDYSLSSITLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC (SEQ ID NO: 85)
3A4 VH3 (N54S*)/Vκ4	Heavy Chain (with wild type human IgG1 constant region) <u>EVQLVQSGSELKPGASVKVSC</u>TASGFNIKDDYMYWVRPPGKGLEWIGWIDPE <u>SGDTEYASKFQDRVT</u>VTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYW <u>GQGT</u>LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSL SLSPGK (SEQ ID NO: 86) Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVT</u>PGEPASISCRSSKSLLHSNGYTYLFWFOORPGQSPRLLIYRMS <u>NLASGVPDRFSGSG</u>SGTDFTLKISRVEAEDVGVYYCMOHLEYPFTFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDYSLSSITLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC (SEQ ID NO: 85)
3A4 VH3 /Vκ4	Heavy Chain (with wild type human IgG1 constant region) <u>EVQLVQSGSELKPGASVKVSC</u>TASGFNIKDDYMYWVRPPGKGLEWIGWIDPE <u>NGDTEYASKFQDRVT</u>VTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYW <u>GQGT</u>LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSL SLSPGK (SEQ ID NO: 87) Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVT</u>PGEPASISCRSSKSLLHSNGYTYLFWFOORPGQSPRLLIYRMS <u>NLASGVPDRFSGSG</u>SGTDFTLKISRVEAEDVGVYYCMOHLEYPFTFGGGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDYSLSSITLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC (SEQ ID NO: 85)

Antibody	IgG Heavy Chain/Light Chain Sequences**
3M12 VH3/Vκ2	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCSVTGYISITSGYYWNWIRPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLDYWG</u> <u>QGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC</u> <u>DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN</u> <u>WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP</u> <u>APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ</u> <u>PENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL</u> <u>SLSPGK (SEQ ID NO: 88)</u> Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTTTCRASQDISNFLNWWYQQKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISLQPEDFATYFCQOGHTLPYTFGQGTKLEIKRTVAAP</u> <u>SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK</u> <u>DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 89)</u>
3M12 VH3/Vκ3	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCSVTGYISITSGYYWNWIRPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLDYWG</u> <u>QGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC</u> <u>DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN</u> <u>WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP</u> <u>APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ</u> <u>PENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL</u> <u>SLSPGK (SEQ ID NO: 88)</u> Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTTTCRASQDISNFLNWWYQQKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISLQPEDFATYYCQOGHTLPYTFGQGTKLEIKRTVAA</u> <u>PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS</u> <u>KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 90)</u>
3M12 VH4/Vκ2	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCTVTGYISITSGYYWNWIRPPGKGLEWIGYITFDG</u> <u>ANNYNPSLKNRVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLDYWGQ</u> <u>GTTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS</u> <u>GVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD</u> <u>KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNW</u> <u>YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA</u> <u>PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP</u> <u>ENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS</u> <u>LSPGK (SEQ ID NO: 91)</u> Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTTTCRASQDISNFLNWWYQQKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISLQPEDFATYFCQOGHTLPYTFGQGTKLEIKRTVAAP</u> <u>SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK</u> <u>DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 89)</u>
3M12 VH4/Vκ3	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCTVTGYISITSGYYWNWIRPPGKGLEWIGYITFDG</u> <u>ANNYNPSLKNRVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLDYWGQ</u> <u>GTTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS</u> <u>GVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD</u> <u>KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNW</u> <u>YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA</u> <u>PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP</u> <u>ENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS</u> <u>LSPGK (SEQ ID NO: 91)</u>

Antibody	IgG Heavy Chain/Light Chain Sequences**
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRTTITCRASQDISNFLNWYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFGSGSGTDFTLTISSLQPEDFATYYCQOGHTLPYTFGQGTKLEIKRTVAA</u> PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 90)
5H12 VH5 (C33Y*)/VK3	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYYINWVRQAPGQGLEWMGWIYP</u> <u>GSNTRYSERFKGRVTITRDTASTAYMELSSLRSEDTAVYYCAREDDYYPYHGM</u> <u>DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPPSSSLGTQTYICNVNHKPSNTKVDDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYT QKSLSLSPGK (SEQ ID NO: 92) Light Chain (with kappa light chain constant region) <u>DIVLTQSPDSLAVSLGERATINCRASESDGYDNSFMHWYQOKPGOPPKLLIFRAS</u> <u>NLESGVPDRFSGSGSRDFTLTISSLQAEDVAVYYCQOSEDPTWTFGQGTKLEIKR</u> TVAAPS FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV EQDSKDSYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 93)
5H12 VH5 (C33D*)/VK4	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYDINWVRQAPGQGLEWMGWIYP</u> <u>GSNTRYSERFKGRVTITRDTASTAYMELSSLRSEDTAVYYCAREDDYYPYHGM</u> <u>DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPPSSSLGTQTYICNVNHKPSNTKVDDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYT QKSLSLSPGK (SEQ ID NO: 94) Light Chain (with kappa light chain constant region) <u>DIVMTQSPDSLAVSLGERATINCRASESDGYDNSFMHWYQOKPGOPPKLLIFRA</u> <u>SNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQOSEDPTWTFGQGTKLEIK</u> RTVAAPS FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 95)
5H12 VH5 (C33Y*)/VK4	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYYINWVRQAPGQGLEWMGWIYP</u> <u>GSNTRYSERFKGRVTITRDTASTAYMELSSLRSEDTAVYYCAREDDYYPYHGM</u> <u>DYWGQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPPSSSLGTQTYICNVNHKPSNTKVDDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYT QKSLSLSPGK (SEQ ID NO: 92) Light Chain (with kappa light chain constant region) <u>DIVMTQSPDSLAVSLGERATINCRASESDGYDNSFMHWYQOKPGOPPKLLIFRA</u> <u>SNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQOSEDPTWTFGQGTKLEIK</u> RTVAAPS FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 95)

Antibody	IgG Heavy Chain/Light Chain Sequences**
Anti-TfR clone 8	VH: <u>QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPG</u> <u>DSDTRYSPSFQGGVTISADKSISTAYLOWSSLKASDTAMYYCARFPYDSSGYYSF</u> <u>DYWGOGLTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYT QKSLSLSPGK (SEQ ID NO: 156)
	VL: <u>DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQOKPGKAPKLLIYAASSLOS</u> <u>GVPSRFSGSGGTDFLTISLQPEDFATYYCQOSYSTPLTFGGGTKVEIKRTVAAP</u> SVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 157)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

** CDRs according to the Kabat numbering system are bolded; VH/VL sequences underlined

[000113] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the heavy chain as set forth in any one of SEQ ID NOs: 84, 86, 87, 88, 91, 92, 94, and 156. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a light chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the light chain as set forth in any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157.

[000114] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 84, 86, 87, 88, 91, 92, 94, and 156. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising the amino acid sequence of any one of SEQ ID NOs: 84, 86, 87, 88, 91, 92, 94, and 156. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 85, 89, 90, 93, 95 and 157.

[000115] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 84 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000116] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 86 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000117] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 87 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000118] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000119] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000120] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000121] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000122] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92 and a light chain comprising the amino acid sequence of SEQ ID NO: 93.

[000123] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 94 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000124] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000125] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 156 and a light chain comprising the amino acid sequence of SEQ ID NO: 157.

[000126] In some embodiments, the anti-TfR1 antibody is a Fab fragment, Fab' fragment, or F(ab')₂ fragment of an intact antibody (full-length antibody). Antigen binding fragment of an intact antibody (full-length antibody) can be prepared via routine methods (e.g., recombinantly or by digesting the heavy chain constant region of a full-length IgG using an enzyme such as papain). For example, F(ab')₂ fragments can be produced by pepsin or papain digestion of an

antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab')₂ fragments. In some embodiments, a heavy chain constant region in a Fab fragment of the anti-TfR1 antibody described herein comprises the amino acid sequence of:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 96)

[000127] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 96. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with SEQ ID NO: 96. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region as set forth in SEQ ID NO: 96.

[000128] In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 83. In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with SEQ ID NO: 83. In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region set forth in SEQ ID NO: 83.

[000129] Examples of Fab heavy chain and light chain amino acid sequences of the anti-TfR1 antibodies described are provided in Table 5 below.

Table 5. Heavy chain and light chain sequences of examples of anti-TfR1 Fabs

Antibody	Fab Heavy Chain/Light Chain Sequences**
3A4 VH3 (N54T*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>EVQLVQSGSELKKPGASVKVSC</u> <u>TASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE</u> <u>TGDTHEYASKFQDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYW</u> <u>GQGT</u> <u>LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL</u> <u>TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS</u> <u>CDKTHT</u> (SEQ ID NO: 97)

Antibody	Fab Heavy Chain/Light Chain Sequences**
	Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVTGPGEASISCRSSKSLHNSNGYTYLFWFOQRPGQSPRLLIYRMS</u> <u>NLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFGGGTKVEIK</u> RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 85)
3A4 VH3 (N54S*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>EVQLVQSGSELKKPGASVKVSCASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE</u> <u>SGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYLW</u> <u>GQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL</u> TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKHT (SEQ ID NO: 98)
	Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVTGPGEASISCRSSKSLHNSNGYTYLFWFOQRPGQSPRLLIYRMS</u> <u>NLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFGGGTKVEIK</u> RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 85)
3A4 VH3 /Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>EVQLVQSGSELKKPGASVKVSCASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE</u> <u>NGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYLW</u> <u>GQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL</u> TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKHT (SEQ ID NO: 99)
	Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVTGPGEASISCRSSKSLHNSNGYTYLFWFOQRPGQSPRLLIYRMS</u> <u>NLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFGGGTKVEIK</u> RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 85)
3M12 VH3/Vκ2	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCSVTGYISITSGYYWNWIRQPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLDYWG</u> <u>QGTITVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC DKHT (SEQ ID NO: 100)
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWKYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISLQPEDFATYYFCQOQHITLPTFGQGTKEIKRTVAAP</u> SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 89)
3M12 VH3/Vκ3	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCSVTGYISITSGYYWNWIRQPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLDYWG</u> <u>QGTITVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC DKHT (SEQ ID NO: 100)
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWKYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISLQPEDFATYYFCQOQHITLPTFGQGTKEIKRTVAAP</u> PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 90)
3M12 VH4/Vκ2	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCTVTGYISITSGYYWNWIRQPPGKGLEWIGYITFDG</u> <u>ANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLDYWGQ</u> <u>GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS</u> GVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KHT (SEQ ID NO: 101)

Antibody	Fab Heavy Chain/Light Chain Sequences**
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVITTCRASQDISNFLNWYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFGSGSGTDFTLTISSLQPEDFATYFCQOGHTLPYTFGQGTKLEIKRTVAAP</u> <u>SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK</u> <u>DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 89)
3M12 VH4/Vκ3	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGGLVKPSQTLSTCTVTGYSTITSGYYWNWIROP PGKGLEWIGYITFDG</u> <u>ANNYNPSLKNRVSISRDTSKNQFSLKLSVTAEDTATYYCTRSSYDYDVL DYWGQ</u> <u>GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS</u> <u>GVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD</u> <u>KTHT</u> (SEQ ID NO: 101)
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVITTCRASQDISNFLNWYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFGSGSGTDFTLTISSLQPEDFATYFCQOGHTLPYTFGQGTKLEIKRTVAA</u> <u>PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS</u> <u>KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 90)
5H12 VH5 (C33Y*)/Vκ3	Heavy Chain (with partial human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYYINWVRQAPGQGLEWMGWIYP</u> <u>GSNTRYSERFKGRVTITRDTASTAYMELSSLRSED TAVYYCAREDYYPYHGM</u> <u>DYWGQGT LVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> <u>SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV</u> <u>EPKSCDKTHT</u> (SEQ ID NO: 102)
	Light Chain (with kappa light chain constant region) <u>DIVLTQSPDSLAVSLGERATINCRASESDGYDNSEFMH WYQOKPGOPPKLLIFRAS</u> <u>NLESGVPDRFSGSGSRDFTLTISSLQAEDVAVYYCQOSED PWTFGQGTKLEIKR</u> <u>TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV</u> <u>TEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 93)
5H12 VH5 (C33D*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYDINWVRQAPGQGLEWMGWIYP</u> <u>GSNTRYSERFKGRVTITRDTASTAYMELSSLRSED TAVYYCAREDYYPYHGM</u> <u>DYWGQGT LVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> <u>SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV</u> <u>EPKSCDKTHT</u> (SEQ ID NO: 103)
	Light Chain (with kappa light chain constant region) <u>DIVMTQSPDSLAVSLGERATINCRASESDGYDNSEFMH WYQOKPGOPPKLLIFRA</u> <u>SNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQOSED PWTFGQGTKLEIK</u> <u>RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES</u> <u>VTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 95)
5H12 VH5 (C33Y*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYYINWVRQAPGQGLEWMGWIYP</u> <u>GSNTRYSERFKGRVTITRDTASTAYMELSSLRSED TAVYYCAREDYYPYHGM</u> <u>DYWGQGT LVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> <u>SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV</u> <u>EPKSCDKTHT</u> (SEQ ID NO: 102)
	Light Chain (with kappa light chain constant region) <u>DIVMTQSPDSLAVSLGERATINCRASESDGYDNSEFMH WYQOKPGOPPKLLIFRA</u> <u>SNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQOSED PWTFGQGTKLEIK</u> <u>RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES</u> <u>VTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 95)
Anti-TfR clone 8 Version 1	VH: <u>QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGHIYPG</u> <u>DS DTRYSPSFOGQVTISADKSISTAYLQWSSLKASDTAMYCARFPYDSSGYYSF</u> <u>DYWGQGT LVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> <u>SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV</u> <u>EPKSCDKTHTCP</u> (SEQ ID NO: 158)

Antibody	Fab Heavy Chain/Light Chain Sequences**
	VL: <u>DIQMTQSPSSLSASVGDRVTTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLOS</u> <u>GVPSRFGSGSGTDFTLTISSLQPEDFATYYCQOSYSTPLTFGGGTKVEIKRTVAAP</u> SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 157)
Anti-TfR clone 8 Version 2	VH: <u>QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGHIYPG</u> <u>DSDTRYSPSFOGQVTISADKSISTAYLOWSSLKASDTAMYICARFPYDSSGYYSF</u> <u>DYWGGQTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHT (SEQ ID NO: 159)
	VL: <u>DIQMTQSPSSLSASVGDRVTTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLOS</u> <u>GVPSRFGSGSGTDFTLTISSLQPEDFATYYCQOSYSTPLTFGGGTKVEIKRTVAAP</u> SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 157)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

** CDRs according to the Kabat numbering system are bolded; VH/VL sequences underlined

[000130] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the heavy chain as set forth in any one of SEQ ID NOs: 97-103, 158 and 159. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a light chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the light chain as set forth in any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157.

[000131] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 97-103, 158 and 159. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising the amino acid sequence of any one of SEQ ID NOs: 97-103, 158 and 159. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157.

[000132] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 97 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000133] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 98 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000134] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 99 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000135] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000136] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000137] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000138] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000139] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 93.

[000140] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 103 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000141] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000142] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 158 and a light chain comprising the amino acid sequence of SEQ ID NO: 157.

[000143] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 159 and a light chain comprising the amino acid sequence of SEQ ID NO: 157.

Other known anti-TfR1 antibodies

[000144] Any other appropriate anti-TfR1 antibodies known in the art may be used as the muscle-targeting agent in the complexes disclosed herein. Examples of known anti-TfR1 antibodies, including associated references and binding epitopes, are listed in Table 6. In some embodiments, the anti-TfR1 antibody comprises the complementarity determining regions (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) of any of the anti-TfR1 antibodies provided herein, e.g., anti-TfR1 antibodies listed in Table 6.

Table 6 – List of anti-TfR1 antibody clones, including associated references and binding epitope information.

Antibody Clone Name	Reference(s)	Epitope / Notes
OKT9	US Patent. No. 4,364,934, filed 12/4/1979, entitled “MONOCLONAL ANTIBODY TO A HUMAN EARLY THYMOCYTE ANTIGEN AND METHODS FOR PREPARING SAME” Schneider C. et al. “Structural features of the cell surface receptor for transferrin that is recognized by the monoclonal antibody OKT9.” J Biol Chem. 1982, 257:14, 8516-8522.	Apical domain of TfR1 (residues 305-366 of human TfR1 sequence XM_052730.3, available in GenBank)
(From JCR) Clone M11 Clone M23 Clone M27 Clone B84	- WO 2015/098989, filed 12/24/2014, “Novel anti-Transferrin receptor antibody that passes through blood-brain barrier” - US Patent No. 9,994,641, filed 12/24/2014, “Novel anti-Transferrin receptor antibody that passes through blood-brain barrier”	Apical domain (residues 230-244 and 326-347 of TfR1) and protease-like domain (residues 461-473)
(From Genentech) 7A4, 8A2, 15D2, 10D11, 7B10, 15G11, 16G5, 13C3, 16G4, 16F6, 7G7, 4C2, 1B12, and 13D4	- WO 2016/081643, filed 5/26/2016, entitled “ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE” - US Patent No. 9,708,406, filed 5/20/2014, “Anti-transferrin receptor antibodies and methods of use”	Apical domain and non-apical regions
(From Armagen) 8D3	- Lee et al. “Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse” 2000, J Pharmacol. Exp. Ther., 292: 1048-1052. - US Patent App. 2010/077498, filed 9/11/2008, entitled “COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY IN THE MOUSE”	

Antibody Clone Name	Reference(s)	Epitope / Notes			
OX26	Haobam, B. et al. 2014. Rab17-mediated recycling endosomes contribute to autophagosome formation in response to Group A Streptococcus invasion. Cellular microbiology. 16: 1806-21.				
DF1513	Ortiz-Zapater E et al. Trafficking of the human transferrin receptor in plant cells: effects of tyrphostin A23 and brefeldin A. Plant J 48:757-70 (2006).				
1A1B2, 66IG10, MEM-189, JF0956, 29806, 1A1B2, TFRC/1818, 1E6, 66Ig10, TFRC/1059, Q1/71, 23D10, 13E4, TFRC/1149, ER-MP21, YTA74.4, BU54, 2B6, RI7 217	Commercially available anti-transferrin receptor antibodies.	Novus Biologicals 8100 Southpark Way, A-8 Littleton CO 80120			
(From INSERM) BA120g	US Patent App. 2011/0311544A1, filed 6/15/2005, entitled “ANTI-CD71 MONOCLONAL ANTIBODIES AND USES THEREOF FOR TREATING MALIGNANT TUMOR CELLS”	Does not compete with OKT9			
LUCA31	US Patent No. 7,572,895, filed 6/7/2004, entitled “TRANSFERRIN RECEPTOR ANTIBODIES”	“LUCA31 epitope”			
(Salk Institute) B3/25 T58/30	Trowbridge, I.S. et al. “Anti-transferrin receptor monoclonal antibody and toxin–antibody conjugates affect growth of human tumour cells.” Nature, 1981, volume 294, pages 171–173				
R17 217.1.3, 5E9C11, OKT9 (BE0023 clone)	Commercially available anti-transferrin receptor antibodies.	BioXcell 10 Technology Dr., Suite 2B West Lebanon, NH 03784-1671 USA			
BK19.9, B3/25, T56/14 and T58/1	Gatter, K.C. et al. “Transferrin receptors in human tissues: their distribution and possible clinical relevance.” J Clin Pathol. 1983 May;36(5):539-45.				
Anti-TfR1 antibody					
CDRH1 (SEQ ID NO: 333)		Additional Anti-TfR1 antibody SEQ ID NOs			
CDRH2 (SEQ ID NO: 334)					
CDRH3 (SEQ ID NO: 335)					
CDRL1 (SEQ ID NO: 336)					
	VH/VL	CDR1	CDR2	CDR3	
	VH1	348	341	342	335
	VH2	349	341	343	335
	VH3	350	341	344	335

Antibody Clone Name	Reference(s)			Epitope / Notes		
CDRL2 (SEQ ID NO: 337)	VH4	351	341	343	335	
CDRL3 (SEQ ID NO: 338)	VL1	352	336	337	115	
VH (SEQ ID NO: 339)	VL2	353	336	337	115	
VL (SEQ ID NO: 340)	VL3	354	336	345	338	
	VL4	355	346	347	338	

[000145] In some embodiments, anti-TfR1 antibodies of the present disclosure include one or more of the CDR-H (*e.g.*, CDR-H1, CDR-H2, and CDR-H3) amino acid sequences from any one of the anti-TfR1 antibodies selected from Table 6. In some embodiments, anti-TfR1 antibodies include the CDR-L1, CDR-L2, and CDR-L3 as provided for any one of the anti-TfR1 antibodies selected from Table 6. In some embodiments, anti-TfR1 antibodies include the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 as provided for any one of the anti-TfR1 antibodies selected from Table 6.

[000146] In some embodiments, anti-TfR1 antibodies of the disclosure include any antibody that includes a heavy chain variable domain and/or (*e.g.*, and) a light chain variable domain of any anti-TfR1 antibody, such as any one of the anti-TfR1 antibodies selected from Table 6. In some embodiments, anti-TfR1 antibodies of the disclosure include any antibody that includes the heavy chain variable and light chain variable pairs of any anti-TfR1 antibody, such as any one of the anti-TfR1 antibodies selected from Table 6.

[000147] Aspects of the disclosure provide anti-TfR1 antibodies having a heavy chain variable (VH) and/or (*e.g.*, and) a light chain variable (VL) domain amino acid sequence homologous to any of those described herein. In some embodiments, the anti-TfR1 antibody comprises a heavy chain variable sequence or a light chain variable sequence that is at least 75% (*e.g.*, 80%, 85%, 90%, 95%, 98%, or 99%) identical to the heavy chain variable sequence and/or any light chain variable sequence of any anti-TfR1 antibody, such as any one of the anti-TfR1 antibodies selected from Table 6. In some embodiments, the homologous heavy chain variable and/or (*e.g.*, and) a light chain variable amino acid sequences do not vary within any of the CDR sequences provided herein. For example, in some embodiments, the degree of sequence variation (*e.g.*, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) may occur within a heavy chain variable and/or (*e.g.*, and) a light chain variable sequence excluding any of the CDR sequences provided herein. In some embodiments, any of the anti-TfR1 antibodies provided herein comprise a heavy chain variable sequence and a light chain variable sequence that comprises a framework sequence that is at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the framework sequence of any anti-TfR1 antibody, such as any one of the anti-TfR1 antibodies selected from Table 6.

[000148] An example of a transferrin receptor antibody that may be used in accordance with the present disclosure is described in International Application Publication WO 2016/081643, incorporated herein by reference. The amino acid sequences of this antibody are provided in Table 7.

Table 7. Heavy chain and light chain CDRs of an example of a known anti-TfR1 antibody

Sequence Type	Kabat	Chothia	Contact
CDR-H1	SYWMH (SEQ ID NO: 110)	GYTFTSY (SEQ ID NO: 116)	TSYWMH (SEQ ID NO: 118)
CDR-H2	EINPTNGRTNYIEKFKS (SEQ ID NO: 111)	NPTNGR (SEQ ID NO: 117)	WIGEINPTNGRTN (SEQ ID NO: 119)
CDR-H3	GTRAYHY (SEQ ID NO: 112)	GTRAYHY (SEQ ID NO: 112)	ARGTRA (SEQ ID NO: 120)
CDR-L1	RASDNLYSNLA (SEQ ID NO: 113)	RASDNLYSNLA (SEQ ID NO: 113)	YSNLAWY (SEQ ID NO: 121)
CDR-L2	DATNLAD (SEQ ID NO: 114)	DATNLAD (SEQ ID NO: 114)	LLVYDATNLA (SEQ ID NO: 122)
CDR-L3	QHFHWGTPLT (SEQ ID NO: 115)	QHFHWGTPLT (SEQ ID NO: 115)	QHFHWGTPL (SEQ ID NO: 123)
Murine VH	QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWWVKQRPGQGLEWIGEINPTNGRTNYIEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQTSVTVSS (SEQ ID NO: 124)		
Murine VL	DIQMTQSPASLSVSVGETVTITCRASDNLYSNLAWYQQKQKSPQLLVYDATNLADGVPSRFGSGSGGTQYSLKINSLSQSEDFGTYYCQHFHWGTPLTFGAGTKLELK (SEQ ID NO: 125)		
Humanized VH	EVQLVQSGAEVKKPGASVKVSKASGYTFTSYWMHWWVRQAPGQRLEWIGEINPTNGRTNYIEKFKSRATLTVDKSASTAYMELSSLRSEDTAVYYCARGTRAYHYWGQGTMTVTVSS (SEQ ID NO: 128)		
Humanized VL	DIQMTQSPSSLSASVGDRTVTITCRASDNLYSNLAWYQQKPKGSPKLLVYDATNLADGVPSRFGSGSGGTDTLTISLQPEDFATYYCQHFHWGTPLTFGQGTKVEIK (SEQ ID NO: 129)		
HC of chimeric full-length IgG1	QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWWVKQRPGQGLEWIGEINPTNGRTNYIEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 132)		
LC of chimeric full-length IgG1	DIQMTQSPASLSVSVGETVTITCRASDNLYSNLAWYQQKQKSPQLLVYDATNLADGVPSRFGSGSGGTQYSLKINSLSQSEDFGTYYCQHFHWGTPLTFGAGTKLELKRVAAPSVEFPPSDEQLKSGTASVCLLNPFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 133)		
HC of fully human full-length IgG1	EVQLVQSGAEVKKPGASVKVSKASGYTFTSYWMHWWVRQAPGQRLEWIGEINPTNGRTNYIEKFKSRATLTVDKSASTAYMELSSLRSEDTAVYYCARGTRAYHYWGQGTMTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSLKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 134)		

Sequence Type	Kabat	Chothia	Contact
LC of fully human full-length IgG1	DIQMTQSPSSLSASVGDRVITICRASDNLYSNLAWYQQKPGKSPKLLVYDATNLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQHFHWGTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 135)		
HC of chimeric Fab	QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPTNGRTNYIEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 136)		
HC of fully human Fab	EVQLVQSGAEVKKPGASVKVSCASGYTFTSYWMHWVRQAPGQRLEWIGEINPTNGRTNYIEKFKSRATLTVDKSASTAYMELSSLRSEDTAVYYCARGTRAYHYWGQGTMTVTSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP (SEQ ID NO: 137)		

[000149] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-H1, a CDR-H2, and a CDR-H3 that are the same as the CDR-H1, CDR-H2, and CDR-H3 shown in Table 7. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a CDR-L1, a CDR-L2, and a CDR-L3 that are the same as the CDR-L1, CDR-L2, and CDR-L3 shown in Table 7.

[000150] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-L3, which contains no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the CDR-L3 as shown in Table 7. In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-L3 containing one amino acid variation as compared with the CDR-L3 as shown in Table 7. In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-L3 of QHFAGTPLT (SEQ ID NO: 126) (according to the Kabat and Chothia definition system) or QHFAGTPL (SEQ ID NO: 127) (according to the Contact definition system). In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1 and a CDR-L2 that are the same as the CDR-H1, CDR-H2, and CDR-H3 shown in Table 7, and comprises a CDR-L3 of QHFAGTPLT (SEQ ID NO: 126) (according to the Kabat and Chothia definition system) or QHFAGTPL (SEQ ID NO: 127) (according to the Contact definition system).

[000151] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises heavy chain CDRs that collectively are at least 80% (e.g., 80%, 85%, 90%, 95%, or 98%) identical to the heavy chain CDRs as shown in Table 7. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises light chain CDRs that collectively are at least 80% (e.g., 80%, 85%, 90%, 95%, or 98%) identical to the light chain CDRs as shown in Table 7.

[000152] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 124. Alternatively or in addition

(e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 125.

[000153] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 128. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 129.

[000154] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 128. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL containing no more than 15 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 129.

[000155] In some embodiments, the anti-TfR1 antibody of the present disclosure is a full-length IgG1 antibody, which can include a heavy constant region and a light constant region from a human antibody. In some embodiments, the heavy chain of any of the anti-TfR1 antibodies as described herein may comprises a heavy chain constant region (CH) or a portion thereof (e.g., CH1, CH2, CH3, or a combination thereof). The heavy chain constant region can of any suitable origin, e.g., human, mouse, rat, or rabbit. In one specific example, the heavy chain constant region is from a human IgG (a gamma heavy chain), e.g., IgG1, IgG2, or IgG4. An example of human IgG1 constant region is given below:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYITLPISRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 81)

[000156] In some embodiments, the light chain of any of the anti-TfR1 antibodies described herein may further comprise a light chain constant region (CL), which can be any CL known in the art. In some examples, the CL is a kappa light chain. In other examples, the CL is a lambda light chain. In some embodiments, the CL is a kappa light chain, the sequence of which is provided below:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 83)

[000157] In some embodiments, the anti-TfR1 antibody described herein is a chimeric antibody that comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 132. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 133.

[000158] In some embodiments, the anti-TfR1 antibody described herein is a fully human antibody that comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 134. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 135.

[000159] In some embodiments, the anti-TfR1 antibody is an antigen binding fragment (Fab) of an intact antibody (full-length antibody). In some embodiments, the anti-TfR1 Fab described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 136. Alternatively or in addition (e.g., in addition), the anti-TfR1 Fab described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 133. In some embodiments, the anti-TfR1 Fab described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 137. Alternatively or in addition (e.g., in addition), the anti-TfR1 Fab described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 135.

[000160] The anti-TfR1 antibodies described herein can be in any antibody form, including, but not limited to, intact (i.e., full-length) antibodies, antigen-binding fragments thereof (such as Fab, Fab', F(ab')₂, Fv), single chain antibodies, bi-specific antibodies, or nanobodies. In some embodiments, the anti-TfR1 antibody described herein is an scFv. In some embodiments, the anti-TfR1 antibody described herein is an scFv-Fab (e.g., scFv fused to a portion of a constant region). In some embodiments, the anti-TfR1 antibody described herein is an scFv fused to a constant region (e.g., human IgG1 constant region as set forth in SEQ ID NO: 81).

[000161] In some embodiments, conservative mutations can be introduced into antibody sequences (e.g., CDRs or framework sequences) at positions where the residues are not likely to be involved in interacting with a target antigen (e.g., transferrin receptor), for example, as determined based on a crystal structure. In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of an anti-TfR1 antibody described herein (e.g., in a CH₂ domain (residues 231-340 of human IgG1) and/or (e.g., and) CH₃ domain (residues 341-447 of human IgG1) and/or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and/or (e.g., and) antigen-dependent cellular cytotoxicity.

[000162] In some embodiments, one, two or more mutations (*e.g.*, amino acid substitutions) are introduced into the hinge region of the Fc region (CH1 domain) such that the number of cysteine residues in the hinge region are altered (*e.g.*, increased or decreased) as described in, *e.g.*, U.S. Pat. No. 5,677,425. The number of cysteine residues in the hinge region of the CH1 domain can be altered to, *e.g.*, facilitate assembly of the light and heavy chains, or to alter (*e.g.*, increase or decrease) the stability of the antibody or to facilitate linker conjugation.

[000163] In some embodiments, one, two or more mutations (*e.g.*, amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (*e.g.*, in a CH2 domain (residues 231-340 of human IgG1) and/or (*e.g.*, and) CH3 domain (residues 341-447 of human IgG1) and/or (*e.g.*, and) the hinge region, with numbering according to the Kabat numbering system (*e.g.*, the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (*e.g.*, an activated Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, *e.g.*, Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631, which are incorporated herein by reference.

[000164] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to alter (*e.g.*, decrease or increase) half-life of the antibody *in vivo*. See, *e.g.*, International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631; and U.S. Pat. Nos. 5,869,046, 6,121,022, 6,277,375 and 6,165,745 for examples of mutations that will alter (*e.g.*, decrease or increase) the half-life of an antibody *in vivo*.

[000165] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to decrease the half-life of the anti-TfR1 antibody *in vivo*. In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to increase the half-life of the antibody *in vivo*. In some embodiments, the antibodies can have one or more amino acid mutations (*e.g.*, substitutions) in the second constant (CH2) domain (residues 231-340 of human IgG1) and/or (*e.g.*, and) the third constant (CH3) domain (residues 341-447 of human

IgG1), with numbering according to the EU index in Kabat (Kabat E A et al., (1991) supra). In some embodiments, the constant region of the IgG1 of an antibody described herein comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat. No. 7,658,921, which is incorporated herein by reference. This type of mutant IgG, referred to as "YTE mutant" has been shown to display fourfold increased half-life as compared to wild-type versions of the same antibody (see Dall'Acqua W F et al., (2006) J Biol Chem 281: 23514-24). In some embodiments, an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat.

[000166] In some embodiments, one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the anti-TfR1 antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260. In some embodiments, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, e.g., U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant domain and thereby increase tumor localization. In some embodiments, one or more amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on Fc region, which may reduce Fc receptor binding (see, *e.g.*, Shields R L et al., (2001) J Biol Chem 276: 6591-604).

[000167] In some embodiments, one or more amino in the constant region of an anti-TfR1 antibody described herein can be replaced with a different amino acid residue such that the antibody has altered C1q binding and/or (e.g., and) reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No. 6,194,551 (Idusogie et al). In some embodiments, one or more amino acid residues in the N-terminal region of the CH2 domain of an antibody described herein are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in International Publication No. WO 94/29351. In some embodiments, the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or (e.g., and) to increase the affinity of the antibody for an Fcγ receptor. This approach is described further in International Publication No. WO 00/42072.

[000168] In some embodiments, the heavy and/or (e.g., and) light chain variable domain(s) sequence(s) of the antibodies provided herein can be used to generate, for example, CDR-grafted, chimeric, humanized, or composite human antibodies or antigen-binding fragments, as described elsewhere herein. As understood by one of ordinary skill in the art, any variant, CDR-grafted, chimeric, humanized, or composite antibodies derived from any of the antibodies provided herein may be useful in the compositions and methods described herein and will maintain the ability to specifically bind transferrin receptor, such that the variant, CDR-grafted, chimeric, humanized, or composite antibody has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more binding to transferrin receptor relative to the original antibody from which it is derived.

[000169] In some embodiments, the antibodies provided herein comprise mutations that confer desirable properties to the antibodies. For example, to avoid potential complications due to Fab-arm exchange, which is known to occur with native IgG4 mAbs, the antibodies provided herein may comprise a stabilizing ‘Adair’ mutation (Angal S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” *Mol Immunol* 30, 105-108; 1993), where serine 228 (EU numbering; residue 241 Kabat numbering) is converted to proline resulting in an IgG1-like hinge sequence. Accordingly, any of the antibodies may include a stabilizing ‘Adair’ mutation.

[000170] In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and/or (e.g., and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and/or (e.g., and) phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecules are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, there are about 1-10, about 1-5, about 5-10, about 1-4, about 1-3, or about 2 sugar molecules. In some embodiments, a glycosylated antibody is fully or partially glycosylated. In some embodiments, an antibody is glycosylated by chemical reactions or by enzymatic means. In some embodiments, an antibody is glycosylated in vitro or inside a cell, which may optionally be deficient in an enzyme in the N- or O- glycosylation pathway, e.g. a glycosyltransferase. In some embodiments, an antibody is functionalized with sugar or

carbohydrate molecules as described in International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, “*Modified antibody, antibody-conjugate and process for the preparation thereof*”.

[000171] In some embodiments, any one of the anti-TfR1 antibodies described herein may comprise a signal peptide in the heavy and/or (e.g., and) light chain sequence (e.g., a N-terminal signal peptide). In some embodiments, the anti-TfR1 antibody described herein comprises any one of the VH and VL sequences, any one of the IgG heavy chain and light chain sequences, or any one of the F(ab') heavy chain and light chain sequences described herein, and further comprises a signal peptide (e.g., a N-terminal signal peptide). In some embodiments, the signal peptide comprises the amino acid sequence of MGWSCILFLVATATGVHS (SEQ ID NO: 104).

[000172] In some embodiments, an antibody provided herein may have one or more post-translational modifications. In some embodiments, N-terminal cyclization, also called pyroglutamate formation (pyro-Glu), may occur in the antibody at N-terminal Glutamate (Glu) and/or Glutamine (Gln) residues during production. As such, it should be appreciated that an antibody specified as having a sequence comprising an N-terminal glutamate or glutamine residue encompasses antibodies that have undergone pyroglutamate formation resulting from a post-translational modification. In some embodiments, pyroglutamate formation occurs in a heavy chain sequence. In some embodiments, pyroglutamate formation occurs in a light chain sequence.

b. Other Muscle-Targeting Antibodies

[000173] In some embodiments, the muscle-targeting antibody is an antibody that specifically binds hemojuvelin, caveolin-3, Duchenne muscular dystrophy peptide, myosin IIb or CD63. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a myogenic precursor protein. Exemplary myogenic precursor proteins include, without limitation, ABCG2, M-Cadherin/Cadherin-15, Caveolin-1, CD34, FoxK1, Integrin alpha 7, Integrin alpha 7 beta 1, MYF-5, MyoD, Myogenin, NCAM-1/CD56, Pax3, Pax7, and Pax9. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a skeletal muscle protein. Exemplary skeletal muscle proteins include, without limitation, alpha-Sarcoglycan, beta-Sarcoglycan, Calpain Inhibitors, Creatine Kinase MM/CKMM, eIF5A, Enolase 2/Neuron-specific Enolase, epsilon-Sarcoglycan, FABP3/H-FABP, GDF-8/Myostatin, GDF-11/GDF-8, Integrin alpha 7, Integrin alpha 7 beta 1, Integrin beta 1/CD29, MCAM/CD146, MyoD, Myogenin, Myosin Light Chain Kinase Inhibitors, NCAM-1/CD56, and Troponin I. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a smooth muscle protein. Exemplary smooth muscle proteins include, without limitation,

alpha-Smooth Muscle Actin, VE-Cadherin, Caldesmon/CALD1, Calponin 1, Desmin, Histamine H2 R, Motilin R/GPR38, Transgelin/TAGLN, and Vimentin. However, it should be appreciated that antibodies to additional targets are within the scope of this disclosure and the exemplary lists of targets provided herein are not meant to be limiting.

c. Antibody Features/Alterations

[000174] In some embodiments, conservative mutations can be introduced into antibody sequences (e.g., CDRs or framework sequences) at positions where the residues are not likely to be involved in interacting with a target antigen (e.g., transferrin receptor), for example, as determined based on a crystal structure. In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgG1) and/or (e.g., and) CH3 domain (residues 341-447 of human IgG1) and/or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and/or (e.g., and) antigen-dependent cellular cytotoxicity.

[000175] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the hinge region of the Fc region (CH1 domain) such that the number of cysteine residues in the hinge region are altered (e.g., increased or decreased) as described in, e.g., U.S. Pat. No. 5,677,425. The number of cysteine residues in the hinge region of the CH1 domain can be altered to, e.g., facilitate assembly of the light and heavy chains, or to alter (e.g., increase or decrease) the stability of the antibody or to facilitate linker conjugation.

[000176] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgG1) and/or (e.g., and) CH3 domain (residues 341-447 of human IgG1) and/or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (e.g., an activated Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, e.g., Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631, which are incorporated herein by reference.

[000177] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to alter (*e.g.*, decrease or increase) half-life of the antibody *in vivo*. See, *e.g.*, International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631; and U.S. Pat. Nos. 5,869,046, 6,121,022, 6,277,375 and 6,165,745 for examples of mutations that will alter (*e.g.*, decrease or increase) the half-life of an antibody *in vivo*.

[000178] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to decrease the half-life of the anti-transferrin receptor antibody *in vivo*. In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to increase the half-life of the antibody *in vivo*. In some embodiments, the antibodies can have one or more amino acid mutations (*e.g.*, substitutions) in the second constant (CH2) domain (residues 231-340 of human IgG1) and/or (*e.g.*, and) the third constant (CH3) domain (residues 341-447 of human IgG1), with numbering according to the EU index in Kabat (Kabat E A et al., (1991) *supra*). In some embodiments, the constant region of the IgG1 of an antibody described herein comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat. No. 7,658,921, which is incorporated herein by reference. This type of mutant IgG, referred to as "YTE mutant" has been shown to display fourfold increased half-life as compared to wild-type versions of the same antibody (see Dall'Acqua W F et al., (2006) *J Biol Chem* 281: 23514-24). In some embodiments, an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat.

[000179] In some embodiments, one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the anti-transferrin receptor antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260. In some embodiments, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, *e.g.*, U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant

domain and thereby increase tumor localization. In some embodiments, one or more amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on Fc region, which may reduce Fc receptor binding (see, *e.g.*, Shields R L et al., (2001) J Biol Chem 276: 6591-604).

[000180] In some embodiments, one or more amino in the constant region of a muscle-targeting antibody described herein can be replaced with a different amino acid residue such that the antibody has altered C1q binding and/or (*e.g.*, and) reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No. 6,194,551 (Idusogie et al). In some embodiments, one or more amino acid residues in the N-terminal region of the CH2 domain of an antibody described herein are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in International Publication No. WO 94/29351. In some embodiments, the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or (*e.g.*, and) to increase the affinity of the antibody for an Fcγ receptor. This approach is described further in International Publication No. WO 00/42072.

[000181] In some embodiments, the heavy and/or (*e.g.*, and) light chain variable domain(s) sequence(s) of the antibodies provided herein can be used to generate, for example, CDR-grafted, chimeric, humanized, or composite human antibodies or antigen-binding fragments, as described elsewhere herein. As understood by one of ordinary skill in the art, any variant, CDR-grafted, chimeric, humanized, or composite antibodies derived from any of the antibodies provided herein may be useful in the compositions and methods described herein and will maintain the ability to specifically bind transferrin receptor, such that the variant, CDR-grafted, chimeric, humanized, or composite antibody has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more binding to transferrin receptor relative to the original antibody from which it is derived.

[000182] In some embodiments, the antibodies provided herein comprise mutations that confer desirable properties to the antibodies. For example, to avoid potential complications due to Fab-arm exchange, which is known to occur with native IgG4 mAbs, the antibodies provided herein may comprise a stabilizing ‘Adair’ mutation (Angal S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Mol Immunol 30, 105-108; 1993), where serine 228 (EU numbering; residue 241 Kabat numbering) is converted to proline resulting in an IgG1-like hinge sequence. Accordingly, any of the antibodies may include a stabilizing ‘Adair’ mutation.

[000183] As provided herein, antibodies of this disclosure may optionally comprise constant regions or parts thereof. For example, a VL domain may be attached at its C-terminal

end to a light chain constant domain like C κ or C λ . Similarly, a VH domain or portion thereof may be attached to all or part of a heavy chain like IgA, IgD, IgE, IgG, and IgM, and any isotype subclass. Antibodies may include suitable constant regions (see, for example, Kabat et al., Sequences of Proteins of Immunological Interest, No. 91-3242, National Institutes of Health Publications, Bethesda, Md. (1991)). Therefore, antibodies within the scope of this may disclosure include VH and VL domains, or an antigen binding portion thereof, combined with any suitable constant regions.

ii. Muscle-Targeting Peptides

[000184] Some aspects of the disclosure provide muscle-targeting peptides as muscle-targeting agents. Short peptide sequences (e.g., peptide sequences of 5-20 amino acids in length) that bind to specific cell types have been described. For example, cell-targeting peptides have been described in Vines e., et al., A. “Cell-penetrating and cell-targeting peptides in drug delivery” *Biochim Biophys Acta* 2008, 1786: 126-38; Jarver P., et al., “In vivo biodistribution and efficacy of peptide mediated delivery” *Trends Pharmacol Sci* 2010; 31: 528-35; Samoylova T.I., et al., “Elucidation of muscle-binding peptides by phage display screening” *Muscle Nerve* 1999; 22: 460-6; U.S. Patent No. 6,329,501, issued on December 11, 2001, entitled “METHODS AND COMPOSITIONS FOR TARGETING COMPOUNDS TO MUSCLE”; and Samoylov A.M., et al., “Recognition of cell-specific binding of phage display derived peptides using an acoustic wave sensor.” *Biomol Eng* 2002; 18: 269-72; the entire contents of each of which are incorporated herein by reference. By designing peptides to interact with specific cell surface antigens (e.g., receptors), selectivity for a desired tissue, e.g., muscle, can be achieved. Skeletal muscle-targeting has been investigated and a range of molecular payloads are able to be delivered. These approaches may have high selectivity for muscle tissue without many of the practical disadvantages of a large antibody or viral particle. Accordingly, in some embodiments, the muscle-targeting agent is a muscle-targeting peptide that is from 4 to 50 amino acids in length. In some embodiments, the muscle-targeting peptide is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length. Muscle-targeting peptides can be generated using any of several methods, such as phage display.

[000185] In some embodiments, a muscle-targeting peptide may bind to an internalizing cell surface receptor that is overexpressed or relatively highly expressed in muscle cells, e.g. a transferrin receptor, compared with certain other cells. In some embodiments, a muscle-targeting peptide may target, e.g., bind to, a transferrin receptor. In some embodiments, a peptide that targets a transferrin receptor may comprise a segment of a naturally occurring ligand, e.g., transferrin. In some embodiments, a peptide that targets a transferrin receptor is as

described in US Patent No. 6,743,893, filed 11/30/2000, "RECEPTOR-MEDIATED UPTAKE OF PEPTIDES THAT BIND THE HUMAN TRANSFERRIN RECEPTOR". In some embodiments, a peptide that targets a transferrin receptor is as described in Kawamoto, M. et al, "A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells." BMC Cancer. 2011 Aug 18;11:359. In some embodiments, a peptide that targets a transferrin receptor is as described in US Patent No. 8,399,653, filed 5/20/2011, "TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED SIRNA DELIVERY".

[000186] As discussed above, examples of muscle targeting peptides have been reported. For example, muscle-specific peptides were identified using phage display library presenting surface heptapeptides. As one example a peptide having the amino acid sequence ASSLNIA (SEQ ID NO: 324) bound to C2C12 murine myotubes *in vitro*, and bound to mouse muscle tissue *in vivo*. Accordingly, in some embodiments, the muscle-targeting agent comprises the amino acid sequence ASSLNIA (SEQ ID NO: 324). This peptide displayed improved specificity for binding to heart and skeletal muscle tissue after intravenous injection in mice with reduced binding to liver, kidney, and brain. Additional muscle-specific peptides have been identified using phage display. For example, a 12 amino acid peptide was identified by phage display library for muscle targeting in the context of treatment for Duchenne muscular dystrophy. See, Yoshida D., et al., "Targeting of salicylate to skin and muscle following topical injections in rats." *Int J Pharm* 2002; 231: 177-84; the entire contents of which are hereby incorporated by reference. Here, a 12 amino acid peptide having the sequence SKTFNTHPQSTP (SEQ ID NO: 325) was identified and this muscle-targeting peptide showed improved binding to C2C12 cells relative to the ASSLNIA (SEQ ID NO: 324) peptide.

[000187] An additional method for identifying peptides selective for muscle (*e.g.*, skeletal muscle) over other cell types includes *in vitro* selection, which has been described in Ghosh D., et al., "Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting" *J Virol* 2005; 79: 13667-72; the entire contents of which are incorporated herein by reference. By pre-incubating a random 12-mer peptide phage display library with a mixture of non-muscle cell types, non-specific cell binders were selected out. Following rounds of selection the 12 amino acid peptide TARGEHKEEELI (SEQ ID NO: 326) appeared most frequently. Accordingly, in some embodiments, the muscle-targeting agent comprises the amino acid sequence TARGEHKEEELI (SEQ ID NO: 326).

[000188] A muscle-targeting agent may an amino acid-containing molecule or peptide. A muscle-targeting peptide may correspond to a sequence of a protein that preferentially binds to a protein receptor found in muscle cells. In some embodiments, a muscle-targeting peptide

contains a high propensity of hydrophobic amino acids, e.g. valine, such that the peptide preferentially targets muscle cells. In some embodiments, a muscle-targeting peptide has not been previously characterized or disclosed. These peptides may be conceived of, produced, synthesized, and/or (e.g., and) derivatized using any of several methodologies, e.g. phage displayed peptide libraries, one-bead one-compound peptide libraries, or positional scanning synthetic peptide combinatorial libraries. Exemplary methodologies have been characterized in the art and are incorporated by reference (Gray, B.P. and Brown, K.C. “Combinatorial Peptide Libraries: Mining for Cell-Binding Peptides” *Chem Rev.* 2014, 114:2, 1020–1081.; Samoylova, T.I. and Smith, B.F. “Elucidation of muscle-binding peptides by phage display screening.” *Muscle Nerve*, 1999, 22:4. 460-6.). In some embodiments, a muscle-targeting peptide has been previously disclosed (see, e.g. Writer M.J. et al. “Targeted gene delivery to human airway epithelial cells with synthetic vectors incorporating novel targeting peptides selected by phage display.” *J. Drug Targeting*. 2004;12:185; Cai, D. “BDNF-mediated enhancement of inflammation and injury in the aging heart.” *Physiol Genomics*. 2006, 24:3, 191-7.; Zhang, L. “Molecular profiling of heart endothelial cells.” *Circulation*, 2005, 112:11, 1601-11.; McGuire, M.J. et al. “In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo.” *J Mol Biol*. 2004, 342:1, 171-82.). Exemplary muscle-targeting peptides comprise an amino acid sequence of the following group: CQAQGQLVC (SEQ ID NO: 327), CSERSMNFC (SEQ ID NO: 328), CPKTRRVPC (SEQ ID NO: 329), WLSEAGPVVTVRALRGTSW (SEQ ID NO: 330), ASSLNIA (SEQ ID NO: 324), CMQHSMRVC (SEQ ID NO: 331), and DDTRHWG (SEQ ID NO: 332). In some embodiments, a muscle-targeting peptide may comprise about 2-25 amino acids, about 2-20 amino acids, about 2-15 amino acids, about 2-10 amino acids, or about 2-5 amino acids. Muscle-targeting peptides may comprise naturally-occurring amino acids, e.g. cysteine, alanine, or non-naturally-occurring or modified amino acids. Non-naturally occurring amino acids include β -amino acids, homo-amino acids, proline derivatives, 3-substituted alanine derivatives, linear core amino acids, N-methyl amino acids, and others known in the art. In some embodiments, a muscle-targeting peptide may be linear; in other embodiments, a muscle-targeting peptide may be cyclic, e.g. bicyclic (see, e.g. Silvana, M.G. et al. *Mol. Therapy*, 2018, 26:1, 132–147.).

iii. Muscle-Targeting Receptor Ligands

[000189] A muscle-targeting agent may be a ligand, e.g. a ligand that binds to a receptor protein. A muscle-targeting ligand may be a protein, e.g. transferrin, which binds to an internalizing cell surface receptor expressed by a muscle cell. Accordingly, in some embodiments, the muscle-targeting agent is transferrin, or a derivative thereof that binds to a transferrin receptor. A muscle-targeting ligand may alternatively be a small molecule, e.g. a

lipophilic small molecule that preferentially targets muscle cells relative to other cell types. Exemplary lipophilic small molecules that may target muscle cells include compounds comprising cholesterol, cholesteryl, stearic acid, palmitic acid, oleic acid, oleyl, linolene, linoleic acid, myristic acid, sterols, dihydrotestosterone, testosterone derivatives, glycerine, alkyl chains, trityl groups, and alkoxy acids.

iv. Muscle-Targeting Aptamers

[000190] A muscle-targeting agent may be an aptamer, e.g. an RNA aptamer, which preferentially targets muscle cells relative to other cell types. In some embodiments, a muscle-targeting aptamer has not been previously characterized or disclosed. These aptamers may be conceived of, produced, synthesized, and/or (e.g., and) derivatized using any of several methodologies, e.g. Systematic Evolution of Ligands by Exponential Enrichment. Exemplary methodologies have been characterized in the art and are incorporated by reference (Yan, A.C. and Levy, M. “Aptamers and aptamer targeted delivery” RNA biology, 2009, 6:3, 316-20.; Germer, K. et al. “RNA aptamers and their therapeutic and diagnostic applications.” Int. J. Biochem. Mol. Biol. 2013; 4: 27–40.). In some embodiments, a muscle-targeting aptamer has been previously disclosed (see, e.g. Phillippou, S. et al. “Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers.” Mol Ther Nucleic Acids. 2018, 10:199-214.; Thiel, W.H. et al. “Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation.” Mol Ther. 2016, 24:4, 779-87.). Exemplary muscle-targeting aptamers include the A01B RNA aptamer and RNA Apt 14. In some embodiments, an aptamer is a nucleic acid-based aptamer, an oligonucleotide aptamer or a peptide aptamer. In some embodiments, an aptamer may be about 5-15 kDa, about 5-10 kDa, about 10-15 kDa, about 1-5 Da, about 1-3 kDa, or smaller.

v. Other Muscle-Targeting Agents

[000191] One strategy for targeting a muscle cell (e.g., a skeletal muscle cell) is to use a substrate of a muscle transporter protein, such as a transporter protein expressed on the sarcolemma. In some embodiments, the muscle-targeting agent is a substrate of an influx transporter that is specific to muscle tissue. In some embodiments, the influx transporter is specific to skeletal muscle tissue. Two main classes of transporters are expressed on the skeletal muscle sarcolemma, (1) the adenosine triphosphate (ATP) binding cassette (ABC) superfamily, which facilitate efflux from skeletal muscle tissue and (2) the solute carrier (SLC) superfamily, which can facilitate the influx of substrates into skeletal muscle. In some embodiments, the muscle-targeting agent is a substrate that binds to an ABC superfamily or an SLC superfamily of transporters. In some embodiments, the substrate that binds to the ABC or SLC superfamily of transporters is a naturally-occurring substrate. In some embodiments, the substrate that binds to

the ABC or SLC superfamily of transporters is a non-naturally occurring substrate, for example, a synthetic derivative thereof that binds to the ABC or SLC superfamily of transporters.

[000192] In some embodiments, the muscle-targeting agent is any muscle targeting agent described herein (e.g., antibodies, nucleic acids, small molecules, peptides, aptamers, lipids, sugar moieties) that target SLC superfamily of transporters. In some embodiments, the muscle-targeting agent is a substrate of an SLC superfamily of transporters. SLC transporters are either equilibrative or use proton or sodium ion gradients created across the membrane to drive transport of substrates. Exemplary SLC transporters that have high skeletal muscle expression include, without limitation, the SATT transporter (ASCT1; SLC1A4), GLUT4 transporter (SLC2A4), GLUT7 transporter (GLUT7; SLC2A7), ATRC2 transporter (CAT-2; SLC7A2), LAT3 transporter (KIAA0245; SLC7A6), PHT1 transporter (PTR4; SLC15A4), OATP-J transporter (OATP5A1; SLC21A15), OCT3 transporter (EMT; SLC22A3), OCTN2 transporter (FLJ46769; SLC22A5), ENT transporters (ENT1; SLC29A1 and ENT2; SLC29A2), PAT2 transporter (SLC36A2), and SAT2 transporter (KIAA1382; SLC38A2). These transporters can facilitate the influx of substrates into skeletal muscle, providing opportunities for muscle targeting.

[000193] In some embodiments, the muscle-targeting agent is a substrate of an equilibrative nucleoside transporter 2 (ENT2) transporter. Relative to other transporters, ENT2 has one of the highest mRNA expressions in skeletal muscle. While human ENT2 (hENT2) is expressed in most body organs such as brain, heart, placenta, thymus, pancreas, prostate, and kidney, it is especially abundant in skeletal muscle. Human ENT2 facilitates the uptake of its substrates depending on their concentration gradient. ENT2 plays a role in maintaining nucleoside homeostasis by transporting a wide range of purine and pyrimidine nucleobases. The hENT2 transporter has a low affinity for all nucleosides (adenosine, guanosine, uridine, thymidine, and cytidine) except for inosine. Accordingly, in some embodiments, the muscle-targeting agent is an ENT2 substrate. Exemplary ENT2 substrates include, without limitation, inosine, 2',3'-dideoxyinosine, and calofarabine. In some embodiments, any of the muscle-targeting agents provided herein are associated with a molecular payload (e.g., oligonucleotide payload). In some embodiments, the muscle-targeting agent is covalently linked to the molecular payload. In some embodiments, the muscle-targeting agent is non-covalently linked to the molecular payload.

[000194] In some embodiments, the muscle-targeting agent is a substrate of an organic cation/carnitine transporter (OCTN2), which is a sodium ion-dependent, high affinity carnitine transporter. In some embodiments, the muscle-targeting agent is carnitine, mildronate, acetylcarnitine, or any derivative thereof that binds to OCTN2. In some embodiments, the

carnitine, mildronate, acetylcarnitine, or derivative thereof is covalently linked to the molecular payload (e.g., oligonucleotide payload).

[000195] A muscle-targeting agent may be a protein that exists in at least one soluble form that targets muscle cells. In some embodiments, a muscle-targeting protein may be hemojuvelin (also known as repulsive guidance molecule C or hemochromatosis type 2 protein), a protein involved in iron overload and homeostasis. In some embodiments, hemojuvelin may be full length or a fragment, or a mutant with at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to a functional hemojuvelin protein. In some embodiments, a hemojuvelin mutant may be a soluble fragment, may lack a N-terminal signaling, and/or (e.g., and) lack a C-terminal anchoring domain. In some embodiments, hemojuvelin may be annotated under GenBank RefSeq Accession Numbers NM_001316767.1, NM_145277.4, NM_202004.3, NM_213652.3, or NM_213653.3. It should be appreciated that a hemojuvelin may be of human, non-human primate, or rodent origin.

B. Molecular Payloads

[000196] Some aspects of the disclosure provide molecular payloads, e.g., for modulating a biological outcome, e.g., the transcription of a DNA sequence, the splicing and processing of a RNA sequence, the expression of a protein, or the activity of a protein. In some embodiments, a molecular payload is linked to, or otherwise associated with a muscle-targeting agent. In some embodiments, such molecular payloads are capable of targeting to a muscle cell, e.g., via specifically binding to a nucleic acid or protein in the muscle cell following delivery to the muscle cell by an associated muscle-targeting agent. It should be appreciated that various types of molecular payloads may be used in accordance with the disclosure. For example, the molecular payload may comprise, or consist of, an oligonucleotide (e.g., antisense oligonucleotide), a peptide (e.g., a peptide that binds a nucleic acid or protein associated with disease in a muscle cell), a protein (e.g., a protein that binds a nucleic acid or protein associated with disease in a muscle cell), or a small molecule (e.g., a small molecule that modulates the function of a nucleic acid or protein associated with disease in a muscle cell). In some embodiments, the molecular payload is an oligonucleotide that comprises a strand having a region of complementarity to a mutated DMD allele. Exemplary molecular payloads are described in further detail herein, however, it should be appreciated that the exemplary molecular payloads provided herein are not meant to be limiting.

i. Oligonucleotides

[000197] Aspects of the disclosure relate to oligonucleotides configured to modulate (e.g., increase) expression of dystrophin, e.g., from a DMD allele. In some embodiments,

oligonucleotides provided herein are configured to alter splicing of DMD pre-mRNA to promote expression of dystrophin protein (e.g., a functional truncated dystrophin protein). In some embodiments, oligonucleotides provided herein are configured to promote skipping of one or more exons in DMD, e.g., in a mutated DMD allele, in order to restore the reading frame. In some embodiments, the oligonucleotides allow for functional dystrophin protein expression (e.g., as described in Watanabe N, Nagata T, Satou Y, et al. NS-065/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy. *Mol Ther Nucleic Acids*. 2018;13:442-449). In some embodiments, oligonucleotides provided are configured to promote skipping of exon 44 to produce a shorter but functional version of dystrophin (e.g., containing an in-frame deletion). In some embodiments, oligonucleotides are provided that promote exon 44 skipping (e.g., which may be relevant in a substantial number of patients, including, for example, patients amenable to exon 44 skipping, such as those having deletions in DMD exons 10-43, 11-43, 13-43, 14-43, 15-43, 16-43, 17-43, 19-43, 21-43, 23-43, 24-43, 25-43, 26-43, 27-43, 28-43, 29-43, 30-43, 31-43, 32-43, 33-43, 34-43, 35-43, 36-43, 37-43, 38-43, 39, 40-43, 41-43, 42-43, 43, 45, 45-54, 45-56, or 45-62).

[000198] Table 8 provides non-limiting examples of sequences of oligonucleotides that are useful for targeting DMD, e.g., for exon skipping, and for target sequences within DMD. In some embodiments, an oligonucleotide may comprise any antisense sequence provided in Table 8 or a sequence complementary to a target sequence provided in Table 8.

Table 8. Oligonucleotide sequences for targeting DMD.

SEQ ID NO	Target sequence [†] (5' to 3')	SEQ ID NO	Antisense Sequence [†] (5' to 3')	SEQ ID NO	Antisense Sequence [†] (5' to 3')	Target Site
160	CAGAUUGUUGAG AAAUGGCGGC	196	GCCGCCAUUUCUC AACAGAUUCUG	232	GCCGCCATTCTC AACAGATCTG	Exon 44
161	CAGAUUGUUGAG AAAUGGCGGCG	197	CGCCGCCAUUUCU CAACAGAUUCUG	233	CGCCGCCATTCT CAACAGATCTG	Exon 44
162	CAGAUUGUUGAG AAAUGGCGGCGU	198	ACGCCGCCAUUUC UCAACAGAUUCUG	234	ACGCCGCCATTTC TCAACAGATCTG	Exon 44
163	AGAUCUGUUGAGA AAUGGCGGC	199	GCCGCCAUUUCUC AACAGAUUCU	235	GCCGCCATTCTC AACAGATCT	Exon 44
164	AGAUCUGUUGAGA AAUGGCGGCG	200	CGCCGCCAUUUCU CAACAGAUUCU	236	CGCCGCCATTCT CAACAGATCT	Exon 44
165	AGAUCUGUUGAGA AAUGGCGGCGU	201	ACGCCGCCAUUUC UCAACAGAUUCU	237	ACGCCGCCATTTC TCAACAGATCT	Exon 44
166	AGAUCUGUUGAGA AAUGGCGGCGUU	202	AACGCCGCCAUUU CUCAACAGAUUCU	238	AACGCCGCCATTT CTCAACAGATCT	Exon 44
167	GAUCUGUUGAGAA AUGGCGGC	203	GCCGCCAUUUCUC AACAGAUUC	239	GCCGCCATTCTC AACAGATC	Exon 44
168	GAUCUGUUGAGAA AUGGCGGCG	204	CGCCGCCAUUUCU CAACAGAUUC	240	CGCCGCCATTCT CAACAGATC	Exon 44
169	GAUCUGUUGAGAA AUGGCGGCGU	205	ACGCCGCCAUUUC UCAACAGAUUC	241	ACGCCGCCATTTC TCAACAGATC	Exon 44
170	GAUCUGUUGAGAA AUGGCGGCGUU	206	AACGCCGCCAUUU CUCAACAGAUUC	242	AACGCCGCCATTT CTCAACAGATC	Exon 44

171	GAUCUGUUGAGAA AUGGCGGCGUUU	207	AAACGCCGCCAUU UCUCAACAGAU	243	AAACGCCGCCATT TCTCAACAGATC	Exon 44
172	UCUGUUGAGAAAU GGCGGCGUUUUC	208	GAAAACGCCGCCA UUUCUCAACAGA	244	GAAAACGCCGCCA TTTCTCAACAGA	Exon 44
173	CUGUUGAGAAAUG GCGGCGU	209	ACGCCGCCAUUUC UCAACAG	245	ACGCCGCCATTTC TCAACAG	Exon 44
174	CUGUUGAGAAAUG GCGGCGUUUUA	210	UGAAAACGCCGCC AUUUCUCAACAG	246	TGAAAACGCCGCC ATTTCTCAACAG	Exon 44
175	UGAGAAAUGGCGG CGUUUUCAUUAU	211	AUAAUGAAAACGC CGCCAUUUCUCA	247	ATAATGAAAACGC CGCCATTCTCA	Exon 44
176	GAGAAAUGGCGGC GUUUUCAUUAUG	212	CAUAAUGAAAACG CCGCCAUUUCUC	248	CATAATGAAAACG CCGCCATTCTC	Exon 44
177	AGAAAUGGCGGCG UUUUCAUUAUGA	213	UCAUAAUGAAAAC GCCGCCAUUUCU	249	TCATAATGAAAAC GCCGCCATTCT	Exon 44
178	AAUCAGUGGCUAA CAGAAGCUGAAC	214	GUUCAGCUUCUGU UAGCCACUGAUU	250	GTTCAGCTTCTGT TAGCCACTGATT	Exon 44
179	AUCAGUGGCUAAC AGAAGCUGAAC	215	GUUCAGCUUCUGU UAGCCACUGAU	251	GTTCAGCTTCTGT TAGCCACTGAT	Exon 44
180	AUCAGUGGCUAAC AGAAGCUGAAC	216	UGUUCAGCUUCUG UUAGCCACUGAU	252	TGTTCAGCTTCTG TTAGCCACTGAT	Exon 44
181	UCAGUGGCUAACA GAAGCUGAAC	217	GUUCAGCUUCUGU UAGCCACUGA	253	GTTCAGCTTCTGT TAGCCACTGA	Exon 44
182	UCAGUGGCUAACA GAAGCUGAAC	218	UGUUCAGCUUCUG UUAGCCACUGA	254	TGTTCAGCTTCTG TTAGCCACTGA	Exon 44
183	UCAGUGGCUAACA GAAGCUGAACAG	219	CUGUUCAGCUUCU GUUAGCCACUGA	255	CTGTTCAGCTTCT GTTAGCCACTGA	Exon 44
184	CAGUGGCUAACAG AAGCUGAAC	220	GUUCAGCUUCUGU UAGCCACUG	256	GTTCAGCTTCTGT TAGCCACTG	Exon 44
185	CAGUGGCUAACAG AAGCUGAAC	221	UGUUCAGCUUCUG UUAGCCACUG	257	TGTTCAGCTTCTG TTAGCCACTG	Exon 44
186	CAGUGGCUAACAG AAGCUGAACAG	222	CUGUUCAGCUUCU GUUAGCCACUG	258	CTGTTCAGCTTCT GTTAGCCACTG	Exon 44
187	CAGUGGCUAACAG AAGCUGAACAGU	223	ACUGUUCAGCUUC UGUAGCCACUG	259	ACTGTTCAGCTTC TGTTAGCCACTG	Exon 44
188	AGUGGCUAACAGA AGCUGAACAG	224	CUGUUCAGCUUCU GUUAGCCACU	260	CTGTTCAGCTTCT GTTAGCCACT	Exon 44
189	AGUGGCUAACAGA AGCUGAACAGU	225	ACUGUUCAGCUUC UGUAGCCACU	261	ACTGTTCAGCTTC TGTTAGCCACT	Exon 44
190	AGUGGCUAACAGA AGCUGAACAGU	226	AACUGUUCAGCUU CUGUAGCCACU	262	AACGTTTACGCTT CTGTTAGCCACT	Exon 44
191	GUGGCUAACAGAA GCUGAACAGU	227	ACUGUUCAGCUUC UGUAGCCAC	263	ACTGTTCAGCTTC TGTTAGCCAC	Exon 44
192	GUGGCUAACAGAA GCUGAACAGUU	228	AACUGUUCAGCUU CUGUAGCCAC	264	AACGTTTACGCTT CTGTTAGCCAC	Exon 44
193	AAAGAUCAAGGUUC UGAAGGGUGAUG	229	CAUACCCUUCAG AACCUGAUCUUU	265	CATCACCCTTCAG AACCTGATCTT	Intron 44
194	AAGAUCAAGGUUCU GAAGGGUGAUG	230	CAUACCCUUCAG AACCUGAUCUU	266	CATCACCCTTCAG AACCTGATCTT	Intron 44
195	AGAUCAGGUUCUG AAGGGUGAUG	231	CAUACCCUUCAG AACCUGAUCU	267	CATCACCCTTCAG AACCTGATCT	Intron 44

† Each thymine base (T) in any one of the oligonucleotides and/or target sequences provided in Table 8 may independently and optionally be replaced with a uracil base (U), and/or each U may independently and optionally be replaced with a T. Target sequences listed in Table 8 contain U's, but binding of a DMD-targeting oligonucleotide to RNA and/or DNA is contemplated.

[000199] In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping) targets a region of a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping) targets a region of a DMD RNA (e.g., the Dp427m transcript of SEQ ID NO: 130). In some embodiments, an oligonucleotide useful for

targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a DMD RNA (*e.g.*, the Dp427m transcript of SEQ ID NO: 130). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to an exon of a DMD RNA (*e.g.*, SEQ ID NO: 131, 273, or 280). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to an intron of a DMD RNA (*e.g.*, SEQ ID NO: 269 or 277). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a portion of a DMD sequence (*e.g.*, a sequence provided by any one of SEQ ID NOs: 268, 270, 271, 272, 274, 275, 276, 278, 279, 281, and 323). Examples of DMD sequences are provided below. Each of the DMD sequences provided below include thymine nucleotides (T's), but it should be understood that each sequence can represent a DNA sequence or an RNA sequence in which any or all of the T's would be replaced with uracil nucleotides (U's).

[000200] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, mRNA (NCBI Reference Sequence: NM_004006.2)

TCCTGGCATCAGTTACTGTGTTGACTCACTCAGTGTTGGGATCACTCACTTTCCCCCTACAGGACTCAGATCTGGGA
GGCAATTACCTTCGGAGAAAAACGAATAGGAAAACTGAAGTGTTACTTTTTTAAAGCTGCTGAAGTTTGTGGTT
TCTCATTGTTTTTAAAGCCTACTGGAGCAATAAAGTTTGAAGAACTTTTACCAGGTTTTTTTTATCGCTGCCTTGATA
TACACTTTTCAAATGCTTTTGGTGGGAAGAAGTAGAGGACTGTTATGAAAGAGAAGATGTTCAAAAAGAAAACATTCA
CAAAATGGGTAAATGCACAATTTTCTAAGTTTGGGAAGCAGCATATTGAGAACCTCTTCAGTGACCTACAGGATGGG
AGGCGCCTCCTAGACCTCTCGAAGGCCTGACAGGGCAAAAACTGCCAAAAGAAAAAGGATCCACAAGAGTTCATGC
CCTGAACAATGTCAACAAGGCCTGCGGGTTTTGCAGAACAATAATGTTGATTTAGTGAATATTGGAAGTACTGACA
TCGTAGATGGAATCATAACTGACTCTTGGTTTTGATTGGAAATATAATCCTCCACTGGCAGGTCAAAAATGTAATG
AAAAATATCATGGCTGGATTGCAACAAACCAACAGTGAAAAAGATTCTCCTGAGCTGGGTCCGACAATCAACTCGTAA
TTATCCACAGGTTAATGTAATCAACTTCACCACCAGCTGGTCTGATGGCTGGCTTTGAATGCTCTCATCCATAGTC
ATAGGCCAGACCTATTTGACTGGAATAGTGTGGTTTGCAGCAGTCAGCCACACAACGACTGGAACATGCATTCAAC
ATCGCCAGATATCAATTAGGCATAGAGAACTACTCGATCCTGAAGATGTTGATACCACCTATCCAGATAAGAAGTC
CATCTTAATGTACATCACATCACTCTTCCAAGTTTGCCTCAACAAGTGAGCATTGAAGCCATCCAGGAAGTGGAAA
TGTTGCCAAGGCCACCTAAAGTGACTAAAGAAGAATTTTTCAGTTACATCATCAAATGCATATTCTCAACAGATC
ACGGTCAGTCTAGCACAGGGATATGAGAGAACTTCTTCCCCTAAGCCTCGATTCAAGAGCTATGCCTACACACAGGC
TGCTTATGTACACCACCTCTGACCTTACACGGAGCCCATTTCCTTCACAGCATTGGAAGCTCCTGAAGACAAGTCAT
TTGGCAGTTCATTGATGGAGAGTGAAGTAAACCTGGACCGTTATCAAAACAGCTTTAGAAGAAGTATTATCGTGGCTT
CTTTCTGCTGAGGACACATTGCAAGCACAAGGAGAGATTTCTAATGATGTGGAAGTGGTGAAAGACCAGTTTCATAC
TCATGAGGGGTACATGATGGATTTGACAGCCCATCAGGGCCGGGTGGTAATATTCTACAATTGGGAAGTAAGCTGA
TTGGAACAGGAAAATTATCAGAAGATGAAGAACTGAAGTACAAGAGCAGATGAATCTCCTAAATTCAAGATGGGAA
TGCCTCAGGGTAGCTAGCATGGAACAAAGCAATTTACATAGAGTTTAAATGGATCTCCAGAATCAGAAAACAGTAA
AGAGTTGAATGACTGGCTAACAAAAACAGAAGAAACAAGGAAAAATGGAGGAAGAGCCTCTTGACCTGATCTTG
AAGACCTAAAACGCCAAGTACAACAACATAAGGTGCTTCAAGAAGATCTAGAACAAGAACAAGTCAGGGTCAATTCT
CTCACTCACATGGTGGTGGTAGTTGATGAATCTAGTGGAGATCACGCAACTGCTGCTTTGGAAGAACAACCTTAAGGT
ATTGGGAGATCGATGGGCAACATCTGTAGATGGACAGAAGACCGCTGGGTCTTTTACAAGACATCCTTCTCAAAT
GGCAACGTCTTACTGAAGAACAGTGCCTTTTTAGTGCATGGCTTTCAGAAAAAGAGATGCAGTGAACAAGATTAC
ACAACCTGGCTTTAAAGATCAAAATGAAATGTTATCAAGTCTTCAAAAACTGGCCGTTTTAAAAGCGGATCTAGAAAA
GAAAAAGCAATCCATGGGCAAACTGTATTCACTCAAACAAGATCTTCTTTCAACACTGAAGAATAAGTCAGTGACCC
AGAAGACGGAAGCATGGCTGGATAACTTTGCCCGGTGTGGGATAATTTAGTCCAAAACTTGAAAAGAGTACAGCA
CAGATTTACAGGCTGTCACCACCACTCAGCCATCACTAACACAGACAACCTGTAATGGAAACAGTAACTACGGTGAC
CACAAGGGAACAGATCCTGGTAAAGCATGCTCAAGAGGAACTTCCACCACCACCTCCCCAAAAGAGAGGCAGATTA
CTGTGGATTCTGAAATTAGGAAAAGGTTGGATGTTGATATAACTGAACTTCACAGCTGGATTACTCGCTCAGAAGCT
GTGTTGCAGAGTCTGAATTTGCAATCTTTTCGGAAGGAAGGCAACTTCTCAGACTTAAAAGAAAAAGTCAATGCCAT
AGAGCGAGAAAAAGCTGAGAAGTTCAGAAAACTGCAAGATGCCAGCAGATCAGCTCAGGCCCTGGTGGAAACAGATGG
TGAATGAGGGTGTTAATGCAGATAGCATCAACAAGCCTCAGAACAACTGAACAGCCGGTGGATCGAATTCTGCCAG
TTGCTAAGTGAGAGACTTAACTGGCTGGAGTATCAGAACAACATCATCGCTTTCTATAATCAGCTACAACAATTGGA

71

TTTCTCTGCTTGATCAAGTTATAAAATCACAGAGGGTGATGGTGGGTGACCTTGAGGATATCAACGAGATGATCATC
AAGCAGAAGGCAACAATGCAGGATTTGGAACAGAGGCGTCCCCAGTTGGAAGAACTCATTACCGCTGCCCAAAATTT
GAAAAACAAGACCAGCAATCAAGAGGCTAGAACAAATCATTACGGATCGAATTGAAAGAATTCAGAATCAGTGGGATG
AAGTACAAGAACACCTTCAGAACCGGAGGCAACAGTTGAATGAAATGTTAAAGGATTCAACACAATGGCTGGAAGCT
AAGGAAGAAGCTGAGCAGGTCTTAGGACAGGCCAGAGCCAAGCTTGAGTCATGGAAGGAGGGTCCCTATACAGTAGA
TGCAATCCAAAAGAAAATCACAGAAACCAAGCAGTTGGCCAAAGACCTCCGCCAGTGCGCAGACAAATGTAGATGTGG
CAAATGACTTGGCCCTGAAACTTCTCCGGGATTATTCTGCAGATGATACCAGAAAAGTCCACATGATAACAGAGAAT
ATCAATGCCTCTTTGGAGAAGCATTATAAAAGGGTGAGTGAGCGAGAGGCTGCTTTGGAAGAACTCATAGATTACT
GCAACAGTTCCCCCTGGACCTGGAAAAGTTTCTTGCCCTGGCTTACAGAAAGCTGAAACAACCTGCCAATGTCTTACAGG
ATGCTACCCGTAAGGAAAAGGCTCCTAGAAAGACTCCAAGGGAGTAAAAGAGCTGATGAAACAATGGCAAGACCTCCAA
GGTGAAATTGAAGCTCACACAGATGTTTATCACAACTGGATGAAAAACAGCCAAAAAATCCTGAGATCCCTGGAAGG
TTCCGATGATGCAGTCTGTGTACAAAGACGTTTGGATAACATGAACTTCAAGTGGAGTGAACCTCGGAAAAAGTCTC
TCAACATTAGGTCCCATTTTGAAGCCAGTTCTGACCAGTGGAAGCGTCTGCACCTTTCTCTGCAGGAACCTCTGGTG
TGGCTACAGCTGAAAGATGATGAATTAAGCCGGCAGGCACCTATTGGAGGCGACTTTCCAGCAGTTCAGAAGCAGAA
CGATGTACATAGGGCCTTCAAGAGGGAATTGAAAACCTAAAGAACCTGTAATCATGAGTACTCTTGAGACTGTACGAA
TATTTCTGACAGAGCAGCCTTTGGAAGGACTAGAGAAAACCTTACCAGGAGCCCAGAGAGCTGCCTCCTGAGGAGAGA
GCCCAGAATGTCAGTCCGCTTCTACGAAAGCAGGCTGAGGAGGTCAATACTGAGTGGGAAAAATTGAACCTGCAGTCTC
CGCTGACTGGCAGAGAAAAATAGATGAGACCTTGAAAAGACTCCAGGAACTTCAAGAGGCCACGGATGAGCTGGACC
TCAAGCTGCGCCAAGCTGAGGTGATCAAGGGATCCTGGCAGCCCCGTGGGCGATCTCTCATTGACTCTCTCCAAGAT
CACCTCGAGAAAGTCAAGGCACTTCGAGGAGAAAATTGCGCCTCTGAAAAGAGAAGCTGAGCCACGTCAATGACCTTGC
TCGCCAGCTTACCACCTTTGGGCATTAGCTCTCACCGTATAACCTCAGCACTCTGGAAGACCTGAACACCAGATGGA
AGCTTCTGCAGGTGGCCGTCGAGGACCGAGTCAGGCAGCTGCATGAAGCCACAGGGACTTTGGTCCAGCATCTCAG
CACTTTCTTTCCACGTCTGTCCAGGGTCCCTGGGAGAGAGCCATCTCGCCAAACAAAGTGCCCTACTATATCAACCA
CGAGACTCAAACAACCTTGCTGGGACCATCCCAAAATGACAGAGCTCTACCAGTCTTTAGCTGACCTGAATAATGTCA
GATTCTCAGCTTATAGGACTGCCATGAAACTCCGAAGACTGCAGAAGGCCCTTTGCTTGGATCTTTGAGCCTTGATCA
GCTGCATGTGATGCCTTGGACCAAGCACAACCTCAAGCAAAATGACCAGCCCATGGATATCTGAGATTTATTAATTG
TTTGACCACTATTTATGACCGCTGGAGCAAGAGCACAACAATTTGGTCAACGTCCCTCTCTGCGTGGATATGTGTC
TGAAGTGGCTGCTGAATGTTTATGATACGGGACGAACAGGGAGGATCCGTGTCTGTCTTTTAAACTGGCATCATT
TCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATACCTTTTCAAGCAAGTGGCAAGTTCACAGGATTTTGTGA
CCAGCGCAGGCTGGGCCTCCTTCTGCATGATTCTATCCAAATTCGAAGACAGTTGGGTGAAGTTGCATCCTTTGGGG
GCAGTAACATTGAGCCAAGTGTCCGGAGCTGCTTCCAATTTGCTAATAATAAGCCAGAGATCGAAGCGGCCCTCTTC
CTAGACTGGATGAGACTGGAACCCAGTCCATGGTGTGGCTGCCCGTCTGCACAGAGTGGCTGCTGCAGAACTGC
CAAGCATCAGGCCAAATGTAACATCTGCAAAGAGTGTCCAATCATTGGATTACAGGTACAGGAGTCTAAAGCACTTTA
ATTATGACATCTGCCAAAGCTGCTTTTTTCTGGTGCAGTTGCAAAAGGCCATAAAATGCATATCCCATGGTGGAA
TATTGCACTCCGACTACATCAGGAGAAGATGTTTCGAGACTTTGCCAAGGTACTAAAAAACAAATTTTCAACCAAAAG
GTATTTTTCGAAGCATCCCCGAATGGGCTACCTGCCAGTGCAGACTGTCTTAGAGGGGGACAACATGGAAACTCCCG
TTACTCTGATCAACTTCTGGCCAGTAGATTCTGCGCCTGCCTCGTCCCCCTCAGCTTTTACACGATGATACTCATTCA
CGCATTGAACATTATGCTAGCAGGCTAGCAGAAAATGGAACACAGCAATGGATCTTATCTAAATGATAGCATCTCTCC
TAATGAGAGCATAGATGATGAACATTTGTTAATCCAGCATTACTGCCAAAGTTTGAACCAGGACTCCCCCTGAGCC
AGCCTCGTAGTCTGCCCAGATCTTGATTTCTTAGAGAGTGAGGAAAAGAGGGGAGCTAGAGAGAATCCTAGCAGAT
CTTGAGGAAGAAAACAGGAATCTGCAAGCAGAATATGACCGTCTAAAGCAGCAGCACGAACATAAAGGCCCTGTCCCC
ACTGCGCTCCCCCTCTGAAATGATGCCACCTCTCCCAAGATCCCCGGGATGCTGAGCTCATTGCTGAGGCCAAGC
TACTGCGTCAACACAAGGCCGCTGGAAGCCAGGATGCAAAATCTGGAAGACCACAATAACACAGCTGGAGTCAAG
TTACACAGGCTAAGGCAGCTGCTGGAGCAACCCAGGAGGAGGCCAAAGTGAATGGCACAACGGTGTCTCTCCTTC
TACCTCTCTACAGAGGTCCGACAGCAGTCAGCCTATGCTGCTCCGAGTGGTTGGCAGTCAAACCTTCGGACTCCATGG
GTGAGGAAGATCTTCTCAGTCTCCCCAGGACACAAGCACAGGGTTAGAGGAGGTGATGGAGCAACTCAACAACCTCC
TTCCCTAGTTCAAGAGGAAGAAATACCCCTGGAAGCCAATGAGAGAGGACACAATGTAGGAAGTCTTTTCCACATG
GCAGATGATTTGGGCAGAGCGATGGAGTCTTAGTATCAGTCATGACAGATGAAGAAGGAGCAGAATAAATGTTTTA
CAACTCCTGATTCCCGCATGGTTTTTATAATATTCATACAACAAAGAGGATTAGACAGTAAGAGTTTACAAGAAATA
AATCTATATTTTTGTGAAGGGTAGTGGTATTATACTGTAGATTTTCAAGTCTGTTATTGTTTTGTAA
CAATGGCAGGTTTTACACGTCTATGCAATTGTACAAAAAGTTATAAGAAAACCTACATGTAAATCTTGATAGCTAA
ATAACTTGCCATTTCTTTATATGGAACGCATTTTGGGTGTTTAAAAATTTATAACAGTTATAAAGAAAGATTGTAA
ACTAAAGTGTGCTTTATAAAAAAAGTTGTTTATAAAAAACCCCTAAAAACAAAACAAACACACACACACACATAC
ACACACACACACAAAACTTTGAGGCAGCGCATTGTTTTGCATCCTTTTGGCGTGATATCCATATGAAATTCATGGCT
TTTTCTTTTTTTGCATATTAAAGATAAGACTTCTCTACCACCACACCAAAATGACTACTACACACTGCTCATTGAG
AACTGTGCTGAGTGGGGCAGGCTTGAGTTTTTCAATTTTATATATCTATATGTCTATAAGTATATAAATACTATAGT
TATATAGATAAAGAGATACGAATTTCTATAGACTGACTTTTTCCATTTTTTAAATGTTTATGTCACATCCTAATAGA
AAGAAATTACTTCTAGTCAGTCATCCAGGCTTACCTGCTTGGTCTAGAATGGATTTTTCCCGGAGCCGGAAGCCAGG
AGGAAACTACACCACACTAAAACATTGTCTACAGCTCCAGATGTTTCTCATTTTTAAACAACCTTTCCACTGACAACGA
AAGTAAAGTAAAGTATTGGATTTTTTTAAAGGGAACATGTGAATGAATACACAGGACTTATTATATCAGATGAGTA
ATCGGTTGGTTGGTTGATTGATTGATTGATTGATACATTCAGCTTCTGCTGCTAGCAATGCCACGATTTAGATTTA
ATGATGCTTCAGTGGAAATCAATCAGAAGGTATTCTGACCTTGTGAACATCAGAAGGTATTTTTTAACTCCCAAGCA
GTAGCAGGACGATGATAGGGCTGGAGGGCTATGGATTCCCAGCCCATCCCTGTGAAGGAGTAGGCCACTCTTTAAGT
GAAGGATTGGATGATTGTTTATAATACATAAAGTTCTCTGTAATTACAACATAAATTATTATGCCCTCTTCTCACAGT

CAAAAGGAAGTGGGTGGTTTTGGTTTTTGTGCTTTTTTAGATTTATTGTCCCATGTGGGATGAGTTTTTAAATGCCA
 CAAGACATAATTTAAAAATAAAATAAACTTTGGGAAAAAGGTGTAACACAGTAGCCCCATCACATTTGTGATACTGACAG
 GTATCAACCCAGAAGCCCATGAAGTGTGTTTCCATCCTTTGCATTTCTCTGCGAGTAGTTCCACACAGGTTTGTAAAG
 TAAGTAAGAAAGAAGGCCAAATTGATTCAAATGTTACAAAAAACCCCTTCTTGGTGGATTAGACAGGTTAAATATATA
 AACAAACAAACAAAAATTGCTCAAAAAAGAGGAGAAAAAGCTCAAGAGGAAAAAGCTAAGGACTGGTAGGAAAAAGCTT
 TACTCTTTTCATGCCATTTTATTTCTTTTTGATTTTTAAATCATTCAATAGATACCACCGTGTGACCTATAATT
 TTGCAAATCTGTTTACCTCTGACATCAAGTGTAATTAGCTTTTGGAGAGTGGGCTGACATCAAGTGTAATTAGCTTTT
 GGAGAGTGGGTTTTGTCCATTATTAATAATTAATTAATTAACATCAAACACGGCTTCTCATGCTATTTCTACCTCAC
 TTTGGTTTTGGGGTGGTTCCTGATAATTGTGCACACCTGAGTTCACAGCTTCACCACCTTGTCCTATTGCGTTATTTTCT
 TTTTCTTTTATAATTCTTTCTTTTTCTTTCATAATTTTTCAAAAAGAAAAACCCAAAGCTCTAAGGTAACAAATTACCAA
 ATTACATGAAGATTTGGTTTTTGTCTTGCATTTTTTTCTTTATGTGACGCTGGACCTTTTCTTTACCCAAGGATTT
 TTAAACTCAGATTTAAACAAGGGGTACTTTACATCCTACTAAGAAAGTTAAGTAAGTAAGTTTCATTCTAAAAT
 CAGAGGTAAATAGAGTGCATAAATAATTTTGTTTTAAATCTTTTTGTTTTTCTTTTAGACACATTAGCTCTGGAGTGA
 GTCTGTGCATAATATTTGAACAAAAATTGAGAGCTTTATTGCTGCATTTTAAGCATAATTAATTTGGACATTATTTTCG
 TGTGTGTCTTTTATAACCACCAAGTATTAACTGTAAATCATAATGTAAGTGAAGCATAAACATCACATGGCATGT
 TTTGTGCTTTTTCAGGTACTGAGTCTTACTTGAGTATCATAATATATTGTGTTTTAACACCAACACTGTAACAT
 TTACGAATTATTTTTTAACTTCAGTTTTACTGCATTTTCACAACATATCAGACTTCACCAAATATATGCCTTACT
 ATTGTATTATAGTACTGCTTTACTGTGTATCTCAATAAAGCACGCAGTTATGTTAC (SEQ ID NO: 130)

[000201] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, exon 43

(nucleotide positions 6362-6534 of NCBI Reference Sequence: NM_004006.2; nucleotide positions 1056909-1057081 of NCBI Reference Sequence: NG_012232.1)

AATATAAAGATAGTCTACAACAAAGCTCAGGTGCGATTGACATTATTCATAGCAAGAAGACAGCAGCATTGCAAAG
 TGCAACGCCTGTGGAAAGGGTGAAGCTACAGGAAGCTCTCTCCAGCTTGATTTCATGGGAAAAAGTTAACAAAA
 TGTACAAGGACCGACAAGG (SEQ ID NO: 131)

[000202] *Homo sapiens* dystrophin (DMD) exon 43/intron 43 junction (nucleotide

positions 1057052-1057111 of NCBI Reference Sequence: NG_012232.1)

AGTTAACAAAATGTACAAGGACCGACAAGGGTAGGTAACACATATATTTTTCTTGATACT (SEQ ID NO: 268)

[000203] *Homo sapiens* dystrophin (DMD), intron 43 (nucleotide positions 1057082-1127546 of NCBI Reference Sequence: NG_012232.1)

GTAGGTAACACATATATTTTTCTTGATACTTGAGAAATGATTTGTTTTTCAGGGAAGTGTAGAATTTATTTTCAGTAC
 CCTCCATGGAAAAAAGACAGGGAAAAAGAGTATCACTCTCATTGAAAAATGGTAAGTAAATGAGAACAATAATG
 ATGAACAATTCAGACAAATGAGCTGAAGTGTAGAAATTTATTCAGTATTAAATTTAGCGTTATGTTGAAGCATTATAT
 CTTCTAAAATTTTCAGGTAATCGTAAATCAGATTGGGGCATTGAGGTGCTATAAACAGTTGTTTCGATATAACATATTT
 ATCTTTAGTCAAATCTGTATCTACAAATTTATAGGAGTTTGATACTTAGATTAAACATGTTTTAAATACTACCTATCA
 ATAAAAAATTTGATTTTCATTTATTTATATTTTGGAGGGTGACACTTTACACTTTGCATTACCCCTCCCCACATTTT
 TTTTTGCCATGGGGAATTTGTTAAGTTGATTTAAATCATGTTTCTTTTTATCTTAATTGAAATATTTAGCTGTTGA
 CTTAATTGGGGGGTGGCAGAAATTCATTTACATTATTTAGCTTCACATCACAAGAAGTGGATTACTCTTTCTTTTAC
 ATTTTATAGATTAAAGTAATAAAGTCTCTAACAGCTTAAAGTGATTTCATTTTCAGAAGCTTTTATCCTCAAGGTAGG
 CTTCTTAATTATTTTCAGAGGAATCAAATCATTGCTCTAATAATTATAGGGAACCTCCATGGTATCTCTTACATCT
 GTCCATTTCTAACCATCTTTACTCCTATTTTAGTTCTTGGTTTACTACATCAGGCACCTAAAGAGAGATTTCTAGCA
 TTAATCTCAGTTGTCTCAAGTGATTATCTCCACTTTGTTCTCAACGATCTTTTCAGTGGCCGTCATTTTTCTAAAGTG
 TAAGAGCTTTGGTACTATAATCTCATTCCCTTGAGAATGAAACCTGACTCCTTAATTGTGCAAAATATCTGGTCA
 GCCTCACTGCTTATTTCTTCGTGCCTGCCCTATAGCAAGCCCCCTCAATTATGTTCTAGCGATATTAATCAATTTG
 CAGATGCCCAAGTGTGTTTGTACTCCCTCTGACCTGCCTGTTCTTCAGGTCTCACTTCAGATGTTGTCTTTTTCTAGA
 AATCCTAAACTATTAGTCGCTCCTAACATCTGGAACCTGGATATTGTTTCATCATTTAATGTAATTTAATATCAA
 TAAATCATTTATGCATTTGTAAATTTTCAGACTTGGTGGCTACCGTGTAGAATATATGATCTGATGTGCCTGCTCC
 TAAAACCTAACACATAGTAATCAATTTGTTTACTTTCTGCCTCCCACACAAGCTCCTTATAGAAAAGGGCTATGTT
 TTATTTGTGTTATATGCTCAGGACTGATATAGTGTGAGCACAAAGTGGGTGTTCAATGTGTCTGGACTCAAGCCTC
 CTCTCCGAAACCTGAGAATATTTCCCTTTGGATAGTCTACCAGATTTATCTCACTGCACCTTCCAGGGCAGGTGCG
 GTGGCTCATGTCTGTAATCCAGCACTTTGGGAGTCCAAGGCGGGCACATCATTGAGGTGAGGAGTCCGAGACCAG
 CCTGGCCAACATGGTGAAACCTTGTCTCCATTAAAAATACAAAAATGACCTGTGCGTGGTGGCATGCGCTTGTAGTC
 CCAGCTACTCGGGAGGCTGAGGCAGGAGAATCCCTTGAAACCCAGGAGGCAGAGGCTGCAGTGAGCCCAAATCCACCA
 CTGCATTCCAGCCTGGGTGACAGAGCAAGGCTCCGTCTCAACAAAAACAAAAACAAAAACAGATTTATCTC
 AACTTCCTTGAAATAGCTGGTCCACAGTATCCAAAGCCAGGCTTGATAAAGGCAAGAAACTCAGCCACTCTGTG

TATATGCTACAAATACAACTTAACTTATAAAATGGTGGCTCATGCCTGTAATCCCTGTGCTTTGGGAGGCTGAGG
CAGGAGGGTCACTTGAGCCCAGGAATTCAAGGCTGCCACGAGCCATGATTGTGCCACTGTACTACAGCCTGAGTAAC
AGACTCTCTCTAAAATAAATTAACAAAAATATTTGAATAAACTTATATCGCCACCATGGTGTACTTTCTCCCAGCAT
TTCACATTGAGACATTATGAGGCTCTGCGGGCTACTCCAATGATGTCAGTTTCATTACCATCTTTTGGGATGTTTCAT
TCCACTCTTGGGAAGTTCTTCCCCCTCTGGTTTGTCTTCTTATAGTCAGTGTTTTCTCCAAGCATCTTAGGCCACCC
ACACCATCCCCTAAGGACCGTTGAGGTTTCTTGATAGCCAGTGATTACTGTGCTTCTATATACACCTACCAGTTTT
GCATAAAGTAGAAATAACGCTTTCTGCTTTTTGAGGTTTCTCCTCCGCTTTACTCATGAGTAATTTTTGGCAAATG
ATCCAGGTATTCCTTCTCACTGGGTCATATGGACATTTCCCTTTCAGTTTACCTTCACCTTAGACTTAAACAGAAA
CACTAACGCCATTCCACAGAGAGGGTCGCTGAAATCTCACCCCAACTCTGAGGACTTTTCTGGTTTTGACAAAAGGAT
AGAGTTTTCTCTAGCCCCAATAGATCCACCCTGTCTTATCCAGAGGTTGAAATTGTACTTCCATTGACATTCTATAG
GAATTGGTCAGGAGCTGTTAAATTTCTTATGACTTTTAGTACAATCTCAGATACAAACTGTTTTAAGTAATTGCTTA
TAAGCACAGGCTCTAGAGTTCCAACCCGTTTTTGGAAATCTGGCCTTTCTGCTATCTATGTGCCCTTGAGCAAGTCTC
TTAAATCTTCTGCTCCATACATTTCTGATGTATAAAATAGGATAAGAATAGTGTCTATGTCACAGGGTTGTTATGAG
GATTATCTGACACAATATATGTGGGGAGCTTAGTGGGTTGCTTAAACACGATAATGGCTCAGTTAAGGTTGGCAATT
TTGATGATGAAAATGGTGATCTTATGGTTCTGATAGTCATGATATCTGTTAATTCATTCTTACATGCTTTCAAATTT
CCCTGAGAAGTACAGAGAGAAGAATTAGACTCAGTCCCTGCTTTGAAGAGCTTCACAGTCTTGAGAGAAAAGGCAC
AACCAGCCAGTAAAATAAGGGTTGATAGACTGGAGCTGTACAAGAGGGCAAGAACAAGATCCCTGGGGAATGGAATG
AAGCTATCTTACTAAGAATGGGGAATAAGTCAAGGCTATAGACCATTCAAGGTTCTGAGTTACAACCTAACAGAAAAG
TGACTCTAGTTACTTTAGGTAGAATTATATAAAATTAAGGATATCAGATACCTCATGGAATCAATAGGAAAGC
CTGAGAGCTAGGTTTAAACAATGGGCAGAACTATAAAGGAAGAGCAGGCTAGGCATCCAGAATATATCTACTATCAA
GCTATGAGGTAAATCTGAATTATTTTGTCTGTCATGCCAGAGTCCATTGCTTTACCAGGAGCACCATTGCACTGGACA
TTGCTTGTCTATCGTCACTGCAAAAAAAAAAGTATCTAAATATTTATTTCTTGTCTGTGTCTCGTCACTTCTACAAC
GGTCTCTGGCAGAAGCATCTGATAGTCAGAGGATGGATATTTTTTCTGTAAAGGGGCAGTTAGTCGATATTTTTGT
CCCTGCAGGTCATGTAGTCTCTGTCACTACTCACTCTGCTGTTTTAGGGTGAAAAAACCATGTATAATATAT
AAATGGATGGACATGTTGTGTTTTAAATAAACTTTATTTACCAAGGCAGATGGCAGGCTGGAATTGCTGATGGGCCA
TAGATTGATGACTGCTGTTTACAATACAGGTTTAGGCCACAGAACTAGGTTCTTATTGCCAGAGATCAGGAAAAATAA
ATAGCTGAATTTGTTCTTCTTATTGTAGTGGCAGTCAACACCTCGTGTCTACTAAGTCCCATACAATGGTAGATTCTT
GAATCCTTGGAGAGATTTAGAAGCTATGCATTCTGAATACACAAATGTTTCACTACAGCCTTCATGTGGTGTCTCA
ACAAAAATCTGCTGAGTTTTTTTAGTAAGCCAATTTGGGTAAATCAAAATAAATTTGAGCTAGTAAGAAGGGCTATA
TTGGTATTTTTCTTAAATGGTACATGTATGGTAGTATTAGCTATGACCGCAATAATGCTGTGACACAAATCACCTTA
GAACCTGCTGACTGAAAACAACAGGCATTTCTGGCTGTTTAGGTTACTTGTACCTTGACTGACTCAGCTGGGCTTGG
CCGGGAAGCTCTGCTTCAAGATGTGGGTTAGTAGAGCTAGGTTCCATGATGCATGTTGGATTAAAGGCTGCTATATA
TGTCTTTGCTCTGGACCTAAGATGAAGGGTCAGTGACATGTTTTCATGACCAGTCACCAAAGTATAAACCTAAACCT
CCCAAGAACACTCATGGCCTCTGCTCCTGTGAAGTTCAGTGACATTTGATTGGCCAAAGCAAATTACGTTGCCAAAT
CTGACATCAATAGAATGAGAAAGTAGACTCTTCTACAGTGGAAGGGGGAGAGATGTTAATATTTGCTGAACCATA
ATTCAAATTATTAGAGATAGTTAATAATTTATAACAGGATTGTTTTACAGCTAGAAAATGCCTTAGTGGTTTTGCCC
TGCTTCATTATTTTATAAGGGAGAAAACTATATTTCAAAGATGTTATGTGACTTGCCTAAGCACATACTAAATAGTA
CATCTGCGTATTTCTCGTTTCACTCATCTCTATTAATGTCATAAGGTAAAAACAGACATTACGCTTTAGATGAGAACA
GGAAGATATTTAAAAAGCCAGACTAATTTATGACTGCTCATTCTATCTAACATACCTGCTTCCATACATTGTCTT
TCAGCAAATAGAATTTCAACATGTATCTCAACAAGTTACACATCATCAAAGTATTTAAAGCCTTATTTTCACGGACA
TTCTGATTGTTTCACTAACAGTCAACACAGTCAACAGTAAATCCACAAGCACCATGAACGTATGGATAGATATGCCA
TATGTAAGATTACTAGTTAATCTTTTGGGAAATTAATATTACTGCTAAATTCAGTTTTTCACTGATTGTTGGTGGG
AACTAATGCTTTATAAAATATACCTATAGGAAACATGTAAAAACAAAGAAATTTACATAAGATCTATCTGGGATTAGA
GAAACAAAGCTCTTTTCTTCTTCAATGAACACTTAAGAGGGCCTACTAAATGTGAGATGTTTATACTCTATTGTCTG
TTAGTTTTCTTCTGATACCATCTTTACTATCTGTAAAGCCATTAGTGAGTGTTCCTTCTTCTTCTGATGTGGATGCTGCTTG
CAAAGACTAAGAGGGTAGAACAGTTCAAATGCTATCATCAAAATGAAGGCAGTTTCTAGACTACAAATGCTGTACA
GCCATAAGATGGCATTATTGTGTAACAACAAGGTCCTGTCAAACATCAAGAAAGTAATGTTTTAAATCAGTATTT
CCTTCTTGGAAATTTACTTAGTCAGATATGTTGGGTTGACTTACCCACCCATATAAGTAGTTAAATTCAGATGGTT
CTGAGCTTTAGATATGATGTAAATAGACATGAGACTAAGAGTATTTATTTCTATATTATTACATTTCTATAGCAAA
AAAAGAAACCTCTAAAAAAATAGAGAAAGAAGTATAAGGGCATTTAATTAATCAAATGTTCTTATTAATAATATTT
CATAAAATAAAGGAAATGTTGAAAAATAAAATATGAACACAGTGTGTATAAAGTAAGTCAGAAATAAGAGAACACT
TACTGTATGAATCTATTATATGAAACTAAAAAATTAGGCACCTTTGGAGTTTAGAGGTCAGATAGGAGTTACCTTTGT
GAGTTGTGATTAAACAAGGGCTGAAGCAGGCTTCTAGGGACTGGGTAATGTTTTGTTTCTTGTATGTGGATGCTGCTTG
CATTGATGTGTTTTCTTTAGGGAAGTTTATGGAACCATACACTTGTGATGTGTACACATTTCTGTGTGAATGCTGGA
CTGAACATAAATTTATACTTACATTTTAAAAATAATAAATATGTACTTTAAGTACAGGAGGGACATAAATCATAATT
GTTTTAATAAAGAAGGTGTAGCTTTAGGAAAAGCATACCGCATTTGTTCTATTTTTTGGCATTTCACCATGGACCCCTG
AACATTTTATAATTGCCAGTACAGCCTGTGAGATAAATATGTGGGCACTACTGCTTTAGAGAAAGTATTTTCCAAA
TTTATCACCACTTCTGGAACCACAGTTCACAGGTCATTAGGATGCTGAGGGTGGGACAGTTGGAAGCTGCTTCC
CCAGGATTTCTCCATTGTTTCACTTCTCATAGCAGTAAGCCTGCAGCATTAAAGCACTACAGGCTCTGGCTGCCAT
TTGTGCTACATGAGAAGAAATGAGAAAATGAAAGAAACGAAAGGAGAGAAAACAGGAGTAGAAACCAATAAATCAG
ATTGGAAGAGAAAGTCCCTAATCGTCTCTGTATTTCAGACAGTAGGGGAATGAGCATGCAATTTCTGCAAGCCCATTCCT
AATGTGAGTTTCTGATAAGAATTTGCTATCTCAGTTGTAATCTTTCTACTGAGACATTCAATAAATAATTTTCTTTC
ATGTCAAGGTAAGGAAATAACCTCACATTACCCATATAAGGAAAGAAATAGTATACTAATCCTCACGTTATCACTATA
GAATTTTATCTTTTAAAGTGGAAGCTAGAGGGACAGATGCATAATCTGGGAGCTTTTCCAGAATTGTTTGTCTCTAA

75

TGTTCTGGTTTTTACCCTCAAGATCTTCTTTGAAAAATCATGATTACTAAGTAACTAGTTGGATAGAATTCATTTTT
AAGAAAAATAATGAATAAGTAGTTCCCTTAGATATAGCAAGCAATGTTCTTATAAACTGACACACCAAAACACTTACC
AGTTCACCTAAACACTGAAAGTATTTAAAAATTTATTTTTAACTTTAAGTTTTTCTCCATTTGAGTATCTTGTGCA
CTATACGCTCTCCTACATATGTCTACAATCTTTGGTCTGATTATTTTTATTGGTTGTTGAATGTCAGAAACCACCTG
AATTTTGCTTGTATATATAATGCCAGTAGAGTGCACATTGGTAATCAATACGACTTGATGATAATAATGGTAATGA
ACACTATAATTTGATAGCATCAACTTGGCATGTATGCCAGAAAATAAACCATCATAAACTTCGAGAAAAACAAGTCTC
ATTAATCTGTCAATTTATTATAATCTCCCTCCATCAAGCGTAGCCTCTATATACTGTCTTTTTTGGCATATGTAAGTT
TCTTCTTGATATATTTAGATTAGAGCTTGCCTCCTCCCACACACTATCTTCTATTTACACTGCTCTGTTCAAGTGT
TTATGTTTTCTGTGAAGGCTGTATAATCTAAGATAAATCCCTAGCTATTGTAAATATCATTCACTGGCCAGTCATTGC
ATTTTGCACACCACTGAGAGAGTGATTGTGAGCCAAATAGAGGAGATTTTTGTTTCCACCCAGCAACCCAAAATGAAT
TGTGTGATTTGACTATTGATGCCAATTACATGGAAGTTTTACTACCAGAGGCAAAGCTTTAAACTGCAAAAGATTAA
CCCCATATAGTTGGTGTGATGAGGTATTTAATGTATATTGGACTATCAAAGCGTCTCCTTACAACAAACCAATTATC
AATGAATAATATTCTTATCTTATTGTGACTTATTGAAACTCTTTAAAAAACATGAACCATTTCAGCACACTATACCGT
CTAAATTAGATATCTAACTAGCCTTCATTTACATTTCTTGTGTTAGTTTTAAATATAATTTCTTCTGAATTCCTAG
TTGTTAAGAGCAGGTGGTGAAAGAATTTAAGAAGAAAAATTTGTTGTATTTATTAAGTGAAAGAGCTTTTTGAAATG
CATTAAATAGAAGTTTGTCTGCCCATCAGCTTATCTTCTGCATATTCCTATTTATAGTTCAAAGCACTTAAGAGT
TGCAGAGTGATTTGCTTTTTATGATCACCGCTTCATCCAGGATCATTGCTTATATCTTCAACATTTTCAGATTCT
TATAAATCTTCACAGTTCACTTAGAGGTTAGTTTAAACTTTCTTCAGATAAGAAATTGACTAGATATAAAATTCAC
ATAATCTCAGAGTTAGCCATAGATCAATATCCCCAGTCTTTTTCTCAAAGTAATTGAACATTTTTGTTTCCCAGGAT
AGTTGTATACAAGCATTTTCATCTCACCATAGATGATTCTTGTCTTCAGTATATGAGGGGACTGTATTTGCCTGC
TTGTTATCTAAATAAACATTTTTATTATTGTCAAAGGAAAAAGACTCTAATACAGAAAAGAAATTTGTGTCCATAGG
ACTAGCCTCATTTTGGAGGCTGATATTAATATTTGACTTTATTCATTGTGTATTTCTTGGTTTTGTCAATTCACAAA
TTTCCCTTCTCTAAATATGCATTTTTTCTCTACCTGGAATAGATGAGTTTTAAAAGACATTACTGTAAATAAAACT
GTGCTAAATGTACTTTTCCCAGAACTCTCTTATTTTATCAATTATAATTTGCTTTGGCTAAGTTGTACAGAAGCT
CAAGGTAGAAATGACTTAAATAAAAGAGAAGCCTATTCTTTCTCTGAAAAACCCTGGAAGTTTGCAAGCAAGGCA
GATATGTTGGCCCCGCTCATTTCTGTTTTCTACTGAGTGAGTTATCTTTACTTGGTGGAATTCATCCCAAGTTGC
AAGATGGAGCTCTCATGACATCCACATTCCAAGAAGGATGTAAGAAGGCCAGAAGAAGGGTCAAAGGGTGCATACCA
ATTGTCTTTTAGGGAAGTTTCGTGGGAGCTGCCATGTTATATTTCCACTTACGCTTCATTGGCCAGATGTCTGTCAC
ATGGCCACATCTAAGCTGCAAGTGGGGCTGGGAAATGTGTTTATTTACATGTGCTCTGCTAAAAACTGTTTCAGTCA
TGAAAAAAGAAAAAGAATATTGGAAGAGAACTAACAGTCTTCAACATGTATATTTAAAAAGAGCGTTATTTTTCTT
TTACTTATTTATTTTTTTTTGAGTGAGAGTGTTGCTGGGGCTGGTCTCAAACCTCCCTGGATGAAGTAATCCTCCCAC
CTCAGCCTTCTGAGAAGATGGGATTACAGAGGCACACCACTGCACCCGGCTCCTGTTTTGTTTTGTTTTGTTTTGTT
TTATTTAAGGAGCCCTAAGAAGAGTGTAAGAGGGCAACTTTGTCTTTAGTTAACCTTCCCTTTTTTTTTCTTTCC
TAATTTTATGAACCTCTGATTCAGCCCGCATCTTACTCTGGCTTACTAAATCTGCCAATATAAGAGTAGAAGTTTTC
ATCATTTCCCTAGGTACCTACTCTTCTGTTTCTCCATATTCTCAAAGTAATTTCTCATTTCATCAACTTTTGTCTGAC
TTAGATTTAAGCTACTGCTTAGGAAATGTGAGAAATGGAGAATTTGGTTGTATAGCGCTCCTACTTAGAGGGCTAA
TGCTTTCTAAATTTTACTAAAGTTGGATCCTAAGTTATATAAGTTACCTAAATTTAATTAGCAAGTTTTGCTTACT
AATTCACTGACTAACCACTATAAAACAAGGACCTAAGTTTAAAGCTGATATTATGACAATGTACTGAAATTTCAAGA
CATTACTTTTTCTGGACACGTAGGATGGACCTTGCAATAAGATAAAAGAGCTTATTTTTAGGCACACCTATGTGCCAG
GCATGGGTTTCAGAGCCTTACATATATCATTTCAATCTCAAGAGAACCTTAATTTTAGAGACGAATAATTTGAGTTT
TAGAATAAATAATTTGCTTAAAGCTCACACATGAAGTATGTGCCAGAGTCTATATCGTGACCCAGTTATGAATCTT
TTCCATCATAGCTGCTCCATCCATGGCATTTCACATAGGATTTCTTATGCTCAAGGATTATGTTCTTCCCTCCAGAT
CTATAGACATCAGTAGAAACAACACAAATACGTATAATGACTTTTTAAAGTCTCATATACAAGACCAAGTCAATTTA
AAAAGATGTTTAAATTTTTGAAGGTGATATCTTTATGTTTCGAGATCAGTAGCAGAAATGGATTGTAATTCATTACAA
GATGCTTAGCAAAGCCAAGTGGTAAAGGATTTTCTGATGTGCTTGAGGAGTCCCTGACTTGCTCCTTAGCAAATTCCT
ACACACCATTTCAGCATTTCAGTGCAAAATACCACCTCTTGAATCCTTCTCTGTTCTTGATCAATTTCCATTGTCTG
GATTCATAGAATCTCTGTTTACCTATTTATCTTACAGGTTATTTATCATGAGTTTATATGCTTACATAGCTGTTTG
CAACATGTTACCATTTCAGTGGAGTACTTTTTCTACAGGGAAGAGGCTGTACTATATACCTTTTGTACCCCTAAGT
GGAATGCAGTATGGTTTCATGTTAGATGTTCAATACATGTTAATATTTTATTGATGAGCCCTTAAATGTATATAATA
AGCTTCTCACTCAAAAGCTGTAATATTCTAGAATGAATAAGTTTCTTGAGAACTCTTTGGTTAACAGAATCTCCAT
TTCCATCATAGTGTATTCAATAAATTATTAATGCAGGGTAAATTTCTTATATTTCTTTTCAATTCGCTATACTAAG
GTCAAATCATGACTTTTAGGTGTGGATACAGCAATATATAAAATAATCTAAGACCTGGATATATGTTTTCTAATTA
GGGAATTGGAGATACATGAACAGTCTCTCATAGAGAAAAATATATCCATTAGTCACTAAAGTCAGTATAACATTCTG
GTGAAAGGTTTGCTTGCTTGCTTGCTTACTTGCTTGTTTACCTTCTATTCTAGGAGGATGTTTGTACAAAT
ATGAAATTCTAACGCTTTAAAAATCTGTTTACCCTATGAAAGTTGCAAATCTTGCTGTAAAGGCAATTTTCACAAG
AATTATTTTCATATTAGTTTTAGTTTATCCGTGGATAGTCTCAAATTCCTCTTGAAAAATACAGTGTTCTCAAGGGA
AAACTGCCCATTACAAGCCACAGATGTGGTTTTTGGAGAGATTTCTGCCTGAAATACAAGTTTTAAATATTCTTTG
TAGTTTCTAGTATGGCTAGATACTTGTAGGAAATGACAATTTAGATGCACATTTGAAAATCTTAGCCTTTGAGTA
ATTTATATGTTTGAATAATTTAACTATCTTGTTCATAAAAAGGCAAAATTTGTCTGTTTGTCTTGAAATGCTTT
TTTAGTTTCTTCTTCAAGTTCTTCACTTGCTTTCTGTATAATTTCAAAATTTAGCATAGTACTTGAAACCAAGGA
TGGTCCAGTCTGTGCTTTGTTTTGAAGGAATTTTGAATCATCAGAGATATAAATCTGGAATTTCTTTGGGTACC
TTCCATAAAATAGTAGCATCCTGATAAGGACGTAGATGCTAACTTTTATTTTTATCTCATTTTCTTTCCCTATCTC
TCAGTAATGTAGGAGTGACCAAGGTAGCTGTTTATTGGGCCCTCACCAAGTCAATCAATATTAGTCAGCTACAAC
CACAATAATGCTGTGTGACAAGCATACCCCAAAAGAACATAAGCACTTATCCTCATATTCACAGGCCTACTTTGAG

TAATCTCTGATTGAGAACTGACTGTAGGTTGACCAACATGTCTGATCTATGTGTCTCATTCTGGGGCTCAAGCTG
GAATGGCAGTAGATATTTGGGGCACATTCTCCATGGCTGAGTTCTAAAGATCTCAGAAGGGTAAGCAGAAACACAT
GATGGTTCTTAAGACCCAGATTTATAACTAGCGTTCTCTCTTCCATCCATAGTCAATTGTCAAAGCAAGTCACGTGG
CATATCCAAAGATCAGGGATAGAGAAATACACTTGGCAGTTAGTGAAACCCATTTCAAGAGTGTGGGTGTATAACACT
ACTACAAAACAGAACTGAGACTTGCAACTTGAAATACCACACCATTCTAGTAGAATTTTATTACAGTATTAATTAAA
CATTTTTGATAAAACACAGACAACTCTGTTAGAAAGCCCAACTTACAATTTGTTGATCCCACTTGGAAAGGTATTCT
GAATCCATTTTTTACAAAGTTTTCTTTCTAATTCATGTGTTGGGGTACTTTTTATTTTACCCAGAAAAGTAATATTA
TAAAGCATAAAGTTAATGCCCCCTGTAAAAATAGAATACTGAAACAACTTTAAGTCACAATTTTATTATTACTGA
CTTGAGAATCTCCTTGTGCTTCAGCACACTTGGTAGTTGGATTTCCAAATAGCATCATGACTTTCCATACCCAGCTG
TCTGCTGCTCAAAACTACCATAAGCTGACTATCACAGCTCACAGGATACCCTTGAAGAAGACCATCTGGTTTATGTC
TCTTGGCAAAATTTGTTTAAAAACAAGCAGCTGCATGACAAAAGTAAGAAAAGAGTCTCTGTCTAGCTGTGGTAAATAA
GTAGCTTTGCAATACTCATAATAAAGCATTTTTCTAATCCAAGCCAACATCTTCAAAAGGAAAGCATTATTTTCTTA
CAACTGAAAGAAAAATCTACAGAATTCAGTGATGAGGGAAGGACTCCATTAAATTTGTTTCAGCAGCTTGAGATAGT
GAGAAAAACAAAACAAAATAAAAACTGTTTGTGATTAGATACAGTCTTGTAATAACTAGTTTTAAAAGTATTTATT
TAGAATCTAATACTTGGATATTATTTAATTCTTTATATTAAGAGATTTACATTTTCAAAAAGCTTGCTCTTTGAAC
CCTAATACTCATATTGTGATGGTGAGCCGGAATGAGTAAGGTCACTTACTATATAGTCGGTATATAATAATTCTGTTG
AATAACTCTCTCTCCTCTGTTACTGGCAGTGAATCCATACGGGTCTTCAGCAACCTTAATTCATGCCTCCTCAGAA
GAAAGAATTCGACCAAGGAGGCATAAGGCAGAAAGAGAGACTGAGGCAAGTGTTAGAGCAGGAATGAAAGTTTTATT
AAAAACTTTAGAGCAGAAATGAAAGGAAATAAAGTACATCTGGAAGGGGGCCAAAGTGGGCGACTTGAGATATTAAGT
GTCCTGTTTGAACCTTTGATTTATGGTTTTGTATTTTGGCATACTTCCATGGTCTTATATACTTCTCCCAATTCTT
CCCTTGGGGTAGGGGGCTATCTGCATGCACAGTGGTCTGCTGACACTTGGGAGGGGAGCATGCACGGTGTATTTACT
GGAGTTGTATTCAAGAGGTGTTCCCTTACCAGTCAAGTGTTTCCAGAGGAAGGTCGTATACCAGTTACACTATGACA
TTTTGCCTCTTAGTGCGCACGCGGGAGCCCATTTGCCCAACTCTGCGATCTTATCGGGAAGCTGCTGATCACCAT
TTCAGGTGTTTTTATCTATTGGGAGACTGCCTTTCCCTGGTATTGGCTGTGACCAATTATTATTTTAAAGACACAGT
TTAATAACCACTGACTGACCATCACTTGATGGTTGCTTGACATTCTGTTGGGTGGCGGGGTGGGGGGTCTCC
TACCCTGCTCATATCTGACTATCTACTGTAACTACTATTAGGTATGTCTGTATCCCATTTACACTCACTCTC
TATTACAAAAAGAGTACCTTATTCATTTTTTCAAAAGAATGAGTGAATTTTCTGCTCCAGTTAAGTGCTTTTCTT
CCTCTATGTAGAGTGTCAAACTAGCCATGCTTAAAGATTGATTCTGGTATTAATAATATAAATTCTTGCAATTATGAG
TGTCTCAGTTTGGGTCTTTACATAAGCAAACTCTGAGACAAGGATGTGAGTTCAAATAGTTTCTTTGGGCAGTGATT
CTAGGAAGCTGTGGTAGGATGTTGGAGTTGTGAGAAAAGTTAAGAGAAAAGCAACCTGTAAAGAGTATGTTATCAAGCC
AAACACCACTGTGAGAACTAGGGCTTAATTCCTGGAGAAAAGTCTGGGAAGGCATAAAACACTTGTCTCAGAGTTAT
CTTAGACAAGGTGCAGGAGCTGAGGTGTTTATATTTCAACTCTTGTTAGTCACTTTTAAAGGGCCGCTCAGGGTGT
AGGGTATTAATTTCTCTTGCAACTACTTCCAACCTGTTTTTGCATGTGGTTGTAGCTACTTTTTCTGCGTCAAAGA
TAGACTTTAGGCTAAGACATGCAGTTTCCGGCTGTAGGACATCAACCAGAGTACCCTGGAGTGTCCAGGCCCAAGAT
AATGGGTGAGCTCCACCTGGATCTGTGGCAATGTGAGGGAGGGGCATTATTACCCTAGCAAGGGCCACTGCATTCC
CTATCCAGCTGGTCACTCTTCTGCGTATTTGTGTTACTTTTTCTGACTCCTGCATTCTCTGGATCCTGATTACCAT
CAGCTTTTGTATTCTGAGGCTTGTGTGGCTGTGCTTTCTATTTCTTCCCTTATTGACTTACTTGTTTAACTTTTGC
TAATGTATACCTTTGATATTCTATGTACTCACCTTTGGTTAGCTCTGTGAATTATTGAGTCTTGCTTTACAGCTTT
AAAAAGATCATAGCCATGGTTTGTTTTTTAAAGTGTGATTTCATAACAGTTAGTGACAAAATTAGAAGTGGAATTA
GGTCACGTGCACAATCCTACACAAGCCAATTTCTGAAACGACATAAAAACTTGAATTTGTCTTTTACTATCACCAA
TATAGAAAATATTTGGGGTATTTCTCAAAGTATTGATTAAACAAAACCTTTATTTTTGTGTGAAGATTTTTTCAAGT
CTCCTGGAATATTTCAAATTATTGTCTTTAAAGTCAAAGGAAAGGTTAATATTAGGGTTACTTTTTCTTTGGTCA
GAATTGCTGGAGGCTTCTATGACTTGTCTTGAAGCAGCTGACTTTATGACAGTTTTGGTTAGAAATTTCACTACCAA
TTCCAACATTTTTCAAAGTCTTAAAGACCAAAAGTACAATTTGAAATATCCCTAGAGAAAGCAAGAATAAATTAG
TTTTCACTAGAAATGAAGACAAATTTTTCTCATTAGTTCAATTTTGCCTCATGATCAGAATTTCTTGGCACATGAAA
TATTTTGGTTAATAGGTTGTAACATAAAGAGTAATATGAATAGAGATCTAGCCCAATTAGATGACAGAAAAAGAGCA
AAGCTTTTGAATGTATAAAGAAGAAAGTTAAGAGAGACATGAACAAGGCTGGATGTAGTTTAAAGTTGAAGAACA
CAGAAAAATGAGATAAGTGAAGTTAAGTGAATACTTCCCTTACTGAGAAGAAAGAGAACTCAAAATTATGTGAAG
GTTTTTGTTTTACTTTGTTTTGCTTCTAATAAGGAAACAACAGTGGCAAATCTGGGGCATTAGGAATGGTGGAACT
TCTATAACAGTGATGTTTCAAAGGTCACAAAGGAAATTAATTTGTAGATTGGGTTTAAAGCACTGGAATTACTTCC
AGCCCCATTTTTTCAAGGATTTTGTATGTAGCAGGAAATAGATCACCGCATAGCTAAAGGGGAGAATTTAGGTTTTAA
CTGGTCTCAGTGCAAACTGCTTCATAGTTCTTTGCATTTGGTGGTGTATGTAAAACATGAAAGGTATAAACATTTA
TTATCATAACTTTTATTATTATACAACATTTTATTGGCTGCATAGGACCATGTGTCTTCTTGCAAGGTATAATCAAAAA
TAAAAAGACAGAAATGTATCTTATATGAAGGCTGCCATTATCGCTCTTATCAATGGCCATAAAATCAGATTTCTTAC
ATGTACAACATATGAAAATATATTAATATGAAACGTTTTCCATTAAATAATTCTGTAAATGATTTTCAACATTT
CTGTCCATGATGTGTAATCTGTAGATCAAATACTGCAAGTGACAGAACTTAAATGCTTTGGTCAAAAAATTTCT
CTTATTAATATGACAATGGCGTTCAAAAGTAAAAAGGTAAAAATACAGTTTAGCATTAAATAAGTAACTCAGAAAGT
AAAATATATTGATCATAACAGTCTGTATTAGTCTGTTCTCATGCTGCTCTAAAGAACTGCCCAAGACTGAATAATTTA
TAAAGGACAGAGGTTTAAATTGACTCACAGTCCACATGGCTGGGGAGGGCTCAGGGAAAACTTACAACCATGCCAGA
AGGGGAAGCAATCAGATCCTTCTCATATGGTGCGAGAAAGGAGAAGTGGTGAGCAAGGGGGGAAAGCCCCCTTATA
AAACCATTTGGATCTCATGAGAACTCACTATCACAGAACAGCACCATGGGGATAACCGCCCTGTAATTCAATTACC
TCCAACCTGGGTCCCTCACATGACACATGGGGATTACAGGAACTACAATTCAGAAATGAGATTTGGGTGGGGACATAGC
CAAACCATATCATTTTATCCCTGGCCCCCTCCCAATGGCACGCTTTCACATTTCAAAACACAATAATGCCTTCCCAA
CAGTCACTCAAAGTCTTAACTCACTCTAGCATTAACCCAGGAGTCCAAGTCCAAGTCTCATCTGAGACAAGGCAAG

TCACTTCTGCCTAGGAGCCATAAAATCAAAAGCAAGTTAGTTACTTTCTAGGTACAATGGAGGTACCAGCATTGGTT
AAATACACCCATTCCAGATGGGAGAAAATTGGCCCCAAACAAAGGGGCTCCAGGCTCCATGCATGTCAAATCCAATGAG
GCAGTAATTAAATCTTAAAGCTCCAAGATAATCTCCTTTGACTCTGTGTCTCACATCCAGGTCACGCTGATGCAAGG
TGGGCTCCACAGCCTTGGGTAGCTCCACTCCTTTGGCGTTGCAGGGTACAGCCCCCTTCTGGCTGCTTTACAGG
CTAGCATTGAGTGTCTGTGGCTGTTCCATGCACACGGTGGATCAAGCCCTCTTCTCACAGCTCTACTAGGCAGTGCC
CCAGTGGGGACTCTATGTGGGGGCTCCAACCCACATTTCTCTTCTGCACTGACCTAGTAGAGGTTCTCTCTGAGGG
CCCCATCTCTGCAGCAAACCTTCTGCCTGGATATCTAGACATTTCCATATATCCTCTGAAATCTAGGTAGAAGTTCCC
AAAGCTCAGTTCTTGACTTCTGTGTACCCACAGGCTCAACACCACATGGAAGCTGCCAAATCTTGGGGCTTGACCC
TCTGTAGCCATGGGCTGAGCTCTATCTTGGCTCCTTTTAGCCATGGCTGGAGTGGCTGGGATGCAGGGCACCTAGTC
CCTAGGCTGCACATAGCAGGGGGGCTCTGGGCCCGGCCAGGAAACCATTTTGCCTTCTAGGCCTCTGGTCTATG
ATGGGAGGGGCTGCCATGAAAACCTTCTGGCATTTCCTGGAGACAATTTTCCCATTGCCTTGGTGATTAACATTTGGC
TCCTCGTTACATATGCAAATTTCTGTAGTCAGATTGAATTTCTCCTCAGAAAATGAGTTTTTCTTTTCTATTGCATC
TTCAGGCTGCAAATTTTCTGAACTTTTATGCTCTGCTTCCCTTTTAAACATAATTTCCAATTTCAAACCATATCTTT
GTGGATACATAAACTGAATGCTTTTAAACAGCACCCAAAGTCAAATCTTGAACACTTTGCTGTTTAGAAATTCCTTCC
ACCAGATGCCCTAAATCATCTCTCTCATGTTCAAAATTTCCACAGATCTCTCGGACAGGGGCAAAAAGCCACCAGTCT
CTTTGCTAAAGCGTAGCAAAGTGACCTTTACTACAGTTACCAAGAAGTTTCTCATCTCCCTCTGAGACCACCTCAG
TCTGGACTTTATTGTCCATATCACTATCAGCATTGGGTCAAAGCCATTCAACAAGTCTCTAGGAAGTTCCAAACTT
TCCCACATCTTCTGTCTTCTGACCCCTCCAATTCTCTAGGAAGTTCCAGAGTTTCCCATACTTTCTGTCTTCTTC
TGAGTCTCTCCCAACTGTTTCAACCTCTGCCTGTTACCCAGTTCCAAAGTTGCTTCCACATTTTTTGGGTTTCTTTATA
GCAGTATCCCACTCTCTGTGGTACCAATTTACTGTATTAGTCTGTTCTCATGCTGCTATAAAGAAGTACCTGAGACT
GGGTAATTTATAAAGGAACGAGGTTTAATTGACTCACTGGTTTGCATGGCTGGGGAGGCTCAGGAACTTACAATC
ACTGTGGAAGCAGAAGCAAACACATCCTTTGTACATGATGGCAAGAAGGAGAAGTGCCGAGCAAAGGAGGAAAAGC
CCCTTATGAAACCATCAGCTCTCATGAGAGCTCACTATCATAAGAACAGCAGCACGGGAGTGACCACCCCATGAT
TCAGTTACCTCCCACCTGGATCCCTCCCATGACATCTGGGGATTATGGGAACTGCAATTCAAGACGGGATTGGGTGG
GGACACAGCCAAACCCCTACTGCTTTAAGATCTATGAATGTTTTTCTACATTGAAGAAATTTGTAGACATTTG
TTTTTATTCTCTTTTTGGTTTTGCTGAGAGCAGTAGTCTTTGGAAGTGAGTTTCATTTACATTTTTTCTTTGGGT
GTCAAATATATAAAATATTTTTTAAATCAATGGCTGAGGGATAAATGAGGGTTGGTAGAAAGGGAAGGATAAGGG
TTGTAGTTAACGGACCATGTTTTAATGTGTCTATAATTAGATGGAAGTTGTCTCTTACCATTCAACATCCTGGATGG
CCTTCTATAGAGGACATTTTCATCTTCTTTTGTCTCCAGAGCTAGCATATGTGTTTCATGCTTTTAGATAGTGAA
AATCAATTCAGATTTTCATGAAAATGCTCTCTCTTCACTAAAGACAGAATTGTCACGGCTATTTCTGTTTATTGA
AAAGTGAAACCTGCTACAGTTAGCATATAGTTAATTCATATATGTTACCTGTATCATTTAATACATTACAAAAGTA
AAAAACCAATTTTGCAGTTCTTGATAGTAAACATAGTAAATGGAATTTCTGTTGGCATATTTTCATGTTATTC
TGAAATGCTGAATGGATTTATTAAGATTGATAACAATATGTTGTACCTTTATGTTCTAAAATTTAATAACAGTTATT
CTTCAAACATGCCAGCGTCTCAATAGTTGACAGTCTGCAAAATATTCTATTATGCAATCAGCCATATCTCCTTCT
TGAGCTTTCTTTAAGTACTTGTATCCTGTATTTTTCCCTGAAATCTAGCAGTAAGTTGAAGAAATGATAAACAAAAT
TGTATCATTGTATATAATGGCTATTTATAAAATACTGATGTACATTTTCATAATGTTATTTAAATGATTACTTCAGAT
ATGTATTTCTGTTTTCTACATTTTAACTTCTCAACATATTAGGTTGTTATCTTAGATTGGATTTTCTAAGACATAGA
CTCTAAGACAGAGATTTCCATGCAGATGGTTTTCTTAGTGAGTGCTTTTAAAGAAAAATGCCGGGAGGGAGTAAAGGC
AGCAGGATTGAGGAGAGAGAGGAGTTGAATGATGATGCAGTGAAATGGAAGATCTTATCTGGTCCCATGTGGGGTTG
GGATGACCATTTAGAGTATTACCGTATGAAGCAAGGAAGGTGGACCATTTGATCCCTAATCCATTAGTCATTAGATG
TGAGCTCCCACTACCAGCTTCCGGGCAATATCATCTTGGTCAAAGAAGTGCTGTCTGCTGAGAGAAATTTCTTG
GAAGCCTTAGTATTGATCTGTTAGTAGATAACAATCCAGCACTGGGAGAATGAATGCTTATTGTAATTTGGTG
AATCTCGGTGGCACACCAGTGTTTCGCTACGGTAATCTTATACCTTATTGAGACATATATTGTTTTAAGTAAAC
TTGTATACCTAGTAATGCATTTAGGTAGTGATTGGCCAAGTCTAGTCTTTTGGAAACAATTTCTATTGTGATATA
ATGATATACAATAAGCTACACATTTAAATAGTACAATTTGATAAGTTTTGACATATGCAATACCAGTGAAACTATT
AGCAGAGTCAAGATAATAACATATCCAATATCCTCACAGTCTGTTTTCGGTAATCACTCTCTCCTGCCCTCCCT
TGATTCCCAGGTTACCACTGATGCTGACTGGCATTATAGATAAGTTTGCCTTTTATAGAATTTTATAAAAGTAGAAT
CATGAAGTATGTACCTTATTTCTGGTCTGCCTTCTTCACTCACAACTACTAATTTTCAATTTTGTGAATAATATGA
TCTCCGTGTGATTACACACATTAAGAAAGTCAATAAAAACATTGTAATTTGATTCCGATACTAGTTTATGGGTCTAC
ATTATGTATTTAAAGATACTATCATGTTTGGATTAGCCCTTAGGTATCAAGTAACCCTGGAGTTGAGGCAGTTACTG
TTTTATTTGCTATCAATCTTTTTATAAGCTCACCTTCCACTAATTACCCAAAAATATTTGATTTAATACCTGAGTAC
AGAAAAAGAACATATTACAAATGTTTAAATTTTATAATTTAATATTATAATTTACAACAGTTTAAATAACTAGTCC
TGAAATTGAGTATTTCTCACCTAATATTCTGCTCTATTTATTACCCACTCCACGAAAAAATTTCCAGAAAAATCAC
AAACATGTCTCTTGAGTGTATTATTACCCAACCCACAGAAGAATTTCCAAAAACAGTCGCAACATTTCTCTCTTGAG
TGCAACCATTTTCTCGGGCCAGCCATTCATTGAAACAAAAATAGCCTGTATAACTTCTGTGGGTAGACATTTGTAGGT
TGTTCTTTTGGAGCATTAGTGCTATTGCATTTAAGATAAAGAAATAACGAATTCACAAATTTTATAAAGTTCTCTTA
AATTTACCAAGTCAATAGCACCACTTTGATTCTATAACCTGTGACTTAGTTAGGCTTCTCAATTTCAAAGAACA
TACCACCATTTTCTTATAATGTCTCAGATTAAACATGTGTTGTCCTTTCTTTATACCTCCCTGCATTTTAAT
GAATATTTTGCATTTACTGGATTCTGTACACTTTTATGTTTTTCATGCCCTCCCTTTTCAATCTCTGGACATCAA
TCGAAGTCAGTAGTACCTTTGTAAGAGATCTCTCCACCCAAATCACTGTTTCTTTTGAAGAGTTTAACCTTTCT
GAAGCAGCATCCTGCTTTCACATTTCCAGCAGGAACCTTCAGTGTTTTCTGTGTTGATAGCTTTGATTTCAAACG
GGTAGCCCCAGGAGAAAAGAGAGCTGAAGGATATGTTTTGCTTGGCTGCTTTGTTTGACCTGCAAGGAACATTAATA
GGCAATGAAACCGGGCAGAGACTGGACTGATCAACACCATCAGTTTAGCACTTATTGCTATACTTTCTAAGGCTTTA
CAATTTTATGTGTCCACGTGTCCCTGAAGGCATTTGATTTTCTAACCTCCTAGGCCAGAGGCTAACATCCAGAAT

TCATAGTCTGGCACTTATAAACCCCTAACTTAGCTTCTGTCACTTGTATCTCTATGCAACTCTACAGCAAAATGTACT
TATTTTCTCTAAAATACCCCTTATTCCATACTTCTTTGGAGTGTAATTTTATATATAAAAGTCCTCACCACCTGTAAA
CATTAGGAAGCTTTTGATTGGAAGAAGCAGAAGCCATCTCCATTTAACTGAAAGTGAATGAACTTACTGGAGGGATA
ATGTATAGTTCTTTGGAAATGAAGGAAAAGAAGGCAACTGTGGCAGAGGGAGGGCAGCACTGAGAGTCAGGAACCTCCA
GGGAAGTTACTTTTTGGATGCTGTCATTAATAATGCTTCAGCTTCAAATTGTAAGTACTGACTCTACCTTTCTCAATTCTAG
ATTCAAATTTCTAAATGTAATTGGCATAAATTAGGAACTTGTCCACCAGTTTATAGAGTTTACAGAGCACTATGAT
TATAGGTCCCCCTAAGATCATGCAGAATGAGGGAAGAGTAATTTTCATCCAAGGAAAAGCAGGGTACCATTACACAAA
GAGTGGAGATACTTATTCAGAACAATTAATGTTAGATGCCACAAAAAACTAACCTGAAATCAAAGTGGCCTAATG
AATGCTTATTTATTGCTCATATAAAGTCTGATATAAATCAGGTAGCATTCCTTCACAGTGACTCAGGGACCTAAATTT
GCTTTCATCTTGTGGCTCTGCCATGTCAACATTGAACTTCAGAGGTATTGACAAAAGGAGAGCTGAGAAATTGACAC
TAACTATCAAGTACCTCAGGCAAGAAGTGATGCATCACTTCTACACTTTCCCACTTTCCAGGATTCAATCACAAAT
GCACTCACGAAACCTCAAGGGAACATGAGAAACATAATGAAATCAATACCAAGATATCCAAAGAGTACTAATTTTCT
TCACCACAGAAGGGATATTGGACAGACAAAAAATTTGGGACAGAGGAATATCCACTAAATGATCCTTCCATGCCCT
GCTCAGATGCTACATTTTCCATTAAGGCTCTCTTGACCAACCCATAAGGAGATGATCTCCAACCTCCTCTGAACATCT
GGAACATTGCATTCTACTTATTTTACTGTCTCTATTGTAATAATTGTTGGCTATTCTTATTAGACAAATTATAA
GCTTTTATGGGACGGTGATCAAAAGTCCTAATTTATCTTGTCTTCTACAGCATTCAAAGCATTGTAGACCTTCAAT
ACATAGCAGTCTTCGAAGCCAGAGTATTAGTATTTTTTCTAAACTGTATTCATCGCAACGAACCTCGATGGATGTTT
AATAAAAATGATTGAATAGTCATTTCATGCAGATAGCAAAATTTCTTAAACATTTCTTACTCAATGTTTACTTATAT
TCATCATGAATATAAAATTTAATATAAATAATATCAAAATCCCATTACATTTAGTACAAAGTAAATATACCAATAATTTT
ATATATGTTTAAAGTGAATTTTATATTTTCATATTATTTGTGAATGATACACATCGTCGTGGAAAATTTACAACGTTG
AAGTAAATTATACAATATAGGGTATTTGTATTAATAATACATTTTCATAGAAGGTGCTTTAAATTTAAAAAGTTAGCAT
GAATACATATTAAATGTAAAAGAGTCTTTAAATGAAAAATATTTTCACTTGTGGGTTTGATCTAAAAATATCAGT
CGCTATATGATATGGCTAGACAGATTTGAGTAGGTATAATTTAATGAATAATATTGTGTGATATTTTAGGGTCCAA
AATTGAATGTTTCTATTAAAGTAACAGATATTTAAATGCCAAGCAGAAGCTACACTGGCAAAACAAGATTTAGTAGT
TATCTTAAGTGTATCCTAAATCCTCTTTCATCTTATGGAGAAGAAATACATGCTTTTAGTTTCCAGCCACTCCTGTG
TATATTCATTTAAAAATAAACTATTATTTATATCAGATATGATGCCATGTGAGTCCACAATTTGTAGTATAGAGAAAT
AATTTTATTGAATATTTTGGCTGTTTGTACCTGAGACCTGATTCTGAATCATTATTTTTTCTATTTAAGTTGTGCT
ATTTTATGATCCTACCTATGGCTATGTTCAAAAACATGACAAAAATATATTTTACCTGATCTTTTTTTTCTATTATTAT
ACTTTAAGTTCTGGGACACACGTGCAGAACGGGCAGGTTTGTGTCATAGGTGTACACGTTCCATGGTGGTTTGTGCTG
ACACATCAACCCATCATCTACATTAGGTATTTCTCCTAATGCTATCCCTCCCCTAACCCCCCATCCCCTGAGAGGCC
CCGGTGTGTGATGTTCCCCGCCCTGTGTCTATGTGTTCTCATCGTTCAACTCCCACTTATGGGTGAGAATATGTGGT
GTTTGGTTTTCTGTTCTGTGTTAGTTTGTGAGAATGATGGTTTCCAGCTTCATCCATGTCCGTGCAAAGGACATG
AACTCATTCTTTTTATGGCTGCATAGTATTCCATGGTGTATATGTGCCAATTTTCTTTATCCAGTCTATCATTGAT
GGGCATTTGGGTTGGTTCCAAGTCTTTGCTATTGTAATAAGTGTGCTGCAATAAACATACGTGTGCATGTGTCTTTATA
GGAGAATGATTTATAATACTTTGGGTATATATGCAGTAATGGGATTGCTGGGTCAAATGGTATTTCTGGTCTGTGAT
CCTTGAGGAATCGCCACACTGTCTTCCACAATGGTTGAACTAGTTTACAGTCCCACCAACAGTGTAAAAGCGTTTCT
TTTTCTCCACATCCTCTCCAGCATCTGTTGTTGCCTGACTTTTGAATGTTTCGCCATTCTAACTGGTGTGAGATGGTA
TCTCATTGTGGTTTTGATTTGCATTCTCTAATGACCAGTGATAATGAGCTTTTTTTTGATATGTTTGTGGCTGCAT
AAATGTCTTGTTTTGAGAAGTGTCTGTTTCATATCCTTAGCCCACTTTCTGATGGGTTTTTTTTTTTTCTTGTAATTT
GTTTAAAGTTCTTATAGATTCCGGGTATTAGCCCTTTGTCAGATGTATAGATTGCAAAAATTTTCTCCCAATCTGTA
GTTTGCCTGTTCACTCTCATGATAGTTTCTTTGTCAGTGTAGAAGCTCTTTAGTTTTCATTAGATCCCATTTGTCAAT
TTTGGCTTTTGTGCTGTTGCTTTTGGTGTTTTAGTCAATGCAGTCTTTCCCCGTACTTGTGTCTGAATGGTATTGTC
CTAGGTTTTCTTCTAGGGTTTTGATGGTTTTTCGGTTTTTAGGTTTTAAGTCTTTAATGCATCTTGAGTTGATTTTTGTA
TAAGGGTTAAGGAAGGGGTCCAGTTTTCCGTTTTCTGCATATGACTAGCCAGTTTTCCCAACACCATTATTAATAAG
GGAATCCTTTCCCCGTTGCTTGTTTTTGTGTCAGGTTTTGTCAAAGATCAGATGGTTGTAGATGTGTGGCATTATTTTTT
TGGCCTCTGTTCTGTTCCATTGGTCTATATATCTGTTTTGCTACCAGTACCAGTCTGTTTTGCTTACTGTAGCCTTG
TAGTATAGTTTGAAGTCAGGTAGCATGATGCCTCCAGCTTTGTTCAATTTTACTTAGGATTGTCTTGGCTATACAAGC
TCTTTTTTGGTTCCATCTGAAATGTAAAGTAATTTTTCTTAATCTGTAAAGAAAGTCAGTGGTAGCCTGTTGGGGA
TAGCATTGAATCTGTAAATTAATTTGGACAGTATGGCCATTTTCACTCCACTGATTCTTCTTAACCACGAGCATGAA
ATGTTTTTTCCATTTGTTTGCCTCTTTCGTATTTTCTTGAACAGTGGTTTGTAGTTCTCTTGAAGAGGTCCTTCA
CATCCCTTGTAAGTTGATTCTTAGGCACCTTTATCTCTTTGTAGCAATTGTGAATAGGAGTTCACCCACGATTTGG
CTCTCTGTTTGTCTATTCTTGGTGTATAGGAATGCTTGTGATCTTTTCACTTTGATTTTGTATTCTGAGACTTGGCT
GAAGTTGCTCGTAATGTTAGGGGCAGCCAGAGAGAAAAGGCTGGGTTACCCACAAAGGGAAGCCCATCAGACTAACAG
TGGATCACTCTGCAGAAACCCCTACAAGCTAGAAGAGAGTGGGTGCCAATATTCAACACTCTTCAATAAGGGAATTTT
CAACCCAGAATTTTCATATCCAGCCAACTAAGTTTCATAAGCAAAAGGAGAAAATAAATCCTTTACAGACAAGCAAAT
GCTGAGTGATTTTGTACCACCAGGCCTGGCTTACAAGAGCTCCTGAAGGAATCACTAAACATGGAAAGGAAAAACC
GGTACCAGCCACTGAGAGAAACATACCAAAATGTAAAGACCATCGACCCTATGAAGAACTGCCTCAACTAACAGGC
AAAATAACTAACCAACATCATAATTACAGGATCATTACACATGACAAATTAACTTTAAATGTAAATGGGCTAA
ATCTCCATGCAAAACACACATAGGCTCAAAGCAAAAGGGATGGCGGAATATTTTCCAAGCAATGGAAAGCAAAAA
AATAAAAAATTAATAAAAAATTAATAAAAAAACAGGGGTACAATCCTAGTCTCTGATAAAACAGACTTTAAACCAAC
AAAGATCAAGAAAGACAAAGAAGGGTATTACATTACATAATGGTAAAGGGAGCAACGCAACAAGAAGAACTAAT
TCTAAATATATATGCACCCAATACAGGAGCACCCAGATTTCGTAAAGCAAGTTCTTAGAGACCTACAAAGAGACTTAC
ACTCTACACAGTAATAGTGAGAGACTTTTATACTCCACTGTCAATATTAGATTAAACGAGACAGAAAATTACCTTGA

TCTTTAACATTCCAGGCAAGTATGTTTTTCAGTCATACATAGTACGTGAATCTGTTATATTTTTAAATCCAAGCTTTTG
GAGGACAAATGATTTTACAGTTATACAACTCAGCCTCTCCCAGACTCAAGTCTCTCACTTGATGCAGTATTTCCACC
CCATCTTCAATAAAAAGAAGAAAGCATGAAACATCGCATTGATATAGGGAAAGTATATCTGAGTTTTCTATATAGCAT
ATAAAGAAGTAAATAAATCTGTGATTTGTGATGAGATAGATTTAGCTGCAACAATGAGGTCTGGATATTAATATTG
GATTAACCTTCTTTGAGATTGCAACTTCCATGTGGCATTTCAGCACTTTCTTGTCTTCATATGTAGGCCGAGAAT
AAAATTATCCTGTTTCTATTTCCCAACATGAAAGGTCTTTAACTGTTTGAAGACATATGTTTCATGTGAAACCAAG
GAATTGCTACTGCAATTTTGTAAAGACAGAAGTTAGCAAACTTATTCTGTAAGGAACAAGATAGTAAATATTATAGGC
TTTGCGGGCCATATGGTCTATCTCACAACATATAAACTCTGCCATTTTTTTTTTTTTTGGCAAAAGCAACCATAGAC
AATATGTAAATGAATGAGTGTGATTATATTTCCAATAAAACTTTATTTTTAACTACAAGACTAGTTCCTTAAATAAAA
ATTTAACAAAGAAGTATTATATGATCCAATAATTCCACTTCTGGGTATATACCCAAAATAATTGAAAACAGGTATTC
ACACAGATATTTGTACACCCAAGTTCATAGCAGCATATTTTACTGTAGAGAAAAGGTAGAAAACAAATGTACACTGTG
TACACTGACCAAGAATGGAGAAAACAAACGTGGTGTATCCATACAGCAGAACAGTATTCTGCTTTAAAAAGGAATGA
AATTCTGTACATCCTAAATAGGGATGAACTTTGGAGATATTCACCTAGAGTAGTTAAATTCCTTAGACAAATAGT
TGCATGGTTGCCAGGGACCAGGGAGGGGTAGGGGAAATGAGCAGTTCTTGTGTCATTGGTATAGAGTTTCAGTTTAG
AAAGATGAAGAGTTTTGGAGATAGATGGTGGTGTATTTACATATCCATGTGAATGTATCTAATGCCACTGAACTGT
ATACACTTACAATGGTTGAAATATTTGTATATTTTCCACAGTTAAAAAGACAAGCCCATGTGCCCAAATTGCTG
ATATAAATCTGTATTCTATTAGTGAGCAGTAATGAGCCATGTTTAGTGCAGCTGATATGGTTAAGATGGAACAATT
GCATGTAATGCAATGGTGGGTAAACATCTAATAAAAAATTGGTACTACCAATTTCCATTTCCATTGTGGATATAAACA
CCCTTCACATTATGAATCATGTTATTTGTTATTTGTGTACTTACTTATTAATCACTTTTCTCCATCTCTCTCACCT
CTATGACTCTGTACATGTACAAACAACATACACACTGTGAACTTCTTTAGAAATGACAGTTACATTTTCGTTACTTGA
TTCATTGTTTGGCCAAGTAGATACCCAGTAAGCATAACTAGCAAGTGAATAATGTATATGTGATCATTTCCTTTTC
AAAAACCACTTCTTATCTCTACCAACACCACACATTATTATATGCTACACTTCTTATATAAAACAAAAAGAATA
GGCCAGGTGTGGTGGCTCTCGCCTGTAATCCCAGCAATTTGAGAGGCCGAGGTGGGCAGATCACTTGAGGCCAGGAG
TTAGAGTCCAGCCCAGCCAACATGGTGAAACCCCATCTCTGCTAAAAATACAAAAATTGGCCAGGCGTGTGGCGCA
TGCTTGTAATCCCAGTACTTTGGGAGGCTGAGCAGGAGAATCACTGGAACCCAGGAGGCGAGGTGCGAGTGAAGT
AAGATCATGCCACTGCCCTCCAGCCTGGGCAACAGAGCAAGACTCTGTCTCAAAAACAAACAAGAAATAAATAAGCT
TTAATAAACTCTTTTGCAGAAGAGTTTTTCATTTTTTAAACATAGAGGAAAAAGAGATGAGGATGAACGATAGTGATG
CCCAGAAGAGAAAAATTGTGTAAGACAAAAATCAATTGACCAGGCGTGGTGGCTCACGCCTGTAATCGCAGCACTTTGG
GAGGCTGAGACGGGCAGATTATGAGGTGAGGAGTTGAAAAACAGCCTAGCCAATATGGTGAAACCCCTGTCTCTACTA
AAAATACAAAAATTAGCCGGGCTTGGTGGTGCACGCCTATAGTCCCAGCTACTTGGGAGGCTGAGGCAGAAGAATCT
CCTGAACCCAGCAGGCGGAGGTTGCAGTGAGCCAAGATCACGCCACTGCACTCCAGCCTGGGTGACAGAGCGAGACT
ACATCTCAAAAAAAAAAAAAAAAAAGATTAAATCAATTTTAGATTGATATAGAGATAAATAATTCCCTAAGTACAATTA
AAGCAAGGATCAGACCCTGATGAGTAAGGATGATCTAACAAGGGCTGACAATATAAAGTGAATGCGATTGTCACCA
AATAACATCTCCCAAGAGCTTTGGGACAATCTTCAGCTAAGCATATTCTGCCTTTACATCGTTCTGCCATATGCC
CTATGTAGCTTTTCATCTCCAGAAATTTGAATAGCACACAGTATTTTTTGGCACCAGTAATTGTGGAACTTAAAC
TTCCTACAAAGAGAGAAGCTGTTTCAGTCAGCTAAGTGACCAGTTAGTAAGCAACTTCTATTCTCTTAGTGTGCGATA
GGGTTAAAGACAGTCATAAGCTCCCCAAACCTTGGCCGCCTCAATTTTTTTCATTTAAATACTTATCTTCTTATCTT
CATCTATTTTTTTAGAGTCACACATAAACTCTGTCTATGAGGTTCTTAAAGACCTGGACAATATATTTAATCTCTGTA
TCCTTAAATCTCACCATGATATCTCAAAGATGGTAGATAAAACTGTTTTCCCTCACTTCTCTGACTCCATACCAATA
CTTAATCGATCGGGAAAGTTTTATAAACCATTTACCGTTGAATATAAATATATATACACACACAAACATATATATAT
TTATATATATTTATGTATATATATATTTATATATCTATATATATTTATGTATATATTTATATATATTTATATATAT
TTTATATATTTATATATTTATATATATTTATATATTTATATATATTTATATATATTTATATACTTATATATATTTAT
ATATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATAT
TATATATATTTATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATATATTTATATAT
ATATATATTTATATATATACACATATTTATATATTTATTTATATATGTTTATATATATATATATATATGGCATATATATC
AGTGAGCAAAGGCATCATAATCTTTATTTTTTATTTCTGTATTCACTTATTCAACATATAGTAATTCCTGATCCTGTCT
CAAAAACCTCTACAGAAATTAACAAAGAACACATTGTTTCTGCCTTTTTTGGAGCTGAATGTTTAGTGGGGGAAAATGT
ATTTTAAGGCAATAATCATATACATGAGTGTATATTTACAAGCCGAGTAGGTGCTATGAATGAAAAGTATAAGGAG
CTATGAGATATTCTAACAACAAAGAAATGCTGCAGTCTAGAGACTGAGAGTAATTATCTGTGAGGAAAAGTATTGAAG
CAGAGACCTGCAACTCAGTAAAGAGTGTAGGGAGTCACATGAACAAAGCTTTGAGATGTTGGTAGAGATCTTGAAT
GTTGCAAAATCTAAAAGAAAGCCCTTGTGTATGGGTATGGTGAGAGAGGAGAGCGTGGCAAGTTTTACGTTGTAC
AAGTCATTGTAGGCCACAAAAATAAGTATAGATTTTATCTAAGTGCAACGGAAAACCATTACAAGTTTATTTTTTGA
TTCTTAAATTTTTGTTTTACTTATTTATTTATTTCAAGACACAATCTCACTCTGTTGCCAGGCTGGAGTGCAGTGAC
ATGATCACGGCTCACTGCAGCCTTGAACCTTGGGCTCAAGCAATCCTCCCATATCACCTCTACCTCAGCTTCC
TGGGTAGCTGGGACTACTACAGGCATTTGCCACTATGCCTGGCTAACTTTAAACAATTATTTTTGAAGAGACAGGGTC
TTGTTACGTTTCTAAGTTTCTAAGGCTGATCTTGATTACTGGGCCAAGCAATCCTCCCGCCTCATCTCTTAAAA
TGGTGGGATTACAGATATGAGCCACCTCACCCAGCAAGGTAGTGACATAATCATTGTTTTTGTGAAAACAATGTAC
TTTAGGGAACCTCCCTGAAAACAGAATGGCCACTTAGAATACCAAAGCATAGACCAAGCCTTGAGATGGCAATGGAA
GTGGAATAAACAATGTCTTTGATACTTATGTTAATGGAGCTATTAGTAGCAACTTTTGACAGATTTGAAAGTGGAGT
TGAAAGACAGTGAAGTGTGAGGATGATCCCTGAGCATATTAGATAATATTGAGCTGGAGAACAGAAAAGAAGGGGC
AGATTGGAGGTGGAGACCTTTCTAGATTTATATTTCAATTTGAGATACATCTGAAACATCTACATGAAACGTGGATG
AAATATCTGTGACCAAGATACATACGTGGGATACCTAGGCATGTAAATAATATTTAAAGTTATGTGAGTGGGTGCAA
TAACCTAAAGAGAGACTGTAGGTAGAAGATTGATCAGGACAAATCTTTGAGGAACCTTTTTTTTTTAAATTATTATTAT
ACTTTACGTTCTGGGATACAGGTGCAGAACGTGCAGGTTTGTACATAGGTATACACGTGCTATGGTGGTTTGTCTGC

ACCCATCAACCCGTCATCTACATTAGGTATTTCTCCTAATGCTATCCCTACCCTAGCCCCCACCCTCAACAGGCAC
CAGTGTGTGTTGTTCCCTCCCTGTGTCCATGTGTTCTCACTGTTCCACTCCCCTTACGAGTGAGTCCATGCAGTG
TTTCATTTTCTGTTCTGTGTTAGTTTGTCTAAGAATGATGGTTTCCAGCTTCATCCATGTCCCTGCAAAGGACATGA
AGTCATCCTGTTTTATGAGGTACTTTTAAATGCATTTAGTGACTGGGTAAAGGAATAACCTGAAAAGGAGCACAAAA
CCATCGAGGTATGAAGAAAGCCAGGAGATGTAGTTTACAAAGCAGCCAGTGACAGTAATGGACACCAGCATAAGC
TTAAGACAGCAGTGATAGTGTTCATCAGTGCTGAAAACCTATTGGAAGTGGCTGACCATATGTTGATTGCCAATGCA
ATGCCCTTCTCCCATCTCCTATTGCTTTTCACTGTTTCCGTCATGTCCAGAGTGAAAACACTGGGGAGGCAGAACTGT
GTACCAAGAAAAATGTTTTGTGTCTAGAGGAAACAAGAGCTCATTAATTTCCCTTTTGACCCGCATGGATAGGAATACG
ATAAGCAGGAGAAAAATAAAACCTGCTAAACTAGGCCAAATAAAGCTTAATAGAAAAAGAGAGAAAAATATTGCTTACAA
AGGGAAGAAGACATTTGCCACAATATTAGCTAAAAAGAGAGTGAGGAAAAATCCACATTTTACCATTTTTATTATGTGT
TTCCAAAGTCGACATTAAAGTGAATATTATCACTTTGAAGACAGAGAATAGATTGTAAGCAGAAGAGGAAGTGGGATT
TTTTAAATGGCATATATTTAAATGTTGAAAAACCATTTCCAATACTCCCCTGAGATATATGCAATAAAAAACACTC
CGCAATCAGTAATATACATGTGAAGCTCCTAAAAATCCTCCATTGAGAAGATTCTATAAACTATAAAGTATTATTA
TTTCTGTCTATCAGAAAATAAACACATACTTTCTAAGAACAAGATGAAGACCTTAATTCATCTTCCCAGGAATATACT
TGTGTACTTAATGGTTCAAGGCGTTTGTGATGCAAAAAAGTGGGACATTATGTACAAAATAGTTTAAATCAGAAAA
TGAAGGAAGTTTGGTATGGTATGGTCTAGGGTTGCAAGTTTTCCTGCAAAAAGGGAGTACTTATGGCTAGGTGATG
CAGCCAAGGAAGCATCTCTGAGGACAGGTTATCCTGGCTCCTATCCAAAATATTTAGGTCTCCTTGAGTGTTCGAT
CCTTGAACCAAGGACAAGAATAGAAAAGAAATAAAAGCCACTTGTATAAAGGTTGCCTTCATTTTGTGTGCAATATTG
ACAGGAGAAAGCCAGATTTGTAGCTTTTCCAGGGATAAGTGAGTCTCAGACACAGTTAAGAGCTTGGCTTTGGAATT
AGATTGACCTGAGTTTGAATCGTGGCTCCATCAATCTCTGATTGTGTGAATTTTGGCAAGTTTGTAGCTGAACCTCA
ATTTTCTCATAAGTAAATAGGCATAATACAGCTATGATTCTGACCTTGGCATTAGCACTCTGAGCTACTTGTCTAG
TGTATCCTGGTCTCTTCTCAAGCACTTTTCCACTTTGTTATTTCAAGATTCTTTGAAATTATGAACAGTAGCTCTT
GATCACCAACAAATGGGAGACCATAGATTCAAAGGAACATTTTAGTAGGATATTTGATAAGCTTTGTATTTTTTTG
TGCTTTGAAAATTAGAGTAGATTAGATTAAAGGAACATAAAGCTATATGTTTACAAAACCTTTATTCAGTTGGGCA
GTTCTGACTCAGTAAAGTAAATGATGAAAACAAAACATATGTTTACTGTTGTGTTCACATTTAAAGATTAA
TTAATGCATAAACCAAAATAGGTTTCAGCAAAATGTTTATACATACATGTACTTAGATATTTGTAATTTCTTATGGTAGA
GCATGGGAATGAATGAGAATTCTCCTAGGCTGGAATAAACTAATGTCTAACTAAGAATTGGCCTTTCACTTCACGA
ATATATATCATTATATATAAAAGATTCACTCTTTGTTAACTTATTTGTTTAGCTTAGTACTTTCTAAGTACTTTTCT
ATCCTGTCTTGGTCCCTATATAAGAATGATACTATTATAAAAAATGAACATCCTATTATTTTCAATGATTAGCATAT
CAGCATATTTAAGAGCAATGCCTATATCTTTACCTTCATTATTATTTTCATGTTTAAATCCTGATAATTCTAGAAA
AACAAGGTTGTAATTATCCATTCAATAAAAGTCACACCAAGTTATTCTTGATAATTAACCTTGGCATAGTGGAGTG
CACTGAGCAATTAATAATTAATTACGTGGTTACTAGCTCAAATTTTATTGAGAACCAAGGAGTTAAAATTAATAGTA
TTGTGTTTGCAATGAGTTAATTACTTTGTTTCTTGTTTTTTTTTTTTGGAAATAGTGCCATAATTAGTATCCTAATAG
AAACAGAATATAAAGTGGGTTTCTGAGTGCTTGTCTGCGAGGTGTGTAACAACATATATTTAATTATAATTTGAG
TCACTAATTGTTGTCAAATACAATTTAATTTCTTAGTTTCAGAGATTAAAAGATATGTAAACAGCTCCAAAAAGAA
TATGATAAGATGGTTTATACAAGTAAATAAAATAACTATATGACTTCAGAAGTTTTATTTAACAACAGTTGTATAAGT
GTTTTAACTAATGTTAACAATGCCTTTTTTGTAAATCTCCTCTACCACAAATATGAGATAAATTTAAGAACGGCATT
TTCATTAAATATTGATTATTAATAATTCATATATAAGTATTGGCTGTACCTGAGCATTTACAGTGAAACCATGAAGGA
CTGGCAGGTTTGGGGCTGTTTGATAATATCCTTCTTAACTCTTCTTCTGATCATCATTGTTTAAATTTTGGCTGACC
ACAATCACTTATGAAAAGAAACAGCTCAAATAATTAGTATAACCTCTTCTCTTCAATAAACCTTCAAATCAATGTG
GTCATAATTATGAAAGTGTAAGATTATAAAATCTTCTCATTTAAATATACATCTTCATATTAGCAGACTTGGCTAAT
TTCTTCACTTATCCTTGTACATCCACACTTAACTCTGTCAAACCTGGTCACTTATCATAGACTCATTATTTCATTCAACAA
GATTAGTGTGACCCCTACTATTGATTCTGAGGGCTAGAAATATAAAACATGAATAACATATAAACCTTGATTCTGTATT
TATATATACAGAAAGGAATTATGAACCTCACAGTTTTAATGCACAGTGACGAGTCTCAGTTCATGTCTGCCTTGGGA
GCTAGGCATATACCAAAGCAGGACTGTCTAACACAGTTTGGGGGTCTCAGTCTGGAAGGATCCGGGTGAGATGATCC
TTGAATTGAGTTCTAAAAATGAGGAGAAATATCCAGATAATGAAAAGTTTAGGAGAAATTAACCAGATAATGGAA
AGTTTAGGAAAGAAACACTATTTATATGTCAAGGACAAAGTTTGACCAAATGTGTCTCTGAATCTAACTGGCTTTAT
GTAAGATAAAATTAATAAATAATTGTCATAAGGTTTTTTCACATCTGCAGCAACTACCATCATATCTGGCTCAATAT
TTAAAGAAATACTTAACGATTTTTTGGCATTATTTGCTACTATAATAGATTGTGCTATTTAAAGAGAAATTTCTAGAT
ACATGCCAAAGTATTTTCAGGTGAAGTAATGTGATTCTGTGGGTTTTGTTTTGACAACTTCCAAGGAAATTTATTTT
AATATAAAGAGCAATGGAGGAAGATTAAACAAGATTGCAAAATGTTGATAATTGCTCAAGGTGGTGACAGGTGCATG
GGGGTCCATAATATACTGTTCTCTTTACTTATATATGTCTTTGAAGATTTTCATGATGTAAATTTTAAATCAGAA
TTACAGTAATACCTCTTTCTTTGACAATCGTTTTTCAAACCTGGTTCAACAACCTGAATTTAAATTACCTACATGGCTA
TAAAAATAAATTAGATATCCTGGTTATTTGGTCTGGGGTGGGTCTGGCCATATCTGTAGGGTGTGTGGGTGTGTGT
GCATTTAGCTTCACATTTGACTCTGAAGTACGTGGAAAAACCAATTCTGGGCTCTACATATGCAATTTCAATGCCTGA
CATTAGGTGGTGTGTTGTGAGCCATGATTTTCAGGTTTGAATTTGATAGATTAAACAGAAGTGATATCACCACCGATC
CCACAGAAATACAACTACCGTCAGAGAATACTACAAACACCTCTACACAAATAAACTAGAAAATCTAGAAGAAATG
GATACATTCTCGACACATACACTCTCCCAAGACTAAACCAGGAAGAAGTTGAATCTCTGAATAGACCAATAACAGG
AGCTGAAATTGTGGCAATAATCAATAGCTTACCAACCAAAAAGAGTCCAGGACCAGATGGATTACAGCCGAATTTCT
ACCAGAGGTACAGGAGGAACCTGGTACCATTCTCTGAACTATTCCAATCAATAGAAAAAGAGGAATCTCCTT
AACTCATTTTATGAGGCCAGCATCTTCTGATACAAAAGCCGGGCAGAGACACAACCAAAAAGAGAATTTTAGACC
AATATCCTTGATGAACATTGATGCAAAAAATCCTCAATAAAAACTGGCATACCGAATCCAGCAGCACATCAAAAAGC
TTATCCACCATGATCAAGTGGGCTTCATCCTTGGGATGCAAGGCTGGTTCAATATACGCAAAATCAATAAATGTAATC
CAGCATATAAACAGAGCCAAAGACAAAAACCATGATTATCTCAATAGATGCAGAAAAAGCCTTTGACAAAATTC

82

GATGCACATGCAACTACTAAATGCTAGATGAGGATACCTGAGGAGAGAGAACAAGACACAAACGTGAACATGGACCT
CCAATAGAAATGACAATCGAAAAACATACATTTATCTTCTCTCTCTCCCAAATTGTTCAAAGATTACGCTAAGGGAAT
AAAAACAATACAGTCATAAAATGACAAATAAAATGGAAGAAGAGACATCTGCACAGACATATCAAGTCAATGAGATG
AAAATTAGGACAAGTAAGCCAATTTGTTTTTTCAGGATCCCAGAAAAACTTGTGGATTGAAGACGCTAGGTGTTTTAG
AAGGCCATATATTCCCAGAGGGGGCTGGAAATAAAGGGGTGTTTTGAATCCCTTAAAAGGGGCAATTACATTTTCAT
GTCCCCAGCTCAGGGTAGTTAATTAGACACTACTCTCTCTCATCCCAGCAGACGTGAGTGAGTGGTTTGCTTTCTG
GTGAGGCTGAAACAACCTTTTGGCATTGAGACAACAGGATTAGTTGATGGAAGAGAGAGCCACCATACTGAAAAATACA
GGATTAAGTTAAAGTCAACATATTTAATGGTGAGACCAGCAGTCCCTCTTCACCTTCTTGGCTCTTAAGTTTCTATC
CTCTGGGCAGTAGATTATAAATTTATTCTCTGAGAGCCTACCTGCAATACGAAAACTATTTTTAGTCAAGTTTTAT
TGCTATAACAAAATACCATAGACTGGATGCCTTATAAAACAACAGACCTTTATTTCTCACCGTTCTGGAGGCTGGGAA
GTTCAAGATCAAGGCACTGGCAGGTTTGGTGTCTGGTGAAAGCTCATTTCCTGTCTTCTCACTGTAACCTCACAAGG
CAGCAGGTCCAAGGGAACGTGCTTGGGCCTCTTTGTAAAGGGTACTATTCTCATTCTGGATGGCTTTGGCCTTATGA
CCTAATTACCTTCCAAAGGCCCCACTTCCTAATGTCATCACCTTGAGGGTGAGGATTTCAACGTATAAATTTTGCAA
GAACACACTCAGATCATAGTAACCTACAATTAATGATATGTAATGATCCACCAGTGAAATAGCCAGATCTGTGCCTA
ATGACCATATATTGAAGCCCACCAAGTATAAGCCCTACATACGCACAAGGAATTTCCAAAAGCATTTAATGCCTCAG
TTTTAAGAGACAATCAAGGATTTCCAGATATTTGAACATGTCTCAAAGATGGAAGACAGAAACCAACATAAAAAACA
AAAGCAGAAATATTGGGAAAAAACAATAGCCACATAAATGAAACAGAAATCTCTGCAGAAAGAGAGACAAGGCATA
GACCTTAAGAAAACCTTTTTAAAGATAGCTATAAAATTATTATCTCACAGTGAGACTAGTCACTGTATTTCATAAGAAA
GAACAAGAGACTATAGAAGGTGGTATTTCCGAGAAAAGATAAGGGTTATTTAAATTAATAGTATAGCAGGTAAAGTTT
TTAAATTTCTTAATTGTATAAATTTATGGGTTACCAGTGTAATTTTGTTATATGAATATATTTTATAGTGGTGAAGGC
AGAGCTTTTAGTATATCCACCAGTGAATAACATACATGGTATGCATAGCAGTTTTAGAGCAATGAACTACTCTGT
GTGATACTATAATGGTGGATACCTTTTATTATATATTTGTCCAAACCCATAGAAGATAACAACATCACAAGCAAACCTC
TAATGTAACTATGGACTTCGAGTGTTAATGATATATCAATGTATGTAAGTCAGTTATAACAAATGTACCCTCTGG
TGTGGGATGTTGATAGCGGGTAGGCTGTGTGTAATGAGGAAGGGGGCCAGAGAGTATACGGGAAATCTCTGTACTT
TCCCCTCGATTTTGTCTATAAATGTAATAATGCTTTAAAAAATCAAGTCTATTAAAAATGAAGAGCAGAAATAAAGT
TCAAAAGTAGAAGATAAATTTGAAGAAATATCTCATAAAGCAGTATAAATAGCCAAAAGATGGAAAAATGGGAGAGT
ATAAGAATCTTAGAAGATCATTCTAGGTAAGTGTTTTACAAAATAGAGGTGATTTTGTCTGCAGAGGACGTTTGACA
ATGTACGGAGACCTTTTTTCGTTGTACAAAATAAGGAAAAGGATGTACTACTGGCCTCTTGTGAAGAGTGACGCAAGAG
GAATGCACCATGCAGCCATCCACAACCAAGAATTACTCATTTCAAAAGTGTCATAGTGTTTTATGTTTAGAAACCTTG
TTCTATGTAATCCAACATTCAAATAATAGATGTTAAAAATAAAACAGAAGAGAGGCAACTGTGGAGAGAAAATTATC
AAAGAAGTGACAACATCAGTTTTTCTTAGAAGTGAAGAAAATGAGTGTCAGGTTTTAAAGGGCTTACTAAATGCCAG
CACAGCAAATGAGCTAAAAATCTACACCAAGGCTCATCATATAAATTTTACAAAAACAAGGACAAAGAGAAGTTC
ACAGATCAGAAATCAGAATGGCTTTGGACTTTTTCAGCAATAGCCATGGAAAAATAGCAGAAAGGAACACTTCCTTTAA
ACTTCTAGGAATAATTAACCTTTGGCTTTGATTTCATATCCTATATGAAATTATGTTACAAATTTCTGTGATGCTCTT
CTATTCAAGAGTTACAGCTAAATGTCCCTGTCAATTGAGTGTTGACTAGATTCAAGTACTCTTTTGTGATGATATGTC
ATTTCCAAGTGTAGGTTGTAGAAAGACTGTGGTTTTATGTCTTGTGTTCTCCATCCACGCCTATCTCTCTCTGTGTCT
CTCTTTCTCTCTCTCTCTCTCTCTCTCTCTCTCATGCATTGCTTCTTCTGTGGGAACACATGTCATGAGCAGCCC
TATGGAGATGCACGTATGCTGAGAACTAAGGCCTCCTGCAAGAGCCACAAGAATGAGCTTAGAAGTGATCATT
AACACCAGACAAATCTCGAGAGGCTGCAAGCATAGACAACAGCTTAACTACAACCTCATAAAATAAGCTATGCCAGT
CCCACCCTGCTAAGCCACTCTCAGATTCTTGACCTTCAGAACTGCCAAATAATAAACATTTTTGTTTTTAAAGCTGC
TAAATTTTGAATGACTTGTTATTCAACAATATATAAATTTGTACACCCTGATAAACTATAAATTTGTGCGGAGAAAA
AATTTTCAGATAGCCTTATGTACTCCCCCTAAACCTTTTTTCCCCAGAAATCTATTTTCAAAAAATATACTCTACCA
AGTGAAGAAGAAACCAAGAAAGACAAAGAATGTTTAGTTGATTTGGAGATCAGAAGGAGAGTGTTTTAGGCTATGA
TTGCGCTTGTTATGCTGCAATAATAAGCAATTCAAAAATATTAGTGGCTAGAAACACAAAGGTTGATTTTGTATCTT
TGCAACATATCCAACACAAGTCAGTCAAGGGTTCTGATCATTGTAGTCACTCAGGAATCTAAGCTGATTTCAGTCTCT
AGTATTCTATCATTCTACCGTAAACAATAAGAAGCTTTAGCGTTTACCATGTCAAGTCAAAAAATGCGTGGAATAATTTA
AACTGACTCTTACATGCCTCTATGTAGGAGTGATATATGTCATTTTTCATTTCACTTCATCATCCAAAGGAAGTCACG
TGGTCATGCCTAACTCTGAGGGGACAGGGGATTATAATCACTAATATTTTTTAAAGAGAGGTAAGAGAATTAGGAAAT
ATTGGAGCATTAGTATTACCTGCAAAGCCTAGGATCCGGAACACAGAGAACCCAAACGTGGGAGGAAGATGCAAAGTG
GTGCCAGAAAGATGGTGGAGGAGATCCTGTAACAACAGCTGTATAACAGTTGTAGAGAGAAACCTGTACAGATTGGA
GAAGAAAATAGTGCTCCAGGAATTTTGTACCAAGAAAAAATAATCTAATGTATTGCAATGTATTGAGAGGTGGTA
TTCTTATTGTGTAAGAGTATAATATATGACATGTATGACAGACAGAAGTACCATTTAAAATTTTATTAAACATAAGA
ATTAGATCCCTATCTCACACTGTACATAAAACATAAAAAATGGTAAATTTGATGGATTGCCTAAACATGAAAGGCCAAAGC
ATTAAAAATATATAAAAAATATTTTGGGGCATGTAGGGCAAAAAGAGGTGTCCCTTAAGCAACAGCACAAAGCAAAAAT
GTAAAGAAAAAGACATATATTTGATCATTTTAATTA AAAACCTGTACAATGCAAAGACTTCATAAAACAAAGAAAAGA
CATAGGCTCAGATAGTATATTTGCAATACTAAAAACAATAAAGGATTTATGTACATAATTTAAGAAAAATATTTACCTA
TCAATAGAACAAAATAAAAAATAACCTAACAGGAAAAATTTTTTAAAGTTTTAAAAATAATAGACAGTTTACAGAACA
TCTGTATGTCAAATACACTTATGAATAGATGCTAACTCTCATTATTATTGGAAAAATTACTTCATATTAGTCGGTT
TTCATGCTGCTGATAAAGACATACATGAGACTGGGTCAATTATACAGGAAAAAGGATTTAATGGACTTACAGTTCCCA
CACAGCTGGGGAGGCCCTACAATCTTGGCAGAAGGCAAGGAGGAGCAAGTCACATCTTACATGAATGGCAGAAGGCCA
AAGAAAGTCCCTTTTATAAAACCATCAGATCTCATGAGACTAATTTACTATCACGAGAACAGCATGGGAAGGACCTG
CCCCCATGATTCAATTACCTCCACAGAGGTCTTTCCACAACATGTAGGAATTCAGATGAGATTTGGGTGGGGACA
CTGCCAAACCATATCGTACTAAGTGAGATAACGTACTCCCATCGGACTGGAAACAAGTAAAAAATAAATAAGATTGT
GAAAGGTCACAACTCTCATTCTTGTAGAAATTTAAGTTGGTACAACCAATTTAGAGTGTAATTTAGCAATAATCTA

GT TAAACTGAGGATGGCATGTCCTACCAAACAGCATTCCAGTTAATCACATTGAAGATAGCATGATTGTTCTCAGGC
TTCCATATTTTCTGTTGAACGGTAAGTTGTCAGTCTAATTGGCATTCCCTTTAAAAATAGACTTGTTTCTCTTGATGA
TTTTACATTGTAATTTTGTCTGATTTTTCAGCACTTCACCGGTCTTTAAATGATTATGTAAGATTTTCATTGCTGAG
GAGGAAATCCTATCACCTCAAATACTATCTTATTAGTTATATTTTCATTTTATTTTACCATGATTTTAAATGAATTC
CTTAAAAAATTAGGTAGAGAACTAATAAATGATAAAGAGAAAAATTATTCTTCATCCTGATAGCTGTTATGTGAGG
GTGGAATGGTATGGCTGGTTTTTTTCTACTGTCATTTTGTAACTTGGAATTTCTTATTTTTTAATACAATGACAATAT
TTTCATAGTTAAAAAACACTAAACTAAACAATAGTCTGTAAATGACAAATTTAAGGGCGATTTCATTAAGTTAAA
AATCCATGTTAAGGCATTATAAGATGAATAAATACTCCAAATGAAAAACAAAGTGAAGGCCACTTTTATTACCTTTT
GTACATGATACTTATTTTTCAACAGTTGTCATGTTAGAAAAAGTTGAAAAAATAAAACAAGATACACCCCTTTTGG
CCTCTAACCTTCCAAAATTGTAATGGGTAGACTTCAAATTAATAATCTAATTCGACTCCTTTCCACTTCTACCCTCA
TAGCATTAGAGACATTTGGAAAAATGAAAAAATATAGTATTTTATGGCAGGGTACCTCAACCCAGAGCCACAGAC
CCGTACCAATCCGTTGCTGTTAGGGACCCGATTGCGAAAGCAGTAGGTGAGCAGCAGCGGGCTAGGGAAGGAAGCT
TCATCTGTATTTACAGCTGCTCCTCATCACTCCATTTCTGCTGAGCTCCACCTCCTGTCAGATCAGCAGCCACATT
AAATTCCCATAGGAGCACAAACCTATTGTGAACACTCATGCAAGGGATCTAGGTTGCATGCTCCTTATGAGAATC
TAATGCTGCATGATCTGTCACTGTCTCCCATCACCCCCAGATGGGACCATCTAGCTGCAGGAAAGGAAGCTCAAGG
CTCCCACTGAATCTACATTATGGTGAGTTGTATAATTATTTTCATTATATATTATAATGTGATAATAATAATAAAT
GTGTGCAATAACTGTAATGCACTTGAATCATATGAAACCATCCTCCAACCCGGTCCACGGAATAATGTCTTCCAC
AAAATCAGTTCTGGTGCCAAAAGGGTCAGGGACCCTGTTTTATGGGATAAGTGAAGCTGGATTGTAATCCAAC
CTACCTTTTACTTCCCATGTGAACATTAAAAAGATGACTTAATGTCTCTGAATCTTTTTTCTTCTAAGTAATAACT
ACCTTGAGAGTTATTACTTGAATTGGCCATAAGGTAAAGAGGACACCAAATACAGTAAATAATAACATAATAATAA
AGAAACCTTATGAATTTCTATTGAGTATCCATATTGAGGTATTTAAGGTGAATGATACTGATGTCAGCAGTTTAC
CTGGATATGCATCAAAAATATGATTGATTGATGGATGGATCGGAGGAAGGAAAAAGATATGTGATCAAAACGAGTATA
GTAAATGTTTCATGGTGGAACTTAGATATATAGATATCACTTGTAATTTTTAAAAATGTTATTGCAATTTTGAAATT
TGTTATGTTAAATATTGGGTGAAAATCTGATGCCCTGGCCATGTCCCAATCAGTTGAATCAGATCTCTGGTGTA
TTTTTTTTTAAAGTACTTGGATGACTCCATTGTACAGCAAGTTTGCAACCCTATTCTAACCCTTCTCACCACCCCT
TTCTTTATAGCTTACAAAATTATATTTTTAAATGTCAAATGTCACAATTTTCACTTTCTTCTTCAAGAAGTATAG
ACTTCTAGCTTCTCCTATGCTCTCATCTTGCTAACGTTTCAATTTGCACGTGGTTAAAACTGATAGGCAATAAATAAT
AACCCTCTGTCTTTTCTGACCCAACATAACTAAAACTTCTTTTCAAGGCGAAAATGAACATAATCTCACAGAC
AAGAGTAGCTATAGACAATAATTCTTTCTGGTCTCTCGTGGTCACTGGGACTATTCACCCTGCGCTCCCTGCTGTC
TATTTGGTGGACAGCCAGTTTTACTGTGACCCATACCATGGCTCTTGAGAAGCATGAAGCTGCCGAAATCGCAGTT
GTAGGGTTAATGGAAAACATGGTGAAGTATAGCTTACATATATATACAATTTTGGCACAAAATGAAGCCTAAGAAAT
TGTACCGGGCTGGGTGTGGTGACTCATGCCTGTAATCCAGCACTTTGAGAGACCAAGGTGGGCGGATCACCTGAGG
TCGGGAGTTTCAGAGACCACTGAGCAACATGGAGAAACCTCTCTACTTAAAAATACAAAATTAGCCAGGCATGGTGG
CGCATGCCTGTAACCCAGCTACTCAGGAGGCTAAGGCAAGAGAATCTCTTCCACCCTGGAGGCATAGGTTGTGGTG
AGAGAAGATCACACCATTCAGCTCCAGCTGGGGCAACAAGAGCGAAGCTCCGTCTCAATAAATAAATAAATAAATAA
ATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA
CTCCCCCTCCAAGAAGTTTTTTTTAATTTATTGTATTGTGAAAAGATCTGCAGCTATTTATTTTGTGTGGTACTCTTT
GCAATAAACTACTTCTGCATAAATGAACTCAAAAACTTTGATATTTCATGAACCTTCATAATGTTGATCTAGTACATC
TTGCCCACTAGCCCTTGGGCCATTTCCTTCCATGCCACTGGTTGAAAAATATGCTCCCCACCCAGTAACATCAGCA
TCAGACCTCTGCAACCAGAAAGATTCCATAGGTAATGAAATCCAAATGCTGGCATTGGAAGTCAAACAGTGTATT
TTGAAATGGAAAGGCAAGGGGAAGTGCATGGAGCAAGTACAGCATGTGCTACAACCTCAGTTTACATACCCTCCTTAA
ATACTGTGCAACTAACTGTCAATTGCCATTGATAGATAGTATGTTTTCAGCTTTACACCTTCCGATTTCAAC
ACACTGTAGCCTCAGGACTAAGCGCTCAATAAATTTATCAAAAGATTGAGTAAATGAATCAGTGGTGAATAA
ATGTACAAACACATACGCTTCATACACGTTTAGGAAGCATTTCTAGTGAGCTTTGTGGATATTTTATTTCTTAAAGG
TTCTTTTTCTTTCCATGTTTCATGTTATTCTTTATTTTTTAAAAATGTTGCTTCTGCTTATTTCTCTTTCTACGGCAGC
TATATTTACTTGCTGAGAGCACAGCATATACTGATGTTAATCAAACCTTTAGATGAAACACCTAAAATGATAGAAAA
GAATCTGCTCTAATTAATAATAAAGCAACCCCTACAGGTTTAGACATGTGCCCTCCGGTGTGGGAAAGAAAAAATT
TAATGAATGTAGTAGTTTTATGCCAAGAATTTCCCTCGTGACCTGTGTTTTAATAAGATAGAATATAAATAAGC
AAAAGGGGCCCCGACTTTTGTGATGATATTTACTCATAAGGTAGTAAGTCAGATGTGATGACATTTTCTTTGACTTAG
AGCTGCTATACTTGGGTGAGATTTGAGTTGAGTAAATTTGCAGTGAAGTTGTCTTTCTAACATGGTGTGATCCTGGA
ACTGCCCTGCTCCCACAGTTACATACAGGCTAGGGAGTGGGTAGGAGTGGGGGTGAAATCCTCTTAATGTTTATGGT
GTCAGTAGATTCAAATAAATAAATAGCCTTACAGCCATACTCCTAATAAGGGGCCCTGGCATATTTAATTGATTTAA
CAAATTTATCAAAAATAGATAAACTGAAATCTGCCTTGAAATTAATTACTGTATCTCTATTTTTATAAGAAAAATATT
TTGGACCCGTTCCCTCTGCCTTATGGGTGCAACTCCCGGCAGAAATAGGTCATGTCTCCTGAAAAATAGTTCTTATTTT
CTTTACTACTTATGACCTCTTATAGCCTAGAAAGTTTTCTTGTCTATTTCTAGTTGAAATGCTAATCTGGCATAATT
TCTAGTTGAAATGCTAATCTGGCATAATTTCAGAACTAATTTCTGTAAATGCCACTTGGAACATCTAAATTCCTCC
TTTTTCAATAATACTATATTTGTGTGTTGCAACACACACAAATCATACTATATTTGTGTGTATATATAGTAAATTC
CAACTTATAAAGTAAATTTGGAATTTTTTCTTTCTTTGGAAAAATTTTTATAAATTGAGAATTATAAATGTCAT
TATGTTCACTAATATGGTAAATGAAAACCTTTATGTGTGTATAGGCTCTTGTTAATTATAACTACCTTACAGGAAA
AACAGTCTTGTGGAAGGTAATGGTGCCAGTTGAGAGAAAAATAGAGAAAGTAGAATAGTAGTAAGAGAGAAAAATAGA
TTCCCGTTTAGAATAAAGCTAAGTAAAAAGTGAATTTGTTTCAGTTTTATTTATGTATTTGTAAGTGTGGTCTCATGC
CATATATATTCAAAGATAGACAGAGATCTTAATCTTTAATTTTTTATGGCCAAAGAAAAATGAGTCCCATGTAAAAGG
GACATTTTCGTAAGCTGATCTCAAGTGGTGTATTTTGATTTGCCGCAGCAGCCTATGGAAGAAATATCATTTTGGCT

85

CTTGTAATAACATAATTAGAACATGAAGTAGTATGTTAATAGAGGTTTTTCACAAAGCTGTGGAAGCTTGTCTTATGA
AGTAACTAATTCCAAGGGAGAGAAGCCTTATGGAATAGTGACATTTTAGATAGGGTGTCTATTCTAAAATACAGCAAA
AGGCCACAGTAAAAAAGGAATTTTGGTTGTTATGAAAAATTTTCAGATTTTCTATGTTTTTCAGTACAGTATACATGG
TGGGCTATGTGAATGTTTGTATAGGGACCAAAGTAGGAAAGTGAGGTTGTCTGTTAGAGAGCGCTGAGAAACCGAAAA
TAGGGAGAGATGAGTTGGAATATGCTGAGGAAAAGTTATTAGGAGTTTTCAAGAAAAGGCCACGACAGTGGGGCTAGA
GAGAAGAGGCTAAATTAAAGAGTCATTTCTGGTTTAGAATTGATAAAATATAGAGACAAGCATGATAAGAAAAGAAGT
CGAGAAGTAAACGATGGTCTCAAGATTTCTAGCTTGGAATCATTGACTAAAAATTAAACTAAGGACTGGATTAGGC
CATTCTTGCATTGCTATAAAGAAATACCTGAGACTGGGTGTTTATAAAGTAAAGAGGTTTAATTGGCTGACGATTCT
GCAGGCTCTACAGGAAGCATAGCAACATCTGTTTCTGGGAGGCCTCAGGGAGCTTTTACTCATGGTGGAAGGCAGA
GCAGGTGTAGGCATTTTCATGCGCAAGCAGAGAGAGAGAGTTGGTGGTGGGGGTGGGTGGCTACCTACTTTTAAA
CAACCAGATCTTGGAGAACTCACTCATTTTTCATGAGGACAGTACCAAGAGGATGGTATTAACCGTGAGAAACCACC
CTGATGATCCAGTCACCTCTCACCAGGCCCCACCTCCAACATTGGGGATTACAATTTAATATGAGATTTGGGTGGGG
ACACAGATCCAAATCATATCAAAGACTTGCATGGGAAAAATAAGGAATTGTTGACATAACATCTTTGAGGTTACATC
AAATGTTCTGATGAGGATAGTCCAAGTAGCAGTTGGCTATATACCTCAGATAAGGGCTGAAATTTGGAGCTATGTCA
TAATCAGCCTAGATTAAGAGTCAATAATCTCTGCCATGGGCCAATTACACCCACCCTTGTTTTTGTAAAGTAGT
ATTGAATCCCAGCCATATCCATTTGCTTATGCTCCATGTATACCTTTTTTTTTGAACTTCAAGGCAGAGTTGAGTAGT
TGTAACAAAAACCATACGGCCCAAAAGCCTGAAATATTTGTTCTCAAGATCTTTATCTATAAAGTTTGCCAATACC
TGCTGTAGATGTTAGTTGAAGCTTTGAAAGCAAAATGAGGTTTCATAAGGCAGTGTCCATACAAGACATTTAACAAGT
TTACCTATAAAAACTAGAATTCCTTTGAGGGGAACACATCCTAGTCTCCATTAGCACAGTAGAAGAGTCCCTTATA
ATGGGAAAGAGGTCACTTTAGGTGTTGATGTTGGTGGTACAGGTCAAAAGAAAATTTATCTTTGCTGTTTTATTAGAA
TGCAATAAGTGAAGTTATGAGAAATAAGGGAAAAAATGTGTAGAATTTCAACAGCGAAGAGAGGGGATAAAGGCATG
AGAATGAGTTCCTAAGCTCAAGTATTATAAACACTGTGAGAACTTAAAAATCAAAGTATGACTCCAAACGTATTTGA
AGCCTGAGAACAAGGCTCACAACTAGGGAGGATTAGGGATCAATAAAATAGAGTGTTACAAAGTATAATGTCAATC
CAGAGTTGTAAAAATATCAGCATTGAATATATTGAAAGCAGTAAACTGAATGAGGAGACTATCATTTTATATCACT
GTGTTTATTTCTTTGCTTGTCTATAAAATTTTAAATTTATAAAATTTTTTATTAACAGTGAGAGCAGAACTACCAG
AGTGAGCAGATCAAAATTTGGGACAGATGCTTTTCACTGCACACACTTTTATTTTTCTGCTGTTTCATGCAATTATCTTG
TACAGTGCACATGTTTTACCTAAAAAATTTAAATGGAGTCTCCTGCTTAGGAAAAAAGTATATATTCTGTTTCAAAC
TATATACAAAAATAAAATCCAGGTGACTAAAAACTGACATGAGAAAAAAACAAATTGATAAAGCTTTTACAGTAAA
ATAGAGGAGAATATGTTAATTAATATAGGGTAAGAAAAAATGCTTACACAAATGATGAAGCACTAATCATGAATAA
AAATAATAAAGTGGACTACCTTGTATATTAATAACATCTATACATCAAAAGACAGCACTGAGAGAGTAAAAATGAAA
CCCACAGAGTAGGATAAATTATTTGGAATACACACATAATGGATGAAATGTGTGTATTTCATAATTATAAAGAATTCC
TACAAATCTTTCAGAAAAGAACAGATAATCCAATAGAAAAATGGGAAAAGTCTTGAAAAGTGAACCATGGCACAAA
AAGGGCTTGTGGCCTGCTGGCAATATTCTGTATCTTGACCTGGATGGCATTTTTTAAGGTGATCACTTTATAGTAAAT
AACTAATGTGTTTTATGCATCATAGTAACGTTAAGATTTTTGTCTATCTTTACAAAATAAGAAATCCAAACGGCCAAT
AAATATATAAAGAATTTCTAAGTCCCATTAAATGGTCCAGGCCATGCAAAATTAAACTAAAAATGAAATATCACTGCTT
ACCAACCAGAATCATTGAAATTTATAAGTCTGACAATTCATGTGGTGGTGAGAATATACAGCAATTAGAAATTTCA
CACAATGTTACTTGGTCTGTGAATTGTAAATAGAAAGTGAAAAATTACACTACTGCTTCTTGGAGTGAAATCCATTG
GCACTATTTAGTAAATTCAAAGATCTGCATAACCTATAGCCCACCAATTTCACTTCTATATATACACTCTACAGAAA
TGCATATGTTTCATATTCCAGGAGACATGTTTGGGAATGTCATAGCAGCATAGTAATAGCCCCAAACCAAACTACTT
CAGTATTTATTAATAGTAAAATTTGCTATAGTTTGAATGTGCTCTTTCCAAATTCAGGTGTGATAATGTGCTAGT
ACTAAGAGGTAGGGTGTAAAGTGGTGATTAGGCCATGAGGGCTCCTTCTTTGTTAATAAAAAATAAGACCCTTATAA
ACAAGGCTTACGACAGCAATTCAGTCAGCTTGCTTCTTGGCCCTTCTACCTTCTGCCTTGTGAAGATACAGCAGGAAG
GCCCTCACCAGACACCAATGCCAGAGCCTTTATCTTGACTTCCAGCCTCCAGAACTGTGAGTGAATACATATTGGT
ATTATTTGTAAATTACCCAGTCTCAGGCATTTTGTGTATAACAGCACAAACAGACTAAGCAATCATACAGTGAGAAA
TTAATCAACAACATAAAGCAAAAGAGGTAGATTAATCTTGAACTATGATATAGAGTGTTCCATTTGGCTGCTGGAA
GTTTTATTTCTTGGTCTGGGTGATGGTCACCATGGGTTTATATGAATGGTTCCCTATATTATGTTTCACAACAAAAA
GCATTTAAAAAGTAAATATATGTAATGTACTCAGGGATAGGCATGGCCAACCATGGATTCTATGCTGAAATAATGAT
TCAGATTTTCATCAGCAGGCTAATGACACTGCCTATTTAAATACTTTAAGTCCTGAAATTAAGAAGGTAATTTCTCA
AGAAGGAATTTCTAATTTATGGGTGGGTCTATTCCCCACCAGAGAGACACTAGCATGGCTCAGATTCTATGTTGGTC
ATTTTATTTGCATTTAAAGTCTTAAGCCAAATAGAGGTACACTAATAATGACAACAACACTACTACTACTACTACTTGT
GGAACACTGCCAGATGCTGTTTTAAGAAATTTGCATTTTCATTTGTAAGTACTGAGCTTACTTGAATCTTCTCTCTTTT
TTCTTGGTTAATCTAACTACTGGTCTATCAATTTTACTTATCTTTTCAAAGAATCAACATTTTGTTCATTGATCTT
TTATATTTTTTGTTCATTTTCAATTTTCAATTTAGTTCTGCTCTGATCTTTGTTATTTCTTTTCTTCTGGAGCTTTGTGTTGGCT
TTGTTGTTGATTCTCTAGTTCCCTTCAGGTGTGATGTTAGGTAGTCAGACTGTGAACTTTCAGGCTCTTTGATGTAGG
CATTTGGTGCTAGAAAATTTCTCTTAGCCTTGCTTTTGTCTGATCCCAGAGGTTTTGAATAGATTTTGTGTTGAAT
GTGATGAAAACGGAACATTTGTACACTGCTGGTGATTGTAAATTAGTACAACCTACATGGAAAACAGTATGAAGATT
TCTTAAAGAATAAAAGTAGATCTAACATTTGATCTGGAAATCTCACTACCGATTATGTACCTAGAGGAAGAGAATT
CATTATATCAAAAAGACACTTGCACGCATATGTTTATAGCAGCACAAATTCACAGTTGCAAAGATATGGAACCATCCT
AAGTGCCAGCCGACCAATGAGTGGATAAAGAAAATGTGGCATATATTTTCATATACCGTGAAATCAATTTACGCCAC
ATACCATGCAATACTACTCAGCCGTAGAAAATAATGAAATAATGTCTTTTGACGCAACTTTGATGGAGCTGGATTGCC
ATTATTTCTAAGTGAAGTAATTCAGGAATGGGAAACCAAAATCTGTATGTTCTCACTTATAAGTGGGAGCTACGCTGT
AGGTACACAAAGGCAGACAGAGTGGTAGAATGGACTTTGAAGACTCAGAAAGGGGCAGAGTGGGAAGGTAGTGAGGGA
TAAAAAATTACCTTTGGGGTGTAATGTACACTACTTGGGTGACACGTGCACTAAAAATATCTGATTTTACTTCTATAC
AATTCATTTCATGTAACCAAAATCACTTGTATTCCAAAGACTATTGAATTTGAATTTTTTAAAAACATTAATAAAAT

AAAAGATGTAAAAAAGAAATTTATATATACTCATTATTGAGCTCCCACAATTAACCTTAGGAGGTAAGTACTTCA
TAATTGGTAGTATACTTATCTTTTACTAAATATTTGTATTACTTGGGAAGTTGAGGGTTGGGGAGAAGTAGCAAGGT
ACTATGATTTGGGGCAGATAACTAACTTATTTATTCGCACATACAGTTTGGACCATGAGACACGAGCTCAGGTCCCT
CCTCCTCACCTAATCAAAGATGAAATATGTGGGATGGGATGAAATAATCAGCAGTCCAATGCTGAGTTTCCAGACCG
AAGTATAAAGCAACAATGGATATGTCAGAAGTCTACTAGGGTGTATTATTTAAATCTATTTTCATGGAATTTACTA
CCACCTTAATGGCCCGAAAGTGTTAAAGTATGCCCCAGAGTACCGAATTACTCCCTAAATGTAATTTATGCTTGAGA
ATAATCTGACTAACTTGATTTAGAACATCAGAAAATAAGTTATGCTGCACATAAATGAAGCAGCAGTGTAATTTTAA
ATACCGGTTGCACGGTGAATGAGAATTTTAATATTTGCAAAATCTAAATCACTTGATTATTTATCCTTATGTTTTA
TACTGACATTTTTTTGCCCTTTGTAAAGTTCATGCCATATTTCTTCTTACTGCCAAGAAAAAACTTTTTTTCCTA
GAAATATTACAGAAGGCCAAAAATTATATTTGTTTTCCCTGAATGCTATTTTTTGATGTCTCTACTTGTTCCTATTGTT
ACCATTTGCTTCATTTCATGGGCAGCCCAATTAATGGAGCGAGACAAATTTAGGGAGCACAGTGACTAATTAGATATT
AAATTGGTAAATCTAACTTTGTAAAACAGAAAAAATATATATATATTTTTTTCATTTGGAATTTTCCTTGGTGGAA
AAGAGTTTAAAGTAGTCATGATAAAAAATGTAATTTTACGTAGTAAATCAAGAATAGATTTAGACTGTGCTATTA
ACAGCACCTATTAAATACTGAAAAGTGATTTTTAAATTTTATGTGAGGCTTGAATGGAGTCTAAAGTATTATTAC
TCACATTAAGTGTATCATCATGTAAAGCCCATGATTTTATTCTTTAATATTTTGTGTAATAGTTACTTATTTCAAC
AGTAATTTCAATAATAAAATTAATCAACTTTACAGTTTTCAAAGGTTTAGCAGTTGCATGCTGTAATAAATACTTC
ATATTTATATATTTTATAAAGTGACAGCATAAGTCATTTTTATTAGGTCCTTGAGGATGCAAAAGTTTGGATTATACG
AGGAGACGAGAGAAAAAGGGAAGAAGGGCATTTTCAGAAATATGCTACCGATATGCAAAATTCACAAGTCCTAAGACAG
TAGCAGGGGTCGGGCAGAAAGTCCATCCTGCCTCCCTCTTGTGGGCCTGGAACAATGGTGTAAGTGGAAGGCCCTGTT
CCCCTTCTCTTCTACCTCCAGCTCTGTCTTACAGAGCTACGGATACCATGAGCAAGTGATGAACCCCTACGGTTT
TCTTCTCTTGGGAGAATGTAAAGGAAAGATAACTTGTAGAAACTTGTAGATAACTTGTAAAAAGGAAAAGAATTACAG
GGTGAGAGGGGGATTTGTTGAATTTGATAGAGGATGGCAATTACCAATATGATGAGTGATTGAGAAACAAGTCTGTG
CAACAGGTTTGAATCGAAAATCTTTGAGGTGTACAGGATCCTGAAATGAAGAATGGGCATTTATAGCAGTATGTCA
GAGAAACAGTCACCTCCTAGTAGCTAAAAGTGTTGGCAAAAGTATAGTTCAAGTGATTGGGTAGGAAAAACAGCAAA
CCAAGAGTGGAGACTGATGGTTGCTACAAAGGTGGAGTGGTAAGTCGTGACCAACTGGTACTTCTCTGTGCTCTGGT
TAGCTGCTGACTGTTTTCTCAGACTGTGGTAGCAGGAGGAGGTGGAGTTAGCAGTCATTTGTCATAGACTGAGCTGCCA
TTTTAAAAAATTTTAAATTTTTCATTTTTCTGACTCTCAATATGAAAAGCACATTGTAGACAAATTGAAAAATA
TAGAAAAATTATATAAGAAAAATATAGTCTCACCAGTATGGAACAATGCTAACTATGTTGCATAGATTTTTTAGATTCT
CATTCAAAAGCAACTCTTTGACTCCAGTGATGCAATGCATGTAACATATGCAATGTGCAATTCATTTTTAAAGGGA
ATAAACTTACGATATATTCATAGGTCAATTTATTGTGTGTTATATACCATTGAAAATATATGAATGCTAAATTATTAG
TAAACATGCAAAAACATTGGCAAGATCATTTTGTGTGGAAGGATATATTGTATCTGAATAACTCTAGAATACCATA
AATCATCAAAGGCAACATTCTTATTTTTCTACTAATACAGTTAGAGAATACCTCTTCGGCTACCTTCGGTTGCCTTT
TTTATGCTACCAAAATGCTGTCTGTTTTACAAGATTTTAAAGGTTAAGCATATAATTATTCATTAAATACAATGAGT
GCAATGTACATGTAGATACATTATTAATTTTGGGTAGTTAATAAAAAAAGGGGAAAAAACCTCTAGAATATCAC
TTTTAATTGTTTAACTGATAAAGTGAAGCTTCATCTTGAAAAATAATTTTCACAAGAGAGCATGTGCACTGGTAGAA
AAGTGCCATTGAAACAAGAGATATTTGGGTTAGAAGCCTCTCTCTACTATTTAATACCATTTTCACCTTTTGGCAAA
TTACTTGGCCTCTGTTTTCTCCAATGGAAAAATGGGAATAATAATTGTTATGCTGCAGGGTTATTGTAGGTGTCAATG
AAATGATGTGTCTGGCACTATAAAAGCACAGAGCCCGGTGCTTGGCTATTAGTAACTGTTTAAATAAATGTTAATTCC
TTTCTCTGCCCAGGACATCAGTAGGCAGATGTAGCAATTTAAACTTCTAGTGTTACTTTAAATTCCTGAATGAAGG
TAGAGGACTGAAAAGATATCATGGTATTCAAAAGTATGATCCATTGCTTCTTAAGAATAGAGTTTCAGAAAAGCTTGA
CAGATTCCTGTACTCTGAGGCAGCACCATAGCCGGTAATCTGTAGGATGGCTATTGGTTTTGTGCTCACAAATGCTT
GCTTGGGCAGGCCCCAGGAAATCTGGTAGACTGTAAGCCAGTAAGATTTCAAATCTTACTTTACGGCAGTGTTTTT
CACCTTGACTGTACATTGAAATCACCTGGATGCTTTGAAAAATAACAGCGTCAGTGTCACCTCCAGCAAAATACATGA
TTAAGTTGGTCTGGAATGGAGCCCCAGGATCACTGTTTGGTTATTGTTGTTGCTGTGTTTTAAATGCCCCAGTTGAT
TCTTATGTGCAACTGTCTTAGGTAAACATACAGCCCTGGTTTCATATTATTTCTGCCTCAGTCTCTTTTATGACTGGA
AGGTGACCAATGCTTGTTTCTTAATATTCTTTCCATGTGTAGTATTAACACATTTGACTTGTACTAAGTTCTTGCA
GTATTCCAATCTAAATTTTAGTGACTACAATAAAATAAGAAGGATTAAAGAAGGCATCGCATAGTTTAGTATATCG
GTTATTTAATGCTTACATGTGAGCCTACAATATGAATTATATCTGTCATCTTATTTTAAATATTGACAGAATCTTTA
ATGATAGTGACGAATTATTGATTTATTGGTGTGATAATGGTATTTTAGTTATATTTTTTAAAGTTTTATTGTAAATA
CTATATGTATTTATGGGGTACAGTGTGACGTTTCAGTGTAATGTTTCATTGTGTAATGATCAAATCAGGTTTCTTGG
CAGATCCATAGCCTCAAACATTTATAATTTCTCTGTGGTGAGAAAAATTTAAATTTCTTTTCACTATTTTGAAATAT
ACAGCACAATATTGGTAACTTTGTTTCATATTACTATGCAATAGAACACTAGAACTTATTACTCCTTTTCAGTTGATGA
ACAGGCAGTTTTGGATCAAGAATAATATTGAAAGTGATAGAATTTATGAAGTAATTTTTATCCAAAAATATTTTGAA
AGGGAATATATTGCTTCCAAATAATTTATTACAATGTTAAGATATTTGTAAATTTCTAGAATTTAAAAAATATATTT
TTAGGAAAGAAAATGCCAATAGTCCAAAAATAGTTGCTTTATCTTTCTTTTAAATCAATAAATATATTCAATTTAAAGG
GAAAAATTGCAACCTTCCATTTAAATCAGCTTTTATATTGAGTATTTTTTAAATGTTGTGTGTACATGCTAGGT
GTGTATATTAATTTTTATTGTTACTTGAACTAACTCTGCAATGCAGGAACTATCAGAGTGATATCTTTGTCA
GTATAACCAAAAAATATACGCTATATCTCTATAATCTGTTTTACATAATCCATCTATTTTTCTTGATCCATATGCTT
TTACCTGCAG (SEQ ID NO: 269)

[000204] *Homo sapiens* dystrophin (DMD), intron 43 target sequence 1 (nucleotide
positions 1057082-1057131 of NCBI Reference Sequence: NG_012232.1)

GTAGGTAACACATATATTTTTCTTGATACTTGCAGAAATGATTTGTTTTTC (SEQ ID NO: 270)

[000205] *Homo sapiens* dystrophin (DMD), intron 43 target sequence 2 (nucleotide positions 1127297-1127546 of NCBI Reference Sequence: NG_012232.1)

TTTTAAAGGGAAAAATTGCAACCTTCCATTTAAAAATCAGCTTTTATATTGAGTATTTTTTTAAAAATGTTGTGTGTAC
ATGCTAGGTGTGTATATTAATTTTTATTTGTTACTTGAAACTAACTCTGCAAATGCAGGAACTATCAGAGTGATA
TCTTTGTCAGTATAACCAAAAAATATACGCTATATCTCTATAATCTGTTTTACATAATCCATCTATTTTTCTTGATC
CATATGCTTTTACCTGCAG (SEQ ID NO: 271)

[000206] *Homo sapiens* dystrophin (DMD) intron 43/exon 44 junction (nucleotide positions 1127517-1127576 of NCBI Reference Sequence: NG_012232.1)

TTTTCTTGATCCATATGCTTTTACCTGCAGGCGATTTGACAGATCTGTTGAGAAATGGCG (SEQ ID NO: 272)

[000207] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, exon 44 (nucleotide positions 6535-6682 of NCBI Reference Sequence: NM_004006.2; nucleotide positions 1127547-1127694 of NCBI Reference Sequence: NG_012232.1)

GCGATTTGACAGATCTGTTGAGAAATGGCGGCGTTTTTCATTATGATATAAAGATATTTAATCAGTGGCTAACAGAAG
CTGAACAGTTTCTCAGAAAGACACAAATTCCTGAGAATTGGGAACATGCTAAATACAAATGGTATCTTAAG (SEQ ID NO: 273)

[000208] *Homo sapiens* dystrophin (DMD), exon 44 target sequence 1 (nucleotide positions 1127547-1127601 of NCBI Reference Sequence: NG_012232.1)

GCGATTTGACAGATCTGTTGAGAAATGGCGGCGTTTTTCATTATGATATAAAGATA (SEQ ID NO: 274)

[000209] *Homo sapiens* dystrophin (DMD), exon 44 target sequence 2 (nucleotide positions 1127595-1127643 of NCBI Reference Sequence: NG_012232.1)

AAAGATATTTAATCAGTGGCTAACAGAAGCTGAACAGTTTCTCAGAAAG (SEQ ID NO: 275)

[000210] *Homo sapiens* dystrophin (DMD) exon 44/intron 44 junction (nucleotide positions 1127665-1127724 of NCBI Reference Sequence: NG_012232.1)

GAACATGCTAAATACAAATGGTATCTTAAGGTAAGTCTTTGATTTGTTTTTCGAAATTG (SEQ ID NO: 276)

[000211] *Homo sapiens* dystrophin (DMD), intron 44 (nucleotide positions 1127695-1376095 of NCBI Reference Sequence: NG_012232.1)

GTAAGTCTTTGATTTGTTTTTCGAAATTGTATTTATCTTCAGCACATCTGGACTCTTTAACTTCTTAAAGATCAGG
TTCTGAAGGGTGATGGAATTAATTTTACTGTTGTTGTCATCATTATTAATAAGAAATATCATAATGAT
AATATTAGAGCACGGTGCTATGGACTTTTGTGTCAGGATGAGAGAGTTTGCTGGACGGAGCTGGTTTATCTGATA
AACTGCAAAATATAATTGAATCTGTGACAGAGGGAAGCATCGTAACAGCAAGGTGTTTTGTGGCTTTGGGGCAGTGT
GTATTTTCGGCTTTATGTTGGAACCTTTCCAGAAGGAGAAGTTGTGGCATACTTAGCTAAAATGAAGTTGCTAGAAAT
ATCCATCATGATAAAATTACAGTTCTGTTTTCTAAAGACAATTTGTAGTGCTGTAGCAATATTTCTATATATTCT
ATTGACAAAATGCCTTCTGAAATAGTCCAGAGGCCAAAACAATGCAGAGTTAATTGTTGGTACTTATTGACATTTTA
TGGTTTATGTTAATAGGGAACAGCATATGGATGATAACCAAGTGTGTAGTTTAATTTCAACTTGTGGTGTCTTTGA
ATATGCAGGTAAAGATAGATTAGATTGTCCAGGATATAATTTGGTTGCTAAATTACATAGTTTAGGCATAAGAAACA
CTGTGTTTATTACACGAAGACTTAATTATTTTTGCATCTTTTTTAGCTCAAATTGTTTCATGTTGCAATAGTCAATCA
AGTGGATTTGAATTGTAGCCAATTTTTAATGCCAGAAAAATACTGATTAAGACAGATGAGGGCAAAAAACACCCAGTA
GTTTATTAAATACTTTAGATATTTCAAAATGCTGGATTCAAAAAAGCAGTATCACATTTGACTTTACAAGTCTTCAT
TCTCAAATATGTTTCCATAGTAAATATGCCCTTTAATATTAAGGAGTTAAGCATTAAACACCTATTTATATGATAA
GCTATTTAAACACAGAAAATATTTTTAAACCTTGTGTAATTATATGTGTATCAATCAAACCTTGCATGCACACCAGC
GTTGGCATTGTATAGAGAGGAAATGTATGGATTCCCAATCTGCTTTAATATAGAAGATACATTTTAAAAATAGCAC
TGAAGTGAATTTGGGCTAATGTAGCATAATGGGGTTTCTGCCTGAGAGGCAGAAACATATTAGAGTTATATAAAAT

GTTTTGGGGTAGATATAGAAACCACTTGCCATTTTCAATGATATCCAACCCAAGGTAGTTATATATTTCAATTTATA
TTTTATTATCAAATTAGTACTTATTGTGAAAAAATCAAGTAACATAGAAATTTGTAAAAGTACCTCCATTCTACTC
TTTGAGGATAGTTGTTTCAGTATGAATTTTGCTACATATTTTCAGGCTGGGTTTCTTGGAAGCCATTGTAATGGA
GATTTGTATGTAGAAGGTTAACTAGGGAGTACTTTTACGATGAAGCAATTTGTTTTGATGTAACCTGGTGATGTTT
CTTCATGTTTCTTGTTCTTGAAGTCAGTTAAGCTCTTGAATCTGTGCATTTAACATTTTCATCAAATTTAGAAACCTT
TCAACCATTTTTTTAAAAAATGGAACCTCAATTGTACATTTATTAGGCTCCTTAAAGTGCCCCACTACTCACTGA
TGTTATGTTTCATTGTCTGTTTGGTCTCTCTTTCTCTGTAATTTGTTTTATATAATCTCTATTGTCAAATTGACTAA
TCTTTTTCAAAGTCTAATCTATGGCTAATCCCATGTAGTATATATTTTAAACATCAGACATTTTCATCTCTTAGAAG
TAAAAGTTGGGTCTTTTTATTTCTTCCATGTGTCTACTCAACATGTTTCAGTCTTTACTTTCTTGACTATATGGAATA
CAGATATAATAACTGTTAGAATATTCTTCTCTACTAATTTTATCATCTGTGTCTATTCTGGGTTAATTTAAATTGAT
TTATTTTTCTCTCATTAAGTGTGTTGTTTAACTGCTTCTTTGGATGACTGGTAATTTTTGACTATATGCCAGACAT
TGTGAATTTTAACTTAGCGCGTGCTTGATACTTCAAATAAATTCAAATATATTGAAATAAATATTCTCAAACCTCGT
TCTGGAACACAGTTAATTCACCTTGAAACAATTTGATCTTTTGAGAATCTTCCTTTTATGCTTTGTTATGACCAGAA
CAGTGTAAGTTTAGGGCTACTTTTTCCCACTACTGAGGCAAAACCTTCTGAGTACTCTCTCTGATGTCCTGTGAA
TGATAAAATTTTTCACTGGGGCTCGTGGGAACAGGTGGTATTACTAGCCACGTGTGAGCTCTGGTGATTGTTTCCTT
TAATTCCTTTGTGAAGTCTTTCTTAGCTTTGAGTGGTTTCTTGCATACATGAAGCTGATCAAGACTCAGATGAAG
AATAAAATAAAGCTTTCTACAAATCTCCAAATTTCTCTGTGTATATATCACCTCTCTGGTATTTTGCCCTGTGAT
CACTAGTCAGCTTGGGCTGCTGAAACTCTCAGCTTCATCTTTTAAACAAAAGCCTCCTGGCAAGGATCACTGTCCTT
CAATGTCTGATGTTCAATGTGTTGAAAACCGTTGTAGCATATATTTTGCTTTTTTTTTTTTTTTTTTTTTTAAAGT
GTTTCAGGTGTTTCAGGCAGGAGATTAAGTTTCAGCCTCCTTTACTCCAACCTTGAAAACAAGTCCAAAACAACTATT
TTGATGTAATTTGATCTTTTAAATACATTAACTTACACAATTTTGTAATATATCATAATTTAAAATTTTCAGAGAA
TGTCTAATGGTCTCATTTCTTGACAGTGTGGTTAGTTGAAACTGATGAACATTTTATCAAACCTTTTCCCTCAA
TTGGATACTTTTTTTTTTTTGAGATGGAATTTGCTTTTGTCACCCAGGCTGGAGTGGCATGATCTCAGCTCACTGC
AACCTCTGCCTCCAGGCTTCAAGCAATTTCTCTGCCTTAGCCTCCCGAGTAGCTGGGATTACAGGTGCCACCCCCA
CAGCTGGCTAATTTTGTATTTTGTAGTAGACGAGATTTCACCATGTTGGTCAGGCTGGTCTAGATCTCCGACCTC
AGGTGGTCTGCCTGTCTCAGCCTCCCAAAGTCTGGGATTGACAGCGTGAGCCACCATGCCTGGCCAACCTGGATAAT
TTTTAAAAGACCATTTTATTTAGTCTATTTTTTCTCAATCTATAGATGAGATAAGAAAAATCATTCTAGATGTCCAA
GGAAAAATTTCTTTCAGAAAAAGAGCTGTGAATGATATCACAAACCCCCCAAACAGTTAAGGTATTTCTTCTCGGTTA
TTTTATGTCCAAATCATGCATATGAACATGTGCACACACATGAGCGTGCACACACACATGAATACATATACACGCA
CATAATGTACCTTAGGTTATCTTTCCATTCTGAGTAATTATCGTAAAAATGGGTAAAATCAACCCCGTAAGATACCTT
CATCGATAAGGCAAATCAAAGCTTTGGTAATTTCTGCTATCTTGGCCTTTGTTGATTGACTAATAATGAATAAGAGA
ATGAGTTTCAATATTTACTATGAAATTATTTTGAAGACAGGATGTAGACAGTGGCTGTTAGCAGGCAATTTGTTTGG
CATGAGCCAGTAATGGTTACTGTGAAAAAATCAACCAAGCAGCCCATATATTAACAAACACACGCAGAAGCACGT
TGGAGTCTGAAGCCTCATATGTACAATTTTCAGTAAAGAAATAACTTTTAGATATGAAATAAACAAATAGATATATG
TTGTAAACTTGTCCCTATGTATTTTGATCAAATTGCATCATATTTTTTTCACTTTAAAGAAGAGAATTTAGTGCTTT
AACTGAGACTTAGTGTTATCATTCAAAATATACTGACTGCCAATAGCAGTAGAAAGATAATCTGGTTCCATGCAACT
CTATTTTTTTTTCTCTGTGCGCAAGTAAAAGACAAAATTAAGTACATGAATTAGTGCTTTTTGAAGATATTCCAGAGC
AATATACCATGCCACTATGGAGAACCTCTCTAAAAATATCCCATTTTTTTTACCTGAGAAAAATATTGATCATGTTAT
ATGCCACTCAAATTTGGTTTATTAAATTCGTTGAATGATATCAGCATCTCTTAATGCATTCACTAAACAAGCAGTAAT
TGAGTGCATATACAAAGTTTTATCATCCACCAAAACAGTGACAATCCACATGAGGCTCTAATAGAAGTTTAGAAAGG
GGGTTAAGTGGTTAAATGCTGGACTCAGAAAGATTGGATTCAAATCCCAGGTCTTTAGCTTAATAGTTGTAGAAATC
TTGTGAAAATATCTTAATCTTTTCATGTCTCTGATTTCTCTCTCTTAAATGGAATATAAATGAGATGTGTATAA
AGCCACTTGAATAGCATTTTGCACAAAATAATTACTCATTAAGTAAAGTAAAGCCCTATTATAACTAATCACTCTTTAT
AAGTGATTAGTTTCATATCAATACAACTAAGACTTATTACTGAATATATCGTCTCTAAACATCCACACTGCAGAAAA
ACCAACCTGGAATTTTCAATAAACCTTATTTTTATGTAGTATAATTTCTTCTCAAAGCATAAGGGCTCTTGGATTAG
GAATTGAGGAAAATTTCAATTCAGCCAAACGCATCTGTTTCAGATAGCTGACACTTCTGCCTACTCATTTCTTAGCT
AACAAGAAGAAATGTTAATGGGAGTTTTCAAAGGAAAAGCTGAACACCATGAAGGAAAGTGACACAAATAATGTTAG
CTCATATATTGACAGGGTGAATTTGTGTGCTTTCAAGTCCCTTCAGTGAAAAATAGGAAAGTAGAAATTATAAAATGC
CCTAACATTTAAAGCTAGCATGTTCTTGGAGACTAGGAAAAAATAAGTTTTTAAACATGGGCTATGATAGAATGAGA
TGGAAAATGTTTGTAGTTGCCAGTAGAAACAATAACAATTACCATTAGATTAAAGTATTTAAACCAGCTGAATATTTT
TATTAATGGAATGGCATCTGTTTTATGAAATAATGCTGCTGAATGAACCATATTAATAATGACCAGTATTTCTCTGC
AGAACGTTGTGCGCAGACATACAAGCCTGAGACCCTAAAATCTTAAGGTATTCATTTGAAATCGACCTTAAGACATT
AACAGTAGTGGTATTGTTTAGATGAAATTTTTTAGGCTTTAAATCAACAAATGTTAAGCAGACATGGGGAGCGAAAC
ACCAGTGTGTTATTCTGACATGAATAAACTGCTGTTTTTAGGGAAAAAATATAGTCTTGTTAAGGTTAAGCTAATTG
GTTTTCTGGTATCTTTTGCAATGTTAGTGTGTTTTACTGCTCCATAACCTATGTTATATGGTAAATGTGCAATATAT
TTATATATGTTGCTGTAAAGAAATGTAATAAAAAACTGTTTACTTTGTGATATGAAAGTAAAAATTTATTCATTGTC
ATTGAGCATACAGAAGTAAATATGGATTACATATGTCATATTTTAAATGTTTCATGTTCCACCATCAAATGTTGAA
AACTTATAGTTTAAAGTCATATTCTATTGAAGAAAAATACACTCCCTTTTCTCAAATGTGAAATGTCCAGAGAGAA
TGGAAAATTACATATAAAGCATGTAGTTATAGCATGGTGACCCTGTGTGATCTCTCAGATGAGGAACAAAAGGGAG
AAAGAAGAGCACACTGGTGCTTTTGGAGTTGAGAGAAGGCAAAAAAGAGTACAAAAATGTCAAAGCCAAGTTTAGC
TGCTCTTCAGCTCTCCCTTTAGCTGCTCTTCAGCTTTTACCTTACCATTGATTAGTTAGTTGAAGAAAAATCTAAAG
CACTTTTTTAAAGGACCCAATTCTGAAGAGTTTATGATTTCAGAGAGCACAAATGGAGTTGGAGTGACTCTGTCTCAAAG
TTTGAGACAAGCGAGTCCATGAAAAGACCGTCTCTCTTAAATGGAAAATACCCAGGTTTTTCTCATTCTTCTCGCCTT
GCTTTCAGCACTCGCAGCCCAGAAAGCCCTTATCTAACAGGTACTGCCGTTGAAAGGTCATTGACTTGTACAAAAAT

GATGAGTGTCTGAATAGATGTGCATAGGTCAGTACTGACAGTATCTGCTACAGAGAATGAGTTTTCTGATTTTTATTAGGA
TACACCTAACATGGCAATCTACTGCCTCAAAGAACTCTATAGGAGGTAAAGTGAATTTATATTAATACAGATTGAATT
AAAGGATAATCTAGAAAAAGGCATATGATGTAAAAAAATCAGACACAAGTATATTTTCTGTATAGTCAGTTTTTACA
TTGTGATTTTACCAGCTGGCTGCTGAGTTTGACGGCTTCTTAACAGCCACACTGCTGAGATTCAAATGCTGATAGAA
ACTTTGATGGA AAAATCACTGGAGTAAATATTTCTACCATCTGTTGCCCTTCACTGGGACCCTAACGTTAAGAATAA
TTCATACCATTGCTTGTCTTTATATTTCCCCAGCAGTAATAAAATTTATAAGATTTTGTGTTTGTGGTCACAAAGC
TATCCTGGTTTTCTGTAAGTAAAGACATACACTAGCATAAGGGAATCAGCCGGAAAAATTTACTGCTAAGAGAATTTG
TCTCTAGTCACTTACTTTAAGGTTACAGCAATGTGTAAGTGTGGGAATACATTTTAAAAATGAGCTTTTCAAAGTTAT
TAGCTGGTAGTGGCATGAGAGTTAAGTCTCTTAATACAGTTAAACAGTTGGGCACCTTCATCCTTGCGTAAATATTGT
TACCCTTTTATTGCTGCTTGGAAACTCCTCTGCAACTTTTTTGGCCCCCTATCCATCTTTTTCAGAAGTAGTAAATAACC
AATTTACTGGGAGTGTGGTACCAGGCAGAAAATTCGAGAGGGGCTTTCAATCCTTGCCCATCAAGTGTATCTTTTCAG
AAATAAGTATATTAATAAATTGGATAATTTTCACTGGCTTGTATTAGACTTCCGTTGTCCAGCATGGCATGTTTAA
GAAGATGACAGATTTTTCATACATTATTGGAAAAGCAAGAACAAAAAACATAACTTACTGTAGTAACACGGTAA
AGAAGTGTCTTAAATGCAGGATAAACATGTCATCCCTAAGGGATTCCCATTCTTAGAGCATGAAATTATCAAGAGAG
TAAGAGACTACAAAAAATGAGAAGAATGCTGATTGCAAATTCAAAATAGAAAAAATCAAAACAAAACCTGCGCACCAT
CATTCTGGAAGCAATGAGAAGCAGAAATGTCAATTAATGAAATGTAAGATTAAAGTTAATAGAAGTAATTTTCATG
AAATAATATTTTGAAGGACGATGTTCCAGCCATATTGATCTTCGTGTTTTCTTTTTCACATCCCTTCTTACTGTTCC
CTAGAATGCTTGTCTTACCTTTAAATTTGCTTTTCTCTTACCAGAGGGCTTACCTTATCTCCAGTTTCTCACCA
TGTCCCAATCTACTCCCTCTCAGAAATTTTGTACACTTCCCTTTATATATATTTGTGCTCTAATTTTATATTTCACAG
ATATGCCTTTTGTAACTCCCCCATCTTAAAGAAAAGCACACACGTACGCACACATGCACACACACAAAATTGAACCTCT
TTCTGGGAGATCTGCTTAACTTTCTTCATAACTCTGTCAGTTGCTGAACTGTAGTATGTGTTTTCATGTTTATTAT
CTTTTCCATTAGAATGAACATATTTTGGGTACTTGGTCTTTCTCGATCACCAATATACCTCGGTACGTAGAAAAATT
GATTCATATATTGAAAATGTAATATTTCAGTAGAACGAATAAATACATAAAATAAATTTAAAAATGATACTTTTATTGT
ATTACCTGAGACAAATGATCCCCAAGTTTGTCTTGTCTTTTCATAGCCAAAACATTCTCTCTTACATTGAGCTTCTCT
TCACCTCTTCTGTGTACAGAGCACTTAAATTTTACATATGCCTGTATCTTTAACAATATGATAGCCCTGTTCTCTT
ACCCATTGGAGCATATGTTAAATACCAGAACCCATGTAAACAAACATATATTGTGATCTTACTGTGTGCAAAAGCAGAT
ACTGCTTGCTGCTAGGAATACAGAGCTGACTAAGAGCTCCTTTTCTCTTTATGAGCTCACAGTCTCATGAGTTCAAC
GTCTTAAGGCACAACGTCTAAAGCAAAGGGCAGTAAGTAAACACTCCAGAAAAGTACTGGATCTGGCCTAGGACAAAT
GGTGGGTTGTTTTTCCAGCTGTTATTTTTCTGCCCCCTAATTGACAGTCTTCCATTACACCTCTGGGATACCTAGT
CTGACTTGGGAAAACCTGACTTTGGGAATCAGAGGCAGTCTCTCTTGTCTTATATATGAGGAACCTAATGGATACTT
ACTGTCAATTAGAGAACTCTGCTTCTAGCCTGGCTCCTTTGTAAAGAAGGTTGAGTCCCCCTTGGAGAGCCTGCAGA
ACATAACCATTGTCATGTAATGAACAGTTTGTAACTTTGAGATTGATGTGCAATTTCTATTTGACAAGGGAAAAA
CAATTAGGATTAAACCGTGGTCGTATATCCCAGAATACCAACGTTGTTTCCACACTCTAAGTGTGTTGGGTCAATTAT
ATGAGATTCAATAATTTGTCTGTTGTACCCACGTTTGCAATTACCATTCACTCTTAATTTATTATACCCTATTAAAA
GTTTTTTTTGGTAATTTGTTCTTATTGCTACTCAGGCATTAAAAATGTCTGCAGGCTGTGAAAATGAATAAATTTAATG
TGGCAGCATAGTTCTCAAAATCCTGGCTTTACAACCTCATAGTACAGGCTTGTATTGTAATCCTAGTTAACATGGAT
TTATTTGAAAATCCAATTTTACTGCTAATCTTAAATAACACATTTTTCAAACATTTTATCCTTGAATTTCTATTTT
TTATAATTTATGGCTGTTGTATGTATTTACAAAAGGACAATGTGTGTACTTTTAAATACTAGTAATGGATTGCTGAA
ACAACCTGTAACTTTAAACAATGCAATTTGTTAAAAAAATAAACTGTGCAGCCTGGCTTAATGGAGGCTTATGAACAT
ATGATTAAGATATATGCTATAATAAGCAAATTCACCTCAACTGATAGTTTCATAGGAACCTTTCAAATTTAATCTCATAA
CCAGTGCTATCTTTCAAAGAATGGTCAGGGCAATTTAACGAGTACATGACCACGCAAGATAATTTTCAATTGAAGAGTG
GCTGAACCTGTTGAAATATTTCTAGTCTCCTTGGGATATCATTAAGAGCAGAAAATTTGAAATGGAATTGTAATGAT
GTTTCAGAAAAGATAAGTAACTCTCTTAATACGTTTGTGTCTGTGTAACAAAGTACCTAAGACTAGGTAATAA
TTTTGTAATGAACAAAAATGTATTGGCTCAAGATTCAGGAGTCTAGGAAGTCTAACATTAAAGGTGTCAGCCTCTGGCG
AGGGCCTACTTGATATGTCATCACATGATGGACGATTAGAGGGCAAGAAAAGATCAAAAGGGGGCTGAACCTCCCACTT
TTATAAGGGAACCAACCCACTCGTGAGGGTGGAGCCCTCAATCCTTAATCACCTCCTAAAGCTCCCACCCCTTAAT
ACTGTACAAATGGCAATTAATTTCAACATCAGTTTTTGGAGGGAAAAACATTGAAACCATAGTAGTGATACTGACTA
CTACCACACAGGGCTTGGGAGGCTACCCTAGCTGTTGCACCCAAGAGATGAATCTTCTAATGTGATTACCTTTATCA
TTTTTTTTTACTTTATTAATAACTTTTATTTTACATGTATACTTTTGTCTACCCACCATTTCATGTCTGACCACTG
CTACTACTATGTCCTAGCATAACATTCCATACATCCTTAAACCAAGCAAAGGGTGGAGTTCCATCTTTAAAAACTA
AACAGGCATTTTGGACAACACATTCTTGGCAATGGAATCTGGACAACATTTATCAAACATGGTAGGGAAGGTTCTCA
CTCTGCATTATCAAAACGACAGCCAGATATCAACTGTTACAGAAACGAAATCAGATGGAAAATTTTTAACAAATTTGT
TTAAACTATTTTCTTAGAGAGACTTCCCTCCACTGCCAGAGATCTTGAATAGCCTCTGGTCAGTCATCTGGAAGCAAT
TCTTTCACATAATTCATGAACCTTGGCTTCCACTTTAGGAAGAGAACCCACCTTTTTCTATACCTTGCTTGCAATTTTGTCT
TTAATGTCTTCTACAGAACTAGGTCTTTTGGGTGTTTTAGGAGTTTTTCCCTTGTTTTGAAGGATTCTTGTCCTTTTG
ATCTTGGTGTTGACGGTTTTTCTTCACTTTCCTCATCATCAAAATCATCATCATCAAAATCATCATCTTCATC
AGCAGCAAGTTTTTACTTTTTTCTGTGGAACCTTGCTACCACCTCCAGGAGCAGATCGCTTTCCAGATATACTTATGA
GTTTCACATCTCCTCCTGTTCTGCTCTTCTGACTCTGTATCTTCTCTCCCAAGTACTAAATGCTGCCACTCACATGC
ACTGGCCCTGAACACACTTCAACCGTAAGACCACTGATGGTGTTATTTCAAAGCCCTCAAGGGAACCACTGGGCTG
TACAGACATTTTTCAAAGCTGCCAGTGTACTTTAATTGGACTGCTTTTGTAACTCATTGCCTCTGCTTCAACAATGT
GCAATTTATCCTTTGCCCCAGCCCCCTAAACTGACCGTTCTTAAAGATAACTGTTGCTCAATTTTCAATTATTATCCACC
TTAAAGTGATCATCTTTGTGCGCCTTTAGTTTCAACACCAAAAAAGATAGTTTTTGGGGCCTCAGAGGACTCATGTCCAT
CATCGTCCATCAGGTGGCAGGACGCACTTAGGTGGGAGAGAAGGCAGATGATGATAAAGGACCACTGCTCAAGAGAA

91

AATAAAAAATCACAAATGTGAGGTCTCTCTTTAGAGCTGCAAAGTCCAATTCAGTGCCCCCTAGCCACATAAGATACTG
AGCTCTTAAAAATGCGGCTAGTACTAATTGAGATGGGCACTGAGTATAACACACATGCCAGGGTTTGAATACTTAGAA
CCAAAAAGGAAGTAAATGCTCATTTTATTGCATGTTAAAAATTATGGTTTTATTATAGTTGATTAAATAAAATATATAA
TTAAATTGACTTCATTTTGTCTTTTAAAAATGTGGCTATGAAAAATTTCAAATTATATATGTGTGTGATTACATATGT
GTGTTTTACATATGTAACCTGATGTTACATGTGAAATTTGATTGTTACATGTGACATGTAAACACGTTACCTAACAC
GTGCATATGTATGCAACACATATGTAACGTGTTACATATATAACACGTTACATATGTATTGTTACATGTGTGCTTGC
ATTACACACATGCATAATATGAAATTACATGTAATTTCAAATTACATGTGTATATTTTGAAAATTACAAATTACGTA
TTTTGTTATTTTGTCTTTTACAAAGTCAAATTTACCTATTTAATAAAGCATCATGAGTTTTTTATAACTAGTAAACT
TTGAGACTTTTGTAGGAGAATAAATAATGCTTATTATAAAAACTGATTGGAAAAGTGAGCTGGAGCAGGGAGCGGAG
GAAAAAGGACTAGAGATCACCTTTCTTCCCAGCTCCGCTCCTCTCCCAACCTTTTTTCTTTCCATTCTCTCATCCCA
ATTCAAAAGTGACAGAGTTCACAGTTGGTGTGCTGATTTAGAAAAACAGATATATAAACAGCCTTAAATTTTCTCCAGG
CTTTTACAATGAAAAGAAGTTCAATATCAAAAAGTAACAATATAATCTGTGGAAAAGGTATAGGGGGCTATGTTTTTGA
GGTAGAACTATAGGTGCTCCTGGCCAAGCATGGTGGTTCAAGCCTGTAATCCCAGCACTTTGGGAAGCTGGGGCGA
GAGTATTGCTTGAGCCAGAAGTTTGAGTCTAGCCTGGCTACAGGGTGAAACTCCACCTCTACTAAAAATACACAC
ACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACAC
CTACTCAGGAGGCTGAGGCGGGAAGATTGCTTGAACCTGGGAGACAGAGTTGCAGTGAGCTGAGATAGCACCCTG
CACTCCGACCTGGGTGACAGAGTAAGACTGTCTCAAAAAAAAAAAGAAAAGAAAAGTATAGGCACCTCCTTATATG
CAGCTGCTCACACCCCTCCTCCTTCACACCCCTCCCCCTTCACACCCCTCCCCCTTCCCCAAAATTTGCAAGGGGAA
AAATGTGTGTAATTGGCAGTATTTAGTGGCGTGCAACCGTGAGTCATCAGACTGCACATCCTCACTTCTGCTAGTGG
CTCAGTACCCAACAGCACTCAGTGAAAACTAACTCATTTCAAAGGTGAAAACAAGTGAGTTTGGCCACCAGGGAGTG
TTCAAACTGTGAGTGTGAAGCAATGTGGAGGGTGTCTGTAGTTTGTTCAGGTTGATATTTGTGGTCCAACCCC
TAGCTGAACTACTAATTATTAATATCTGTCTTGATGGTGCCTCAGGAGAAAAGCTTCTCAAAGGGAATCAATGTTCAA
ATTATAGTAGGTATCTTGGCCATGGAAGTTATTGAATTTTAGCCAATACTTGCTACTCTTTCATTTATAGTGTGAGA
ATGCAGTGTAATGAACCTGACTCTCACTGTCTGACTTGCTTCTCATCGCATTACAAATAAGCAGCTCAATACGT
ATACACATTTTCATATTTCTAAAGTTTACTTTATTTCTTATTGTACATCGCTGTGCTGTGATGGAAGAGAAAAGGA
AAAAACACTATTGATTGCAAAACTGTTTTATCTTTGGTGGCTTAGATTTTTTTTGTATGATATGTAACGCTTGCATA
CCTAAGGCAACACGAAGCTAAATAGATTTGCATATAGCATGTATTTTTTCCAATTAATGTTTAAATTTTGTTCAGAG
TATACTGGGGACATTTTGAATAATGGAGAAAAAGTACAAAAGAAAATTCATAATTCTACCACCTATCAGCACAGTGAAA
TTTTATGAAGAAACATAATTTTCATGTAAATCATAGTGAACCTCACGGTAGGTTTTATTTAATACAGTAATTGGAGAG
CTGGTAGGAAGACAAAAGTGGTTCAAAAGAGAATACAAGAAAACAAATGCTTCTATAATGAGTGAATTTTTTAAAAAG
TATTCTGGAATAAGATTAGTGAATAAGATACTAACTCGTTGATACCTACAGCCTTTGGGGTTATATCCTCTACTG
GGTAAAAAGTCATTTACATCATATCAGTTTTCTAAAATTTGCATTGAACCTTCATAGCGTTGTAACATGTGTGGGCCC
AAATTAATAGTAAACAGTAAGAGTTGCTTTACTCTGAAAAATTGAAGCTCTTGTGAGGGTGTGAGGAGTTTGTAG
AAAACAACGCTACCATTATTTTGAACACACACGATCATCTTTTGTTTTACTTCTAAGTTTTGGATAATTTTTCTTA
AATTATCTTATTATCTTATCCATTTTCTTAATTTCTTAACCTTTTAAATGTTTCTCCTAGGCACTTTTATTGATTT
TTGGAATATAGTTGATATGTGCTGAATTTTTATCATCCAGTTTTAATTCTACTGAAAAATCTAAAAGATGTTTCATCA
ACTACTATATTTCAAATGCATACATCCCCCTTTCATGCTAAAGAAAAGTGTATGGGAAACACAGTCTGACATTTTCAGG
ACCTGGTATCATTAAGTCTTGACACTGTTAAAAATTAAACAACGCCTTTTTTAAATCAAAGGATACAAAAGGGCT
GTGTTGGTCAGAGGATACAAAATTTAGTTAGATAGGAGACATAAGTTTCATGAGATCTTTTGTACGACATAGTGACT
ATAATTAATAATAATATGTTTTCGAAAATTACTAAGAGAGTCGATTTTAAAGTGTCTCACCAGCAAAAAAATAGTATG
TGAGGTAATGCATATGTTAATTAGCTCATTTTAGCTAGTCCACATTTTTCAATACAATGTGTTGTATAATACGTGAT
ATATAACACTTATATTTTCCAATTCCAATAAGTAAAAATAAATGTAATTTATTGAAATAAAATAAATGTTGAAGAAC
ATCCACTTTTCATATGAACCATGAGATATTTTCTGTGTAAAGATTAATGTCCAATAAATTTTGTATGTTAAGACA
AACAAAAATGTTTAAATTTAAATACATATTTGTCATGCTATTGACCCCTGAAAGTTCAGTGGGCTAAGTGAACC
AACTATATCTTAAGTCAAAAATGCTGAAATTTCTTCCCCAAATCCCAAAGCTCATGAAAACATAAACAGAAAATTTCC
AAATAATTCTACAGGGAAAAATAAGACACACTATTTGATCTGATCAAAACAACGGGATGATTATGGTTAATAATGAGTT
ACTTGTACATTTAAAAATAACTAAAGGAGTGTGATTGGATTGTTTGTAAACACAAAGGAGAAATGCTTGAAGGGATGG
ATACCCCGTTCTCCATGATGTGATTATTACCCATTGCTGCTGTGTCAAAACATCTCATGTACCCTACAAATATAT
ACTCCTACGATGTACCCACAAAAATTAATAAAAAAGAGAGGGACCCGAAGATAAGCTAATATTTAAGCTCATCAT
ACTTATTAAGATAAGCAATACATACCGAAAGTAATAGCATTTAAACCAGATGTTGGGGGAGGGTTCTAACTTGTTT
ATTAAATTTCAAAGTCACCTGTCTTGTTTTTCTTTTGTTTTTTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
CTCTGTCACCCCAGGCTGGAGTACAGTGGCGCGATCTTGGCTCACTGCAAGCTCTGCCTCCCGGGTTTACGCCATTC
TCCTGCCTCAGCCTCCCGAGTAGCTGGTACTACAGGCGCTGGCTACCACGCCCCGCTAATTTTTTTTGTATTTTTAGT
AGAGACGGGGTTTACCGTGTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCTGCCACCTTGGCCTCCCAA
AGTGCTGGGATTACAGGCGTGAGCCACCGTGCCAGGCCACCTGTCTTGTTTTATCATGATCCCAGAGTATATATGT
ATGTGTACAGCTCATCTAAACCCCTTTTTCTTTCAACATGATCAATAGATTGAACATTGGAGATATTTTATAAGAAAT
AATGAAGACAACCTCAATCAGCACATATATATATAATGTGGAATCTATAATGATTGCGAAGCCTGAAGCAAACCTAA
ATATTAGTAATAGGTTCTTTTTTTCCATGGTATATCCATTTGAATATATAACATAAATGCCTTACATTTGTTTTAA
CTATTTAAGGTTTATGTTGTTAGTGTGATGAAATGGCTGGCAAAAGTCAGAACTCAGGAAAGTTTCAGGCTTATAT
CTGGAGCCTGGTTTTCTTTCTCAAGGTAGAACCTCTGTGAAGTGAAAAATTTTTTTTATATCTGGAGCAATAATGT
AGAAGCTTAAATGATTATCAAGTTGTCTATAAGCCTATTATTTCTTTTACATTACTGAAGTGAAGACAGCATTAAT
GGCTAAATGCCATACTTGGCTATAATTTATATTGTTTAGGACTGGAAATGAGCCTGAAATGTACATTTTTTTTCCAAA
ATAGTTTCATGTAATATTTGAAACCTGACAAGTAACCTGATGATTTTCATGGAATACCATCAAATATAAATGTGAAGTT
TTAAAGACACAGGGAAATACTCAGAATAAACCCCTAACCCACAGGCCAGCAGAAGAACTAGACTTGAGAAAATGAAT

GGGAAGATAGATAGTAACAAATGACTTCTTTGGCAGCCTTATATATGCTTAGTCTTATAGACTGTTTTATGGATGCT
CTGCACTCTATTTCCAGCAAGTATGGCATTGGAACAGGACCACACGAGACAACTATGAGTTCACATTTCCCACAA
CTGCACAGATAGAAAGAGGGAACAACAGAATACTCCCTTTCTTCTTGAAACAATAACTTCTGTTGAAGCTCACTGGC
TTCTTTTTCAGCTGTTTCTGCTAGCTCCTCCTCCGCTCTTGACCTCTAAGGCAATGCTCTTCAAATTTCAAGACTG
CTTTCTAATTGAAACAAAACCTTATAAGCACATTTCTTCCCACAAAATGTACATTTATTTGTAAATCATATATGAATA
TGACTAAGCATGTAAACGTATGTGAAAATAGAAATCAATAAATATAAATGCAAAACAAAATAGAAGCATTACAGTT
TTCTTTTGTGTCCCAGTGAGTTGTTCCAAATTCCTCGGAGGTAGGTATGTCACAGTTTGAGACTATACCTTCAATCC
TAGGGTTTCTGGTTTCGCTCTCCTCCTAGGTGATAGCATCCATTTCTACGGACTTAACAGCCATCTTTAGTTGAATA
ACTCCTCTATCTTTCCATCCCATAATTTCTCTTGATTCCAAACCTGCTTGTTACCTGAGCATATGACACAATTCATT
GGCTGCCGCACATGCAGCTTTGACATTTTATTTAAAAATCTTTCCCTTCCCCAGCCCTCATCTATTTACAGTAGTA
TCTTCTTCTTATCTACTTGATTGGTAAGCAGAGTCCACATGATTCCATCATTATCTCCCATTTTATATCTAATCTA
TAAGCAAGTAATGCAATGCAACTTCTGTCTCCAAAAATTTATTTTGAATTTGCCTTCTCTTCTCTGCATCTCCCC
ATCTTAGGCCAGGTACCTCTGCCCTCTTGCCAGATTAGGTACATTTCTTACTACTGTTGTTATTTCTCTTCTTAT
TCAATCCTACACCGCAGCAAAAATGGATCTTCTCAAATGTGAGCTAGATAAAGGCATTTCTGTGCTTAAGGCCCTCA
TGGATTTATCTTATTAGGATGAACACCCAACTCTTTATTATGGCTTAGAATAACAATGAATTACAACACATAATGAAT
ATATTATATTTCTATCTTTACCATTTTCTTCTTAAGTCAACCTTTCTCAATCCATATAGGATAATCATATTAGTGCT
TCCTCACTTTCTAAAACATCTCAGGGCCTTTGCACGTGTTTCTCTGTTCTTAGACCCAGAATGCTCTTCTTTTCTC
TTTGTGTAGCTAGGTGCTTCTTTCCATTTACGTATCACATGAAATGCAGTCATTCCCTCCTCTTCCCTCACTACCT
CACAAAAAGTTGATGCCTCTGTTAAACCATGAATGGAATTTTACTCGGCAGTGAATAGAGGAAAAACCAATGGTAAA
AGCAACCATATGAATGAATGAATGTCAAAAAATATTATGCTGAGCCAAAAGTCATAGACACAAATATGGGTATTTACA
TGAAGTTAAAGCACAGCAAACTCAATTACGGTAATAGAATTAAGAAAAGTGGTTACCTCTGGGTGAGGGTTGGAATT
GAGTGGACAGAGGCATTAGTGACTTTTTCGGGGTAATGGAATGTTGTCTATTTTGTTCAGGTGGTGAATACATAGA
TACATTCATTTGTCAAAACACATCCATCCAAACACTTAGACTTTTGCACTTTATTATATGCAAATTTATGCCTCACT
GAAAAAAGTTTGTTTTCAAATTTATATCAACAGTTGAAATCTTTTAAAGATTTGATTCAAAATGAGATTAATTTCTGT
ATCCATCATTGATGATAGTTTGTATGTAGTTAAGGTTATTGGAGATAATTGAAAGTTATACCTACAAAGAAGG
CTGCATAAATATGAAGTTTATCTGCCTTGATCTTTAATAGCTTTTCGCGATTTCAACTTCTTCACAGCTCTGTAAGAAG
GCAGTGTGGCATGTTGAAGCAAGCATGTGTTTTAGAGTAACACAGAGCTGGTATACAACCCCATGTCTACCAATTAT
CAATGATGTGGGTATGTTGCTGGATCTCAATAATCTTCCACTGTGAAATGGAATGTAACACCTGACTCACAACGCAA
AGGTATTTACCTTATGTAATATAATTCCTGCGATCCTGGGACCTCCCTTAATCCCATCCACAGATGCCAGGTAAAG
ACCCCATCACAGACTAGAACAAGTTGGGATGTCAAATGAATAAATATTAATCGAAGGGCCTATTGTGATTGAACAC
CACGCAGTAGGCACTCTCTAATACCTACCGTCTCCCTCCTTTTTGGGGGAAACATTCTAAATGTGCAAAAAATAAAG
GGTTATTTGCTTTCTGGCACTTGGGATCGATTTATTGAGGATATGTTAGCAGAACAGCAAAGGTGAAACACTAAAAG
CACCATCAATACACAGGCAGAGGTGAAGCCATAAAGCCTTTATTTTTTAAATTAATGCACAATATATAAGAGGTATG
TTAGAATGAACGTCCAATCCCTGAAAGGATATACGAAAGACATTCATAAAATTACATGGGCATGTTTTCTTAATGTT
CAAAATATTGTTTTAATTAGTGATTATGAGTTTATTCATGTGTCTGTGTGTTGTGTTATATTAATCTTTTCTTGCA
TTGCTATAAAGAAATACCTGAGACTGGGTAATGGATGAGAAAAAGACACTTACTTGGCTCACAGTTCTGCAGGCTGTA
CCGGAAGCATAGCAGCATCTCCTTCTGTGGAGGCTTCGGGAAGCTTCCAGTCGTGGCAGAAGGCAGAAGGGGAGCAG
GCACTTCACCTGGCTAGAGCAGGAGCAAGAGAGACAGAATGAAGTACCACACACGTGTAAACAGCCAGATCTCAGAG
AACTCACTCATCATCATGAGGATGGCACCAAGAGGATGGTGTAAACCATTTCATGAGAAATCCACACACATGATCCA
GTCACCTCCCACAGGCCCCACCTCCAACACTGGGAATTACATTTCAAGATGAGATTTGGGCGGGGACACATATCCA
AATGATATCCATGTTTAAATCAGAAAAATAAAGTTAACAGTAACAGTGATTTTACTTTGTAGACCTTTGCTAATGGC
TGAATCTAGCTCCATTTCCGAGAACAGCCTGCGGTACACATTTTGAAGATAGTTGATTAATGAAAGAAGCCTTA
TCTGTAGTCCTTAAGGCCATTATGGTTTACATATATGATGATAAATTCCAAAGTAGCCATGCCAGTTAACATATATC
CAGAGTCTAAAGGCCACTGGGCGACAAAAAGATAAAGATACATAGCAATTGTTACTTTTATATCAGATTAATCTTGTA
TATTTTAAATGGATATTTGCATTTGAGGATATCCACTTAAGAGTTAGGTACATGGCTCTTACATTTAAGTAACATTT
ACTTAAATTTCTGGCTGCAGCAATTCCACATAGGTAGAAATGAAGTCTGAATTGAGTTGGGGGTCTTTGCAGTGCTC
TCTCTGTTTATTGGCTATTTTGACAATGCTGAGAGATGTGGTTAGCCATTCTTTTTTCAATTTCATATTGGCAACCTAG
AGAGCAATTAAGCCTTCTCCCTTAACTAGATGTATGTTTTACTCATTTCTGGATCTTTATGGCTGACTTTGAATCC
TAGCCTGTGGTAGAAAGCATGGTGTGAGAAGGAACATATGAGTTAAGACTATGCATACTTGGCTTTGAGTCTTGGGTA
TCATACCTCCCTCATAGAGTGAAGGAACAGGGATTCTTCTTGAGGCCAGACCCGGCATCCATGTTAAGAATACCT
GTGCAATTTTGTCTTCTGATATTTAAGGTGAAAATGCATGTTTGGGTCAATTGTGAGGATTATGTGAGATGTTACTTT
TAAATATAGGCCCCCTTATTATATGCTCTCATAGTTTCAGGCAACACTTGTCGTATTTGTAACCTCAGTTTTAACTG
TAATGTTTTCCATCAATGTCCCTCTTACCTGGTACAGGGGCTCTTCATATTCTTGGATTACAAATCTGTGAATGCAAC
CATGCATCAAAAAATATTGAAAAAACAATGAATGCCTACCTCTGTAAGTATGATTTATAGGTGTTTTTCTTGTCAAT
ATTCCCTAAACAGTACAATGTAATAAGTATTTATATAGCATTACATTGTATTAAAGTATTATAAGTAATCTAGAGAT
GTTTTAAAGTATATAGGAGGATGTGTGTAGGTTGTATGGAAATAGTATGTCATTTTATATGTCATTGAACATTTGT
GGATTTGCTATCCGTGGGGATCCTGGAACCAATCCCCCATGGATACTGAGGGACAATTGTATTATAAGCAGCAAGAG
GGAAAGGAATCTGTCTATTTTGCCAAAAATCGTGTTCCTGGGACCTAGCATAGCTCCTGGCAAAGAGTATACAACAA
AATATGCTATTAGGAGAGAACAAGAGGAACCAATTACCCCTTATTCTCGCTGTTTCTTCATGTAATGAATAAACAGTC
AAATCTTACAAGAGATTTTAAACAGTCAGAGAAAAGTTGGAAGTTAGTTAGTTGTTTATACATTGAGAAGCCCTCGA
CGCTGTGTCTAGTAAATGAAAGATCTAGGGAAGTTTACGAGGGAAGAAGAGAGATGATAGTTGTCTTCAAAT
GTTTGAAGGACTGTTACGGACACAAAAATTTAAACTTGTGCTGAATAATTCCAAGAGGTACACAGTCTCTCGATAGA
AGCTAAAGTGGGGGGTGACATTTGACTCAACAAAAAGCCATCTAAATATCAGAACTTTCAAAGCAGGAACCTGGTGC
CTCAATTAATAGTGTGTTTTCTAGCACTTATGATACCTGATCATAGGCAAGATAATGAAAAATTGGGACCTGGGAGT

TATACATGGGAATTTGTTTATCAGTTGGGTGATTAGGAGAGGTGGCCTTAAAGTCCTGTTGTGTTCTAAGAGTCTGT
GATTCTGAGTCTTATTTCCCAACAAGAGAGGTACAGAGCAGAAAGATGGGATTGGGAGAAATAGGATAAAGATACCAG
GAAATCCTAAAGGTAAGAAAAGGAAGGCAGACCTGAAGCTAACTCTATACTTCAGGTGCTTGCCTAGAGCCAGCCCT
ACCTACTTAGAGAATGTTGAAGAGCCAGTTAAAAACATCTTTAACACGGATGTAAAAACAAACATCAAAACCTGAAG
ATTTTCGAATGTTCTAACCTACTCGTCAGTTGGGCTTTTTTCACAAATACTTCAGTAAATAGGCATAAATTTATTTTT
TAATGATAGAAAATATCTCTTAAAGAACTTATAACTGTGGATAAAAAGCACCACCATAAAAAATCTTGTGGTGAAATAT
ATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATATAT
ACACAGAGACTCTTGACAAGTCCCATGTATACACTATAAACTTTAAGTTATCCACTATTCACTACACTAAGCTTATA
CTTAATGAGTGTCTGCTGTGTCACTTATTGCGGAAGGCACAGCGGTATAGCATTGCACAAAACATATGTGGTCTCT
GATGGAGTTTTTTCAGTCTAGTGGTGAAAAGCAGTGAATGGGTGTACAGATGTTAAATAATTGTACAATTAGTTGCATG
TGTAACGTCAAAGTTCAGAAGATGACAATTGATCTACGGCAATGTTTCTCAATCTCTGACGTTTTGAGCCAAATAC
ATCTTTGTTGTGGTGGACTGCCCTGTCCACTATAGGATGTTTGGCATCACAACTGACCTCTGCCCATTAGATGCCAA
TAGTACTCTCTTCTTTAATCACAAATTTGTCCAGACATTTCCAAATGTCCCTTGGGGAGCAAAATCATCCCTAGTT
GAAAATCACTGGTCTAGGGGGAGGTCTTTATGAGGAAGTAACATCTAAGAAAAGCTGGTATGTTTACATATAGCTACA
GTCTATTACACATGTATACATATGTAACAAGCCTGCATGTTGTGCACATGTACCCTAGAAGTTAAAGTATAATAAAA
AAAATGTAACAAAACAATACAGTATGATAAGTGCTATGGGACCAAAGATGAAAGGGTTCTACTGCACAGTTATGAAC
TCATAGTTAGGCTTTTTGGGGTCAAAATTTTGTCTGAAGATATTTGCCACCCACGTGACCTTTGGCAGGTGACTTAGCT
TATTCATGCCTCAGTTTTATCCAATGTGAAATGGGGCTGGAAAGTCCCATGTACTTCCTAATAACTTTGCGGAAATA
ATATGTGGTTATATAGGAAAAAAAAAAAAAAAAATCCTAGAAAGTATGCCTGCTGCGTAGTAAAAGGAAGGAGAAGGATAAA
GAGAAATCTGCATTTTTTCTTCTGTAATGGGGCAGATAGTAAATATTTTAAAGTTTTGTGGCCCAAATAGTCTCTGTC
ACATTTACTTGATTCTGCAGTTGTGGCATTGGAAGCAGCTATGGACAATACTTAAATTAGTAGGTGTGCCTGTGCTT
TCAATAAAATTTTATAAATACAAAGTTTGCAAAACAAAGTTGTTTTTTTTTTTTTGTAGTTTGTGACACCCTAGT
AAAGAAGCACCATTGTCAACGTTAAAAATTATCAAAATTTTATTTTTTCAAAGTTTTCAAATTTGCTTTGCTTGGTCT
AGCTCATGAAATAAGTCAAAAGTAGCAAGACCTCCACCTCTAAAAATAATAATAGTAATGATAACCTCAAAAGGAAAG
AAGAAATATTTTTAAAGAAGAAAAATTATTGTTAAATAGGATTATTGTGCAGAGAAAACCTAGGAGACTCAATTTTA
AAATCTGTGAAATAATTTTTAAAAATACTTTATGAATAGATACATAAATAGCTTTTATTCTATTAAATGACTATAAATG
CAAATGGAAATATTTTCATTACACTGATGACAATGTATAAATTAAGGAGGAATAAAAAATTGTAGACCCTATAGGTGA
AAAGCATAAAAAATATACATAAGAAAAAGCAAAAAATTGACTACGTAGGATTGTTTTAGGATTTAAGATTTATTGTCAT
TAACTTGCAATACCAGCCAAGTTAACATTTGAATTTAATACAGTTATAATCAGAATGCTTTTGATGTGTTTGGGGG
CAATATAATTTCAAAGGAAATAGGCAATGATGTAATTTAAAGTTTATATAGAAGGAAATTGTGTGCGTGTATGTGTG
TGTATAAATTGGAACAATTTTATTAATAAGCATATTATGGCAGCAACATACACTTCCAGATTTCTACTATACTTTG
AAGTAATTGTGATCAAAACCACAGTGTGCTGGCATAAGGCTAGAGAAAATGGGTTAGTGGTTTACAAGTGAGAGTCCA
GGAAAACATCCAAATAAGATTGGATATTTTAGTCTGTGTGGATAGCCTATTTCACTTAATAAATAGTGTCTCGTAA
TTGACTATTCATGTACCTATAAGTTTAACTATAGACCAAAAAACGCCCTACTAGATTAAGGAGCTAACTAGAAATA
TAAATTCATATAAACAATAAAGGAAAGTGTAGGACTTTATAAGCTTCATGGGAGACAGATTTTTGGTAAGTCAGGAA
GCCTGGAAGACTTAAAAACATAAAATTTGGCAGACTGAATTAAGTATAGTTTAAAGCTTCCATAGAGCAAAATAAATC
ATAAACCAAGTTTTTAAATATATAATGGATTTAGAGAAGGTATTTACAAAAATATATGACTAATGGAGGTAAATAAT
AACAATATGTAAGAAGGATATGAAATGGCATTTTACTATAAAGGTCAAAACAAATGACCTATAAGCATAATAAATCAT
ATTAATCTCCACTAGTAATAACTACACACATCTACATAATATAGATGTTACGCCCTGCATTTGATTTACTTTATCTGT
CTTTTGGCAGAATATTTGTCAACAGATAAAAAATTTCTATATCATTACCAGAAAGGTATATTATTATAATGTTTATT
ATGTTGCAGTTGTAAAAGAAATAACAGCTTTTCAATTGTTTACAAATCCTATAGAACATTTACTGAAATACATTTAC
ATTTTGTGGCAAACTTGGATTTAAATACCGTGTTCGTGCTTTGTTTTATGCCGTTTTCCCATCTTTTCTCCAGGTA
TTGATTGTGCTTTCATTGAAAGCTAAAAAGAAAAAAATAATCTGTTTTTGGTTTTAAAAAATTAGTTTAGGGGTT
AAAAAGTTGTACGTTGTCTTCTGTAAAAATAAAAAACAAGTTTTCTTTGTTTTCTGGAGGCTTTATATTAAATGGAT
TTTTAATTCATAGACAGCATATTGTGATGAAATTTCCCATGAGCTTCACATTTTGTTCATAGCAGAACTAACT
TGTTTGCAGTTACTGCCCTTCTGAGAACAGTGTCTGGAATAATTTTGACATACATATGTATCTCTTTTTAAACAT
GTGTTAATCTTTTCATAAAGAAAGTTTTCCAGCTGTGTACCTGTGACTCCAACCTTTCTGGGGGGACAGGGATATG
AGATGTTGGAAGGGAATGGCTTGAAGAAATAAAGTGCAAAAGACGTAATGCTTTCCCTGTGGTAGAAATGTATTCAGT
GACCCTGAATGACCTTCTACTCTTGTCCCTTCATTTTTCCACAAAGTATGGTCTGGGCAATTATAAAAAATTGACAT
TTGCAGTGGGCTCTTCTGTAAAAGATGCTCAATCAGAAATGATTTATTTTAGAAAAAGAGATGATATAAACATATAT
ATCCCCTGTCTCGGAAGTGTGAAGTTGAAAAGCAAGGAGATGATCTTCAAAGTGTCTAAAAATATTGATTTGTAACA
TCGTTTTATGAAAGTGCTTCAGATTATTTTTTTTCTTGATGGCCCCCTATGCTTTGGTCAGTTGATGCTAAAACT
GAACCTCTTTATTTTTAAAAAAAACTTTTAATTTTTGAAAAAGGAAGTTACCGGTGCTGTCTAATTTCTTTTTAGATAGT
CATTAAATGTAAATGTAAAGAGTCATTCTGAGAACCACATCTGCTGATATGTTCCGTTAAATTACAAGTTCTATGTGTA
TTTGCTTTGCTTTTCATACAATGAATCTTCTTTACTCTCTTCCCCACCTGCCAGAAATTGCCCCACTCAACGTTCCATA
AAAGGTCCATTTTCAATCGCTATATTTATTTTCAAGAGCAGAGATATCATATATTCAAATTTTAGTTACTTTCCAATA
TCAAGCTAATAACTCACACAAATAAATCAAACCTACAGCAAAACAGCAATCTAGCATTCAACAAAACCTCCCCAATGC
ACATATTTCAAGCTGTAGATATGTATCATCCACCATGCTGAAATAATGTACATGTTCAAATCAAATGGAAAACCTAGA
ATCAAAATTTGTTGATTACTTCTTATCAGGGCATTTTATTTATTTAAGAAAAATACAAATTAATCATTTTCAGGAA
GCAATCCTTCTGGCTAAGATTTTTTTAGCATAATGCTTAAAGTTAATGTTGATCTTTATCTATAAAATCAAAGGTG
GACTAAAAATCGAGAATCAATCAGGTAGTCCATTTTGCATCAGGTGAAATATATAAAGCATAAAACAGCGAGTTACA
TTTTCTAACAAAATTGAATTACAGTGAGTAAAAAGTGACAGGACAAAATGCATTAAAGAAAAGATGGACTGAAATGGATA
GAGTAGAATATATGCATCTATAAAACACAGTCATATATAATACTCACTTCTTTTTTTCTTACGAGTGTGAGATTAAATG
GAAGAAAACAACAATAATAACAAAACCAGTGTGATGTGTCAGATTTACCTTTTAAATTAAAAAATTATTCACCTTCAG

AGGGGAATTTTCTTTCTTGGGTTAGCTCAATCATGTCAGATCTTGTTCATTTAAAAGGTCAGTTTACTTGCCTTCTG
AGGTTTTTGTGGGAAAAAGAAAAAGAAATAGATTTTTCATTGGTATCCTGGGTAGAAATTAATTGTTTATCATTTCAT
TTTTAAGATCTCCGAGAGGCAGAAAAAGGGGAACGTGCAACCCCTTTGTCCCTCTGGATCTCAAAATGAAGGGATA
CATTCTGCTACATGAAATGTGGAATTAAGACCATGATGCAACATGATAAACACACAAATTTGGGGGTGTCTCTGTG
CTATACATTATTGAATTTTCCATGCTATACACTTTTGGATGTGTCTGTGCTATTTATTTCAGTTTTTTTTAAATAAA
AGTTTTTGTAGACTAAATTGCCCTCTCTACTTTGCATCGTTTTTGAACAAAGGATTTTCAAGACTGATAAGCTCAAA
TGTATCATTATTGTATTCAAGTAGCATTCAATTTTCTTTAGAAGTATAATTTGTAGATATTTTAAACACAGAAAAC
TTGCAACACTGCTCATGATAGGCACCTTATTATATATTTTGAAGACTATATGGATAATGATTCTAACCTTTGACTT
TTCCTGTTTTTGCCTTTCACTTTAGAATTAAGCAGAGAATCAAATCCATATTCCCTGGGGGCGATGCTTGGACAACAGTA
TCTCTTTAAAGATCTTTGTGTGAGTCGAAGGTGCAGCCAGACTGGGAGTTATTGTGAAGAAACAGATTTCAGGAAGGT
TGAGAACTTGCCTAAGGCTAATCAGATAGTTACTGGCAATGTTGTTTTCTAAATCACTGTTTGGCTCCCTCATTCAA
TGAATCTACACTATGTGGGACTGCCTCTTGCTCCTGACATCTTTTGCTGCTGAAATAAATGAACCTCAAAGCCTAGAA
GGTAGAAAAGAGGGAGTTCAGAATTATATTCAGGCACAAATACCAATAAGGCTATTGCCCCCAGAAGTCAACTTCT
CTTGGTTTTAACAGATAACTATTTAGCTGTGAGGTACAACCTGAGGAAGTGGACACACAAGTTATCAGGAGATTCTGAT
GTGCCAGTTTATATTTCTTGTACAGGTAATGATTGCAAAATTTCTTAAAAACAGCTGTCTCACAGTGGAGTAACCTG
GGAGTACATGAAGGCATTCCAAGGAGTAGGCACAGATAGTTTAAAGGGAATTTATTTCTAGATCTTCTACTTTATTT
TGTACTCTTCCCTGAAAACCTGAATTGCCTGAAAAAAGACATCTGTAGTCAAGACCTCAGGCT
GTTTTCTCTTTCTAACCCTTGCCTTTTCTAACCCTTCTCCCAATTTAAGAAAAAGCCTTATATTTTCATCCAAC
TCTGATCTTACTAAGGCTTCAAACAAAAGCATGAATGACTTTCATGACAGGGCAACATAGCTTTTTGCAAGAAG
AGTGGTTGCTAACTCTTTGCTTTCAACTGAACCCGAAGAGAAGACCTGATAAGTTGTCAGCCGATAGATCATTAAAA
ATACGTTTTGGTAAGCAATCATCATGTACTTTTAGCATATGCCATAGCAGGAGCACAAATGATTAAGCAATGCTACT
ATAATACAATTCCTTCCGTTTCTTTCTACTCACCTATTTGAATAAGATTTTTCATCATTTCATCTATACAGACAAA
AATTAGGGATAGAATTGATGCTGAAGCCTTTCCAATTGTAGAATTAATTTATATTTCTTGAAGGTGTATAAATTGT
TAAATACCCATCCATCTTATTAAGAGATGTATTTCAATAAAATTTTATTTTTATGTTTATCAAATTTTATAATATA
CATATATTGTTTGGTCAATTGCACGTTAATAATGTAAACAATACCTCAATTGAAAAGGTTTGTTTTTTACATTTAG
GACCTTACAGTAACAGAAAAAACAACCTCATTTGTGTATACATACTGTTTAAAGAAAAGTATCTTAGTGATCAATAAGA
TTTTTTTTCAGGCATAAACATATATCTTAGTTTTTAAAGATATCGATATTTACAATGTCCCTCAAATTTATATTTTTCAG
TCATTTTAAAGATGAAAAGTACATTTTGAATGCGGATTTTAAATCTGCAAGGGTTGACTCATTTTTTCAAGAGTCTTTT
TAGGGGATACAGAAGCAAGAATGTTTGGAGTTCCTGATCAGTATCTTTAAGAGAAGGTATTTGTTGGTAGTTCCTA
GCAAATTCACAGCCTGATGCTACTTAAAAGATAATAGTAATTTATTTTAAATAATGCTTCTGATAAAAAACATTCA
TGCACACTCAGTTTAAAAGATATTTAAACATTTGTAGTTGTAGTTTGGGAACCTCATGATACAAGTACAGTCTGTAA
ATGAAGCTCTTAGTTTGCAAATATCAGAGATAAGCTATTTAAATGCAGAAATGAAATGCCCCTGATATATGCATAA
ATTAGTGTCTATCTCCATCTTGTGCTAGTTAGAGTATTTTGTAGATTCTCTCTATGTATACATATATATATATATA
TATTTATATATATATATATATTTGTGTAGCTGTGCATGTGTGATTTTGGACTAATGGGTCAAAGGACAGTACTAACC
CAATTCAATAATTAAGAAAAACATAATTTTGAAGAATTAGCTTTATGGTAATGTTTGAAGTTAAATGAGTAGATCAGA
GAAGAATAAGGGCTTTCCCTTATTTAAACAAGCTTCATTTTTTTATCCAAACATTTACTTAGCTGATTAAGCTTCAC
TTGTTTTATTTTCTTCAAAGCATTTCATTTCAGGTGGGTACTGAGTAACTGAAATATCACACCAGGGAACCTCAACACC
ATCCAAGTCTTAAAGGCTTCACTTGTTTCACAGTTGGCATTTAGTGAATGTCTAGGCTACTGATAATATTGTGAGTAA
GTTGGCAGGGATCATAAGAAATGATAAAATACAGTTCTTGAAAATGTTATGGTTTGAAGAAAAGATCTATGTTTGA
ATTAGACTGACTTGGATTCAAACCTCTGGCTGTACCTTTGGGACAAGGTGTTTCAGAACTCTAGCCTATGTTTTTTT
CTGCAAAATGATCCTCTTTTCCAGGATTCCTGTAGAGATTCAAAGATATGTGAATGTTTGAAGAAAAGATAGACTTT
TGATCATTGTTAATTCCTTACTTTCCCCAATTAGACTGTGAAGACTGGGAAGAAAGCTACACAAAAGATTGAACAA
ATTATAGCTGACAGCAATAGCAAAAGATACAGGGCAAACTTAAAGGGGAAAACTACACATTAATTTATTTTAAAC
CATTAAATAGCACTAATTTTGTGATATTTACAACCAACCACTCAAAATTAAGTAACTGAATTAATTAATGCCTG
TTTTTTTCTGTTTACTGATGTTTTTCATTTGCTTCATTTCATTTATTGGAAGATATAAAATGTGTTAGACACTGTTAGG
TGCTGAGTGTATAAAAAATCTTATTAATACAATTTAAACACGCACACACATATATATGGTTATAACAATTGATGCC
ATGTATGTACTGTTTATATGCCTATACATTATTCACAGACCTGGGGGGAGGGGGATGTAGAGTCTTACCAGAACCA
TAGGAATCTTCTCACATCAACATTTCCCTTTGAAGTTTGTTCATGAGGCACCATCCAGATAATACTACCATCTGCAA
TGTGGCTTGAGAAGATGTTAGATTTTTTTTATTACACATAATAAGGCTGTAAAGTATTTCTGTATTTAGGTAGAGGTA
TGTAATACAATATGTATATAAAATTACATATCCAATAAAATCTGGTGTAAATAAGGACTAGCTTCTATGATAATAT
AGTCTAAAGGCTTTTCATTTGGTGTATAGAAATTATGTGAAATATGTTTCTGGAGTAGAATTATTCGCATTTTCAG
CTCTCTGACAGTGAAGAAAAGCTAGAGGGAGAGGTGAACAAGAGAGGGAGCATAATGGACAAAGCTTTGCTGGAAG
CCAAACCACCACTTCATATGTCAAATCTGACAGGCCTCCCATTTTAGGTGTGCTGTTCATTGAAGCTTTTCAGCTGCAC
CTTGCTGTGGCTAGGCTATTTTCAAAGATTAAAAATGCGAAAAGTGGAAATTAATGCAACTTAATTCCTCAATTTAAA
TTTCCATTATTTTTGAAAAGTAAAAGATTAAAAGAAATGTATAATTGCAATTCCTGGTGAAGAGGTAATTATAGGAA
AGGTGGGATGATTTTCAAGTGGGGGATATAGCTTACTGCAGCAGAGAGGAATCTAAGCTATCATTCTTTTGAATTTG
GTCTGGAAATATGTTTTACATGGAAAATATACTATATTTTAGGAATTTCCCTGTATATTACTGTATCCTTTTCT
GTTAGAATATAAATCTGAATTCCTATTCCTGTAGATCTGCCTCCGATTATATTAGCTCTTCTGAAGTTATCAA
AAAATAATGAGATATACAATATTCATATATGTCAAAGCAATTTATTTTAGGTAAAGTAAATAAACCAATGACCTTTA
ACCGGTAATATTCTGGGTTGTTTCAAAAAAATCTATTCAGGTAATAATGTTTTCCTTAAAGCACTGAAAAA
ATACACAATACTTAACATTTGGTTAATTAATACTACTCCAGACAAAAGGATTTTCTGTTTTCAAGTTATCTTAGC
AAGCTGAGCAGGAAGCAATGATATATCCAATCAGAATATCCATGGAAGCTCTGCTACAGTTTCAAAAAGTTCTCATC
AGGCAGCTTTTAAATGCCTACTCTGAAAATGGTCCAGGTTAAAGAAACACAGCTTCCCTCGTCAGATAGCAGTATTG
CTTGCCATGTTTCTTCTAGCACAAAAAGTACCTGCTCTTCTCTGAGTACCTACATTCTAAGGACTATGGCTTAC

96

AAACTGAGAAAGGAAAAACAATTTAGAAAAGTGGGAAAATATTATGCACAGAATTAATAAAAAAGAGAAAAATCTTGAAA
AAGTCTTCAATACCTCACTTGGGAAGGTGATTTTGAAGAAGAACTGATGGACAACTAGAGTCAGCCATGTAATGATG
TAGGGGCAAAGCATTCCGGGCACAAGGGACAGCTTATGCAAAAGACCTTAAAAATGAACTAGCTTTGTATGTTGGAGA
AGGATAAAGAGAACTAAGGTATCTATAAGGTAATTAGGAAGAGGATGAGTTATTTAGTCCCTTAGTCTTTGAAGCAC
ATTATCTCATACTTCAATTGAGTTTATTCTTAGTGTCATTCTTCTGGATGCAATATTTGAGATAAATGTCTTAATGA
ACGTTACCTCCCTCCGTAGTAATGCCTGAGTGTCACAAAACTTTTTTGTGTACATACGTAGCCATCTAATGGAA
ACATAAAATAGGAATCAAAAGTTGAGTTTCATGTACAAAAGGTAAGGACTGTACATGTGGTCATAACAACTTCAAAA
GCACCTGAAGGTAACCTTTAAGGAAGATACAAAGGCTAGGAAATATCTAGGATCCATGAAGACAGACTTACTTAAGG
TCATAGTGTGTCCAGAGTTGGTTCCCGCGGTGGGTTCGTGGTCTCGCTGACTTCAAGAACGAAGCCACGGACCTCT
GCGGTGACTGTTACAGCTCTTAAAGGTGGCAGCAACCCAAACAGCGAGCAGCAGCAAGATTTATTGTGAAGAGCAAA
AGAACAAAGCTTCCACAACGTGGAAGGGGACCCAAAGCAGGTTGCCGCTGCTGGCTTGGGTGGCCAGCTTTTATTCCC
TTACTGTCCCCTCCCATGTTCCATTTCTGTCTATCAGAGTGCCCTTTTTTCAATCCTCCCCACGATTGGCTACTTT
TAGAATCCTACTGATTGGTGCATTTTACAGAGCGCTGATTGGTGCCTTTTACAATCCTCTTGTAAGACGGGAAGGTT
CCTGATTGGTGCCTTTTACAATCCTCTTGTAAGACAGAAAAAGTTCCCCAAGTCCCCACTCGACCCAGAAAGTCCAGC
TGGCCTCACCTCTCAATAGCATTAGAATATAGTTTCACGAGCATATATGAATCAAACTTACATTTGCCAATTTTA
TTTGCTTGTATGTGTTTCCAACATGTCTGTCTTAGGGCCAAATGTTTCCCTAGAGAATAACTATTCCAACATATC
TTAGTTGCTGTATTTTTATGCAACCTTCAACTCTCCATACTAAAATGTCTCCAGAATAGAAAATAAATCTTTTCAAA
GTTTTCAAAAGAGGCTCTCTATATATTTCCCTTAAAAAGTACCAGGCAGACATATTTCTAGGTTTCTAACATTGCGTGT
TGCCAGGAAGTATATCCAAACCATCACAAAGTTATTCATGTAACCAAGCACACTTATTGGAGTGCTTCTGCTTCTGTT
CTTGCTTGAAATTGGAAGCTCCTTCCAGGAAAAAAAAAAAAATATCTATAGAAGGGGAAAAAAGTAATTTTACTTTGA
AAATAAAATATACGTGAGCAATAGTTTTATTCTGTTTTTAATTTACCATAGCTTCCAAAGACAACATTGTTTTATAG
TAGGGGTAGCAAGTGTTTTCTGTAATGTAAACGTAAAGGGCCAGAGAGTAAATATTTTAGGCTTTGTTTTCTATAC
TCTGTTGCAACTATTCAACTCTGCTGTTAGAATGTTGAAGCAGTCATAGACAATAGAGAAATGAAGATGTGTCATTG
TGATCCAATAAACTTTATTTACAAAAATGGCAATGGGCTAGTTACGGCTTGAGGGCTGCAGTTTGACAGACTCTCAG
TTCAGAGCTAACAGTTGTTGTGTCAGGAGTCACTGTTTTTGGAAACCTACAATGAGGTACTATAACACCAAAAAAGAGT
TATCCCTTCTTTTTCTCTCACTTTTTGAATTATGAGAAGAATTAGAAATGTAGTTAATGATAATGTCCAACCAG
TGTAATTATACTTGTAGAAAACACAGCTGGAAGCCTGTTGTCCAGTCTTATTTCTCCTCTGTGATCCTCATTTTCAG
AGGTTGAAGTCATAAGTTTGCCATGTCTACTTTCTGACAGGGGAATTATAATAATGTGGAGTCACTTTTGTTTGTG
ACTTTGACAATGCTTCATTGACTTACTCACCAATTTTCTAATTTTTATGAAGACTTTTTGCCGAAATGTAGACTCAG
TCTTCTCTCTGTCTACTCTTTCTATAACAATTAACAATGAACCTTATTTACCTTTTTTAACATCTTTTTAAAAATTTT
CTATACACCTTGAAATGTGAATACAAAGTAATGCTGCATCATGTATATTGCCTTATTCACACATAGCCTCTTATGG
TATATCATATAAAAAATGGAACAATACAGCAACAGGTTGAATGAACAGTAATCAGGTAACAGGAAAATGAGATGTCTT
TAATATTTCACTTAAAACTCAATTTCTTAAAGCATACATATAAATATTTGGAAGTATAGTTAGAAGAAAAATATCT
TTAAATATTTTAATTGATTAGTCTTATTTATAAGATAATTTTTAGGAGGCTGGTTGCGGTGGCTCACACCTGTAAT
CCCAGCACTTTGGGAGGCCGAGGTGGGCAGATCATGAGGTGAGGAAATCGAGACCATCCTGGCTAACACGGTGAAAC
TCCGTCTCTACTAAAAATACAAAAATTAGCCGTGCATGGCAGCGCATGCCGTGAATCCCAGCTACTCGGGAGGCTGA
GGCAGGAGAATCACTTGAACCTGGGAGGCCGAGGTTGCAGTGAGCCGAGATCGCGCCACTGCCTCCAGCCTGGTGA
CAGAGCTAGACTCCGTCTCAATAATAATCATAATCATAATAAATTTTTAGGAAGCATCAGAAATATATAAGAAAA
AGATTATTTTCTTAATTGCTTTACTAAAAACACCTCTATGATTTTTTCAGTAAACCTTGATTCTTATGTCATGTGTGA
GTGTGATCTGCCTCTCTTGGGATACTACTGTACTCATGAGGAGTGATTTTTTCTCCAACGACCTCTTTGTCTACGTC
AACAGGTCACAGGAATAGTGTAACCTAAAAAGCCACCTGCCACATGCTGCTGAAAAATGTAAAAGTACACACATACAC
ACACACACACACACACACACACACACACACACACCAAAAACTCAGGTATCACAAAGCTGAAAAATAAATTGAGTCCAA
TTTTTTTTTAATTGAGCAGTTAATGTCTTAAAAACAAATCCTTACTGCAACAAATACTTAGCCAGATCATTTCTGA
TACCTCCAAACTGTGGTGATTCCAAAGATACCTCTATGATCTTTGATTTGATCCACAGCTTTTTCAGTTATCATGCAA
ATACCTTCAAGTTTTATCTCATTTCTCAGTGCAAACTCATTAATAAATTTTTCAGCTGAATTTCAATTTTTATAAACATGT
TGTGAATGTCCTCTTTATATAAGCAAGGTTGTAAGGAACTGGCCACATAAAACAGAAAATTGAATAACATATGGTTTC
TGGCCTTAGTGATCTCATGTGTGAGTTAGGCATATGGGCAAAATCAGAACACTATAGAGTATAAGTCTAAAAATGGTA
GTATTTTATAATAGAGGATGAAGAGGGTGCTGTGGGATCATAGGTGACAGATATAACTCCCCTTGTGGGACTTGAGA
AAGGCTTACAGTCTGGAACATTTAGTTGCTATTGAACACAAAAATAAGACTCACTGTTGAGAGAAGGGAGAGGGAG
GGCATTTCAATCAAATTAAGATTCTGTGGCATATTCGAAACTGATGTTTTTAAAAAGAGTAATGTTTATTACATTC
CTCTACATAAATTATATTTCTATGTAATATGAATGACAAATATTTAACACAAAATGCCTTATAACATTTGAATGAAA
TCCATCATATGACCTGTTATCTATTTCCATTTCTTTTTGCTCATATCATATGAACAATGACCTGATAAATTTTTT
ATAAGACTTTGCTGAATTAGTAAAGGATTATTAAGTTTAGAATGAACAAAGCTGACCAATCATTACAGGCAAATTTGA
CCGTTTTTGTGTCGCTTTTCTTATTTCTGAAACCATAACAATTCCTGAAATGAATAAGTACATATTTGATAACTTCC
TAAATTAAGGCTCAAAACACTGGTAATCTACTGGGCTTTTCAATTTGTTTCTTCTATTTGTCTAATCCTATCTATATTT
CTTTATATGAGCTATGAAAAATATTAGATTTATTAAGTTGTCCTTTATCTTAATAGAGAAGAAATGTTTTCTATGACA
TTAAGAGGAATTTGATTTTTTTCTTTAATGATCTACTTTTAATTTTGGTAGAGTAGCATTGATAAGATCAATATTAC
ACATTGTTAAGTATGCATTACATGTTGATAAGATAAATATTACACTTAAAAATATGTTTATCAAATGTATGAATGATA
AAAACGAATCTGAAATGTATGGGAAAGATCTTGAATAAAGGTCTATGTACATTTCAAGGATGTCTACATATGCAAA
TTATCATAATATAATACTATTGAATATGATTATCTTACATACTTTCTTTATTTTTCATCTCTTAGATGAAATGG
GTATTTGTTTTCTTATAGCTGGAACAAAGCATTACAGAGAATTTCTAGTGTGATTTCATTGAAACTCACTGTTATATG
AGTTCAACAAAGTTTAAATTAGTCCATGACTTAATCATCCTTTTATAAATCCTATCACTAGTATTCGGTAAGGACAAA
GTCAATTAATAAATTAGCAACAGAAGCATTAAAAAGAGGATTAATAAATACAAAAAAGGGATGTGATATCTTTACG
TATTGCTGAGATGTTAGTGCTAAGGAAAAACTTCCCTGTTTCAATGTGAGGTGGGAAAAAGAAGAACTATTATTGT

ATATTTCTCTCTCTAAAACTGCCTATCTGACTGTGTTTTTCTGTGTCTAGCCGTATTAACAGATGTTTAAATTTTACT
CACTTTTAGTATATAAGGCATCATAATGTATGAACTATTTCAAAGGCCCTATGATGGCTAATTAAATAAAAAATATATT
AAATATTAGCTGGACAAAATAAAATATGTATTAATTTTGGAAAAAGTAGATCAAGGTTTTGCAGATCTTTTCATATC
AATATATTCATTTGCTGAATAAGCTTTTATTGTTTACCAATATTACTAGTTTTATAGAGATGTAGATATCACCACAG
TATGACTAATTTTATAGGGACACAGATAGATAGATGTTATTTTATTCCAATCTTATTTTTACATATAACAGGTATAA
ATATGCGCTTGAAAGGAGTATATCACTTAGGAGTCAGTCAGAAAAAGTAAAGATCTTCTAGTCTAATACAGTGGTTCT
CAGCCAGGGGTGATTCTGCTGCACGCTGAGGGATAAATTGGCAATTTCTGGAGACATTTTTGGTTGTGACAATTGCA
GGAGTGTACTGGTATTTCATTTGGTAGAGACAGAGATATTGGTAGACACTGTACAGGACACAGGAAAGTCTCTTACA
ACAAAGAATTATTCTGTCCAAAATGTCAGTTGTGGTGAGGTTGGGAAACACTGGTCTGGAAGAAGGAATTTACTATG
AGGAAGTAGTTACGAAAGTATAGAGACATTTAACAAGCTGAACAAAAGGATAGTGAGATGGCTCAGAGATTAGCAACT
GTGGCATGAAGCCACTACTACGTTTAGGTAAAAATAAGCTACCATTATTCTTATAGTAATAATAATAAATTATT
ATTATTATTATTTGAGATGGAGTTTCGCTCTGTTGCCCGGTTGGAGTACAATGGTACAATCTCGACTCACTTCAAC
CTCTGCCTCCCAGATTCAAGCGATTCTCCTGCCTCAGCCTCCTGAATAGCTGGGATTACAGGTGTGCACCACCCCTC
CCAGTTAATTTTTTGTATTTTTTGGTAGAAACGGGGTTTACCATTGTTGGTCAGGCTGGTCTCGAACCCTTGACCTCA
GATGATCCATCCACCTCAGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCACACCTGGCCCACTCTTTCTTT
TTTAATTATTGAGAAATATAAAAAATATGTCAAAAGTAACAGGTGTGGTGGAGTTACAGCATGCACATAATGGGATAC
AGCCCATTAATCTAATCTCAGATGGAACTAGAAAAAAAAGAGAAGATCTTTGCTAAAGCACAGATTATGTGGAAAT
CATTTAGAAAAATAGCTTATCACAACATTAAAAATTAAATCCTTTAGCTGATCATTTTTCTTGCTATTTTTCTTTT
AAAATTGAGAAGACAGTGAGTTTTTTTTCTTTATTGTCTATTATCTTGATGTCAAAAAATAATATGCACATTATAAGT
GGGAAAAAAGATAAGTCGAAATGAAATGAAACAATGCGAGGAAAAAAATGTCACAACACTCTTCAATTAGAAAAAT
GACCCCATCTTTCTCCAAATAGAAATGACGTAACTGAAAGTAGTGGAACTTTCTCTTCCATGGCAACTCTAGAGAA
GGGGTAGATGGCATGGGATTGTGGACAGATGGACACAGAAAGAGGCCTCATTATTGTTATTGTTAAACTTTTACT
TCTAGTAATAGTGACACCTCCTTCAGCATTTCTTTATCAATTGTCAATATTTTTTGGATCACCAGCATCACCTTCTA
TATGTATGTCTAGAAACCTCCTGTTATGAATTTACACTTCTCAGAGTCAAGACAGAAATGCTGTGAATTTGGGCGATA
AATAAAATACCCCTTTTATTGCTTGTCTTAAAGAAAGATGCCTGTTGGGGACATATGAGAACTGCTTTT
GTGCTTCTGGACCTCAAGGGACAAATCTATAATAAAAAATTATGCATAGTGATGAGAAATATATATAATGCAAGTTG
TAGAGATCAGTTAACTTATCTTGTCTAGGCAATTATTTCTAAACAATGATTTCAAATCATTAACTATAATATAGCCC
ATTCTATACCTCCATTTTTGTCAAATCCCTGTACCTTCAAGGACTTGGCCATCCCATAGGCTGCTCTGCTTTTAAAT
AGAGGAAGATGCTGTAACCTTTGGTACCATTGCCAGTTATGAATTTATCCATTAATGAACATTGCATTTAAGGCATA
GGTTTATCTCCTTCTCCAGGTATGAACCTGCAGGATTCTACCTGAAGCTTAAGGGAGAATAAATCCACCTGGGACA
ATCAAGGACAGATCAACCAATCAGCTCAAAGCAGGTGTGAATTACACAGTTTATTTGAGTGACAAGGTAGCTAAAGC
AGGGATAATAAAAAGAAGGGAGTGGGTTGATGTGGACAGACGAACTATGGCTTTAGGAAATTTGGTAGGGACTGAAAC
ATATTTTGTGTAATTTATGTGGGTCTAATAGCTTTTGAACTTGTTTACAAGACCTGTGTAAGTGGTACTGGCATAT
TCATGCATGAGAAAACATCAAGGGAAAACCTTAATAGTTCAAGGAGGTGACAAAGAAGAGAGGAACCAATTATTTTCA
CTAGCCGTCAAAGCAAGAAAATAATCAGCTTGAGCCCTTCGGGGAAAAGATAGGTTAAATATTAAGTAACAGTTTG
TTATTATTCCAAGTGTTTTCTTAAAGTTGCTCCCATACTTTCTGTTTTCTCTGAGGGAATTTAGTTTTTTTTGTGG
TTTTTTTTTTTTTTTTTTTTTATAACTGTCAATTGGTCAGAGCTTGATTTGATGCCAGTCAAATTTTTTAAAGAGATTA
TGAAACTGCTTAACTCTTCCAAAGGGAAGATGGGTCACTTCTTAACATGTGTTTCAAGAGGAAGAGCATAAGAGCA
TTATATGGTAAGGCTGAAAGCAGATATCAGCGTTTAGGGGCCATGAAGAGGTAGAGCTCACATTGGTAGGATCATTG
ACTAGAATTCCAGAGATCAAAATTGTATGTTAGTCTAGCATTGGGGAGGACTTGTAGCTAGTATCTTCATTCTAGCT
TGGGAGCCTAGGAATCAGGTTAGGCATCTTGCACAGGAATGGGCCGATGGGCTAAAATCTCCTTGAGAGAGATGATT
AATCAGGACAAACCAAGCAGTCATGCCAATGAATTACTTTAACAAGGGTACTTCATATCCTCATCTTTGGGCAGCA
CGTCTTTCAGAGATGGGGCAGGCCCCAGGCTGCATTTGAGATTCTATAAACTAAGGTCAAAAAGATGCAGCAGTGAA
GAAGTCATGCTTATCTTGATAAAATCATGTTTTCTTTTTCTTTTATAAGAAATGTACATTTAACACATTTTAAACT
AAATATTGACCCTAAAATTCCAACCAAAAAATGCTACATAAGTGGTATTTATTTTTGAAATTTCCCTCATGCTCCTCC
CACTGTGGGGACAAGGAGTGGTGGTGGAAAGAGAGATCTTTTAGCAAACCTGTGAGTAGAGAATTAGAAGGTAATGGG
AGGAAGGTAAGGAAACATCATAGATGGATAGGCTCACAAACATTAAAGGCCCTCGTGCCCTGCTCTTCATGCCTA
TTCATCCCTCTCCAGTATGTGAATCAATGTACTTGTAAATATTCAATCACCTCACATATTTAGCATTAAACCGTGA
TCAGGGACGTTGTTAGACCGTTGGTTACGATGATGTGTAATAATCATTTGTAACCTCAGACTAACTGGAAGTGCTC
AATATAATAAGATGTAATGTTATGGAACACTAAGTCTGTGCTGAAGACTTATCTCCTTTAATCCTAAAACAATCCTG
GTGGGTAGTCTCAATGATCATCTCCAAGTCACAGTTGAGGAAATTAAGGCTTCAAGAAGTTAAGAACTGGACCAAC
ATCACAAGGTAGCATCAGAGTGACAGTTTGATTTCAAAGTGTAAGTTGACTTCAAGGCCACATTTCTTGACGTT
TAATATTGCCTTTCTCAGGTAAATATACCATTAAATGTGATACAACCTTAAGCATTGTAATTACTTACAACGTGCAG
AGTTAAACCAGCATTATTTACACTATACTTCAGCTCGTTTATAAGTGAACCTATTATTTTGTGGACTAACCTATGAA
ATGTAACCACATTGAATTCCTCTGTTAGGTACAGGTTTGGTGATTCCAGGGAATAGAGTATGACTGAATGCACAGGT
AGGGGTGAAGTGAACCCGGTCAGAAAATTTAGAGAGCATCGAGCAGATCATTAAAGCAGCTGTCTTTCAAATGTGCAG
AACACAACCTCATTTGTAATCTAGGGACTATCTGTATTGATTCTTCCAGGGGAAGTTACTTATTTTTATACATATGTG
GTGTGTTCTGTCCATAATACCATTCTACATGGTAATGCTCAACTTTATTATTTAAAAAACTGCTAATAATGAGGTT
TTTCTTTGTATCACAGAAGCAGCAGGAGCAAGTTTCTTTTCTTCCAGTTTTTTTAAAGTACTGCCAAGGAATGT
GATTTTGTCTCAGACTTGTATTTCTTATTAAGCCAATCTGCATGACTGTTCTTCTACTAGCTTTTACCTGTTCTACTCAT
TTATTAATTCATCAAAATTTGTAGAGTGACTATTGTGTGCCACATACTAATATAGGCACAAGGATAACCAAAAAACA
GACAAACGCTGTCTTTTCAAGGAGCTCATATAGTAATGGGAAGTTAGGAAAGGAGAAAAATAAATATGTGGTATTTCA
AATGGAAGTATTAAGTGTAAAGAAAGAAAAAGAGAACTAAACAAGATAGGGAAAAAGTGACAGGAACATGATGTTTTA
TTTTTTATTTATATATATTTTTTTGAGACAGGGTCTCATTCTGTTGCCAAAGCTGGTGTGCAGTGACGTGATCATGGC

TCACTGCAGCCTTGACCTCCCTGGGCTCAGATGATCCTCCCACATCAGCCTCCCAAGTAGCCAGGTCTACAGGCATG
TACCACGATACCCAGCTAACACGTTTTCTTTTCTTATAGAGACAGAGTCTCACTGTGTTGCCAGGCTGTTCTTGAA
CTCCGGGGCTCAAGCAGTCCACCCACATCTACCTCCTAAGGTGCTGGAATTACAGGCATGAACCACCATGCCCAGCC
GAAATTGATGTTTTATATATGGCAGTCTGGGCAGACCTCTTTGATGTGATATTTGAACAGAAATCTCAAGAGAGGGA
GTGTATTAGCCCGTTTTTCATACCGCTAGAAAAGAACTGCCCCGAGATTGGGTAATTTATAAAGGAAAGAGGTTTAATTG
ACTCACAGTTCAATATGGCTGGGGAGGCCTCAGGAACTTAAAAATCATGGCAGAAAAATGAAGGGGAAGCGAGGCACC
TTCTTCACAAGGTGGCAGGAAGGAGAAGTACTGAGGAAAGGGGGAAGAGACCCTTATAAAACCATCAGATTTTGGGA
GAATTCACCTCATTATCATGAGAACAGCATGGGGGAAGCCAACCCCATGATTCAATTACCTCCACATAGCCTCTCCTT
TGACACCTGGGGATTATGGGGATTATAAGGATTACAATTCAAGATGAGATTTGGGTGGGGACACAAAAGCCCAAACAT
ATCATTTTTGCTCCTGGCCCCCTCCCAAATCTCATGTCCCTTTTACATTTTCAAAACCAATCATGCCTTGACAACAGTAC
TCCAAAGTATTAATTCATTTTCAGCATTAACCCAAAAGTCCAAAGTCCAAAGTCTCATCTGAGACAAGGCAAGTCTGTT
CTGCCTGTGAGCCTGTAAAATCAAAAGCAAGTTAGTTACTTCTTAGATAAAAATGGAAGCACAGGCCTGGGTAAATA
TACCCATTACAAATGGGAGAAATTAGCCAAAATGAAGGGGCTACAGGCCCAAGCCAGTCCAAAATCTATCAGGGCA
GTCAAATCTTACAGCTCTGAAGTTGTCTCCTTTGACTCCATTTCTCACATCCAGGTAACACTGATGCAAGAGGTGGG
TTCCCATGGTCTTGGTAAGCTCCACCCCTGTGGGTTTGCAAGGTAGAGCCCTCTCCTGGCTGCTTTTACAGGCTGG
CATTGAGTGTCTGCAGCTTTTCCAGGCACGTGGTGCAAGCTGTTGATCGCTCTACCATTGTGGGGTCTGGTGGACAG
TGGCCCTCTTCTCATAGCTCCGCTAGGCAGTGCCCCAGTGGGGACTCTGTGTTGGGGCTCCAACCCACATTTCCCT
TCCACACTGTCTAGCCGAGGTTCTCCATGAGGTCTTCATTCTGTCAGCAGACTTCTGCCTGGACATCCAGGAGTTT
CCATACATCCTCTGAAATCTAGGCAGAGGTTCCCAAATTCATTTCTTGAATTTCTGTGTATCCACAGACTCAACACC
ACGTGGCAGTTGCCAAAGCTTGGGACTTGCTCCCTCTGAAGCAATGGTCCGAACGTGACCTTGGCCCCCTTTTATCCA
TGGCTGGAGTGGCTGGGACACAAGGCACCAAGTCTGATGCCGCACACAGTGGTGGGGTTGGGGGGGGGACCTGGTC
CACGAAACCATTTTTGCCTCCTAGACCTCTGGGTCTGTGATGGGAGGAGCCGCAATGAAGGTCTCTGACTTGCCCTG
GAGACATTTTCCCCATTGTCTTGCCTATTAACATTGGGCTCCTTGTTAAATATGCAAAATTTCTACAGCCAGCCTCTC
CAGAAAATGGGTTTTTCTTTTCTACTGCATTGTGAGGTTGCAAAATTTTCAAACCTTTTATGCTCTGTGACCTCTTGA
ATGCTTTTGTCTGTAGAAATTTCTTGTGCATACCTTAAATCATCTCTCAAGTTCAAAGTTCCACAGATCTCTAG
GTCAGGGTCAAATGATGCCAGTCTCTTTGTTAGTCAATAGCAAGATGACCTTACTCCAGTTACCAATAAGTTCTT
CATCTCCATCTGAGACCACCTCTGCCTGGACTTCAGTGTTCTGATCACTATCAGCATTTTGGTCAAACCATTC AAC
AAGTCTCTAGGAAGTTCCAAACTTTTTCCACATTTTCTGTCTTCTTCTGAGCCTCCTAACTGTTCCAACCCCTGCCT
ATTACCCAGTTCTAAAGTTGCTTCCACATTTTCAAGTATCTTTATAGCAGTACCTCACTACCTCAGTACCCTGGTC
TTAACTCCTGCGCTCAAGCGATCTGCTTGCCTCCACCCCTAAAGTGCTGAAATTACAGACATGGTCCATTGTGCCGA
GCCAAAATTGATATTTTATGTATGACACTCTGGGCAGACCTCTATGAGGTGACATTTGAACAGAAATCTCAAGGAAG
GGGAGAAATTATCCATTTACATATTTGGGGAAGAGCATTCCAGGTAGAAGAAACAGAAAATCCGTAGTCTTGAGGA
ATGCCGTGTATATGCAGTATTTTCAAACCTGTTATTTGAAATACATATACACTTACAGGAAGTTGCAAAAGTATT
AAGAAAGATCATGAGTACCCCTTCACTCATCTTCAGCTAATGGTTACATCTTACATAATTATATGTAATATCAAAGCC
AGGAAACCAGGAAATTGATGTTGATACAATCTATGCTTTATTTCAGATCTCACATCTTACATAGCTATGCACAATATA
AAAACCAGGAAATTGATATTAACACAATCTATGCCTTATTTCAGATCTCACCAGCTTTTACATGCACCTTATCTGTGTC
TGTCATTCTATGCAATTTTATACCATGTTTATAGAGTCATATAACAACTACCCCTATTTTGTATACATGGTACTGAATAG
TTCCAGCGTCACAAAGGAATCTCTCAAGCCACCCTTTAATTGTTCACACCCATCCAATCTCCCATTCTACTTCTGTA
ATCACTAGCAACCCCTAATCTGTTCTCCATCTCTATGATTTTGTCTTTTCAAGGGAGTTTTCTAAGTAACTCATT
GGGGAAAGAAAGGAGATGAATTGTTCTAGCCACGGAGTGAGAAACAGAGAGTAAGAGTACCTATTGAAGCAGAGGGA
GTCATTGCAATAATTCAAATGAGAAATAATGGTGATTCTAAACCAGGAAGCTTTCAGTGAAAACAATGAGAGGTACA
TGGATTCTGGGTATTTTGGGAAGGTAGCACTACCAGGTTTGCTGATGAATGGGGTATGGGGTGGGAAAGAAAGAGAA
GAGCCAGGATGAGTCCAAGGTGGATAAGGTGAATAGAATGAGAAAATGGTAGAAGGATCAAGTTAGATTGGTAGAG
GGGTAAAGGTGGAAGCAATAATTTGTTTTGGAATGTTAGGTTTGAAATCTTGTTAGACATCCCGAGTAAAGTCACA
AAGAGTGCAGTTGGATGAAAGTATGGGATTGAGGGAAGAGTATGTGCTAGAGATGCAGATTTGAGAGTCATCTGTG
TGGAGGTATTATTCAAATTCAAGTCCCTTGGAAATGAATGGCTATTGAGGCAGGGTCTTCATAAAAATGCTTGTGTC
ATGCCTGTAATCCCAGCACTTTGGGAGTCTGAGGTGGGTGGAACACTTGAGGTGAGGAGTTGAGACCAGCCTGATC
AACTTGGTGAACCCCATCTCTACTAAAAATACAAAAAAGTTAGCTGGGCGTTGTGGCACATGCCTGTAA
TCCCAGGTACTTGGGAGGCTGAGGCAGGAGAATTGAGCCAAGATTGTGCCATTGCATTCCAGCCTGGGCAACAAGAG
CAAACTCCGCTCAAAAAAAGAGCTTGTGCTTCAAATTCATGTGAGTCTGTAAAATTA
TCTGGGAAGGCAGTACAAAACTGTCACTTTGACTACGATGTTTCTGGTGACCCATCTTCATTGATCAGTATGGAAA
AGGCATGTCTCTGAAAATCTCTGAGAGTCTTTGATACAGCAAGAACATAAGGATAAATCATTCTTCTATGTTTCATGG
TTGTAGAGGATCTTGAATGTTTAAATGGCAGAATAGCCAGATCACACTCTGGCACTTCTGTATGAGAGGCTGAGGGAT
GTTACTGATTACCCCCGAGAAATATTTACTACTAAGGGGACAGAGGCAAGGGGATACAAGACTTCACCCCTGAGCTG
TAGCGCTCCCTCCTTCCCTATCCTGCTTTTCACTTCTTCACATTGTTTTCTTCTTTTATTTATTTACTTTAA
GTTCTGGGATACACGTGCAGAAATGTACAGGTTTGTACATAGGTATACATTTGCCACGGTGGTTTGTGTCACCCATC
AACCCGTATCTAGGTTTTAAGCCCCACATGCATTAGGTATTTGTCCCTAATGCTCTCCCTCACCTTTTCCCTGTGTC
CACATTGTTTTCTTTCTTTTGAAGCCTCTCATTCACTAGGTTTCAATCCTGCCTTGTAGTGTCTAACTCTAAGG
CCTAGGCAAGTATTTTACCAGAACTTAGCCTCAGTGTCTCATCTGCAAAATGGATAGTTTTATGATATCTTTCAGCC
CTTAAAGTCAATGGTTCTGACAGCTAGGGTGACTACTTCTTGGATATCAGTCATCTCAAGCAAGCCCTCTTTT
TGGACCTTCTTTTTCACACACTTCACATACCTTAGAGAACATAATACACATCCTCTTTACTCAGGGCTTATCTTTAT
AACAGGCTTCTTAATTCAATTAACCTCAACTTTTCAAAAAATATTAGTGACTACTGTGATGTAAATAAATTTGCATTTT
ATAGGGGTCTTAGTAACCCAGAAGGGAGTGGGGAAAAATTAATATATATTGAGAGTTTATTAAGTGCTAGGTACTGTA
AATATTTTCTTGTATTTAATCTCCGAGTAATCTACAACAAAGATATTATCATTGCTATTATGTAAATAAAGAAC

100

GAAGTGTGCTATTTCATTCACTGAGGAATGGGCTATTATAATGAACTATTATGATATTAGAAAATTGTCAGGGCAATAA
GCAAATAATACATACGGTTTTTCAACAAACTTTCTAAGTATTGTTATCAGTGGGTTTGCTTAAATCTTTTTTTACAAA
TTTTATTTATTTTTTTGAGACGAAGTCTCGCTCTGTGCGCAGGCTGGAGTGCAGTGGTGCAATCTCGGCTCACTGCAA
CCACTGCCTCCCGGGTTCAAAAGATTCTCCTACCTCAGCCTCCCGAGTAGCTGAGATTACAGGTGTGCGTCACCATG
CCCATCTAATTTTTGTATTTTTAGTAGAGACGGGTTTTACCATGTTGGCCAGGACAGTCTCGATCTCTTGACCTTG
TGATCCATCTGCCTCAGCCTCCCAAAGTGCTGGGTTTACAGGCGTGAGCCACCGTGCCAGGCAATAGCCCCATTGC
TCAGTGAATGAATAGCACACTTTATTTTAACTCATTGATATAATGTATATTTATCATCAGCTATACAGGTGTGTGTG
TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGAATGACAAAAGGATACACACACACACTCTTTATTAACCCCTC
TGGAGCTGTTTACGCAAAACCTTGCATTTTTTTACTTTTCATTACAGTGTGTAAATAAATTTAGCAAATTTCTAATTTGAACC
TGATATCAATTGAGCATTTAATATTTTAGCCAAATATTTATCAAGTGCTGACTGTGTTCTAGATGCTGGGGCTGCAAT
TTCGAAACAGACCATTGAGGCCCTCATGGAGCTCACAAATAATGATCTTCCTTAAAGTATCAGGTCTCTGGTTTGT
ACCGTATTTTTTAAATTGTTAAGGAAAGAAAAAGGCCCTATCTTTTTGTAGACAAACATGCCCTAAGTGCTTCCAGA
AATAATCTCCATCAGGTAATGCAGACTGTGTGTGGAGTGAAATTGAGTCCAATCCATGATCCAGCAGAGTTTCAGCC
CAGGATTTCTTTAGAGCCTTTGCTACACACAAAGTTGGCTGATGTGCCATTACAGCATCCCAGCAGCTCTTTCTCTTC
ACACTAGCAATGGCAAAGCTTTGTGCGGAGGCATTGCTGGCTGCTCTGAACTAAAAGCATCCGTGGGGACCGAAAGA
GGTTTTTGCACACCTTATTAAGGTAGGCAAGTGTGTCTGAGTGTGTGTGTGCCTAAAAGCTGGAAGACATCTGTTGA
GAGGAAAGTGCTCTTCTGTGGGTCTGGCAGCTTTCTGTAAGTCTTCTATTTCTGATGCAGGAGCGTGTGAGCAGTGG
GTGGGAGGAGATGCTTTGGTACTTGGAATGCTGAGGTCCGGATTAAAGTGGTATTGTAATAGCTAGTTAGAGGCAGAA
TAAAAAGCTGGGAATCAAAGCATTTAAAAATGCATCCTTCCATTATTTGCTCTCAAGTTAAACCATATTCATTCTAG
GGGAAATTAAAAAAAAAAAAAAAAAACACAGCAAGGGCAAGTAGCCCAAAATCTGTAAGGTCTTTGAGCTTCTCTGTTCG
TCCAGCTTTTGAAGTCTTCTACAGCCAATTTGTTTGGCTCCTCTGGAGGGGGCAATTCATATCCACTTCCCTCTCC
TGGAGCATTTCTTTCTTCTATACTCCATCAGGGAACAATAGAGTTTAAACAGTAACAGGCAATTTTTTTTTTTTTTCA
AAGCTTGTGCCCTCTTCTGCGTTTTAAAGGTGTTTTTAAAGAGACTCCTGCTAGGGGAATCTTGGCGCCTGTGTGTTA
AGACGGCAATTAACATTTTAGTATCAGTGCTTACATTAATTTTCTCTCTTTCTGCTTTACTAAAGCAGTCATTA
TTCAGTGTGAGTAGCAATGAACCTTTATCATAAACCCTGCTTTGCTTAGAGAACCCTGATTGTTTTCTGAAACAGC
CTTCTCAGTTTTATATATACATAGCTGCCTTCTTGGAAATACAAATTTGCTTTGTGTCAATTAAGAAACACTAGGTT
GAACCTCTATACTGTGTTTTATCTGAGAAAAATACTACTGCAAAAAGTTTGATTGTTTCAAGTTTTAGGATGAAAA
TTCTTTGTAACAAGTTATTTGAGTTGCATACTATGTCATCGTATATCTCTTTAGTTCAAGTAATTTTGAATTAACA
TACGGTTATGTAAAGAAGATAATGATTTATTTTTTATTTATATTTTTTAAAAAGTTATTAAGTGAGGTTTTCTTTT
TAAGAGTTTAGAAAAATAGCCAGAACAAAGTAACTGGACTTGGAAGATAAAGATACCTTTGCACCTCTAAATTTTAC
CTTTGTACACTTCGGTTGTGATTTAATCATTGAAATGCCTCTGCTTTGAAGTAAATGCATCACTTATGGTGTATGCT
GTGTTTTAATAAAGGGAACAGTTATGGGTCTCTGTGTCACATTTGAATGTTGTTATTTTTTGTCTGTATTTAATA
ACCTCTTTTTTCTCTTGTGAGGTTTACTTTGGAATGAGGCATGTTCAAAAATAGGCTGACATTACAGCTTCTATGTT
TTAAATTTAAATGCTGTCTGTGTTTTATCAGTCTGGAATGTGTGGGAGAAAAAGATACCAAGTTTTATTATTTAGA
TTTAATTTAGAAATGAGATTGATATTTTCAATGCATTTTCATTATAGTTTCTGCCATGGAGGCAGCGTGAGGGC
TTTTAGGAAGATGGAGTGGTGTAAATTACCAGGTGCGCACGTTCAATTAATCCTTCCCTGGCTAGAGAAAGCTTCAAGTT
CTTCTCCAGTGGCCCATTCGTAAAGCTATAAAATATCTAAATTTGTGTGAGCCCAAGAGTCACACAGAATGGTGGCTCT
TTTTGAGTTCAATTTTCATGCACTGTTGCTTTGGTCTTGTGAGGAAAAGCTCTGAATTCCTTAGGATAGTCTTGGTTGT
GAAGTTCCAAAAACAAATATCAAATCATTAAGGATTTAATTTAAAAATACATACTCTTCTTTTACAAACTAGATGAT
TGCAGTAATGTGGATTATAAATTTTTTTTTTGTCTTATTTCTTTAGAGCTCCTCTTTTTATTTTGTATGATCAAGA
TTATAGCTGAGATTTTGGTGATTTTTTAAAAAGATTTATGGCTTATGGTCCATCAGTCTCTCCACTACTTCAAACC
TGTGTACCCCTGTATATTATCTGCACTGGAATGTTGCATTGTATGTGGAAGCTATATACGATTTGGTAAAAAA
TAACACTTAAAGGTCTTCGCTAAGAGTGCTTATTTAATCAATTAATAATCCCTTAAATAAAAAATAATCCAGAGATATT
GTCTGTGTACAAACTTAAAAAAGAGAAATATAAAATCTGTGATGTGAATAAAATGTATAGAAATACACTCCAATA
ATACCATTCTTATGTTTTTCCCTTGTCTCAACTGAAATAACTAAGCTAATAGAGACGTCAGTAAGGAATGTGTTGTT
TCTTCATAATACAACTACAACTCATCTGATAAGAACAACTGAGAGTGAAACGTTAACTTTCTCATTAGAAAGATT
CAATTTAACACATATATACAAATACATTTTTTAAAGATAATGATATTTGCAGAGTTTTTGTATTCTATGGAGTAAAGGA
GAATTATCACATATTCAAAGTAAAGGTATAAAATACATCTTAATGTTTTACTTAAATTTTAAAGGGTCCAAATATA
CTAAATTTGTTTTTCTAATTCTTTCTATGTTTAAACGTGCCAGAGTCATTGGAAATAGGACATTCTTTTTCTTAAAG
AAGATTTTGGCCAAATATTTAAACTATTTTCTTTTCCCTTGATTTTACAATTTCAATATTTCATGGATTTTTCTAC
TTTAAAAATAACAGTAGTTTTTATGATCTTAAACAAATGTTTAAAGGGCACTTTCGCTCTCTGGAGACTATACCATC
CACATATTTATTATCAGCAAAAGAAAGGGCAGGGCATACTTTTATTTGAAGTTGAGTATAAAAAATGTGTCTGTGTGT
GAGTGTTATTAATAAAGATAAGTGAAAGAGACAAATATAGAATCCAGGAACATTTTCAGCCTGGCTTTTACTCTCTCTA
AAAACTAATGAAACCCCTTGAGCATCTCTTATCTCAAGGTACATTAGGAACTGTCCAACACTATGATCCGATGGGAG
ATCAGTATATTATATAAAGAAGAAAAATTTGTTGTTAGTGAAAGTCAAGTCTTTTAAAAAATAATAGTTACAGCAT
TTGCAATATACAAGCATAATAGATTTACTCAACGCCCCACCCCCATCTTTAAAAAATCAATTTCCGACAGTTGTCTA
CTTTAAATTTGAACATATTTGCTACCTGGAGGGAACATTGTAATGTAGCCCATATGTGGTATGCATCCTGAAGAAAA
CCTGAAATTATAGAGGAAGTTATCCTGCCTTCTTTCTTCTGTTGAATGAGTTAAAAATATATTAACAATTTGCCTTTC
ACTTTGTATTTATCATTTTGTATCTTTGCATATTTACATATACATTCATGTGTACAAGGGCATATATACTACAGGT
CAGGGTATTTTAAACAGCTATTTTATTTGAATATGCCAGGGAATACTCCAAGATATAAAGAAGCAGTTATTAGATAC
TATGTGAGTATAGAATTAACAGCCATCTTTTTTAAAGATGGAAGAGAAAAATTAATTAATTACATACAATTTCTAACCT
CAAGACATTTTCTTTCTGGAGACAAGGAATACTGAGGTGCTCACGATAGTGAAGACTCAACAAGACCCTAATAAAAT
AGATGAGGATAAGTAAACTACAATAGCCAATAAAAAACAAAAACAATAAACCATGTTTCGCTGGCATGTTGGTGA
GTATCTCTGTAATATCTGTCAATAAGGGTCTCTGTAGATTTGGAGTAATGTTTCAAGAACTACCTGTACTAGAGAAGA

CAGTGGAGAGGACTCCAGTGGCTAAATTCTGCTGCCTTTGCTTCCAGAAATGTAAATAATAAGGAGGTATTGTGGCA
TTTCTGGAAGCAGTAGTCTTGTTCATGGTCTGACTGTATAAGAAATGCCAGAGAAACATAACCTCAGCTGACTAA
ACTCCCTTGATGATTGTCACTTTGTCACTGAACTCTGACCATACTTTTGCTCCAGAGGCAAAAGACGGGTGAGGA
AGTGATCTCCTCATCTGGTTTTTAAACAAGTATATAACTAGAGAACTGGATTATCTCCTAAACCCACTCTTGTCCT
GGAAAAAGGGGAGTCATCCTATCCGTTTCTTAGCCAATTTATGTATACTCTTAGTTTGAGAGCATGAGAAGGAAAAC
TATTTTCTTTTCTTACCTTGGCTGGGTTTTAAGAATTTATTTTTAGTTTAAATCAAAAATAATTTTTAAAAGGTAGT
AAGCCTCTCATAAGCAGTTTGATCTGTTCTAAAATAACTTCAATTTTTCTTTTTTAACTTTCTTTTATCTTACAC
ACAAAGTATAATAGTAATATGTACTCACTAGAACAAATGAAACAGGATGGAGTCACATAGAGAAATATATCATATTC
TCCCTATCCCCTCCCTTAATATTAACATTTAGGTGTCTATGTGCTTCTCCATTAATTTTCATTGCAAAGGCCATAATT
TTCTTCCAAGAGTGAGGAGTAGCAGCACGGTAGTTTGGACCTGATATAGCTCTCTTTCCCTAGCCTTTTGCTTAAGT
GCTTTCCTAGGGGCTGACTTTACTTACCTAAAAGATGTTTCAAGCAAGGGCTCACATTTTTGGTAGCAGAAGACACTT
ACTGATTGCTCTCACTAATAATTTTGAAAGGAATGTCAAAATCTGGGAGGATCATGAAAGAAATATCAGAAATTTCC
TTTCAGCTGCCATTCTCCTTAATACTGTTATCAATAAATTCAGCATCTCATATGTGATAGCAAAAAAGGTGCTGCCT
TTTGTCTTGCATCCTGAGGTTCTTACCTAATACCATGGTAGCAATAAAGATGGTGAGAAAATTGCTTCTTCTATGG
TGTTTAGGTCCTGAACGAGCACCTCACCTCCACAGACGGTGGCAGGTATTCAAGCATTTTACAGACTTTGGAGTTA
AATATAGCAGTGTTATTCTAATTTAGGTATGCCACCACCAGCGGCACCGGCAACTGCAATAGGAAAAATGATTGGCA
ATGCCAGCTATCTGATGTTTTCATGTGCCAGGTGCTGTCTAGTTCTTCACAGTATTACATTCCATCCTCACAACAAGA
GAGTGCCAGTGAGTGTTGCTGTGTGCCAGTGCCAGGCTAAGGGCTTTGAACACATTACCCTGTTTTATCCTCATAA
CTTTCCACGTTATTTTTATTCTGAATGAAGAAAAAAGTTCTCTGTAGAGATGCTGTCTATTGATCCACTCATATCCT
TTCACATCCGTTTAAACATTTTCCCTGCTGTGCTTTTACTCCCAACAACCTAGCTCCCTAATCGCTCTGTTGGAGGGTG
GCCTTGAGGCTGCCAGAGCCTATTTGGTCTGTGTAAAGAGAGAGATGGATCTATCCTGGAATTTATGTCCTGTGTG
TGGGAAGCCCTTAATCAATGACTGCTGGTTGCAGACACATAAAATACGTGAGCTTTCTTGTTCCTCAACTGAGAAATTC
AGAAGTGTGAATGGCACTGCCACCCTGGGCTTTTATGCCATATATGTGTTTGGTCTGTTTCCCTTCCCAATCTCACT
TCATTTTCCCTTACCAGTGTTTCTTGAAAACACATCCCATTAGATCATTTTTGCATGAAGCTTCATCTCAGAACCCTC
CATTTAGGGAACCCAACTAAGATATTCTCTGAAATAGAACTTTATTGATAAAGTTTCCAACTGTCTTAGTAGAT
GGCCAATATAAGACCAAGCCAAATCTTTCTGGGTCCAAATTCCTGTCTTTAATTAATAGACTCCATTACAACACAT
TCTTCAATCTTTAGTCAGCAAAACCTTACCACGTGCCTATTTTATGGCATATTATATTTATACCATAGTTAGGATAT
TATGGTTTCATGAATATTTTATATCTGTACACCTGAAATTCATTGACCTCTCTGGGCCACAGTTTTGCATCTGTAAA
ATCAGCACATAATGCTACTTATCTCATAGAGTAGACTTAAAAACGAATGAAATGATATATGCCAAGTGTGAGAAT
CACAATTGGCAATTACTCATGCTCATTAATATTAGCTGTTTTTATGAGTATTGTTTCATTTTCGGTGCATAATATC
CTATGCAAAGAACAAAAGGTATTGGTATAGGCATTGAACTTGAAGCATAGAAGAAAAAGTTAATTAACCGGTGCC
CACTAGATGCCTCTAACTGCTGGCTCCGTGTATCCCTTTAGCCTTGGCTCGTCACGAGAAAACCTTGGAGACATTT
TGCTGGACTCAGCAGATCAATTTAAGAAAGATGAATGACATTTTTCTTGAATGTATTGAGTCATAGCTGCCTTTTT
CTACTTTTCATATTTTGGAGTTCTTAGAAAAAATTAAGGACTCCTTTTTTAAAGAAAATGGTATAAAGAAAATGCA
TATCACTTTGTCACTTTATTATTGTAACCTCATCAAAGTATTCAGTGTAAGACAGTAGCCAAGTGAACCTCTCTTG
TAATGCTCGGAAACCATTTTAGCAATGGTAAAAATGCTGCAATTTATATTCGTCAAATTGCATGATTTGACTTATTT
TAGAAAAGTTATTAACCTTCTGAAGAGAATGCTTCAGAAGCATTTAAATGAGTACAAGTTATCACCAGTGATATACAT
AAATTTTCATTTCAAATATACCTTCTAGAACTGTACTTAGTTAGCTATAGTATTTGTACAAGGATTAATTCCTATTT
CATTTTGTAGGAATTTATTTATGAATGTCTATGGCTGCCAGTGTAAGCAGACTTAGAGCATCATCTTTTACAATA
ATCTTTTTTTTTTAAATCAAAGGGGAGATATTCTGGTAAAAACAAAACAAAACAAATAGTTTATCTGCATTT
TTATTAAGTCCCTCTGTAAGTCATCCCTGAAATGGGATATGTAGAGTCTTATATTTATTTTCTCAGAAGCTTAT
TGGAGGTGATATGAGCAATTTTAAAGACCTACTAATAACAAAACAAATTTAAATTTAAATTTTCAAATACCTTA
ACAAATCTTATTTCTCTTATTTTCAAATCTTTTAACTAGTTTCTTATTACTAACATAATATCTTCTGATGTAGT
CATAATAATATCTAAATGACAGGTCTAAGTAACTTACATGGATTAATTGAGTCTTCTAATAATAGGTAGATGGC
ACTATTACTTCTATATGAGAAATGAGGAAGTAGAGGTATAAATAAGAAATTTTTTGGCCGGGTGCGGTGGCTCACGC
CTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCTGATCACGAGGTGAGGAGATCGAGACCATCTGGCGAACACG
GTGAAACCCCGTCTCTACTAAAAATATAAAAAATTAGCCTGGCGTGGTAGTGGGTGCCGTGATGCCAGCTACTCGG
GAGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGTGGAGGTTGCAGTGAGCCGAGATCGCGCCACTGCCTCCAG
CCTGGGTGACAGAGCGAGACTCCATCTCAAAAAAAAAAAAAAAAAAGAAATTTTTTGGAGTGATACAGTTAGA
AAATGGCAAAATGGGAATTCAGACCCAAACAGTAAGACTCAAGGATACCTTTCTTATCAGTATGCTAATATGAAAAC
CTAAGCATACTAGAAAATCTAAGTGCCAGTTGGAACCCAGAATTAACATTTTGGTGTGTAACCTTTCTGGCTGCTTTT
TCTATGCTAACAAACATATATGACATACAAAAATACACACATACACAAATTCCTGTTCACTACTTCTTTTATGTTAA
CATCACAATGTACCGTACACAGCTGTATTATTTTATATTTGATTTTCATATTTTTTCTAAAGTCAGTGTATTTGTCAA
ATATCAACTTATCTATTTAATAGGAATATGGGATGATCTTTGCTTATACATACATACATATGTATATAAAAAACAAA
TCAAGTATTTTAAAGCGTTACCAGAAAGTCATATGTCAATCAGTAAAGTATATAATTTTTTGTGCCAATGACATATA
TCATAAAAAACGCTACCTATCATAGAATGAAATGAAACACAGCAATATTGGGACACCTATTTCAAGCAACAGCTTT
GTGATTTATTAGCTATCTCACATGAAATAACTCATTAACCTGGTATTCCAAGCAGCAAAAGAAGGATCACTTAGGTC
ACTTGCAAAATAATACAAAGCTAGGTTTAGGGGTGGGTGCGCTGGTGGGATGTAGATGAAACCATATGGGCCCTT
GAGTTTATAATTGCTGGGATCTGCATGGTGGGTATATGGATGTTTATTACAGTATGCTAGTGAGTTAAGAAAGAAGA
GGAATTATTATTGACTTACATCATAGAGTTTATGCAAAAAATTAACGATAATTTATTTTTAACTCTAGAGGTATAG
GTACCATCATGAAGGGACCCACAGAAGTGTAGTACCAAGTAATTATTGGAGCTGGAACAGATACCTGTGTGAGTT
GTTCTGGTTTTTGTGGTCAATTGTTCTTGCTTTGCAAGTTACCAACTCTAAGACCTTGGGCAATACTTTAAGTCTTGG
TTGTCTCATCTGTAAAATGGGGAGAGCAGTAAGTGTCTTAAAGGTTTATTCTCATGTTATATGACTTACGGTATGTA
AAACATCTGCGTTTAGACACATAGAGGGTGCTTAATGGATGATTGCTCTCATTATTAGGCTACATCTAATCTATGAA

TTTAAAACTGTATAGAAATATGTGACAGATTCTTTAAGAGCCAAATACCAACTACAGTGAAAAATACCTTAACACTT
GCTGAGCTCTTAGTATGTGTGTCAGGCTTAACTACCTTAATGCTCATAGCAATCCTATAAGATAGGTACTCTTGTTATC
CTATTTTATATCTTCTAAAATTGAAGCAAGGGAAGTTAAATAATAGGACAAAAGATCATACGCTATCTATCCATATAT
ACCCATCTGGCTGTCTACCTGTCTCCTTCCATCCATCCATCCACTTATTCATCTACCCATCCATCCACTCAGTTACT
TCTCTCTCTCCCACCATCCCTTTCCCTTTCCCTCTCCCTCTCCCTGTCTCTGTCACCTCTCCTTTACTTATCTATCTA
TCGATGGATCGGTTTATCTATCATCTATCTATCTATCATCTATGTATAGTTGTTAATAACACTAACATTTTATAA
ATTACAAGACTGAAAAATGTTTTTCACTTAATCTATGGTAACAAAAGACCACATTGTGAATAAAAAAAGCAGTAAACAC
AGGTCTCTGCACATATGAAAGAGATGTCCTAAACAGGAAGAGATGTCCTAAACAGTAGGGATACATAGTATCATACA
ATCAAAACATGGCAGCCCTATAAAACTTACAAAGCAATTTTCATGTAAAGTTATTTTCATTTGACTCTTACCACAATCTA
TGAGGTTACTATTTTTATTTTTTCTCATTTTTACAGGTTAAATTTAATATGGCTTCCAATAAAAAAATTAGTATGGTTAA
TAAATATCTTGACGTCTTGCTCCTATAATCCTACCGATAGTTTACAGTAATTAGTAAAAATAAAATAATAGGAAAAAT
ACCTTTGATACTAGTATTAAATTATAATCATATCATTAGGTAATTTCAATTTGTGATTTTCAAGAATCTGTAATATG
GTAGCTTCTTCTACTGACATGTTTGAATTCATTTTTAAGGCTTATAATTCACAAGTAATCTATATATTATCTAAAAT
GTAAATGCACATTCACATGGAGATAATAAATTAGCGTGAAATGGCTGTATTTTGCTCTCTATAATTTTTTAACATACA
GGAAATCACTGTTGTCTCAAAAATCAAGGAAATATAGTATTTGAGGTGAACTTATCTTTCTACTATTAACACATTT
TAATATAGTTCTCTCAGAGTGCAACAGAGCAAGAAGCTTTCAGACACATTTGCTGTCTGCAAGGAGCATGCTGTGCTG
AACTTAAACACCTTCCCTTTCAAACCTCTTGGGACTGTTTTTTTCCAAGAGACTTCAAATGCCTAAATTTAGCAT
CCGTTGGAGGCACACCCAGGCATATTATAGTGAAAGCCCCAATAACTGAATGTGTTACCCTATTACCAATGTTTAT
GTGTGTATATGCCTTATCTATGATGTATTGCAAAATACAAAAATTGTGTTATTATTCACAGTAACAAAAACACTTCC
AGCAATTTCTAACAGTGATCTCTTTTGAAATAACTTACATACATGTGTGTCATGGGTCTTAACTTTGTCACCTTTTAT
GTTTCCATCATGTTGTTTTAGCCAGTGAGGGTTTTGTTGGTTTTTCAATTTATGATTATATACTTTCAAAAAATAGAT
TTCAAAGTGTGAATTTGATTGATTGATTGACTGATTCATTGAGACGGTGTTTCACTCTTGTTGCCCAGGCTGGGGTG
CAATGGTGCGATCTCGGCTCACCACAACCTCTACCACCCAGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCTAGTAG
CTGGGATTACAGATGTGCACCACCACGCTGGCTAATTTTTTGTTATTTTTAGTAGAGACAGGGGTTACCATTGTTGG
CCAGGCTGGTCTCGAAGCTCTGACCTCAGGTGATCCACCTCCTCAGCTTCCCAAAGCATGGAATTTCCAGACGTGA
GCCACCGCGCCAGCCCGTAATTTTATTTTTGAAAGACAAGAATGTCTTGCCTAATTCATAATAGTTTTAACATC
ATGAAGACTAAATATGCTTTTTTAGCCATGACAATTTTATTTATTATTGTTTTTCAATTTTTTAATTTTTCTCAAAGATCCT
CATCAGTGACTCTTTTTTGGTCTTCTTTATAAGCGTATTTTAAACAGGACATAATAATAAGATAAATCCCAACTTTTT
AAAGTTGTATCCGTATGTATTACTTTAAAGTGCTATTAATATAAACGAATTAGAGGCAACTTTTTATTCAATCAGATT
TTAAGTAATTTTACCAAAATATGGCCTTGATAATGTCTCTGTAAACAGGTTCTCTGTAATATACATGCTGAGGATTG
GTTTGTCTTTGCTTTTGATACTATTTAATTAGAAAAGTAATGGGGAATCCAGACCCTTCTCATTTAATAATCCAGA
GAAAAATCAGTCCATGTTCTAATAGTTTAAATTTTTCTACTAAAACCCATGTGAGAATCCATATGAGTGGAAATGGAG
AGGAGTTTCACTTCAAAGTTGGCAGATTTGAGATGATTCTATGGCAACAGAAATGTGCTTGAGGGAAATCAGTTGCG
GCATCTTCTATAATTGTGTACCTAGATTTTGCTTAGGAATTTCTAGATTTCCATAGAACATTGTGACCTCAAATG
CTTTATCTTAATAAAGAAATAAAGCAGATTAGAAGAATTATTTGCCACAGTTTGTGGGAGATGGGCAAGTCTTAA
GAGTTTATTAGGTACCCAGAACGAAACATATTTTTCTTGGGCCCTCATAATCACATTGAAATACAAGGATTTAGTTATA
CACAGTGACCAGTTAGTGAATGACAGTCTTCAGTATCTAGTAGACAGTAAACATATAAAGATGTATTTGTGGCCGGG
CACGGTGGCTCACGCTGTAAATCCAGCACTTTGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGAGACCGAGACC
ATCCTGGCTAACACGGTGAAACCTCGTCTCTACTAAAAAATACAAAAAATTTAGCCATGCGTGGTGGCGGG
CGCCTGTGGTCCCAGCTACTCGGGAGGTTAAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCA
GAGGTCAAGCCACTGCACCTCCAGCCTGGGCGACAGAGGGAGACTCCATCTCAAAAAGAAAAAATTTATGTTATT
TTTACTTTTTAACTACAGCAGAGACCCCTGGCAGCCTACAGCATACAATTAGTGTTCATTATTAGATTGATGGATT
TAATGTGAGGGGTCAATTACTTGTCTAACCAGTGAGCCTAGCCTTGTCTCAATACTGCCTGCTTCATGAGGGTGAA
CTGTGCTGGAGAAATATATTACAGGATTATCTGCAGATTTTTTTTAAATGAGTGTTAAGTCAAAGTTCTTGTGAA
AATTCAGAGTAATAAATTATTATGAAGTTGTGTAACTAGGTAAAGGATAGTTTCTTTTACACGGGTAAAGATTAAACA
TGAGGAGGAAAACTTTAGCAATGGCATTTAATTCCATTCAATATATTTATATTGAGCTCCTTTAAAAATACAGGGCC
TTGTGGTGGGTGCTGAGGACAGAAACAAAACCAAGTAATACATGAACATAACCCCTGATTTTCATGATCTAGTAGACC
TATAAAAGTTGTGATATCTGATGAAAAGAAAAATGGTAAAGATATTTCCAAACAGTGTATGCAAATCCAGAGATAGGA
TGGAGGGGCTCTACCTGAAGGATGATGATAAGAAAACCGTGTGAGTGAAGGGTGATTTGTGGAATTCAGATAAAAT
ATCAGTCTTGAATGCTGAGTGAATACTCAATGATTGACTAGATCCCATGGACAGTAATTTCTTCAATTATGACGATG
CTAGTGTTTATGACTATACTATCATTCTCCATGCCAGGCACTTTGCCATTTGGTAAATGTATAGTGTGCTATTCTA
ACAAGCATGCACAGAGCTTTTACTTTAATGTATCCATGAGTTTATTGGGGTTTCAAGATTTAGGTAAAGCTTTGCAAGG
TCGTAGCATGGAGTAAATATCTGAAATTCAGACCCATATCTAACTAAGTTCAAAGACTGTACAGATATTTCTCCTC
CTTTGTGTCAGAGAAGGATAGGAATGGTTCCATATTATCATGGACTTAGTCAGATGTTTTAAAAATTATAATGTCCTGT
GTTAATGAAGAAGGGATGATATTCAGTGCATATTTCTTAACCGTTACTTTGCTTAATGCTCTCGACTTTTCTGTGAGA
TGGATAGTGTAGATAAAATCCCCAAGGGGACTCAGCAAGTGCAAGTAAAAACAATGAACTTTAAAGCCCTTTGTCAA
AACCTCTCTTTTTCTCAGAGGATGGAAGGGCCGTAAAGGTTGGTGAGGAAGGATGGACCATTTCCTATGTAGTCTTC
TGACAATATTCAAACAAAAGGAGAGTCAGCAAAATCCCCCTTGATGTGGGAAGTTTTAATAAATTTGCAGAGTGTCT
CTCTGGAGTAGACATCCTCTCTGCAATCGTGTCTCTATATAGCCTCAGGGCTTTGGGTAGGTAAATCTTCCAAG
GAGAGTCCTGGAGAGGGCTGTCTACCCCCCTTGACCATCTCTAACATTATTCTATAGCTCAGCTCCTTGTCTCTG
TTTTCTGCCTTGTTTTTGTCTGAGTCTGCAATTATGATGTAAGCACCATGAAGGAAGGTATGTTGCCAGTGTTTGCA
TCAGCATATCCCCGTGTGTAGCAGCGCAAGGGATATAGTGAGCCCTCAATGTCTATTTGTAGAAAAAAGAATGAAC
GTATCAACGAAATCTGATACATATTCATTGTGTCTGTTATCTCCATCTCTCTTGTCTGCCTTGTATCTTGCCATT
TTCACAAAAGGCCCAAGGCCCATCATTTCTTGTGTAACTTCCAGAGTGTTAATTTTTTAAATTTAAATTAAGGCTTT

104

105

106

AATAAACTAAGCTTATACAAAGCATATTGGTCAAGGAATGTTGCTGGCCTTATTAATTAGATAGCCCAGTTAAAAGAA
GAATTTTTTAAATATAATTAATGTTAAAGTAGGATGATAGTATATAAAACGTGTCTACTGTCTGAATACAAACTAAA
CTGTTTTGGTTTAGCATTTACCTCAAGATCTCTTAATATCCCCCAAAGGGTCCCTAAAACCACAACCTTATCTTTGTGC
TCATGAAGTAGAGAAGAGACAGTTAATAGACATTTCTAGCTGATAGACTGTTGTAGAGCAGAGAACGCTCTGTGTTT
TTGAAAATTAAACATATGAATTTGCCCTCTTCCCCTATTAAGGAAGAAGAGTTTCTTAATTGTGCGAACACATCAA
GTGAACATATTCAATTAGATTTTTGTGACCCAGGGTATAAACATCTGGTTAAGGTTACATATTTCAAAGGAACAAAAC
ACTAGAACTCTTGGTTTTAAATCTCATGGCTGGAGGATAATTTGCAGCAGAGATTTATCTGGCAAGCATAACAGAAT
TGCTGAGACTGTTCTAAAGATGTAAGTGTGGTGTGTTGTGTCGTGAAAATAGCTGTTTACATCTATTAAGTGGATAC
CGATGGTTGAAAGTGCCGTCTATGTCAAGTTTTTACCAAATCAACTTTTGCCCTCACTGTGTGACAGCCATTTTACCTA
ATCAACTTGGACTGCTAATGTCTTTTCCCCTGGCACCACCTATCTGTCTCTTTTGCAAAGCACAGAAACGGCATGCAT
GATTGTAGTTTATAAAACACATGTACCAATGTGGTCTACAGCTTCTGTTGAGTTTCGAGAGGGTCAGTTTCTGTAATC
TCTTCTGGCACAGAGTCAAGAACAGCTTCACTTTCTCTCTGCTACCTCTCTACCCGTAAGTGTGAACCCATCAGTTT
GCTAACACTCAGGAAGGGGATTACACAAAATAGAGCAGGAGCCCTCTGACCTGAATATGCATCTGAGCCCTAGCCAT
AGAGCTTCTGATTACAGTAGATCTGGGATGGGGCTAAATATTTGCATTTTTAAGTGTATAAGTGATGCTGATGCTGC
TGTTTCCAGGACCACATTTTAAAGAAATATCGATAAAGGTGGAGAATTAAGTGCAGCTCAGAAGACCTGAGTTCTTG
CCCCAGCTTGACTTTTACAATCTAGCAAATGGATAAAACTCGCAGGACTTCAGTTCTCTTCATCTACACAGTGAGTG
GTTAGATTGGCTTTGTAATTTAAAATTAAACAGGGTTTGATTCTGATTCACTACACAAGGTTCCAAAGAAGGAATGA
TATCTCCTTTCAATTTCTTCACTTTGTCTTCTGTCCCTAGGTAATCTTATCTATGTTCTGATTTAACCTAACTAATG
TTTTCTGCAAAGCTTCTAATATTTACATCTCCAGCCCTGAAACTCTCATTGTAATGCTAGTCTTATATACATACCCCC
CTGCCTAATTGACATCTCCACTTAAATGTATCAGAGGCAACTCAGACTCAACAAGGACCAAACCTGAATGTTTCGACCT
TGTCCTTCAAACCCGATACACATCCAGGTTCTCCATCCCAGTGAATGACACTATCCAGTTAAGCAAGCCAAAAGTC
TGGATTTTTTTTTCTCACTCTTCTCACTGTCCGTCAACTACCATTATTAATCTGTCACCTGGTCTTACTGATTTA
ACCTTCTCAATATCTCTACAGTTTTTCTTTATGCCCATTAGTATCCTAGTGCAAGCTACCATCGTCTCTCATTGGAA
TTAACACAGTAACCCCCCTACCCACCAGACTGTTCTGCCTACAGATAGTGTGATATTTAATAAATAAATCTAGCC
TTGGCTAGATTTCTCTCTCAAAGGTTACATTAATTTAGCCTTAAATGGTGTGCAAGCTTTGCATAGTCTGTCTG
CTTTGTCTATGTTGGCAGTATTTTTTACTATCCCTCTCATCTGCTCATCTCTGTACTCTCACTCACTAAGCTTTGTT
TTTTTTTTTTTTTAGATTTCTCTAACTACAGTGCTGTAATCTCTTTTTCTTTGTCACGTACTATTCCGTTTGTGAGG
GAATCTGCTCACTGTCTCCACCCACTCCACACACTCACGTTTTCTGCCCCGTCTTACCGGTCTTGATCGGTTGTGAC
TTGCTCAGGAAGGTTTCCCTGGTCACCCCTCCACAAATGAATTAAGTCTCTTGCTGCATGCTGCTCTAGTGCTC
TTTATTTTTCTCTCCTCATCCTTAATTCAGTTTGTAATTACATGTTATTTGTGTGAGGATTTGATTATTATCTGTGT
CACCCACTAGATATTGGGCATTCTTTACTTACTCACCCTGAATTCATAGAACCACAGTAATTGTACACAACAAATA
TTCAAGAGAAATTTATTGAATTGATGAATGAAAAGTTGTACCTTAACATGTTCTGACATGTATCCAAAAAAGAGCT
CCCCTTTGGGGTCTATTAGGACTTTGGACCTAGGTAAACGTAACCTAGTTTCGCTCAGGTTTAAACAGTAGAAAGT
AATTGGGTCTCTTTTGCATGTGGCTTTTCTAAGGGCTAACCCTGTCTTCGGAATGAGTCAATACAGCAGAGCTGTTG
AAAGCAGACTCTAGCTTCGGACAACGTTGGTCCGAATCATGGTTCCGTCATTTCTTAGCTGTGTGATTTAGAATAAA
TTAATGTTTTAAAGCTTTGATTTTCTCTTCTTAACTCTGGAGATGCTAATAAAGCCAACCTTCGTAGAGGTATTGCGA
TGAGTAAATAAGCATAATTTGCTGTAAACACCTTGCAGATTGCTGTGATGCTAACTAATCAATAAATTTGAAGCT
CTTAACATCATTATATTAGATATTTCCAGCATTGAGTATACTATCAGGCATGTGGTAGAAGCTCAATATAAAGTTTT
GTTAAATTGAATAGATTCCATATATGGTATTTCTACAGCATTATGCTCCTTATTTAAGTGTCTCTAAGTATTTTTTA
AGTATCACCTCACAAAAGACAGATGTTTAATTCATTACACATGTGAATTGTTTTAGATAGAAAATAAAATAAAAAAT
TCAAACATTGAAATCAATAGTGTACCTTACCTTAGGATTACACCATAAAATTTCTACCAATCGAGAATAAAGTGTAC
AGTCTATTTCCTTTCTAATACTTTTAAACGCAACAAATGTTTATTGAACACTTACTACTTCTAATCTATGACAGACAT
AAAGATGAATAAAGCATGCCACAATGTTTAAAGAGCTCACTATATCAAGAAAGCGGATTACACAGACAACTCT
ATAAGATAAAGTGGTAAATTTAGGCTGGCTGTGAAACAAAGGATTAAGGTATAGTTAAGAGGTGGAATTTATTTT
ACTTCGAGGATTTTCACTTTTATATTCTTTGTCTAACCTTTTCATGTTTCTCTTTCTTTCAGAAAACAGAGCACCTT
TTTTCTGACACATTCAATTTCCCCCTATGGAGTAGAGCAGTTGTTTTCAAAGTGTGGGTCCCAGATCAGCATCACGGG
GATGGTTAGAAATGCCATTCTTGAGCCTCACACAGACCTACTGAAACAGAAATTTCTTGAGAGTGGAGCCCGCAG
ATCTGTGATCAAGCCCTGTAGGCAATTCTAACGCACACTCAAGTTAAAGAACCACGGGAAGAAAGTCCATCTGTGA
ACAAGACAGATTTTTTTTCAATTAGCATCAATTTTGATCATTATATATATATATATATATATATATATATATATAT
ATATGCATGCTCACAAAACCATTCACCTTACTAGGTTTTAGTATTCCCCTTCTGTATTCTATGTGGTATGTATGTAT
ACAAGATGAACACACATTTACCTGAGACAAGGTAAAGCTACACATGTCTCATTGGGGACCAGAGGCTGTAATCTTA
CTCAAGGTCAAAGCGTCTTCACTGCTTTCTTTCAGTCTTTTCAAAGTAAATTTCCATGTAGGTGTCATTTGTTT
TCTTTTTGTGTTTTAGAAAACCGATTAAAGGGGTGAAGTCTGGCTAAACTTAGTGTCAGGACATTTACTTAGATAAAA
TTATTTTTAATTTATCTTGTAATGTTCAATGTGAGAAGAAAAAGTCTTATGAGTAGTGTATTCTTAAATAACAACAA
TTTTAAAACTACCACTGAAGTCTGTGAGAGTAGTTTTGCTCATTTGTCTAGATAAGAGAAAAAAGGTTACATTAG
GGATTGCAATTTGTCTGCCAAAGTGCAGTTTATTTATTAGAAAACATTTAGAGAGGAATGTGTGAGTTCTGTTGCAG
GCACTGTGCTGTGACGGGGAGCTCAAGATGATCTCAAAAAATTTACAGATGGGGTGGGCAGGGGGCACAGAGAGAT
GTATTTAGTGGTTGAGATACTATTTAGACTGTGGCCAGCATTTCTCTAAATGCAATCCAGATAACACCTTACAGAAT
CATCTAGGGCAGCTTGATAAAAGCTGTAGACTCTTACCCTTCATCCCAAACCTATTGAATCAGTGTCTGTGTGTGAAG
ACCTAGATTGTGACTGGTAATTATACCAAGTCTTAGAAGCAACTTAGGCCAGTAATCTACATCAGAACTCAGCT
GGAGGGTTTGCTATACCACAGATTGCTAGGTAGCTTACAGAGTTGCTGGTCCAGTAACTTTGGTGCAGGTCCAGAT
TTTGCATTTCCAGCAAGTTACCAGGTGATACTGATGCTGCTGGCCTTGATCGTGCTTTGAAAACCACTGCTTTAGCT
ACGCTATAGGAAAAACCATATAAGGCTTTTATACTGGCCAATGACTTCACAGGCCCTGAATTTTAGAAAGCCCCCTTC
TGCAGCTTGGCCTATAGATTGGAAGGAAACAGAACTAACACAAGAAAGCTAGTTAGGAGCTAGTTAAAAATCATCTC

108

ATGTAATGGAGTGAGGCTTAGAAACATGAGGAAATTTACTCAAGCTATCCATTTATTGATGTGTCCATTTGTGTTGT
CAGGGAAGAAAACTTTTTACTCCCCTCTTAGGTTCACTACTTGGGGGGCTGCAAATTAAGCTGACGACAGATAGA
TTGGCAATAGAAAAGACAAAGTTTATTTCAGAGAAGTATGTGGGAGCTCACAGAAAACATAGCTCAATGAAGTTAGAA
TTTGGGGCTTATGTACTATTTTAAACAAGGGTTTTGAAAAAGAGAGTGTAGAATTTCAAGCCACAAAGTTGGTGGGA
AATATGAAAGAACTAATGAAAGGTAATGTTTGTGTTTAGTAAAGTCTGTTTATGTAATTTCTTTTCCCAGCGACAA
CTTCTCATCTCTGGTGACAGGAGTCACTCTTACCCCTGGTGCAAGAACTTTTCTTAAAGGAGGATTTAAACAGT
TGAATTATTTTCAGAAATCTTTGCTTTTAGGCAGATAGGGGGAGTACAGAAAAAGCCCCTTCCCGTATCTGTTGATCC
TCAAATGGCTTTAGCTCAAAACAATTTTACATCACGATGGCATAATGTAGATCTCTTCAATGTGTTTCATTTATCC
ACAGATATTTGTGAAGTACATGATATATGCCAGGTACTTGGGATACAAGAAATACATAAGTATGTCCCTAGTCTCGTA
GAACTTACACTCTAGTAGTGAGCTAGAGAATAAATGATATTATTTATTATATGCATACACATATGATTTTCAGATAGT
GATCCATATTGGAAATAAAGCTGGTTAAGGGAATAGAAAAATGATATTGAAGGTGGACTTGTTTAGATTGGGTGGATT
GGCATGGCTTCTCTAGGGGGCAGTATTTGAGCAGATATGAGAGCAGATATTCTCCAATTTGGGCAAAAACATTCCAG
GCAGAGGAAACAAGGGCAAGGGCACTGAGTTCAAAGAGACTTGACCTAGCCAACAAATAGCAAGGATTCAGTGTA
AGAGAAGGTGGGGAAGGAAGGAGGTGCAAGTATAGGCAAGGGCAAGATCACACGGGATCTTGCAGGCCGTGATAAAA
GAATTTAACTCTTTTATAATTTTACAGGACATCATTGAAGAATTTAGAAAAATAGAGTGGAGATACCTGATCTGCT
TTCTTCAAAGAGTTCATTCATCATTGCTGAGTAGAGTTAGACTGAAATGGAAGCAATAGTGAATACAGGGAGATAG
CACAGGAAGCCACGTTACTAGTCCACATCAGAGGTGGTTTCAGACTAGGGTGGAGTGGTGGGGTCAGTTAGAGAGCTG
GATTTTAGGATACATTTTAAAGACAAAGCTGACAGGATTTGCTGTGATGAATTAGATGTAAAGTATGAGAATAATTG
AGAATTATTTCTAAGTTCTTTGCTGGGGAAAAAGTGGAGGAGGAAAAAGTTAGGGTACAAGGTGTGATGAAATCAAGA
GTCTCTCTTATTATCAGAGTCTCATTAGATATCCAAGTGGAAATGCTGGAAAGAAAGTTGGGTAGATCAGTCTGAAG
CTGAAGACAGATACTGTGACTGGAATAATAACGTAAGAGTTGGCCGGACACAGTGGCTCACTCCTATAATCCCAGCA
CTTTGGGAGGCCAGGATAGGAGAATTACTTGAGCCCAGGAGTCCAAGACCAGCCTGGGTAAACACAGCGAGACCTCGC
CTCTACACACACACACGCGCGCAAAAATTAATCGGGTGTGGTGGCACATGCCTGTAGTCCCAGATACTCAGGAGGCC
GAGGCTGAAGGATCACTTGAGCCTGGGAAGTCAAGGCTGCAGTGAGCCGTGATCACACCGCTGCACCTCCAGCTGGG
CAACAGAGTGAGACCTGTCTCAAAATAAATAAATAATGTGGCAGTCAATAGGCCCTTAGATGGTTTAAAAAGA
CATGGGACTGGATGAAGTCTTCTAGGAGGAGAGTTTGGGAAAAAGAGCCCGAGAATTGACTGCACCTTTCAAAACAGG
AGGAAGAAAAAATACTCAAAGGAGACAAAAGCAACTTCTGTGATTTATAGAGAAAACCAGGCAAGTGGGATGAAG
AAAGTCCTTCATGATAGAATCAAAAACAGTGTCAAATGTTGAAAAATACAATTAGACAAACACAAAAGAATAGACCAT
TGGGTTTTGCAATATGGAGCTCATACTTGACCTTGATAAAAAGACATTTTCACTGGAAGCATGCATCAAAAACATATT
TGTGGTAGGTTAAAATGTAGTAGGAGGTGAGGATATACAGACAGTGGCTTTCACTGTGCAGATACTGCTGCTCATGC
ACTAATTTAAAGACATTTGTTGAGTATCTACTATGTTGTATCCATTGCTAAATAGTAACAGCTGGGTTTAGTCAGGT
AGAACAGCATCAAAATCATTATAGTATCCCAAGATAGGTACAGTAAATCTGTGAAGGAATCAGAGTAGTCTCTTCT
CCAACAGAGCGTAAGACCCAGCTTCACGGAGAAGGTGGTAGATTAGCTCATCTGGGAGGCTGAGTAGAAGCTTGTCA
TTATAGAGGGAGAACATCAGAAGTGTGGACAACAGCTTGAATAACCTTGAAGGACAAAAGAGGACGGTCTGCCCTG
GAAATATTAAGAAGTCTCACATGATTAGACACAAGATATTAGGGGAAAGGCATAAGGTGAATTGAGTCAATGAGGTC
AAAGAGAAGCTAGCTGGAGGAACAGGCGATCATAAAATGAGTAAAAAGTATATATTCAAAGATTCTTTTTAGAAAGGGC
TACACAGGATGGATAAGGGGAGAGAGAGAGTGTAGGCGACAGAGACAAAATTGGAAAGGTGCAATCATAACCAGAGACA
TGAAAAACCCATAGAAATCTGATGTAGATTATGTGGTCCCCAAGGTTGAACAATTAAGTACGCTTTTCACTGTTGTTATG
CCCATGATATTAACATATTTTATAACTGCAATAAGTGTGAAAGCTAAAGATAAATACAAAACATGTAATTTCTTATTC
TGTGAGAAAATGTTGTAGCTGGAAGTTAAACATGTTTCTTAGCTAAAGAAAAATATTGTGTGATCTGGATTACTTAA
TGTTATAATTTAGCAACAAAATGTTGACATTGAGCCTTGCAATAATCAAAAAAGTAGTCTATTCAATAACCACATTCT
CAGAAAAAACAAGAAAATATTAGAAACAATGATAAATATCGTAGTAATTTAATTCAGTATTCTATTGTTTATT
TGGATTTAGGAAAGGCAGAAATGTTGAAATATTAATATATATCCCTGTAATAATATAAATTTGTGTCTGAGAGGTAGG
AATGAGGGCATGAGGTCAAAGTTTGATAATGAACCTTCAAAGCTATAACTATGATCAGGAAATTAATAATTGGACAATA
AATTCCTAGAATCGTCAGGAGTTGCTTGTGAAATCGAGAAAAGGAAAGGATATACACAAAAATAAAGAACAGCCAATG
CTCTCAAAGGAGTCTAACTTTTATAATAGTCTTCTGTGTTAGAGCTGAACTCTTCTGGTTTTAGAAGGACACTCTGTT
GCCTGGAAATAGGGCATGGAAAAAGTCATCAGAGTCATGTCATCTTTTCACTTCTCCCATGAACGAAATCGAGGCCCT
GAAAAGTCACCTGTGTTTGTGTTGTTTATTGCAACTAAGATGTGCATTTTAAATTGATACATAATAATTGTACAT
ATTTGTGGGATACATGTGATATTTGATGCATGCATACCATGTGTAATTATCAAATAAGGATATTTCTGTATCCGTC
ACCTCAAACATTTACCATTGCTTTGTGTTGGGAACATTTACGATTTTTATTATAGCTATTTTGAAATACAAAATAG
ATTGTCAATTAATATAGTACCCCTACTGGATGCACCTTGTTTTTAATATTTCTGAAAACAGATACGCTCTCATAGGTG
ATGGTGTACAGCTGTGCATTAGTTATTATTGCTGTGCAGGTGCAACGTAACCTATTCATATTGTTGTCAATTAAT
TAAATAGTTACATTTATTTATATGCGTTTATTATACTAATAAAACACAATATTGAGATAGTTGAGCTCTAGTTTTGAC
TCTGCTGTTAACTAGCTGCGTTACTTTAATTTACTTAACTAATTTGGCTTTCAAATTCCTGATAAGTAAAATTACAA
CATGAGTTTCTCCTGCTATAATAGCCTGAGAAATCGGTGAAACACATGAATTCAGATGTTGATGCTATTTAATAGCG
GGATTCCAGATATCTACTTGCCATTATGGGAGGGAGAGAGGAGGTGGACTGGAGGCTGTGATTTCCCTAGGAGGTTG
TTAAATTTGGCCAGGTGAGGAAAGCTGAGACAGACCATAAATATGAAGCATGATACCTAGCCCTCAGTGTGAAAGA
AAATCAAATCTCATCTTTGTGGTCTAAATATCAGTATGATACAATCCTCTGTGTAGACATATCCTCTGCCCTATTGT
TTTCTTTCTAAAAGCTAAAGCCCAGGTGTGATCAGATCCCTCCGTTATTTACAAATTTCTGATGATGATGATTCTTC
TAATATCTACATTTCTTACCATTACCATGATGTCCAAAACCTATTATAATCTATTCTGATGATGATGATTCTTC
GTACCCCTATGCACCTCTAAACCCACCATATGACCTTCCCGCTGCTACTTGAATACAGTTGGCCCTCTACCTCGTT
GTGTCTTTGCATTGCTTATTTAATTGCTTTTCCATTCTCTAAATCACTCTTTTCTGCTGGACCAGCAACATCAGCACCA
TCTGGGAATTCATTAGAAATATAGATCCTCAGGCCTCATCTCAGACCTGCTTGATCAGAAACATTGGAGAGTGGAGA
TGAGCAGCCTGTATTTTTATCAGCCCTCTAGGTAAATTTGATGCACACTAAAGTTTGAGAACCCTGGTCTAGAGCAT

TCTTCTTTAACTCTCTTCTAAAAATTATTAGAATGAATTCGAGGGACGGGATCTCCTTGAAAGCCAAGAACATTTCT
TTGTCATCTTTCTGACTTCAGGGCGTAGTACACTTTTTGGCCCATAAATTAAGCTCGATAAATGCATTCTATGCCAA
TAAATCAGCTAATCAAATATATTATTCATGCCCTTGAGGTATCTGAAAATTTGTTTGCAGAATGTAATATATAACTAT
AGAGTAAACAAGAGAATAATTTATTGCCATAGATAATAAAACAATATCCTCTGTATAATAAATCCTAGCCTCTGCTCA
ATGGGCAAAAACGGGACTGGGGTTTCAGATTTTAAAAAGATTATTGGTAATTAAATCACCTGGAGAAGCACTTGCTG
CAGAGATGGGACTTGAAGCATCATAATAAACTGTTGTTTATTATGATTGCGTCAGAGCTGATGGAATCACAGGGATT
GTGTGAGGTATGGAAAGTGGTTGACATTGAATTCAGGCTGCACAGTTGGGACTTGATATGATAACCAAAAAGAAAAG
AATGTCCTGGGGTGGTAGCAAGCTCTAAATTTAGACAATCTAGGCTTATCCTAAGGAGAATATAGATACAGATAACTG
AAGTTTGATTAAAGGGAACCTGGTGTATCACAATAGTAAAAAGCTGTAGTTAGTCTATGCAGCTATCAGCTAGCCA
CATAATACTTTTTGGGCAAAATACATTATAAAACCAAAAAGAAATGACATGGCTTATCTCTGTAACAAAGTGGCTCATTGTT
CTTTATTCTACTGTTATCCTTAAGAAAAAAATTTTAGTAAATTTGTTATGCTATACTCAACTTCAAGAAGGGATAGC
GCTTATAAAAAAATTGTTTAAAGAAAACAGGCCTATTTCTCTTTGGGAGAAAGCCACGGAGAAAACGAAAAGAAATGGAAC
GTGTGTTTCTGCCAGATGGCAATAAAATGTAGGGTAAATTTCTGTCTTTTAAACTGTATTTTTTCCATCCCTCTG
TATATACACATATCCTAGGACTGTTATAAAATGCTGCATGCGTATGTGAAAATGGAACCTTATTGGGCTGTTTGATG
GACCTTTAAATATATTTGTTGGTTTGGGGTACATACTAGCTATGCAATATAATCCGCATTATTTCTTATGTAAACA
ATGGATAAACTGTTTCACAGTCCAGACATTTATTTGGTCACTGTTTGTAGAATGTCTATTTTATTTACTTCTGAATT
TGTATTCCAGAGATCTGCCTTCAATGTTGGATACTTCCACTGTAATATTCCTAGGAGATGCTCACTTTCTTTTTTCAGC
ATCTGACACAGTACCATCTGCCTCCTCTTTCTTGCCACAAGTAATAACAAATTTTATAAAGGAGGATCACATTACAG
AATTATAGGTGGTAAACTTTCTACCACCAGATTTACCCAAGAACCTGAAACACATTTTTTTCAAAAGGAAATAGAATG
TCCTTCTTGTGACTACATCGGAATTTTGCTTGCGAGCATTATGCTTTTTTTTTTCCCCCTAGTGTAGCTAGCCATGTGG
AACTGAAGCCATTAGCCAGCTCCTCATCTATAAAATGCTATTACCTGGGAAAAGAGGCAGAAAATATACTCTCTTCT
CCAGTTAGAGTCTAAAGGAAGAGAACAATATGGGTAGTTGTGTTTACCACAAATTGATAGAATCCTTTATTTTAA
TGCTAAAACCAATAAATCTGTTTATATGACTTCAACATTGACTATCACACACTGTTGCATGATAACAGAGTGAAAAC
TACCTCTATTGGATTTAAGTGGGGAATCTATGTCTCATTCTCATTCTTTTTTTACTGTGGAACACTAGTTGATTCCAG
GATCAGCCTTAGCTCCAACCTGCCACACTTTGAGTTTGGTTTTCCTTGCATTGTCACAGGAACTTCTATTAGGA
TAAATCGAGGAAGATTTTACTCTGCAACGTGTTGCGAATTAACATTTAAAGTGGCAAAACCTTCGTGTGTAGGTT
GTCTCCCCAGAGAATGTAAAAATGAATTGAAGGCAGCACCTAATAGGTAAACGACAGCCAATCAAACAAGAACAAT
GAAATTTGACTGGCAAAATCAAATTGAAAAATGTATAACGCTGAATCTCAGAATATAGGAGGATGCATAGAACTAAG
CTGTACTATTATAAAAGTCATAGCCATTGAAAAATAATGACTGGTTAATTTGGTTTTCTTTACCTCATGGATGTGAA
TGGTTAGATTTTGATGTTGGTGTATTTGACGTGTGTTTGTCAAGAAGTTGCCTTAGTCGGCTCGCATTTAGGATAA
AAAAAATATTTTAAGAAATGTTTAAGAGATTATGTTGGAGACATTAGAAAACAAAATAATTATGCAGAGGGCAGGACT
ATCAAAATATAATAGAAAAATTACACCGCTCTTTTATGATTTCTCTCTTTTTTGGCATTAAACACAAAACCTTTATGAT
TACACACACCACGCACTCCAGAAATGCTTAAAGGAAGATGAGAGGAAAATCAATAGAAGTAGCAGGCATTTCTGTG
AGGACAGCAGAATGATCACTTCATCTCTGTATTTTTTTTTTTTCAAATTTCTGTATCTGTACAATGTCTTTTCCAGC
TCTAATATTCTGTGATTTGGTAATTTCCGCACTCAGATTTCTTTAATGAATTTTGTATGATATTACCTATTTTTAT
ACCAGATATTACCTGGCTCTAATTTCTTTTTTACCCTAGGAAAATAAAAGTATCGGGTGAATTTCCCATTTTTCTTATG
TTATTGATACAGGTCTCTGTTGGATATCCCCACGATTAACTTTCTCTGCAGCATGTTTCGATGGTGGCTTAAAGAAGAA
ACCATGTATCAGAGCCCCCTTGCTATATAGACTTTTAGATAAAAGAGAAAATACATATCACAGAATTATTCTGGGCGCA
TAGAGTCTCTAAATGCAAAAAAATTTGTATTGTAGCTGTTGATTCTTCTCAGATAGATTGAGTGTAGAGAGAGAG
CATTTCAAAAACCTGAGCAGAAGAAACACAGTCTGAATCAAATAACATGAAATTTTAGCTAACAAAGTAAATAACACTT
TTTTCAGAATATGCAATAATATTGGTTTATTATGAAAAATGTATAGGCTGATAGATGAGCATAGAGAAAAAATTAT
AAATATCTTCTTTAATATCACTTTCCCCAGCAAAACCACTTTTAACTTTTGATACATTTTCAACATTTTCAACATTTCC
TAATAGTCTTTTTTCTGTATATAAATGAATTTTAAACATTCGTATGTTTATGAAAAGGCAATAAGATACTGTCT
CTTTTATAACAGGCTTTCTGAACCTTCAACATCAGCTGATTTCTAATATGCTCCTTGTGTTCTTAACTAATAAAAA
ACCTCACGTTATTTAAAAAACCATCTTAAACATAATTATCCATTAAGAGAAGAGGTTGGGGTAGAGAGTTTCAGACT
ATCAATATCAAAGTTATATTTTCTGTAAAGTATTTTAAATTTTAAAGTGTAGCTATAGGTATATGATTATAAAACCAAT
AGCAGAGAAAAGATAACCACCTTTGAATATAGTTTTCTTGGTTCCATGAAAATGGCCTCCTTTCTTTTTTGGCAGTCC
CTCAGTATCATTAACCTCATTTTTCTGTAAATGCCATCATTGTATCACATGTCTCAGGAAAAGGCACCTTTTCTCTTT
TAAGCTAGTGTGTTGTTCTGTTCTAATTTTATGGCAATTTAACGAGTAACAATCCTGTTTCTATAAATACTGTTTCC
TAATTAATCTATTGCATTCTATCCATGAGAATTTAGATGACTTTCTTTGTAAGAGAAATCTCTGTAGCATGAGATTC
TTCTTTGCTCTTAAATTTCACTTTTCACTTTTAAATGACCTGATAGTATTTTGTGTATTGTGTGCTGATTTTTT
TTAACCAATCTTACCTTGTGAACATGTAAGTTGTTTCTAATATTTGCAATGATCAAAATGTGGATCCAACCTTCACT
AAAGCGTTAAGAATCTAAAAACAAAACAAAAGAACAAAAGTTGGCTGTCACTTGCTTGGACCACCCCGTGAGTTACT
ATTTTCTTGTGTTCCGGTCACAGTTCATCCTAAATCATTTTCACTACACAAAATGTTTTTTAAAGTTTGGGACAGGGGG
TAGAGAATGTCAATTATTCTCCAAGGCAGTCATATGAGCATTGAGTATCATGTGGAATAGTTGTTACTTGTAAGT
TATGGGGCATCAAACCCAGTCAATATGTTTCTGGAATTTGAAAAAGTCCCTGGACATTCTAATGATACTGTTGTTTAC
TTTGACCTACTGTTACCCTACTTTGATCTGTCAACACTGCCCGTAATGGTTAATTTTGTGCATCAACTTGACTGG
GCTACAAGGTGCCAGATATTTGGTCAAACATTATTCTGGGTGATTCTGTGCAAGTGTATCAGATGAGATTAACAT
TTAAATTTGGTAGACTGAGTAAAGTAGATTGCCCTTCCTAATGTGAGCAGACTTCATGTAATTAATTAAAGGCCTGAA
TAGAAGAAAAACACTGACCTCCCTGAGCAAAAGGGAATCGTTCTGCCCAGTGCCTTCAAACCTGGGACATGGGCT
TTTTCTGCTTACAGACTTTAACCACAATATTAGCTGTCTGTATCTCAAGTCTGCTCTCACTTTCGATTGGAACATAC
ACTATCAGCTCTCTCGGGTCTCCAGCTTGCTTGTTCACCTGTATACCTTGGGAGTTGTCTAGTCTCCATAGTTGCCT
CCATAATTGCATGAGCCAATTTCTTACCACATACAAACACACACAGAGACACACACACACACACACACACACACA
CACACATATAATTATATATGTGTGTGTATACATATTCTCTTATTTCTTTTTGTTTCTCTAAGGAACCTAATATACTC

111

TTATTTATTCAACACACTATGTGTCAATAAAATCTTATACTGTGAAAGAATTCTGTCTAAGTCCATTTGCTGTTGCTT
GTAACAGAATACCTGAAAAATGGGTAATTTACAAAAGAAAAGGAGTTTACTTCTTACAGTTACGGAGGCTGAGAAGTCC
AAGGTTGAGGGGCCACATCTGGTCAGAGCCTTCTCCCATCCAAGTACTAACCAGGTCGAACCTCAGTTAGCTTCCAA
GATCAGATAAGAGTGGGCGCGTTTAGGCTGGTGTGGCTGTAGACTTGTTAGAGCCTTTTTGCTCATGGGGACACAGC
AGAGCCCTGAGGCAGTGCAGGACATTACATGGCAAGAAGGCTGAGTATTCTAATGTGTTTCATGTCTCTCTTCTGT
CTTATAAAATCATGAATCCTACTCCCATGATAACCCATTAACCTATTAATTTATGAATGGATGAATCCATTCCATAAG
GGCAGAGCCCTCATGATGCAATCACCTCTTAAAGGCACAATCTCCCGGTGCTGCCACGTTGGGGATTAAGTTTCCAA
CACATGAAATTTGGGGGACACATTTAACTATAGCAAAATTTGTAATAAAATGTTATATAGAAGCAATGTTCTTACTG
ATTATAATTGTTATATTGGTAAAGTGTTAAGTCCTCTAACCAGGGATATATTTTCAGCTTATTATAATAGTTTTAAAA
TTTACAATTCAATATGAATAACATCTGGTAAAAAGTTCTTTTCAAGAAATGGGAAAATTAGAAATGTTTAGAAGAAAA
TAATTTCAATAAATATTAAGTTCAAACCTGGATTTCATAGTTTATGTGAAAATCTGGGAACCAATTGCAAGGGGAGAAAA
TAGTTACAATAGCAATGGTGAGGATGAGAATAAGAGCAGGTATCAACGTTAATTGAGGGTGTGTTATAGTTCTAATC
GTGCTATGCCACTACATGACTTTTCCCTGTGTGAGGTTTCCGAGCTTCTTCGTAGTAATCCTAAATTGAGCTGGAG
AGAGGCTAGGGTAACCTTACTCACGCTCATAGAGCCATAGAGTAGTAAAACCTGTATTTGAACTCTGGCCTGTCTGAC
ATCATTCTGTGGTCTTTTAAACCACCACTGCTTCTCCATATTAACCTCCAAATCTAGGTGAAAAGAAGAAAACCTCA
GAACATGTTCTGCAACAAAATATAACAAAATATAATGTATATAAACACTTATACATAATATCATAATATCTTTACT
ATGAAAAGACTCTGATACGAACATTTTACATAATTCATGCAGAAGTGTTAATCACATTGTCTGTGATGAGCTGTGTA
TGTATCTGATAAAATTTCTGGCAACCAGACATCAACTCGTAGGCATAGATCTGTAACACTAAATATTTGCCTCGAGAA
ACTTAAAGAAATAAAGACAAATGAATGAATAGGAACATGGAACCTGAGTACAAGATAAAATCCTCTAAAGCAATCGA
TGTACTTGCTGCTGCGTTATTGTTCTAAGCAAAAAGAGCATGGCGAAGGGAGATGTGAAGCTAAAAACAGAATGCTT
AGAAGGAGATGATAGCAGGAGGGAAGCAAGATGGGACCAAGCTCCCAAAAGGCGGGCTTTGAACAAAACAAACAGA
AAGCTAAGCCTTTGACGGATGCACGGGATGCAAGAACTTTAGTCAGGAAAGAGGAGGCGAAGAAAAACCTCCAAA
GAAAAGGTGAACAATATTTTAATAGGCAAAATGACAGATAGCAAGAGATATATACCATGCTATGTTTTCTCATTGCA
GCTGAAGACAAACTGGGGTTATTTATGCTTTGAAAAAGCGTAAATCTAAAAACAATTTGTGGAGGAAGAAGCGATGA
AAACACGTGTTAATACAGAAAACATGGCTCCAAGGCTTTAACTTCCCTGTGAGATAAAATGCATTTACATTTCCGCT
AGTAGCTAATATATATATATATATACATATATATATATATCTGGGAAATAAATACACAGTGATTTTCTTTCTTTTT
TCATCTACTTATGTGAGAAAAAAGTAGGCTATCTGAAAGCTTTTTCAGTTAAATGAGGAAGAAAGTTAGGTGATCTTG
TAAATAATATATATGTTCAAGATAATGTAAGGCCCTTGTGTAGTTTTCAAAACTTATCTTTAATAGCAGTTTCTTCT
GGGGATGGGGTAGTTCAAAGTTGAAATGTTAGAAAAGATGTTAACTTTTTTTTCTTTTACTTCTCCCTTTCAGGATG
GAATTAACAAATTTGATTACAAATAGATCTCAGAGAGAGGCAAAATGCATTGAATCCAGAAGTAACATAAAATTAGAT
CATGTTTAGTTATGCCCGAGGTCACATGGTGATAAAAAATGAGGATAAACTGAAATGTCTGTGAGCCAGATTAGTTT
ATTTTATGCCAGTCTTAGGAAAAAGACACATCATGGTAGGATACATCCTTTTTTTTTTTAATTATACTTTAAGTTTT
AGGGTACATGTGCACAGTGTGCAAGTTAGTTACATATGTATACCTGTGCCATGTTGGAGTGCTGCACCCATTAACCTC
TTCATTTAACATTAGGTATATCTCCTAATGCTGTCCCTCCCCCTCCCCCACCACACAGTTCCAGGGTGTGA
TGTTCCCTTCTCTGTGTCCATGTGTTCTCATTGTTCATTCCACCTAAGAGTGAGAACATGCGCTGTTTGGTTTTT
TGTCCTTGCGATAGTTTACTGAGAATGATGTATTCCAGTTTCATCCATGTCCCTACAAAGGACATGAACCTCATCATT
TTTTCTGGCTGCATAGTATTCCATGGTGATATGTGCCACATTTTCTTAATCCAGTCTATCATTGTTGGACATTG
GTTGGTTCCAAGTCTTTGCTATTGTGAATAGAGCCGCAATAAACATATGTGTGCACGTGTCTTTATAGCAGCATGAT
TTATAGTCCTTTGGGTATATACCCAGTAATGGGATGGCTGGGTCAAATGGTATTTCTAGTTCTAGGCCCTGAGGAA
TCGCCACACTGCCTTCCACAATGAACAGACACTTCTCAAAAGAAGACATTTATGCAGCCAAAAACACATGAAAAAA
TGCTCACCATCACTGGCCATCAGAGACATGCAAAATCAAAACCACAATGAGATACCATCTCACACCAGTTAGAAATGGC
AATCATATAAAAGTCAGGAACAACAGGTGCTGGAGGATGGGGAGAAAATAGGAACACTTTTACACTTTGTGGTGGG
ATTGTAAACTAGTACATTCTTAACATCAATTTATTTCTTAAAGCAATGTTTCATAGGGCACACTGTAGGCCATAGATT
TGCTCACAATTTAAAGGCCTAAGCCCTCAACATGCACAGCAGTATACTCAGAGACTATTTGTAAAGATGACGATT
CTGGAACTTTTTAATGACCCCAATCATTAGCAATGATTAATAATTAATATTCAACATTCTATATTTACCAAGGCAATA
AAGTAGACTAATCTATTTTAAAGGGTTTTAAATGAAGAGATGAAACAAACCAATGATTTTGATTTAAACTTCAT
GAAAACATAAGTTGCATTAATCAGGTGATTTTGTGTTTATGAGCATTCTGATTGAAGTGATCATATTTAGCCCCGGGA
GAATAAGAGAAGGTAAAGTATGGGTATGGCACTGAATTTACTGAGATGATTATATTGTTTGAGTTAAAGAACTTGTA
TTAAGAAACAAGTATGTGCCAAACATTGTGCTAGGAGCAAGCAATGCTAAAAATACATGGGTAGAAAGAGAGAATGA
AATATCTAGAATGAGTTAGAAACATCAGTGTTTTCCAATGTGGAGCCCTGACTTCACATGAAAATTCTCATTTTCAA
ACAAGGTAGTTTATGAAAACCTGGACTATTAGCAAGACAGGGTGGGCATGCCATCAGTATAGTACCTGGTGTAAACT
AGAAATTTTAATCATTGTGCTTTCAATTTATAATCAGTAAAAATCCAAGGTAGGACAAACTTTTACTTTTTCTGTAT
AATGGACTGATATTTGAATTATACCCAACTTTAATTTTTTGCAGAAATTAATGCTTTATTGTTTCTTAAAAATGGTA
CTATAGATCTTTATTTATTTCTATATATTTATATGATTTTTACATATATGTGCATTACATGTATATACATCCATAA
ACTATATACATATATACACATAAAATTACAAATATGTGTACCTACGTACATATATATGCATATATCACGCAAAATACAG
GCACATTTTCAATACCCCTTTTTGATTTTTTCTTGAAGAGCATAGCATCTGAATTTATTATGGATTTATTTTTAA
TTTATGGTCATGTTCTTTGAGTGCTTTTGGTGTGTTATCTGGTTGCCCAAACTCGCTAGCATTGTAAAGAAGATGTG
CAAAGCCTGAATCTAGACTGACTTTTCATATTGACTTTATTAGTCAAAAAAAGTAGATGAAAATGTAAACAGTCCGTGT
TAAAAATGGGAATAAGACAGATGTTCAAGCCCTAGCTTCAGCAGTTTTTCTAGCTGAGATTACTGGAAGAAAACATTT
TCTGAACTGTAACATGCAAAATGCCTACGTGACAGACTTCATTAACATTATTAATGCTATGATATAGTAAAAAGA
ATTTGTAAACTGTCAAGTGCTTTGTCAACATTAGGAATTTAGTTATTATAGGTATTTCCATATACATGTTGTATTTA
GAATTCCTTTAATTTTATACTTAGGGTTGATTTGTATTTTAACTAAGTCACTTTATATATCTGGTCCCATTATACA
AGTATACTTTTCTTAGGATAAGAAAGTGATCTTTATATATGTTTATCAACCCAAATGCCCATCAGTGATGGACTGG
ATAAAGAAAAGGTGGCACATACACCCATGGAATACTATGAATCCATAAAAAAGAACGAGTTCATGTCCTTTGAAGG

GACATGGATAAAGCTGGAAGCCATCATCCTCAGCAAACTAACACAGGAATGGAAAAACAGACACCGCATTTCCTCAC
TCATAATTGGGAGTTGAGCAATGAGAAACACATGGACACCGGGAGGGGAACATCACACACCGAGGCCTGTCGCGAGGT
GGGGGGCAAGGGGAGGGAGAGCATTAGGACAAAATACCTAATGCATGCGGGGCTTAAACCTAAATGACGGGTTCATA
GGTGCAGCAAACCACTATGGCACATGTGTACCTATGTAACAAATCTGCACGTTCTGCACATGTTTCCAGAACTTAA
AATTTAAAAAACTTTAAAAAAGAAGCTGTAGATACTGATCCAAAAAAATGTTTCATTAAATGGGGGTAAATGATTAT
TTCTAAGTAGACTACTCTTGAACCCCTGAATCTTTAAGAAATTTCTTTTGCTATTGAAGCCATTCAAACCTCTATTTTA
TTAAAGCTGTCTGTTATTCTAGTAGATTTTAAACAGTAATACCTGAATACATTAGAAATATGCAAATCTGCATTACAT
ATGGCATCTGCAGAGCAGAGGAGTTTGGTCATCTGGACTCATGCTAAAGTCTCCGAAAAATCCGCTTGCTTGAATGA
TGGTTGACTCGCTAATGCTATGCGTATATAGTCTTATTTTAAAGTGATTGAATGATGTGGCTAATAACCCCTCTGTTA
GATGCACTCAGAACCTCACCTACCTGGGTCTCAGCTCTCCAGTGAAATCTCTACTTTAAGTTTATTTTCTAACATG
GTAAGAGCCTTCAGTTTATGTTATGCTCAGGCCCGTCACTGTGAATAAAAAATATTAGAAATGGACTTTTTTTTTTTGT
ATTTTTTTAATGGATCCCTTGGAACCTTTAAAAAAATTTATTTATTTGAGCTTTCTACTGTTATCACAGTGTCTCCTAA
GCATGGCCTCCCGTTTTTTTGTGGTAATATAATTTCTTACGTTATTCAAATTAGTAACCATTATTTTTTCTCATGGCTA
GAATTCTGGAACTATTAGGAAATCACTGAGCATAATTGAATGGCTGTTTATTTGAAGAGCTATGTCAAGGCAGCAT
AGAGTTGTATTTTCTTGACGGGGCTCTGGAGTCAAAGAGCCTGGGTTCAAACCTTGGCTCCACCACCTTTCTATCTGT
GGGGCATTGGGCGTGTTACATTTGTGAACTTTTGTCTCCATTTGTAAAGTGAGGTTTGGGGGATGATTAAACCA
GATAACTCATGTGAAATATTTAATGGAAATGTATTTGGTAGGGGATTTATTATTTTTAAATTTGGATTGCACATGAC
ACATGTGAGGGATCATGCTATGCATTTTGGATAGAAAGATGGCTAAGATATCATGCCTGACTCTTAAAAACTTACCT
AATGGTAAATGACGAGTTAATGGGTGCAGCACACCAACATGGCACATGTATACGTGTGTAACCTGCAATGTTGT
GCACATGAACCTTAAACTTAAAGTATAATAAAAAAAAAAACTTATAATCAACTGTAGTAGAAAGAGATCTGAATGG
CTTGCCATTTAGCTAGGCACATGGTATATGTGCTTAATTCATACTAGCAGCCACTACAGTTGTCATGATTAATAATG
AGCTTCCAACCTGCACAGAATGCTTTTAATCCATAGAAAAATCAAATCAGAAACAAGTTTTTGTAAATTAATGTGAAA
GGAGCAACAATTAAGATGCAAGATTGACATTTATTTCTAAATTTGGTTCTATTTTCTTTACATTTACAAAATTTAT
AAGAAAATTTCTTTATTTCTATGTGATATAAAGAACTAGAATGTACTTTGATGTGAATATTGTTGCCAGTGTCTGTT
AATTTTTATCCATAATTTACTAAGCACCTATATTAGACAAAGGCATTATCCATCCCTTTGGGGAGGATTTCAGATG
ATTCATACACAGACCTGGTCTCGAGGAATTTAAGATTTTCTTTGGGGAGGGAATAAGGACTTTAAACCAACTCAAGA
GTACTTAGAGAATTTTCTGAAAATAATTTTATCAATGAAAACTTGTTATATTAAAAAGAACTGTCATTCTGACTTCC
ACAAATCTAGGCTTGAAACTATGGATAACGAGATATTTTCTATTACTCTCACTCACGTCAATTTTACAAAAGTGAAAA
GGTACATTTTAACTAGTGAAAGAATAGAGGAAATGGAAGTAGCTCGAGGCAGTGGACGATGATTCAAAAAGACAGGG
CCCTATTATTTGATCAAGTTATGCAACGACTCTGGGCTGTTTCTTACCTCTGGAAGGAGGAATAATCTCCAAGCC
CTTTGAGACTCTTTTGGTAATTCACCTCCAGCACATCTTCTAAATGCCAGCATTAACTGTCTCTGATTTGTCTCAT
GTTTTTCTAGCCCCATGCTCTCCTGTTGCGCATTTACCCTCATGCAAGGTACAAATTACACCCATCATCACAAGACA
CTTGCTCAAGTCCCATTGCCCCCTTGAAGACCTGCCACACCTACTCTCTCAAAAACCATCATTTTCTGAAAGTCCCTA
TACAGCTCATTTGGTATTTACAGTGTACTGCCACAAGCCACTAAGCATCGTTTTGTGAATACATGACTTACAGACTT
AGCTTGAGTAAAGATACTTGAAAATGAACACCATTCTTGCTATCTTCCATTTTGTATGTACCCTTCAGGCCTATG
AATTTTAGTATAATAGATAACCAATAATTTCTTGGTTCTTTCTGCAATCTGAATAACCCATGCAAAGTGAT
AGAATGTTTTTCTATAAGGAGGTCTTACACTGGAGATTGTGTATTTCTTAATGCTGTTGAAGGAAGAGATGTGTATC
TAAATAAATAGACTCTAACAAACATTAATTTATATTTCTATTATCTGTTTTGTGTATTGAGATATCTCACAAAAT
AACTAAACATTTTGGCATTATTGATATTACATATTTGCCATGAATATTTGTAATGAAGAAAAATATATATACATCA
GTAATTATCTTGGCAAACCTCTTCAATTATGCAATATTGTTACATAGATTACATATCTAAGTGAACACTGGAGTTTTA
ACAATATTGTGTGTTTATAAATGTTTTATTTATTTATTTGCCACTAATTTCTATTGCCATTTCAAGAACTATGTATAAG
TTGTTCTAAAAACTATTAAAGTATAGGTGACCATGGTCACTACTGCCTACTTTGGTAAAGGCCAAATATGTGAAGAC
TTTTTAATGTGTTAAACAAACGTTGAAGGTTTTTAACTGTTTAAACATCAGTAGGACTCTTGAATTTATTTCTTAAAG
AGAGTAAATTTTACAACCTTGCAAAGCATGATTTAACCTCTGTGAATATATAAACCATCTCTTGTAGTTATGTAGCATTT
TGTTAATGAGCAAAGAACCATTGTGGTTCTTTTTTACATTTCTTAAAAATAATTTCTCCGTAACCTCATTGATATCTCC
AGTAAATTTAGATAAGCTTTTTTTTTTTTAAAGGAGGGTTAAAAATGACATTTTAAACTAATTTTTCTTGTAGTTATAC
AGAGTTGAACATCTGAGGGTTTTATTGACAGTCATAAAAAATTTGTTATTTTCTGTGAAATATAGAGAATTTAAT
CATTATCATATTATTAATTTCTGTGGGCCATTGTCTTAATTTCTAGAGGCACAAGCTGTTTTTATCCCACTGAAATAGA
GGAATCAAAGTATGTTCTTGTCTCAAAGCACAAAAGTGACATACTACATAGTATGCTTCTTGAGTAGTCGTAAATCT
CATGTGTTAAATTACATCCCAAAGATTTCAAGTATGTTTATGACTTTAATAATTTATGGTAATTTCTAATCTGGCCT
TTGTTGACCTGTCTTGCTTTTTTAAATTTTTAGTTTTTCGACAAAAATAATTAACATATTTTAAATAATCTTCCAAAGGT
GTTTAAATGGCATTGTATAGAGATAGCTGAAGGCTTTTGAGCTTCTGTGTTGTAAACACTTTCTTAAATAAAACATG
AATTGCTACCAGATGATCCAGCAATCCCCTACTGGGCATTTATCCAAAGAAAAGGAAATCAGTATCTTTGAAGAGA
TAGCTTTGTTCCCATGTTTACTGCAGCACTTTTCATACTAGCCATGATATGGAATCAACCTAAACGTCCATCAGTGG
ATGAATTGAAAAGAAAATGTGGTATGAAACAGAAATGCTGCTTTAATTTATATTAAACACACTCATATTCTTCTCA
GCTGTAAAGTATTGAGTTATAGATTTAAAGAAATCTATTGTGAAGACTAAAGTGACTATTAAAGTAAGAAATTTATTT
TTTCCATTATATTTAACTTATTTTCACTTTAATGTTAGCGCCAATGAGCAAGACTATTGAATACAAAACCTAATTA
AGTAGTGGTGATAGTACAGTATATAAGGGAGAACATTTCTTTAGAAAAGGAACAATAACAGGGAGCAATAGAAACAT
GAATGAGTGTAAGGTCACTTAGTGTTAAAAAGCTAAAAATATAGTACAAATAAGTTGCGTTTTAATAGTGATTTTTAT
ATAATTACACCTTGATGTTTTATTGTTTACAAGAATGTCCAGGAAGATTTCTCTAAAGACCAAAGGCACCTTTCCC
CTAAATAACTCCAAAGCCAGTCTGTGTTTTCTATAAAAAAAAAAAAAAAAAAAAAAAAAAGTGAAAAATAA
CGTGATGAACATTTTTTGAGGAAGTATAAAACCAAAATACTCCACTGCATAGCTGTTTCTGCAGGTATTGTATTGATA
TATTACATTATTCAGCTTTGGAGTCTCCACATCCAATGTTACATCATCACTCTAAATTAACATGTATAGATAAATG
AAATAAATGAGATAGCATATGAAAATCTCATAGCCCAGCCCCGCACTATTTAAATAGAAATACCAAAGAATTGTA

TTCTCATCTGAAAGCTATTTAGTGGTGGTGTTCAAAATAAAAAATTCCATCTACTGCTGTTGCTTCCATTGTATCTT
TTTCTCTGCGGTACTGAAAGAGAAAGAGACCCAGAAAGGGGCCCTTGCTGGAAGTGTCCCTCTTTTAAGCTGTTGCTGC
TTTAAGCACAGGGTGGACAAATGTAATAGGAGTTTCATAAAGGTGGAATAAACCCAGCGGATTACGGTGTGGGTGAAT
ACTTTCAGATGTTAACCAGGAGCTCTGCTTGCATGCTGGGAGTTGCCCATGCCTCTTCTAGATTGAGGCACATTATC
ATGCACAACCTAACTCCAAGAAATCTTTTAAACCACTGGAAATTAACCCAGAACATGTCTCTAAGCCAGCCTTTTC
ATCCTGACACCGAATCATAGCATGAGCCAGTCTGTCAGGGATGCTGCTGCTCTCTAGGCCAAATTTTAAATGTTGAAA
TAATGAATCATGTTTTCTTGAAAACCATGTACACCAAAGAAAAAGTTAGTCATTTTATAGATGATGAATATTAACATT
TTCTTAGACAATCTGATAAATTATCAGATCTCACTTTTGGCTCTTTTAAAGACAGTTATGCCCTCAGAAAATATTAATA
AACCCCCAAGCCCTTATACTGATCAGTATGTTCACTACTAGCTATGAGAAAATCTTGAAAGTTCTTGTAATTATTGTA
TTATTTCTTACTTTTCATTTTATTAGTATGTGAATAATATTTTAAAAAATTTCTAGTGTATGTCTTGTATATATTTTA
ACAACATGACTTTTAAATTAATGTCTTGATAACATTTCTTCTAGTGTATGTTTTAGTAACATGATTATTAACGTGTA
CTTTAAAAACCTGTGGATTAGATGGGACCATTTTAAATGTTTTAAACCTGGAAAACTGATGGCTTTAGGTTTAGT
TCAAGCTATAGATCACCTGTGGAGAATGGAAGTCCAAAAAATAAATAGCTGTAGCAGCCCTTTGAGTATTCTAAA
ATAGGGATGTTATCCAGAGCATTGGTTTCTAAAGCTTCCATTATTTATTGATGTTGAGCTTTTCCAGGATTTAGCTACA
ATATTTACTCAACATCTAAGCCATGCTTTTTTATCAGTCATGTTTTATATCTTTTATAATCAAACCTGCTTATCACTG
AAAAAATATATAAGTTTCTATGTATCTGGAAGAATTCTCTGGTGTCTTTCTTAGATATGGATTTTGATGTGTGGAATA
AGAATTCATTTCAAGGATAACAGAGATGTTGTCTGAAAAAATCGAAGAAAATCAGCTTTTCTTTAACATTCTGTC
AAAGCTCCTGACTATTAGTTTATCAGCACTGTTTTGCCAAAGGTGCTTCTCTTCTCTTTTGAaaaaaatCATCT
GCTGCTGCTACGCCGCAAGTGTGTTCCCGCTGTGCTGAGAAGATGTGTGGCATAAAAAAATGGGCATGGCCTGAGT
TAAAAGTGCTACATTTAAGCCAGAGCTGGCTTATTTATTAGTTGTCTAATCATAGGAAAATGACAGAGCATGCTTTT
CTCTTGCAATATCCGTTGCTGAAAATTAACACATGAGCAGAGCTTTCAGAGAGGTTGACTGGCCTCTCAGACAGCA
CCTCATAGGATGGCCTGTGTTGAAGCATCTCCTTTAACCAGGGTCTGTCCCTCAGCATTGGGTTGGCTCACCTAGAT
TGGATTGTCCAGCAGAAAAAATAACCAAAATTCAGAATCATATCCAAACCGGAATACTCTTTCATTACATTAC
TTGTACTACCTTTTTCAGAACTGGATACTGAGTGTGTGAGGGTAACTTAGAACTTATCTCATGGTTAGAAAGTTT
AGAATTAGAGAGCGATGATCATGAAACGGACTCATGATCAGAACGCAATGGAGCAAGGAATGAGATGCTCTTTGAGGA
GTATTTCCCTGAGGCTGTGGATAACGCTGACGAATAATCCCCACCTTAAAAAGTGGGTTGACCACCTCTAGTAGCTGA
AGGTGGGAGGGTTCTTTCTTCAGAGATAAATCTGTGCTCTTCACTTGCCCATTTCCCAGGTTTTTCATGTAGGTAGAA
GAAACACCTGTAATCTGAAGACACTCTTCCCTCAGCTTTGTTAGTGACAGGGATTAAATATGTCTTTCACACATTT
TCCTTAGATAGTTAAATTTCACTTTTCTGTTTGTGTTTTCTCTGAAGGTATTCTAACTCCCCCTCTAATGGACTTCT
AGAGCTTTCTAATTCTATGCAATTTCTGTTGATTTGTTCTGGTAAACTTTGAAGGTAATCTCTGATTCAACTTCTTG
GAGATTCTATCATGTCTCTGTTTATTAACCTTTATGTTACTCATGGTTTCTTGATGAGGACTCATTAAACATAAT
GTAAGTAGAAAATTATTAACACATAATATTTACTACGGGTGTTTATTTCTGATAGTAGCTAGCTGTAAGATTCCAA
TTGTTCTTCAAATCTTTGTCTCAGTGATCTCTGTGTAGTTCTTGACTACTTCAAATAACTTCTTAGAAGGATAGGGA
TTTAATAATCTCTTAATAGGAACACTTAACACACTGCTGGTGGGAACGTAAATTAGTTCGGTCTGTGAAAGCAGTGT
GGTGATTTCTCAAATAACTTACAAAAGAATTACCATTGACCCAGCAATCCCATTATTGGGCATATACCCAGAGGAA
TAGAAATCATTCTACCATAAAGACATATGCACGTTGTGTATGTTCAATTGCAACACTACTCACAATAGCAAAGACATG
GATTCAACTTAAATGCCTATCAATGAACAGACTGAATAAAGAAAAATGTGGTACATATACACCATGGAATACTATGTG
GCCATGAAAAAGAATGAGATCATGTCTTTGCAGCGACATGGATGGAGCCAGTGGCCATTATCCTTAGCAAACCTTAT
ATGGAAACAGAAAACCAAATACTGCGTGTCTCACTTATAAATGGAAGCTAAATGATGAGAACATATGGACACAAAG
AGGGGAATAACACACACTGGGGCTACTGGAGGGTGAACACAAGTGGAGGGAGAAATCAGGAAAAATAATTATTG
GGTACTATGTTTAGTACCTGCGTGAGAAAATAATCTTTACACCAAACCCCGCAAAATGCAGTTACCTGTATAGCA
AACCTGCACGGTTACCCCTGAACCTAATTTAAAGTTATAAATAAACGTATCTTATTTTCAGTACAATAGCAGCA
GAGTAGAAGGGTTAAAGAGATTGCTTCTGAGGAGGTGAGATGGGGGTAAGGACAGCACAAGAGCAGCTTTTGGGGGT
GATGAAGCTGTTCTGTGCTTGGCTGCGATGGCTACAGCATAGCCCTTGTCAGAAGTACAGAACTTTACTT
CAAAAGGAGCGGATTTTACTACACATCAATTCCAATAACAAATACTTTGTCTTTAAGCAAAGGGATACCTAAATATA
GCGTATTGAATGGATCTCCAGAAAAACACATTTTTTCAAGTTTATGTTTTCAGCCTAGGCCCTCATCTCATCCAGGAAACC
TTGTCTTGCTTGCCCTTACATACATGTGGCAATCAGTAGTTTCTTTTAGGGCTCGGACTGAACACTCAATGAACCTC
AATCTTAGCGCTTGTGCTAGCAGATTGACATGGTTTATTTATATGTGTCATTCTCTGTAGTAAAAGGAAAGGATCAA
GGCCATTCACTTTTGTAGTGATTGTGCATGGCAGTATTTGGCACATAGTAGATTATTAATTATGGAACCTTCTGTTTT
CACACACACACACACACACACACACACACTTCAGAGCTATTTTCATTTAAATATTTGCTTTAGTCTCCAAAGC
CCCTCTGCCTCAACACCAACCTTCTATCTCATTATTCATCAGCTTTTCTCCTATTACGAAACTACTTAGGAAAGCC
CACTTATTTAGCTTATGATGGCAAAAATAAATATTTGTACTTTTTTTTTTTTTTTTAGTCATCGCTTCATAGAACAG
CCTCTGTCTCTGCTTATGCCATGTCTGAATATATGCTGGAGGTAAAAAGAGTTCTGGTTGAGAGCTTCAATTTGA
GAAACTATCTGAGATTACTTTCCAGGTTCCACCGTGGAACCTGTCTGACCTTGAACAAATGACCTCGAACAAAGTGGC
TGAAATCTCTTCTATTTTCGTCAACTGTAAAAATGGGGGAAAAACCATGTCTATCTCATGGGGTTTATGTGAAGGTTAAG
AAATTGCTTATTCAGTGTTTAGCACAGTGCCTGATATGCATAAAGCTCCTAGGAATATTAGCTGTTATTGTATTTCC
TTAAGAAGCCCATAGCTCTATATGCCCTTTCATTATATGTTTTAGTAGCCCAATTTAACATATGGATAAAATATTT
TTAAGTTAAATGATTTGCTAATGGATTGTTGAACGAGTGGCAGACACCCATATTATAGACGAAGGTCAAGTCCATAA
CATACAGTACATTTCCCACTTTTCATTTCCCATACCAAAATTCATTATTCTCTGAGAACTCATTATAGAAATTC
TGTGAGATTCATCTGTGTGTTCCAGCAGTGCCTTATATCCAGAAATAACACTGAGTCATTGTCTAGATGTAGCAGA
GGTGAATCCTCCAAAGAGAAGCCTCAGAGTGGCCAGGTTTGCCAAGTATAGGGATGCCTTGATTACTGGCCTTACT
CTTTATGCTCGTGAATTCCTAAGTTTTATTCTCTCTGTAGTCATAGATTGGCTTTTAAAGCTACAAGCTGAAGAGAGA
GAAAACCTCTTCCACCTCGTTGGAATATGTCTCTTCAATCCATTTGAGCCAAATTTAGGACATGAGACTGCTCTTAGT
CTAGAACCAGTCATCAGGAGAATTCAGGTCTGATTGACTCGGACTAGCGGGTCAATATCAGGGCAAAAATTCACAC

GCACAACACGATGTATCAGTAAGGAGAACCTCAAAATTATTTCTTAACGTCCAGATCATGTTCTATTTTTATATAT
CTATTTTCTCACATAAGTCATTAAAAATGATGTACCTGTGCGGGTCCCTTAAATGATACTCAAAGATCTTGAATTATAG
GCTAATAACTAACTTAATAAGCTGCAGAAATTAACATTTCTGCTACGTTTATGTAGCATTTCACATGTACTTCA
GAGGCTTGAGAAAAGACCCTGAAATAATGACTGAATAACAGCTTTACTCACTTAATTTCAAATTTGTTAATTTCTTCT
GGGAAATACCGTCAACATCCATTTTATTATTTTCTCAATTACATGTACGTTTCTACATCAGTGGATAAGTTAAGGA
GAAGAATTCCTCATGATAATTTTTTTCATGCTCGAAAATTTTGAATCAATTTTTTATTTTACATTATACTCTTTCCCT
AGTCATTAGAAAGGGAGTGGTGGTTAAGATAGGCAAGAATGCTTTATAAGGATACTACTCTCGTTTCAATTCCTTAAC
ATCAAAAACCTTAACAGTGTGTAGACTATAAAATAAAATATCTAGGGATCAGAGCATTGTGCTGAACCTTGCAGGTT
TTTTAGTCAATAATATATATGACGTGTTACAGAAATCTTTGTCAACAAAGTACTTTTGGAGCTCCAGGCCATTTAA
GTTGGTTTTTGTACTTTTTCTTTTTCTTCGGAAGACTTTTTTTGTTCTATTTACCTGGAAGTGTTTCTTTTTTGGTA
CTGTGAATTAATAAGAGACCAATCTACTAGGCAGGAAAAAACCTTAATTAGATTGTTGACACAGACAAATAAGAATG
TCAATTAGCATCTACTGTCACATGCCTCTCCAGACTGCTTCTAGGATGAGTGGCCTCAAGCAGCTACATCATCTTTA
TACTCCTAAAGCATCAAGGAACTTGGAGTGACAATTCATATCATGAACACATCCACAGTGATGATGATTGTGCTTC
TTCCCCCCCCACCAACAACAAAGGATGAATGCCAATTAATGTATTCAAGTTTTTTCGCTCAAAGGCTGGATCACTTGT
GCAATGAGGGTAATCATCCTGACCAGACAGGCCATACAATCCATATTGTGTGAATTAAGATAATATGCGTGAAACA
CCTTACTCTGGATGTGGTTCATAGCAGTAGCAAAAAGATGAAAACCTATGGTATGCTAACATTTTAGAGATCTGTACT
CTATTTTAAATAATTTTATAAAAAGTGCATATACAATAAAAAGTGCACGTATCACAAGTATATGCCTCAAAATCTAAA
GCCAGTCATGTAATCAGCATCCACTTCAAGAAAGAAAAACAAACAGTACCCCTGGTTCCTCTTTGCAATCATTAGTC
TCCCAAGAGTAATCACCGATCTGATCTGTGACAGCATAGATTGGTTTTGCCCCTACTATATTTTTTGCTGAATTATACA
ATATATGCTCTTTAATGTCTGGCTTCTTAGTGCAATTGTATTTGTGTATCAGCTATTCTCTTGTGTGTAGTTATTA
CAATCATTTTATGGGCTGCATAATATCCATAGGGTAAATATAACAGTTTTATTGATAACTTAGCTATTACAAATAG
TGCTGTTGCAGACATATATTCTATTACATGTCTTTTGGTATAAGAATTTACACATTTACATGGGTGTATACCCAGA
ACTGAGATTGCTAAATATTGGGGCACATTGTATACATTTTGATTTAGTAGATAAGATATTGCCAGATATCGTAAATG
CACAGTTTGATAAATATAGAGATTTATACTTTTTCTAGAGAAAAGCCATCAATATCAGTGTATGTGTATATATATA
GCGTGTGTATATATACGTATATATATACGCGTGTGTATATATACGTATATATACACATATATATACGTATATATG
TGTATATATATACGTATATATATACACATATATACATATATGTGTGTGTATATATATATATGAAACAACCTCAGAA
GCAGAAAGATACCCCATGTTCTCACTTATAAGTGAAAGACAAATAATGTATAAACATGTACACATGGACATAGAGTG
TGTAAGTATAAGCATTGGAGACTGAAAGTGTGGGGGTGTGCAAGGGAATCAGTGATAAATTAATGGCTACAATGTACA
TAATTTGGGTGATGGATACACTAAAAATCCAAAGTTCACCACTATCCAACATACTCACATAATAAAATTGCACTTGT
ACCCCTTACATTACATACAATAAAAAATTTTAAATAAAAAATAAATATGTGTATATGTATGCATACATACATATGC
ATATACATATGTGTTTGTGTGTGTGTATATAACTTACACTTAAAAATAAGCATGGATGCTGCAATGAATGCTCAATTT
ACAAGGGTTGTCCATCCAACTTGTGGCAAGTATCTCACCTCTCAAGTTGTTTTCTTTTTCTTCATATATTTCTTG
CTTTTGTCTAGGAAGGAATAATTTGGCTTGCTTTCAAGAGTGTACAGTCAGCATGATAACCCAAACACTTAAGACA
CGTGCTAACCCATGTGGATCCCTTGAGAGAAGGAAAACAGTGGTCTTTTACTGGGCAGATAGAGCCCGGGGCCAGG
TTTCGTGGCTTGAAGATTTCAAGCTTCTCTGCGCTCTCAGCTCAGTGCTCTGGAAGCAATTTACAACCTTGTGAGGC
CATACTCAAAGGCCCTGTTATTAATTTCCCGCCTTCCGAGACCCCATTTTCAAGAGGATCTCAATTGCTCTCAGAGTGA
ATTTACTGTTTCTGAATTCCGTAATCCCAATAGCAGGTCTGTTGTCTCATTAGATAGCTTAAGTTAGAGTCGGCA
GTGTAATTGGCAACTGAGCTACTAAGTATCCAATGCTTATGTGGAAAAATATGTTCCCTATTGCAAACAACCTGATATT
CATATTCAATTTGGCACCATCATCTATCTATAAAGCAGATACTACTTGTGTTTATTAAGTTTTATCCCAAATAATTA
TTTTAGTAATAATGCTTGAAAATAGGCCTTGGTCATTTGCATGCTGTATATGGCATATCCTGAGTCTTTGTATGTA
TTAGAAAGATCACTCGTTTTGACTTGATGGTTAATAAAAGATGTCCCTCACTTTGGGCAGAGACATTTGAAAAGG
CACTCAACACAGGCACTAAGAGGTGAATGAGATGCAGCTCTGAATCAGGTCACACGGCCTCAGGAAGGAAACATCT
TGGTTTTTACATCCCTCACTTCTCGATGTCTGCAATACACAAATGACCCCTCAACACACACACAGGCACATACA
CAAACACACACTCACTCACTCACTGTATTGTCTCTTTCTTGAAGTCTTCTTACTAAGCTCAAGCTCTAAAGCT
TTTTTACTTACCTAAGGTGAGTGTGTGAGGATTTGAGGTTTCAATATTAATAATTCAGAAACATTTAAAGTTCAATTT
AAATATTAGTAAAAAAAATCTTGACAAAATACAATTATAGACAAAAAGAAAATTCAGAATATTTGGAATTTAAGGT
TGAGGTTACAGCCCTATTTATGAAATATTAGAAGAAAAATGCTGGAGAGAATAAAGCAGGTTTATGAGTCTGATAGA
AAGCATAACCAGATGATTATGCATATATTTGCATATGCAAAGCTTTCTAGGCAATCTGAACATTTAAACCTACAAAT
GTGGCTGCGATGAACAGCCACAGAAGAGCAGGCTAGAACAGAAGAGGAGGCTAGAACAGAAGAGCAGGCAGAAGTTG
TAAATGAAATGTTAATTTTCAATGGTTGATCTCCAAGTACTGGAACAGATTTGTGCTGTTTTCAAGGTTTTGGTTC
AAAGAATCCAGTAGTGTATTGAATTGTTTTGTGGCACTTCCCTGTTATTTTGTGTTGTAAGCTACCTCAATCCATGA
AGTGGCTATGAGCCCTTATACAACACTGTTGATTTTTTTTTCTTATCTACGCAAAAGATTTTTGATTTCAGGGCCA
GGCATGGTGGCTCACGCCTGTAATCCAGCACTTTGGGAGGCCGAGGCAGGCGGATCATGAGGTCAAGGATAGAGA
CCATCCTGGCTAACACGGTGAAAACCCACCTCTACTACAAATACAAAAATCAGCCGGGCGTAGTGGCATGTGCCGG
TAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATCACTTGAACCCGGTAGCCGAGATCCTGCCACTCCACTCCAG
CCTGGGCGACAGAGCCAGACTCCATCTCAAAAAAAGAAAAAAGAGATTTTTTATTTCAGGTGGCTATCAGACTC
ATTAAATAGAAGCCTTAGGTTAAGTTCACGGGTGCTAGTTGGAAGCCTCCATGGACTATGTTTATAAAATAATAGA
AAGGAGTTATGCAGGACTTCTTGAAATGTTATTTAAAAAGTCAGAATAGGCTTTCTATTACTTGTCTGAGGTCAAAT
ACATGTAGTGCTTTCTGACATTTTATCCAGGGTGTAGCTAGGACAATAAGAGGTGCTTAAAAATATTAGATTGA
GTAAATGAGAAAGCCCTTAGAAACATAGGAACAGAGTACCCTTGCTTTGGATCTAATATTGACTCCCAAGCCTAAA
TCCCTTTGGAGAACTCCTTTATTTTCTCTTCCATCAAGAGCAGGTATAAATTAAAAAACACCATTAAAGGGGCCATCT
AGCTCAGCTGAAGCTTTTATCACACATGTAGGGGAGGTATGGTTGGGAGGGATCTTTTTATCCTTTAGGTCTTCAAT
TTACATAGGACTTTTGAATAATCAAAATAGCCCCAAAAGAGCTGATCTTAGGACTAGTTGTAATTGAGACTATTTCTCC
ATGGGGTAGAAAAATCTAGTTGTAGGAAAACTGAGAAAGTAGATGTATGTTAACCTCAAAGGCTGTTTTTTACAAAGG

ATGTTAAAGCATCATCTTTGCTCAGAAAAGGGAGCAATAAAACAAATGAGTGGAAATAACAAAAGGAAATAATGGCCA
GGTGCAGTGCCTCACACTAGTAATCCCAACACTGGGGGGCTGTGGTGTAAAGGATCGCTTGAGGCTAGCAGTTCAAGA
CCAGCCTGAGTAAAATAGGCCTCATCTCTACAAAATAGATAGATAGATAGATAGATAGATAGATAGATAGATA
GATAGCCGGGCGAGGTAGTGTGCCCTGTAGCCCCAGCTACTCAGGAGGCTGAGATGGGAGAATCGTTTGAGCCCAT
GAGGTCAAGTCTATGGTGAGCTGTGCTCCCTCCTGCCACTGCACTCCAGCCTGGGTGACAGAGTGAGATCCTGTCTC
GAAAACAAAAGGCATACTTTTTAGATGTAATGGAATAGAGTACTTCCAAACCTGGCTGCCTGCTGGAGTTGTATTGG
AAGAGGTTGCACGACTTCAGTGGAGATGGCCTAGATGCCTGCTCAGCAGTCATCTAGTTAAAGCAACTAAGAACATG
TAATATGAAACTGCAAAAAGAGATCGTGTACGTAAAACTCACTCTGGGCTCCTCAGATAGAGTAATAAACACAACCTCC
TGACAGCCAAATAAAAAAGAGAAATAATACAGCCCTTGACTTCCTTGGTTGCTTTGACATACTAAGTAGGTGTTACAG
GTTGGGTTCTCTGGGAAACAGACTCTAAAAACATTTTTATTTTTACTTTATTTGTTGTTATTATTATTATTATTATTA
TTTTAGACAGAATTTTGCTCTCGTTGTCCATGTTGGAGTGTAATGGCACAATCTCGTCTCACTGTAATTTCCGCCTT
ATGGGTTCAAGTGATTCTTCTGCCTCAAACCTCCCAAGTATCTGGGATTACAGGCAAGTACTACCACGCCTGGCTAAT
TTTGTATTTTTAGTAGAGACGGGTTTCATCATGTTGGTCAGGCTGGTCTCAAACACCCGACCTCAGGTGATCCACC
CACTTCTGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTACGCCCCGCCAGACTCTAAAATAAAGTTTAATA
TGCAGAATACTTATCAGGGAATGCCACTGGACCAATACATATTCAAGAGAGGGCTTAGAAGCAGGATTGGACAGAA
AGAGAAGTTGAGCTGTAATGCAGGCCCAATAACAGCCTTAGTGTTAAGCAGGCTGAGAGATTGAGCAGTTAATGAGA
CAGTCAACCCAAACAGTTTTATAGGCATCAAAGTATGATCAGCATGGTGTGAGTTTCCTGTGTCACTTGTCCACA
GTATGATACCAAAATTAAGAGACCAGATGACATGCAACACAAGCAGTGTGCACTCTGTTGTTGAGAAGCCAATTTT
GTCATGCAATTAAGCAGTTTTATACTCTGCAGCTGTACTTTAAGGGGAGCTGAGATGGAACATCATATGTCTCACCA
TAACCAGAAAGGCAGATGAGAAATGTTCTATCGCCACCTCCCACAAGGTAAGGGACTTCCCTAAAGATACAGAGGTG
GGTGAATATTGCCTTGGTAGACTTCCTCTCAAGACTGCCTATCTTCCCATGTTGGAAGGATCACAGAGCATTGTGTC
AAGACGTGGGTCAATCTGCAGTTGAACTTTGTGTATGTGGCTATGTGGATACTTATAATATCATTGGGCACCTCCA
TAGAGCTGTTTCCCAATTGACCAAAACATATGGGAAGCTTCAGAGCTTCGAATGACCCTTCAGAGTAGTCTTGAGAAC
AGTGAGCCTTACTACTCCTGCATTAATCAGTCATTGGATGATAGCCTTCTCAGAAATAAGTCATGACCTTGTGCAAG
GGGGCTCTTTCATGGCTGGGACCACCCCTAAAAGTGAAGCTGTCTGCCACCAGCCCTCCACCTGGGCTGGG
ACAAGTTCTTTATTGAAGGGAATCTGAGTAGTTCATCAGCGTCCATCACAGTAGTCAAGCGTTTCACTTCTTCCTTC
TTATGACAACATTGTGCTTATTGTTATGTAATCCCTTTCCAGAACATTTTAGGTTAAGTTTTAAAAATAATGCATAT
AAATAGACAATTCAAATACTGGGGAAGGAAAGCTTGCACTTATATTGTTATAGAAATGTGCACACTTAAAGAGCTGA
TTTCTTCTGGGTATTTACATAACTTTATTTAAAAATCCATCCATTTTAAATTAGCTGTTTTTAATATGCAGTTAGCT
AAGATATTATAAGCCATATATTAGGCTAATGGACATTTAACAGCTTAGTTAAGTTCTTTTAAATGGAATGCTGACAA
ACCTTTGTCTGTAATTATAGCAACACTGTGATTACAGAAGGAGGTGCCTCTCCTTGTGTTTGCAGCCCTAAAATTC
CATGTGGCTATAAGTAACAAAGTCCATTATTAGATAAACACAAGTCATACTTGGCATTACTTGCATTACTCGTCTCC
TTGCTTTATTTGAATCATTTTTTTAAAGTTGTAATGTTTTTCAAACTCAGAATAGTGGCCAGTTAATAATATGAT
TCCTCTTATATTATGAGATTTTTAAAAATAGTTTACCAGTTTCTGTTGGCTCTATACCCATTGGCAAGTCCTAGCC
ATTGTGAATTAAGTAAACAATTCTTTATGGAAATTTTTTAATCCTTAAACCTTATAAGTTTTTATTCATCATGTGAG
GTCACCTGTCAAAGGGTTTAAACATTGAGAATTCAAACAAAAGTTTATCAAACACCTATTACAGGACGTGCAATTTTGG
GCGCACTGGGATTTTCAAGCAATTAACAATCAAGATATGATTTGTATCGACATGGATATTACATTCTCTCACAGGAGAC
AGAAAACAAAATAACTAGAAAATATACATAAAGAGACTTTAAAAATGGGGTAAAAATTACAGATTGTGACAGGATGACC
ACTTTGGTTTCAAGATATCTAGGACATTTTTTTCTTTTTTTTTCCCTCCCTCCCTCTTTCTTTTTTTTTCTTTTTCTT
TTTCTTTCTTTTCTTTCTTTTCTTTCTGCTTTTCGGAGTCTTGCTCTGTTGCCAGGCTGGAGCGCAGTGGTGCAA
TCTCAGCTCACTGCAACCTCTGCCTCCCATGTTCAAGCTTTTCGTGTGCTTCCGCTCCCAAATAACTGGGACTAGA
GGCATGCACCACCGCCAGCTGATTTTTGTATTTTAGTAGAGATGGGTTTGACCATGTTGCCAGGCTGGTCT
CAAACCTTCTGACCTCAAGCGATCCACCCGCCTCAGCCTCCCAAGTGTGGGATTACAGGCGTGACCCACGAGGCC
CAAGCAAGGACATTTTTTTCTGAGCCATGTTATTTAAACAGAGATCTGAATGACAAGAAGGGGCCAGCTCTGTGATG
TAGGGGAAGAAAAATATGTTCCCTTCTACCTTCTAGGCTGCCAGCTGGAGTCTTACAAAGTTAGAGTGACAAAAGA
CAGATTAAACAAGAGGAAAAGCCTAGAAAGTTTATTAATAATTCAGTGCACATACACCTGGTAGAACTCAGTGATGA
GTAACCTCAAAGGGGTGGTTAGAATGTTGGGTTTATATAGCATCTGAACAAAGAACAGTAAACTTGTAGAGAAATGAC
AAAACAAAGAAAAAAGGGGTTTAGGTATTTAGGGTTGCCAACTGTAGGAAGGTAAATATATGGGAGAAACATGGAG
TATAGTTTGTGTTATGCCAAGTCTATCTTGAGATCAACTTTTCGTATTCTTCATGGCCATAACAATTTCCAGGAGAG
AGGGCTTATAGCAGTTATCATTTCTCAGAAGTTTCTGCTTTTATTTAGACAAGGGAAGCACTGGGAAGGCTTCTTTT
TGCTTATATTGATTCTTACTTGCTCTAACTAAAAGTAATCTTTATGTCAAAGTGCCATATTTTGGAGTGGTATATA
TTGATCTCCTATAATAACAATCAAAAGGAACAGTATTCTAGGCAGGAGTACCCTAATGCATAGTGTGTTGGTGTA
GACAAGTTAACATATTGAGGGGCAACAACAATAAGCCAATATGGCTAAGACATTGAGGATGAGTGAGTTGGAG
AAGTAGGCAATGGCCAGCTCATATAAAGACTTGTTCGTTTTTATAAATGTTTAGATTTTATTGTAATTATGGTGGC
AAGTGATTGGAGAGTATTAGCTTCACTTTGACTGGCTTATCGAAAAACGGAATGTAGGGGGTGAAAGTGGAATAAAAA
GACCAGTCATTAATTGAGTAGTCCGTGTGAGAGATGATAGTGGCTTGACAAAGGACGATTGTACTGGAGAGATTGAA
GCGACTGATTTGAGATTTGTAGTCAACAAGGCTTAATTGGTAGGAGAAAAAATAAATCAGTGTTAACTCTTTAATG
TTAACTTGAATAATTATGATGAGGGTATTACCATTTATTGAGATGTAGAATATTATAAAGTAAGAGCAGATTTGTT
CAAAAAGTATCAAGAATCTTTATTTGGACATCTAGTTTGGGGATGCTTATTAGAGACCTTAGGAACTGAATATAA
ATGTGGATTATTAGAGAAGAGCTTAGGGCTGCGAGATGACATTAAGGATCTGTCTAGAGCCATGGCGCTAGAGACCT
CCAGGAGAACATAAATAGTCTCAAGATCAAGCCCTGAGACACTCAGATGTTTAGAAGTGGAACAGAAGAGGGACATC
CAATATAGAATACCAAGAATTAGGAGGGGAATCAAGAGAGTGTGGCAATATGAAAGATACAAAAAGAGTGTTGAAGG
GAGGGAGTAATTAATAACCAGCATGTTATGAGGGGCTCAGTATAATGAAAAGATAAGTGACTATTGGATTGGCAAC
ATATAATTTTTTGGTGATCTGGACAAGAGCAATTTGAACAGAATGATGGATATGGAAGGTCCAGAGGAGTAGGCTGA

GTAAATAATATAAGGTGGGAAAAATAGATACAAAGATTATAGACAACTTTTTCAAGAAGTTTTACTGTGAAGGGGCAC
AGCAAGCTGAGACAGTGAGGATAAATAATAGACTCAAGGATGGTAACTTTAGAATAAGAAATTTCAATCTGATGGGA
TTTAAGTGTTAGCAAGGAAGCTTTAAGAAAGTTATTTTCCCCATTAGAATGATCTGAAAAATGTTTTAGAACATTCTT
CTTATATTCTATTTTATCACATTTATATAACTTTTCAGAGAATTGAAAGAGGTATTAAGTTATTATGAAATTTTTCTGA
GATTAATAAGATAACAATTATAGGATGTTTTCTTTTAGTTGAAATACACCTACTCAGCCTAATTTTTATAACTTCTT
ACTGAAGTATAATATACTTCAGTAGAAAAAGCATGCCTAATATAAAGGTGCAGCTAGATGAATTTGCACAACTGAAC
ACATCCCTTTAACCAGCACTTAGATTAAAAACAGAACCTTGATGATACCTCAGAGGCCCTTCTGCCCTTTTCAG
TCTCTCCGTGCTACCCCATGGATAAGCATTATCGTGATTTCTAATACCATAGATTAATTTTGCCAGTTTTTTGAATT
TTATGCAAATGGATCTATTTTACCTAATTGTAAATATAAATGTCATAGCAAGGCACCTCATTGCCTTACACTGA
AAATTACATTGACTCTTTTGCCACAAGCTTAGACTTGCTTTCTCATTTTTATTATCATCAAGCCTATAGCTTTTACACT
ATACCTTGTTCTGCTCTTCCCTACTCTATTTCTTGGTAGATATTCTATATCAGTCTTAGAGTGCAGTTTGCAGAAC
CCCTCCATCAGAATCTCTAGGGAGCTTGTTAATAATGCAGATTCTAGGCCCTCCCATGGTTTTATGAATCTGAGA
GTGAGGCAGACAAGACTATACCTCTCATGCCTCTATAATGTAATAATGTCTTCCCTAGAATGTTCTTTGCTGCATCT
CTTATTAAAGAAATCTTATGGGCCGGGCAGGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGCCTGAGGCGGGC
GGATCACATGGTCAAGAGATCGAGACCATCCTGGCTAACACGGTGAAACCCCATCTCTACTAAAAATATAAAAAATT
AGCCGGGCGTGCTGGCAGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAAAATGGTGTGAACCCGGGAG
GTGGAGCTTGCACTGAGCTGAGATCACGACACTCCACTCCAGCTGGGTGACAGAGCGAGACTCTGTCTCAAAAAAA
AAAAAAGAAAGAAAGAAAAAAGAAAGTCTTATGTTTCTTTATGGCCAGAGCACAACTTGTCTATGAAGTCATCTA
AAATTTCCCACTAGAGGTAACATCTCCTTCCCCTGTCTAGCTCTTTTAAAGCATTACCTCCATTTGCCTTGTATCAT
AGCTGCTTGTACACCTGTCTGTCTTTCCGCTGAGGTTATAATCCTCTGGAGGGTTCATGACTTTGCATTCTTTGTGT
CTCCCATTAGCAGCCAGCACAGTGCCTTGCATACTGTTAGTTCTAAATAACTTCTCTCTCTCTCTCTCTCTCTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTAGACAGAGTCTCGTTCTGTCAACCAGGCTGGAGTGCAGTGCATGG
CATGGTCACAGCTCACTGCAACCTCCCCATCGTGGGCTCAAATGATTCTCCTGCCTCTGTCTTCCAGTAGCTGGGAT
TATAAGTGTCTGCCACCACGCCTGGCTAATTTTTGTATCTTTAGTGAGACGGGGTTTTACCATTGTTGCCAGGCTG
GTCTCGAATCTCTGGTCTCAAGCAGTCTGCCCTACTCGGCTCCCAAAGTGCTGAGATTACAGGCTCAGCTGCTGC
GCGCATCCCTAAATAAACTTTTTTTTTTTTGGCATGAAATCTGTAACACTGGAAGATGTTTATGCTTTAGAATAAT
TAAGAGATTAAATGTAGAATCTCAAAAAACATTCATTTTTTTCCATGAAAACTTTACCAGGCCTCAAGGGATAGGAAA
ATTATGGGTACAGAATTGAGAATCTGTAGGAACTTGCAAGATAAAACAACGGTTTCACAAGAAAGACCTTGTGGAGA
GTTAAATTTTCAGACAGTTGTAATAACTTCACATTAAAGTTTTGTCAAAAAATAAGTATCTGCATGTTTTGTTGCC
TTCCAATGCCCTCATTTTATTTGATTTTTTCCCATAGTAACATAGTGAAAGCACGAAAATGTGTTTCTGTGTTTG
TGTGCTGTATGTTAATTGTGACTGTTTCTATTGCATTGTTATTGCAGAACCTAGGCACGCACTCTGTAGGCTTGGG
TGCTTTCTCCAAGTAAAAAAATCCTACATATGGATAAATTATTTTTACAGCCAGTGTTTAATTTTACAAGTGGTCC
CCCTCCTTCTGTTTTTAGGATGGCAGAGAGAATACATATTTACTTACCATTATCACTTACTCATGCTTTGAGCTTGA
AGGAAATGAGACAGAAAAATGAAGTAACATTAACCTCTCTCTGGAATATGTTTCTCATATTAGAGCTTTATCTGAG
GAGTTCACTTCTCTCTCTTCAATGCTTTGTTCCTCTCCAGTCGATTCAAATGTCCTCTTAAAGCAGAAGTTCCGAA
CCTCTTTCTGTGACTTCAGGAGAGCATGAGAATGTAAATATAAGTTTTAGGACTAAATTTTCAAAGACTTTTTCCAC
TCAGCTCTCTTTTCTCTTCCGTTTGTGTTGTCGTTGTTGTTGTCGTTGTTGTTGTTGCTGCTGCTGCTGCTG
TTTTTCCCCTTCCACTTCCGTAACCTGAGCTCTTAGGGTCCATCTGGAATCTGATTGCAATTAATAAAAAAAAAAGTTT
ATTTTTACCTCCTTGTACGTGCTTTCTCCTAAAGCAGGAGTCAGAAAGCCTTTTTTCTTTGAAGGGCTAGTTAGTAAA
TATTTTAGGCTTGTGCTCTTTGTGCGCAATTACTCAACTACGCTGTTGTAGTATGAAAGCAGACAATACATACCTGAA
TGAGCATGTTTTGTTCTTAGCAAACTTTACGCACAGAGAAAATTTGGATATCGTATAATTTTTATGTGTTGCAAAGT
TGTATTATTTCTGTTTTGATTTCTCCCAACCATTTAATATGTAATCCCATCTTAGCTTGTGTGCCATACGCACAG
GCAGATAATGCGAGTTGTACACAGGCTATAGTTTCTGACTTTATGTTTAAAGTAAACAGTAAATAATCATCTCTT
TTTTCAAACAGTCCACTAATCTCCCTTTGTATTGAGCCCTTGATAGTAAACGCCGTTTCTTCATCATCTGATTTT
TATTCTGAGAAAAATACTGTATATTGTTCCCATGCACTAGGGTTTCGGGGAAATTTAAAGGATGTAGGATCTCCTTTT
CATTGGTCTTAAATTTGCACTGGGGAGGCAGGTCATGTTTATGAACAGATAAAATAGTATCATAATATAATCATGCAT
TTCTATGGCTAGCATTTAGAATATAGCTTTTGATGTCATGTGGTTTTTATATGGTTGATTATTTTTTTCTTATTTA
TAAATGAAAAAGTTTTGAGAATTTTTCTATCTCCTTAATGTATTCCCTTATTTGAGGGAAAAGTATTTACCTACTACA
TAGGAATTTATCTTAAATTTTTCTTTGTCTATCTATTTTTATGGAATATAATCGAGCAACTATTTTACTAATTAATA
CTTTAATATCATTATGAAAATGTTCTCATATTTTTAACCTTATAAGATCAGATAATTGCTATGCCAATCTATGGTTG
AAATGGGTTCTTATACTTAACGCTATGCTCTTTCTCTGAGATGTAAAAATATGTTTAAATCAGAATTTATATAGGT
GTCAATTTCAAATGACAGTAGTTTCAATTTTTGATTAGTATAAATGTTTCACTAATTTCTATTCTCTTATCTATTA
AGTCACCAATAAAGTATATTTGTTTTAAATATTTAACAGTTTAAATTTATCTTTGAAAACCTTATGAGTCTAAAGTA
AGAACAATTAACCCATTCAATTTTGCAAGTGGGATAGTTGAATTTTACTTGCAATCCAGGGATTTTTTGACAGTTTGAA
ATATACATACATACCATGTATGTTTAGGAAAAATTTAAAAAGAGGGGGTTGTAATAATAATAGTTCTTCCATGA
TTTTTTAGCCATAATGTTTATAATATAAAATATGTATACTCTTGTTATTGAATGTAGTATGTTTCTAATTTACCAGA
AGGCAAGAGAATAATCCTGGAGAATTTCTCAAGGCATCTTCGAACTCTTTGATTTATTGCTCACATATAGTAATTTG
CCAAATGACGCCCTAGTGAACCTGAAAGAATTAATGCCCCGTCTTAAGTCATTTTACCAGGGGACTGAAAACCTGCA
GCAATTTGCGCAATTAGAGGAGGAAACAATCTACCTTGCAAGTCAAGGAGTACTGGATAAAGGAGCTAAGAGTGTTCG
TTTTTTTCCCCTTCTTACTTTAAAAATCCCAATTCATCCCATGCTTTTCTTAAAGGCTAAGTGAAGTAGTAAGTACG
TTTTTGCAACATACGAATTTAGCAGACTGGCTTGTGTTTATTTTTGGCCGGAACCATTTACACTTATTTTCCAAACCT
CTCCTTTATTTGTTGGTTGATAATGGGCTAATTTTGAATCTTTACTGTCAAAAAGAACATTAAGAGAAGCAGCCCTGC
CTGCATCGCAGGCTATGTCTGTCTTTGCCGAGTATTAAACACTAAAAAATAAAGAAAATACTAACAAAATGAC
AAAGCATTAAGAAAATAAACTAGATGTTAAAGGAAATGAGAAAAATAGGAAAGGATGCTGTACCTGGAGTGATTTTT

TTTCCCCAGGCTACCTAAGATGATCAAAAAAGAGCTAATTTCTCTTAGGTTTCTATTAAGGAATTACTAGAAATATCG
GGCACACCAGGAAACTTTATCAGTGGACCTGTCTGAAACCAATTTTCTTAATGTATATATGATAATTTGTTACCAC
ATCCCAGATTATTTTACAGGAATTAATAATATATTTGAAACACTGACAGGGAAAAATTGGGTAAGACATTGATAGATAC
TACAATCTGTACTTGAAACTGCACTCAAGGAATTCGTTAGTCAAGAAAAGAACACAATGACTGTGGGCCCTCTGGGT
TTTGGAACCTCTTTTGTAAGCATTTTTTTTTTTCCCAATAGAAGATATTATTTTGAAAAGGTTAAATAAAAAAT
CTTTGTTCACTATATAGTTTCTCCTAAGGAGTAAATTAATTTATATAAAATATTGCAATATAAATAACAATTTTAA
AATCTCAAAAGAGCAGTGTTTTAAAAATAATGTAGAAACATTAAGAAATGACTTCAATGATAAGAATGTCATTGGA
GAGCAAAGGGTTTTTAATATTACATATCGTGGCAGTATATCAGCACCCCAACCGCTCAAGATACAGAGTTCTTTTACA
AAAAATCAACAGAAAGGAAATGTGCCACCTTGTTCATAAACTATATTTAATAATAAGCCAGGCAGATAAAAGTCACCTT
CACAAATAATGAGCAAGCCCATGGTAATATAATTCATTTACAATAAGATTTTATCTCATGGAATTCTTAGACTGTGCT
TTGAAATTTAAATAATTCTGATAAATGCCAACAGAAATAGAGAAATCAATTCCAGAGCAATTACTAACACGTTGCATT
ACCTTTCTAACATTAATATTTCTCTTCATACATATCATTGAAGAGAAAAATGAGGATGGAAAAATAAAAAGATCAGGTA
ATATATTTGCTTTCTCATCTAGGGTTGTTATGATCTTCAAGATGAAGTTTTATTTTTTACTCCTAGCAAATGATATT
CTTTTTTATTTTAGTTTTTATTATTTTATTTTTCTGTAAATATTGGGGTACAGGTGGTATTTGGTTACATGAGTAA
GTTCTTTTTTTTGATATTTCTGAGATTTTTTTTTTATTCTACTTTAAGTTTTAGGGTACATGTGCACAACGTGCAGG
TTTGTTACGTATGTATACATGTGCCATGTTGGTGTGCTGCACCCATTAACCTGTCATTTAGCATTAGGTATATCTCC
TAATGCTATCCCTCCCCCTCCCCCACCACACAACAGGCCCGGTGTGTGATGTTCCCTTTCCTGTGTCCATGTGT
TCTCATTGTTCAATTTCCACCTATGAGCGAGAACATGCGGTGTTTGGTTTTTGTCTTTCGATAGTTTGTGTGAGAA
AACCACGAGGTACCATCTCACGCCAGTTAGAATGGCGATCATTAAAAATCAGGAAACAACAGGTGCTGGTGAGGATG
TGGAGAAACAGGAACACTTTTACACTGTTGGTGGGACTGTAAACTAGTTCAACCATTGTGGAAGTCAGTGTGGCGAT
TCCTCAGGCATCTAGAACTAGAATTACCATTTGACCCAGCCATCCCATTACTGGGTATATACCCAAAGGATTATAAA
TCATGCTGCTGTAAAGACACATGCACATGTATGTTTATTGCGGCACTATTCACAATAGCAAAGACTTGGAACCAACC
CAAATGTCCGACAATGATAGACTGGATTAAGAAAAATGTGGCAGATATACACCATGGAATACTGTGCAGCCATAAAAA
AGGATGAGTTCACGTCCTTTGTAGGGACATGGATGAAGCTGGAACCATCATTCTCAGCAAATATTGCAATGAGTA
AGTCTTTTTTAGTGTAATTTGTGAGATCTGTTGTCACCCATCACAGTAGTATACACTGCACCATATGTTTATCT
TTTTGTCCTCGGCACCCCTTTTCTACCCCCAAGTCTCCAAGGCCATTGTATCATTCTTATGCCTTTGTCATCCTCA
TAGCTTAGCTCCACGTATCAGTGAGAACATATGCTGTTTGGTTTTCCATTCTCTGAGTTACTTCACTTACAATGATA
GTCTCCAATCGCATCCAGGTCATTGCAAATGCTGTTAATTCATTCTTTTTATGGCTGAGTAGTATTCATATATATA
TATATAGACACACGTACATACATATGTATATATACCGCAGTTTCTTTATCTACTTGTGCGATTGATGGGCATTTGGGT
TGATACTTGCACACACATGTTTATAGCAGCATAATTCACAATTGCAAGTGATATTCTCAGGAAGCATGATGTAAGTG
ACAGAGACTTACTTTGTAGACTGCACTCATTCACTTGTCTCTGAATGTGCTCTAGGCAGCCTGAGTTTCTACTATG
TCAGTGTTACATAGATGAGAAACCCCATGGGTGGTTTCCACAGAGGCTGCAATACTATTTTTTGATACCAAAAATCTG
TTTGTTTTGTGAGCCCCAGATGCCCATATGGAAACTGAAGTGTGATACCTCTTTGTAGCCCTCTGATGAACCTGC
ATGGTTCACCTTCTCAGCAGTTTGTAGCGGGGTGGGGAGAGCGCTGCTTCTAGCCATCCGATTGGCCTGAATCAT
CAAAAATGCTATCATGAAACAGGTTCTGTTTATCTGCTCCAGATTACACCCATCATGTTCTAGAGTGCTGGTTTCAT
GCTTGAATCTAGATCAAGCCTGCTTTCTCCCTGCCTGTACTCCCTGTGGCTACCTACAGTCTGCTGTGCTGACAGA
TAATCTAAACCAATAGCACCTAATTAGCCTATTTGCTCATGTGTTTTTCCATCGTGGTATAATGTCTCTCTGTCA
ATTTAGGGTGAAATGTAGCAACACGTTGCTGATGGTTAATTTCTGGAATGCAGGTAATGAATGTGTTTTTGCTTA
TCCAAGTCTTCCCATCAGATGTCAAATATAGAAGAACAGTGTTTCAAGAGTCTTAAATTTAAATTGGAGTGAGAAAT
CACAGCGCCCCCTGAACCTCAGGCAAAATGCACTCTGACAAGTCAACCAGATATTCACAGATGGTCTGGAGGATTTGAA
GCCTAATTTGGTGAAATAAAATTAATGAGTGAAATGTATGCAGTCATTAATCTATCACCATACTTAAATGCTTC
ATTGAAATTTCTTTTACTGCTTCAAATGAAAAAGATCAAACATATGTTATAGAAAAGCATTCAAAACCCCTTACATAA
CATAGATAAAAATTTGGTTGGAGACTTACAGAACTTTCTCTGCTGCTTCCGAGAAAGTTACAGTGCCCAAAATCTATT
GCTATTAGAATATTTTATTGTATTCAACACTCAATTTCTACCATAATTAATGATATATGAGAAAAATATTTTTACCTATA
AAATAATTATTATTACCTTTTTAAAAATCTGACATTCTTCTTTTTTCTAAAGAAACATATTTAGATTTAGCTTTTTAT
TTTTTTTTTGTGTTGATACATAGAGATTGTACATATTTCTAAGATTCTAGTGATATTTTGATACAAGCGTATAATGT
GTAATGATCAAATCAGGGTAATTGGGATATCCACCATCTGAAACACTTATCATTCTCTTTTTCAATGCCATCATAC
CAAAAGGAAGTAAATAGAATTTCAAATATAAGGACAGCCATGATTTTACATACATGCCACGATTCCACCACAAACC
ATAATTACGTCCCCCAAACCTTTTAACATTTAGATACTTTGTCCAGGTATTTTATGATAAGGATTGGGCTATGACT
CTGTTACAGAAGGGCCAAATGACTAAAATGTCTCTGAACAATATTGATTGCAAATATTCTACCCAGTTGTCAGGTCA
ATATGTTCCAATTCGGAATTTATAACATTGTATCTCTACTCCAAACCATCCAATCTCACCTACCTCACTTCCATAT
TATGGTGGGTGATCTCAGATTATATTTAAGCTCATGGTTACTTGTCAAGTAGATATGGAGTTTAGCCTAACTTTTTGA
AATTTATGCTGAGATTACCTTCTCATTATAGAATTAAGTAGGCAGTTTCCAAGTTTAGATTTAGCAGGCAGTTTTT
TTCAAATCACTTAAAGTTATATTTTTTTTAGGGCATTGAACAGGTTTGAAATCCTACCAAGATGTCATGTACACATA
GACCAATAGAACAGAAATAGAGAACACATAAAATAAACTGCACAGCTACAGCCAACTGTTCTGTCGACAAAGTCAACAA
AAAAATAAGCATTGGGAAATGGATTAAAGATTTAAATGTAAGACTTCAAGCTATAAGAATCCTAGAATAAAATCTGG
GAAATACCATTCTGGACATTGGCTTGGGAAAGAAATTTTGTACTAAGTCCTTAAAGCAATTGCAAAAAAAAAAAAAA
AAAAAAAAATGACAAGCAAGGACTTACTAAAATAAAGAGCTTCTGCATGGCAAAATAAATGATCAACAGAGTAAACAG
ACAAACACCAAATGGGAGAAAACCTTTGCAAGTTATGCATCTGACGGTGGTGTAATATCCAGAATCTATGAGGAACC
TAAACAATTGAACAACAACAAAATCATAAAACATCATTTAAAAAATGGGCAAAAGACATGAACAGACATTTCTCAAAA
GAAGATATACACGCAGCCAATAAACATGAAAAATGCGTCACATCACTCATCATCAGAGAAATGCAAAATCAAAACCGC
AAGGAGATACCATCTCACACCCGTGACACTGGCTTTGTTAAAAAGTCAAAAGACACCCAATGCTGGCAAGGCCGCAG
AGACAAGGGGATGCTTATACACTGTTGTTGGGAATGTTAATTAGTTCAGCCACTGTAGAAAGCAGTTTGGACATTTCT
TCAAAGAATTTAAATAGAACTATCATTTGACCCATCAATCCCATTACTGAGTAGATATCCAAAAGAAAACAAATGG

119

TTTCAATAATCAGTTTCTAATCCAAAATTGAATATCAGTTCCAACTCTACATTTCAGTTTCTGTTTTACTTGTGGG
CTGGCTTTTGGTTCTGTTTTCCACATAGATCCTCTCTGTGTAAGACAAAGCCATTTGTGCAGATTAAATTTTACTGA
GCGTGTTAACCTATTTAAACATTCATCCAAAAAGACTAGTATGAATTCCTCATATGGCAAGCTGCTTGTGTTTTAAAA
CTTCCATTTATTCTAAAATCCTTTTTACTTATACTTTTTAAGAAACGTATTCCCGATATACAAAAGTAACACATGCT
CATTAAAACAAATTA AAAATAGTATTGTATAAAGAGCTGATACATTTCTGCCTTGCCCCATTTAACCTTCTTAAGTG
TTCATGTGAATCATCCATTCACATCAAGACATTTATCTGTATTTCATATGAACGTGTTTTAATATATATAACATATAT
AGAATTTTATATAAACTTTCCTTTTAAAATAGAAATGAAATTATATGATATATTTATTCTGTGTCTAGCTCTTGTC
CGTAATTATTCAAGAACATATTTCTAGGTTAATATCTGTATTCTTAGGTAGCATTCACTAACTCCTCATCTACTTGT
TTTTCTTCCATTCTAATTGTGTTTAAACATTTCTTCATACAATGGGTGTCATTTGGTCTTCTTTTCATGGAGGGTGCA
AATGTTTCATTCTCACCAATTCTTTACACTTTACATAACTGCTTGATACGAAGCCAGACCTTTATAAATATCAACAAAG
CAGGAACACTGTAATCAGCTATCAGTTTCAGTTGAGCTGAATGACCCTGAATATGTGTACACATATTTTCCAGGAGA
TTTTAAACTGACACCTCAGATTTCTAAGACCTGGAGAAATCAGCATGAGAAACATTGATCTATATTATCCGTGAA
ATGATTTCACTAAATAGTGAAGCATCTCCACATGTGGACTCTGTAATTTATTAGAATAAAGAGTTCATGTGCTTCT
GAAGAACTGAACTACTCTTCTGGCCTCCGTACATTGGTTTCTTAGCTATAGGAAGGCTGAGCATGTTTTTCCATG
CGTTTCCCTTCTAGCTCATCATTTTAGTGACAAAACAATCTTTCGTGGTGTGTGCTAGCTATAGAATTGTTTCAGA
TTCATTTGACCAAAGGTGGCAAATACAACAGTCCCAACAAAAACAAAAGACCTATTACAGAATGATGGAAATGACCC
CAGGGAACAATGGCACCTCCACATTTCTTAATTCCAAGGTTATAAGCAGTGGTGTGGACAATTCTCAATTCCAATGC
TGAATCGCCTTCTAATTTCAAATACCTGTGCTAAAAATTATTTACGTCTACTGAAATAATGAACTGGACCCACCAG
GAATGGCCGATATGCTTGTAGTCAGAGCACAACTGTAGAAAAGAAAAAATCAATTTTAAATTTATAGAGGTATGATGATA
GCTGTTTCATACTGTTTTTCAAGCATGAATGGCCTGCTCAGTAGTTTCTTGTCATCGTACTGAGACACTTTAATTT
CTTACCAGCTGAGATGAGGAATACGAGCCCAGTGTGCAGGTGAAATTGGTTAACAGGAGCCATTAAAATTTGGAAGA
GTCAGAATAGCATCAATCAAAATGCTTTCAGTGTAGGAAGTAAACATGTACTAGCCTGACCCACCTGTCTTTTCTTT
TAGGTATGTTGGTAATATTACAATCATTTTGAGGTATCCATAAACAACCTGCTTAGATCTGAAGAATTGTATATCTTT
CTTTACTCTGCCCTGGCCTGGGGTTATGGTTCTCATTGAGCTCTAACCTTTCAGAAAAAAATGTAGAGGAAGTGGTT
CAAGAAGAATGCTTTATCTTGCTTCATAAAAAATGATAGTAGTTTATTGAAGGCTTACTATGTGCCAGGCCAAA
GTGCGTTTTATTATCGTTCCCATTTTCCAGGCCAAAGAAGCTGGAGCACAGAGAGGCTAAGTAGTTGTCCAGGATGG
CTCAGCTAACATGCTGCAGTTGGGATTTGCACCCAGACCAACTTCTTTTCAACCACTGTCCCATCCTGTGTCTTCTC
TACTCAAAAAGTGTTCAGCTCCAAACCTGAAACTTTAAAAGAAAAGGAAATCCTTAGTGGAAGACTAGGTTTTAGT
CACAAATTATCTCCTTCCCTTACATTATTTGTCTCTTTTTCAAATACTCCAAGCTTTGATTAAAACGTCTATCACTA
GGAACATTGTAGAATTGCTAAGGTGGAATTGTTAAAAGAACTCAATTCCAATTAACCTTGCCATTGATTACTGTGTG
TTCTGGAGGGGTGTTCTTTCTTTCAGGTTAATGATGCTTTATTGTATATCTCAAAGATTAAAAATAACAATGAAGGA
AGTAGCAAACCGGAACCTTCTCTACAATGCATCTTCAATCTCGTGCTTTAAATGAAGATAAAATCATGGCTGTGGT
AAGGTTGCAGGAAGGATGATATAGATTAAGTTTCTTGCAAACCTGCCCTCTGAATTTTCAATAGCTGTAGAAGGTATT
GGTTTTTCAAAAAATTGACAAATTGAGGATTCATTACAGCAGTTTTTTTTCTAGGTCTCTTACCAGAAAGTGATCACTA
AAAAGTGATAGGGAACCACTCAAAGTTGGATAGATCATTATTTTCACTTAAGCATTTTAAATTTCTTGAAGGAGCTTT
ATAATGCAACAAAGAATTTACAGTCCTGTGTACCCGCTTAAATTTTCTAGGGTCATCAGTAAACTCAGTGGAAATAA
ATTAGTTCATGAATATAATTGACCCTTAAATTTCTGTCACTGTGCAAGTAATCGGTGGGTCTGCTGGATATGGCTTTC
GAGCAGACAGGTCAACTTCTTCAAACAGAGAAGAAGCATAGCATAAATTGAAGACAAATAACAACTACTTGTTTTCC
TCCTTCTTTGGCATCACCTATGGATGGAGTATGCATTTATAATTTAACACAATCAAGAGATCTTTATTATCCTACT
TTTGGGTACAACCTGCTTCGTTTCTCTTTTGAATCTCTACAGCTATTTAAAAATCTGTTTTGTAAAATTTCTTTAAAA
ACTAAACATCAGATTATATTTTCAAGGTATCTTACTATCTTATACCAACTTAAGCATCCAGTATTATCACCACCCCT
TCCCCTGAGTGAATCCTTAGCACTGGGCTCTCTCTGTTTTTATCCCTGTGCATGCTGAGCTCTTTCTGGCCCTCAAGT
CTACTTCCGTGTCAACTGTTGTCTGAATGGTCTCTCTATGTCCTTCTTACTCTCTAAATATTTCGGAATTTAAAGCC
TGGAATAATCTACCTTAGTCCAAAAGATATGCTACATATTCTAGTTTCACAATGATCTCAGACTGCCGTTGATACAC
AACATTTAATATCAACTTAATATCTATTTTCAAGTTCATTACGAGGTCACTTATGCTACATCTTATATTGTTGCCTTGG
ACTTTTATTATCTCTTCATATATGTGTTTATGGTGCTCCACCCCTCACGAGAAGTTGCAAATACCATGTTAGCTGTC
TGATGGCTTTCTATGTTGTCAGGTATACCATTTCCCAACCAGTTGGCATTCAATGATTAAGTTCATTAACAAAGAAT
TGTATGTGTTGAAAAAGATGTTTTTTTCTTAATGAAGCACTTGTTTTTATTTTTTAAATGAAATCCACCCTCTTAAT
AAATTTTAAAGTGACAATACAGTATTGTTAAATATAAGCAAAATGTTGCATAGCAGATCTTTATAATTTTTTTAAACC
CTACATGCCTGATAGTCTATACCCATTGCACAGCATCTCACCATTTCTTCCCTCCTCCAGCCCTTAGCAACCACCAT
TGTACTTTCTGTTTCTATAATTTTGACTACTTTAGATACCTCATGTAAGTGGATGCGTGCAGTATTTGTCCTTTTAC
GACTTGCTTATTTTATTTAGCAAAATGGCTACAAGATTCATCCACATGTAGCATATGGTAAGATTTCCTTTTTGTG
GCAGAATGATATTCATTGTATGTATATAACATAGCTTTATACATTTCCCTGTCAATAGACATTTAGTTTGTTCACA
CCTCTTGGCTACTGTAAAAATGCTACAATAAACATGGGAATGCAGATATCTCTTCAAGATCCTAAATTTGAATTCGTT
TAGATAAATATCCAGATGCGGGATTGCTAGATCTTATGGTAGTTATATTTTTTATTTTTTTGAGGAACTCCATATT
GTTTTCCACAAAAGCTGCACAATTTTATATTTCCACCAGCAGTCTACATCTCCAATTTTCCCTACACCTTCACCAACA
CATGTAATGATCTTGGGCTTTTTTTTTTTTTTTTTTAAATAATGGTTATCCTAATCCGTGAGGTAGTATATCATTTGT
GGATTTGATTTGCATTTCCCTGGTAGTTAGTGATGTTGAACATCTTTTCATATAACTGTTGGTCATTTTAAATGTCTT
CTTTGGAGAAATATCTATTCAATTCCTTTGTTCATTTAAAAATTTGGGTTGTTTCGAATTTTTGTTGTTGTTGTTTATT
ACGTTCCCTCATGTATTTTAGATATTGACACCTTATCAGATATATGTTTTCGAAACCTTTTCTCTCATCTATAGGTT
GCTTTTAAATCTGTTGATTGTTTCCCTTGCTTTGTAGAGCTTTTTTAGTTTGATATATTTCTGCTTTATCTAGTTTTG
TTTTTGTGCTGTCTTTTGTAGCGTCATATCCAAAAAAATTTATTGTGAAGACCAATGTCAGGAAATTTTTCCCTTA
TGTTTTCTTCTATGAGTTTCATAGTTTCAGATCTTATTTTTTAAAGTCTTTACTCCATTTTCAATTTTGTGTTGATTTTAA
TGTATAGTTTAAAGTTAAAGGTCCAATTCCATTCTTTGCAATGTGTATATCCAGTTTTCACAGCACCATTGGTTGAAG

121

AGTGGTGTGGGAATAGACAAGAGAGAAGGGGAAAAGACTCTTCAGGAACTAAACTCACAATTTATGAGTATTCTTTA
TTGCCCAAGTCTTCCCAAAGTCTTTCATCAAGAAAAGAGGCATTGCAACTCTCCTTTTATAGTTTGTATTTATTCTGG
AGCAGTGATGTTTTGGTGGAGTTGTTCTCAGTGCGTAATTAAGGGCCTATGACAATTACAGTTCATCTCCTGCTG
CTCAAGGTACTGCAGATATTTGGATCTACTACTCTCATTCAATTTCCAATTAATGTCAGCTTTAGATTTCTTCAGTA
TGCTATGTTATAAAATTTGATTATCGTTGTGCCACCTTCCCACCTTAATTTCAAGCAGGTTTCTCGATTACCTGACT
AAACTAATGAAATCTGACTAACCAATATCTGTGGACAGTAGTGTGATGTTACTGATTTTTGTATGATTAGTCAAGT
CATATTCATGCCACGTTTTTCATATAGTACCATAAAGGATATTCTTCTCGTGGTCCTTTTCTTTTATTCTGAACATAC
AATGAGAAGACCGGTAAAGTGGGCTAGGAAATTAAGAAAAATACAAATGGCAAAAAATATGGGTCACTCGAAGTCT
AGAATAGAGAGCACAAATCAATTTTGAATTAAGGGGTGATAAGGTGATTTGGTCAGGTGACTGGTGAAACAGGAAAGA
AACTATACTTTTTGAAGTGTTCATCCATGTGTTAAGATTCAATTTGGGGTCAAGAATCTAAATTTTCATATCCCTGGG
AGTGGAACCTAAGTAAAAAATTTATGGACCTTGGTTTAATAGCTAGAGGAGCAAGAGTGTATCTTTATGTGAC
TTAACTTCTATGTGAAAAGTGAACCTTAAGATTAATTTATGGGGGAATTTACTTACTCAGGTTCTATGCCTAGATGG
TCTGCCCACTAAGAAAATTTATTTCTGTACTCCATCCTATTTTTCATACTTTTATACTGCACCTTGCAGAAAAG
CATATATTTCTACCAATACGAAAATTTCTGGGAACATATTTTCTACATTTCCCAAATTACTTCAAAAAGTAACT
TAGGTTATTTTCATGATCTCCATTACAATGGACAGGTGGCTTATTGAATGTTGTCTGTGAATACAAAGATCCAGAG
TTTAAAGAACAAGGTGTACTTGCATCTCCCACTTAGGGTTGCTTGTGGTGGAGAGAGAATCTAGTTTGCTTAAAG
GATGACAGTGCAGTGCCCCAAAATATCTGATATCATTAAAAGTCTCATATTTGTCTTTCGTAACCTTCTCTAGGGCTG
TCGATGACAGGAGACCCTTAACCTCTATGCCTTGATTATGTGAATAAGCACATGAAAATATTTTAGTTATCTTAGTT
CACTTTTAAACTAAGTTTTCAATTATCACTAGATTCTAAATATCATCATTGAGCCGTTCTTAAGGAAGTATTTTCTA
CATATTCATTCACTTACCTATATCTAGTGTGTCTACTATTTGCCAAGAAAAATTTACTCTCTTAATTCAGCATTC
ATATACTTAACATCATAAAAAGTAGGCCATTTTATGTTTTCTAAATTAATTTTAAACATTTCTTTAAATTTACAT
TCTATCATTACACTATATTTCAACACTACAGTAAGCAGCCTATTTTGTGATTTTTCTTATATAAAAATACATAATTG
AAATTAATAATGAAGTTACCAAGAGCCATTTTCACTCTGGGGAATGCACATTTATAAATTTATGGGGTTATTTTTCT
TCATCAGCTTTTCATATTATTAACCTTTGTCTCTTCATAATTACAGAGATGACTAGACACAGAAGGGAATTTAACATT
TGGTGTGCATTTGTCTACCTTATCTTATGTTAGAAAAATACATTTCCATTTGAAAAAATCAGTAATTGTGGGTG
TGATCAAGAGGGCAGCCTGAAAGTCGGGTGATGTGACTCACACCTGTAATCCCAGCATTTTTTGAGGCCAAGGTGGG
ATTATCGATTGAGCCCAGGAGTTCAAAACCAGCCTGGGCAACACAGTGAGAGCCTGTCTCTATTAGGGGGAAAAAA
AAAAAGAGGAAGTTAGCCTGAGGCAATGTAAATGAAATACATATTTCAAGGATATTTATACATGATTCAGTTATT
CATATAAAGATGTGCCAGAGAAGACTATAGGTACGTTATTTTACACTATTTTGTAGGATTTTAAGAAATTCATGT
GTTTTTATTTTCAAGTTAACTTAGAAAACTTACCTAACTTATACTTCTCATGGACACAAAAGTTTTTAAAGATAGGATC
AAAAAGCCCATGTTGAAGCATTTTGAAGTGGATGAAAAACATCTATTATCTTTAAATTTTATGATATTACTGAT
TGTAATAGACTCCCTTTTTAAGAAATCATTCCTTATAGAACATAAGGTTTACATTTACAATCAACAATTTCTATCCT
TACTACAATAAAGGCACATATAAAAAGTACAGTTGCATATTTAGCAGTTTAAATGTACATTTTAAATGTAGAAATCA
ATTCAATTCCTTTTCAATTTATCAGCATTATTACAGTGATTTCAAATTAAGCATAGGTAACCTTGATATAGATAAATGAT
GTACACAGCAGTTAAATTTTATTTTCAATTATGTAGTAATTGTATAACCTAGGCAGTATAATTTGTAACTTTGTAT
TTTATTATTATGCTTCTCCCACTTGGCATAAGCACAACTTCTTAAAGCATAATTTTCTATAGACTTAATAACTC
CCTAAAAACCTGTTTTGGACCCCTATACTATTTGATATAGGCAGAAAAAACAATAATCCATGCTCAAATTTGAAAA
ATGACTGGTCACATTTGGTATAATACTAAAGGTAAATAAAATCAAGAGTCTATGAACATTTCCGGACCTGCACATTT
GTTTTTATTAATAATGCATAATTGTCTTTAGTGTGTTTCTATTTGTTTATACTCTACTGATTTTAAATTAATAACCAA
AATACGTTTATTAATAAACTGTGCAATCTAAGTTGTTAAATATACTTAACTAGGAAAGTAACTGTTTAAACGAGAT
AATTTATAGAGAAATGTGGTGTATTGCCAATTAGATGTCAAGATACAATACAACCTGATAATGAAAAAGTAGCATTTT
CTTAGGGATGGAATACAGTGTAAGGAACACCCAGTAAGAATACAAAAATTAAGTAAAAAATCTTCTTCTCCTGAA
AAACCAAGTGCCTTCAAGTGCAGAACCTCACTCACTAATGTTTGTAGTATCACTAAAGCCTGATACCTTCAATTTT
CTGGATCATTCAAGCTGTATTTTGTAGTCTTATACTAGAGGAGGTAAAGAGCTATAAAGACATTAATGGTATCTG
ATGTGAAGTGTGGATCACTTTGACCCATCACTTCTACGTCTACATCTTGGATAAATTTCCATTGTTGTATAGATTG
TACAGGTTTAAATGGTGCCTTTGTGGAGGGGGCTCGCTTATAGAAAAATGGAGACTCTGAAGGGATAAGGAATAAATGT
ATCACTTCAGGTCTTTTATTTGAAATGGGGTCCAGAGAGCCTTTTTGTATCAGACTTGTCAAACCATTTCCATTTA
GTAATTATATATGCACTAGCACTTATTCCTACTTACCTCACCTCTTTATGCCCATTTTCTTGTAGTTGCGGTTATGC
ATGAATAATTTATTGCACCCCTTACCAACAATGGAATAAACTTCCATTCTGAAAGCTTTCCATACTCATTTCCAAT
AGCAATAGGGTTTTTTTAAACGGACGTATTACAAATGTACGAGTCAGTTGAACATAGTATTCCTCTTTGTAAAGACTC
CAAGTGGATGCATGCTGTTGTCTCAAATCTCAATTAGACCTTGCTTTGAGGTCCCTTCATTGCCAGTCATCTGTTCT
CCTTCCCCTGACTTGAGTATTTCTCCAGATATAGATAATACATTTTCCCAACTCTGTGTTCCAAGAACTGACAGTGG
CTTTTCAATTCATTTTGTGTTGTTGTTGTTGTTCTTCTCGTTCTCAAGTATCCCGCAGTCTACTGTTTCTTCCCTCCATT
CGTTTGTCTTTTTCAGAGTTTCAAAATCCAGCATAGGTACTTCTTCTAAATGTCTTACCTTTCACATACACACACCA
CTTGAGACCCCATCAGCCTCTGTCCACACAGTTTGGTTACATTCATAGACTATTTTTATACATCAAAATATTTGAAA
ATTTTAGGGTAAATCTCAGTAGTCATTCATTTTGTCTTATTCAACCAATACTAGTCAATCAGCCTGTGCCAGGTT
TTGTTGCAGGTACCAGGTATCCATCCATAAAGAAAAACAACGTCCCTTTGTTGTGGAATTTACATTTTAGCAGGGGAG
GCAAAGAACCCAATAAATATGATAAAATATCAGATTAAGAGTACGATGAAAAAATCATCAGGGTAAAGGAAAAAGG
GAAGCAGTATTTTAGCAAGAGTGGTGAAGAGAGAGGCTGAGAGTGTGACATCTGAGCAGAGACCTAAATCAAGTCA
AGGAATGAACATGCTACTATCTAAAGAAATGAGTCAGGATAAGGAACTAGTAAGAGCCGAGGCCAGAGATGTGAA
TATGCTGTTCCAGGAACGACAAAGAGACTGGTTGATATGATGTGAAAAATGAGAAGAAACCTTATGATATGTGTCAA
GAGAAAAAATTTTAAAGCATGCTTGGGAACGGAGGCCTCCAGATGAAAAAATACACAGTTCAAATCCTTG
TTCATGCATTTAGTTTGTCTTGGCAATCTGGGCAAAATGTTAAATTTCTGTACGTTTTATCTTCTCATTTTTTAA
TAGGCACAAGGACATCTACTTAATAGGTTTATTGTGAGGAGTAAATGAGATGATATATCTAGGATGCCTGGCATTAT

ATCATACACTTAATAATACACTGAATAAATAATAGTTATGTCTATTTATTTTCCTTATCGTTTTTATTATTATTTCAA
TGCACAGACCTGTTTCATAAGATAATGATAAAATATTAGTGGCAGAAAAGTGAAGATGTTATAAAATTATTAGGAGGCGGG
ACCACTCAGTTCAATGTATCTGTTTTAATATAGTCAGCAAAAAGTGTGAAGATACCAACAAATTAAATTTCAATGCATT
CTTCCATTTCACTAGTTTTATAAACTGATGAACTACCAGAATGTCAATGTATGAATTGCATACTCATTCTTAACAAA
CAGATTTGCAAAATTATGTGTAAAATTAGCCCTCAGCCTTCCAATTTGTTATTGTCATATTTTCATGGAAATACATAA
TCTGTAAATTTTTGTTTTAATGATATGTGAACTGCCTAAAGTAGAGTCTTGGCACTACTTCACATTTGTCCTCCA
GAGATAGTGGATAAAAGTGTCAATAAATGAACACTCTATATTCATAATCACAGGCAAGGGACAAGGAACAGAGTGG
TCACAAAATACCACAAAATTAAAGCACATTCCAAATTAAATATATATGTTTTTATTACAGATAATGTTTGCCTAGACT
CTTTCTAATTATCTGCAAGATTTTAGGAATGTTTTAATGTTTTAATAATTACACACCTGTGTATTTCAAGTTCAGT
CAAACACTATTGTTAAAACTAAATCTTCTCATCTCTAATAATAAGATGTGAACTTATCTTGGAAAGGTGGTTATTAGG
ATGGGAGAGATAATGTATTTTCAATCAAAGTAAAAATATTTCTCTGTTTCTATCTTTCTCTTTCTCTGTCTATCTATTT
ATCATCTATATCCAGGTATCTATGCACCTATGTAGACTAGCATTCAATGAACCATAGATATTATTAGTAGTAGAATT
GTTACTAATATTAATAAAGAAGTATTTAAGAAGAAACATGTCTAAAGCATAAAGTCAATTATTACTCTCATGTTT
TTTGGCATATGAAGCCTAAAAAGTGTCAATTTCAAGAGAGTATTAATAAAGATTGTGATAACTGAAAGGTTCCCTGCT
TGAAATTTTGTGTGGTCTTACAAATATATAAACTCTAAGCATTTCAGTGAGCCAATTACTGACTAGGCACATATGTCT
TATGACTCTTTTGTCTATAGTATGTAAAAACAAAGAGTAGAGACATCATAAAATATAGTAGATGGGCACTAGGGA
ATTACGCAAAATAATTTGTAGATTTAATGTGAAACCAAAACATCTGTTCAAGTCAATTTCCACAGGTCTATGTGGCA
AAGAGTATGAGTTCCAGACTGAGGAGAGGAAAAGGTTGTTCTTCCACAGGGAATAAACTGAGTGTAATAAACATAA
TTTTTCTTCTTAAGCATTATTTAAAAACAAAAAAATGCCATTAAATCTATCTTTCTGCTCTCTTATCAATGCTCC
CTTCCCTTTTACCACCTGTTTCAAACCTCCAAGCCTTGGGATTTTATTTTGGCTTTTGGCTTAATGTAACATAAATG
AGAGCATCACAAATATGAAGCTCATCAAATAATTTAGCAGCATTTTCCCTGTTTTTAACTTTCTCTTTGGAAACGT
AGATTTTCGAAATTTAAGGGCCCCAAAATATGAAATGCAATTATAATAGGCCATTTGTTTCATTTCAGCTTGATAAACTTG
AATAAATAGTATTGAACTTTTAATGCAAAAAGAACAAAAACAAAATAGAACTCTCCACGAAGAACTTTTCAATGTTT
GCATTTCTGTGTGAGGAGGAAGGGTAATGAATGTGGGAACCTTAATGGAATCCATGTTCTTCCAGTGTGACAAAGGGT
CAAAATGGAGAAAATGGTCACTTTCTACCCAGTACATATATATAGTTCTATGTGGACAACATAACATAGCTAGTG
CTGGTTTTTCAGGCCATAAATGTAGGTATGTATTTCTTACTATTTTATAAGGCAAAATTTCTATTTGTTTTAATGATTT
CTATATAGGTAGATTATTCTGTCTTTAGGATTAAAAAACGACCTGTAGACCAAGAGACTTTCTAATGTCCACCTTAGA
GTATATGGCTTTTACTGTTACAGTTTCCATTTCTTTGCTTGCCCTTTGAGAGAAGGAAAGGAGACATTTGGGATA
CATACATCAATGAGGAGCTATTAATGAATAAATGAATGAAATGTGAGTCAATTTATCCACATGATCATCAATTGCC
AATAATTTTATCACCTCTGTGGGATTAAGTAGAGGTAACAGTTTAGAAATTTGATTTTTTGAAGCATTTAAATGT
TCAAATATATCACTCTGGTAACTAAGGGAAAGTGTATTATTTCTTATGCTTAGTCTTATTTTGGTTTTTGCCTTTTT
AATTTAAATTGAACACTTATATCAAAGAGCTTGCAGGATTATAAATTTGAATTTTTGAAGCAAAGATCATTTTCTTAA
CATCAAACAAAGAGTAGATACAATAGGAATAAAATCGGCAGAAAAACAAGAGTATCAAGGACAGACGGGGAGGGTGG
GTCTGTGTTAGCATGTATTGCTATGAAGAAATAGCCGAGACTGGGTAATGTATTTTTAAAAAGAGCTTTAATCGATT
CATGATTCTGCAGGTTGTACAGGAAGCAGGACACCAGCATCTACTCAGCTTCTGGGGAGGCCTCCGGGAGCTTTTAC
TCATAGTGGAAGATGAAACAGGAGTAAGCATGTACATGGCCAGAGCAGAAGCCAGGGGGAGGTTGCCACACATTTA
AAAAAAAAAAAAAAAAACAAAACAGATCGCTCAAGAACTCAGCTGCTATCATGAGGACAGCATCAAGCTGTGAGGGATCCA
CCTCCGTGACTCAAACATCTCACACCAGGCCCAAGTCCAACACTTGGCATTATATTTCAACAAGAAAAAAGTTTA
ATTGGCTGATGGTTCTGCAGGCTGTACAGGAAGTGTGGCACAGGCATTTGCTTGGCTCCTGGGGAGGCCTCAGGGAG
TTTTTGCTCATGGCAGAAGGTGATGCCCACACACTTTAAAAAACCAGATCTCATGAAACTCACTCACTACACT
GAGGACAATACAAAACCATGAGGGATCTGTCCCATGACCCAAAAACCTCCCGCCAGGCCCCACCACCAACATTGGG
AATTATATTTCATTTGAGATTTGAGTGGCGGCAAAATATCCAACTATATCAGGGCTCATGTCCAGTTTCAATATGTCAA
CATGCCTGCATTGAAACATCCTGTCCAACTCACTGCTTGTCTATAATACTTATATTTTCTTTATTTGAATACGAAC
ACAAGAAGATTAAATAATAGCATTTCTACTTTAAACAGTGGGCACCATAATTAACATTGGAATTAATAGTAGTAATAA
CGATAGTAATAACAATGATATAGGCTGGGTGCGGAGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCAAGGCGG
GCGGATCATGATGTGAGGAGATCGAGACCATCCTGGCTAACACAGTGAAACCCCGTCTCTACTAAAAATACAAAAA
ATTAGCTGGGCATGGTGGCAGGCACCTGTAGTCTCAGTACTTGGGAGGCTGAGGCAGGAGAATGGCGTGAACCTGG
GATGCAGAGCTTGCAGTGAGCCGAGATCGTGCCACTGCACTCCAACCTGGGCGACAGAGCGAGACTTCATCTCAAAA
AAAAAATTAAATAAATAAATAAATAAATAAATAACGATAAAAGGATATGTGTAGGTTTTTTTTTAAATAGGCTGTAA
CATTAAATAGGCATTGTGATTTTCAAGGATATCATCAAACATCTGGTCTTAAGACATCCCCTATTGAATAGGAAGGGC
TTAAGTTAACTTCTCATGAGCCACAATTTCTGATTATATGTTTGGTGTGTGTAATAGCCACCTCAGTGATGATTT
GATTAGCCTGGACCCTTACATAATCATTGAAGTATACCCATGTTCCCTTATATACTTCTTTAGTGTGAAAGCTCAA
AATTAAGCAAAATAGTCCCTTGATAATGTTTAGATTCTTAACATTTGCTTTCTAAAGCTGGCAAATACTCTCTTCC
CAGTGTCTATGAAGTTAAATAACATGTTGCTTAGTGAGGACTTTAATGTTGCCATGCCATAGGAAGACCTTATTCGAA
ATCCCTTACCTGGGAGAATGTGAGATTATTACCCCCCAACTTGTTAAACACTTTTAGGATTTTAAAGGTGTTTACA
TTTGTATTAGAACAAAATACTATTGAGAAACATTTCTAGAAAAAATATCTTTCCAAATTTAAATCAGTGGTATGT
AATGTAGGAGTCTGATTATAATGATTAATAATACATGGGCTTTGGGCATACTGCCTAGGTGAACTCCTGGTTTTATTG
CATCACTATTAGTATAACCTATGGGAGTTAACCTACGTAAGCCTCAGTTAATTTTTCTCTCAAATTGATCTAATAAT
CGTCTCTCATAGGCTTGTTTTGTATAGATATTTTCACTGTATATAATACTTAGGACAGTGCCTGATATCAGTAAGTC
TCCTTATATGCTATTTTTCTTTCTATTTTAAATATTTATGCAAGAGAACTATTATGCTTTTAACTCAATTAATAA
AATGCCCTTGTATTTTCTCATGTCAAAGGAAATATGCAAGTATTGCATTCACTTCCTAGGTGCCTTTTTGAATTGAG
CTTTGCATGGTTAGTTTGTATAAAAGGTTTCACTGAACTTTCTCATAATGATTTTTTTATTGAACATATGGAATCCATT
AAGTGTAGCAAAAGTCACTATCCACTGAGCTGTGTCCAGGGGCTGACAGTTATGTCTATCTTTGCAAAAAATAAAC
ACATACATAAATGCACTAAGACGTATATTACCTGTCTCATCTCTTAGAGCATTTCCATTTTTCTTTTAAAGTTTTTT

CTTTCAATGGGTTTTTATCTTTGTGAGTACATGGTAGGTGTATATGTCAACGGGGTACATGAGGAAGGTGTATATA
TTGATGGGGTACAAGAGAGGTTTTAAACACAAGCATTCAATATGAAATAGTCACATCATGGAGAATGGGTTATCTATC
CCTTCAAGCATTGTGCTTTGTATTACAAACATTCTAATTATACTCTGTTAGTTATTTTTAAATGTACCATTAAGTT
ATTACTGACTATAGCAACCTATTGTGCTATGAAACAGTAGATCTTATTCTTATTTTTCTAACATCTTAGAACATTT
CCACAAACACTACCTGCTTGTTAAATATACCTATTCTAATCTTCATATAATCAATTACTTTTTCTCTAGAAATGTA
CTATGACACATCCATGGGGAAAATGTAGTAATCTAATTAAGACTATTTCTCTCATTTTTATATTTAAAAGAATGTGC
TCTATCAATTTATTTACTTGTACAGCCGTAGGCAACCTCTAAAATATTTAAAAGTTCTTAAAAGTCAGATATTTTCAGT
TAATATTGTGATTATATAGTTGATTTTGTATGAACATGTTTCATCTACCAGAAAATAAATTATACACACACATTGATATG
GTTAGGCTTTCTGTCCCCACTCAAATCTCATTTTGAATTATAATCCCCGTGTGTCAAGGGAGAGACCAGGTGGAGGC
AATTGGATCTTGAGGGTGGTTTTGCCCATGCTGTTCTCTGATAGTGAATCATGAGATCAGATGGTTTTATAAAGGG
CTCTTCCCCCTTCCCTCTCACTCATTCTCCTTCTTGCCACCTTGTAAGGAGGTTGCCCTTGCTTTCTACTATGCCCT
TTCTACTATGCCCTTACCTTCTACTATGATTGTAAGTTTCTTGAGGTCTCCCCAGCCATGCTGAACATGAGTCAA
TTAAATCCCTTTCTTTATAAATTACCCAGTCTCAGGCAGTTCTTTATTGCACATATATGTGTGTGTATGTGTATGT
GTGTGTGTGTATATGTATGTATATATGTATACATATGTGTGTATATGTATGTATATATGTATGTATATATGTATA
CATATGTGTGTATATGTATGTATATATGTATACATATGTGTGTGTGTATATATGTGTACATATATATATATATAT
ATATATATATATATATATATATGAACAGAGAGAGAGAGAGAGAGAGGGAGGAAGGGAGAGAGGGAGGGAAGCATGGAGA
AAGAGAGAGTAATAGCCTAAATAGAAATAAACTAGCTCCAAGTACAGGTTTCGTCAACACTCTCCTATCATACCCCC
ACCAAAGTTAATGTTAACCCTTGGAGCCCTGTTCTTCTTAGTTGTGGAGTACTTTAGCAAATTTTAAATCTAAT
TATGCCTAATTCAACGACAGTGCTAATTTGAAAGTGTTAGAACTGAAGACCTATAATAAATGAGAGTTACAAAA
CATAAATAGTGAGACAATGATGAATGTAGTGGATGCATGTACGAGGGCTATCATTGTGACAGTAGAGATGATGCTCAA
GGACAGACAATGAGTCTTTCAATGTGTGGAGAATGTGCTGCTGTTACAGTGATGTACAGGAAAGAAACAAAACTGA
GGAAGTATCAGTAAACAAAACACTCAAACATATGAGTATACAGCTAGAATAAAAGCAACAGTACTAGATGACAATAA
GCCAATGTAACTCAGAAAGCAGAAGGTTTTTAAGAATTTGGGGAATACTGTGGCTGATGATACTTATGTCTCAAG
CCACAGATGCCATATGGGCTCTGCGCCAGTTGAATCGGCACCACCTGGCAGTAAGTGGGCAGGTCCACGACTGCCA
GGACATCCCTTCCAACACTTGTGGAGATCACCAGGAAGGGGGAGAGACCTGCCTTGACAGATTTTCAATGTGGCGC
AAACAGGTCTATTTTGAGAAAAGATGTTCAATAGAACATATGTACGCAAGGAAGAAGAGATGATGCTTAGTTCTAAA
GCTCCAAAGAGCTGGCTTACACTCCAACCTTGGGGAAAATGCATCCGGGAAAATGCAAGATTAATCTCATCTTAGCCAT
TCTTTTGAATGGATGGACATGACCCCTTTCTACTTGAAGACAGAAAAACATAACCATATTGATTTTCAAGTTTTCTTCA
TTGGTTTCCATTTAGGATTGTTCTCTCCCATCTTCTTTCTGTGTAGGCATCCCAGTTCCCAAGTGTTCATGAAGCAC
GTATGGCCTTCAGGGGATGTGTCTGTATACATTGTTATCTTATGGATGCACGGTTTTGTCTGCACCTTGGTTCTGAA
TGTCTTTACTCTTGAGCATCTGCCCATGGGTCCCCTTCTCAAGGCCCTCAATTTCTTGAGTTTAACTGCATGGCCC
ATGCAGCTTTTCAAGTAAAGCATCTCTTGCTATGACCAACTCTTTTCTCAGTCAACTCCCACACTCTTTTCAAGGGAC
AGGAAAAATGTAGCCACTTGGCTGGCTGCACTCTGAGGCCTCAAGAAATTTAGTGAATCTGCCTTTGCCCTTCTTGCT
GATGAAATACTGCCACATCAGGCCCCCTCTTCGAAACCTACAAGCATCTAATTTTCTTGCTTCTCTCCCAACTTTC
TTTTTGACTCCCCCATCCAGAGAGTTCTTATGTCTACTGTACTAGGAAAACTCATTCTTAAGGTATGGTTTTCA
AATCATTCTCTGGTCTGGACTTTAGCTACGGTTTTTAAATGAAGAAAACAACCCAGAGCCAAAATATAATGAACTATT
TCCTTCTTCCACAGAGTGGAACCTGCTTTGGGGTTAAAGGGCCAGTGAAACCAATAGAAAAGGATCTCAGGGAACAC
AGATTGAAGAGAGAGAAGAAAAATATGAAGGCATTGTTGGTTCTCTTTTGAAGTTTAAATCTAGTGGGGATTGTAA
GCACACACACATATACACACACACGCTTACACACACACACCAGTGAAGTTATGAAGGATTTTGTCACTCCAACGACC
TTGAATTTGATTATCTAGGTCAGTTGTTACCAAAGTGGAATGTACATGCCCAATAATATGCGTGCTAAACAGTTGGG
GTAGTGAGAAAAAATACTTTTTATTTATCTTGTCTCTAGAAATTAATATTTTGATTGTATATTTATAGTGTATGT
GATGTGTAAGTTGTGTCTACAAAACACTAGTGTCAATGTAATTTAAAATTACATATGTCTGTGAATATATATTTATATA
GGGTACATGCTTAAATGTGTTTACTTCTGAGGTACATGAACATTTTCCCCCAGGCACAGAAAGACAAATACACACA
TGATGTCACTTAAATGTGCAATGTAAGAAAAGTTGAATTTACATAGAGATGTAGAGTAGAATGATGGTTAACAGAGGCT
TGGGAGGTGGAGTGAGGGAATAGAGAGTTACTGTTCAAAGATTACAAAAGTTTCAACTAGACAGAGGGAATACATTTT
GAGATCTATTTCAAGAACATTTTGAAGCCCTCACTCTAAGTAATAGGAAATCATTACTTTAGTTAACATATTTGAAT
ATGAGTTGTGATGTTCTATATCGTTTATTTGGATTCTACTAACCCACACCTAGATTTTTTATGGCATTACCTTTTTAC
TCACTGTGAATATCCTACTCATAGACAGATGCCCTGGGAACTTGGACTTGAGGCACCCAAGAACTGAGACAGTGAGA
TTTGGGGGCACAAGGATCTATGGATAAGTTTCATCTTAGTGATGATAAAATCAATTTGGCATGTTTCACGGACAGTGT
GCATTTTGAAGAGGTAAGACTTGGAAACGGGATATTTTGAAGCCCAAGTGTTCCTCAATAAATAGCTGTATAATTT
GAAGCAAATAATTGATTTTTTGTCTCTTTGTGCCCTCGCTGTAAATGGGAGAAATGTATTCCTTTCTCATCCTT
CTCATGAGGCCATTGAGAGTATCTAATGAGATCAGACTGTGACATAGCATAATAATTCTCATTCTTGAAGGCCTAT
TATACACTTTGCAAGCACTGTATGTGTTGTTTCTACTTCTCTGTTTCGTTTTCTTGGAAATAAATATCCCCCCTCC
TTTACATTGGATTGCCATTATTCACCCCTGTAAGGAAGGCTTCATGGTTCTCATTCTCATCTGAGAAACTTAGGCTC
AGAGAAGATCAGTAACTTATCTAAAACACACACATACACACACAGACATATCTATGCCCATTTATCTTAACCTAGTT
TCTCTATTTCAGGAGTTATCTCTGCTGTCTCTGCTTCTGATTATAATCTGTGTAAAGTGTATCCAAGTGACACGATTAC
AGGGAAATTGTAAGCCCTTTGAGAGCAGAGACTACCTATTGATATCTACATTTTAAATTTGATTTTAGCCAACCTG
TTTATATGCAATGACTAACAGGTTAGTTTGAAGTTGCAATAAATATCCAAATCCTAGACTAAGTAAATTTATTAATG
TAATGATTTAACTTGATTTTTTCAATTGGCATGTTTCCCTGAAGTCGTATGCAAAATGAAAAAAGGATATAG
TGTGTGATTTAGATTGAAATTCAGGAATCCTCCAGGTTACCTTGTGTTTCCAAATAGTTTCAAGTTGCTTAGT
CTGACCAACAAGGTCCTGACACTTGGAACTGTCTATCCCTCTAATTTGACTTTGTCCCTGATGACCTCGCCAGAG
GATACTCTTACCCAGCTATACTGTGTTGCTAGAGTTTCTCTGATATCCCATGCTATTGTTTCTTTGTTCTCTTC
ATAAGGTACCATTTCCACCCGCCAACTCCTGTTTTCTGATGGACTTTTGTTCACCTTACAAGATCATTGCTAAT
GTATTTATTTTGAAGATAAAGAGTGTAGGAAAGGTCACGGGACAAAAGCTGTACACCAGACCTTTCCAGACGAACCT

AGTGATAATCTCCCTAGTCCAACATCATGGCTTAAGGCAGTCGATAGATCCGTCTTAATGTCCCTTTTGAGTTTTCT
TACTATTATTATATGAGGATTTATTTTTGTCTGAATTCCTCCCTAGATTTGCCCTAGAGAGCAATGACTATTTACAG
TTTATTCTCTTTGTATCTCTTATGTTAAGGCCAGACCTTGGCACATATTCTAGCTGATTAGAAGACGTTTGTGTGAA
TGACCAAGTGATTGAACAAATGACCATGTGCTCTGCCACAGTCCGGTCAGTTCTACTTTGGTTTTGGTTATGTGTTTG
CCACATTAAAGTTGTAGCCTGGGAAGTTCAGTTGTGAGATGTCTGCAGAACATGAAAAATTGGAATAATGAGGTTAT
TTCTAAAATTGCTATAATTTAAATAAATAGTGGTTTATTCCATATATGAATATACACTGGAAACAAAGAATTTCTA
GAATACTGGAGATTTCAATGATAACATCATTGAAATTAATAAATAATAGGATTATGCTAGTTACTTTCTAATTTACT
AGAAATTGACCGTGTGCATGGCACGTATAATGAGTATCATGGGATAGTTACAAAAAGTGGTGCTTAGTGAGTTTCTG
TGGAAAACTCTCGGTACCAATAAAACGGAGGATTTCCAGAAATCGATATTCTCAAAGCTTGACAGTATTTATGACAG
GTTACACTTTTGTGTGTCTTTTCGTTTGAATCAATGGAAGGAGGCTATAACTGAAAATTATTGTTTTAGTGATTATAT
CTTTAATAATAAGAGTTTTAAGAATCTATCATTAGAAAATAATTATTCTCAATTTGTAATTTCTCAACATTTGAACAA
ATAAATGCTCTGTGTCTATCAGTTAATCTTGCCCATGAAGATTTAATAAAGCACGCTAGTTTTTACAAATGTGATTT
TAGAGATGGTCATTACTTGGTAAAATATTTTGTGTTAACACTTCCATGAATATGTTCTGTGGGAATATACTGCCTCC
ACATTGCTTGCTCATGAAGACATGATTTTTTCACATCATCTATCAGTATTTTGAGAAAGAGATTGATCCCATATTCT
ATGAGCATTTGAACATTCTCTAGTATTTTGTGTTAATCATTAAACAACCTTGAAGTCTATGTGCTACACTGGTTA
TTTCCCTCTTGACTTTCTTTACAGATAACCTCTATCATAAACAACCTATCTATATTTGTTGTCTCCACATCATGT
TGCCAGCCCTGCTTTAACACACTGCACATTGACTTCTAGCAGCAAAGGCTCATGGGAGGTACTCTCATCAAGGACAC
TGATGGTCCCTCATGTTGCTAAATTTGGTGGGTCTCTACAGTCTTTATCCTAGTTCACCTTATTATGGACCACTGTC
AACTCTGTTCTGCTTAAACACTCTGTTCCCTTGCTTATATGACTCTACACTCTTAACTCCTTTGTGAATTCCTCATC
TGCCCTTCCATTAAAGTATTGACGACATCCTTCATAGTTTTGATCTAGGACCTCTTTTCCCTCTTACTTGACATTATGT
GGGTAATCTTGTCTTTGAACGCAATTACCATTCTTATGTTGATGACCCCTAAGCTATAATTCAGCCCAAATCATT
TTCTGAGGAAGCTACAAGAATACACAAATGTCTAATAGATCTCTATTTAGATGTCCCTCAGGTGCTTCAAGCTTAAA
ATACTCACCTGAGCTCATCACCTCATCTATAAATCTGCTTCTCCTCCCTGGCTCCCTGATTTATTTAATATGACCA
CCATCCACTTAGTTGAATAAAGCAGAAGCCTGGACACCATCTATACCTCCAATTAATCACTAAGTTTGTGTTTAA
TACGTTCTTACATTTTCTCTCTAGAAATGTCTTATTTCCCATCTTTACACCCAAAACAAAAGCTAGATGACCTG
ATCTCCTGCTTAGATTTCAAACACTATCTCTTGCTAGACTCTGGAATTTTCAGTCTTGCTCCTCTCCAATCTATTT
CTACACCTTAGACTCTGGAATTTTCAGTCTTGCTCCTCTCCAATCTATTTCTACACAAAAGCTAGAGTAATTTTTTAA
AAAACAAAAATCTGAATGTGTTTCAATTTTCTGCCTAAAAAGCCTTCAGTAATTTCTTATTTGTTCTTCCAGGGATAGAGT
AACAATTTTACAGACCTAGTTTATTAGCTAGTTCTTTAACCACAAAAGGACTCTCTCACTTGCTTACTCCCCCTAACAC
ACTTCGCCCTAACCTTTGCCATTCTCCTCCCTTTCCCTTTTCCCTTCCAGATGGACTTAAGTCCTTTTACAGATTCTTAAA
TGTTTCTTCTCCAGTCTCTTACATCTCTTTTCCCTGTAACCTCTAAAACTACTTAGCTTACGCAAGGAAAAAGGTC
TGTACAATTTCCCGGAATCAGCGATCCTAACGTTCCCTGTTGTTTTTTTTCGTTGGGACATGAATTCATTACAGTGGC
TCTAAACATCACCACCCCTGCCTATCTCTCCCATCTCTACTTTATCTGAGCTTATCCATACTCTTGAAGACTTACAT
ATTTTTTTTTCTACCAGGAAATCATTACTAGCCTTATTATCCCACTGTCCAAACCAATAAGTCTGATTAGGTATCTGT
ATATATTTAATATTACTATATGTGTTTTTCTAACACTCTAGTAGAGGAGAAGGTGATTTCTTTCTGTTTTTTAGAA
GCCTGTATTTCTGCTATTATAGCTCTTAAGGAACCTCATGCAATTGCCTACTAGAATGTAAGTTACGGTAGGATAA
GAACTGGATCAGTCATATCACACATCCACATATAGGACCTAGCACCATATCTAACACACAGCAGGTACTCAATACAT
TTCTTTCCCAAATAACTAAAGAGTTTTAAACAAACCAAAATGATTAATGAGAAGTAACTGTTTTGGTAATTTCTGTG
TCCTTACTAGAGTCTAAATTGAGTGATTTTTATATCATCAGTTTATACTCCCCCTTTCCCAACCCCAATTTCTTTCTT
TTTAAATTTTTTAAATCAAATATGCCTTAAACTTCAGGATCAGTTGAGTAAATGATGCTTTTGTGCTCTTTTGCA
AAATAATTGTATTTCAGAATTTTGATTTAGATATTATAAACACACCTAAAAATAAGCTTTAGTCTTAAGATGAAGT
GCTTCTTAAACTCCCTAAGATGGGTTGGACTATGGATGAACATGGACAATATCACATTAATTTGTGTACACAGTT
CTAACACAGGGTCTGGCATATAAGAACAAGTCAGTAAATAGTTGTAATGGAATTGAAAATTTAAGTAGCAAAATAA
AGTATTTTGACCTACAAAGCAAGAAATCACATTTTCTTTTGTTCACAGTTCCCTTAGCAAGATAATTAATTTTTTAG
TATTTAAGGATGTTAAATATTTATTTTATGTTCTATTTACTAGGCTTCTTTTTATGAAAATTAATTGGTGAAAATAG
CGTACATATCTTCTTTACCAGAACATTTACATTTTGGGCAGTAACGCTGGCTTTTGTAAAAAAGCAAAATATGTG
TGAAATTTATGTTTGAGTTGATTTCAATGCATTACATTTCCATTTTAAATCTTCTTTGAAATACTCTATTTTTGACA
CCATGAAACTGTATTAGATCTTAGTATGTTAGCAATGTTTTGCAGTTTTAGAGCCATAATTTATTTAATGACCACTT
TCAGCATATACGTTTTCTACAGGAAAAATAATCTCAAGAACATGAAAAGTGAATCTATATTTTGGGTTTTCAAATG
ATACATTTTAGCTAAAATATCATAGTTTTAATTTCTCAGTGAAAAATATAGTGTGGTAATTTATGAAGAGACTCAGT
GTTTAAAAATTATGACTCTATAGTCAAGTTTATGTTTATAGGACATAGTTTATTCAATTACATTTAAATAAATTAAT
TTAGAAAATGTGATCAATGTAACAAATTTTACCTGTCTTTTCTAAAGCTAAATTTGTTGTTTGAAGTGTTTCTTCT
AAAATGCTAATGAACTATCAATTTAATTGTTGAGCTTAGAGTTAGAAACTTAATTTATATTGCCAGAAAATAAGAAAC
AAATGGATCCCAAAAGATTACACATTAGAAAATGTATGCCAGGGAAATGCTTTTGAATGTGTTCAAGTCATGGCTTC
TAACTCGTAACTTATACTTGTGTTATGTCTGGCTTCATTCCCTTAAAGAAAAAGGAATAATAATGCCTTCGGAGAGC
ATCCCAGCTGTAAGAGCTATGCATTGGTGTCTAAAAAAGCTTCTCACTCCTCATACCATCCTGGTCTGGGAATTTAA
AAAATTGTCATCTTTTGATAATCTGTATCACATAGTCTTCTGCATAGTCATATGAGGTTAGAACTGCCCCATAACTT
TTGCAGGGCCTATAGTAAGTGTGCAAATGGTTGCCTGCATGCCACATATTTAATATTTATAAGGTATAAAGTCAACA
GACTATTAAATATATCCTATCTGCTTTTCTTGACAATTATACAATCATAATGATATGGACATCTAGATTTCGATTAG
AATTCTCTCTCTCTCATTTTCTTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT
TTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT
AAATAGTGCAAGCAGTTTATTCCCTGGCAAGGAATTTGGAAAAAAGCTCAAAATAGCAAACCACTTGATACAATAAAAT
AAATTCCTTAGAGTTTTGTACTGGAATGAGGCAGCTTGGTTAGAGCTAACCCTAAGCCTGTTATTTAGGATACATTG
GCTTTTCTTAAAGCTTAAAAAAAATTTTACTGTGTTAATGACATTTAACATGAGATCTATCATCTTAATAAATACTAC

ATGCACAATACATTATTATTGACTCTAGGTAGAAATGTTGGACAGCAGATCTCTAGAGCTAATTCATCCTACTTAACT
GAAATGTAATGTCTGTTGATTAGTAACTTCCTATTTTCGCCCTATCCCCAGCCCCCTGGCAACCACCAGTCCAGTCTTT
GATTTTATGAGTTTGACTGTTTTAGATACCTTATTTCAAGTAAGTGGAATCATGCAGTATTTGTCTGTGTCTGTCTT
GTTTCACCTTAGCGTAATCTTAAGGTCCATCCATATTGTTTCATATTGCAGAAATTCCTTTTATAAAGGCTGAATAGT
ATTCCATTGTGTATATATACCACATTTATCTATTCATCTGCCAATGGGCATTTAGGTTGTTTCTGCATCTTAGCTAT
TGTGAATCTGTTGCCTTTTTTCCCTACCTCCTTTACTCCATCCTGCAGTGTGAGGAACCTGTGCACATAGATCTGG
TCGCCCCATTTCCCACCCACATGTTCAAGTTTTTCCCACTCACCTCATGCAAAGATTTACCCCTTAGCCATACCCAG
TAACTGACTTTGAAACATTTGCCAGGGAGTTGAGGGATTCTGAATGCCAGATCATGGGAGCGGGCTTCTAGTGAG
CATGTTGGCTTGGTCTACAGACTCCTAATCAGAGCTTTGCCTTTGAAAAGCATGGGGCCCAAGGGCAAGGACCCTAC
TTGTTAAGGTCTAAATTTTTTTTTCTGAAATAACCACATCGAGCTTTTATGTGTAGATGGCCTAAATTGGGCTAACCC
AGAGGCAGTGACACTCAAGTAGTTTACATCTAAGCGCTTTCCATGTGCTTCTTTTCCCATTTCTGTTACTTCTTACA
AAATAAAAAATCAGCATCTCAATTACCCTGATTTGATCATTGAGCAATCTAAAAAGTATCAAAATATCACATGTAGC
CCCCATATACATACAACCTGTTATATATCACTATAAAATAAATATATACACATTATATTTAAAAATCAATACTTTAATT
TTACATGTTTAAACAAATCACTAGCATATACATTCCAGATTGAACTTACGAGGGATGTGGAAAAGATTTCAGTGACTAA
ATAACAATAAAGTACTCTAAAAATGAAAATGTGAAATGGAGACAGTATAAATCTAAAAATCATATCACTTATGAAGTA
TTGTTTCAAATAAACAATAAAATATATCTTCAATCAATTTAATTTTATTTTAGTTGTATAAAATCTTTCGGTCAGCA
TTAACCTAATTGGAACACTAAATAGGTACATCTAAAAAATAAATCCCCCCCCAAAAATATGTAGCTCATAAGAGATA
ATGCATTGAACACAGATAAATATTGGCGTTAAAAACAGAACTCTACCACATTTGCAACGAAATGTTTATCTGTTCTTC
CTACTAGAAAATAATAAAATAGTTCTGCATGAGCTTGAAGTCTGAAGTATTAGGTGTACAAAGACCTTTTAGTGAATG
AATGCTAGCTGAAAAGCAAATTTTAAATATGAAAAATTAGCAAGACAAACATTTGAATTTGTGGGAGATGAGTAAAA
CTCCTATAAAAAATGAATTGTTTAGTGTTAAACAGATTGTGTATGAAATATTAATGGCATAATTGCTCTGAGCTCCCCCT
TCCGCTGTTTCCATGTAGATGACTGAATTTCAAACAGAAATATGCCAGGAATGATTACGTGAATGAATATTACTACA
TGAGATTGCTTAAAGAGTATTTCTTCTTTTGCCTTCTTTTACTTTTCGTTATTTTCATTTAGTAGTTAGAAAATACTG
TCTACAAATATGTGAGAACTGCTTAATTTATTTTTGAGACATTAATTAATTCAACTAACTATATTGACTGTGTGAG
AGAGATTCCCTTGGTGAATATGTGGATTTTTGCGGTGTTAAGAACTCTCCTCTGGAGCGCAATGGTATTGCTCTAG
GAATAAAGCATATACCTCAGGCCAGATGAACCAAGTGCAATCTACAGTAACAGGTTCAAGATGACCTCATGACCTA
CTGTGGACTAATAAAAAATCAAGGAGACCTACTGCAAAGGTTTCTGGGAAATTCCTTTTTCTTCTGCTTGAACCTAAGT
AATATACATATGTGATAGTTAGAGCTGCAGCCTTTGTAATACCATGACAGAAAGATAACCTGAAATAAGGCTGACAGA
CACAAGAGGGAGACCTAAGAGTACTGAGAGATATGGAGCAGGACCCCCCTGATTGAACTTCACCTGCAGCCCCCTTCT
GCAGTTTTCAATGACGTGAACCAGTAGAATCCCTTTGTTTACTGTTTTTGATTAAATTTGAGTGCAGCTTTATGTTAT
GAGCAACTAATAGCATCCTCACTGTCACAACTGCCCTCTATACGGCAGGCACCTTTGTGATACTAAAGAAAGCAGTAT
ACAGAGTAGAGCCCAGTGAATAACAGGGCAGATGTTGCAATTAAGTGCCTGTTTAAATTTCTAGCTCTTCCACTAGC
TAACTTGTGACTATCTAAGTAATTTAACCTTCTCTATAATCATACCTATCTTGAAGACTTGTGTGAAGATTTAAAGCA
CAACAGTGCTACTATAAAACAGGTATACAGTAAAGCTTAGCTACTTTTTTATTAGGCCATATGATATCATTTTCAATTA
AAATCTTATAGCCATGCTATAAGGTATTATGATCCTCAATTTATAAATAAGACAGCTCAAGTTTTGGTCAAGTGACT
TTACCAAGGTCATAGAGCTAGAAAATAATGATTCCAAGTTACAAGCCAAACCTCTTCAATGCCAAATTTACATCATC
CCCCATTACTTGAAGTGTAAGATTACATGGACAGAAAATTTTTGACTGTTTGATCACTGCTATCTCCTTATCATCTA
AAACAGTCTCTGGTCCATATTAGGTGTTCAATAAAATATTTGTAGAGTACATAATTTCCCTTCACAGACTCCACAATCT
GGTGAAGGAGGCAGACATGTAAGAGAATTTTTCAGGATTCACAGTTGATGCTGTAACAGAGCTAAATATAATGAA
TGGAGGAGGAATGAATAAGTTTTGTCTGGGAGCAATGCTATGGCTATTGAAATAAGTCTTGCTCATGCTTTGATTGAA
ATGGTGGATATAGATCACACAACAAATAACAATTAGATAACAGCTTGTGAGGAGAAAGCGAGGATCAGTGTGTTGCCA
TAAACATTTCTCATAGCTAATGTCAAGGTGTTGATTCTCAACATTTTATATCTTTGACTTTGATTTTCTCTCTGTTT
TATTTTTTAACTCCATTCTCAAGAAGTCTGCACATAAAGAGTTTCAACATCTAGCACTTCATAACTCCGCTCATCTCCT
CTCAGGCTTAGAGCAAATTTCTGAGACGTGGATTATCGTCGAGTGATTCTTCTCCTGGCATTATCTCTGAGACCAG
GATCTGGTTGCTAAGCATGTAGACATAGAAATGCATTTCTTCATTGAACCCCATAGGTTCAAACCTAGTGGATAATGA
GCACAATGTCAATGTGATTATTTGTAATGGGGGAAAAGTTACCGGAGAATATTACACGACCATCCACATAGACTAAC
ATTTTCTCATGACTAAGTTTACTTAGCAAAAACAAATTAAAAAACAGAAAGTTTGTGTTAGCAGCACAGAATTGAAGGAA
GACAACCAGATGGTTATGAGGAAGATTTCATCCAACTATGCCAGAACTGAAAGAAATTAAGTTTCATTTCAGTACAAGA
ATTGTCTAGAATAAGAGAATCCATTTTGTGTCAGCACTTCCCAAGTTCTTGTTAATGCTACCTTAAGTTCAATTTCAA
ACCAGGCAGCATTTATTACGTGTTGTGCTGGGTCTAGGAGGACCGCGTTTTAAGAACTTACTGTGATCTTCTAGAT
CAAGTTTTTATTTCAATATTTCTACCTCATTTCTGATTCTTAGTGTTCTTATTTCCCAATTTATCCCCTGCAGAA
ATTGAGGCAATAAGATGTCTATCTTATTGCCTATGGTGTGATTATTTATGTTATATTCTGTTTTGTGAAGTTTGAC
CTCTACCTAATTAATTAATTTCAATTTGATCTTGGATTGATTTATTCATAAGTATTCTTTAATATTTTTGTCAT
GAGGTGGTTCAGGTTTTCATCAGACATTAGGAATTAATTTATAAAAAATCTCTAGATTGGTACTTGGAGCTTAAAGGAAT
AAGGTGGTGAACGTTAAATGAGGAGGAAAGAACAGCAGAGCTGGGATAAAATTCATCTCTATCATCTTCCCACCT
GCTTGATCTCTGGCATATAATTTACTATCCGTGAACCTCAGGTTTCTCTTCAGAAAAGCTGCAGGGTTGTTGGGGGA
AATAAGGCAATTCCTGGGCTTCAGTATGTTCAAAACAGAGCATTAATATTATTATAGACTTTTGATGATTTACACAA
TTTTAGCTTTTTTGGCAAGACATATTTACTAGTACTAAGTAAAAGCACGTTGACTTTCTAAAAATGAAAATGTGTATGT
GAGGATGAAGAAAAAGAAAGTGTGTTTGTGATAATATAGCATTATAACACTGCACAAAAAATGTTATATATGCA
GAGACTTCCACTCACTTGTATGATGCCGATTTGGGATCTCATTAATAAGACACTTCCCTCAGACACTTCCCTTTGTGT
TCAATAAATTTCAATTTTCTCCTTTCTCCTTCAGTTTCACTTCAAGAAAGGACGGCAGCAACTTTCTTGTGTTGCCAAACCTG
ACAAATGTTTTTTAGTGCTGATTATACTCGAGCATTCTGTAGCAAAATGCTGTGGGTGAAAATGCCTTCTCTTAA
GGGAATTTAGCTTCTGTAGTACCAGAATCTCCTTGTGTAATGAACATGTACTGCCCTAAGTCTTAGTAATCCCTCCTT
TTTGAGCCCATTTTCTGGCATCTCTCCCTTTAATATTCCTCAAAAAAGTTGGATTTTTCTCTGGACTTTTCATATTACA

127

TAAGTGCAGTTTTATTGACAGAGTGAGACATACACGTCGATATTGTGACTAGCTGCATGTCTTCTATTATTTAGAGG
TCTCACTCAAATGTAGATTATCAAATCTGTAGTGAAGAGGGTAGAACAGCAGAACTAATGCTGGTTTCCTTCTCT
AGCATTATTTGATGATAAACTAAGATGATAATACCCCCAGGTCTTAGATACCTGCAGTAGGACAGGCACCCTACAT
TTAATGCTCCTAGGAATCCTTCAAAGTGATAGCATAGTTATTATACAGTAATTGAGAAAACGTATGTTTCATAAGTTA
GAAATTTTTCCGAAGTTGCAAAGAAAGTGAATGGAAGAATTATACCAAGTTCTGGCCGGGCGCAGTAGCTCATGCCT
GTAATCTCAGCGCTTCAGGAGGCCGAGGCGGGCGGATCATGAGGTCAAGAGATTGAGACCATCTGGCCAACATGGT
GAGACCCCGTCTTTACTAAAAATAGTAAATTAGCTGGGCGTGGTGGCAGCACCTGTAATCTCAGCTACTCGGGAG
GCTGAGGTAGGAGAATCACTTGAACCCGGGAGGCGGAGTTTGAGTGAGCCGAGATCGTGCCATTGCACCTCCAGCCT
GGGCGACAAGAGCAAACTCCGTCTCAGAAGAAAAAAGAGGATTATACCGAGTTCTCTTTGATT
CCAAGCCCCAAACAAATCCTTTTTTGCATATATGACATTGTTTCCCTGTTTGCATTCCCCATTCTGTGTATCACACA
TCCTGTGGCCTGATCAAAATTCATTTTCAGATTCTGAATTTATTTTCCATTGAATCTATATAAACTATAAAGACAGA
AGATATATGTATGTGTGTATACCCACGTTTCTCTCCAGTGTCAACTGATAAAAAATAGATTTCAAAGTCTCAATAAC
CTTTAATTCCCTTTTTCTCTTAAAAATCTTTAGAACTTGACATGACATTCTGACTCTAGCAGATTTTAGAAAACA
GAGAGGCCATTAGATATTCATACCTTACTATTGAGATGAAGTATTCAATGCTAAATTATGTAATTTATCTGCTTTGC
AAATTGTATGGTCAGATTGAGTTCCACAAAGGAGAGATAATTTTTAATATAGGCATTCTGTAGCTTCCCTAATTATT
GAATTAGTTTAGAGCAAAATCCTTAAATTGTATCGTTGCTATGCTCAAATTTTGTATACTTGTCCACGTAGGCTATA
TTAAGATTTTCATTGAATTTTGGTTTCTTCTCAGTGATAATCAATATATCAACTCACCCTCAGATTTGCCTTTGG
GAAAATCCAGGCCCTTTTCTGGATTTTGTAGAGCAGATTTAAAAAAGTGATTCTGTATATGTGTTGAAATTAACCA
CATCTCATTGCTTTTGAATGATTGAGGTAATGTATACCTACTACTTTAAAAAATGACTTACTTAGAAGGTGTCCA
TAGTTTTATAAGTTCCATTGAACTGGTTTATATTGTATTTAGAAAAGGAAAACTACTCCTTTTATCCTTAAGGGTGAA
AACCTGGATTTTATTATACAATTAACACATATTTATTTTTTATTATGAAATATATCACAAATATAAACGTTTACAGGG
AGTGTTTAAAGTGGTGTGTCCAATGGAAATATAATGTGAGTCAAATACGTAGTTTTCAATTTTCTACTAGCCATAT
TAGAAAAAGAAACAGAGAAATTAATGTAATAGGATACTTTATTTAGCCTAGTATATCCAAATCACAAATATTTAAAT
ATGTAATCAATATAAAAAATTACTAATTATGTATTTAACCTTTTTCTTTAGTAAGTCTCTGAAATCTAGTGTATATTT
TACATTTATGGCATTGCAATTTGCATTAGTCACATTTGAATTTGTTCAATAGCCACAGGTGGCTAATGGCTACCGT
GTTGGACAGCACAGGTTTAAAGAATAATATGAACATCTGTGTTCCAACATTCTGAGTTTCAAATAAGAAGAACACCA
TCAGTATTTTTGGGAGAAGCTCCCTATGTTACCCCTTGCTAATCACCTTCTTCCCCCAGAGCCAAAAGTAACCATT
ATCTTGAATTTCTAGTAAACAATGCTCATTTTTTAAAAAACGTATGTTCAACACCTGTATTTGTATCTTTAAAGAGT
AGCTAGTTTTAGTTTGCTGGATTTGAACTTTATATTAAGGGAACCAACCCCATCTCTAATCTTCTGTGAATTTCTT
TTCTCTCAATACTATGTTTTACATATTTACGTTTCAATGTGCAACTCATTGTATGTATATAACACAATGTATATA
TTTTACATGCGTATGGACATTTGGGTTGTTTTATGTTTTGTTTATCACAAACCACAACACACATGTGTTCTTGTA
TATGTTTTATAGTGCATGTTTAAAAATTTCTCAACAGTATTCGCTAGTAGTATTGTCAGGTCATAGGGTATGCACAC
ATAAATAGAAATGATTGATTAGCTGCAATTTGTAGTGCACACATATTTGCTATGTAAGTGATCCATGTTTAAAGACTT
TAACTGAATTTAAAAAATATTTTATTGGAGCCAATCTAAATGAGCTAAGGGTTTGTATTGTTTACATAAGCAAAGAT
TACACTTACTGGGTCAATTCGGTTGATTAACCTTTGGATATATAAAAAATATAGCTAGTTGTTAAATAGATATAATTA
TTAATTGGCATTACTTTTTGTTTGTATATAAAAAATTTCAAAATATCCATGACTTAAGCAAGGTAAACACCCACTGGGT
GGCTTAAGCAACAGAAATGTATTTCTTGAGTTCCGGAAGTTGAACGTCTAAGATTAAAGGTGATGACAGGGTTGGTT
TCTGGTGAGTCTCCCCCATTTGGCTTGACAGATAGCCGCTTCTCCTTCATGACCTTTCTCTGTGTATGTGCATCCC
TTGTAGCTGTTCTTCTTTTATGAGGACATTAGACTTATTGGATTAAAGGTCTACCCATATGAACCTATTTAACCTT
AATTACCCCTTTAAAGGCCCTACCTCCACTTGACAGGGGTTAAAACTTCAACATATGAATGGGGTTGAGGAGACCTAC
TTCAGTCCATAACAGTTTCTATATTCTGAAGATGGTCTTTAATTAACATAACAGTTAATGTTACTTTACTTGGGAATG
TCTTTTGGATGGGGATAAGCTGATGATATGAGAAGGGTTGGTGAATTTCTCATAAGTGTGAAATTTAGTGGCCG
GCCAGCATGATTTTCAATCAAAATACGCTTTGGGACAAGTAGTTGAATCACTACGAGAGGTTTAAAGAAAGCAA
GTTGTAATTGCAACTTTTAAATGAAAGAAAGACAGGCTTTGTGTATGTGCCAGCAAGACTGATAACTGGCTTTAACG
TAGATAGTAAGGCAGCAGATTCAATCCACTGATCGTGATCTACTAGTGAATTTCAAAGCCTTATGCAATAGAACTAC
AAACCTTTCTTGGCCACCTTGACAGGTGGATCCATAGGCAAAAATGAACATTTGCAAAAAAGCCGCTATGTTTCAGA
ATTTGTGCTAGGGCTTTAATATCTATAATTTCTCCAAATCCTCACAAATTAAGAATTAATCAACTTAGCCCCATGA
ATAGGGTGAAAATTTCTGAGATTTAACAACATAAAATAAGTTATCTGAAGACAGACAAATAGAAAGAGTTGAGATATT
CTATTTGAATGTAAAATTTTCAAAAAGTAGAATGACAGCGTCAGGAATTACAGTCTCAGTGTGTAACACAAGACTTA
GGAACAAATTTGCTGCATGTAATTTTATTGAGATGGGACAAAGTACAGCATACTAAGGAAGTTTTAGAACAAATAA
GATAATTATTTTACGAGCTTTGAAACATGTGTAAGAAAGATACGAATAAAAGTATAATCACATTTGACTAAAACATG
AATACCTTAAACCTGAAAAGCACTGAGATTATCATTATATAATTTTGAAATTTTTAAACCACAATGCTTTGGGAGTG
CACTGTAATATTTTAGAATTGGAATTTTAACTTACTGGCTTAAAAAGTAATGTACTTTGTTTTAAATTCAAAGATTA
TCTTGTAATTCAGTTTCGATCTATTGAAAAAATTATAAAATTCGGCAAGAAGCCAAAGAAGCAATATGTAGCTC
AAGATAATTAAATTTTCATGTTTGGCTTTAGAAATATATTCGTCTGTACATAGTACATGGTAATCTAGTGAGCCCAG
ACAAGTAGTTTTCTCTTTTTGTCAAAGGGAACAATTTGATGCGTGTTCAAGTTGCTTAAATAAAATTTTGTATGTGC
TTTCTCATCACAAAGAGAACAATATGATTTTTGAAATTTATTTTACTTTATAAAAGAAAAAAGCCCTCACAGAG
AAAAAGAAAAAATGATGATGTCTTTGAAAAACAAAGTTAATACAGCTTTACATATATTTGACCTACATCAGGGTT
AATATTTTTCAAGGTGAAACATTAGATGCTGGAACCTGCAAAAACAGGCAATCCTCCTTTAGATGAAACGGACACTC
TAAGGGTTAATTCATTCACTGAGACCTATTGTGAAGTAAGCCCTACAGAGACTGAAAAAGTTAAATGCAACTCACAA
AAGTTGTAGTAAGAGTCATGATGTTAAATAAAATAAGTACACAATGTATGCTGCAAGTATACCTTAGGCCATGTCTA
GGTGCGGTTGAGAAGTTCAATACAGGTCCAAGATAATAGCTGCTTCTCCTATAGAACATGTCTTCTCATTGGAGGGA
TAAGACCTGTGTCTATGAAACAGGCGTAATTACATAGCTCTGGAACATATATATGCCGAAATAAATGAGACAGTAAGT
GTTATTGTACTATAAAGAATGAAGAAATCATGATGAGAAGTAACAGTTAATGAATGTTTTCTAGAAAGAGTAGGATC

TGAATTGGCCTTAGGTTGTAAGCAGAGTTTTATAGATAGAGTAGTGGTATGTCAGAGTCACCTCTGGGTGCTTAAACAT
ACAAATCCCCAAGTCTCACCCAAATGTGTCTTCAGATGAAAGGAAAAACAAATGACTTGAGCTCCCCCGCAAAGAA
CACGGGTGGTATATTGAGCAGCCAAGGAGTGACCAGAGTGGCAGGCCCATGTTGAGGGACAAAAGAGGACAATTAGA
ATATGATTAATACAAATTTACAGTGGGATGAGTTGTTAGCCTGAGGAGCTTGAATGTGAACCTCTGTGCAAAAAGGA
GTCATTAAATACTTTTGA AAAAGGTGGGATGGGAAGAAAAATGACATTCTCAAGACAATTAGATCGAACAGTATTAAG
CATGCTGACTTATTAAGTTATGCACCTTGAGAGGGTGGAAATGAGGGAAAAAGGGTCTTTATCTGGAGTAAGACAGGAA
GAAGCTAAGCTGTAATTCCTTACTGGACTGTAAATTATGTGCAGATATATTATCTGTCATGTTCTGTGGGCGCATTCTC
AGTACATAGCACTTGAACAGGTACTCGATAAATTGTCAAATGGATGCATGGAGTGATTTCATGCAAAATCTAATA
TTGTATAGTATTAGAAGGGGGAAAAAAGCATGGCATTATGCTAGCAGAAATGTCATTTGGTATTGAGGATGAAACAT
TTTCAACAGTTTGC AAAAGCCATCCACTCAAAACATTCTGTCACTTTCCAATAATTTTGAAGGATGTTCTTTCTACTTC
TACCTTATTACACAATGAGTTGAGTAAGATAAAAGAGTCATGTGCAACAAAAACAGAGGGAGATTTTCTGAAAGGCAC
TACACCAGGAAGTTGTTGTA CTCTTGCTTCATCTTGCCATCTTGATATACTTCTGGCGCTACCTCCAGGCCAGTTC
CTCGTTACATATGTCATTTACTTCCCACATGCTAGACTCACCGAGTTAATCATTTTGCTGCAGTTAACACATTTTAG
CAGAGTGTAGGTTTATGGGTGAGAAGGAAATCAATGATGTTTCAATACAGGGTTCTTTTCCCATCCCCCTTATTTCC
ACTTAGAACTGTCTCTCAAGTCTTAATTTGCCTCTAAACTTTTTTCCCAGCTTACATTCTTTTCTGAAAAATGCAAC
GACGATGCCAATGTTTGTGACCTGAAATACATTGTAAACATTCATAATACTTTGAGCAGAGCTTCCAACTCCCA
TTTGCTCTTTTATCTCCCTTACCTTGCCCCCTTTTTGAAGGCAATGTGATATTTAATCCGTTTCTATTGATGCTTC
AAAATTATTGAAAACTGGTAATTGTATTTTCCCTTACTTATCAGTTGCTAGTTGACAATGAGTGTGTCGAAAA
CAATAACCAATCAAAAAGGTAAAAAGGAGATTCCAGACATATCTGAGAAGAAATTTCTTTGGAAGAAGCCCGTAAATGG
AATGGGAATTCAAAACAAAGCCGTTTCCAAAAAGAAATACTAAATGGTCTCTAAATGCAAAAGGATTGCTCCCCAAGCA
TTTTATGGGAGCATAAAAAGCTCCCAACACATTTTATGACAATACTTCTACTCAATGACTTCTTGTTGTTGACATATT
TGTTGCACTCGACGTTAGTATTTACAGCTTCTTATCCCAAATATTTACTTAACTGAAGCCCTGATGTTTTTAAAAAC
TTTTCATCTGTGTTTAAACAGCCCATTTTACAGAACTTATTTGTTTTCATCAGGCAGATATTTACTGAGAACTTGCAA
GTGCCATATATTCTAAAAATGCTGATGATAAACTGTGAACACAATAGATTCTCATGGTGCTTATGGTCAGGGCTAG
CACACACATTTGTGAAATGATCACTGATGATCAAAAGGCATAAACACTACATTGGAAGAAATACCGAGGGATCCGAA
AGTATCTTTGGAACACTAGCAAGTATAGCAGATGGTGAGGATTGGTGCTTCAAAGAACTCTTGTGGAAGATGTTACG
TATGTACCTTCTCTGTGCCAGGCAGTCTAGGAAGTGCTGGAGAGAAAAAGATGTGCTAGATACCGCCTCTGTCTTA
TGTGCTTGTGCTTTGTGGGGAGGTGAGTAGGATAATCCAGTTCTCATGCAGTGTAATGAGTACCATGACGGAAATG
CACTCCAAGAACTAGGCAGCATGACCAGAGATAGGACATTTGAGAAAAGACTTCACTCGGGTGGTACTATCTTAGTCT
GGGTGCTAAAATAGATGTGATAGATGAGTAAGGGTGACCCGGAAGCAGGAGGGAAAGGGAGGGGCTTTCAGAACAAC
AAGTGCGAGGACATTAAGGTGAAATAGAGTATAATAGTATTCCCAGATCCTTGGGATTGTTCTCCATTAGGCTAAAA
CAAAGGTGTTTTCTCTCTTTAAGATTTCTGACTGCAGATTGCATAACAGAAGGTCATTTAATAGACCTCTAACT
GAAGGAATTCTTGAATTAATCACAACATATCTTCCATGGCCAGAGAAACCATTGCCTCCTTATGTCGACATTACTA
ACAGCACCAGCACCTGCTGCTCAGGCCAGCGGGAGGGTTGGGTGTTGCTGCCTAGGTAATGCTCACCACCTGATGTC
CTGCCATGAGTAGTTTTGCCAAGTTCCACAAAAAAAACCTAGTGTTCTATCAGCATCTAATGAGAATTACAGTCATT
AGTTAAATAAAAGAACTATTAGATAAGGAGCAGAATGAACAACACACAATCCATCAGCTTGGTGAATGGTATCAGAT
GGTTTTCTGGGTGCTGGGCAGCTGTGCATCCAAGTAGACAGGGAGAAATATATATGTCCTTTGCCTTATGTACTTGTTT
CTCTAATCCAAAGGCACAGCAATCCGTGGAAGCTGCTATGATAAGGTGTTTAGTGGTGAAAATGCTTGAAGGCCAG
TAGATTATTAAAGTGATGTTTTTAAAAATGCAGATGGAGAGTAAGTACTTTTTATCTAGAGTAGTAGTTCTCAAAGG
GAGGTCCCGGGATCAGCAGCGTTAGCATCACTTGGGAACCTTAGACCTGCATGGGCCCCATTCCAGATCTCACTTGAA
AACTCTAGGGGGTGTAGCCCCGCAGTCTTTGTTGTGACCAGCTCTCCAGGGGGTTCTGACACTCCAAATGTTCAAGT
TTCAGAACGCTACTACAGGCCATCATGCTCGGCATCACTTGAAGCTTGTAGAACTAGAAAGTCTTGGCCCCACC
CCAAGCCTACTAATCAGAGTTTTTGGGAGTAGGGCCAAGAAAACTGTGGGTTAACAAGGTCTCCAAGTGATTCTTA
TTCATGTCAAAATTTGAAAAGCGTCGATCGAACTGTTGGTTCTCAGCTTTGATTGCGTATCTGAATCACCTGGGGAG
ACAGTTGAGCTATTCCGGGCCAGATCACATCTAGACCAATTGAATCAGAATCTATGGAGGCAGGACCCAGACATCA
GTATTTTAAAATATTTCTTGAATGATCCAGAGTGATAGCTAAGGTTGAGAAACACTGTTCTAGGATTAAAGGATTAA
TGTGTTTGAGAGTATGTTAAGATCTTAGGCAAATCACAAGGGTGTTAAGAACTACCATCTTCGCAAAAGGAGAATGT
GCCTCAGATATTCTGGTACTGCTTTGATTTTACCTTCAGTAGTCTTACCTATTTTGTAGTATGCTTAGTAGTACTAAT
ATGAGGCTTATTACTAATATGTTAAAATTTGTCTTTTAAATTAAGTGGGTCTAAACGTTTTAATCTTTAATCTCTGAC
CCAAGTAGAACTTTTCTAAACATTTTCTAATAAGTCTCCACCTTGTCTTCTGACCTTCACTTATGTTCTTTTCAAGGT
TCTTCGTGTGTTACTAGTAATAGTAATGGCAAGTGTTTATTGAACACTTACTATGTGAAGATTCTAACTGGCTTTTA
ATAATCACATCAGCTCTGGGAGGTAGAAGGTAGGGATCCTCCTTGCTTATCAGGTGAGAAAACCTGTACTATAGAGAA
GTTAGCAACTTTTCCCAGGTCATAATATGTGACAGCTAAAGGGAGCATAATGGTTGGAATAAAATAAATCTACTCTA
GTTGTACCGAAGGCTCATATTTGTCTCACGTACTTGATTTGGTGCAGAGGCCAAGGGGTCAATTTCCAATGCTTGGAT
TCCTGGATATGTAGAGTTGTATTA AAAATGCTAAAAACCTATTATGTATCATACAATCATACATATCACCTAAAGTA
TTATGGAAATGAATCTGTATTATTAAGGGAAAAAGGCCTGTGTGAAGAACAACTGAACTTCATTTTAATTGAAATT
AAATAACATGCATCATACACTAAAAGTGCACGTTATGACCCCATGAATTACTTCAGGTGGCTTTGATTTCATGTTACA
TACACTAACAAATATAAGAAGAGTGATATAATGCTTCTTAATTAACACTAATGGAAGTTTACTATTTAATGCTTCT
TATGTAAGAATGTAAATGTTTTCTGAAATATCAGA ACTTTTCATTAGGAAGCACTTTTAAAAATAGCAAACTGATA
TGCATATGATTTCCATATACATTAATGAACCTGTAAATGATGTTATAAATTATAGAAACCAAGGGGATGTTCAA
ATTAGATATTTGTCTAAATAAATCATGTATGGATTGAACAAATACTCATTGAGAAATAAATGTATTTCTTTTCTTTC
AATTATCTAGGATTCCTTGTTTATCTCTTCAGAAGCAAAATGTCTTCTGTCCGTTTTTATTTCCAGTTAAACATTCTT
CAGATTATGTAAATAAGTTAACTTCCAATCCTCTTATTTCTGTTTATCTCACCACCTCTTCTAATTTAGACGTGATCA
ATATCTTATCTTTTTGCATTTTCATAGACATCAGGATCCAGAATAATTGAGTGAGCTCAAAACAACATGGCAAGAAT

130

CACCTCTTACCTCCTATAGCACTTATTTTTTCATGCAGCATTTTTTGAGACTTAATTTAAATCTACAGTTTTAAAAAATG
TTTTTCTACCACAGTCTCTTATTCTACTAAAACTTTCAAGTCTATCCATTTTGCTTATACAACCACACCGTTAGGT
CTTTTAGGTCCAAGAATACAAGAGAATGGCAAAGCACGTTGTTTACATCCACACATACTGTGTAAATTCAGGTAATT
TTTTTTAATCCTATGATCCTCAATTACCTCACCTGTAAAAATAGGTACTACTCATACTGCAGAACTCTTGTTGGAATT
AAATAAATGAGTGTATTAAAAATGCTCAACAAGATTTGGCACAAAAATCGGTACTCAGTAAATGCTAATCATTATTCC
CTTTCTCTTCAAAGCTCCACAATTCTGTATTATATCACCCTCTTTATATCATTGCAAAAAATGTATCCTATTCCAA
CTCTTTCCACCTAGCCTCAACATTTACAAACACTCCTGGTGGGAAGGGAAAGCTTTTGAGGAGAGCACATCTATACT
CATTTACTTTCTCAGGGATGCAAGCTGCCCTGCTTACTGAGGGCATATGTTTCATAGTCACACCGGAGCCCACGTGCC
CTTATACTCTCAAATGGGCAGTAGCAAATCATCTTGATCGGTAGTAATGACCTGTCTCTAAATTTTACATGCATCA
GATAATTTCTTTTTTAGTAAGTGTTATCTTACATATATGCCAAAAATATCACCATTATATGGAACACTAGCTGAAAGA
AAAATTATTAGTAGTCTTAATTTTCTAGCTAACATAAAATCTCTCCATTTTCATCATCCATTTAGATTAAAGACTT
TACTGTTAGCTGAATATTAGAGACTTTATTCTGATTTTTTAAATTTATGAGGTTTATAATGTTAAGACTTCAAGGG
TGAGCTGTTTGTGTCAATTTATAATGCGTGACTAGACAGTAACTAGAAAAATGGATTGTTGACTTTACAAGATTTCTCC
CCACCACGTCCCCCAAACCTGTGCTGCTGTGATTTGGCCTGAAATCTTTACTTCTAGTCAATCTTTGGACCTAAA
GCCTACCAGCTTTTAGCATCTTTAAGATTGACGTGTCTCTGGGAGACCAATAGATGCTAAACCAAATTTTCGTATGC
ACTTGGCAATATAGGATAATAACAACCATACTCCCTGCAATTGTTTCCTAACACAGATGTAACAAATTACCACAAGC
TGGGTGGCTTAATAGACATTTATTCTCTCAAAATCTGGAAGCTAGGTGTCCAAAATCAAGGTCAATTATCCCTCTG
AAGGCTCTGGGAAGAATTCTTCTTGCCCTCTTCCAGCTTCTGGTAGCCCCAGGTGTTCTTGATTTCAGCAGCAC
AAGTTCAACATCTGCTCCTGACCTCACATAACCTCTTCTTTGTGTGCTTTTCTGTGTCCACTCTTTCTTTATTAT
TATTATTATTATTATTATTATTATTATTATACTTTAAGTTTTAGGGTACATGTGCACAATGTGCAGGTTAGTTACAT
ATGTATGCATGTGCCATGCTGGTGTGCTGCACCCATTAGCTCATCATTTAGCATTAGGTATATCTCCTAATGCTATC
CCTCCCCCCTCCCCCACCCCAACAGTCCCCAGAGTGTGATGTTCCCATTCCTGTGTCCATGTGTTCTCATTGT
TCAATTTCCACCTGTGAGTGAGAGTATGCAGTGTGTTGGTTTTTGTCTTGCGATAGTTTACTGAGAATGATGATTT
CCAATTTTCATCCATGTCTCTACAAAGAACATGAACATCATCATTTTTTTATGGCTGCATAGTATTCATGGTGTATAT
GTGCCACATTTTCTTAATCCAGTCTATCATTTGTGGACATTTGGGTTGGTTCCAAGTCTTTGCTATTGTGAATGTG
CCGCAAAAGGACACCAAGTCTTTGGATTTAGAGCCCCACCTAAATTCATGGTGATGTCATTTTGAATTTCTTAACATA
TTACATCTTCAAAGACCTTATTTCCAAATCTGGTGACATTCAGGTTTTCAGGGACATGTGACTATTACAGGGGAACT
ATTCATCCCACCACATCCCCCTTGAAAAATCTGGAAAAATGTAGTAATAAAGGCTTCTGATAAAATAGTGTGGAAAGT
ATTCACGGTTATAAATTACTAAAAAGTCTCACTGTGAGCTCTTAATCAAAAAGGCCCTATAAAACATTTATTTGCTTG
ATTAAACTACACATCCGATATTTGGTTTTGGATTTATTATTATTTTTAGACTTGGAATAACTATTTTATGTGAAA
TAGATTCCATAACTGAAGCAGCATACCTCTCAATTTCCCAACATTTATTTTATTATTTTTGTCTTCACACTACTTA
ATAACTGAGGAAAAATCATTTAGACCAAAGTTCACCTTGGTTGACACCATCCAGACAGCTACAGGAAATAACAATGG
AAACTAAATCTCTAAGAAAAAGAGTCTTTCATGTGAAATATTGCAGAGTTGATTCTAGATATATAGCTGTTGGAAGA
ATGGATACTATTACATAGATATGGCAGAGTGGTATCCAGCACCTTTCAACAAAGATCTTTCAGAGTCAGTCTTATTA
TGTCTGGAGAATTTACCCAGGGCTTAGGTGCTTTTACTGACAATCTAACCACCTGCACCCACCCACCGTCTAAAGC
TAAAGTTTTATTGGAAGACTTAGGAAATCAGTCTTCGGAATGTTTCTGAGACTGGTACACCCACCACCTTCATTAAAGT
GCTTCACCTTCACTTCATTAGACAAGAAGTAAAAATACTTGTGAGGAAATTAATTTATAGTACCATGTATATGGGTATCT
TATTTAATACTACTTAATGATGGTACTACAAGTTATATAAAATGGAGAAATAAGTCATCAAGTTTGACAATAATGAT
ATTTGATATTATCATTATCTTTTTTATTCGTTCCACAGAAAGTACTCTGTTATTGGTTTAGAAAAATGATATTTGAT
ATAATAAAGAAGGAAAAGGTGGTAATATTCTTTATTTTTTGTATCTTTATACCCAGCTCTTTTACCAATCTCCCC
ATCTCTGTAGTTCTCTCTGGTGTCCCAGGCAGTGAACATTTCCAGTGGTTAGGGAACATCTCATTGAGTAAGTT
ACATCAATATTTCTTACATTTTCAGGACAACAGGAACATGCCAAATCCTAGCCCATTTGTTCAACTCTCAAGCCTTA
TTATCTTAATAACACATCCATCCCAAGAAAGAAATTCATCAAGATCAGAGAGGAATACGTATAATTTTTTATAGTACA
GTATTTAAATGAAACAGCTTTTGGCCCGCGTGGTCTCAGTGGGCTCAAGGGGGAATTCAGGATGCTAGCTCATCT
CACACCAAGTTTTAATAAAGGGTGTCTTATAAAAAAGCTAATTTCTTGCTGGTAAATTGCTTTTTTAAGTAATCCTTGCT
GTTGCAAGAGACCCATTATAGCGCTGACACTGGGAGCCATGTTGGAAAGGCTAGATATGCTCTGGGAGATAAGGTA
AGATCCAGGTGGAATCTTCTCTTTACAGAATGACAATGTATATAGCTAATATTGTCCTTTGAGGCTAGTTTGATGC
AGTTGCTGGTATGGCACTGCTCAGCAGCCTGCTGCAGATAAAGATGAGTGATGATGCCCTAGATTTTAAATGGAACCT
TTAGAGTGATGCAGCAGTGGGGTGCAGTCTTCAGCAAAAGAAAAACGAGCTGACTTGCCAGGCATGAGAGATCATCAA
GAAAGATAAAGAAATAGGACATCCACTCTAGGTTAGGCAAGGCTTTTTAGAGGATATTATGGAATGAGCAAGAACC
AATTTAATTTTTTATAATGCCACTCCATTTAACTTTAAAAATACAAGGTCAAGGTACTGTGTTTTTTCATAATGATTAAA
GATTTGGAGCACTCTTCTGTTGAAACATACTGCATCTGTTTGGCAGAAAAAAAAGTGACAAAGAATAAACTGGG
ATCAGAGAACAACAAAAACATATTCTGTCACTTGCCTAACACAAGTTAAAAAGCAAAGGAAAAAGAGACAACCTCTGA
TGGACATGTTTCATCCTTATCCCAACAGAAAGGATTTATTTACCTAAGGTCCCTATTATTTCAAGTTACTTTGATCCCAG
GATGGTAACATAAAATGTACATTTTAAAAATAAAATGGAAGTATAAGATCAATAAAAAACCACATATCTGTGGATAAAA
CAGCAGATTCAATCTTGTGGCTGAAAGTTTGCTTTAACCCAACATTTGGTAAACTATTCACTCTGTAATTTATTAAA
AGACATACTGTTATTATAAACTATCTCAGTTTGCATCTTGTGGTTCTGTCAAAATTTTCATCCTGCTAATTTCTCAA
CTTGTAATATCTCTGATATACATGATTAATCTATTTTAGGAATAAAAAACAAAACTACCTTTATCTTACGCATTTCTA
GGAAGTGTTTTTTAGATGTAAAGTAGGGGTAATTAGTATAGTGGAAGGATTTTGAACCTGAAGCCAGAACATATG
TCTCTGCCAAAAACATAGGTGTGTGACCTTAAATAAGTTACTAGCTTCTGAATCTTAGTTTGTGTTAGCTTTTTTCT
ATAAAGTGGACACCTATCCACATCAGATTTTGTGTGCAAAATTAATAAAAAATACTATATTAGAAAGAAACTTTTA
GAAAGAAATTTATAAACTGAAATGTACTATACAAGTTTAAATCATTCTCATTATTTTCTTACCCTAAAAATTTTGACC
TTATTTTTCTTAGCAAAATGGCTGAATCTGTAAAAATTTAACCCCCACGCAGCATCTGGATTCAAGAGAACTACGGTCA
TTTCTTTATACAGAATACTAATTATACACATATAGCAAAACACAAGTTTTTTTCCAACACTCTGTGTTTTTTAAAGAT

TCAGTGTGGGCAGAAAGGAATTTTATCAACTATGTTAGGGGAAAAAAGTCTGAAGAAATGAAAATAATGAGAAAAAGC
ACTGTTGATTTAAGTGCAGGAACATAAACTTCAAGGCAAAATGTGAGGCCAACTGAGTTCATATATATCCTCACAAA
ATGATTTAGTTAATTTAAAACTTTTCTAATAAGCAACACAGGTAATCCCAAATTTCTATCTTTTATAGCTCTAAGAG
TCCCCATAATTTATTTCAGCAATTATTTACCACCCACTTATTATAAGAAAAAGCCCTGGGATAAGTCTTGAGAAGAAAC
TAACAAAAACAAAACCTTGATTGTTTGTCTCTCAAAAAGCTGGGTCTAAAAATAGGCAAGGTAAGATTTTGTGTTTGAGGA
GCCCCGATTTTTCAGCACTGTCCATTGTAACATTAATAATAGTTTGCCTCACTCTGTGGGTGTATTTGCCT
AGGGTGCTAAAATTGCTTAAAACTTTGTATTGCTTAACTAAAAATCACTGAATAGTAAACAGTAGCATTAGAGAT
GGCAGAGACATTAGGTGTCATGCAGTTCAACTGCTTCACCTAGCAGACAAAGACATTAAGTTCCATTTCTTAAATTT
AACTATCTGGTTGAGGATACACAGTAGCAGAGCTAAATCAAGAACCCTCTTGGGGTTAGAGTTTTTGTGTTTATGCATTA
CTTTGTTTTTGAATTA AAAACAGTGCCTGTTTGCTAAGTTAAATTGAAAAATATGCTCTGAAGGAGAAAAACAGCTAT
AAAAATAGACTTAACTTCCAACTATGGATCACAAATAAACTAAAAGAAATAATTTCTGTAGCAATAAACTCCAACACT
TTCCATAGGACCAGAAAGGCTTGAGAAAAGAGGAGAACAAAAAATGCTTTGGGGCTTACCATATATATGGAGAAAGC
TAAATGAATAAACAGTTGAAAGACAGCGAGTTATACTAGTAACAATATTACTGATATCGGAGCTCTCACTTATAAAA
TTGTATATTATGATCATAGTACTAGGTACTTTATATCTGCTTTCTCATTCTCTCCTCACATTAATTCACATGTAGG
ACAGATTACCTCTTCTGTTTCTATCCAGAGGCCTAGAGCTCAGGCCCTCATCGAAGACAGACAGAGCTATCATCCTT
ATTCTAAAAAAAACCTAAGACCCCAGACATAGCTGTGCTACTTATAGACTAGAATGTGAGAGAAAAAGACAAGCTTT
CATCATGGGCTTAACAACTGAAACACTTCTTCAATTTTGAGATTGAGAACTTAGCTAATGCTAGGTGTAAAGATG
ATATGCTACCTTCATAACCTTGGTGAGGAGAAATTAGCATTTCTCTCAGTCTTAGAAGGAGGATGACCATGAAGGTC
TTCATTCTCTTGAGAAGATAATCAAAATGCTTCACTGCCCTGTTAACGGTTTACTCAATATTCACCAAGAAAAGTAGA
TGGGATTATTTTTGCAGACACTTATACGGGTAATTTATTCTGATAAGCAGAGACATAACCTTTAGTGCATAAATTGTT
CCCTTTGTGCTCTTTGTAATAAACATCACCATAGAGAACAAACACGAAGTAATGACATTGAATTAAGACACCATA
GAGGCAACAGCGACTGGAATTTGTGAAAGTAAAGGATAGTGCAAAACAGTTGTGCGTTGCATTCTGCTCTGAAGATT
AACAAAGCTGGGTGAGGCTTTGACCATCATGATGAGCAGGAGATTTTTCTAATGGAAATCCCCAATCAAGTTCTTGCT
GCACCCAGAAAGCAACGGCTTACAGAAATCTTACATTTCTTTGCACATACCAAATGCTTGGCATATTCTATCACAA
GGTTTACTTTCCAGGAATGTGATCAAGAAATCATGATCCTAATTCCTAGTTAACCTCAAGTTTCTCAGAACAGT
CAGTGATCATCTGTCAACTTTTGTGCAATGTGAAATCAGAATTGGTCACACGTTTTTCCGGCCACTGTTTTTAGATT
CATATAATATTAGTGAAATCATGTGCACTGGTATAGCCATGAATTTATACTTCATGAATAGGCACCTCAATAAATAG
TGGATTAAATCGACCGATTTGATTTTTACCTCCAATAATTTCAAAAAATATCATTGAAGACAAGGTTGTTGAAGCTGT
CACTTTTCTTGCTGAACCTTTGTTGTGCCAGGAGGAACAGATGGTAAAAATCAAAAGTGATTAGAGAATCAGTGGGGT
GGGGGTGAGATTGGAGGGGAGAGGTCTTCCAGTGAGACCCGCTAGCGTCTTCCCTGAGCAGTATGTTAACCCAAGA
CAATTTTAGAAATCTGTGCCCTAAGTTGCTTGACATCCAAAGCACACTTGATGCATCCTACATTTCTAAATATTTT
TATTGTTGTTTCTCGGTAGTAATCATCTGGTTAGTCACTCTAAAAGTCAAGGATGAAATTTTAAATGCAATAAA
AGTGCTACTTTCTCTCTTTCCAATTCCTTTTTGTTTTATTGAGGTATAATTTACATGCACAAAAAATCGCCTTTT
TAAAGTGATACAGTTTGATGAGTTTTGACAAACATATGCAGTCTTACAACCACGTCCGTGATCAGAATAGGAAATATT
TTTATCACTTCAAAAAGTTTTCTTGTACTCCCGTTGCAGTCAGTCTCTGCCCCACCCAGCCCTGGAAACCCTG
ATAGGTAAAAGCACTTTTAACTGAAAGGTATTTAATGTATGGCAGTGTGAGTGGTAATAATAACAAGATTTATTCA
TTGGTTCACTGTATTTTTGAGCACTTATATGTGCCCGTTGTATGCAACCCATTATGCTCAACCCCTGCCCTCCTCAC
CAGGGATAAACTAGTGGCAGAGATAGACAAAGAAGCCGTCTCTATCACCCCTATCTTATAGAACATTTCTCAATG
TTAGAAATGCAGTATAATGTGGCCATTGAGAACTGAAATGTGCTTAGTGGGAATGAAGAACTGAAGTTTTAACTTT
ATTTAATTTCAATTAATTTAAATTTATATAGCCACATGTGGCTAATGACTATCCCACTGGAAAGTACAGCTTCTATA
CAATATGATAATATGATACATTATAACGCAGGAGTTTAAACCAAGTGCTAAAGCTTTACTATCACCAGGGTCACTGGT
GTTATGTGAAAAGAACTTACAATAGAAAAATAAATCCTTTAAATAGTCACAGACCTGAGAAAGTTTCTCTCAA
GGGAACACACACTTGGCTCATTCAAAGGAGGTTAAAACTAGCAATTAAGGTAATTTTCATGAAGCTTTCTCTTGATT
TCTCATGCTTATTGTATACATAAAATAGGCAATTTTCGATGGGACCTAATAAATCACTGTTTTTTATTTGAACATTTT
AACAAAATTATCAAAACAGCATTGCATTTATGTTCAACCTATTTGTTCTGAGAAAGACAACGATTAAGTAGAAGTCAT
CAAAGTTACCAGAACAATTTTTGTTCTTATGTTTTAGAAGGCATTGAAGGTGTTTTAAATGTACACTTATAGAGTCA
GAGTACTATGCAACTGTGGCCCTTATAGTTTATCCGTGATGCATCTAAAGCCATTGTTACATCTGTTTCTAATTGTG
CATGGATTGTCCAAGATACACAATTGGAAATTCATTTTATTTATCAATTTGAAGAGGTTTACCCCATGTGGTCACT
ATGATCACTATGGAGTCACATTAATTTGAGAAGTCTCCAGAAGTTGCAGTATTTATTTAAATTTCTAATTTCTTCA
GAGGAACAAATTTCTCATTTCTGGATTCTGAATCCTCATTAGCCATAAGGTTGTTGTAAGAATTTGCAGCTAATAGG
AACACATCCTGGGGAGAGACCAGTTGAAAAGTAACCTTGTTCTGAGTGAAATTATACAGAGACAGTTTCTACTTCAG
GTGGTGTGCTAATGAAGCTATCATGGTAATTTTAGCCCATATGATCCCTAAACGACTTCAGAACCACTTTTTCATCC
ACTAAGAACCCACTTCAACCACTGCCACGTTCACTACCACAGTATAATATGGAACACCCTCTGGAATTCAGTAAGTA
ACTTCTTAACTCATTGGCTATAGAGCTTTGCTTTGTAAATTTCTTTCTTTTGCAGTAAAAGAGATTGTTTCAAAGT
AATCCAATTAGTCCCTAGGCATGTCTAGAAAAGGTAGAGTCAACAACAGTAAGGTAATAGTCTTATAAGATATGTAA
GAAATTATCAGTCATTTACTTTAAAAATAATTTGTACACTTTTCTTTTATATGGTTCTTCTATGTTGAAGCCAGTGG
TCATCCAGTGATTAAGATTAGCCAACTCAAAAGGCTAAAACTAAATTCAAATGGTATTATTTTGTCTTAATTTTAT
GCAATGCTATGTATTTAAATTTTCATGAAAGTTTCGTATGGCATTGCTATCAATTTCACTCAGGATAAATTTCCCGTG
AAATATCCACAATTTTCACTGTACGTTGGGTACAGGTAAGGAAACACCCTTAAGAGCTTATCCAGTTATTAGCTG
GTATTATAAATTTCAAGTAATTTCAATGATTAATAAACAAGTTACTTTAAATGGGAAAGTATGAGTCAAGAGTTA
GTACAAAGGAGAATCTTAAAGATGAACATCAAGAATCTTACTATTGATTGTTGTTGGTGCTTTTGCTTGCACTTCTC
CAAATTGACTTGACGTTTTTAAATTTGTACTGATAATCATCAGAGTCAAATCTGCTTTTAGGCAAAAAGTATCCGCTA
GTTATTCCCTACTATGAAAGTGATGAGATGAATTGATCATGTCTCCAGTGTATGGATGGATGTCTTTGAGGAAGAC
CTACTGACCTTATGTTTATCTTCTGTGACATGGTGTGACTATGTGGAGAGACAGTGTCTATTTGCTAAATACCTTTGT

TTTTCAAATAAAAAGATTTTCACAGATTATGCATTGTAGAAATTTATAAGTATTCTTTTATGTCTTTGAATGTGCCAAT
ACAATTTTTTATGAAGTTGGAACATTTTTATCTATTTTAAATGAAATTTGTAAGCCTTCTGTGAATTTCTTTTATTAATTT
TATTCTGAAGAAAATCTGACCAGGTTAGGGAAATCAGGTCAGGTTACGACGTGATCCCAGTGGAAGGCTGAACGTGT
GGACTGTGATTTAAATAGGGAAAGAGGTACTGAAGTGTTGTTTTATTTTTGTTTACAAATCAGCCTTTCTAACTAT
TATGTACTCCCATCCTTCTATCTTTTTCTCCACCAGAACGTATTAACAGGCATGCATATAATTAATGCTTTTCTTGA
GATAATATTAAATTAACCTTCATCTGTGAGGCGTCTGGGCTAAAAAGTACACAGTCAGATCTGGGTAAACATTTGAGT
TGATGTAAATATGCCACACATACTGACAATGCTTACCATTATTTGTGTGAATGAAAAGCAGTGTAATATTGTTTG
TTCTACTAGGGAAGCTCCACATTTTAAATCAAACCTTTGACCGTATTTCTAAAAATGCCAGAGCATCTGGAATTTGTTAA
GGAAGTGTAGTTTTTGTGTTTTTAACTGTTAGGATAGTTGAAATCCAAAGGGTAAAGAAAACCTCAGCTGATTTATAC
GTTTTCTTCTCTTTATTTTAAATGTGATAAAATGTAGTTTTTGTGTCATGGGCTGACAAACAGTGGTAGACTACACTAAC
TCTGCGTTTGTGTTTAACTTTACCCTCTCAAGGCATGGAATGGGAGCTCACTTCAGACCCAGCCATGCTTCACT
GTCCACTGCCTTCTCATGGATATAGTGTGAACATTAATTAGATGAATTCATAAAAGTGCTTTAAGCTCTTTGGAGAA
AGATACTCGCTGCATAATTATTCTTAACTCCCATACGCTCTTATGATATAAACCATTTCTGCCAGGAAATCCTTTTTA
GGGATTATCACTTAAATGAAATTTTCATTATTTAAAGCAGGAAGAATATACATCTACTGACAGACGAAAATGTGCT
TAAGGCGACTGCTTTTAAATAGGCAGAAATCCTGAACATATGGAGCCATCCATGCCTGAAAATACTGAGTAATAATGA
AACTGGTAGCAAATTTGGAATATTAATCATCACATTAAGTTGCAAAGAAAAAATAACAAGCCACATGCCCTTTA
AAAATACGTGCACAAATCTTTATTCTAGAAATATATAACTTTAGGCCATAAAAAAGTACAAAAAGTAAATTTATTTTAT
GGCTCTGAAAGTATCCTTAATTTACTCAGGTGACAACAATTAGTGTTTTAAAGAGTTAGTTTTCAATCTTAGCTACAA
GTTGGAATTACTCTGGAAGCTCTAAAAAACAACAAAAAATAGAGATGCCTAGTTCCCACCTGCAGAAAT
TCTGATTTGATTTTTCTGGTGCGAGACCTGAGAATAGGAATTTTTTAAAGCTTCCCTAGTGATTCTAGTGTGCCAC
CTAGGTTGCCTTAAGGTAAACCTCATATTATGCAGAACCTAGCAATCACCTATCCTGATTTTATAGACGAAGATCAT
AAGACCCAAGAGGGCAAATTTGATTTATTCAAGATTGAATATACAAATGATAGAAGATTACATAAGATGCAGTATAC
AGAGTGGCTTGTGGATTCTTGCCAATGCAGGCAGCAGAATTTCTTTAGGGTTACCCAGTTCAGGCACCTCTTTGC
AGCAGCACTTGACTAAGGTTCTTCTGATTGGATCATTATATGGGCAAAAAGAAAAGCTTAATTGAAAAGAGCTGAA
CCCACATTGTGGAATGGAAGATATACAGTTTACACGTTATAAATGATTATTCATGAAAGCATACTGCCCTTTCC
TCTTCCCTTCCCATAGATGACATCATTGCATTGGTGATTTAGGTTGGTGGTTTCTTGGTTGATCTTGGTTCTGA
CACAGTTTCATCACTTATTATCCTGGCTTATTATCTACTTCTACATTCATTGTTCACTCACTCACTAATTAATTC AAC
ATGGTTTTTATTGTTTTTGACCGGTTATATGCCTGCAACGCTACGTAAGGCTGAGGATATTACAATGAACAGGAAAC
AACCTGAAGTTTAAAGGTATCAAGCCTTTGAGTTACTGTCTTTTATCATAGCTGATATAAAATGAAGCCCCACTTT
TTTTGTTTTCAATTACTGAAAATTCAGTGCTAAAAAATGTGGATTTTTATTCAACTAGATAAAGTACTACAATTAG
GTTTCCACTGACCTTGGCTGTTTTTGTCTCCAGTTGCCATTACATAAATCTGTGCCACTCACAACTTAGGAAGGGTG
TAACATTCTCTGTAATAGTTTGCTTTTGAATAGTGTGTTGGATTCACTACTGTCCTCGCAGTTTGAATAATGACC
ACTGAATAATCAGTGTTTGGAGACTAAATTAGTGCTGCAAAATTCCTCAAATTACCTACTGTTCTTTTCCCTGTCTG
ATGTATCCTCATATTCATATGATTACCCTGAGAAGAAAGATATTGTTGAGAACCCTTTACCTACTCGAAGTTTTG
GTATTTCAAAGATTCACTATTATGTCATGTTGATTACATTAGCACTAATACTATTGGCAGAATTCTAATTCACGTTA
TTTTCTTTTTTTTCCAATTTCTCTCCATGCCTATGTGTTGTCCCTTCGCAGCTATAAAGCCATGGCCGATTTCATGGGT
GCTTTTGTAAAGGCGTTTACAGCAGTCACGTTTGTAGATTTTTGAATGGGACTTAGAGCCCTTTTTTGTCTTTATGTA
TTTCTCTATTTCTCAGCAAAGGAAATGCAGACATGCAAGAAATAGTGATCAAATGTCTGTGTACTATTGTGGGTGT
CATTAAATGGTATAGGGAGAAATAGAAAATAGTTGCAAAGATGCATTTAACAAATAAACGAGGCTTTGAGATTACCA
TGAATGTGGCCCCCTTCTATGAAAAGTAGTTAAACATCCAACCTGCAAAGTTGTACTGGATCAGTTTGACTTTAACCTTT
AGCTAATATGAAAATATGGAATTGTGTGGTGGTGCTCACAAAAAGAAAACCTCATTTTTCTTAATTATCATCAATTA
ACATGTACTGACTACCCATGAGGGAAGTTAATTTGCTCTTGAGTGGAAACCAGTTATTTGCCCTATTATTTCTCCCT
TGCTTATTTCCCTCTCCCTCCCTCCCTTCCATTCAACAAAGAAAATAGATAAAGCAATTTCTGATTAGCCAG
TGAAAGCCTCTAACATAAAATTTCCAAAGATGTGCCATAAATATCCACAAAATGTAAACATTTTCAATTTTGGTTT
GCATTTTCTTTTTTCTTATTATAAAGGTAATAAGTGCTCATTATAGAATTTGAAAAATATAGGAAGTTGCACGGAAG
ACGAATAAAATCAGCCATAATCCTACAAACCTATTGACACTTGTACATATGTTTGTATCTCTAATGCATTCATTAT
GATAATGCATCTTTTCAACCAATAGAGTAATCACTGGTGACTTTCAAATTTGCCTACTCATTTTTCACTCTGTGGAC
TTACTTTACTACCTCTTGCCCTTTTTCAGTAAATGAATAAATATTTAAGTAAGTAAATACAAATGTAATAACTTATG
CGCTCAAGCACACAGATACACACAGAGAGAATTTGGAACCTCGGAAATGCCATCCTCTCCCTAGGGCCGCAAGTGAG
TTGATAAGCACGTAAGGAAGGATAATCAGGGGAGCCTTCTCGTATTGCCAGATGGCTCAAATTCGTATCTCTAC
CAAACAACCTATTTGGAGCTTTGAAGAAATATCCATGACCCCTTTGAATTTCTCAGTTTCTTTGCGGTTCACTTTGAG
AACCAAGTGACAAGTGAATTTCTGACTTGGTCTTTTAAACCTGTTAGCGCAGTTCCATTGAGATTTTGTGGGCACA
AGATTGCAATGAAGAGATCAACAGGGAGAAATTCATTTCCCTATATATGTGCGATTAAATCCGGAGTGCTAAGGGCAG
ATATAAAGCAGGTGCCTACTCCTGTATAACTTTGGAATAAAACCATTTCCAAAGGCTGATGATCCTCAAGTCTTGTTT
TGCAATGACTGATGTATAACTTCAGGCCAATTTTTCTCCAGTTAGTCTGTGTCACTGGGAGTCCATTTCTCGGGG
AGCAGCCCCATGCTTTGTGAGGTGCGGAGCCACAGAAGGTTAATGCGAAAAAGAGGCTCTTGCCAGACTGTTTTT
CAGATGATACGTAGGGTTATTAGTTTGTAGCTCCTTAAGAAGATTTTTCTCACCTGTCTACCACTTATGTTTTATT
CATTGGTGTTAGAGGGTTTCACTGGCGGAAGTAAATATTTAGCGGGGAAGGGACAGCGTTTATGGGAATTTTGCTT
AACCTAATTTTGTATCTTTAGCTCATTCTGATGATCTTGTGTTTTGTCACTGAATTTTGTGTCATACAA
AGGCAAAAATGTTTGTCTGAGCTGTCATCTTATTTTATGATGTTTGTGCACTGAATTTTGTGTCATACAA
CTAACTTATCCAGTTTAAAGTGCTGCAAAATCTCCAGGCAATGTGATGGGCAACTAAGGGATAAAATCAGAGATTT
AAAGGTGCCAGGTTTTCCACGCTTCTAACAGTTGGCGTTTTGGGTGTATACAATCCCTCAGCTTTCTTCTTTAGTTT
ATGGAGTCTTGTGGAGGGAATAGCAGGTTTTTGTAGCTAAAATATCATGCTGTGCGAGTTGGGTCTCTAGTGCATCCTG
AAGAGCTTGCATTATTTACAGAGGCTGGGCTATCATTTTTAAATCCTGATGCTTCAATGCCGTTTATCATTCTTGACA

AAC TCTTCCAGCCCCGTGGTCTGTTTTCTCTGTTTGCTTCCATTTACTTTCTCTGAGCAACCAGCTGAGCAAAGATTT
ACATAACTTTTTGTTTAAACAAACCCCTGTACAGTTCACCTTTTCAGCCAGTATGTAAACACTTTTTGAGACACAGTTAC
ATTTTTCTATTTTAGTCCCAGATTCTGTTTATTTGCTACATTTTTTGTCGCCACATTTTTGCTTTTGTTAAGTCTCT
TACAGATTCACATGAAAAACCAGAAACCGTGGCTGCTCAAAAGTCATTAATAATGAGATTTTTAGCTACTGTTTCTG
CTTGTAATTTCTTCATTTTACATAATACAGTCTCAAAAGGCCACAGAGAATTCAGCCTCGCTTATCTCTGTGTTGCA
GATGATGGCTTCTAGCCTTACCCAATCCCAGTGCAGCTTGCTTGCCATCCAGGAGTCGAATTTGTTTCCATCTGACA
TTAGCGTATTA AAAAGATTGGAGATCAACAAGCAACAATGTTCTTGTAGAAAGGTAATCAAGGTTTAGAGCCTGTGT
GTCATGAGACTCCTAGCATTGAAACCGCTAAGGGGTTGACCACCATTTGTCCCAAGCACCTGTTTAAAGATTCTTTCC
TATGATAAGGGACCTAAAGTGATTAGCATACTGATAAGATTTTCTTAGAATAACCTATTTATTTTCAGTATTATCTT
TCAAATCTTAATTACCATCTTTTCTTTTACCCAGGGTCTTCTTTCTACCTCTACGACACATTTAATTACCTATATTC
CCCAACCTGTACCATATTA AATTTTGAATGGAAGTTTTATAGGGTAATTTATTGGAAGGATGGCCTTGAGTGTCAAT
ATGTTCAATGAATGCCCTATTTTGACAAAGAGATGACTAAATGTTATTGAAATCTTTTTAATCCACCACGCTTCTGC
TTAGATGTAAATGCAAATCTGTTCTTTACATTTGTGATTGAATTGAACTTGAAAAGTACCGCCATATTGATTCTTCT
TGCAAATAAAATATAATTACATTTCCCTAAACTTTCTACACTCTCCCAAGAGATTGGCTGGCTTTGTATTGTAGATT
TTTGGTGATCACAGAGGACAATGCATTATCATAAGACCAATAAGATTTATTTTTACCTTGGTAAAGAATTTTAATTT
ATTTCTAGTTTCATTTTCATTTATATCCATCTCTTCTCACCCTCTGCTCTACAAAAGTATATATGACTATATAAATT
GAAAAAATATCAAGTGCAAAATTACAGAAATAAATAATTAGGTTATTTTAGTGGAGGAAGGTTTGTGTGGGTGGA
GGAGGAGAGGAGTGAGCCAAGAAAAACGAGGGACCATACGTGATCATATTTTTGCAGCTATTTTAAATTGTTTGTGT
ATATACTTTAAATATTATAAAATAAAATTTTAAAGTGCAATGCATATTTGGAGCCAATGATGAGGGATAACTTCAGA
AACGTAGCATCATCATCTAGTGCTTTTCATAGTCTTTCAACATTTCCAGATAGTTTTAATGGCCTGCTCATGGAGGC
AATGCCCTAATTTTAAACATATCTCTTCACAACTCTGATTTCTTGCTTCCCTAACATTAAATGCTTCAAAGCTTCTTT
CACCCTAATTCCTTATCAAGAGGATAAGCCAGTTTATTTCTTTAAGAAAACTAGCTACACAAAACCGTAAGTCATT
CCAACATAAATCCTTCACTATCCTCTCTCTATAGATTTGGTTTTGATTCTCTCTGCTGAAATTCAACCTTCTTTCTT
CAGCTATCCACACGCTCTTACCCTCTAACTTCCCTCAGGAGTGTCTATTAGCTCCCATACAGTGACCACAGTAATAT
AGTAAATCCCCTGCTGTTCTCACTCTCCACTTCTTACACTGCGTTTTAAGTCTCTTCATATCTTTATCACCTTGTA
TCATGCATCGGTTTTCTAGTTGTTTATTTTATGTTGCTTCAATAAATCCATGAGAGCTACTGCCGTATCTTTAG
AACATGGAACAGTGCTTGGAACATAATGGGCATTCTTAAATAGCTGTAGAATAAACTTTCAAAATCAACAATAATG
TATTTGCCAAATCCATTGGCTTCTCTGCCATTTTATCTTGTTCATACCCTGCGATATTCCCTTCTTTTTTTTTT
TTTTTTAAAGTCTGTAAACCTTTAGCTTCTGTAAATATTCCTAGTTTTTTTATTCCTCTCATGTGTCAAATCATCAGT
TGAGGCTTATTGTTTTCTTTCTCACTCTGACCTCACCTTTGTTTACATCTCATCTTCTGGCTTTGGCTATCCTGT
TTTTTATCTCTGTTCCAACCTGTATTTCTAGCCCTACTACCTGGACATGACATGTGGATATCTCCGTATGACCGCAG
TTTCCATATGACTTTGCAAATTCATCCCTGCTCTCCCTCCAAAGTCATCCCCACAATTGACTTCCGTGTTCCCTCCA
ACCTATTAAGGTTCAAACCCACTTTTGCTCCTCCTTTGCAGGCTACACTTTTCTTCTCAGTACCTCTTTTTTTTTCC
AAGTTCTTAGATAAAAGTCATAGTACCTTACGTTGTAATTGCCACTGGTCTGGTCTTTCTGCCTGCTTTCCCTTTCCA
TTTGTAATCACATTATCCATTCCAATCCATTATAATACTGTGATCAGCCATAAAAAAACATTTATCATATCGTTT
GTCTCCTTAAACCTGTAGTAGATCCCCCTCTATTTACAAGATCTGGTATAAAATCACCTTCCCTGATATTCAATGCC
TGTTTTAATATAATCTCAATATTATGCGTCATAAATCCCCCTGTGTTCTTGCACTTTTTATTTCTTATACATCTCAT
CAACCATGTCTTATCAACTCTCAAAACCTGTATTGGTTTTTCAGGAAAACTCATAAATTATCTTTTGTAGACCTTTT
GTTTGTCTATCTTTGAAGATCTCTCTCTGAACTACAATATTTTGCTGTATAATCAATTTGGAATTCATCAGGTATT
GAAATATGACATGTCTTCTATTGTCTTGAACATTAATTA AAACTTTATTTGACTTTTTATATGCTTACATCTTGTTT
CCTCACGGAGTGTTAACTTACTAGAAAGTAATAGTTAATCTTATATTTATTTTAAATTCAGATTTAGTAGCATACTT
TACACTGTGGTAGGATGTGTAACCTGCCTTACACCTTGCTTACGTGAGTTATTAATGTTTTCGTATATTTAATCTGAGG
ATGTACTAGCAATGTTAAAACCTGATCCCGCATGAAATGAGTAATGAACTATTGTTTTAAATGTGTGCTTAACTT
ATTGTACCATTTTCTCATAATCACAGCTCAAGTTAACTTTGTGGTTGTACGTATTTATTTTGTGAAATGCCAACAA
ACTTAGAGCAAGGAAAAATAACAGGTATAATCATACTATAAAGGCAACCTTAACACTAGCATAGTCTCTTAGCTCATA
TGGAATACTACAATAATGTACAGTGACAAAGAGAATATTGTACTTTCTTAGCACACACTTTCTACTACTCTACTGTT
GTGGATAAAAAACAGACATACTTTAGGAGAACTATGTTATTTCCAAATAATGCCTTAAAGGTTACTCCAGGAAAAGG
CATTTACATAAACTATCTAGGAAAAGAACCTTTTAAATAATATAAAGAGCTACCCAAAAGGACTGAAGTGTTTAGT
TGAAAAAAGTAAAAATGTGGAAGACTTTGAAAAATAGTTTCTTGCAGTATATTTTCATCGCTTCCACTTACGTTAT
GAAGACATTAAGCGCTAGTTTATCAAAAACCTATTTTGTACATGTCTTCTAATGACAGAACAAATGTCAACATGATTT
TCATCATTGAGAATGCGTAAAGAAACCTTTGTACAGTTTTTTCTATGAATGTCCCTAAGATTAAAGCAAATTTT
CAACACGAATTAGGCACTCCGAAAGGAGGAGGGGAGGGAGGGAGCAAGTGCTGCAAACTTCTGTTGGGTACTAT
GTTCACTATCTGGGTGATGGAATCAACAGAAAGCCCAAACTCAGCATCACGCAGTATACCCTTGTAACAAACCAACA
CATGTACCCCTGAGTCTACATTA AAAAATAGAGATTAAAAAAGGAAATCAGTATATAATCTAATAAATACCTCTCAA
GCTTTCTCATTTTTTAAATAAAAATTTTAGATTATTTTATAGGAATAAAAATAGGCTCTTCATTGTATATAAGTTTCA
TTCTGAGTTGCAAAAATCCTCTCTTTATGTTTTTTTCCCGTATTAGCATGTTTTTCTCTGTTTTTCCCACTCAA
CTTGGCTGCCACAATCAGAAAGCACAAAGACAATTTTTCTTGCGCTTGTAATCAAACCTTAGCATCAGACAAAA
TAACTGCTCCAGGTCTGTCAAATAGATTCATTTGAGCTTTCTTCATGCATTGAATACGGCAGAAATTTCTGACCTGAA
GAAATCTAGCCTTTTCCAATTTGCTTTAAGAACATTTTGCAATAAATTTAATAATAAAGGAAAAAACACATCA
GGCTAGAATTTGGAACCGATTGTTATTA AAAATCTCAAGTCTATCAAAATTAACCTCAACAAATTACTTAAATTTCTGT
GATGGTTAATTTTCATGTGTCAACTTGGCTGGGCCGAGGGTACCGAGACATTTGGTCAAACATTTATCTGGGTGTGT
TTATGAGGCTGTTTCTGGAGAGATTACATTTGAATCAGTAGAGGGAGCAAAGCCGATTGTTCTCCCTTGTGTGGGT
GGGTCTGATCCAATCAATTGAGGACCTAAGTCCAATCGATTGAAGACCTAATCAAAAAGCCTGATTAAAAGGAACCTC
CTGCCTGATAGCTAAAGCTGGAACACCCATCTTTTCTGCTTTGAGCTTGAATTGAAACCTTGGGTCTTCTTGAGT

135

AGTGTAACAACCTTGCCGATTTTTTTGTACTTTCTACTTTTCATGTCTCGCATATATCTCTTTAATATCTAAGTATTTG
AGTCAGAAAAAGAGCCAGTACCGAATAATGGGAATCTCACTGAAATGTGATAACAATCTGGGGCCTGGTCTGGGACC
TTTATCTGCAGGACAACCTTGACAAAATATTTAGACCCCCAATTCCTCGTCTTTACCCTAGGAATAATAACACATTTT
TCTGACCTCATACTTCACGTGGATCTCAAATGGAACAATCATCTGATAGCACTTTATGAAGTATATGAAAGCAATAA
ATTATCACAATAAGATAATTGCAATTATTTCTTTGGCATAGTATTAGTGATGTCTTTATCTGTCTGACAAAATCAACA
TTTCTGTATGGTAACTGCCTTTCTTTGTTTTAACAGAAGATCATGCCAGAAAAGATGAGTAGGTAGATACTTAACTT
GTTGTTCCCTGAATCTGGAATGTATTGCAGATGTCCCAGACTGATCTTTGTTCTTTTTTTTCCTTACAAATTTCTTTT
CACATTGACAGTGTGATATTTCTTTAAATGTGCAATACATAGCTAACCTTATTTGTTTGTGTTTACTAATTAATAA
TCTAAACTGCTTAAAGGAGAAAAATTCAGTTTTAAGTTTTATTGATTTATACCCCTTCTTCAATCCACATAGGATTAGG
GTAGTATGTAACAAAATTTCAAACATAAAATGAAATATTGAGTTTTGTATTAAAGGCCAAGGATGAGGAAAAAAAAG
TAAGTATATATGGAAGAAAGATGGTATTGAATGGGAGTTTTGATGGAGCATGTTGACATCATGATAATACCTATTAT
CTTTATATTCTGAATGTCAGAACAAAATTAGAGCAATTTTCCCTTATTTCCCTACAATACGCTGTCTTAATAATTC
TAAGCTTTCTGATTTTCAGTAGTAATCTGTATTTTGCAAAAGGCAGCATGTTTATAAGATATCAAGTAACTAAGTT
TATGGAACCTTGTAACAGCATTTTTTAACAACATTTCTCCCTAGATAGTTTCATGGTAGACATGAATTTATTCAAACCTA
GTATGTAGAAAAATACCATTAAACAAAAGCTCTGAAATTATATTAGAGGAGCTGAATAATGTTACTTGAGAAAGAATA
AAATGTTATTTATGATTTTTTGGTATCTTTTACCCACTATATATGGCCATATCTCTGAAAACTTTAGTAATATGTAC
TAATGCAAAATATGGTAGTAAATTATGTCTACAGGTGCTGATACCATAGTAGATAAAAGTATGATAACTTTATTTTAAA
ATATCATATTTAAATAATTAATATACAGTACTGGGAAAGACTATTTTATCTATTCTCTCACTCTTGAATAAAAAAAT
CCAGAAAAAATACCTTGTTTTGGTAAAGATTATATCAATTTATTTCCCAAATGGGTAGAGGGTTATTTTTTTCTGAT
CATAAACGTATGTCTCTTCATTATAAAAAATCCACTAAAAAGTGATAGAAGAAAAACCAAAAGAATAAATGTAAACAATG
ATGCCATTTTCCAAAAATCACCTTCGACATTTTTCTGGATATTGATACAGTCTAAATCTCTTTTCGGAAGACTCCCT
CCTGTGTAGGTTCCCAACTACTCTGCAATCTTATTTCTCTGTTCTGTCTGTAGAAAGGAGACCCATTGTAC
CATGTCAAATAACACAAAATGGTGCACGTATAAGATCATTGTCTCTGTCCATTATTTGCCAGAGGACCTCAAACCTT
TTCAGGTGGTGGGCAACTGGATGTCTGTCTCTTGTACAACAGAACACAATTCATTATTTATATGGTTATTTCA
TTTTAAGAAAATTTAATCTTTTCAATAGCTGGAAAAAAGAGTGGTTTTAAGTTGTTTGAAGTGTGAATTAACAA
TTTTCATACTGCAAAAGAGATTCAACTGCAAAACACAGGCACACATGTCTGGTGTAAAGAACGAGTTGTCTACACAAACC
CAAATTAGCTGCCTCCACGTTGTCTTTGTTAACAAGTGTGTTGTTGCTCCTTGTTCCATCATTTCAGAAATGCTCTTT
AGCAGGAATTGATGGAACACAGTCGCAGTGACCTCTTCCTGTCTTTAAAAATCGAGATGACATTTGCCCATCTGCAG
TGTTAACATAGTTTCTCAAAGACCACTGACAGTGGGGTAGGACTGTATTGCGCAAGTTCTCTCATTTCCTTAGAATA
TAATTGGTCCAGGGCCAGAGATTTAGCTCATTTAGAGCAGCAAGGTGCTCTTTTAAATTCCTCACCTATTTTGG
GCTTCATTTCCCTTATACGGTTATGCCTTTTCCAGTCTGATGAACATTCTCCTTGACAGAGCAGACAAGCAAAAGGA
GCTGCACACTGCTGCTTTCTGTGTCGTCTCTATCCCTAACCTTCTCCCTTCTGCCCCAATCAGTGAACCTTCGTCTT
TCTGTTTCTTCTTCCCTCAAATGGAAGTAAAAAGGCCCTGAATGTTGTCTTTACCATTATCACGAGCCTCAATTCAT
TCCAAGCTCAGCTTTTCTCACTGTTTATACAGTTCTATATTGTTCTTCTAATATTGCCCCCAGTTCCTCTGTCCCT
CGTTTCTTCCCATGTTTCATACTCTATTAGAATCTGAGCACCTTTGAGGTTGTCCATACAGTGGCACACATCTTTGTT
TTATACTCACTGGGATGATTTGCCATTATATTGTCAAAATTTTATTCTAAAGAGCTTTTACAGGCTTTCTTGAGCCA
TTTTCTCTTGAAATTCAAGATCGTTGAATCTCTACGCTTTTTCTTCTTAATCTAATAAACATACACCCCCACATAC
ACACGTGTGTTTCTGAAAGACAGATGCCACTTGACTCGTCTTATAGATTGTCTAAATTGATCATTGTGTGTGGGGAT
AAAAGGGTGAATTGTATAATATCCCTGATGGTTTCACGAAGTCTGTTCTGTATAACCTGATTAGTCTTCTGAACCTCT
TTTAAATTCTGTCTGCAAATGACTGAGGTTTGGAATCAGCCTATTTTCAAGTTAGTTGTTTTCTTGCATAAGAAGGGT
CCATATGTACTGTGTGAAGTAAGAGAGAGAAAGTACTTAGATTGTCTGGATGCCCTGATTGTTAGCATGGCTAAGGT
ATTGTGTAAAGTAAGGAGAGCAGTTAAAAATGATATTGTTTTATTTCTTAATTGAGGTAAAAATTTATATAAGATGA
AACAGACTTATTTGGGAGAGGAGGTTGTTCTTACATAACATTTCAACCTGTCAATTTAGTTAGTAGAAGTCTC
AATCTGTCAAGATACTTTGTATAATATTTCAGATTCTGCCATCTAATAATATTTTCCACGCTTTCTTACTGGGTGTGAC
AGTAACTTATACTGTGGCAGGTGTATAAGTTAGTAAAGATATTAATGCTCAATCTGTAACTTTTGTGAAGTGGTC
CCACTGATAAAGTGACACCTCAATAAAAAATAAAATTTCCATTACCTCAGAAAGCTTTTTTCATGCTACCTTCCAGTCA
ATTCCCAGCCCCAATAGGCACCTATTCTTCTGATTTATATCACCATAGATTAGTTTTGTCTTTTTTAAAAATTTGTAT
AAATGAAATCATACAAAATGTACTATTTTGATCAGCATACTACTTTTGAGATTTCATCCATGTAAGTGTATCAGCTGT
TCATTCTTTTATTGATGATTAATATTCTATTGTATAGATATACCACAATTTATTTATCTATTCTCCTTTTGTATGGAC
ATTAGGTGGTTTTTCAGTTTTTGGCTGTTATGAATAAGATGCTGTGGACATTTGTGTACAAGCCATTTGTGAGCATA
TGTTTTCATTTAGTTTGAGTAACTCTGTAGAAGTGAATGGCTGGGTGAAATGTTTAAATTTATGAGATATTGTCAA
ACAGCACCTAAACAGTTTTCTAAAGTGGTTGTGCCATTTTGCAATGCCACCAGTGATGATGGAGAGTTCCAGTTACT
CTACATCTTTGTCAATATTTGGTCTTTGTCTAGTCATTTTAAATTTTTGCTATCTTACAGAATATGTAGGTATATTGTTG
TGGTTTTAACTTATATTCTCTGATTACTAGCACTATTAAGCATCTTTTCATGGATTTATTGGACATTCATATAGAT
TATGTGTGTTGAAGATTATTACCTTTATGATTATTGGGTGAAAAAGTATCATTTTGAGGTCATTCATATAACTTGA
AGACTGGGAATGACAGACATTTTCTGTGTTTTGTTCTTTTTCTTTTTACTTTATCTGAAGAGTCTACTAGAATGCAGT
GTTGCTGCCTGAGCAGCAGGGCATTAGCTTTGTAAAAGCTCTGTTCCCTGGCAACCCACCCTAATATGAAGTGCA
GAACATTTGAATTGTCTTTGACCAGCTTCAGCATCAGCACTATTTTTTTTTTTTTGCTAGACCCCTAGTAGGTATTTA
AAAGTACAGAAATAGAATTTAATCATGCTTTTTTACCAAAATGTGCTATGCTCTTAGAGATTCTTTCAACGTGCATAAA
AATCTGCAGTTTTTACCACATACCAGTAAAAAGAACTCAGTCACTCATTTAGCCATTTAGTAAAAAGAACAAATTA
CTGATGAGCATAGTGGAGACCTCAAAGGTAAAGAGACAATGTCCCTGAAATAAAGACAATCATAAATTTTCAATCA
AAATAATGAAATTTAGGCTGGGCATGGTGGCTCATGCCATGATCCTAGCACTTTTGAAGGCTAAGGTGGGAGGATT
GTTTGAGGCCAGGAGTTCAAGACCAGCCTCAGCAAAAAAGTGAGACCCTGTCTCCACAAAAAATTTTAAAAATTTAT
CTGGGTGTGGTGGTATGCACCGGTGGTCTCAGCTACTCAAGAGGCTGAGGTGGAGGATCACCAGAGCTCAGGGGTTG

GAGACTACAGTGAGCTATGATTGTACCACTGCACTCAAACCTTGCATGACAGAATGAGTCCTTGTCTCTAATAATAAC
AAAATTTAATTTTTATAGACTGTGAAAAACCATTATGTAGATACAGTTCAAGTACAGTATGATTTTATAGGATAGAT
AACTTTTGCTTGAAAATGTATTCCCAATTTATAGGATAGATAACTTTTGCTTGAAAATGTATTCACAATAGAGTTAG
TATTTGGGGCACACCTTTATCCATTTAACAACATGTTTTGAGCACTGCCAGGTAGCAACACGTTACTAGGCACCTAG
AGTGAGAAAAGATTACAGTTCCTGCTCTCATGGATCTCATGGTCTAGTCAACTGGAATGAAAGGATTACATAAGTAG
AGGTAAAGACACACATGATGGAGGATGGAGAATAGTCAAAGGTCTGGAGAATGACCAGGACGTCAGTGTGAGTTGTC
TAATTGCACTGAAGCATGGATGAAGAATTGGAAAGTCATTGTAAGAAGCCTAAAAAGGTATCTCTCAGGGATGCTAT
GAGGTTCTGAATGTTATGTACGCTATTTGGGCTTCAACAGGCAGGCACTGAGTATTCAGTATAAAATTTTTGAGCAGG
GAATCCACCAGAAGAAGTATGCATCTGGAGGATTAATCTGGAAGATTGTGTAGAATGTTATGCAGTGAAAAGAGTCT
GAGATGAAACAGTTAGGAGGGTGTATTAATAACATAGGTGAAGTGAATGAATAACCAGGCTGGAGGAAAAGCAATA
ACGATGGAATCAACCGGGCAAGAAGTATAACAATTAGGATCAGTAAAAATAGAATTTGGATTGGAGGAATGAAAAAA
AAGGGACAAAACAAAGTTGAAGTCTGGTATCCATACTGGAATAACAGATGTCATTCAAATAAATAATGTAATGAA
TATAAGAAACCAGTTTTAGGAGTGAAGTGGATGTTGGCTTGAAAATATTTCCCTTGAGGTTTCAGTCAAATGAAAAG
GTCCTGAAATGCTACGTGGTAGCCTAAGAAGGAAGCGTTCTAGAGAGAAAAAATTAGAAAAGATTTACATTTGAT
AATTTAATCTTTTCCCTCATAACAAGCTAAATTGATAAGAAAGTAAAACCTATAGTTTTCCACACTCTTTTACAAATA
TCCCTAACCTTTTAGATATTCACATGAATAATTGAGAAAAATCTAACAGATGACTTGCTTATGTCAATTTGTCTGCTT
TATCCTTAGGTTCTCTGGCTTATATATTGTTCAATAAAATACAGATCATTGATATTGTACAATGTACTGATAATGG
GGAGTGAATCCATGCTTGTGCATTCTTTTTTTTTTTTTTTTTGATTTGCAGAGGGCGTGCCAGTCAACAAGAGAG
GCACAATTGTTTTTATCATCACCTCTTCTCATCTAATTCCATGAAGGAGAGTAGTATTACCATAACAACAGATAATGA
GTTGGAAAACAAGAAACCTAACCTCAGAACTTAAGGCTTGGGGAAAAAATAAAAGAGTAATTTGTGTTTAAATGCCTGT
ATAACTTGGCAAGAGGGACATATAAGGCTTAGTGATGCCCAACATGTGCTTAGATGTGGATTGTTAGTTGATGTCTT
GGGGGTTCTGTAATCTAAGCTAAATGCTCAAAATCAATTAATTGATGTTAGACACAGAGATCTGCTTTGATCCCTCT
TTATCGTATTTCTAGGCCTTCCCATTTCTCAAGAGCCTGAGAAACGACAGCTTTCCCTTAATAACTTGTATTTGTGGT
AGGAGATGAAACCTTTGATAAAAAACACAATTATTTTAAATGTCTCTTTTTCACTCTAGGCTGTTGTATGTATTTCAA
AAGTTACTTTTGACCTTTTCCAGAATGAGAAGCAATCAAGAAGATTATAATCTTGGTTAGTTTCTGCTCAAT
TTATCAACAAATATTTCTTAAGCAATTATTAAGCTGAGCAGTGCTCAGCGCTGTACTTGGTGATATAGGAAATGGGG
AAAAGACTGTCTTTAAGGCTTTTATAATAGTAATTACCTCAACTTGCTGTTTCTTTTCCCTTACCATTTCCGCAAAAT
TCATTGATCTATCTTGTCTCAAGCAATCGCCATAGTTATATTGTAACACAGCATTTTCTAGGGTGTCCCATTTAA
GTTGAGAGTGTTGACAAGAAAATACAAGCTTATTTATCATTGTAAAACTTGAGACACCTAGTAGTTACCCTAAATTA
AATATTTGTTGGAGTCAGTCACACTAAAGAGAACACTTACTGCATTGAACAATTTACCTACATTAGACAGCATTTAA
AGACTATGCCACAGCAAAGGCCCATGGAATTTCTGTGAACACAGAATAGAAGTGTATTAAGGAACAAGCTTAATTTCT
GTTCTCTTAAAGCACAACTTTCTCAAAACATATTTTGAAATCACCTTTGACCATTTTTTTTAACTAATAGGTGGG
TGGGAGTTAGGGTAGGAAAACACAAGCAGCTTCATCAAAACGATATTCTATTTTCTTCAAATTTGTGGGGAATCATA
CGGCCTCTCAATTTTCTACATTATGCTAATTATGATATTAATCTCTCTGCCAGCAAATGAAAATAATACATATTAGA
TGTAGCAAATGTCAATAATGACAAAATTAGTCATCATGCAGATACTCAGGGATTCCCAAAATATGTTTGGATTATGA
TTGCTAGCTTTGAGTTTGCCAGAAATCGTTTCAATAAAAAATAAGGGACTCAAACACATTTGGAGCAAAACTCACATC
ATAAATTTTAGACATAGCTCTGCCAATAATGCTCTCAGTTATATTTTTCAGTCCTAATATTTCTCTGAGTTCCAGAC
CAGTATCTTCAACTGTCTGATTGATACTCTCTCCTTCATTTCTGTCTCCAATGCATTAAGTCTGTGATTTTACTTT
CCAAATGCCACTTGGTTCCATGCATTTCTCTCCATTTCTGCCACTGACTCCTCCTCAATCCAAGCGACCATCTTTCC
TCACTTTAACTACCATGATATCTCCTGCTTGGTCTCCTTACTTCTATTCCCGGGCTCCTCCAATCCATTCATCCTCC
AGCAGAGAATGATGACTAGCACCTTCCACAGTGTCTGGCTAATAGGAGGTATCCAATCAATAATTGACTTTACAGAGT
GAAAATATAGGCATGGCAATAACACAGTAGAAGTCAAGGTTTGAACCAATGACATTAGTACTTTCCATCAAT
ATTTACAGTGTATAATCAAGTTGACTTGACATTGCACATTGTCTATTTTGA AAAACAATTTTGTGGCTTTTTCTATATGC
ACACATACATATTGTATCACCTCTACCCGCCAAATGGCTTTTGAAGAAGTATTTATGTGGCTCCAAATTGATAATA
CCTCTAGAGAGAAGAGAAATTAGAAATTTTAAATGACCTATGCTTCCCTTTCGAATATCACGTCTGAGACAGTGT
TTTTGAGTTACGTGCAATATGTTCCACGATGAAACATTTAATGTGTTTCAGAGGCATGCTAGTAATCATGTAGAAAGA
ATTTTATGCCTGAAGTCACATGTTCTATAACCAGGATCACTTAATAAGAAAACAAGTACAGCTGTGGACAAGATGCC
TTTTTATCAGGGAAAGGCCAATTTGTTTTCTTTGCAAATCTAAGTAAATGGAGAGAAAAACACAGCCCTTAAATGTT
TTCTATTTGTCTGAAGTTCTCATGAATGAGTTAGAAGGCGAGAAGGATTAAATAAATCCTTGAACGTAGAGAGAGC
TAACATTTATTTTAGCAAACCTAAACCTATTTCGCTTTGCAAAGTTCTGTTCTGTACTTTGTAACAACAGTTTTCTTT
AAAACAAGAGCCACCAATTCAAATGCCTTTACAGAATGATTGAATGCTTTTCATGCCCCACCTAAAGGCATTCAAATC
ATTAATCAAACAAAGTTCTAACGCCAAAACATGTCTGGGACCAGATTTAAATGTAGCCCTCAGTTTCAGAGGGCAA
AACTTAACATATTTTATATTTTCTCACTTTAGGTAACACTGTATTGAATCTCTGCTTGAAATTGAGGAGCACGTGA
TTTTTTCTTTTTTGCCCGAGGGCAGCATTTCTTGGAAGAGAAAAGAAAAACAACCCAAGATACCCTTACAAAACATGTA
GTACTTAAAGCTCTTTATGATGAATTAATTTTGGTATACACATTAATAGCAGTGATAATAACAAATCTATATATATA
TATATAATTGATATGAATAAGATAAAATACATCAAAAGGAAATTTCAATTACAATTTGATATTAGGTAAATGTCCCAT
AAAATAAATTGCTACTGTACATAATTTTCTTTCAGTTTATTGGCAGGATGTTTGCTTTGGAAAATAAACAGTCTATT
TCTAGTTTTAGAAGGAATTTCTATTATTCTTTTATAGCAACCATTTATCAGGAGCAGATGGGAAATTTGACCAAGAGC
ATATCACTATTATACCTCAGAGAAAAAGAGAGTATTAATGAAATCTAACAGGCGCTGCTCCTGACTCTAGTTCC
TGTAACAAATGAACACACACATTTGTATGGTTTTCAGCATTTGTATTAGTAAGGTACAATAAATGTTTACTGAAATTG
AAAAAAAAGAAATACACAGGAGAAAAGAGAGGCTAAAAAGGTGCATTTTATTTCTGATCGTTTCAATTGTAAAGACTGC
TCCTTTTTTAAATAATCAAATTTTATTTTATATACAGAGGGTACATGTACAGGCTTGTACAGGGGAATAGCGCATG
ATGCTGAGGTTTGGGGTACAGATCTCATCCCCAACAGTGAGCATAGTACCTACCTGATGAGTAGTTTTTCAACCA
ATGCGCACCTCCTCCTTCCCACATCTACTAGTCCGCGGTATCTGTTGTTTCGCATATTTACGTCCATATATGCTCT

138

TGTGTGTAAGTTGGTTGTAATATTCTCCTTTTCAATTGAGCTATTTTTCTGATACTTTACTCTTAAAAATTTTCATTTCAG
 GAAAAAAGTAAACAATATTTAAGCTTGACAATCATAAAAATGCTCTGGTGACTATAGATTATTTTAAAAATTTATTAC
 TGTAGCTTAGGGATATCTTGATGGGATGCTCCTGAAAGCAATTAATTCTCAGTTTTTTGTGGCTTCTAATGCAAAAT
 ACATTGACGCAGACAGAATTTGAAATGAATTTTCTTCTAATATAGCAATTAATTTTATTTAAATATCTCTAGAGTTT
 TTTTTTAATACTGTGACTAACCTATGTTTGTCTTTTTTCACCTCTCGTATCCACGATCACTAAGAAACCCAAATACT
 TTGTTTCATGTTTAAATTTTACAACATTTTCATAGACTATTAAACATGGAACATCCTTGTTGGGGACAAGAAATCGAATT
 TGCTCTTGAAAAGGTTTCCAATAATTGATTGTAGGACATTATAACATCCTCTAGCTGACAAGCTTACAAAAATAA
 AACTGGAGCTAACCGAGAGGGTGCTTTTTTCCCTGACACATAAAAGGTGTCTTTCTGTCTTGTATCCTTTGGATAT
 GGGCATGTTCAGTTTTCATAGGGAAATTTTCACATGGAGCTTTTGTATTTCTTTCTTTGCCAGTACAACATGCATGTGGT
 AGCACACTGTTTAAATCTTTTCTCAAATAAAAAAGACATGGGGCTTCATTTTTGTTTTGCCTTTTTGGTATCTTACAG
 (SEQ ID NO: 277)

[000212] *Homo sapiens* dystrophin (DMD), intron 44 target sequence 1 (nucleotide positions 1127752-1127796 of NCBI Reference Sequence: NG_012232.1)

TAACTTCTTAAAGATCAGGTTCTGAAGGGTGATGGAAATTAATT (SEQ ID NO: 278)

[000213] *Homo sapiens* dystrophin (DMD), intron 44 target sequence 2 (nucleotide positions 1127752-1127796 of NCBI Reference Sequence: NG_012232.1)

TGACAAGCTTACAAAAATAAAAACTGGAGCTAACCGAGAGGGTGCTTTTTTCCCTGACACATAAAAGGTGTCTTTCT
 GTCTTGTATCCTTTGGATATGGGCATGTTCAGTTTTCATAGGGAAATTTTCACATGGAGCTTTTGTATTTCTTTCTTTG
 CCAGTACAACATGCATGTGGTAGCACACTGTTTAAATCTTTTCTCAAATAAAAAAGACATGGGGCTTCATTTTTGTTTTG
 CCTTTTTGGTATCTTACAG (SEQ ID NO: 323)

[000214] *Homo sapiens* dystrophin (DMD) intron 44/exon 45 junction (nucleotide positions 1376066-1376125 of NCBI Reference Sequence: NG_012232.1)

TTTTTGTTTTGCCTTTTTTGGTATCTTACAGGAACCTCCAGGATGGCATTGGGCAGCGGCAA (SEQ ID NO: 279)

[000215] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, exon 45 (nucleotide positions 6683-6858 of NCBI Reference Sequence: NM_004006.2; nucleotide positions 1376096-1376271 of NCBI Reference Sequence: NG_012232.1)

GAACTCCAGGATGGCATTGGGCAGCGGCAAACTGTTGTCAGAACATTGAATGCAACTGGGGAAGAAATAATTCAGCA
 ATCCTCAAAAACAGATGCCAGTATTCTACAGGAAAAATTTGGGAAGCCTGAATCTGCGGTGGCAGGAGTCTGCAAC
 AGCTGTCTAGACAGAAAAAAGAG (SEQ ID NO: 280)

[000216] *Homo sapiens* dystrophin (DMD), exon 45 target sequence 1 (nucleotide positions 1376096-1376145 of NCBI Reference Sequence: NG_012232.1)

GAACTCCAGGATGGCATTGGGCAGCGGCAAACTGTTGTCAGAACATTGAA (SEQ ID NO: 281)

[000217] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a splicing feature in a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a splicing feature in a DMD sequence is an exonic splicing enhancer (ESE), a branch point, a splice donor site, or a splice acceptor site in a DMD sequence. In some embodiments, an ESE is in exon 44 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a branch point is in intron 43 or intron 44 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a splice donor site is across the junction of exon 43 and intron 43, in intron 43, across the junction of exon 44 and intron 44, or in intron 44 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a splice acceptor site is in intron 43, across

the junction of intron 43 and exon 44, in intron 44, or across the junction of intron 44 and exon 45 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, the oligonucleotide useful for targeting DMD promotes skipping of exon 44, such as by targeting a splicing feature (*e.g.*, an ESE, a branch point, a splice donor site, or a splice acceptor site) in a DMD sequence (*e.g.*, a DMD pre-mRNA). Examples of ESEs, branch points, splice donor sites, and splice acceptor sites are provided in Table 9.

[000218] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets an exonic splicing enhancer (ESE) in a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets an ESE in DMD exon 44 (*e.g.*, an ESE listed in Table 9).

[000219] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) comprises a region of complementarity to a target sequence comprising one or more full or partial ESEs of a DMD transcript (*e.g.*, one or more full or partial ESEs listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising one or more full or partial ESEs of DMD exon 44. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising one or more full or partial ESEs as set forth in SEQ ID NOs: 286-296. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 286-296. In some embodiments, the oligonucleotide comprises at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE antisense sequence as set forth in any one of SEQ ID NOs: 306-316.

[000220] In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 6 (*e.g.*, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) nucleotides of one or more ESEs (*e.g.*, 2, 3, 4, or more adjacent ESEs) of DMD exon 44. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 6 (*e.g.*, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) nucleotides of one or more ESEs (*e.g.*, 2, 3, 4, or more adjacent ESEs) as set forth in SEQ ID NOs: 286-296. In some embodiments, the oligonucleotide comprises at least 6 (*e.g.*, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) nucleotides of one or more ESE antisense sequences (*e.g.*, antisense sequences of 2, 3, 4, or more adjacent ESEs) as set forth in SEQ ID NOs: 306-316.

[000221] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8)

consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 286-296. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 20-30 (*e.g.*, 20, 25, 30) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 286-296. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 20-25 (*i.e.*, 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 286-296. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 286-296.

[000222] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a branch point in a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a branch point in DMD intron 43 or intron 44 (*e.g.*, a branch point listed in Table 9).

[000223] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) comprises a region of complementarity to a target sequence comprising a full or partial branch point of a DMD transcript (*e.g.*, a full or partial branch point listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial branch point of DMD intron 43 or intron 44. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300. In some embodiments, the oligonucleotide comprises at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point antisense sequence as set forth in any one of SEQ ID NOs: 303, 304, and 318-320.

[000224] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon

skipping, such as for skipping exon 44) is 20-30 (e.g., 20, 25, 30) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 44) is 20-25 (*i.e.*, 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 283, 284, and 298-300.

[000225] In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping) targets a splice donor site in a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping) targets a splice donor site across the junction of exon 43 and intron 43, in intron 43, across the junction of exon 44 and intron 44, or in intron 44 (e.g., a splice donor site listed in Table 9).

[000226] In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 44) comprises a region of complementarity to a target sequence comprising a full or partial splice donor site of a DMD transcript (e.g., a full or partial splice donor site listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice donor site across the junction of exon 43 and intron 43, in intron 43, across the junction of exon 44 and intron 44, or in intron 44 of DMD. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice donor site as set forth in SEQ ID NO: 282 or 297. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 282 or 297. In some embodiments, the oligonucleotide comprises at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a splice donor site antisense sequence as set forth in SEQ ID NO: 302 or 317.

[000227] In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 44) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 282 or 297. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 44) is 20-30 (e.g., 20, 25, 30) nucleotides in length, and comprises a region of

complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 282 or 297. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 20-25 (*i.e.*, 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 282 or 297. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 282 or 297.

[000228] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a splice acceptor site in a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a splice acceptor site in intron 43, across the junction of intron 43 and exon 44, in intron 44, or across the junction of intron 44 and exon 45 (*e.g.*, a splice acceptor site listed in Table 9).

[000229] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) comprises a region of complementarity to a target sequence comprising a full or partial splice acceptor site of a DMD transcript (*e.g.*, a full or partial splice acceptor site listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice acceptor site in intron 43, across the junction of intron 43 and exon 44, in intron 44, or across the junction of intron 44 and exon 45 of DMD. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice acceptor site as set forth in SEQ ID NO: 285 or 301. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, 8, or 9) consecutive nucleotides of a splice acceptor site as set forth in SEQ ID NO: 285 or 301. In some embodiments, the oligonucleotide comprises at least 4 (*e.g.*, 4, 5, 6, 7, 8, or 9) consecutive nucleotides of a splice acceptor site antisense sequence as set forth in SEQ ID NO: 305 or 321.

[000230] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, 8, or 9) consecutive nucleotides of a splice acceptor site as set forth in SEQ ID NO: 285 or 301. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 20-30 (*e.g.*, 20, 25, 30) nucleotides in length, and comprises a region of

complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, 8, or 9) consecutive nucleotides of a splice acceptor site as set forth in SEQ ID NO: 285 or 301. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 44) is 20-25 (*i.e.*, 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, or 8) consecutive nucleotides of a splice acceptor site as set forth in SEQ ID NO: 285 or 301. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, 7, 8, or 9) consecutive nucleotides of a splice acceptor site as set forth in SEQ ID NO: 285 or 301.

[000231] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a junction of an exon and an intron of a DMD RNA (*e.g.*, any one of the exon/intron junctions provided by SEQ ID NOs: 268, 272, 276, and 279). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to at least 10 (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleosides of a junction of an exon and an intron of a DMD RNA (*e.g.*, any one of the exon/intron junctions provided by SEQ ID NOs: 268, 272, 276, and 279). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is complementary to any one of SEQ ID NOs: 268, 272, 276, and 279.

[000232] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 270, 271, 274, 275, 278, 281, and 323). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to at least 10 (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleosides of a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 270, 271, 274, 275, 278, 281, and 323). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is complementary to any one of SEQ ID NOs: 270, 271, 274, 275, 278, 281, and 323.

Table 9. Example target sequence motifs

Location in DMD	Type	SEQ ID NO:	Motif Sequence [†]	SEQ ID NO:	Motif Antisense Sequence [†]
Across exon 43/intron 43 junction	Splice Donor	282	GGGTAGG	302	CCTACCC
Intron 43	Branch Point	283	TATTAAT	303	ATTAATA

Location in DMD	Type	SEQ ID NO:	Motif Sequence [†]	SEQ ID NO:	Motif Antisense Sequence [†]
Intron 43	Branch point	284	TCTTGAT	304	ATCAAGA
Across intron 43/exon 44 junction	Splice Acceptor	285	ACCTGCAGG	305	CCTGCAGGT
Exon 44	ESE	286	TGACAGA	306	TCTGTCA
Exon 44	ESE	287	CGGCGTT	307	AACGCCG
Exon 44	ESE	288	TCAGTGG	308	CCACTGA
Exon 44	ESE	289	GGCTAACA	309	TGTTAGCC
Exon 44	ESE	290	ACAGAAG	310	CTTCTGT
Exon 44	ESE	291	TCTCAGA	311	TCTGAGA
Exon 44	ESE	292	CTCAGAA	312	TTCTGAG
Exon 44	ESE	293	GACACAA	313	TTGTGTC
Exon 44	ESE	294	AATTCCTG	314	CAGGAATT
Exon 44	ESE	295	CTGAGAA	315	TTCTCAG
Exon 44	ESE	296	GTATCTTA	316	TAAGATAC
Across exon 44/intron 44 junction	Splice Donor	297	AGGTAAG	317	CTTACCT
Intron 44	Branch Point	298	CTGAC	318	GTCAG
Intron 44	Branch Point	299	CTAAC	319	GTTAG
Intron 44	Branch Point	300	CCCTGAC	320	GTCAGGG
Across intron 44/exon 45 junction	Splice Acceptor	301	TCTTACAGG	321	CCTGTAAGA

[†] Each thymine base (T) in any one of the sequences provided in Table 9 may independently and optionally be replaced with a uracil base (U). Motif sequences and antisense sequences listed in Table 9 contain T's, but binding of a motif sequence in RNA and/or DNA is contemplated.

[000233] In some embodiments, any one of the oligonucleotides useful for targeting DMD (e.g., for exon skipping) is a phosphorodiamidate morpholino oligomer (PMO).

[000234] In some embodiments, the oligonucleotide may have region of complementarity to a mutant DMD allele, for example, a DMD allele with at least one mutation in any of exons 1-79 of DMD in humans that leads to a frameshift and improper RNA splicing/processing.

[000235] In some embodiments, any one of the oligonucleotides can be in salt form, e.g., as sodium, potassium, or magnesium salts.

[000236] In some embodiments, the 5' or 3' nucleoside (e.g., terminal nucleoside) of any one of the oligonucleotides described herein is conjugated to an amine group, optionally via a spacer. In some embodiments, the spacer comprises an aliphatic moiety. In some embodiments, the spacer comprises a polyethylene glycol moiety. In some embodiments, a phosphodiester linkage is present between the spacer and the 5' or 3' nucleoside of the oligonucleotide. In some embodiments, the 5' or 3' nucleoside (e.g., terminal nucleoside) of any of the oligonucleotides described herein is conjugated to a spacer that is a substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or

unsubstituted heteroarylene, -O-, -N(R^A)-, -S-, -C(=O)-, -C(=O)O-, -C(=O)NR^A-, -NR^AC(=O)-, -NR^AC(=O)R^A-, -C(=O)R^A-, -NR^AC(=O)O-, -NR^AC(=O)N(R^A)-, -OC(=O)-, -OC(=O)O-, -OC(=O)N(R^A)-, -S(O)₂NR^A-, -NR^AS(O)₂-, or a combination thereof; each R^A is independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, the spacer is a substituted or unsubstituted alkylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted heteroarylene, -O-, -N(R^A)-, or -C(=O)N(R^A)₂, or a combination thereof.

[000237] In some embodiments, the 5' or 3' nucleoside of any one of the oligonucleotides described herein is conjugated to a compound of the formula -NH₂-(CH₂)_n-, wherein n is an integer from 1 to 12. In some embodiments, n is 6, 7, 8, 9, 10, 11, or 12. In some embodiments, a phosphodiester linkage is present between the compound of the formula NH₂-(CH₂)_n- and the 5' or 3' nucleoside of the oligonucleotide. In some embodiments, a compound of the formula NH₂-(CH₂)₆- is conjugated to the oligonucleotide via a reaction between 6-amino-1-hexanol (NH₂-(CH₂)₆-OH) and the 5' phosphate of the oligonucleotide.

[000238] In some embodiments, the oligonucleotide is conjugated to a targeting agent, e.g., a muscle targeting agent such as an anti-TfR1 antibody, e.g., via the amine group.

a. Oligonucleotide Size/Sequence

[000239] Oligonucleotides may be of a variety of different lengths, e.g., depending on the format. In some embodiments, an oligonucleotide is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, the oligonucleotide is 8 to 50 nucleotides in length, 8 to 40 nucleotides in length, 8 to 30 nucleotides in length, 10 to 15 nucleotides in length, 10 to 20 nucleotides in length, 15 to 25 nucleotides in length, 21 to 23 nucleotides in lengths, 20 to 25 nucleotides in length, etc.

[000240] In some embodiments, a nucleic acid sequence of an oligonucleotide for purposes of the present disclosure is “complementary” to a target nucleic acid when it is specifically hybridizable to the target nucleic acid. In some embodiments, an oligonucleotide hybridizing to a target nucleic acid (e.g., an mRNA or pre-mRNA molecule) results in modulation of activity or expression of the target (e.g., decreased mRNA translation, altered pre-mRNA splicing, exon skipping, target mRNA degradation, etc.). In some embodiments, a nucleic acid sequence of an oligonucleotide has a sufficient degree of complementarity to its target nucleic acid such that it does not hybridize non-target sequences under conditions in which avoidance of non-specific binding is desired, e.g., under physiological conditions. Thus, in some embodiments, an oligonucleotide may be at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary to the consecutive nucleotides of a target nucleic acid. In some

embodiments a complementary nucleotide sequence need not be 100% complementary to that of its target to be specifically hybridizable or specific for a target nucleic acid. In certain embodiments, oligonucleotides comprise one or more mismatched nucleobases relative to the target nucleic acid. In certain embodiments, activity relating to the target is reduced by such mismatch, but activity relating to a non-target is reduced by a greater amount (*i.e.*, selectivity for the target nucleic acid is increased and off-target effects are decreased).

[000241] In some embodiments, an oligonucleotide comprises region of complementarity to a target nucleic acid that is in the range of 8 to 15, 8 to 30, 8 to 40, or 10 to 50, or 5 to 50, 15 to 20, 20 to 25, or 5 to 40 nucleotides in length. In some embodiments, a region of complementarity of an oligonucleotide to a target nucleic acid is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length. In some embodiments, the region of complementarity is complementary with at least 8 consecutive nucleotides of a target nucleic acid. In some embodiments, an oligonucleotide may contain 1, 2 or 3 base mismatches compared to the portion of the consecutive nucleotides of target nucleic acid. In some embodiments the oligonucleotide may have up to 3 mismatches over 15 bases, or up to 2 mismatches over 10 bases.

[000242] In some embodiments, the oligonucleotide is complementary (e.g., at least 85% at least 90%, at least 95%, or 100%) to a target sequence of the any one of the oligonucleotides described herein (e.g., the oligonucleotides listed in Table 8). In some embodiments, the oligonucleotide is complementary (e.g., at least 85% at least 90%, at least 95%, or 100%) to a target sequence of the any one of the oligonucleotides provided by SEQ ID NO: 196-267. In some embodiments, such target sequence is 100% complementary to an oligonucleotide listed in Table 8. In some embodiments, such target sequence is 100% complementary to an oligonucleotide provided by SEQ ID NO: 196-267. In some embodiments, the oligonucleotide is complementary (e.g., at least 85% at least 90%, at least 95%, or 100%) to a target sequence provided herein (e.g., a target sequence listed in Table 8). In some embodiments, the oligonucleotide is complementary (e.g., at least 85% at least 90%, at least 95%, or 100%) to any one of SEQ ID NO: 160-195.

[000243] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 160-195). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleosides of a target sequence of a DMD RNA (*e.g.*, a target

sequence provided by any one of SEQ ID NOs: 160-195). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is complementary to any one of SEQ ID NOs: 160-195.

[000244] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a sequence comprising at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleobases of a DMD-targeting sequence provided herein (*e.g.*, an antisense sequence listed in Table 8). In some embodiments, the oligonucleotide comprises a sequence comprising at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleobases of any one of SEQ ID NOs: 196-267. In some embodiments, the oligonucleotide comprises the sequence of any one of SEQ ID NOs: 196-267.

[000245] In some embodiments, it should be appreciated that methylation of the nucleobase uracil at the C5 position forms thymine. Thus, in some embodiments, a nucleotide or nucleoside having a C5 methylated uracil (or 5-methyl-uracil) may be equivalently identified as a thymine nucleotide or nucleoside.

[000246] In some embodiments, any one or more of the thymine bases (T's) in any one of the oligonucleotides provided herein (*e.g.*, the oligonucleotides listed in Table 8) may independently and optionally be uracil bases (U's), and/or any one or more of the U's in the oligonucleotides provided herein may independently and optionally be T's. In some embodiments, any one or more of the thymine bases (T's) in any one of the oligonucleotides provided by SEQ ID NOs: 232-267 or in an oligonucleotide complementary to any one of SEQ ID NOs: 160-195 may optionally be uracil bases (U's), and/or any one or more of the U's in the oligonucleotides may optionally be T's. In some embodiments, any one or more of the uracil bases (U's) in any one of the oligonucleotides provided by SEQ ID NOs: 196-231 or in an oligonucleotide complementary to any one of SEQ ID NOs: 160-195 may optionally be thymine bases (T's), and/or any one or more of the T's in the oligonucleotides may optionally be U's.

b. Oligonucleotide Modifications:

[000247] The oligonucleotides described herein may be modified, *e.g.*, comprise a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide or nucleoside and/or (*e.g.*, and) combinations thereof. In addition, in some embodiments, oligonucleotides may exhibit one or more of the following properties: do not mediate alternative splicing; are not immune stimulatory; are nuclease resistant; have improved cell uptake compared to unmodified oligonucleotides; are not toxic to cells or mammals; have improved endosomal exit internally in a cell; minimizes TLR stimulation; or avoid pattern recognition receptors. Any of the modified chemistries or formats of oligonucleotides described herein can be combined with each other.

For example, one, two, three, four, five, or more different types of modifications can be included within the same oligonucleotide.

[000248] In some embodiments, certain nucleotide or nucleoside modifications may be used that make an oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide or oligoribonucleotide molecules; these modified oligonucleotides survive intact for a longer time than unmodified oligonucleotides. Specific examples of modified oligonucleotides include those comprising modified backbones, for example, modified internucleoside linkages such as phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Accordingly, oligonucleotides of the disclosure can be stabilized against nucleolytic degradation such as by the incorporation of a modification, e.g., a nucleotide or nucleoside modification.

[000249] In some embodiments, an oligonucleotide may be of up to 50 or up to 100 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30, 2 to 40, 2 to 45, or more nucleotides or nucleosides of the oligonucleotide are modified nucleotides/nucleosides. The oligonucleotide may be of 8 to 30 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30 nucleotides or nucleosides of the oligonucleotide are modified nucleotides/nucleosides. The oligonucleotide may be of 8 to 15 nucleotides in length in which 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2 to 8, 2 to 9, 2 to 10, 2 to 11, 2 to 12, 2 to 13, 2 to 14 nucleotides or nucleosides of the oligonucleotide are modified nucleotides/nucleosides. Optionally, the oligonucleotides may have every nucleotide or nucleoside except 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides/nucleosides modified. Oligonucleotide modifications are described further herein.

c. Modified Nucleosides

[000250] In some embodiments, the oligonucleotide described herein comprises at least one nucleoside modified at the 2' position of the sugar. In some embodiments, an oligonucleotide comprises at least one 2'-modified nucleoside. In some embodiments, all of the nucleosides in the oligonucleotide are 2'-modified nucleosides.

[000251] In some embodiments, the oligonucleotide described herein comprises one or more non-bicyclic 2'-modified nucleosides, e.g., 2'-deoxy, 2'-fluoro (2'-F), 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2'-O-dimethylaminoethoxyethyl (2'-O-DMAEOE), or 2'-O-N-methylacetamido (2'-O-NMA) modified nucleoside.

[000252] In some embodiments, the oligonucleotide described herein comprises one or more 2'-4' bicyclic nucleosides in which the ribose ring comprises a bridge moiety connecting

two atoms in the ring, *e.g.*, connecting the 2'-O atom to the 4'-C atom via a methylene (LNA) bridge, an ethylene (ENA) bridge, or a (S)-constrained ethyl (cEt) bridge. Examples of LNAs are described in International Patent Application Publication WO/2008/043753, published on April 17, 2008, and entitled "*RNA Antagonist Compounds For The Modulation Of PCSK9*", the contents of which are incorporated herein by reference in its entirety. Examples of ENAs are provided in International Patent Publication No. WO 2005/042777, published on May 12, 2005, and entitled "*APP/ENA Antisense*"; Morita et al., *Nucleic Acid Res., Suppl* 1:241-242, 2001; Surono et al., *Hum. Gene Ther.*, 15:749-757, 2004; Koizumi, *Curr. Opin. Mol. Ther.*, 8:144-149, 2006 and Horie et al., *Nucleic Acids Symp. Ser (Oxf)*, 49:171-172, 2005; the disclosures of which are incorporated herein by reference in their entireties. Examples of cEt are provided in US Patents 7,101,993; 7,399,845 and 7,569,686, each of which is herein incorporated by reference in its entirety.

[000253] In some embodiments, the oligonucleotide comprises a modified nucleoside disclosed in one of the following United States Patent or Patent Application Publications: US Patent 7,399,845, issued on July 15, 2008, and entitled "*6-Modified Bicyclic Nucleic Acid Analogs*"; US Patent 7,741,457, issued on June 22, 2010, and entitled "*6-Modified Bicyclic Nucleic Acid Analogs*"; US Patent 8,022,193, issued on September 20, 2011, and entitled "*6-Modified Bicyclic Nucleic Acid Analogs*"; US Patent 7,569,686, issued on August 4, 2009, and entitled "*Compounds And Methods For Synthesis Of Bicyclic Nucleic Acid Analogs*"; US Patent 7,335,765, issued on February 26, 2008, and entitled "*Novel Nucleoside And Oligonucleotide Analogues*"; US Patent 7,314,923, issued on January 1, 2008, and entitled "*Novel Nucleoside And Oligonucleotide Analogues*"; US Patent 7,816,333, issued on October 19, 2010, and entitled "*Oligonucleotide Analogues And Methods Utilizing The Same*" and US Publication Number 2011/0009471 now US Patent 8,957,201, issued on February 17, 2015, and entitled "*Oligonucleotide Analogues And Methods Utilizing The Same*", the entire contents of each of which are incorporated herein by reference for all purposes.

[000254] In some embodiments, the oligonucleotide comprises at least one modified nucleoside that results in an increase in T_m of the oligonucleotide in a range of 1 °C, 2 °C, 3 °C, 4 °C, or 5 °C compared with an oligonucleotide that does not have the at least one modified nucleoside. The oligonucleotide may have a plurality of modified nucleosides that result in a total increase in T_m of the oligonucleotide in a range of 2 °C, 3 °C, 4 °C, 5 °C, 6 °C, 7 °C, 8 °C, 9 °C, 10 °C, 15 °C, 20 °C, 25 °C, 30 °C, 35 °C, 40 °C, 45 °C or more compared with an oligonucleotide that does not have the modified nucleoside.

[000255] The oligonucleotide may comprise a mix of nucleosides of different kinds. For example, an oligonucleotide may comprise a mix of 2'-deoxyribonucleosides or ribonucleosides

and 2'-fluoro modified nucleosides. An oligonucleotide may comprise a mix of deoxyribonucleosides or ribonucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise a mix of 2'-fluoro modified nucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise a mix of 2'-4' bicyclic nucleosides and 2'-MOE, 2'-fluoro, or 2'-O-Me modified nucleosides. An oligonucleotide may comprise a mix of non-bicyclic 2'-modified nucleosides (e.g., 2'-MOE, 2'-fluoro, or 2'-O-Me) and 2'-4' bicyclic nucleosides (e.g., LNA, ENA, cEt).

[000256] The oligonucleotide may comprise alternating nucleosides of different kinds. For example, an oligonucleotide may comprise alternating 2'-deoxyribonucleosides or ribonucleosides and 2'-fluoro modified nucleosides. An oligonucleotide may comprise alternating deoxyribonucleosides or ribonucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise alternating 2'-fluoro modified nucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise alternating 2'-4' bicyclic nucleosides and 2'-MOE, 2'-fluoro, or 2'-O-Me modified nucleosides. An oligonucleotide may comprise alternating non-bicyclic 2'-modified nucleosides (e.g., 2'-MOE, 2'-fluoro, or 2'-O-Me) and 2'-4' bicyclic nucleosides (e.g., LNA, ENA, cEt).

[000257] In some embodiments, an oligonucleotide described herein comprises a 5'-vinylphosphonate modification, one or more abasic residues, and/or one or more inverted abasic residues.

d. Internucleoside Linkages / Backbones

[000258] In some embodiments, oligonucleotide may contain a phosphorothioate or other modified internucleoside linkage. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages between at least two nucleosides. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages between all nucleosides. For example, in some embodiments, oligonucleotides comprise modified internucleoside linkages at the first, second, and/or (e.g., and) third internucleoside linkage at the 5' or 3' end of the nucleotide sequence.

[000259] Phosphorus-containing linkages that may be used include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent

pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'; see US patent nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050.

[000260] In some embodiments, oligonucleotides may have heteroatom backbones, such as methylene(methylimino) or MMI backbones; amide backbones (see De Mesmaeker et al. *Ace. Chem. Res.* 1995, 28:366-374); morpholino backbones (see Summerton and Weller, U.S. Pat. No. 5,034,506); or peptide nucleic acid (PNA) backbones (wherein the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone, see Nielsen et al., *Science* 1991, 254, 1497).

e. Stereospecific Oligonucleotides

[000261] In some embodiments, internucleotidic phosphorus atoms of oligonucleotides are chiral, and the properties of the oligonucleotides by adjusted based on the configuration of the chiral phosphorus atoms. In some embodiments, appropriate methods may be used to synthesize P-chiral oligonucleotide analogs in a stereocontrolled manner (e.g., as described in Oka N, Wada T, Stereocontrolled synthesis of oligonucleotide analogs containing chiral internucleotidic phosphorus atoms. *Chem Soc Rev.* 2011 Dec;40(12):5829-43.) In some embodiments, phosphorothioate containing oligonucleotides comprise nucleoside units that are joined together by either substantially all Sp or substantially all Rp phosphorothioate intersugar linkages are provided. In some embodiments, such phosphorothioate oligonucleotides having substantially chirally pure intersugar linkages are prepared by enzymatic or chemical synthesis, as described, for example, in US Patent 5,587,261, issued on December 12, 1996, the contents of which are incorporated herein by reference in their entirety. In some embodiments, chirally controlled oligonucleotides provide selective cleavage patterns of a target nucleic acid. For example, in some embodiments, a chirally controlled oligonucleotide provides single site cleavage within a complementary sequence of a nucleic acid, as described, for example, in US Patent Application Publication 20170037399 A1, published on February 2, 2017, entitled "CHIRAL DESIGN", the contents of which are incorporated herein by reference in their entirety.

f. Morpholinos

[000262] In some embodiments, the oligonucleotide may be a morpholino-based compounds. Morpholino-based oligomeric compounds are described in Dwaine A. Braasch and David R. Corey, *Biochemistry*, 2002, 41(14), 4503-4510; *Genesis*, volume 30, issue 3, 2001; Heasman, J., *Dev. Biol.*, 2002, 243, 209-214; Nasevicius et al., *Nat. Genet.*, 2000, 26, 216-220;

Lacerra et al., Proc. Natl. Acad. Sci., 2000, 97, 9591-9596; and U.S. Pat. No. 5,034,506, issued Jul. 23, 1991. In some embodiments, the morpholino-based oligomeric compound is a phosphorodiamidate morpholino oligomer (PMO) (e.g., as described in Iverson, Curr. Opin. Mol. Ther., 3:235-238, 2001; and Wang et al., J. Gene Med., 12:354-364, 2010; the disclosures of which are incorporated herein by reference in their entireties).

g. Peptide Nucleic Acids (PNAs)

[000263] In some embodiments, both a sugar and an internucleoside linkage (the backbone) of the nucleotide units of an oligonucleotide are replaced with novel groups. In some embodiments, the base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, for example, an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative publication that report the preparation of PNA compounds include, but are not limited to, US patent nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen *et al.*, Science, 1991, 254, 1497-1500.

h. Mixmers

[000264] In some embodiments, an oligonucleotide described herein may be a mixmer or comprise a mixmer sequence pattern. In general, mixmers are oligonucleotides that comprise both naturally and non-naturally occurring nucleosides or comprise two different types of non-naturally occurring nucleosides typically in an alternating pattern. Mixmers generally have higher binding affinity than unmodified oligonucleotides and may be used to specifically bind a target molecule, *e.g.*, to block a binding site on the target molecule. Generally, mixmers do not recruit an RNase to the target molecule and thus do not promote cleavage of the target molecule. Such oligonucleotides that are incapable of recruiting RNase H have been described, for example, see WO2007/112754 or WO2007/112753.

[000265] In some embodiments, the mixmer comprises or consists of a repeating pattern of nucleoside analogues and naturally occurring nucleosides, or one type of nucleoside analogue and a second type of nucleoside analogue. However, a mixmer need not comprise a repeating pattern and may instead comprise any arrangement of modified nucleosides and naturally occurring nucleosides or any arrangement of one type of modified nucleoside and a second type of modified nucleoside. The repeating pattern, may, for instance be every second or every third nucleoside is a modified nucleoside, such as LNA, and the remaining nucleosides are naturally

occurring nucleosides, such as DNA, or are a 2' substituted nucleoside analogue such as 2'-MOE or 2' fluoro analogues, or any other modified nucleoside described herein. It is recognized that the repeating pattern of modified nucleoside, such as LNA units, may be combined with modified nucleoside at fixed positions—*e.g.* at the 5' or 3' termini.

[000266] In some embodiments, a mixmer does not comprise a region of more than 5, more than 4, more than 3, or more than 2 consecutive naturally occurring nucleosides, such as DNA nucleosides. In some embodiments, the mixmer comprises at least a region consisting of at least two consecutive modified nucleosides, such as at least two consecutive LNAs. In some embodiments, the mixmer comprises at least a region consisting of at least three consecutive modified nucleoside units, such as at least three consecutive LNAs.

[000267] In some embodiments, the mixmer does not comprise a region of more than 7, more than 6, more than 5, more than 4, more than 3, or more than 2 consecutive nucleoside analogues, such as LNAs. In some embodiments, LNA units may be replaced with other nucleoside analogues, such as those referred to herein.

[000268] Mixmers may be designed to comprise a mixture of affinity enhancing modified nucleosides, such as in non-limiting example LNA nucleosides and 2'-O-Me nucleosides. In some embodiments, a mixmer comprises modified internucleoside linkages (*e.g.*, phosphorothioate internucleoside linkages or other linkages) between at least two, at least three, at least four, at least five or more nucleosides.

[000269] A mixmer may be produced using any suitable method. Representative U.S. patents, U.S. patent publications, and PCT publications that teach the preparation of mixmers include U.S. patent publication Nos. US20060128646, US20090209748, US20090298916, US20110077288, and US20120322851, and U.S. patent No. 7687617.

[000270] In some embodiments, a mixmer comprises one or more morpholino nucleosides. For example, in some embodiments, a mixmer may comprise morpholino nucleosides mixed (*e.g.*, in an alternating manner) with one or more other nucleosides (*e.g.*, DNA, RNA nucleosides) or modified nucleosides (*e.g.*, LNA, 2'-O-Me nucleosides).

[000271] In some embodiments, mixmers are useful for splice correcting or exon skipping, for example, as reported in Touznik A., et al., *LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts* Scientific Reports, volume 7, Article number: 3672 (2017), Chen S. et al., *Synthesis of a Morpholino Nucleic Acid (MNA)-Uridine Phosphoramidite, and Exon Skipping Using MNA/2'-O-Methyl Mixmer Antisense Oligonucleotide*, *Molecules* 2016, 21, 1582, the contents of each which are incorporated herein by reference.

i. Multimers

[000272] In some embodiments, molecular payloads may comprise multimers (e.g., concatemers) of 2 or more oligonucleotides connected by a linker. In this way, in some embodiments, the oligonucleotide loading of a complex can be increased beyond the available linking sites on a targeting agent (e.g., available thiol sites on an antibody) or otherwise tuned to achieve a particular payload loading content. Oligonucleotides in a multimer can be the same or different (e.g., targeting different genes or different sites on the same gene or products thereof).

[000273] In some embodiments, multimers comprise 2 or more oligonucleotides linked together by a cleavable linker. However, in some embodiments, multimers comprise 2 or more oligonucleotides linked together by a non-cleavable linker. In some embodiments, a multimer comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more oligonucleotides linked together. In some embodiments, a multimer comprises 2 to 5, 2 to 10 or 4 to 20 oligonucleotides linked together.

[000274] In some embodiments, a multimer comprises 2 or more oligonucleotides linked end-to-end (in a linear arrangement). In some embodiments, a multimer comprises 2 or more oligonucleotides linked end-to-end via an oligonucleotide based linker (e.g., poly-dT linker, an abasic linker). In some embodiments, a multimer comprises a 5' end of one oligonucleotide linked to a 3' end of another oligonucleotide. In some embodiments, a multimer comprises a 3' end of one oligonucleotide linked to a 3' end of another oligonucleotide. In some embodiments, a multimer comprises a 5' end of one oligonucleotide linked to a 5' end of another oligonucleotide. Still, in some embodiments, multimers can comprise a branched structure comprising multiple oligonucleotides linked together by a branching linker.

[000275] Further examples of multimers that may be used in the complexes provided herein are disclosed, for example, in US Patent Application Number 2015/0315588 A1, entitled *Methods of delivering multiple targeting oligonucleotides to a cell using cleavable linkers*, which was published on November 5, 2015; US Patent Application Number 2015/0247141 A1, entitled *Multimeric Oligonucleotide Compounds*, which was published on September 3, 2015, US Patent Application Number US 2011/0158937 A1, entitled *Immunostimulatory Oligonucleotide Multimers*, which was published on June 30, 2011; and US Patent Number 5,693,773, entitled *Triplex-Forming Antisense Oligonucleotides Having Abasic Linkers Targeting Nucleic Acids Comprising Mixed Sequences Of Purines And Pyrimidines*, which issued on December 2, 1997, the contents of each of which are incorporated herein by reference in their entireties.

C. Linkers

[000276] Complexes described herein generally comprise a linker that covalently links any one of the anti-TfR1 antibodies described herein to a molecular payload. A linker comprises at

least one covalent bond. In some embodiments, a linker may be a single bond, e.g., a disulfide bond or disulfide bridge, that covalently links an anti-TfR1 antibody to a molecular payload. However, in some embodiments, a linker may covalently link any one of the anti-TfR1 antibodies described herein to a molecular payload through multiple covalent bonds. In some embodiments, a linker may be a cleavable linker. However, in some embodiments, a linker may be a non-cleavable linker. A linker is typically stable *in vitro* and *in vivo*, and may be stable in certain cellular environments. Additionally, typically a linker does not negatively impact the functional properties of either the anti-TfR1 antibody or the molecular payload. Examples and methods of synthesis of linkers are known in the art (see, e.g. Kline, T. et al. “Methods to Make Homogenous Antibody Drug Conjugates.” *Pharmaceutical Research*, 2015, 32:11, 3480–3493.; Jain, N. et al. “Current ADC Linker Chemistry” *Pharm Res.* 2015, 32:11, 3526–3540.; McCombs, J.R. and Owen, S.C. “Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry” *AAPS J.* 2015, 17:2, 339–351.).

[000277] A linker typically will contain two different reactive species that allow for attachment to both the anti-TfR1 antibody and a molecular payload. In some embodiments, the two different reactive species may be a nucleophile and/or an electrophile. In some embodiments, a linker contains two different electrophiles or nucleophiles that are specific for two different nucleophiles or electrophiles. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody via conjugation to a lysine residue or a cysteine residue of the anti-TfR1 antibody. In some embodiments, a linker is covalently linked to a cysteine residue of an anti-TfR1 antibody via a maleimide-containing linker, wherein optionally the maleimide-containing linker comprises a maleimidocaproyl or maleimidomethyl cyclohexane-1-carboxylate group. In some embodiments, a linker is covalently linked to a cysteine residue of an anti-TfR1 antibody or thiol functionalized molecular payload via a 3-arylpropionitrile functional group. In some embodiments, a linker is covalently linked to a lysine residue of an anti-TfR1 antibody. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) a molecular payload, independently, via an amide bond, a carbamate bond, a hydrazide, a triazole, a thioether, and/or a disulfide bond.

i. Cleavable Linkers

[000278] A cleavable linker may be a protease-sensitive linker, a pH-sensitive linker, or a glutathione-sensitive linker. These linkers are typically cleavable only intracellularly and are preferably stable in extracellular environments, e.g., extracellular to a muscle cell.


[000279] Protease-sensitive linkers are cleavable by protease enzymatic activity. These linkers typically comprise peptide sequences and may be 2-10 amino acids, about 2-5 amino acids, about 5-10 amino acids, about 10 amino acids, about 5 amino acids, about 3 amino acids,

or about 2 amino acids in length. In some embodiments, a peptide sequence may comprise naturally-occurring amino acids, e.g. cysteine, alanine, or non-naturally-occurring or modified amino acids. Non-naturally occurring amino acids include β -amino acids, homo-amino acids, proline derivatives, 3-substituted alanine derivatives, linear core amino acids, N-methyl amino acids, and others known in the art. In some embodiments, a protease-sensitive linker comprises a valine-citrulline or alanine-citrulline sequence. In some embodiments, a protease-sensitive linker can be cleaved by a lysosomal protease, e.g. cathepsin B, and/or (e.g., and) an endosomal protease.


[000280] A pH-sensitive linker is a covalent linkage that readily degrades in high or low pH environments. In some embodiments, a pH-sensitive linker may be cleaved at a pH in a range of 4 to 6. In some embodiments, a pH-sensitive linker comprises a hydrazone or cyclic acetal. In some embodiments, a pH-sensitive linker is cleaved within an endosome or a lysosome.

[000281] In some embodiments, a glutathione-sensitive linker comprises a disulfide moiety. In some embodiments, a glutathione-sensitive linker is cleaved by a disulfide exchange reaction with a glutathione species inside a cell. In some embodiments, the disulfide moiety further comprises at least one amino acid, e.g., a cysteine residue.


[000282] In some embodiments, a linker comprises a valine-citrulline sequence (e.g., as described in US Patent 6,214,345, incorporated herein by reference). In some embodiments, before conjugation, a linker comprises a structure of:



[000283] In some embodiments, after conjugation, a linker comprises a structure of:




[000284] In some embodiments, before conjugation, a linker comprises a structure of:



(A)

wherein n is any number from 0-10. In some embodiments, n is 3.


[000285] In some embodiments, a linker comprises a structure of:



(H),

wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.

[000286] In some embodiments, a linker comprises a structure of:



(I),

wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.

ii. Non-cleavable Linkers

[000287] In some embodiments, non-cleavable linkers may be used. Generally, a non-cleavable linker cannot be readily degraded in a cellular or physiological environment. In some embodiments, a non-cleavable linker comprises an optionally substituted alkyl group, wherein the substitutions may include halogens, hydroxyl groups, oxygen species, and other common

substitutions. In some embodiments, a linker may comprise an optionally substituted alkyl, an optionally substituted alkylene, an optionally substituted arylene, a heteroarylene, a peptide sequence comprising at least one non-natural amino acid, a truncated glycan, a sugar or sugars that cannot be enzymatically degraded, an azide, an alkyne-azide, a peptide sequence comprising a LPXT sequence, a thioether, a biotin, a biphenyl, repeating units of polyethylene glycol or equivalent compounds, acid esters, acid amides, sulfamides, and/or an alkoxy-amine linker. In some embodiments, sortase-mediated ligation can be utilized to covalently link an anti-TfR1 antibody comprising a LPXT sequence to a molecular payload comprising a (G)_n sequence (see, e.g. Proft T. Sortase-mediated protein ligation: an emerging biotechnology tool for protein modification and immobilization. *Biotechnol Lett.* 2010, 32(1):1-10.).

[000288] In some embodiments, a linker may comprise a substituted alkylene, an optionally substituted alkenylene, an optionally substituted alkynylene, an optionally substituted cycloalkylene, an optionally substituted cycloalkenylene, an optionally substituted arylene, an optionally substituted heteroarylene further comprising at least one heteroatom selected from N, O, and S.; an optionally substituted heterocyclylene further comprising at least one heteroatom selected from N, O, and S, an imino, an optionally substituted nitrogen species, an optionally substituted oxygen species O, an optionally substituted sulfur species, or a poly(alkylene oxide), e.g. polyethylene oxide or polypropylene oxide. In some embodiments, a linker may be a non-cleavable N-gamma-maleimidobutyryl-oxysuccinimide ester (GMBS) linker.

iii. Linker conjugation

[000289] In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload via a phosphate, thioether, ether, carbon-carbon, carbamate, or amide bond. In some embodiments, a linker is covalently linked to an oligonucleotide through a phosphate or phosphorothioate group, e.g. a terminal phosphate of an oligonucleotide backbone. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody, through a lysine or cysteine residue present on the anti-TfR1 antibody.

[000290] In some embodiments, a linker, or a portion thereof is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by a cycloaddition reaction between an azide and an alkyne to form a triazole, wherein the azide or the alkyne may be located on the anti-TfR1 antibody, molecular payload, or the linker. In some embodiments, an alkyne may be a cyclic alkyne, e.g., a cyclooctyne. In some embodiments, an alkyne may be bicyclononyne (also known as bicyclo[6.1.0]nonyne or BCN) or substituted bicyclononyne. In some embodiments, a cyclooctyne is as described in International Patent Application Publication WO2011136645, published on November 3, 2011, entitled, “*Fused Cyclooctyne Compounds And Their Use In*

Metal-free Click Reactions". In some embodiments, an azide may be a sugar or carbohydrate molecule that comprises an azide. In some embodiments, an azide may be 6-azido-6-deoxygalactose or 6-azido-N-acetylgalactosamine. In some embodiments, a sugar or carbohydrate molecule that comprises an azide is as described in International Patent Application Publication WO2016170186, published on October 27, 2016, entitled, "*Process For The Modification Of A Glycoprotein Using A Glycosyltransferase That Is Or Is Derived From A $\beta(1,4)$ -N-Acetylgalactosaminyltransferase*". In some embodiments, a cycloaddition reaction between an azide and an alkyne to form a triazole, wherein the azide or the alkyne may be located on the anti-TfR1 antibody, molecular payload, or the linker is as described in International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, "*Modified antibody, antibody-conjugate and process for the preparation thereof*"; or International Patent Application Publication WO2016170186, published on October 27, 2016, entitled, "*Process For The Modification Of A Glycoprotein Using A Glycosyltransferase That Is Or Is Derived From A $\beta(1,4)$ -N-Acetylgalactosaminyltransferase*".


[000291] In some embodiments, a linker comprises a spacer, e.g., a polyethylene glycol spacer or an acyl/carbomoyl sulfamide spacer, e.g., a HydraSpaceTM spacer. In some embodiments, a spacer is as described in Verkade, J.M.M. et al., "*A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates*", *Antibodies*, 2018, 7, 12.

[000292] In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by the Diels-Alder reaction between a dienophile and a diene/hetero-diene, wherein the dienophile or the diene/hetero-diene may be located on the anti-TfR1 antibody, molecular payload, or the linker. In some embodiments a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by other pericyclic reactions such as an ene reaction. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by an amide, thioamide, or sulfonamide bond reaction. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by a condensation reaction to form an oxime, hydrazone, or semicarbazide group existing between the linker and the anti-TfR1 antibody and/or (e.g., and) molecular payload.

[000293] In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by a conjugate addition reaction between a nucleophile, e.g. an amine or a hydroxyl group, and an electrophile, e.g. a carboxylic acid, carbonate, or an aldehyde. In some embodiments, a nucleophile may exist on a linker and an electrophile may exist on an anti-TfR1 antibody or molecular payload prior to a reaction between a linker and an


anti-TfR1 antibody or molecular payload. In some embodiments, an electrophile may exist on a linker and a nucleophile may exist on an anti-TfR1 antibody or molecular payload prior to a reaction between a linker and an anti-TfR1 antibody or molecular payload. In some embodiments, an electrophile may be an azide, pentafluorophenyl, a silicon centers, a carbonyl, a carboxylic acid, an anhydride, an isocyanate, a thioisocyanate, a succinimidyl ester, a sulfosuccinimidyl ester, a maleimide, an alkyl halide, an alkyl pseudohalide, an epoxide, an episulfide, an aziridine, an aryl, an activated phosphorus center, and/or an activated sulfur center. In some embodiments, a nucleophile may be an optionally substituted alkene, an optionally substituted alkyne, an optionally substituted aryl, an optionally substituted heterocyclyl, a hydroxyl group, an amino group, an alkylamino group, an anilido group, and/or a thiol group.

[000294] In some embodiments, a linker comprises a valine-citrulline sequence covalently linked to a reactive chemical moiety (e.g., an azide moiety or a BCN moiety for click chemistry). In some embodiments, a linker comprising a valine-citrulline sequence covalently linked to a reactive chemical moiety (e.g., an azide moiety for click chemistry) comprises a structure of:




wherein n is any number from 0-10. In some embodiments, n is 3.

[000295] In some embodiments, a linker comprising the structure of Formula (A) is covalently linked (e.g., optionally via additional chemical moieties) to a molecular payload (e.g., an oligonucleotide). In some embodiments, a linker comprising the structure of Formula (A) is covalently linked to an oligonucleotide, e.g., through a nucleophilic substitution with amine-L1-oligonucleotides forming a carbamate bond, yielding a compound comprising a structure of:




wherein n is any number from 0-10. In some embodiments, n is 3.

[000296] In some embodiments, the compound of Formula (B) is further covalently linked via a triazole to additional moieties, wherein the triazole is formed by a click reaction between the azide of Formula (A) or Formula (B) and an alkyne provided on a bicyclononyne. In some embodiments, a compound comprising a bicyclononyne comprises a structure of:




wherein m is any number from 0-10. In some embodiments, m is 4.

[000297] In some embodiments, the azide of the compound of structure (B) forms a triazole via a click reaction with the alkyne of the compound of structure (C), forming a compound comprising a structure of:




wherein n is any number from 0-10, and wherein m is any number from 0-10. In some embodiments, n is 3 and m is 4.

[000298] In some embodiments, the compound of structure (D) is further covalently linked to a lysine of the anti-TfR1 antibody, forming a complex comprising a structure of:




wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000299] In some embodiments, the compound of Formula (C) is further covalently linked to a lysine of the anti-TfR1 antibody, forming a compound comprising a structure of:




wherein m is 0-15 (e.g., 4). It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (F) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000300] In some embodiments, the azide of the compound of structure (B) forms a triazole via a click reaction with the alkyne of the compound of structure (F), forming a complex comprising a structure of:




wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000301] In some embodiments, the azide of the compound of structure (A) forms a triazole via a click reaction with the alkyne of the compound of structure (F), forming a compound comprising a structure of:




wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4. In some embodiments, an oligonucleotide is covalently linked to a compound comprising a structure of formula (G), thereby forming a complex comprising a structure of formula (E). It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (G) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000302] In some embodiments, in any one of the complexes described herein, the anti-TfR1 antibody is covalently linked via a lysine of the anti-TfR1 antibody to a molecular payload (e.g., an oligonucleotide) via a linker comprising a structure of:



wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.


[000303] In some embodiments, in any one of the complexes described herein, the anti-TfR1 antibody is covalently linked via a lysine of the anti-TfR1 antibody to a molecular payload (e.g., an oligonucleotide) via a linker comprising a structure of:




(I),

wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.

[000304] In some embodiments, in formulae (B), (D), (E), and (I), L1 is a spacer that is a substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, -O-, -N(R^A)-, -S-, -C(=O)-, -C(=O)O-, -C(=O)NR^A-, -NR^AC(=O)-, -NR^AC(=O)R^A-, -C(=O)R^A-, -NR^AC(=O)O-, -NR^AC(=O)N(R^A)-, -OC(=O)-, -OC(=O)O-, -OC(=O)N(R^A)-, -S(O)₂NR^A-, -NR^AS(O)₂-, or a combination thereof, wherein each R^A is independently hydrogen or substituted or unsubstituted alkyl. In some embodiments, L1 is




wherein L2 is




; wherein *a* labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and *b* labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.

[000305] In some embodiments, L1 is:



wherein *a* labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and *b* labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.


[000306] In some embodiments, L1 is



[000307] In some embodiments, L1 is linked to a 5' phosphate of the oligonucleotide. In some embodiments, the phosphate is a phosphodiester. In some embodiments, L1 is linked to a 5' phosphorothioate of the oligonucleotide. In some embodiments, L1 is linked to a 5' phosphonoamidate of the oligonucleotide. In some embodiments, L1 is linked via a phosphorodiamidate linkage to the 5' end of the oligonucleotide.

[000308] In some embodiments, L1 is optional (e.g., need not be present).


[000309] In some embodiments, any one of the complexes described herein has a structure of:



(J),

wherein *n* is 0-15 (e.g., 3) and *m* is 0-15 (e.g., 4). It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (J) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000310] In some embodiments, any one of the complexes described herein has a structure of:



wherein n is 0-15 (e.g., 3) and m is 0-15 (e.g., 4).


[000311] In some embodiments, the oligonucleotide is modified to comprise an amine group at the 5' end, the 3' end, or internally (e.g., as an amine functionalized nucleobase), prior to linking to a compound, e.g., a compound of formula (A) or formula (G).

[000312] Although linker conjugation is described in the context of anti-TfR1 antibodies and oligonucleotide molecular payloads, it should be understood that use of such linker conjugation on other muscle-targeting agents, such as other muscle-targeting antibodies, and/or on other molecular payloads is contemplated.

D. Examples of Antibody-Molecular Payload Complexes


[000313] Further provided herein are non-limiting examples of complexes comprising any one the anti-TfR1 antibodies described herein covalently linked to any of the molecular payloads (e.g., an oligonucleotide) described herein. In some embodiments, the anti-TfR1 antibody (e.g., any one of the anti-TfR1 antibodies provided in Tables 2-7) is covalently linked to a molecular payload (e.g., an oligonucleotide such as the oligonucleotides provided in Table 8) via a linker. Any of the linkers described herein may be used. In some embodiments, if the molecular payload is an oligonucleotide, the linker is linked to the 5' end of the oligonucleotide, the 3' end of the oligonucleotide, or to an internal site of the oligonucleotide. In some embodiments, the linker is linked to the anti-TfR1 antibody via a thiol-reactive linkage (e.g., via a cysteine in the anti-TfR1 antibody). In some embodiments, the linker (e.g., a linker comprising a valine-citrulline sequence) is linked to the antibody (e.g., an anti-TfR1 antibody described herein) via an amine group (e.g., via a lysine in the antibody). In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000314] An example of a structure of a complex comprising an anti-TfR1 antibody covalently linked to a molecular payload via a linker is provided below:



wherein the linker is linked to the antibody via a thiol-reactive linkage (e.g., via a cysteine in the antibody). In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000315] Another example of a structure of a complex comprising an anti-TfR1 antibody covalently linked to a molecular payload via a linker is provided below:



(E)

wherein n is a number between 0-10, wherein m is a number between 0-10, wherein the linker is linked to the antibody via an amine group (e.g., on a lysine residue), and/or (e.g., and) wherein the linker is linked to the oligonucleotide (e.g., at the 5' end, 3' end, or internally). In some embodiments, the linker is linked to the antibody via a lysine, the linker is linked to the oligonucleotide at the 5' end, n is 3, and m is 4. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195). It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000316] It should be appreciated that antibodies can be linked to molecular payloads with different stoichiometries, a property that may be referred to as a drug to antibody ratios (DAR) with the “drug” being the molecular payload. In some embodiments, one molecular payload is linked to an antibody (DAR = 1). In some embodiments, two molecular payloads are linked to an antibody (DAR = 2). In some embodiments, three molecular payloads are linked to an

antibody (DAR = 3). In some embodiments, four molecular payloads are linked to an antibody (DAR = 4). In some embodiments, a mixture of different complexes, each having a different DAR, is provided. In some embodiments, an average DAR of complexes in such a mixture may be in a range of 1 to 3, 1 to 4, 1 to 5 or more. An average DAR of complexes in a mixture need not be an integer value. DAR may be increased by conjugating molecular payloads to different sites on an antibody and/or (e.g., and) by conjugating multimers to one or more sites on antibody. For example, a DAR of 2 may be achieved by conjugating a single molecular payload to two different sites on an antibody or by conjugating a dimer molecular payload to a single site of an antibody.

[000317] In some embodiments, the complex described herein comprises an anti-TfR1 antibody described herein (e.g., the antibodies provided in Tables 2-7) covalently linked to a molecular payload. In some embodiments, the complex described herein comprises an anti-TfR1 antibody described herein (e.g., the antibodies provided in Tables 2-7) covalently linked to molecular payload via a linker (e.g., a linker comprising a valine-citrulline sequence). In some embodiments, the linker (e.g., a linker comprising a valine-citrulline sequence) is linked to the antibody (e.g., an anti-TfR1 antibody described herein) via a thiol-reactive linkage (e.g., via a cysteine in the antibody). In some embodiments, the linker (e.g., a linker comprising a valine-citrulline sequence) is linked to the antibody (e.g., an anti-TfR1 antibody described herein) via an amine group (e.g., via a lysine in the antibody). In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000318] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 of any one of the antibodies listed in Table 2. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000319] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 71, or SEQ ID NO: 72, and a VL comprising the amino acid sequence of SEQ ID NO: 70. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000320] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 or SEQ ID NO: 76, and a VL comprising the amino acid sequence of SEQ ID NO: 74. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000321] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 or SEQ ID NO: 76, and a VL comprising the amino acid sequence of SEQ ID NO: 75. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000322] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 77, and a VL comprising the amino acid sequence of SEQ ID NO: 78. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000323] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 77 or SEQ ID NO: 79, and a VL comprising the amino acid sequence of SEQ ID NO: 80. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000324] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 154, and a VL comprising the amino acid sequence of SEQ ID NO: 155. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000325] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a

heavy chain comprising the amino acid sequence of SEQ ID NO: 84, SEQ ID NO: 86 or SEQ ID NO: 87 and a light chain comprising the amino acid sequence of SEQ ID NO: 85. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000326] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 or SEQ ID NO: 91, and a light chain comprising the amino acid sequence of SEQ ID NO: 89. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000327] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 or SEQ ID NO: 91, and a light chain comprising the amino acid sequence of SEQ ID NO: 90. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000328] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92 or SEQ ID NO: 94, and a light chain comprising the amino acid sequence of SEQ ID NO: 95. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000329] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92, and a light chain comprising the amino acid sequence of SEQ ID NO: 93. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000330] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a

heavy chain comprising the amino acid sequence of SEQ ID NO: 156, and a light chain comprising the amino acid sequence of SEQ ID NO: 157. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000331] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 97, SEQ ID NO: 98, or SEQ ID NO: 99 and a light chain comprising the amino acid sequence of SEQ ID NO: 85. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000332] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 or SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 89. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000333] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 or SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 90. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).


[000334] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 93. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000335] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a

heavy chain comprising the amino acid sequence of SEQ ID NO: 102 or SEQ ID NO: 103 and a light chain comprising the amino acid sequence of SEQ ID NO: 95. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).


[000336] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 158 or SEQ ID NO: 159 and a light chain comprising the amino acid sequence of SEQ ID NO: 157. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195).

[000337] In any of the example complexes described herein, in some embodiments, the anti-TfR1 antibody is covalently linked to the molecular payload via a linker comprising a structure of:




wherein n is 3, m is 4.

[000338] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 antibody comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 of any one of the antibodies listed in Table 2, wherein the complex has a structure of:




wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000339] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 antibody comprises a VH and VL of any one of the antibodies listed in Table 3, wherein the complex has a structure of:




wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000340] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 antibody comprises a heavy chain and light chain of any one of the antibodies listed in Table 4, wherein the complex has a structure of:




wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000341] In some embodiments, the complex described herein comprises an anti-TfR1 Fab covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 196-267, or complementary to any one of SEQ ID NO: 160-195) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 Fab comprises a heavy chain and light chain of any one of the antibodies listed in Table 5, wherein the complex has a structure of:




wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000342] In some embodiments, in any one of the examples of complexes described herein, $L1$ is:



wherein L2 is ; wherein *a* labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and *b* labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.

[000343] In some embodiments, L1 is:



wherein *a* labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and *b* labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.

[000344] In some embodiments, L1 is linked to a 5' phosphate of the oligonucleotide. In some embodiments, the phosphate is a phosphodiester. In some embodiments, L1 is linked to a 5' phosphorothioate of the oligonucleotide. In some embodiments, L1 is linked to a 5' phosphonoamidate of the oligonucleotide. In some embodiments, L1 is linked via a phosphorodiamidate linkage to the 5' end of the oligonucleotide.

[000345] In some embodiments, L1 is optional (e.g., need not be present).

III. Formulations

[000346] Complexes provided herein may be formulated in any suitable manner.

Generally, complexes provided herein are formulated in a manner suitable for pharmaceutical use. For example, complexes can be delivered to a subject using a formulation that minimizes degradation, facilitates delivery and/or (e.g., and) uptake, or provides another beneficial property to the complexes in the formulation. In some embodiments, provided herein are compositions comprising complexes and pharmaceutically acceptable carriers. Such compositions can be suitably formulated such that when administered to a subject, either into the immediate environment of a target cell or systemically, a sufficient amount of the complexes enter target muscle cells. In some embodiments, complexes are formulated in buffer solutions such as phosphate-buffered saline solutions, liposomes, micellar structures, and capsids.

[000347] It should be appreciated that, in some embodiments, compositions may include separately one or more components of complexes provided herein (e.g., muscle-targeting agents, linkers, molecular payloads, or precursor molecules of any one of them).

[000348] In some embodiments, complexes are formulated in water or in an aqueous solution (e.g., water with pH adjustments). In some embodiments, complexes are formulated in basic buffered aqueous solutions (e.g., PBS). In some embodiments, formulations as disclosed herein comprise an excipient. In some embodiments, an excipient confers to a composition improved stability, improved absorption, improved solubility and/or (e.g., and) therapeutic enhancement of the active ingredient. In some embodiments, an excipient is a buffering agent (e.g., sodium citrate, sodium phosphate, a tris base, or sodium hydroxide) or a vehicle (e.g., a buffered solution, petrolatum, dimethyl sulfoxide, or mineral oil).

[000349] In some embodiments, a complex or component thereof (e.g., oligonucleotide or antibody) is lyophilized for extending its shelf-life and then made into a solution before use (e.g., administration to a subject). Accordingly, an excipient in a composition comprising a complex, or component thereof, described herein may be a lyoprotectant (e.g., mannitol, lactose, polyethylene glycol, or polyvinyl pyrrolidone), or a collapse temperature modifier (e.g., dextran, ficoll, or gelatin).

[000350] In some embodiments, a pharmaceutical composition is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, administration. Typically, the route of administration is intravenous or subcutaneous.

[000351] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol,

propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. In some embodiments, formulations include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Sterile injectable solutions can be prepared by incorporating the complexes in a required amount in a selected solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.

[000352] In some embodiments, a composition may contain at least about 0.1% of the complex, or component thereof, or more, although the percentage of the active ingredient(s) may be between about 1% and about 80% or more of the weight or volume of the total composition. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

IV. Methods of Use / Treatment

[000353] Complexes comprising a muscle-targeting agent covalently linked to a molecular payload as described herein are effective in treating a subject having a dystrophinopathy, e.g., Duchenne muscular dystrophy. In some embodiments, complexes comprise a molecular payload that is an oligonucleotide, e.g., an antisense oligonucleotide that facilitates exon skipping of a pre-mRNA expressed from a mutated DMD allele.

[000354] In some embodiments, a subject may be a human subject, a non-human primate subject, a rodent subject, or any suitable mammalian subject. In some embodiments, a subject may have Duchenne muscular dystrophy or other dystrophinopathy. In some embodiments, a subject has a mutated DMD allele, which may optionally comprise at least one mutation in a DMD exon that causes a frameshift mutation and leads to improper RNA splicing/processing. In some embodiments, a subject is suffering from symptoms of a severe dystrophinopathy, e.g. muscle atrophy or muscle loss. In some embodiments, a subject has an asymptomatic increase in serum concentration of creatine phosphokinase (CK) and/or (e.g., and) muscle cramps with myoglobinuria. In some embodiments, a subject has a progressive muscle disease, such as Duchenne or Becker muscular dystrophy or DMD-associated dilated cardiomyopathy (DCM). In some embodiments, a subject is not suffering from symptoms of a dystrophinopathy.

[000355] In some embodiments, a subject has a mutation in a DMD gene that is amenable to exon 44 skipping. In some embodiments, a complex comprising a muscle-targeting agent covalently linked to a molecular payload as described herein is effective in treating a subject having a mutation in a DMD gene that is amenable to exon 44 skipping. In some embodiments,

a complex comprises a molecular payload that is an oligonucleotide, *e.g.*, an antisense oligonucleotide that facilitates skipping of exon 44 of a pre-mRNA, such as in a pre-mRNA encoded from a mutated DMD gene (*e.g.*, a mutated DMD gene that is amenable to exon 44 skipping).

[000356] An aspect of the disclosure includes methods involving administering to a subject an effective amount of a complex as described herein. In some embodiments, an effective amount of a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload can be administered to a subject in need of treatment. In some embodiments, a pharmaceutical composition comprising a complex as described herein may be administered by a suitable route, which may include intravenous administration, *e.g.*, as a bolus or by continuous infusion over a period of time. In some embodiments, administration may be performed by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, or intrathecal routes. In some embodiments, a pharmaceutical composition may be in solid form, aqueous form, or a liquid form. In some embodiments, an aqueous or liquid form may be nebulized or lyophilized. In some embodiments, a nebulized or lyophilized form may be reconstituted with an aqueous or liquid solution.

[000357] Compositions for intravenous administration may contain various carriers such as vegetable oils, dimethylactamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, and polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like). For intravenous injection, water soluble antibodies can be administered by the drip method, whereby a pharmaceutical formulation containing the antibody and a physiologically acceptable excipients is infused. Physiologically acceptable excipients may include, for example, 5% dextrose, 0.9% saline, Ringer's solution or other suitable excipients. Intramuscular preparations, *e.g.*, a sterile formulation of a suitable soluble salt form of the antibody, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution.

[000358] In some embodiments, a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload is administered via site-specific or local delivery techniques. Examples of these techniques include implantable depot sources of the complex, local delivery catheters, site specific carriers, direct injection, or direct application.

[000359] In some embodiments, a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload is administered at an effective concentration that confers therapeutic effect on a subject. Effective amounts vary,

as recognized by those skilled in the art, depending on the severity of the disease, unique characteristics of the subject being treated, e.g., age, physical conditions, health, or weight, the duration of the treatment, the nature of any concurrent therapies, the route of administration and related factors. These related factors are known to those in the art and may be addressed with no more than routine experimentation. In some embodiments, an effective concentration is the maximum dose that is considered to be safe for the patient. In some embodiments, an effective concentration will be the lowest possible concentration that provides maximum efficacy.

[000360] Empirical considerations, e.g., the half-life of the complex in a subject, generally will contribute to determination of the concentration of pharmaceutical composition that is used for treatment. The frequency of administration may be empirically determined and adjusted to maximize the efficacy of the treatment.

[000361] The efficacy of treatment may be assessed using any suitable methods. In some embodiments, the efficacy of treatment may be assessed by evaluation of observation of symptoms associated with a dystrophinopathy, e.g., muscle atrophy or muscle weakness, through measures of a subject's self-reported outcomes, e.g., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, or by quality-of-life indicators, e.g., lifespan.

[000362] In some embodiments, a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload described herein is administered to a subject at an effective concentration sufficient to modulate activity or expression of a target gene by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% relative to a control, e.g. baseline level of gene expression prior to treatment.

ADDITIONAL EMBODIMENTS

1. A complex comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to a molecular payload configured for inducing skipping of exon 44 in a DMD pre-mRNA, wherein the anti-TfR1 antibody is an antibody identified in any one of Tables 2-7.
2. The complex of embodiment 1, wherein the anti-TfR1 antibody comprises:
 - (i) a heavy chain complementarity determining region 1 (CDR-H1) of SEQ ID NO: 33, a heavy chain complementarity determining region 2 (CDR-H2) of SEQ ID NO: 34, a heavy chain complementarity determining region 3 (CDR-H3) of SEQ ID NO: 35, a light chain complementarity determining region 1 (CDR-L1) of SEQ ID NO: 36, a light chain complementarity determining region 2 (CDR-L2) of SEQ ID NO: 37, and a light chain complementarity determining region 3 (CDR-L3) of SEQ ID NO: 32;

(ii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 8, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(iii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 20, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(iv) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 24, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(v) a CDR-H1 of SEQ ID NO: 51, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50;

(vi) a CDR-H1 of SEQ ID NO: 64, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50; or

(vii) a CDR-H1 of SEQ ID NO: 67, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50.

3. The complex of embodiment 1 or embodiment 2, wherein the anti-TfR1 antibody comprises:

(i) a heavy chain variable region (VH) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a light chain variable region (VL) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(ii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 69; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 71; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iv) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 72; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(v) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(vi) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

- (vii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;
- (viii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 78;
- (ix) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 79; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80; or
- (x) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80.

4. The complex of any one of embodiments 1 to 3, wherein the anti-TfR1 antibody comprises:

- (i) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
- (ii) a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (iii) a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (iv) a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (v) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
- (vi) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
- (vii) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
- (viii) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78;
- (ix) a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80; or
- (x) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

5. The complex of any one of embodiments 1 to 4, wherein the anti-TfR1 antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, an scFv, an Fv, or a full-length IgG.

6. The complex of embodiment 5, wherein the anti-TfR1 antibody is a Fab fragment.
7. The complex of embodiment 6, wherein the anti-TfR1 antibody comprises:
 - (i) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;
 - (ii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 97; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
 - (iii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 98; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
 - (iv) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 99; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
 - (v) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;
 - (vi) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;
 - (vii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;
 - (viii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 93;
 - (ix) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 103; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95; or
 - (x) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95.

8. The complex of embodiment 6 or embodiment 7, wherein the anti-TfR1 antibody comprises:

(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 97; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 98; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 99; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 93;

(ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 103; and a light chain comprising the amino acid sequence of SEQ ID NO: 95; or

(x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

9. The complex of any one of embodiments 1 to 8, wherein the anti-TfR1 antibody does not specifically bind to the transferrin binding site of the transferrin receptor 1 and/or wherein the anti-TfR1 antibody does not inhibit binding of transferrin to the transferrin receptor 1.

10. The complex of any one of embodiments 1 to 9, wherein the molecular payload comprises an oligonucleotide.

11. The complex of embodiment 10, wherein the oligonucleotide promotes antisense-mediated exon skipping in the DMD pre-RNA.

12. The complex of embodiment 10 or 11, wherein the oligonucleotide comprises a region of complementarity to a splicing feature of the DMD pre-mRNA.

13. The complex of embodiment 12, wherein the splicing feature is an exonic splicing enhancer (ESE) of the DMD pre-mRNA.
14. The complex of embodiment 13, wherein the splicing feature is in exon 44 of the DMD pre-mRNA, optionally wherein the ESE comprises a sequence of any one of SEQ ID NOs: 286-296.
15. The complex of embodiment 12, wherein the splicing feature is a branch point, a splice donor site, or a splice acceptor site.
16. The complex of embodiment 15, wherein the splicing feature is across the junction of exon 43 and intron 43, in intron 43, across the junction of intron 43 and exon 44, across the junction of exon 44 and intron 44, in intron 44, or across the junction of intron 44 and exon 45 of the DMD pre-mRNA, optionally wherein the splicing feature comprises a sequence of any one of SEQ ID NOs: 282-285 and 297-301.
17. The complex of any one of embodiments 12 to 16, wherein the region of complementarity comprises at least 4 consecutive nucleosides complementary to the splicing feature.
18. The complex of any one of embodiments 1 to 9, wherein the molecular payload comprises an oligonucleotide comprising a sequence complementary to any one of SEQ ID NOs: 160-195 or comprising a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
19. The complex of any one of embodiments 10 to 18, wherein the oligonucleotide comprises at least one modified internucleoside linkage.
20. The complex of embodiment 19, wherein the at least one modified internucleoside linkage is a phosphorothioate linkage.
21. The complex of any one of embodiments 10 to 20, wherein the oligonucleotide comprises one or more modified nucleosides.

22. The complex of embodiment 21, wherein the one or more modified nucleosides are 2'-modified nucleosides.
23. The complex of any one of embodiments 10 to 18, wherein the oligonucleotide comprises one or more phosphorodiamidate morpholinos, optionally wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).
24. The complex of any one of embodiments 1 to 23, wherein the anti-TfR1 antibody is covalently linked to the molecular payload via a cleavable linker.
25. The complex of embodiment 24, wherein the cleavable linker comprises a valine-citrulline sequence.
26. The complex of any one of embodiments 1 to 25, wherein the anti-TfR1 antibody is covalently linked to the molecular payload via conjugation to a lysine residue or a cysteine residue of the antibody.
27. A complex comprising an anti-TfR1 antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 44 in a DMD pre-mRNA, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ ID NOs: 160-195.
28. The complex of embodiment 27, wherein the anti-TfR1 antibody is an antibody identified in any one of Tables 2-7.
29. A complex comprising an anti-TfR1 antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 44 in a DMD pre-mRNA, wherein the oligonucleotide comprises a region of complementarity to a splicing feature of the DMD pre-mRNA.
30. An oligonucleotide that targets DMD, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ ID NOs: 160-195.
31. The oligonucleotide of embodiment 30, wherein the region of complementarity comprises at least 15 consecutive nucleosides complementary to any one of SEQ ID NOs: 160-195.

32. The oligonucleotide of embodiment 30 or 31, wherein the oligonucleotide comprises at least 15 consecutive nucleosides of any one of SEQ ID NOs: 196-267, optionally wherein the oligonucleotide comprises a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
33. A method of delivering a molecular payload to a cell, the method comprising contacting the cell with the complex of any one of embodiments 1 to 26.
34. A method of delivering an oligonucleotide to a cell, the method comprising contacting the cell with the complex of any one of embodiments 27 to 29.
35. A method of promoting the expression or activity of a dystrophin protein in a cell, the method comprising contacting the cell with the complex of any one of embodiments 1 to 26 in an amount effective for promoting internalization of the molecular payload to the cell, optionally wherein the cell is a muscle cell.
36. A method of promoting the expression or activity of a dystrophin protein in a cell, the method comprising contacting the cell with the complex of any one of embodiments 27 to 29 in an amount effective for promoting internalization of the oligonucleotide to the cell, optionally wherein the cell is a muscle cell.
37. The method of embodiment 35 or 36, wherein the cell is *in vitro*.
38. The method of embodiment 35 or 36, wherein the cell is in a subject.
39. The method of embodiment 38, wherein the subject is a human.
40. The method of embodiment 39, wherein the subject has a DMD gene that is amenable to skipping of exon 44.
41. The method of any one of embodiments 35 to 40, wherein the dystrophin protein is a truncated dystrophin protein.

42. A method of treating a subject having a mutated DMD allele that is associated with a dystrophinopathy, the method comprising administering to the subject an effective amount of the complex of any one of embodiments 1 to 29.
43. A method of promoting skipping of exon 44 of a DMD pre-mRNA transcript in a cell, the method comprising contacting the cell with an effective amount of the complex of any one of embodiments 1 to 29.
44. A method of treating a subject having a mutated DMD allele that is associated with a dystrophinopathy, the method comprising administering to the subject an effective amount of the complex of any one of embodiments 1 to 29.

EXAMPLES

Example 1. Exon-skipping activity of anti-TfR1 antibody conjugates in Duchenne muscular dystrophy patient myotubes

[000363] In this study, the exon-skipping activities of anti-TfR1 antibody conjugates comprising an anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to a DMD exon 51-skipping antisense oligonucleotide (ASO) were evaluated. The DMD exon 51-skipping ASO is a phosphorodiamidate morpholino oligomer (PMO) of 30 nucleotides in length and targets an ESE in DMD exon 51 having the sequence TGGAGGT (SEQ ID NO: 322). Immortalized human myoblasts bearing an exon 52 deletion in the DMD gene were thawed and seeded at a density of 1e6 cell/flask in Promocell Skeletal Cell Growth Media (with 5% FBS and 1x Pen-Strep) and allowed to grow to confluency. Once confluent, cells were trypsinized and pelleted via centrifugation and resuspended in fresh Promocell Skeletal Cell Growth Media. The cell number was counted and cells were seeded into Matrigel-coated 96-well plates at a density of 50,000 cells/well. Cells were allowed to recover for 24 hours. Cells were induced to differentiate into myotubes by aspirating the growth media and replacing with differentiation media with no serum. Cells were then treated with the DMD exon 51-skipping oligonucleotide (not covalently linked to an antibody – “naked”) at 10 μM ASO or the anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to the DMD exon 51-skipping oligonucleotide at 10 μM ASO equivalent. Cells were incubated with test articles for ten days then total RNA was harvested from the 96 well plates. cDNA synthesis was performed on 75 ng of total RNA, and mutation specific PCRs were performed to evaluate the degree of exon 51 skipping in the cells. Mutation-specific PCR products were run on a 4% agarose gel and visualized using SYBR gold. Densitometry was used to calculate the relative amounts of the skipped and unskipped amplicon and exon skipping was

determined as a ratio of the Exon 51 skipped amplicon divided by the total amount of amplicon present:

$$\% \text{Exon Skipping} = \frac{\text{Skipped Amplicon}}{(\text{Skipped Amplicon} + \text{Unskipped Amplicon})} * 100.$$

[000364] The results demonstrate that the conjugate resulted in enhanced exon skipping compared to the naked DMD exon 51-skipping oligonucleotide in patient myotubes (FIG. 1). This indicates that anti-TfR1 Fab 3M12 VH4/Vκ3 enabled cellular internalization of the conjugate into muscle cells resulting in activity of the exon 51-skipping oligonucleotide in the muscle cells. Similarly, an anti-TfR1 antibody (*e.g.*, anti-TfR1 Fab 3M12 VH4/Vκ3) can enable internalization of a conjugate comprising the anti-TfR1 antibody covalently linked to other exon skipping oligonucleotides (*e.g.*, an exon skipping oligonucleotide provided herein, such as an exon 44 skipping oligonucleotide) into muscle cells and facilitate activity of the exon skipping oligonucleotide in the muscle cells.

Example 2. Exon skipping activity of anti-TfR1 Fab-ASO conjugate in vivo in cynomolgus monkeys

[000365] Anti-TfR1 Fab 3M12 VH4/Vκ3 was covalently linked to the DMD exon 51-skipping antisense oligonucleotide (ASO) that was used in Example 1. The exon skipping activity of the conjugate was tested in vivo in healthy non-human primates. Naïve male cynomolgus monkeys (n= 4-5 per group) were administered two doses of vehicle, 30 mg/kg naked ASO (*i.e.*, not covalently linked to an antibody), or 122 mg/kg anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to the DMD exon 51-skipping oligonucleotide (30 mg/kg ASO equivalent) via intravenous infusion on days 1 and 8. Animals were sacrificed and tissues harvested either 2 weeks or 4 weeks after the first dose was administered. Total RNA was collected from tissue samples using a Promega Maxwell® RSC instrument and cDNA synthesis was performed using qScript cDNA SuperMix. Assessment of exon 51 skipping was performed using end-point PCR.

[000366] Capillary electrophoresis of the PCR products was used to assess exon skipping, and % exon 51 skipping was calculated using the following formula:

$$\% \text{Exon Skipping} = \frac{\text{Molarity of Skipped Band}}{\text{Molarity of Skipped Band} + \text{Molarity of Unskipped Band}} * 100.$$

Calculated exon 51 skipping results are shown in Table 10.

Table 10. Exon 51 skipping of DMD mRNA in cynomolgus monkey

Time Group	2 weeks			4 weeks	
	Vehicle	Naked ASO ^a	Conjugate	Naked ASO ^a	Conjugate
Conjugate dose ^b	0	n/a	122	n/a	122

ASO Dose ^c	0	30	30	30	30
Quadriceps ^d	0.00 (0.00)	1.216 (1.083)	4.906 (3.131)	0.840 (1.169)	1.708 (1.395)
Diaphragm ^d	0.00 (0.00)	1.891 (2.911)	7.315 (1.532)	0.717 (1.315)	9.225 (4.696)
Heart ^d	0.00 (0.00)	0.043 (0.096)	3.42 (1.192)	0.00 (0.00)	4.525 (1.400)
Biceps ^d	0.00 (0.00)	0.607 (0.615)	3.129 (0.912)	1.214 (1.441)	4.863 (3.881)
Tibialis anterior ^d	0.00 (0.00)	0.699 (0.997)	1.042 (0.685)	0.384 (0.615)	0.816 (0.915)
Gastrocnemius ^d	0.00 (0.00)	0.388 (0.573)	2.424 (2.329)	0.00 (0.00)	5.393 (2.695)

^aASO = antisense oligonucleotide.

^bConjugate doses are listed as mg/kg of anti-TfR1 Fab 3M12 VH4/Vκ3-ASO conjugate.

^cASO doses are listed as mg/kg ASO or ASO equivalent of the anti-TfR1 Fab 3M12 VH4/Vκ3-ASO dose.

^dExon skipping values are mean % exon 51 skipping with standard deviations (n=5) in parentheses.

[000367] Tissue ASO accumulation was also quantified using a hybridization ELISA with a probe complementary to the ASO sequence. A standard curve was generated and ASO levels (in ng/g) were derived from a linear regression of the standard curve. The ASO was distributed to all tissues evaluated at a higher level following the administration of the anti-TfR1 Fab VH4/Vκ3-ASO conjugate as compared to the administration of naked ASO. Intravenous administration of naked ASO resulted in levels of ASO that were close to background levels in all tissues evaluated at 2 and 4 weeks after the first dose was administered. Administration of anti-TfR1 Fab VH4/Vκ3-ASO conjugate resulted in distribution of ASO through the tissues evaluated with a rank order of heart>diaphragm>bicep>quadriceps>gastrocnemius>tibialis anterior 2 weeks after first dosing. The duration of tissue concentration was also assessed. Concentrations of the ASO in quadriceps, bicep and diaphragm decreased by less than 50% over the time period evaluated (2 to 4 weeks), while levels of ASO in the heart, tibialis anterior, and gastrocnemius remained virtually unchanged (Table 11). This indicates that anti-TfR1 Fab 3M12 VH4/Vκ3 enabled cellular internalization of the conjugate into muscle cells *in vivo*, resulting in activity of the exon skipping oligonucleotide in the muscle cells. Similarly, an anti-TfR1 antibody (*e.g.*, anti-TfR1 Fab 3M12 VH4/Vκ3) *in vivo* can enable internalization of a conjugate comprising the anti-TfR1 antibody covalently linked to other exon skipping oligonucleotides (*e.g.*, an exon skipping oligonucleotide provided herein, such as an exon 44 skipping oligonucleotide) into muscle cells and facilitate activity of the exon skipping oligonucleotide in the muscle cells.

Table 11. Tissue distribution of DMD exon 51 skipping ASO in cynomolgus monkeys

Time	2 weeks			4 weeks	
Group	Vehicle	Naked ASO ^a	Conjugate	Naked ASO ^a	Conjugate
Conjugate Dose ^b	0	n/a	122	n/a	122
ASO Dose ^c	0	30	30	30	30

Quadriceps ^d	0 (59.05)	696.8 (868.15)	2436 (954.0)	197 (134)	682 (281)
Diaphragm ^d	0± (144.3)	580.02 (360.11)	6750 (2256)	60 (120)	3131 (1618)
Heart ^d	0 (396.03)	1449 (1337)	27138 (6315)	943 (1803)	30410 (9247)
Biceps ^d	0 (69.58)	615.63 (335.17)	2840 (980.31)	130 (80)	1326 (623)
Tibialis anterior ^d	0 (76.31)	564.71 (327.88)	1591 (253.50)	169 (110)	1087 (514)
Gastrocnemius ^d	0 (41.15)	705.47 (863.75)	2096 (474.04)	170 (69)	1265 (272)

^aASO = Antisense oligonucleotide.

^bConjugate doses are listed as mg/kg of anti-TfR1 Fab 3M12 VH4/Vκ3-ASO conjugate.

^cASO doses are listed as mg/kg ASO or ASO equivalent of the anti-TfR1 Fab 3M12 VH4/Vκ3-ASO conjugate dose.

^dASO values are mean concentrations of ASO in tissue as ng/g with standard deviations (n=5) in parentheses.

Example 3. Exon-skipping activity of anti-TfR1 antibody conjugates in Duchenne muscular dystrophy patient myotubes

[000368] In this study, the exon-skipping activities of anti-TfR1 antibody conjugates comprising an anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to a DMD exon 44-skipping antisense oligonucleotide (ASO) are evaluated. The DMD exon 44-skipping ASO is a phosphorodiamidate morpholino oligomer (PMO) and targets a DMD exon 44 splicing feature. Immortalized human myoblasts are thawed and seeded at a density of 1e6 cell/flask in Promocell Skeletal Cell Growth Media (with 5% FBS and 1x Pen-Strep) and allowed to grow to confluency. Once confluent, cells are trypsinized and pelleted via centrifugation and resuspended in fresh Promocell Skeletal Cell Growth Media. The cell number is counted and cells are seeded into Matrigel-coated 96-well plates at a density of 50,000 cells/well. Cells are allowed to recover for 24 hours. Cells are induced to differentiate into myotubes by aspirating the growth media and replacing with differentiation media with no serum. Cells are then treated with the DMD exon 44-skipping oligonucleotide (not covalently linked to an antibody – “naked”) at 10 μM ASO or the anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to the DMD exon 44-skipping oligonucleotide at 10 μM ASO equivalent. Cells are incubated with test articles for ten days then total RNA is harvested from the 96 well plates. cDNA synthesis is performed on 75 ng of total RNA, and mutation specific PCRs are performed to evaluate the degree of exon 44 skipping in the cells. PCR products are measured using capillary electrophoresis with UV detection. Molarity is calculated and relative amounts of the skipped and unskipped amplicon are determined. Exon skipping is determined as a ratio of the Exon 44 skipped amplicon divided by the total amount of amplicon present, according to the following formula:

$$\%Exon\ Skipping = \frac{Skipped\ Amplicon}{(Skipped\ Amplicon + Unskipped\ Amplicon)} * 100$$

[000369] The results demonstrate that the conjugates facilitate enhanced exon skipping compared to the naked DMD exon 44-skipping oligonucleotide in patient myotubes. This indicates that anti-TfR1 Fab 3M12 VH4/Vκ3 enables cellular internalization of the conjugate into muscle cells resulting in activity of the exon 44-skipping oligonucleotide in the muscle cells.

EQUIVALENTS AND TERMINOLOGY

[000370] The disclosure illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of”, and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the disclosure. Thus, it should be understood that although the present disclosure has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this disclosure.

[000371] In addition, where features or aspects of the disclosure are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

[000372] It should be appreciated that, in some embodiments, sequences presented in the sequence listing may be referred to in describing the structure of an oligonucleotide or other nucleic acid. In such embodiments, the actual oligonucleotide or other nucleic acid may have one or more alternative nucleotides or nucleosides (e.g., an RNA counterpart of a DNA nucleoside or a DNA counterpart of an RNA nucleoside) and/or (e.g., and) one or more modified nucleotides/nucleosides and/or (e.g., and) one or more modified internucleoside linkages and/or (e.g., and) one or more other modification compared with the specified sequence while retaining essentially same or similar complementary properties as the specified sequence.

[000373] The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted

by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (*i.e.*, meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (*e.g.*, “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[000374] Embodiments of this invention are described herein. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description.

[000375] The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

CLAIMS

What is claimed is:

1. A complex comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 44 in a DMD pre-mRNA, wherein the oligonucleotide comprises a region of complementarity that is complementary with at least 8 consecutive nucleotides of any one of SEQ ID NOs: 160-195.
2. The complex of claim 1, wherein the anti-TfR1 antibody comprises:
 - (i) a heavy chain complementarity determining region 1 (CDR-H1) of SEQ ID NO: 33, a heavy chain complementarity determining region 2 (CDR-H2) of SEQ ID NO: 34, a heavy chain complementarity determining region 3 (CDR-H3) of SEQ ID NO: 35, a light chain complementarity determining region 1 (CDR-L1) of SEQ ID NO: 36, a light chain complementarity determining region 2 (CDR-L2) of SEQ ID NO: 37, and a light chain complementarity determining region 3 (CDR-L3) of SEQ ID NO: 32;
 - (ii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 8, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (iii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 20, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (iv) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 24, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (v) a CDR-H1 of SEQ ID NO: 51, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50;
 - (vi) a CDR-H1 of SEQ ID NO: 64, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50; or
 - (vii) a CDR-H1 of SEQ ID NO: 67, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50.
3. The complex of claim 1 or claim 2, wherein the anti-TfR1 antibody comprises:

(i) a heavy chain variable region (VH) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a light chain variable region (VL) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(ii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 69; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 71; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iv) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 72; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(v) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(vi) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(vii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(viii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 78;

(ix) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 79; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80; or

(x) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80.

4. The complex of any one of claims 1 to 3, wherein the anti-TfR1 antibody comprises:

(i) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75;

(ii) a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70;

(iii) a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70;

(iv) a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70;

(v) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74;

(vi) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75;

- (vii) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
- (viii) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78;
- (ix) a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80; or
- (x) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

5. The complex of any one of claims 1 to 4, wherein the anti-TfR1 antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, an scFv, an Fv, or a full-length IgG.

6. The complex of claim 5, wherein the anti-TfR1 antibody is a Fab fragment.

7. The complex of claim 6, wherein the anti-TfR1 antibody comprises:

- (i) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;

- (ii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 97; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

- (iii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 98; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

- (iv) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 99; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

- (v) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

- (vi) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;

(vii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(viii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 93;

(ix) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 103; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95; or

(x) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95.

8. The complex of claim 6 or claim 7, wherein the anti-TfR1 antibody comprises:

(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 97; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 98; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 99; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 93;

(ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 103; and a light chain comprising the amino acid sequence of SEQ ID NO: 95; or

(x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

9. The complex of any one of claims 1 to 8, wherein the anti-TfR1 antibody does not specifically bind to the transferrin binding site of the transferrin receptor 1 and/or wherein the anti-TfR1 antibody does not inhibit binding of transferrin to the transferrin receptor 1.
10. The complex of any one of claims 1 to 9, wherein the oligonucleotide comprises a region of complementarity to at least 4 consecutive nucleotides of a splicing feature of the DMD pre-mRNA.
11. The complex of claim 10, wherein the splicing feature is an exonic splicing enhancer (ESE) in exon 44 of the DMD pre-mRNA, optionally wherein the ESE comprises a sequence of any one of SEQ ID NOs: 286-296.
12. The complex of claim 10, wherein the splicing feature is a branch point, a splice donor site, or a splice acceptor site, optionally wherein the splicing feature is across the junction of exon 43 and intron 43, in intron 43, across the junction of intron 43 and exon 44, across the junction of exon 44 and intron 44, in intron 44, or across the junction of intron 44 and exon 45 of the DMD pre-mRNA, and further optionally wherein the splicing feature comprises a sequence of any one of SEQ ID NOs: 282-285 and 297-301.
13. The complex of any one of claims 1 to 9, wherein the oligonucleotide comprises a sequence complementary to any one of SEQ ID NOs: 160-195 or comprises a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
14. The complex of any one of claims 1 to 13, wherein the oligonucleotide comprises one or more phosphorodiamidate morpholinos, optionally wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).
15. The complex of any one of claims 1 to 14, wherein the anti-TfR1 antibody is covalently linked to the oligonucleotide via a cleavable linker, optionally wherein the cleavable linker comprises a valine-citrulline sequence.

16. The complex of any one of claims 1 to 15, wherein the anti-TfR1 antibody is covalently linked to the oligonucleotide via conjugation to a lysine residue or a cysteine residue of the antibody.
17. An oligonucleotide that targets DMD, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ ID NOs: 160-195, optionally wherein the region of complementarity comprises at least 15 consecutive nucleosides complementary to any one of SEQ ID NOs: 160-195.
18. The oligonucleotide of claim 17, wherein the oligonucleotide comprises at least 15 consecutive nucleosides of any one of SEQ ID NOs: 196-267, optionally wherein the oligonucleotide comprises a sequence of any one of SEQ ID NOs: 196-267, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
19. A method of delivering an oligonucleotide to a cell, the method comprising contacting the cell with the complex of any one of claims 1 to 16 or with the oligonucleotide of claim 17 or claim 18.
20. A method of promoting the expression or activity of a dystrophin protein in a cell, the method comprising contacting the cell with the complex of any one of claims 1 to 16 or with the oligonucleotide of claim 17 or claim 18 in an amount effective for promoting internalization of the oligonucleotide to the cell, optionally wherein the cell is a muscle cell.

1/1




FIG. 1

```

<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ST26SequenceListing PUBLIC "-//WIPO//DTD Sequence Listing 1.3//EN"
"ST26SequenceListing_V1_3.dtd">
<ST26SequenceListing dtdVersion="V1_3" fileName="D082470063W000-SEQ-COB.xml"
softwareName="WIPO Sequence" softwareVersion="2.1.0" productionDate="2022-07-07">
  <ApplicantFileReference>D0824.70063W000</ApplicantFileReference>
  <EarliestPriorityApplicationIdentification>
    <IPOfficeCode>US</IPOfficeCode>
    <ApplicationNumberText>63/220,108</ApplicationNumberText>
    <FilingDate>2021-07-09</FilingDate>
  </EarliestPriorityApplicationIdentification>
  <ApplicantName languageCode="en">Dyne Therapeutics, Inc.</ApplicantName>
  <InventionTitle languageCode="en">MUSCLE TARGETING COMPLEXES AND USES
THEREOF FOR TREATING DYSTROPHINOPATHIES</InventionTitle>
  <SequenceTotalQuantity>355</SequenceTotalQuantity>
  <SequenceData sequenceIDNumber="1">
    <INSDSeq>
      <INSDSeq_length>8</INSDSeq_length>
      <INSDSeq_moltype>AA</INSDSeq_moltype>
      <INSDSeq_division>PAT</INSDSeq_division>
      <INSDSeq_feature-table>
        <INSDFeature>
          <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
          <INSDFeature_qual>
            <INSDQualifier id="q1">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
    </INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q2">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>

```

```

                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>
                                <INSDSeq_sequence>GFNIKDDY</INSDSeq_sequence>
                            </INSDSeq>
                        </SequenceData>
                        <SequenceData sequenceIDNumber="2">
                            <INSDSeq>
                                <INSDSeq_length>8</INSDSeq_length>
                                <INSDSeq_moltype>AA</INSDSeq_moltype>
                                <INSDSeq_division>PAT</INSDSeq_division>
                                <INSDSeq_feature-table>
                                    <INSDFeature>
                                        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                                        <INSDFeature_qual>
                                            <INSDQualifier id="q3">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                            </INSDQualifier>
                                        </INSDFeature_qual>
                                    </INSDFeature>
                                    <INSDFeature>
                                        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                                        <INSDFeature_qual>
                                            <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                            </INSDQualifier>
                                            <INSDQualifier id="q4">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                            </INSDQualifier>
                                        </INSDFeature_qual>
                                    </INSDFeature>
                                </INSDSeq_feature-table>
                                <INSDSeq_sequence>IDPENGDT</INSDSeq_sequence>
                            </INSDSeq>
                        </SequenceData>
                        <SequenceData sequenceIDNumber="3">

```



```

        <INSDSeq>
            <INSDSeq_length>10</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..10</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q5">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..10</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q6">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>
            <INSDSeq_sequence>TLWLRRGLDY</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="4">
        <INSDSeq>
            <INSDSeq_length>11</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

```

```

<INSDFeature_location>1..11</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q7">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q8">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>KSLHLSNGYTY</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="5">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="6">
  <INSDSeq>
    <INSDSeq_length>9</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

```

```

<INSDFeature_location>1..9</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q11">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q12">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>MQHLEYPFT</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="7">
    <INSDSeq>
        <INSDSeq_length>5</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q13">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>

```

```

        </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
        <INSDFeature_qual>
            <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
            </INSDQualifier>
            <INSDQualifier id="q14">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
            </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>DDYMY</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="8">
    <INSDSeq>
        <INSDSeq_length>17</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q15">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

```

```

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q16">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>
                                <INSDSeq_sequence>WIDPENGDTYASKFQD</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="9">
    <INSDSeq>
        <INSDSeq_length>8</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier id="q17">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q18">

<INSDQualifier_name>organism</INSDQualifier_name>

```

```

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>WLRRGLDY</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="10">
  <INSDSeq>
    <INSDSeq_length>16</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..16</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q19">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..16</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q20">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>RSSKSLLHSNGYTYLF</INSDSeq_sequence>
</INSDSeq>

```

```

</SequenceData>
<SequenceData sequenceIDNumber="11">
  <INSDSeg>
    <INSDSeg_length>7</INSDSeg_length>
    <INSDSeg_moltype>AA</INSDSeg_moltype>
    <INSDSeg_division>PAT</INSDSeg_division>
    <INSDSeg_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
        <INSDFeature_qual>
          <INSDQualifier id="q21">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
      <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
        <INSDFeature_qual>
          <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
          </INSDQualifier>
          <INSDQualifier id="q22">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
    </INSDSeg_feature-table>
    <INSDSeg_sequence>RMSNLAS</INSDSeg_sequence>
  </INSDSeg>
</SequenceData>
<SequenceData sequenceIDNumber="12">
  <INSDSeg>
    <INSDSeg_length>7</INSDSeg_length>
    <INSDSeg_moltype>AA</INSDSeg_moltype>
    <INSDSeg_division>PAT</INSDSeg_division>
    <INSDSeg_feature-table>
      <INSDFeature>

```

```

<INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q23">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
  </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
  </INSDQualifier>
  <INSDQualifier id="q24">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
  </INSDQualifier>
  </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>GFNIKDD</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="13">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="14">
  <INSDSeq>
    <INSDSeq_length>6</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

```



```

<INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q27">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
  </INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
  </INSDQualifier>
  <INSDQualifier id="q28">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
  </INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>LRRGLD</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="15">
  <INSDSeq>
    <INSDSeq_length>12</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..12</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q29">

<INSDQualifier_name>note</INSDQualifier_name>

```

```

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..12</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q30">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  </INSDSeq_feature-table>
  <INSDSeq_sequence>SKSLLHSNGYTY</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="16">
  <INSDSeq>
    <INSDSeq_length>6</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q31">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>

```

```

        <INSDFeature_qual>
            <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
            </INSDQualifier>
            <INSDQualifier id="q32">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
            </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>HLEYPF</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="17">
    <INSDSeq>
        <INSDSeq_length>117</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..117</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q33">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..117</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q34">

```

```
<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPENGDT EYASKF
QDKATVTADTSSNTAYLQLSSLTSEDTAVYYCTLWLRRGLDYWGQGTSVTVSS</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="18">
  <INSDSeq>
    <INSDSeq_length>112</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>
      </INSDFeature>
    </INSDSeq_feature-table>
  </INSDSeq>
<INSDFeature_location>1..112</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q35">
      <INSDQualifier_name>note</INSDQualifier_name>
      <INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>
  <INSDFeature_location>1..112</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>
      <INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q36">
      <INSDQualifier_name>organism</INSDQualifier_name>
      <INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
```

```

        </INSDFeature>
    </INSDSeq_feature-table>

    <INSDSeq_sequence>DIVMTQAAPSVPTPGESVSISCRSSKSLHNSNGYTYLFWFLQRPQGSPQLLIYRMSNLASGVP
    DRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPFTFGGGTKLEIK</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="19">
        <INSDSeq>
            <INSDSeq_length>8</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

    <INSDFeature_location>1..8</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q37">

    <INSDQualifier_name>note</INSDQualifier_name>

    <INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

    <INSDFeature_location>1..8</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

    <INSDQualifier_name>mol_type</INSDQualifier_name>

    <INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                    <INSDQualifier id="q38">

    <INSDQualifier_name>organism</INSDQualifier_name>

    <INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>
            <INSDSeq_sequence>IDPETGDT</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="20">

```

```

        <INSDSeq>
            <INSDSeq_length>17</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q39">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q40">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>
            <INSDSeq_sequence>WIDPETGDTEYASKFQD</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="21">
        <INSDSeq>
            <INSDSeq_length/>
            <INSDSeq_moltype/>
            <INSDSeq_division/>
            <INSDSeq_sequence>000</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="22">

```

```

        <INSDSeq>
            <INSDSeq_length>117</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..117</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q43">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..117</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                <INSDQualifier id="q44">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPETGDTEYASKF
QDKATVTADTSSNTAYLQLSSLTSEDYAVYYCTLWLRRGLDYWGQTSVTVSS</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="23">
    <INSDSeq>
        <INSDSeq_length>8</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

```

```

<INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q45">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
  </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
  </INSDQualifier>
  <INSDQualifier id="q46">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
  </INSDQualifier>
  </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>IDPESGDT</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="24">
  <INSDSeq>
    <INSDSeq_length>17</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q47">

<INSDQualifier_name>note</INSDQualifier_name>

```



```

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q48">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  </INSDSeq_feature-table>
  <INSDSeq_sequence>WIDPESGDTEYASKFQD</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="25">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="26">
  <INSDSeq>
    <INSDSeq_length>117</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..117</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q51">

<INSDQualifier_name>note</INSDQualifier_name>

```

```

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..117</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q52">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPESGDTEYASKF
QDKATVTADTSSNTAYLQLSSLTSEDTAIVYYCTLWLRRGLDYWGQGTSTVTVSS</INSDSeq_sequence>
      </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="27">
      <INSDSeq>
        <INSDSeq_length>9</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
          <INSDFeature>
            <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q53">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

```

```

<INSDFeature_location>1..9</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q54">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
  </INSDSeq_feature-table>
  <INSDSeq_sequence>GYSITSGYY</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="28">
  <INSDSeq>
    <INSDSeq_length>7</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q55">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
      <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>

```

```

        </INSDQualifier>
        <INSDQualifier id="q56">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
        </INSDQualifier>
        </INSDFeature_qual>
        </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>ITFDGAN</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="29">
    <INSDSeq>
        <INSDSeq_length>12</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..12</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q57">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..12</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q58">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>

```

```

        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>TRSSYDYDVLDY</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="30">
    <INSDSeq>
        <INSDSeq_length>6</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q59">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
            <INSDQualifier id="q60">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>QDISNF</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="31">
    <INSDSeq>
        <INSDSeq_length/>

```

```

        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="32">
    <INSDSeq>
        <INSDSeq_length>9</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q63">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q64">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>QQGHTLPYT</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="33">
    <INSDSeq>
        <INSDSeq_length>6</INSDSeq_length>

```

```

        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q65">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q66">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>SGYYWN</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="34">
    <INSDSeq>
        <INSDSeq_length>16</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..16</INSDFeature_location>
                <INSDFeature_qual>

```

```

<INSDQualifier id="q67">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..16</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q68">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>YITFDGANNYNPSLKN</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="35">
  <INSDSeq>
    <INSDSeq_length>10</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..10</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q69">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>

```



```

        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..10</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q70">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>
                                <INSDSeq_sequence>SSYDYDVLDY</INSDSeq_sequence>
                                </INSDSeq>
        </SequenceData>
        <SequenceData sequenceIDNumber="36">
            <INSDSeq>
                <INSDSeq_length>11</INSDSeq_length>
                <INSDSeq_moltype>AA</INSDSeq_moltype>
                <INSDSeq_division>PAT</INSDSeq_division>
                <INSDSeq_feature-table>
                    <INSDFeature>
                        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
                        <INSDFeature_qual>
                            <INSDQualifier id="q71">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
                                    <INSDFeature_qual>
                                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

```

```

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q72">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>
                                <INSDSeq_sequence>RASQDISNFLN</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="37">
    <INSDSeq>
        <INSDSeq_length>7</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier id="q73">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q74">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>

```

```

                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>YTSRLHS</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="38">
    <INSDSeq>
        <INSDSeq_length>8</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q75">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q76">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>GYSITSGY</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="39">

```

```

        <INSDSeq>
            <INSDSeq_length/>
            <INSDSeq_moltype/>
            <INSDSeq_division/>
            <INSDSeq_sequence>000</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="40">
        <INSDSeq>
            <INSDSeq_length>8</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q79">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q80">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>SYDYDVLD</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="41">

```

```

        <INSDSeq>
            <INSDSeq_length>7</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q81">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q82">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>
            <INSDSeq_sequence>SQDISNF</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="42">
        <INSDSeq>
            <INSDSeq_length>6</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

```

```

<INSDFeature_location>1..6</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q83">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q84">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>GHTLPY</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="43">
    <INSDSeq>
        <INSDSeq_length>119</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..119</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q85">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>

```

```

        </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..119</INSDFeature_location>
        <INSDFeature_qual>
            <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
            </INSDQualifier>
            <INSDQualifier id="q86">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
            </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DVQLQESGGLVKPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYITFDGANNYNPSL
KNRISITRDTSKNQFFLKLTSTTETATYYCTRSSYDYDVLDDYWGQGTTLTVSS</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="44">
    <INSDSeq>
        <INSDSeq_length>107</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q87">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>

```

```

                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q88">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQTTSSLSASLGDRVTISCRASQDISNFLNWKYQRPDGTVKLLIYYTSRLHSGVPSRFSG
SGSGTDFSLTVSNLEQEDIATYFCQGGHTLPYTFGGGTKLEIK</INSDSeq_sequence>
                                </INSDSeq>
                                </SequenceData>
                                <SequenceData sequenceIDNumber="45">
                                    <INSDSeq>
                                        <INSDSeq_length>8</INSDSeq_length>
                                        <INSDSeq_moltype>AA</INSDSeq_moltype>
                                        <INSDSeq_division>PAT</INSDSeq_division>
                                        <INSDSeq_feature-table>
                                            <INSDFeature>
                                                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q89">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>

```



```

        </INSDQualifier>
        <INSDQualifier id="q90">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
        </INSDQualifier>
        </INSDFeature_qual>
        </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>GYSFTDYC</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="46">
    <INSDSeq>
        <INSDSeq_length>8</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q91">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q92">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>

```

```

        </INSDFeature>
      </INSDSeq_feature-table>
      <INSDSeq_sequence>IYPGSGNT</INSDSeq_sequence>
    </INSDSeq>
  </SequenceData>
  <SequenceData sequenceIDNumber="47">
    <INSDSeq>
      <INSDSeq_length>13</INSDSeq_length>
      <INSDSeq_moltype>AA</INSDSeq_moltype>
      <INSDSeq_division>PAT</INSDSeq_division>
      <INSDSeq_feature-table>
        <INSDFeature>
          <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..13</INSDFeature_location>
          <INSDFeature_qual>
            <INSDQualifier id="q93">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
    </INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..13</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q94">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>AREDYYPYHGMDY</INSDSeq_sequence>
    </INSDSeq>
  </SequenceData>
  <SequenceData sequenceIDNumber="48">
    <INSDSeq>
      <INSDSeq_length>10</INSDSeq_length>

```

```

        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..10</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q95">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..10</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q96">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>ESVDGYDNSF</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="49">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="50">
    <INSDSeq>
        <INSDSeq_length>9</INSDSeq_length>

```

```

        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q99">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q100">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>QQSSEDPWT</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="51">
    <INSDSeq>
        <INSDSeq_length>5</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
                <INSDFeature_qual>

```

```

<INSDQualifier id="q101">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q102">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>DYCIN</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="52">
  <INSDSeq>
    <INSDSeq_length>17</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q103">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>

```

```

        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
                <INSDQualifier id="q104">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>WIYPGSGNTRYSERFKG</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="53">
    <INSDSeq>
        <INSDSeq_length>11</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q105">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

```

```

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q106">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>
                                <INSDSeq_sequence>EDYYPYHGMDY</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="54">
    <INSDSeq>
        <INSDSeq_length>15</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..15</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier id="q107">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..15</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q108">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>

```

```

                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>RASESVDGYDNSFMH</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="55">
    <INSDSeq>
        <INSDSeq_length>7</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q109">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
                <INSDQualifier id="q110">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>RASNLES</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="56">

```



```

        <INSDSeq>
            <INSDSeq_length>7</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q111">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q112">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>
            <INSDSeq_sequence>GYSFTDY</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="57">
        <INSDSeq>
            <INSDSeq_length/>
            <INSDSeq_moltype/>
            <INSDSeq_division/>
            <INSDSeq_sequence>000</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="58">

```

```

        <INSDSeq>
            <INSDSeq_length>9</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q115">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q116">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>
            <INSDSeq_sequence>DYYPYHGMD</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="59">
        <INSDSeq>
            <INSDSeq_length>11</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

```

```

<INSDFeature_location>1..11</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q117">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q118">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>SESVDGYDNSF</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="60">
    <INSDSeq>
        <INSDSeq_length>6</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q119">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>

```

```

                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q120">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>SSEDPW</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="61">
    <INSDSeq>
        <INSDSeq_length>120</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..120</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q121">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..120</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

```

```
<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q122">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>QIQLQQSGPELVPRGASVKISCKASGYSFTDYCINWVNQRPGQGLEWIGWIYPGSGNTRYSERF
KGKATLTVDTSSNTAYMQLSSLTSEDSAVYFCAREDYYPYHGMDYWGQGTSVTVSS</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="62">
  <INSDSeq>
    <INSDSeq_length>111</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..111</INSDFeature_location>
<INSDFeature_qual>
  <INSDQualifier id="q123">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..111</INSDFeature_location>
<INSDFeature_qual>
  <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q124">
```

```
<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DIVLTQSPTSLAVSLGQRATISCRASESVDGYNDSFMHWYQQKPGQPPKLLIFRASNL ESGIPARFSGSGSRTDFTLTINPVEAADVATYYCQSSSEDPWTFGGGTKLEIK</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="63">
  <INSDSeq>
    <INSDSeq_length>8</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>
      </INSDFeature>
    </INSDSeq_feature-table>
  </INSDSeq>
</SequenceData>
</INSDSeq_data-set>

<INSDFeature_location>1..8</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q125">
      <INSDQualifier_name>note</INSDQualifier_name>

      <INSDQualifier_value>Synthetic</INSDQualifier_value>
        </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
  </INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>
</INSDFeature>

<INSDFeature_location>1..8</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>
      <INSDQualifier_name>mol_type</INSDQualifier_name>

      <INSDQualifier_value>protein</INSDQualifier_value>
        </INSDQualifier>
      <INSDQualifier id="q126">
        <INSDQualifier_name>organism</INSDQualifier_name>

        <INSDQualifier_value>synthetic construct</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_data-set>
```

```

        </INSDFeature>
      </INSDSeq_feature-table>
      <INSDSeq_sequence>GYSFTDYY</INSDSeq_sequence>
    </INSDSeq>
  </SequenceData>
  <SequenceData sequenceIDNumber="64">
    <INSDSeq>
      <INSDSeq_length>5</INSDSeq_length>
      <INSDSeq_moltype>AA</INSDSeq_moltype>
      <INSDSeq_division>PAT</INSDSeq_division>
      <INSDSeq_feature-table>
        <INSDFeature>
          <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
          <INSDFeature_qual>
            <INSDQualifier id="q127">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
    </INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q128">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>DYYIN</INSDSeq_sequence>
    </INSDSeq>
  </SequenceData>
  <SequenceData sequenceIDNumber="65">
    <INSDSeq>
      <INSDSeq_length>120</INSDSeq_length>

```

```

        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..120</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q129">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..120</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q130">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>QIQLQQSGPELVPGASVKISCKASGYSFTDYYINWVNQRPQGQLEWIGWIYPGSGNTRYSERF
KGKATLTVDTSSNTAYMQLSSLTSEDSAVYFCAREDYYPYHGMDYWGQGTSTVTVSS</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="66">
    <INSDSeq>
        <INSDSeq_length>8</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

```



```

<INSDFeature_location>1..8</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q131">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q132">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>GYSFTDYD</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="67">
    <INSDSeq>
        <INSDSeq_length>5</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q133">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>

```

```

        </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
        <INSDFeature_qual>
            <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
            </INSDQualifier>
            <INSDQualifier id="q134">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
            </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>DYDIN</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="68">
    <INSDSeq>
        <INSDSeq_length>120</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..120</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q135">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..120</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

```

```
<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q136">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>QIQLQQSGPELVPRGASVKISCKASGYSFTDYDINWVNQRPGQGLEWIGWIYPGSGNTRYSERF
KGKATLTVDTSNTAYMQLSSLTSEDSAVYFCAREDYYPYHGMDYWGQGTSVTVSS</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="69">
  <INSDSeq>
    <INSDSeq_length>117</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..117</INSDFeature_location>
        <INSDFeature_qual>
          <INSDQualifier id="q137">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
        </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
  </INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..117</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
        </INSDQualifier>
        <INSDQualifier id="q138">
```

```
<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>EVQLVQSGSELKKPGASVKVSCTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPETGDTEYASKF
QDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRGLDYWGQGTLVTVSS</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="70">
  <INSDSeq>
    <INSDSeq_length>112</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>
      </INSDFeature>
    </INSDSeq_feature-table>
  </INSDSeq>
</SequenceData>
<INSDFeature_location>1..112</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q139">
      <INSDQualifier_name>note</INSDQualifier_name>
      <INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>
  <INSDFeature_location>1..112</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>
      <INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q140">
      <INSDQualifier_name>organism</INSDQualifier_name>
      <INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
```

```

        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>DIVMTQSPLSLPVTGPGEPAISCRSSKSLLSNGYTYLFWFQQRPGQSPRLLIYRMSNLASGVP
DRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPFTFGGGTKVEIK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="71">
    <INSDSeq>
        <INSDSeq_length>117</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..117</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q141">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..117</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
            <INSDQualifier id="q142">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>EVQLVQSGSELKKPGASVKVCTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPESGDTEYASKF
QDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRGLDYWGQGLTVTVSS</INSDSeq_sequence>
    </INSDSeq>

```

```

</SequenceData>
<SequenceData sequenceIDNumber="72">
  <INSDSeq>
    <INSDSeq_length>117</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..117</INSDFeature_location>
        <INSDFeature_qual>
          <INSDQualifier id="q143">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
      <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..117</INSDFeature_location>
        <INSDFeature_qual>
          <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
          </INSDQualifier>
          <INSDQualifier id="q144">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>EVQLVQSGSELKKPGASVKVCTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPENGDT EYASKF
QDRVTVTADTSTNTAYMELSSLRSED TAVYYCTLWLRRGLDYWGQGLTVTVSS</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="73">
  <INSDSeq>
    <INSDSeq_length>119</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>

```

```

        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..119</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q145">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..119</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q146">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLQESGPGLVKPSQTLSTCSVTGYSITSGYYWNWIRQPPGKGLEWMGYITFDGANNYNPSL
KNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DYWGQTTVTVSS</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="74">
        <INSDSeq>
            <INSDSeq_length>107</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
                <INSDFeature_qual>

```

```

<INSDQualifier id="q147">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q148">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWFYQQKPGQPVKLLIYYTSRLHSGVPSRFSG
SGSGTDFTLTISSLQPEDFATYFCQQGHTLPYTFGQGTKLEIK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="75">
    <INSDSeq>
        <INSDSeq_length>107</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q149">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>

```



```

        </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
        <INSDFeature_qual>
            <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
            </INSDQualifier>
            <INSDQualifier id="q150">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
            </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWWYQQKPGQPVKLLIYYTSRLHSGVPSRFSG
SGSGTDFTLTISSLQPEDFATYYCQQGHTLPYTFGGTKLEIK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="76">
    <INSDSeq>
        <INSDSeq_length>119</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..119</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q151">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..119</INSDFeature_location>

```

```

                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q152">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLQESGPGLVKPSQTLSTCTVTGYSITSGYYWNWIRQPPGKGLEWIGYITFDGANNYNPSL
KNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLDDYWGQTTVTVSS</INSDSeq_sequence>
                                </INSDSeq>
                                </SequenceData>
                                <SequenceData sequenceIDNumber="77">
                                    <INSDSeq>
                                        <INSDSeq_length>120</INSDSeq_length>
                                        <INSDSeq_moltype>AA</INSDSeq_moltype>
                                        <INSDSeq_division>PAT</INSDSeq_division>
                                        <INSDSeq_feature-table>
                                            <INSDFeature>
                                                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..120</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q153">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..120</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>

```

```

</INSDQualifier>
<INSDQualifier id="q154">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYYINWVRQAPGQGLEWMGWIYPGSGNTRYSERF
KGRVTITRDTASTAYMELSSLRSEDVAVYYCAREDYYPYHGMDYWGQGLTVTVSS</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="78">
  <INSDSeq>
    <INSDSeq_length>111</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..111</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q155">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..111</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q156">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>

```

```

                                </INSDQualifier>
                            </INSDFeature_qual>
                        </INSDFeature>
                    </INSDSeq_feature-table>

<INSDSeq_sequence>DIVLTQSPDSLAVSLGERATINCRASESVGDYDNSFMHWYQQKPGQPPKLLIFRASNL ESGVPD
RFSGSGSRTDFTLTISSLQAEDVAVYYCQQSSEDPWTFGQGTKLEIK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="79">
    <INSDSeq>
        <INSDSeq_length>120</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..120</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q157">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..120</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q158">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYDINWVRQAPGQGLEWMGWIYPGSGNTRYSERF

```

```

KGRVTITRDTASTAYMELSSLRSEDVAVYYCAREDYYPYHGMDYWGGTLVTVSS</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="80">
    <INSDSeq>
        <INSDSeq_length>111</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..111</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q159">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..111</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q160">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>DIVMTQSPDSLAVSLGERATINCRASESVDDGYDNSFMHWYQQKPGQPPKLLIFRASNLQESGVPD
RFGSGSGTDFTLTISSLQAEDVAVYYCQQSSDPWTFGGGTKLEIK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="81">
    <INSDSeq>
        <INSDSeq_length>330</INSDSeq_length>

```

```

        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..330</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q161">

<INSDQualifier_name>organism</INSDQualifier_name>
                    <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKHTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE
PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFS
MHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="82">
    <INSDSeq>
        <INSDSeq_length>330</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..330</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q162">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>

```

```

        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..330</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
                <INSDQualifier id="q163">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVV
VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVTLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE
PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCSSV
MHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="83">
    <INSDSeq>
        <INSDSeq_length>107</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q164">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

```

```

<INSDFeature_location>1..107</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q165">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="84">
    <INSDSeq>
        <INSDSeq_length>447</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..447</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q166">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..447</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

```



```

<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q167">
</INSDQualifier>
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>EVQLVQSGSELKKPGASVKVCTASGFNIKDDYMYWVRQPPGKLEWIGWIDPETGDTEYASKF
QDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRGLDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP
CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="85">
<INSDSeq>
<INSDSeq_length>219</INSDSeq_length>
<INSDSeq_moltype>AA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..219</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier id="q168">
</INSDQualifier>
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..219</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>

```

```

<INSDQualifier id="q169">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DIVMTQSPLSLPVTPGEPASISCRSSKSLLSNGYTYLFWFQQRPGQSPRLLIYRMSNLAGVP
DRFSGSGSGTDFTLKISRVEAEDVGVYYCMQHLEYPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYP
REAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq
_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="86">
<INSDSeq>
<INSDSeq_length>447</INSDSeq_length>
<INSDSeq_moltype>AA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..447</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier id="q170">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..447</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q171">

<INSDQualifier_name>organism</INSDQualifier_name>

```

```

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>EVQLVQSGSELKKPGASVKVSTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPESGDTEYASKF
QDRVTVTADTSTNTAYMELSSLRSEDYAVYYCTLWLRRGLDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP
CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>
      </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="87">
      <INSDSeq>
        <INSDSeq_length>447</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
          <INSDFeature>
            <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..447</INSDFeature_location>
          <INSDFeature_qual>
            <INSDQualifier id="q172">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
    <INSDFeature>
      <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..447</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q173">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>

```

```

        </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>EVQLVQSGSELKKPGASVKVCTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPENGDEYASKF
QDRVTVTADTSTNTAYMELSSLRSEDVAVYYCTLWLRRLDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP
CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK
TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="88">
    <INSDSeq>
        <INSDSeq_length>449</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..449</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q174">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..449</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q175">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>

```

</INSDSeq_feature-table>

<INSDSeq_sequence>QVQLQESGPGLVKPSQTLSTCSVTGYSITSGYYWNWIRQPPGKGLEWMGYITFDGANNYNPSL
KNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DYWGQTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC
PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>

</INSDSeq>

</SequenceData>

<SequenceData sequenceIDNumber="89">

<INSDSeq>

<INSDSeq_length>214</INSDSeq_length>

<INSDSeq_moltype>AA</INSDSeq_moltype>

<INSDSeq_division>PAT</INSDSeq_division>

<INSDSeq_feature-table>

<INSDFeature>

<INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..214</INSDFeature_location>

<INSDFeature_qual>

<INSDQualifier id="q176">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>

</INSDQualifier>

</INSDFeature_qual>

</INSDFeature>

<INSDFeature>

<INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..214</INSDFeature_location>

<INSDFeature_qual>

<INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>

</INSDQualifier>

<INSDQualifier id="q177">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>

</INSDQualifier>

</INSDFeature_qual>

</INSDFeature>

</INSDSeq_feature-table>

```
<INSDSeq_sequence>DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWWYQQKPGQPVKLLIYYTSRLHSGVPSRFSG
SGSGTDFTLTISSLQPEDFATYFCQQGHTLPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
QWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequ
ence>
```

```
</INSDSeq>
```

```
</SequenceData>
```

```
<SequenceData sequenceIDNumber="90">
```

```
<INSDSeq>
```

```
<INSDSeq_length>214</INSDSeq_length>
```

```
<INSDSeq_moltype>AA</INSDSeq_moltype>
```

```
<INSDSeq_division>PAT</INSDSeq_division>
```

```
<INSDSeq_feature-table>
```

```
<INSDFeature>
```

```
<INSDFeature_key>REGION</INSDFeature_key>
```

```
<INSDFeature_location>1..214</INSDFeature_location>
```

```
<INSDFeature_qual>
```

```
<INSDQualifier id="q178">
```

```
<INSDQualifier_name>note</INSDQualifier_name>
```

```
<INSDQualifier_value>Synthetic</INSDQualifier_value>
```

```
</INSDQualifier>
```

```
</INSDFeature_qual>
```

```
</INSDFeature>
```

```
<INSDFeature>
```

```
<INSDFeature_key>source</INSDFeature_key>
```

```
<INSDFeature_location>1..214</INSDFeature_location>
```

```
<INSDFeature_qual>
```

```
<INSDQualifier>
```

```
<INSDQualifier_name>mol_type</INSDQualifier_name>
```

```
<INSDQualifier_value>protein</INSDQualifier_value>
```

```
</INSDQualifier>
```

```
<INSDQualifier id="q179">
```

```
<INSDQualifier_name>organism</INSDQualifier_name>
```

```
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
```

```
</INSDQualifier>
```

```
</INSDFeature_qual>
```

```
</INSDFeature>
```

```
</INSDSeq_feature-table>
```

```
<INSDSeq_sequence>DIQMTQSPSSLSASVGDRVTITCRASQDISNFLNWWYQQKPGQPVKLLIYYTSRLHSGVPSRFSG
SGSGTDFTLTISSLQPEDFATYYCQQGHTLPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
QWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequ
ence>
```

```

        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="91">
        <INSDSeq>
            <INSDSeq_length>449</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..449</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q180">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..449</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                <INSDQualifier id="q181">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLQESGPGLVKPSQTLSTCTVTGYSITSGYYWNWIRQPPGKGLEWIGYITFDGANNYNPSL
KNRVVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DYWGQTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKD YFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC
PPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTV
LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSV MHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>

```

```

<SequenceData sequenceIDNumber="92">
  <INSDSeq>
    <INSDSeq_length>450</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..450</INSDFeature_location>
        <INSDFeature_qual>
          <INSDQualifier id="q182">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
    <INSDFeature>
      <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..450</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
        </INSDQualifier>
      <INSDQualifier id="q183">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
        </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
  </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYINWVRQAPGQGLEWMGWIYPGSGNTRYSERF
KGRVTITRDTASTAYMELSSLRSEDVAVYYCAREDYYPYHGMDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKCDKHT
CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="93">
  <INSDSeq>

```



```

        <INSDSeq_length>218</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..218</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q184">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..218</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q185">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>DIVLTQSPDSLAVSLGERATINCRASESVDGYDNSFMHWYQQKPGQPPKLLIFRASNLESGVPD
RFGSGSGSRDTFTLTISSLQAEDVAVYYCQQSSEDPWTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR
EAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_
sequence>
            </INSDSeq>
        </SequenceData>
        <SequenceData sequenceIDNumber="94">
            <INSDSeq>
                <INSDSeq_length>450</INSDSeq_length>
                <INSDSeq_moltype>AA</INSDSeq_moltype>
                <INSDSeq_division>PAT</INSDSeq_division>
                <INSDSeq_feature-table>

```

```

        <INSDFeature>
            <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..450</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q186">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..450</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
                <INSDQualifier id="q187">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYDINWVRQAPGQGLEWMGWIYPGSGNTRYSERF
KGRVTITRDTSASTAYMELSSLRSED TAVYYCAREDYYPYHGMDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTPVSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT
CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN
NYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVSCFVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="95">
    <INSDSeq>
        <INSDSeq_length>218</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

```

```

<INSDFeature_location>1..218</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q188">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..218</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q189">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DIVMTQSPDSLAVSLGERATINCRASESVDDGYDNSFMHWYQQKPGQPPKLLIFRASNLESGVPD
RFGSGSGSTDFLTITSLQAEDVAVYYCQSSSEDPWTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCCLNNFYPR
EAKVQWVKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_
sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="96">
    <INSDSeq>
        <INSDSeq_length>108</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..108</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q190">

```

```

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..108</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q191">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="97">
  <INSDSeq>
    <INSDSeq_length>225</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..225</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q192">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>

```

```

        </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..225</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
                <INSDQualifier id="q193">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>EVQLVQSGSELKKPGASVKVCTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPETGDTEYASKF
QDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRGLDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT</I
NSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="98">
        <INSDSeq>
            <INSDSeq_length>225</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..225</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q194">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                            </INSDQualifier>
                        </INSDFeature_qual>
                    </INSDFeature>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

```

```

<INSDFeature_location>1..225</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q195">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>EVQLVQSGSELKKPGASVKVCTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPESGDTEYASKF
QDRVTVTADTSTNTAYMELSSLRSED TAVYYCTLWLRRGLDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT</I
NSDSeq_sequence>
      </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="99">
      <INSDSeq>
        <INSDSeq_length>225</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
          <INSDFeature>
            <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..225</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q196">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..225</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

```

```
<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q197">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>EVQLVQSGSELKKPGASVKVCTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPENGDT EYASKF
QDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRLDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLV
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKCDKTHT</I
NSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="100">
  <INSDSeq>
    <INSDSeq_length>227</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..227</INSDFeature_location>
<INSDFeature_qual>
  <INSDQualifier id="q198">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..227</INSDFeature_location>
<INSDFeature_qual>
  <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>
```

```

<INSDQualifier id="q199">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>QVQLQESGPGLVKPSQTLSTCSVTGYSITSGYYWNWIRQPPGKGLEWMGYITFDGANNYNPSL
KNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DYWGQTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT<
/INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="101">
  <INSDSeq>
    <INSDSeq_length>227</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..227</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q200">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..227</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q201">

<INSDQualifier_name>organism</INSDQualifier_name>

```



```

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>QVQLQESGPGLVKPSQTLSTCTVTGYSITSGYYWNWIRQPPGKGLEWIGYITFDGANNYNPSL
KNRVVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DYWGQTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVKDKKVEPKSCDKTHT<
/INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="102">
  <INSDSeq>
    <INSDSeq_length>228</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..228</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q202">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..228</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q203">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>

```

```

        </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYYINWVRQAPGQGLEWMGWIYPGSGNTRYSERF
KGRVTITRDTASTAYMELSSLRSEDYAVYYCAREYYPYHGMDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT
</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="103">
    <INSDSeq>
        <INSDSeq_length>228</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..228</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q204">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..228</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q205">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYYINWVRQAPGQGLEWMGWIYPGSGNTRYSERF
KGRVTITRDTASTAYMELSSLRSEDYAVYYCAREYYPYHGMDYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALG

```

```

CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT
</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="104">
    <INSDSeq>
        <INSDSeq_length>19</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..19</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q206">

<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..19</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q207">

<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>MGWSCIIILFLVATATGVHS</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="105">
    <INSDSeq>
        <INSDSeq_length>760</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>

```

```

        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..760</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q684">

<INSDQualifier_name>organism</INSDQualifier_name>
                    <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>MMDQARSASFNLFGGEPLSYTRFSLARQVDGDNHVMKLAVIDEENADNNTKANVTKPKRCSG
SICYGTIAIVVFFLIGFMIGYLGKGVPEKTECERLAGTESPVREEPGEDFPAARRLYWDDLKRKLSEKLDSTDFGTIKL
LNENSYVPREAGSQKDENLALYVENQFREFKLSKVWRDQHFVKIQVKDSAQNSVIVDKNGRLVYLVENPGGYVAYSKAATV
TGKLVHANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFHGAHLGTGDPYT
PGFPSFNHTQFPSPRSSGLPNIPVQTISSRAAAEKLFGNMEGDCPSDWKTDSTCRMVTSSEKNVKLTVSNVLKEIKILNIFGV
IKGFVEPDHYVVGAQRDAWGPGAAKSGVGTALLKLAQMFSDMVLKDGFPQSRSIIFASWSAGDFGSGVATEWLEGYSSL
HLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNWASKVEKLTLDNAAFPFLAYSGIPAVSFC
FCEDTDYPYLGTTMDTYKELIERIPELNKVARAAAEVAGQFVIKLTHDVELNLDYERYNSQLLSFVRDLNQYRADIKEMGLS
LQWLYSARGDFFRATSRLTTDFGNAEKTDRFVMKKLNDRVMRVEYHFLSPYVSPKESPFRRHVFWGSGSHTLPALLENLKLK
QNGAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="106">
    <INSDSeq>
        <INSDSeq_length>760</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..760</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

```

```
<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q209">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>Macaca mulatta</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>MMDQARSASFNLFGGEPLSYTRFSLARQVDGDNSHVEMKLGVD E EENTDNNTKPNGTKPKRCGG
NICYGTIAV I IFFLIGFMIGYLG YCKGVEPKTECERLAGTESPAREEPEEDFPAAPRLYWDDLKRKLSEKLDTTDFTSTIKL
LNENLYVPREAGSQKDENLALYIENQFREFKLSKVWRDQHFVKIQVKDS AQNSV I IVDKNGGLVYLVENPGGYVAYS KAATV
TGKLVHANFGTKKDFEDLSPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVKADLSFFGHAHLGTGDPYT
PGFPSFNHTQFPSPSQSSGLPNIPVQTISR AAEKLFGNMEGDCPSDWKTDSTCKMVTSENKSVKLT VSNVLKETKILNIFGV
IKGFVEPDHYVVVG AQRDAWGPGA AKSSVGTALLLKL AQMFSDMVLKDG FQPSRSIIFASWSAGDFG S V GATEWLEGYLSSL
HLKAFTYINLDKAVLGT SNFKVSASPLLYTLIEKTMQDVKHPVTGRSLYQDSN WASKVEKLTLDNAAFPFLAYSGIPAVSFC
FCEDTDYPYLGTTMDTYKELVERIPELNKVARAAAEVAGQFVIKLTHTDELNLDYERYNSQLLLFLRDLNQYRADVKEMGLS
LQWLYSARGDFFRATSRLTTDFRNAEK RDKFVMKKLNDRVMRVEYYFLSPYVSPKESPF RHVFWGSGSHTLSALLESLKLRR
QNNSAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="107">
  <INSDSeq>
    <INSDSeq_length>760</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..760</INSDFeature_location>
<INSDFeature_qual>
  <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q210">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>Macaca fascicularis</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq feature-table>
```

```
<INSDSeq_sequence>MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNHVMKLGVDDEENTDNNTKANGTKPKRCGG
NICYGTIAVIFFLIGFMIGYLG YCKGVEPKTECERLAGTESPAREEPEEDFPAAPRLYWDDLKRKLSEKLDTTDTSTIKL
LNENLYVPREAGSQKDENLALYIENQFREFKLSKVWRDQHFKVIQVKDSAQNSVVIIVDKNGGLVYLVENPGGYVAYSKAATV
TGKLVHANFGTKKDFEDLDSPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVKADLSFFGHAHLGTGDPYT
PGFPSFNHTQFPPSQSSGLPNIPVQTI SRAAAEKLFGNMEGDCPSDWKTDSTCKMVTSENKSVKLTVSNVLKETKILNIFGV
IKGFVEPDHYVVVGAQRDAWGPGA AKSSVGTALLKLAQMFSDMVLKDGFPQRSIIIFASWSAGDFGSVGATEWLEGYLSSL
HLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQDVKHPVTGRSLYQDSNWASKVEKLTLDNAAFPFLAYSGIPAVSFC
FCEDTDYPYLGTTMDTYKELVERIPELNKVARAAAEVAGQFVIKLTHTDELNLDYERYNSQLLLFLRDLNQYRADVKEMGLS
LQWLYSARGDFFRATSRLTTDFRNAEK RDKFVMKKLNDRVMRVEYYFLSPYVSPKESPFRHVFWGSGSHTLSALLESKLRR
QNSAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF</INSDSeq_sequence>
```

```
</INSDSeq>
```

```
</SequenceData>
```

```
<SequenceData sequenceIDNumber="108">
```

```
<INSDSeq>
```

```
<INSDSeq_length>763</INSDSeq_length>
```

```
<INSDSeq_moltype>AA</INSDSeq_moltype>
```

```
<INSDSeq_division>PAT</INSDSeq_division>
```

```
<INSDSeq_feature-table>
```

```
<INSDFeature>
```

```
<INSDFeature_key>source</INSDFeature_key>
```

```
<INSDFeature_location>1..763</INSDFeature_location>
```

```
<INSDFeature_qual>
```

```
<INSDQualifier>
```

```
<INSDQualifier_name>mol_type</INSDQualifier_name>
```

```
<INSDQualifier_value>protein</INSDQualifier_value>
```

```
</INSDQualifier>
```

```
<INSDQualifier id="q685">
```

```
<INSDQualifier_name>organism</INSDQualifier_name>
```

```
<INSDQualifier_value>Mus
```

```
musculus</INSDQualifier_value>
```

```
</INSDQualifier>
```

```
</INSDFeature_qual>
```

```
</INSDFeature>
```

```
</INSDSeq_feature-table>
```

```
<INSDSeq_sequence>MMDQARSAFSNLFGGEPLSYTRFSLARQVDGDNHVMKLA ADEEENADNNMKASVRKPKRFNG
RLCFAAIALVIFFLIGFMMSGYLG YCKRVEQKEECVKLAETEETDKSETMETEDVPTSSRLYWADLKTLSEKLN SIEFADTI
KQLSQNTYTPREAGSQKDESLAYYIENQFHEFKFSKVWRDEHYVKIQVKSSIGQNMVTIVQSNGLDPVESPEGYVAFSKPT
EVSGKLVHANFGTKKDFEELSYVNGSLVIVRAGEITFAEKVANAQSFNAIGVLIYMDKNKFPVVEADLALFGHAHLGTGDP
YTPGFPSFNHTQFPPSQSSGLPNIPVQTI SRAAAEKLFGKMEGSCPARWNIDSSCKLELSQNQNVKLIVKNVLKERRILNIF
GVIKGYEEPDRYVVVGAQRDALGAGVAAKSSVGTGLLLKLAQVFS DMISKDGFPRPSRSIIIFASWTAGDFGAVGATEWLEGYL
SSLHLKAFTYINLDKVV LGTSNFKVSASPLLYTLMGIMQDVKHPVDGKSLYRDSNWISKVEKLSFDNAAYPFLAYSGIPAV
SFCFCEDADYPYLGTRLD TYEALTQKVPQLNQMVRTAAEVAGQLI IKLTHDVELNLDYEMYNSKLLSFMKDLNQFKTDIRDM
GLSLQWLYSARGDYFRATSRLTTDFHNAEKTNR FVMREINDRIMKVEYHFLSPYVSPRESPFRHIFWGS GSHTLSALVENLK
LRQKNITAFNETLFRNQLALATWTIQGVANALSGDIWNIDNEF</INSDSeq_sequence>
```

```

        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="109">
        <INSDSeq>
            <INSDSeq_length>197</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..197</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q212">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..197</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q213">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>

<INSDSeq_sequence>FVKIQVKDSAQNSV IIVDKNGRLVYLVENPGGYVAYSKAATVTGKLVHANFGTKKDFEDLYTPV
NGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFFGHAHLGTGDPYTPGFPSFNHTQFPSPRSSGLPNI
PVQTISRAAA EKLFGNMEGDCPSDWKTDSTCRMVTS ESKNVKLT VSNVLKE</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="110">
        <INSDSeq>
            <INSDSeq_length>5</INSDSeq_length>

```

```

        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q214">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q215">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>SYWMH</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="111">
    <INSDSeq>
        <INSDSeq_length>17</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
                <INSDFeature_qual>

```



```

<INSDQualifier id="q216">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q217">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>EINPTNGRTNYIEKFS</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="112">
  <INSDSeq>
    <INSDSeq_length>7</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q218">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>

```

```

        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
                <INSDQualifier id="q219">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>GTRAYHY</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="113">
    <INSDSeq>
        <INSDSeq_length>11</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q220">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

```

```

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q221">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>
                                <INSDSeq_sequence>RASDNLYSNLA</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="114">
    <INSDSeq>
        <INSDSeq_length>7</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier id="q222">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q223">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>

```

```

                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>DATNLAD</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="115">
    <INSDSeq>
        <INSDSeq_length>9</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..9</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q224">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..9</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q225">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>QHFWGTPLT</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="116">

```

```

        <INSDSeq>
            <INSDSeq_length>7</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q226">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q227">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>
            <INSDSeq_sequence>GYTFTSY</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="117">
        <INSDSeq>
            <INSDSeq_length>6</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

```

```

<INSDFeature_location>1..6</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q228">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q229">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>NPTNGR</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="118">
    <INSDSeq>
        <INSDSeq_length>6</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q230">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>

```

```

                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q231">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>TSYWMH</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="119">
    <INSDSeq>
        <INSDSeq_length>13</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..13</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q232">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..13</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

```

```

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q233">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>
                                <INSDSeq_sequence>WIGEINPTNGRTN</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="120">
    <INSDSeq>
        <INSDSeq_length>6</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier id="q234">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q235">

<INSDQualifier_name>organism</INSDQualifier_name>

```



```

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>ARGTRA</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="121">
  <INSDSeq>
    <INSDSeq_length>7</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q236">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q237">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>YSNLAWY</INSDSeq_sequence>
</INSDSeq>

```

```

</SequenceData>
<SequenceData sequenceIDNumber="122">
  <INSDSeq>
    <INSDSeq_length>10</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..10</INSDFeature_location>
        <INSDFeature_qual>
          <INSDQualifier id="q238">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
      <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..10</INSDFeature_location>
        <INSDFeature_qual>
          <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
          </INSDQualifier>
          <INSDQualifier id="q239">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>LLVYDATNLA</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="123">
  <INSDSeq>
    <INSDSeq_length>8</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

```

```

<INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q240">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
  </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
  </INSDQualifier>
  <INSDQualifier id="q241">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
  </INSDQualifier>
  </INSDFeature_qual>
  </INSDFeature>
  </INSDSeq_feature-table>
  <INSDSeq_sequence>QHFWGTPL</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="124">
  <INSDSeq>
    <INSDSeq_length>116</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

```

```

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q686">

<INSDQualifier_name>organism</INSDQualifier_name>
                                <INSDQualifier_value>Mus
musculus</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLQQGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPQGLEWIGEINPTNGRTNYIEKF
KSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQTSVTVSS</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="125">
    <INSDSeq>
        <INSDSeq_length>107</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q687">

<INSDQualifier_name>organism</INSDQualifier_name>
                                <INSDQualifier_value>Mus
musculus</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPASLSVSVGETVTITCRASDNLYSNLAWYQQKQGKSPQLLVYDATNLADGVPSRFSG
SGSGTQYSLKINSLQSEDFGTYQCQHFWGTPITFGAGTKLELK</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="126">
    <INSDSeq>
        <INSDSeq_length>9</INSDSeq_length>

```

```

        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q244">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q245">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>QHFAGTPLT</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="127">
    <INSDSeq>
        <INSDSeq_length>8</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
                <INSDFeature_qual>

```

```

<INSDQualifier id="q246">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q247">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>QHFAGTPL</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="128">
  <INSDSeq>
    <INSDSeq_length>116</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q248">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>

```

```

        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
                <INSDQualifier id="q249">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQRLEWIGEINPTNGRTNYIEKF
KSRATLTVDKSASTAYMELSSLRSED TAVYYCARGTRAYHYWGQGTMTVSS</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="129">
    <INSDSeq>
        <INSDSeq_length>107</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q250">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

```

```

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q251">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPSSLSASVGDRVTITCRASDNLYSNLAWYQQKPGKSPKLLVYDATNLADGVPSRFSG
SGSGTDYTLTISSLQPEDFATYYCQHFWGTPITFGQGTKVEIK</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="130">
    <INSDSeq>
        <INSDSeq_length>13993</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..13993</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q688">

<INSDQualifier_name>organism</INSDQualifier_name>
                                <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>TCCTGGCATCAGTTACTGTGTTGACTCACTCAGTGTGGGATCACTCACTTTCCCCCTACAGGA
CTCAGATCTGGGAGGCAATTACCTTCGGAGAAAAACGAATAGGAAAACTGAAGTGTACTTTTTTTAAAGCTGCTGAAGTT
TGTTGGTTTCTCATTGTTTTTAAGCCTACTGGAGCAATAAAGTTGAAGAACTTTTACCAGGTTTTTTTTATCGCTGCCTTG
ATATACACTTTTCAAAATGCTTTGGTGGGAAGAAGTAGAGGACTGTTATGAAAGAGAAGATGTTCAAAAGAAAACATTCA

```


AAATGGGTAAATGCACAATTTTCTAAGTTTGGGAAGCAGCATATTGAGAACCTCTTCAGTGACCTACAGGATGGGAGGCGCC
TCCTAGACCTCCTCGAAGGCCTGACAGGGCAAAAAGTCCCAAAAGAAAAAGGATCCACAAGAGTTCATGCCCTGAACAATGT
CAACAAGGCACTGCGGGTTTTGCAGAACATAATGTTGATTTAGTGAATATTGGAAGTACTGACATCGTAGATGGAAATCAT
AAACTGACTCTTGGTTTTGATTTGGAATATAATCCTCCACTGGCAGGTCAAAAATGTAATGAAAAATATCATGGCTGGATTGC
AACAAACCAACAGTGAAAAGATTCTCCTGAGCTGGGTCCGACAATCAACTCGTAATTATCCACAGGTTAATGTAATCAACTT
CACCACCAGCTGGTCTGATGGCCTGGCTTTGAATGCTCTCATCCATAGTCATAGGCCAGACCTATTTGACTGGAATAGTGTG
GTTTGCCAGCAGTCAGCCACACAACGACTGGAACATGCATTCAACATCGCCAGATATCAATTAGGCATAGAGAACTACTCG
ATCCTGAAGATGTTGATACCACCTATCCAGATAAGAAGTCCATCTTAATGTACATCACATCACTCTTCCAAGTTTTGCCTCA
ACAAGTGAGCATTGAAGCCATCCAGGAAGTGGAAATGTTGCCAAGGCCACCTAAAGTGAATAAAGAAGAACATTTTCAGTTA
CATCATCAAATGCACTATTCTCAACAGATCACGGTCAGTCTAGCACAGGGATATGAGAGAACTTCTTCCCCTAAGCCTCGAT
TCAAGAGCTATGCCTACACACAGGCTGCTTATGTACCACCTCTGACCCTACACGGAGCCCATTTCTTTCACAGCATTTGGA
AGCTCCTGAAGACAAGTCATTTGGCAGTTCATTGATGGAGAGTGAAGTAAACCTGGACCGTTATCAAACAGCTTTAGAAGAA
GTATTATCGTGGCTTCTTTCTGCTGAGGACACATTGCAAGCACAAGGAGAGATTTCTAATGATGTGGAAGTGGTGAAAGACC
AGTTTCATACTCATGAGGGGTACATGATGGATTTGACAGCCCATCAGGGCCGGGTTGGTAATATTCTACAATTGGGAAGTAA
GCTGATTGGAACAGGAAAATTATCAGAAGATGAAGAACTGAAGTACAAGAGCAGATGAATCTCCTAAATTCAGATGGGAA
TGCCTCAGGGTAGCTAGCATGGAAAAACAAAGCAATTTACATAGAGTTTTAATGGATCTCCAGAATCAGAACTGAAAGAGT
TGAATGACTGGCTAACAAAAACAGAAGAAAGAACAAGGAAAATGGAGGAAGAGCCTCTTGACCTGATCTTGAAGACCTAAA
ACGCCAAGTACAACAACATAAGGTGCTTCAAGAAGATCTAGAACAAGAACAAGTCAGGGTCAATTCTCTCACTCACATGGTG
GTGGTAGTTGATGAATCTAGTGGAGATCACGCAACTGCTGCTTTGGAAGAACAACCTAAGGTATTGGGAGATCGATGGGCAA
ACATCTGTAGATGGACAGAAGACCGCTGGGTTCTTTTACAAGACATCCTTCTCAAATGGCAACGCTTACTGAAGAACAGTG
CCTTTTTAGTGCATGGCTTTTCAGAAAAAGAAGATGCAGTGAACAAGATTCACACAACCTGGCTTTAAAGATCAAATGAAATG
TTATCAAGTCTTCAAAAAGTGGCGTTTTTAAAGCGGATCTAGAAAAGAAAAAGCAATCCATGGGCAAACCTGTATTCACCTCA
AACAGATCTTCTTTCAACACTGAAGAATAAGTCAGTGACCCAGAAGACGGAAGCATGGCTGGATAACTTTGCCCGGTGTTG
GGATAATTTAGTCCAAAAACTTGAAAAGAGTACAGCACAGATTTACAGGCTGTACCACCACTCAGCCATCACTAACACAG
ACAACTGTAATGGAAACAGTAACTACGGTGACCACAAGGGAACAGATCCTGGTAAAGCATGCTCAAGAGGAACTTCCACCAC
CACCTCCCCAAAAGAAGAGGCAGATTACTGTGGATTCTGAAATTAGGAAAAGGTTGGATGTTGATATAACTGAACTTCACAG
CTGGATTACTCGCTCAGAAGCTGTGTTGCAGAGTCTGAATTTGCAATCTTTCGGAAGGAAGGCAACTTCTCAGACTTAAAA
GAAAAAGTCAATGCCATAGAGCGAGAAAAAGCTGAGAAGTTCAGAAAAGTGAAGATGCCAGCAGATCAGCTCAGGCCCTGG
TGGAACAGATGGTGAATGAGGGTGTTAATGCAGATAGCATCAAACAAGCCTCAGAACAACCTGAACAGCCGGTGGATCGAATT
CTGCCAGTTGCTAAGTGAGAGACTTAACTGGCTGGAGTATCAGAACAACATCATCGCTTTCTATAATCAGCTACAACAATTG
GAGCAGATGACAACTACTGCTGAAAAGTGGTTGAAAATCCAACCCACCACCCCATCAGAGCCAACAGCAATTAAGAGTCAGT
TAAAAATTTGTAAGGATGAAGTCAACCGCTATCAGGTCTTCAACCTCAAATTGAACGATTAAAAATTCAAAGCATAGCCCT
GAAAGAGAAAGGACAAGGACCCATGTTCTGGATGCAGACTTTGTGGCCTTTACAAATCATTTTAAGCAAGTCTTTTCTGAT
GTGCAGGCCAGAGAGAAAGAGCTACAGACAATTTTTGACACTTTGCCACCAATGCGCTATCAGGAGACCATGAGTGCCATCA
GGACATGGGTCCAGCAGTCAGAAACCAAACCTCTCCATACCTCAACTTAGTGTACCGACTATGAAATCATGGAGCAGAGACT
CGGGGAATTGCAGGCTTTACAAAGTTCTCTGCAAGAGCAACAAAGTGGCCTATACTATCTCAGCACCCTGTGAAAGAGATG
TCGAAGAAAAGCGCCCTCTGAAATTAGCCGGAATATCAATCAGAATTTGAAGAAATTGAGGGACGCTGGAAGAAGCTCTCCT
CCCAGCTGGTTGAGCATTGTCAAAGCTAGAGGAGCAAATGAATAAACTCCGAAAAATTGAGAATCACATACAAACCCTGAA
GAAATGGATGGCTGAAGTTGATGTTTTCTGAAGGAGGAATGGCCTGCCCTTGGGGATTGAGAAATTCTAAAAAGCAGCTG
AAACAGTGCAGACTTTTAGTCAGTGATATTCAGACAATTCAGCCAGTCTAAACAGTGTCAATGAAGGTGGGCAGAGATAA
AGAATGAAGCAGAGCCAGAGTTTGCTTCGAGACTTGAGACAGAATCAAAGAAGTCTAACACTCAGTGGGATCACATGTGCCA
ACAGGTCTATGCCAGAAAGGAGGCCTTGAAGGGAGGTTTGGAGAAAAGTGAAGCCTCCAGAAAGATCTATCAGAGATGCAC
GAATGGATGACACAAGCTGAAGAAGAGTATCTTGAGAGAGATTTTGAATATAAACTCCAGATGAATTACAGAAAGCAGTTG
AAGAGATGAAGAGAGCTAAAGAAGAGGCCCAACAAAAAGAAGCGAAAGTGAAGTCTTACTGAGTCTGTAATAGTGTGAT
AGCTCAAGTCCACCTGTAGCACAGAGGCCTTAAAAAGGAAGTGAAGTCTAACCACCAACTACCAAGTGGCTCTGCACT
AGGCTGAATGGGAAATGCAAGACTTTGGAAGAAGTTTGGGCATGTTGGCATGAGTTATTGTCACTTTGGAGAAAGCAAACA
AGTGGCTAAATGAAGTAGAATTTAACTTAAACCCTGAAAACATTCTGGCGGAGCTGAGGAAATCTCTGAGGTGCTAGA
TTCACTTGAAGTTTGTGCGACATTAGAGGATAACCCAAATCAGATTGCGATATTGGCACAGACCCTAACAGATGGCGGA
GTCATGGATGAGCTAATCAATGAGGAAGTGTAGACATTTAATTCTCGTTGGAGGGAAGTACATGAAGAGGCTGTAAGGAGGC
AAAAGTTGCTTGAACAGAGCATCCAGTCTGCCCAGGAGACTGAAAAATCCTTACACTTAATCCAGGAGTCCCTCACATTCAT

TGACAAGCAGTTGGCAGCTTATATTGCAGACAAGGTGGACGCAGCTCAAATGCCTCAGGAAGCCCAGAAAATCCAATCTGAT
TTGACAAAGTCATGAGATCAGTTTAGAAGAAATGAAGAAACATAATCAGGGGAAGGAGGCTGCCCCAAGAGTCCTGTCTCAGA
TTGATGTTGCACAGAAAAAATTACAAGATGTCTCCATGAAGTTTCGATTATTCCAGAAACCAGCCAATTTTGAGCAGCGTCT
ACAAGAAAGTAAGATGATTTTAGATGAAGTGAAGATGCACTTGCCTGCATTGGAACAAAGAGTGTGGAACAGGAAGTAGTA
CAGTCACAGCTAAATCATTGTGTGAAC TTGTATAAAAAGTCTGAGTGAAGTGAAGTCTGAAGTGGAAATGGTGATAAAGACTG
GACGTCAGATTGTACAGAAAAAGCAGACGGAAAATCCCAAAGAACTTGATGAAAGAGTAACAGCTTTGAAATTGCATTATAA
TGAGCTGGGAGCAAAGGTAACAGAAAGAAAGCAACAGTTGGAGAAATGCTTGAAATTGTCCCGTAAGATGCGAAAGGAAATG
AATGTCTTGACAGAATGGCTGGCAGCTACAGATATGGAATTGACAAAGAGATCAGCAGTTGAAGGAATGCCTAGTAATTTGG
ATTCTGAAGTTGCCTGGGGAAAGGCTACTCAAAAAGAGATTGAGAAACAGAAGGTGCACCTGAAGAGTATCACAGAGGTAGG
AGAGGCCCTTGAAAACAGTTTTGGGCAAGAAGGAGACGTTGGTGGAAGATAAACTCAGTCTTCTGAATAGTAACCTGGATAGCT
GTCACCTCCCGAGCAGAAGAGTGGTTAAATCTTTTGTGGAAATACCAGAAACACATGGAAACTTTTGACCAGAATGTGGACC
ACATCACAAAGTGGATCATTCAGGCTGACACACTTTTGGATGAATCAGAGAAAAAGAAACCCAGCAAAAAGAAGACGTGCT
TAAGCGTTTAAAGGCAGAACTGAATGACATACGCCCAAAGGTGGACTCTACACGTGACCAAGCAGCAAACTTGATGGCAAAC
CGCGGTGACCACTGCAGGAAATTAGTAGAGCCCCAAATCTCAGAGCTCAACCATCGATTTGCAGCCATTTACACAGAATTA
AGACTGGAAAGGCCTCCATTCTTTGAAGGAATTGGAGCAGTTTAACTCAGATATACAAAAATTGCTTGAACCACTGGAGGC
TGAAATTCAGCAGGGGGTGAATCTGAAAGAGGAAGACTTCAATAAAGATATGAATGAAGACAATGAGGGTACTGTAAAAGAA
TTGTTGCAAAGAGGAGACAAC TTACAACAAAGAATCACAGATGAGAGAAAGCGAGAGGAAATAAAGATAAAACAGCAGCTGT
TACAGACAAAACATAATGCTCTCAAGGATTTGAGGTCTCAAAGAAGAAAAAAGGCTCTAGAAATTTCTCATCAGTGGTATCA
GTACAAGAGGCAGGCTGATGATCTCTGAAATGCTTGGATGACATTGAAAAAAAATTAGCCAGCCTACCTGAGCCCAGAGAT
GAAAGGAAAAATAAAGGAAATTGATCGGGAATTGCAGAAGAAGAAAGAGGAGCTGAATGCAGTGCCTAGGCAAGCTGAGGGCT
TGTCTGAGGATGGGGCCGCAATGGCAGTGGAGCCAACTCAGATCCAGCTCAGCAAGCGCTGGCGGGAAATTGAGAGCAAATT
TGCTCAGTTTCGAAGACTCAACTTTGCACAAATTCACACTGTCCGTGAAGAAACGATGATGGTGATGACTGAAGACATGCCT
TTGGAAAATTTCTTATGTGCCTTCTACTTATTTGACTGAAATCACTCATGTCTCACAAGCCCTATTAGAAGTGGAAACACTTC
TCAATGCTCCTGACCTCTGTGCTAAGGACTTTGAAGATCTCTTTAAGCAAGAGGAGTCTCTGAAGAATATAAAAGATAGTCT
ACAACAAAGCTCAGGTCGGATTGACATTATTCATAGCAAGAAGACAGCAGCATTGCAAAGTGCAACGCCTGTGGAAAGGGTG
AAGCTACAGGAAGCTCTCTCCAGCTTGATTTCCAATGGGAAAAAGTTAACAAAATGTACAAGGACCGACAAGGGCGATTTG
ACAGATCTGTTGAGAAATGGCGGCGTTTTTATTATGATATAAAGATATTTAATCAGTGGCTAACAGAAGCTGAACAGTTTCT
CAGAAAAGACACAAATTCCTGAGAATTGGGAACATGCTAAATACAAATGGTATCTTAAGGAAGCTCCAGGATGGCATTGGGCAG
CGGCAAACTGTTGTGAGAACATTGAATGCAACTGGGGGAAGAAATAATTAGCAATCCTCAAAAACAGATGCCAGTATTCTAC
AGGAAAAATTTGGGAAGCCTGAATCTGCGGTGGCAGGAGGTCTGCAAACAGCTGTGAGACAGAAAAAAGAGGCTAGAAGAACA
AAAGAATATCTTGTGAGAAATTTCAAAGAGATTTAAATGAATTTGTTTTATGGTTGGAGGAAGCAGATAACATTGCTAGTATC
CCACTTGAACCTGGAAAAGAGCAGCAACTAAAAGAAAAGCTTGAGCAAGTCAAGTTACTGGTGGAAGAGTTGCCCTGCGCC
AGGGAATTTCTAAACAATTAATGAACTGGAGGACCCGTGCTTGTAAGTGCTCCCATAAGCCCAGAAAGAGCAAGATAAACT
TGAAAATAAGCTCAAGCAGACAAATCTCCAGTGGATAAAGGTTTCCAGAGCTTTACCTGAGAAACAAGGAGAAATTGAAGCT
CAAATAAAAGACCTTGGGCAGCTTGAAAAAAAGCTTGAAAGACCTGAAAGAGCAGTTAAATCATCTGCTGCTGTGGTTATCTC
CTATTAGGAATCAGTTGGAAATTTATAACCAACCAAAACCAAGAAGGACCATTTGACGTTCCAGGAACTGAAATAGCAGTTCA
AGCTAAACAACCGGATGTGGAAGAGATTTTGTCTAAAGGGCAGCATTGTACAAGGAAAAACAGCCACTCAGCCAGTGAAG
AGGAAGTTAGAAGATCTGAGCTCTGAGTGGAAGGCGGTAACCGTTTACTTCAAGAGCTGAGGGCAAAGCAGCCTGACCTAG
CTCCTGGACTGACCACTATTGGAGCCTCTCCTACTCAGACTGTTACTCTGGTGACACAACCTGTGGTTACTAAGGAACTGC
CATCTCCAACTAGAAATGCCATCTTCTTGATGTTGGAGGTACCTGCTCTGGCAGATTTCAACCGGGCTTGACAGAACTT
ACCGACTGGCTTTCTCTGCTTGATCAAGTTATAAAATCACAGAGGGTGATGGTGGGTGACCTTGAGGATATCAACGAGATGA
TCATCAAGCAGAAGGCAACAATGCAGGATTTGGAACAGAGGCGTCCCAGTTGGAAGAACTCATTACCGCTGCCCCAAAATTT
GAAAAACAAGACCAGCAATCAAGAGGCTAGAACAATCATTACGGATCGAATTGAAAGAATTGAGAATCAGTGGGATGAAGTA
CAAGAACACCTTCAGAACCGGAGGCAACAGTTGAATGAAATGTTAAAGGATTCAACACAATGGCTGGAAGCTAAGGAAGAAG
CTGAGCAGGTCTTAGGACAGGCCAGAGCCAAGCTTGAGTCATGGAAGGAGGGTCCCTATACAGTAGATGCAATCCAAAAGAA
AATCACAGAAACCAAGCAGTTGGCCAAAGACCTCCGCCAGTGGCAGACAAATGTAGATGTGGCAAATGACTTGGCCCTGAAA
CTTCTCCGGGATTATTCTGCAGATGATACCAGAAAAGTCCACATGATAACAGAGAATATCAATGCCTCTTGAGAAGCATTC
ATAAAAGGGTGAGTGAGCGAGAGGCTGCTTTGGAAGAACTCATAGATTACTGCAACAGTTCCCCCTGGACCTGAAAAAGTT
TCTTGCCTGGCTTACAGAAGCTGAAACAAC TGCCAATGTCTACAGGATGCTACCCGTAAGGAAAGGCTCCTAGAAGACTCC
AAGGGAGTAAAAGAGCTGATGAAACAATGGCAAGACCTCCAAGGTGAAATTGAAGCTCACACAGATGTTTATCACAACCTGG

ATGAAAACAGCCAAAAAATCCTGAGATCCCTGGAAGGTTCCGATGATGCAGTCTGTTACAAAGACGTTTGGATAACATGAA
CTTCAAGTGGAGTGAACCTCGGAAAAAGTCTCTCAACATTAGGTCCCATTGGAAGCCAGTTCTGACCAGTGGAAAGCGTCTG
CACCTTTCTCTGCAGGAACCTCTGGTGTGGCTACAGCTGAAAGATGATGAATTAAGCCGGCAGGCACCTATTGGAGGCGACT
TTCCAGCAGTTTCAAGAAGCAGAACGATGTACATAGGGCCTTCAAGAGGGAATTGAAAACCTAAAGAACCTGTAATCATGAGTAC
TCTTGAGACTGTACGAATATTTCTGACAGAGCAGCCTTTGGAAGGACTAGAGAACTCTACCAGGAGCCCAGAGAGCTGCCT
CCTGAGGAGAGAGCCCAGAATGTCACTCGGCTTCTACGAAAGCAGGCTGAGGAGGTCAATACTGAGTGGGAAAAATTGAACC
TGCACTCCGCTGACTGGCAGAGAAAAATAGATGAGACCCTTGAAAGACTCCAGGAACCTTCAAGAGGCCACGGATGAGCTGGA
CCTCAAGCTGCGCCAAGCTGAGGTGATCAAGGGATCCTGGCAGCCCCTGGGCGATCTCCTCATTGACTCTCTCCAAGATCAC
CTCGAGAAAAGTCAAGGCACCTCGAGGAGAAATTGCGCCTCTGAAAGAGAACGTGAGCCACGTCAATGACCTTGCTCGCCAGC
TTACCACTTTGGGCATTACAGCTCTCACCGTATAACCTCAGCACTCTGGAAGACCTGAACACCAGATGGAAGCTTCTGCAGGT
GGCCGTGAGGACCGAGTCAGGCAGCTGCATGAAGCCCACAGGGACTTTGGTCCAGCATCTCAGCACTTTCTTTCCACGTCT
GTCCAGGGTCCCTGGGAGAGAGCCATCTCGCCAAACAAAGTGCCCTACTATATCAACCACGAGACTCAAACAACCTTGCTGGG
ACCATCCCAAAATGACAGAGCTCTACCAGTCTTTAGCTGACCTGAATAATGTCAGATTCTCAGCTTATAGGACTGCCATGAA
ACTCCGAAGACTGCAGAAGGCCCTTTGCTTGGATCTCTTGAGCCTGTCAGCTGCATGTGATGCCTTTGGACCAGCACAACTC
AAGCAAAATGACCAGCCCATGGATATCCTGCAGATTATTAATTGTTTGACCACTATTTATGACCGCCTGGAGCAAGAGCACA
ACAATTTGGTCAACGTCCCTCTCTGCGTGGATATGTGTCTGAACTGGCTGCTGAATGTTTATGATACGGGACGAACAGGGAG
GATCCGTGCTCTGCTTTTTAAACTGGCATCATTTCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATACCTTTTTCAAG
CAAGTGGCAAGTTCAACAGGATTTTGTGACCAGCGCAGGCTGGGCCTCCTTCTGCATGATTCTATCCAAATTTCAAGACAGT
TGGGTGAAGTTGCATCCTTTGGGGGCAGTAACATTGAGCCAAGTGTCCGGAGCTGCTTCCAATTTGCTAATAATAAGCCAGA
GATCGAAGCGGCCCTCTTCTAGACTGGATGAGACTGGAACCCCAGTCCATGGTGTGGCTGCCCGTCTGACAGAGTGGCT
GCTGCAGAACTGCCAAGCATCAGGCCAAATGTAACATCTGCAAAGAGTGTCCAATCATTGGATTACAGGTACAGGAGTCTAA
AGCACTTTAATTATGACATCTGCCAAAGCTGCTTTTTTTCTGGTCGAGTTGCAAAGGCCATAAAATGCACTATCCCATGGT
GGAATATTGCACTCCGACTACATCAGGAGAAGATGTTTCGAGACTTTGCCAAGGTACTAAAAAACAAATTTGAAACAAAAGG
TATTTTGCGAAGCATCCCCGAATGGGCTACCTGCCAGTGCAGACTGTCTTAGAGGGGGACAACATGGAAACTCCCGTTACTC
TGATCAACTTCTGGCCAGTAGATTCTGCGCCTGCCTCGTCCCCTCAGCTTTCACACGATGATACTCATTACGCATTGAACA
TTATGCTAGCAGGCTAGCAGAAATGGAACAGCAATGGATCTTATCTAAATGATAGCATCTCTCCTAATGAGAGCATAGAT
GATGAACATTTGTTAATCCAGCATTACTGCCAAAGTTTGAACCAGGACTCCCCCTGAGCCAGCCTCGTAGTCCTGCCAGA
TCTTGATTTCTTAGAGAGTGAGGAAAGAGGGGAGCTAGAGAGAATCTAGCAGATCTTGAGGAAGAAAACAGGAATCTGCA
AGCAGAAATATGACCGTCTAAAGCAGCAGCACGAACATAAAGGCCTGTCCCCACTGCCGTCCCCTCTGAAATGATGCCACC
TCTCCCCAGAGTCCCCGGGATGCTGAGCTCATTGCTGAGGCCAAGCTACTGCGTCAACACAAAGGCCGCTGGAAGCCAGGA
TGCAAATCCTGGAAGACCACAATAAACAGCTGGAGTCACAGTTACACAGGCTAAGGCAGCTGCTGGAGCAACCCAGGCAGA
GGCCAAAGTGAATGGCACAACGGTGTCTCTCCTTCTACCTCTCTACAGAGGTCCGACAGCAGTCAGCCTATGCTGCTCCGA
GTGGTTGGCAGTCAAACCTTCGAGCTCCATGGGTGAGGAAGATCTTCTCAGTCCTCCCAGGACACAAGCACAGGGTTAGAGG
AGGTGATGGAGCAACTCAACAACCTCTTCCCTAGTTCAAGAGGAAGAAATACCCCTGGAAAGCCAATGAGAGAGGACACAAT
GTAGGAAGTCTTTTCCACATGGCAGATGATTTGGGCAGAGCGATGGAGTCCTTAGTATCAGTCATGACAGATGAAGAAGGAG
CAGAATAAATGTTTTACAACCTCTGATTCCCGCATGGTTTTTATAATATTCATACAACAAAGAGGATTAGACAGTAAGAGTT
TACAAGAAAATAATCTATATTTTTGTGAAGGTAGTGGTATTATACTGTAGATTTTCAAGTCTGTTATTGTTT
TGTTAACAATGGCAGTTTTTACACGTCTATGCAATTGTACAAAAAGTTATAAGAAAACCTACATGTAAAATCTTGATAGCTA
AATAACTTGCCATTTCTTTATATGGAACGCATTTTGGGTGTTTTAAAAATTTATAACAGTTATAAAGAAAGATTGTAACTA
AAGTGTGCTTTATAAAAAAAGTTGTTTTATAAAAAACCCCTAAAAACAAAACACACACACACACATACACACACACA
CACAAAACCTTTGAGGCAGCGCATTGTTTTGCATCCTTTTGGCGTGATATCCATATGAAATTCATGGCTTTTTCTTTTTTGC
ATATTAAGATAAGACTTCCTCTACCACCACACCAAATGACTACTACACACTGCTCATTTTGAGAAGTGTGAGCTGAGTGGGG
CAGGCTTGAGTTTTTCATTTTATATATCTATATGTCTATAAGTATATAAATACTATAGTTATATAGATAAAGAGATACGAATT
TCTATAGACTGACTTTTTTCCATTTTTTAAATGTTTATGTCACATCCTAATAGAAAGAAATTACTTCTAGTCAGTCATCCAGG
CTTACCTGCTTGGTCTAGAATGGATTTTTCCCGGAGCCGGAAGCCAGGAGGAACTACACCACACTAAAACATTGTCTACAG
CTCCAGATGTTTTCTATTTTAAACAACCTTTCCACTGACAACGAAAGTAAAGTAAAGTATTGGATTTTTTAAAGGGAACATG
TGAATGAATACACAGGACTTATTATATCAGAGTGAGTAATCGGTTGGTTGGTTGATTGATTGATTGATTGATACATTGAGCT
TCCTGCTGCTAGCAATGCCACGATTTAGATTTAATGATGCTTCAGTGGAATCAATCAGAAGGTATTCTGACCTTGTGAACA
TCAGAAGGTATTTTTTAACTCCCAAGCAGTAGCAGGACGATGATAGGGCTGGAGGGCTATGGATTCCCAGCCCATCCCTGTG
AAGGAGTAGGCCACTCTTTAAGTGAAGGATTGGATGATTGTTTATAATACATAAAGTTCTCTGTAATTACAACCTAAATTATT

ATGCCCTCTTCTCACAGTCAAAAGGAAGTGGGTGGTTTGGTTTTGTTGCTTTTTTAGATTTATTGTCCCATGTGGGATGAG
TTTTTAAATGCCACAAGACATAATTTAAATAAATAAACTTTGGGAAAAGGTGTAAACAGTAGCCCCATCACATTTGTGAT
ACTGACAGGTATCAACCCAGAAGCCCATGAAGTGTGTTCCATCCTTTGCATTTCTCTGCGAGTAGTTCCACACAGGTTTGT
AAGTAAGTAAGAAAAGAAGGCAAATTGATTCAAATGTTACAAAAAACCTTCTTGGTGGATTAGACAGGTTAAATATATAAA
CAAACAAACAAAAATTGCTCAAAAAAGAGGAGAAAAGCTCAAGAGGAAAAGCTAAGGACTGGTAGGAAAAAGCTTTACTCTT
TCATGCCATTTTATTTCTTTTTGATTTTTAAATCATTCAATAGATACCACCGTGTGACCTATAATTTTGCAAATCTGT
TACCTCTGACATCAAGTGTAATTAGCTTTTGGAGAGTGGGCTGACATCAAGTGTAATTAGCTTTTGGAGAGTGGGTTTTGTC
CATTATTAATAATTAATTAATTAACATCAAACACGGCTTCTCATGCTATTTCTACCTCACTTTGGTTTTGGGGTGTTCCTGA
TAATTGTGCACACCTGAGTTCACAGCTTCACCACTTGTCATTGCGTTATTTCTTTTTCTTTTATAATTCTTTCTTTTCC
TTCATAATTTTCAAAGAAAACCCAAAGCTCTAAGGTAACAAATTACCAAATTACATGAAGATTTGGTTTTTGTCTTGCAATT
TTTTTCTTTATGTGACGCTGGACCTTTTCTTTACCCAAGGATTTTTAAACTCAGATTTAAACAAGGGTTACTTTACAT
CCTACTAAGAAGTTTAAGTAAGTAAGTTTCAATCTAAAATCAGAGGTAAATAGAGTGCATAAATAATTTTGTTTTAAATCTTT
TTGTTTTTCTTTTAGACACATTAGCTCTGGAGTGAGTCTGTCATAATATTTGAACAAAAATTGAGAGCTTTATTGCTGCATT
TTAAGCATAATTAATTTGGACATTATTTCTGTGTTGTGTTCTTTATAACCACCAAGTATTAACTGTAAATCATAATGTAAGT
GAAGCATAAACATCACATGGCATGTTTTGTCATTGTTTTCAGGTACTGAGTCTTACTTGAGTATCATAATATATTGTGTTT
TAACACCAACACTGTAACATTTACGAATTATTTTTTAACTTCAGTTTTACTGCATTTTACAACATATCAGACTTCACCA
AATATATGCCTTACTATTGTATTATAGTACTGCTTTACTGTGTATCTCAATAAAGCACGCAGTTATGTTAC</INSDSeq_s
equence>

</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="131">
 <INSDSeq>
 <INSDSeq_length>173</INSDSeq_length>
 <INSDSeq_moltype>AA</INSDSeq_moltype>
 <INSDSeq_division>PAT</INSDSeq_division>
 <INSDSeq_feature-table>
 <INSDFeature>
 <INSDFeature_key>source</INSDFeature_key>

 <INSDFeature_location>1..173</INSDFeature_location>
 <INSDFeature_qual>
 <INSDQualifier>

 <INSDQualifier_name>mol_type</INSDQualifier_name>

 <INSDQualifier_value>protein</INSDQualifier_value>
 </INSDQualifier>
 <INSDQualifier id="q689">

 <INSDQualifier_name>organism</INSDQualifier_name>
 <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
 </INSDQualifier>
 </INSDFeature_qual>
 </INSDFeature>
 </INSDSeq_feature-table>

 <INSDSeq_sequence>AATATAAAAGATAGTCTACAACAAAGCTCAGGTCGGATTGACATTATTCATAGCAAGAAGACAG
CAGCATTGCAAAGTGCAACGCCTGTGGAAAGGGTGAAGCTACAGGAAGCTCTCTCCAGCTTGATTTCCAATGGGAAAAAGT
TAACAAAATGTACAAGGACCGACAAGG</INSDSeq_sequence>

```

        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="132">
        <INSDSeq>
            <INSDSeq_length>446</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..446</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q254">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..446</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q255">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPQGLEWIGEINPTNGRNTNYIEKF
KSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>

```

```

<SequenceData sequenceIDNumber="133">
  <INSDSeq>
    <INSDSeq_length>214</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>
        <INSDFeature_location>1..214</INSDFeature_location>
        <INSDFeature_qual>
          <INSDQualifier id="q256">
            <INSDQualifier_name>note</INSDQualifier_name>
            <INSDQualifier_value>Synthetic</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
      <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>
        <INSDFeature_location>1..214</INSDFeature_location>
        <INSDFeature_qual>
          <INSDQualifier>
            <INSDQualifier_name>mol_type</INSDQualifier_name>
            <INSDQualifier_value>protein</INSDQualifier_value>
          </INSDQualifier>
          <INSDQualifier id="q257">
            <INSDQualifier_name>organism</INSDQualifier_name>
            <INSDQualifier_value>synthetic construct</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
    </INSDSeq_feature-table>
  </INSDSeq>
  <INSDSeq_sequence>DIQMTQSPASLSVSVGETVTITCRASDNLYSNLAWYQQKQGKSPQLLVYDATNLADGVPSRFSG
  SGGTQYSLKINSLQSEDFGTYYCQHFWGTPITFGAGTKLELKRVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
  QWKVDNALQSGNSQESVTEQDSKDYSLSSITLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequ
  ence>
</SequenceData>
<SequenceData sequenceIDNumber="134">
  <INSDSeq>
    <INSDSeq_length>446</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>

```

```

        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..446</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q258">

<INSDQualifier_name>organism</INSDQualifier_name>
                    <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQRLEWIGEINPTNGRTNYIEKF
KSRATLTVDKSASTAYMELSSLRSED TAVYYCARGTRAYHYWGQGMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC
PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="135">
    <INSDSeq>
        <INSDSeq_length>214</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..214</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q259">

```

```

<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPSSLSASVGDRVTITCRASDNLYSNLAWYQQKPGKSPKLLVYDATNLADGVPSRFSG
SGSGTDYTLTISSLQPEDFATYYCQHWGTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
QWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequ
ence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="136">
  <INSDSeq>
    <INSDSeq_length>226</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..226</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q260">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..226</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q261">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>

```



```

        </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPQGLEWIGEINPTNGRTNYIEKF
KSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQGTSTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP</
INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="137">
    <INSDSeq>
        <INSDSeq_length>226</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..226</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q262">

<INSDQualifier_name>organism</INSDQualifier_name>
                                <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQRLEWIGEINPTNGRTNYIEKF
KSRATLTVDKSASTAYMELSSLRSEDYAVYYCARGTRAYHYWGQGTMTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP</
INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="138">
    <INSDSeq>
        <INSDSeq_length>8</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

```

```

<INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q263">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
  </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
  </INSDQualifier>
  <INSDQualifier id="q264">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
  </INSDQualifier>
  </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>GYSFTSYW</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="139">
  <INSDSeq>
    <INSDSeq_length>8</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q265">

<INSDQualifier_name>note</INSDQualifier_name>

```

```

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..8</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q266">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>IYPGDSDT</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="140">
  <INSDSeq>
    <INSDSeq_length>15</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..15</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q267">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..15</INSDFeature_location>

```

```

        <INSDFeature_qual>
            <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
            </INSDQualifier>
            <INSDQualifier id="q268">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
            </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>ARFPYDSSGYYSFDY</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="141">
    <INSDSeq>
        <INSDSeq_length>6</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..6</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q269">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..6</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q270">

```

```
<INSDQualifier_name>organism</INSDQualifier_name>  
  
<INSDQualifier_value>synthetic construct</INSDQualifier_value>  
      </INSDQualifier>  
    </INSDFeature_qual>  
  </INSDFeature>  
</INSDSeq_feature-table>  
<INSDSeq_sequence>QSISSY</INSDSeq_sequence>  
</INSDSeq>  
</SequenceData>  
<SequenceData sequenceIDNumber="142">  
  <INSDSeq>  
    <INSDSeq_length/>  
    <INSDSeq_moltype/>  
    <INSDSeq_division/>  
    <INSDSeq_sequence>000</INSDSeq_sequence>  
  </INSDSeq>  
</SequenceData>  
<SequenceData sequenceIDNumber="143">  
  <INSDSeq>  
    <INSDSeq_length>9</INSDSeq_length>  
    <INSDSeq_moltype>AA</INSDSeq_moltype>  
    <INSDSeq_division>PAT</INSDSeq_division>  
    <INSDSeq_feature-table>  
      <INSDFeature>  
        <INSDFeature_key>REGION</INSDFeature_key>  
  
<INSDFeature_location>1..9</INSDFeature_location>  
          <INSDFeature_qual>  
            <INSDQualifier id="q273">  
  
<INSDQualifier_name>note</INSDQualifier_name>  
  
<INSDQualifier_value>Synthetic</INSDQualifier_value>  
      </INSDQualifier>  
    </INSDFeature_qual>  
  </INSDFeature>  
<INSDFeature>  
  <INSDFeature_key>source</INSDFeature_key>  
  
<INSDFeature_location>1..9</INSDFeature_location>  
  <INSDFeature_qual>  
    <INSDQualifier>  
  
<INSDQualifier_name>mol_type</INSDQualifier_name>  
  
<INSDQualifier_value>protein</INSDQualifier_value>  
      </INSDQualifier>  
    <INSDQualifier id="q274">
```

```
<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>QQSYSTPLT</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="144">
  <INSDSeq>
    <INSDSeq_length>5</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q275">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..5</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q276">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq feature-table>
```

```

        <INSDSeq_sequence>SYWIG</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="145">
    <INSDSeq>
        <INSDSeq_length>18</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..18</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q277">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..18</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q278">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>IIYPGDS DTRYSPSFQGQ</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="146">
    <INSDSeq>
        <INSDSeq_length>13</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>

```

```

        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..13</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q279">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..13</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q280">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>FPYDSSGYYSFDY</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="147">
    <INSDSeq>
        <INSDSeq_length>11</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q281">

```



```

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q282">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>RASQSISSYLN</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="148">
  <INSDSeq>
    <INSDSeq_length>7</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q283">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

```

```

<INSDFeature_location>1..7</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q284">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
  </INSDSeq_feature-table>
  <INSDSeq_sequence>AASSLQS</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="149">
  <INSDSeq>
    <INSDSeq_length>7</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q285">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>

```

```

</INSDQualifier>
<INSDQualifier id="q286">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>GYSFTSY</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="150">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="151">
  <INSDSeq>
    <INSDSeq_length>11</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q289">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>

```

```

        </INSDQualifier>
        <INSDQualifier id="q290">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
        </INSDQualifier>
        </INSDFeature_qual>
        </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>PYDSSGGYYSFD</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="152">
    <INSDSeq>
        <INSDSeq_length>7</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q291">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q292">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>

```

```

        </INSDFeature>
      </INSDSeq_feature-table>
      <INSDSeq_sequence>SQSISSY</INSDSeq_sequence>
    </INSDSeq>
  </SequenceData>
  <SequenceData sequenceIDNumber="153">
    <INSDSeq>
      <INSDSeq_length>6</INSDSeq_length>
      <INSDSeq_moltype>AA</INSDSeq_moltype>
      <INSDSeq_division>PAT</INSDSeq_division>
      <INSDSeq_feature-table>
        <INSDFeature>
          <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
          <INSDFeature_qual>
            <INSDQualifier id="q293">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
          </INSDQualifier>
        </INSDFeature_qual>
      </INSDFeature>
    </INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..6</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q294">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>SYSTPL</INSDSeq_sequence>
    </INSDSeq>
  </SequenceData>
  <SequenceData sequenceIDNumber="154">
    <INSDSeq>
      <INSDSeq_length>122</INSDSeq_length>

```

```

        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..122</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q295">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..122</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q296">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSF
QGQVTISADKSISTAYLQWSSLKASDTAMYCARFPYDSSGYYSFDYWGGTGLTVTVSS</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="155">
        <INSDSeq>
            <INSDSeq_length>107</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

```

```

<INSDFeature_location>1..107</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q297">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q298">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSG
SGSGTDFTLTISSLQPEDFATYYCQSYSTPLTFGGGTKVEIK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="156">
    <INSDSeq>
        <INSDSeq_length>452</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..452</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q299">

<INSDQualifier_name>note</INSDQualifier_name>

```

```

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..452</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q300">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSF
QGQVTISADKSISTAYLQWSSLKASDTAMYCARFPYDSSGYYSFDYWGGTLTVTVSSASTKGPSVFPLAPSSKSTSGGTAA
LGCLVKDYFPEPVTWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP
ENNYKTTTPVLDS DGSFFLYSKLTVDKSRWQQGNVSCSVMHEALHNHYTQKSLSLSPGK</INSDSeq_sequence>
    </INSDSeq>
  </SequenceData>
  <SequenceData sequenceIDNumber="157">
    <INSDSeq>
      <INSDSeq_length>214</INSDSeq_length>
      <INSDSeq_moltype>AA</INSDSeq_moltype>
      <INSDSeq_division>PAT</INSDSeq_division>
      <INSDSeq_feature-table>
        <INSDFeature>
          <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..214</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q301">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>

```



```

        </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..214</INSDFeature_location>
        <INSDFeature_qual>
            <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
            </INSDQualifier>
            <INSDQualifier id="q302">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
            </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSG
SGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNFFYPREAKV
QWKVDNALQSGNSQESVTEQDSKDSYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</INSDSeq_sequ
ence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="158">
    <INSDSeq>
        <INSDSeq_length>232</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..232</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q303">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

```

```

<INSDFeature_location>1..232</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q304">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSF
QGQVTISADKSISTAYLQWSSLKASDTAMYICARFPYDSSGYYSFDYWGGTLTVTVSSASTKGPSVFPLAPSSKSTSGGTAA
LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT
HTCP</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="159">
  <INSDSeq>
    <INSDSeq_length>230</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..230</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q305">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..230</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

```

```
<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q306">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDS DTRYSPSF
QGQVTISADKSISTAYLQWSSLKASDTAMYYCARFPYDSSGYYSFDYWGQGT LVTVSSASTKGPSVFPLAPSSKSTSGGTAA
LGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT
HT</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="160">
  <INSDSeq>
    <INSDSeq_length>23</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
<INSDFeature_qual>
  <INSDQualifier id="q307">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
<INSDFeature_qual>
  <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
  <INSDQualifier value>other
```

```

RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q308">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>cagatctgttgagaaatggcggc</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="161">
    <INSDSeq>
        <INSDSeq_length>24</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q309">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q310">

<INSDQualifier_name>organism</INSDQualifier_name>

```

```

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>cagatctgttgagaaatggcggcg</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="162">
  <INSDSeq>
    <INSDSeq_length>25</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q311">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q312">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

```

```

<INSDSeq_sequence>cagatctgttgagaaatggcggcgt</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="163">
  <INSDSeq>
    <INSDSeq_length>22</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q313">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q314">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>agatctgttgagaaatggcggc</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="164">
  <INSDSeq>
    <INSDSeq_length>23</INSDSeq_length>

```

```

        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q315">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                </INSDQualifier>
            <INSDQualifier id="q316">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>agatctgttgagaaatggcggcg</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="165">
    <INSDSeq>
        <INSDSeq_length>24</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

```

```

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q317">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
RNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q318">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>agatctgttgagaaatggcggcgt</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="166">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q319">

<INSDQualifier_name>note</INSDQualifier_name>

```



```

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q320">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>agatctgttgagaaatggcggcggtt</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="167">
  <INSDSeq>
    <INSDSeq_length>21</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..21</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q321">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>

```

```

                                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..21</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q322">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>
                                <INSDSeq_sequence>gatctgttgagaaatggcggc</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="168">
    <INSDSeq>
        <INSDSeq_length>22</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q323">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

```

```

                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q324">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>gatctgttgagaaatggcgcg</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="169">
    <INSDSeq>
        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q325">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q326">

<INSDQualifier_name>organism</INSDQualifier_name>

```

```

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>gatctgttgagaaatggcggcgt</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="170">
  <INSDSeq>
    <INSDSeq_length>24</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q327">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q328">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

```

```

<INSDSeq_sequence>gatctgttgagaaatggcggcggtt</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="171">
  <INSDSeq>
    <INSDSeq_length>25</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q329">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDFeature>
      <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
        <INSDQualifier_value>other
RNA</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q330">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>gatctgttgagaaatggcggcggtt</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="172">
  <INSDSeq>

```

```

        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q331">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                    <INSDQualifier_value>other
RNA</INSDQualifier_value>
                        </INSDQualifier>
                    <INSDQualifier id="q332">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>

<INSDSeq_sequence>tctgttgagaaatggcggcgttttc</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="173">
        <INSDSeq>
            <INSDSeq_length>20</INSDSeq_length>
            <INSDSeq_moltype>RNA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>

```

```

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..20</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q333">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..20</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
RNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q334">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>ctgttgagaaatggcggcgt</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="174">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q335">

<INSDQualifier_name>note</INSDQualifier_name>

```

```

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q336">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>ctggtgagaaatggcggcgttttca</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="175">
  <INSDSeq>
    <INSDSeq_length>25</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q337">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>

```



```

<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q338">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>tgagaaatggcggcggttttcattat</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="176">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q339">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
</INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

```

```
<INSDQualifier_name>mol_type</INSDQualifier_name>
RNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q340">
</INSDQualifier>
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>gagaaatggcggcgttttcattatg</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="177">
<INSDSeq>
<INSDSeq_length>25</INSDSeq_length>
<INSDSeq_moltype>RNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier id="q341">
</INSDQualifier>
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
RNA</INSDQualifier_value>
<INSDQualifier_value>other
</INSDQualifier>
<INSDQualifier id="q342">
```

```

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>agaaatggcggcggttttcattatga</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="178">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q343">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q344">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>

```

```

        </INSDSeq_feature-table>

<INSDSeq_sequence>aatcagtggtacagaagctgaac</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="179">
    <INSDSeq>
        <INSDSeq_length>24</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q345">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                    <INSDQualifier_value>other
RNA</INSDQualifier_value>
                        </INSDQualifier>
                <INSDQualifier id="q346">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>atcagtggtacagaagctgaac</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="180">

```

```

        <INSDSeq>
            <INSDSeq_length>25</INSDSeq_length>
            <INSDSeq_moltype>RNA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q347">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q348">

                                </INSDQualifier>

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>atcagtggctaacagaagctgaaca</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="181">
    <INSDSeq>
        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

```

```

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q349">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
RNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q350">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>tcagtggctaacagaagctgaac</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="182">
    <INSDSeq>
        <INSDSeq_length>24</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q351">

```



```

        </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q354">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>tcagtggctaacagaagctgaacag</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="184">
    <INSDSeq>
        <INSDSeq_length>22</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q355">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
            <INSDFeature_qual>

```



```

        <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
        <INSDQualifier_value>other
RNA</INSDQualifier_value>
        </INSDQualifier>
        <INSDQualifier id="q356">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
        </INSDQualifier>
        </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>cagtggtacacagaagctgaac</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="185">
    <INSDSeq>
        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q357">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
            </INSDQualifier>
            </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                <INSDQualifier_value>other
RNA</INSDQualifier_value>
            </INSDQualifier>

```

```

        <INSDQualifier id="q358">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
        </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>cagtggctaacagaagctgaaca</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="186">
    <INSDSeq>
        <INSDSeq_length>24</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..24</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q359">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..24</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
                        <INSDQualifier_value>other
RNA</INSDQualifier_value>
                            </INSDQualifier>
                        <INSDQualifier id="q360">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                            </INSDQualifier>

```

```

                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>cagtggtacagaagctgaacag</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="187">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q361">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                    </INSDQualifier>
                                <INSDQualifier id="q362">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                    </INSDQualifier>
                                </INSDFeature_qual>
                            </INSDFeature>
                        </INSDSeq_feature-table>

<INSDSeq_sequence>cagtggtacagaagctgaacag</INSDSeq_sequence>
    </INSDSeq>

```

```

</SequenceData>
<SequenceData sequenceIDNumber="188">
  <INSDSeg>
    <INSDSeg_length>23</INSDSeg_length>
    <INSDSeg_moltype>RNA</INSDSeg_moltype>
    <INSDSeg_division>PAT</INSDSeg_division>
    <INSDSeg_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q363">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q364">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
</INSDSeg_feature-table>

<INSDSeg_sequence>agtggctaacagaagctgaacag</INSDSeg_sequence>
  </INSDSeg>
</SequenceData>
<SequenceData sequenceIDNumber="189">
  <INSDSeg>
    <INSDSeg_length>24</INSDSeg_length>
    <INSDSeg_moltype>RNA</INSDSeg_moltype>
    <INSDSeg_division>PAT</INSDSeg_division>

```

```

        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q365">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                </INSDQualifier>
            <INSDQualifier id="q366">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>agtggtacacagaagctgaacagt</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="190">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>

```

```

                                <INSDFeature_qual>
                                    <INSDQualifier id="q367">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q368">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>agtggtacacagaagctgaacagtt</INSDSeq_sequence>
                                </INSDSeq>
                                </SequenceData>
                                <SequenceData sequenceIDNumber="191">
                                    <INSDSeq>
                                        <INSDSeq_length>23</INSDSeq_length>
                                        <INSDSeq_moltype>RNA</INSDSeq_moltype>
                                        <INSDSeq_division>PAT</INSDSeq_division>
                                        <INSDSeq_feature-table>
                                            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q369">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>

```

```

                                </INSDQualifier>
                            </INSDFeature_qual>
                        </INSDFeature>
                    <INSDFeature>
                        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q370">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                            </INSDFeature>
                        </INSDSeq_feature-table>

<INSDSeq_sequence>gtggctaacagaagctgaacagt</INSDSeq_sequence>
                                </INSDSeq>
                            </SequenceData>
                        <SequenceData sequenceIDNumber="192">
                            <INSDSeq>
                                <INSDSeq_length>24</INSDSeq_length>
                                <INSDSeq_moltype>RNA</INSDSeq_moltype>
                                <INSDSeq_division>PAT</INSDSeq_division>
                                <INSDSeq_feature-table>
                                    <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q371">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                            </INSDFeature>
                        <INSDFeature>
                            <INSDFeature_key>source</INSDFeature_key>

```

```

<INSDFeature_location>1..24</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q372">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
  </INSDSeq_feature-table>

<INSDSeq_sequence>gtggctaacagaagctgaacagtt</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="193">
  <INSDSeq>
    <INSDSeq_length>25</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q373">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other

```



```

RNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q374">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>aaagatcaggttctgaagggtgatg</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="194">
  <INSDSeq>
    <INSDSeq_length>24</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
<INSDFeature_qual>
  <INSDQualifier id="q375">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
<INSDFeature_qual>
  <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other
RNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q376">

<INSDQualifier_name>organism</INSDQualifier_name>

```

```

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>aagatcaggttctgaagggtgatg</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="195">
  <INSDSeq>
    <INSDSeq_length>23</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q377">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q378">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

```

```

<INSDSeq_sequence>agatcaggttctgaagggtgatg</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="196">
  <INSDSeq>
    <INSDSeq_length>23</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q379">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q380">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>gccgccatttctcaacagatctg</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="197">
  <INSDSeq>
    <INSDSeq_length>24</INSDSeq_length>

```

```

        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q381">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q382">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                            </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>cgccgccatttctcaacagatctg</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="198">
        <INSDSeq>
            <INSDSeq_length>25</INSDSeq_length>
            <INSDSeq_moltype>RNA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

```

```

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q383">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
RNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q384">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>acgccgccatttctcaacagatctg</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="199">
    <INSDSeq>
        <INSDSeq_length>22</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q385">

<INSDQualifier_name>note</INSDQualifier_name>

```

```

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q386">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>gccgccatttctcaacagatct</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="200">
  <INSDSeq>
    <INSDSeq_length>23</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q387">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>

```

```

<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..23</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>
          <INSDQualifier_name>mol_type</INSDQualifier_name>
          <INSDQualifier_value>other
RNA</INSDQualifier_value>
        </INSDQualifier>
      <INSDQualifier id="q388">
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>cgccgccatttctcaacagatct</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="201">
  <INSDSeq>
    <INSDSeq_length>24</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>misc_feature</INSDFeature_key>
        <INSDFeature_location>1..24</INSDFeature_location>
          <INSDFeature_qual>
            <INSDQualifier id="q389">
          </INSDFeature_qual>
        </INSDFeature>
      </INSDSeq_feature-table>
    </INSDSeq>
  </SequenceData>
</INSDSeq>
</INSDSeq_data>
</INSDSeq_data-set>

```

```
<INSDQualifier_name>mol_type</INSDQualifier_name>
RNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q390">
</INSDQualifier>
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>acgccgccatttctcaacagatct</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="202">
<INSDSeq>
<INSDSeq_length>25</INSDSeq_length>
<INSDSeq_moltype>RNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier id="q391">
</INSDQualifier>
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
RNA</INSDQualifier_value>
<INSDQualifier_value>other
</INSDQualifier>
<INSDQualifier id="q392">
```



```

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>aacgccgccatttctcaacagatct</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="203">
    <INSDSeq>
        <INSDSeq_length>21</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..21</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q393">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..21</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q394">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>

```

```

        </INSDSeq_feature-table>
        <INSDSeq_sequence>gccgccatttctcaacagatc</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="204">
    <INSDSeq>
        <INSDSeq_length>22</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q395">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                            </INSDFeature_qual>
                        </INSDFeature>
                    <INSDFeature>
                        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                            <INSDQualifier id="q396">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                            </INSDFeature_qual>
                        </INSDFeature>
                    </INSDSeq_feature-table>

<INSDSeq_sequence>cgccgccatttctcaacagatc</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="205">
    <INSDSeq>

```

```

        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q397">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                    <INSDQualifier_value>other
RNA</INSDQualifier_value>
                    </INSDQualifier>
                <INSDQualifier id="q398">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>acgccgccatttctcaacagatc</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="206">
        <INSDSeq>
            <INSDSeq_length>24</INSDSeq_length>
            <INSDSeq_moltype>RNA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>

```

```

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q399">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
RNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q400">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>aacgccgccatttctcaacagatc</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="207">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q401">

```

```

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q402">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>aaacgccgccatttctcaacagatc</INSDSeq_sequence>
                                </INSDSeq>
                                </SequenceData>
                                <SequenceData sequenceIDNumber="208">
                                    <INSDSeq>
                                        <INSDSeq_length>25</INSDSeq_length>
                                        <INSDSeq_moltype>RNA</INSDSeq_moltype>
                                        <INSDSeq_division>PAT</INSDSeq_division>
                                        <INSDSeq_feature-table>
                                            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q403">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>

```

```

        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q404">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>gaaaacgccgcatcttctcaacaga</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="209">
    <INSDSeq>
        <INSDSeq_length>20</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..20</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q405">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..20</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

```

```
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other
RNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q406">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>acgccgccatttctcaacag</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="210">
  <INSDSeq>
    <INSDSeq_length>25</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>misc_feature</INSDFeature_key>
        <INSDFeature_location>1..25</INSDFeature_location>
        <INSDFeature_qual>
          <INSDQualifier id="q407">

<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>
  <INSDFeature_location>1..25</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other
RNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q408">
```

```

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>tgaaaacgccgccatttctcaacag</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="211">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q409">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q410">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>

```



```

        </INSDSeq_feature-table>

<INSDSeq_sequence>ataatgaaaacgccgcatcttctca</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="212">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q411">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                    <INSDQualifier_value>other
RNA</INSDQualifier_value>
                        </INSDQualifier>
                <INSDQualifier id="q412">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>cataatgaaaacgccgcatcttctc</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="213">

```

```

        <INSDSeq>
            <INSDSeq_length>25</INSDSeq_length>
            <INSDSeq_moltype>RNA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q413">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q414">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                            </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>tcataatgaaaacgccgccatttct</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="214">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

```

```

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q415">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
RNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q416">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>gttcagcttctgttagccactgatt</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="215">
    <INSDSeq>
        <INSDSeq_length>24</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q417">

```



```

        </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q420">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>tggtcagcttctgttagccactgat</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="217">
    <INSDSeq>
        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q421">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
            <INSDFeature_qual>

```

```

<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
RNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q422">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>gttcagcttctgtagccactga</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="218">
<INSDSeq>
<INSDSeq_length>24</INSDSeq_length>
<INSDSeq_moltype>RNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..24</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier id="q423">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..24</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
RNA</INSDQualifier_value>
</INSDQualifier>

```

```
<INSDQualifier id="q424">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>tgttcagcttctgtagccactga</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="219">
<INSDSeq>
<INSDSeq_length>25</INSDSeq_length>
<INSDSeq_moltype>RNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier id="q425">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other
RNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q426">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
```

```

                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>ctgttcagcttctgttagccactga</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="220">
    <INSDSeq>
        <INSDSeq_length>22</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q427">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q428">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                            </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>gttcagcttctgttagccactg</INSDSeq_sequence>
    </INSDSeq>

```



```

</SequenceData>
<SequenceData sequenceIDNumber="221">
  <INSDSeq>
    <INSDSeq_length>23</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q429">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q430">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>tggttcagcttctgttagccactg</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="222">
  <INSDSeq>
    <INSDSeq_length>24</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>

```

```

        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q431">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                </INSDQualifier>
            <INSDQualifier id="q432">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>ctgttcagcttctgttagccactg</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="223">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>

```

```

        <INSDFeature_qual>
            <INSDQualifier id="q433">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
            </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
        <INSDFeature_qual>
            <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
            <INSDQualifier_value>other
RNA</INSDQualifier_value>
            </INSDQualifier>
            <INSDQualifier id="q434">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
            </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>actgttcagcttctgttagccactg</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="224">
    <INSDSeq>
        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q435">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>

```

```

                                </INSDQualifier>
                            </INSDFeature_qual>
                        </INSDFeature>
                    <INSDFeature>
                        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q436">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                            </INSDFeature>
                        </INSDSeq_feature-table>

<INSDSeq_sequence>ctgttcagcttctgttagccact</INSDSeq_sequence>
                                </INSDSeq>
                            </SequenceData>
                        <SequenceData sequenceIDNumber="225">
                            <INSDSeq>
                                <INSDSeq_length>24</INSDSeq_length>
                                <INSDSeq_moltype>RNA</INSDSeq_moltype>
                                <INSDSeq_division>PAT</INSDSeq_division>
                                <INSDSeq_feature-table>
                                    <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q437">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                            </INSDFeature>
                        <INSDFeature>
                            <INSDFeature_key>source</INSDFeature_key>

```

```

<INSDFeature_location>1..24</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>
          <INSDQualifier_name>mol_type</INSDQualifier_name>
            <INSDQualifier_value>other
RNA</INSDQualifier_value>
          </INSDQualifier>
        <INSDQualifier id="q438">
          <INSDQualifier_name>organism</INSDQualifier_name>
          <INSDQualifier_value>synthetic construct</INSDQualifier_value>
        </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
  </INSDSeq_feature-table>
<INSDSeq_sequence>actgttcagcttctgttagccact</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="226">
  <INSDSeq>
    <INSDSeq_length>25</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>misc_feature</INSDFeature_key>
        <INSDFeature_location>1..25</INSDFeature_location>
          <INSDFeature_qual>
            <INSDQualifier id="q439">
              <INSDQualifier_name>note</INSDQualifier_name>
              <INSDQualifier_value>Synthetic</INSDQualifier_value>
            </INSDQualifier>
          </INSDFeature_qual>
        </INSDFeature>
      <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>
        <INSDFeature_location>1..25</INSDFeature_location>
          <INSDFeature_qual>
            <INSDQualifier>
              <INSDQualifier_name>mol_type</INSDQualifier_name>
              <INSDQualifier_value>other

```

```

RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q440">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>aactgttcagcttctgttagccact</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="227">
    <INSDSeq>
        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q441">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q442">

<INSDQualifier_name>organism</INSDQualifier_name>

```

```

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>actgttcagcttctgttagccac</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="228">
  <INSDSeq>
    <INSDSeq_length>24</INSDSeq_length>
    <INSDSeq_moltype>RNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q443">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
RNA</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q444">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

```

```

<INSDSeq_sequence>aactgttcagcttctgttagccac</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="229">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q445">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                    <INSDQualifier_value>other
RNA</INSDQualifier_value>
                        </INSDQualifier>
                    <INSDQualifier id="q446">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>

<INSDSeq_sequence>catcacccttcagaacctgatcttt</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="230">
    <INSDSeq>
        <INSDSeq_length>24</INSDSeq_length>

```



```

        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q447">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                <INSDQualifier_value>other
RNA</INSDQualifier_value>
                </INSDQualifier>
            <INSDQualifier id="q448">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>catcacccttcagaacctgatctt</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="231">
    <INSDSeq>
        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>RNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

```

```

<INSDFeature_location>1..23</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q449">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
RNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q450">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>catcacccttcagaacctgatct</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="232">
    <INSDSeq>
        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q451">

<INSDQualifier_name>note</INSDQualifier_name>

```

```

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
DNA</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q452">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>gccgccatttctcaacagatctg</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="233">
  <INSDSeq>
    <INSDSeq_length>24</INSDSeq_length>
    <INSDSeq_moltype>DNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q453">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>

```

```

<INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
DNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q454">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>cgccgccatttctcaacagatctg</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="234">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q455">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

```

```

<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other
DNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q456">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>acgccgccatttctcaacagatctg</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="235">
<INSDSeq>
<INSDSeq_length>22</INSDSeq_length>
<INSDSeq_moltype>DNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..22</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier id="q457">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..22</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other
DNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q458">

```

```

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>gccgccatttctcaacagatct</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="236">
    <INSDSeq>
        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q459">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q460">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>

```

```

        </INSDSeq_feature-table>

<INSDSeq_sequence>cgccgccatttctcaacagatct</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="237">
    <INSDSeq>
        <INSDSeq_length>24</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q461">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                    <INSDQualifier_value>other
DNA</INSDQualifier_value>
                </INSDQualifier>
            <INSDQualifier id="q462">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>acgccgccatttctcaacagatct</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="238">

```

```

        <INSDSeq>
            <INSDSeq_length>25</INSDSeq_length>
            <INSDSeq_moltype>DNA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q463">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
DNA</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q464">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>aacgccgccatttctcaacagatct</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="239">
        <INSDSeq>
            <INSDSeq_length>21</INSDSeq_length>
            <INSDSeq_moltype>DNA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>

```



```

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..21</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q465">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..21</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
DNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q466">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>gccgccatttctcaacagatc</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="240">
    <INSDSeq>
        <INSDSeq_length>22</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q467">

```

```

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q468">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>cgccgccatttctcaacagatc</INSDSeq_sequence>
                                </INSDSeq>
                                </SequenceData>
                                <SequenceData sequenceIDNumber="241">
                                    <INSDSeq>
                                        <INSDSeq_length>23</INSDSeq_length>
                                        <INSDSeq_moltype>DNA</INSDSeq_moltype>
                                        <INSDSeq_division>PAT</INSDSeq_division>
                                        <INSDSeq_feature-table>
                                            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q469">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>

```

```

        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q470">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>acgccgccatttctcaacagatc</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="242">
    <INSDSeq>
        <INSDSeq_length>24</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q471">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

```

```
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>DNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q472">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>aacgccgccatttctcaacagatc</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="243">
<INSDSeq>
<INSDSeq_length>25</INSDSeq_length>
<INSDSeq_moltype>DNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier id="q473">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>DNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q474">
```

```
<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>aaacgccgccatttctcaacagatc</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="244">
  <INSDSeq>
    <INSDSeq_length>25</INSDSeq_length>
    <INSDSeq_moltype>DNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>misc_feature</INSDFeature_key>
        <INSDFeature_location>1..25</INSDFeature_location>
          <INSDFeature_qual>
            <INSDQualifier id="q475">
              <INSDQualifier_name>note</INSDQualifier_name>
              <INSDQualifier_value>Synthetic</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
          </INSDFeature>
        <INSDFeature>
          <INSDFeature_key>source</INSDFeature_key>
          <INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
              <INSDQualifier>
                <INSDQualifier_name>mol_type</INSDQualifier_name>
                <INSDQualifier_value>other DNA</INSDQualifier_value>
                  </INSDQualifier>
              <INSDQualifier id="q476">
                <INSDQualifier_name>organism</INSDQualifier_name>
                <INSDQualifier_value>synthetic construct</INSDQualifier_value>
                  </INSDQualifier>
              </INSDFeature_qual>
            </INSDFeature>
          </INSDFeature>
        </INSDFeature-table>
      </INSDSeq>
    </INSDSeq>
  </SequenceData>
</INSDSeq>
```

```

        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>gaaaacgccgccatttctcaacaga</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="245">
    <INSDSeq>
        <INSDSeq_length>20</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..20</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q477">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..20</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                    <INSDQualifier_value>other
DNA</INSDQualifier_value>
                </INSDQualifier>
            <INSDQualifier id="q478">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>acgccgccatttctcaacag</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="246">

```

```

        <INSDSeq>
            <INSDSeq_length>25</INSDSeq_length>
            <INSDSeq_moltype>DNA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q479">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                    <INSDQualifier_value>other
DNA</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q480">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>tgaaaacgccgccatttctcaacag</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="247">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

```

```

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q481">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
DNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q482">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>ataatgaaaacgccgccatttctca</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="248">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q483">

```



```

        </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q486">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>tcataatgaaaacgccgccatttct</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="250">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q487">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>

```

```

<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other
DNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q488">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>gttcagcttctgtagccactgatt</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="251">
<INSDSeq>
<INSDSeq_length>24</INSDSeq_length>
<INSDSeq_moltype>DNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier id="q489">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other
DNA</INSDQualifier_value>
</INSDQualifier>

```

```
<INSDQualifier id="q490">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>gttcagcttctgtagccactgat</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="252">
<INSDSeq>
<INSDSeq_length>25</INSDSeq_length>
<INSDSeq_moltype>DNA</INSDSeq_moltype>
<INSDSeq_division>PAT</INSDSeq_division>
<INSDSeq_feature-table>
<INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier id="q491">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
<INSDFeature>
<INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..25</INSDFeature_location>
<INSDFeature_qual>
<INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>other
DNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q492">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
</INSDQualifier>
```

```

                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>tggtcagcttctgttagccactgat</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="253">
    <INSDSeq>
        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q493">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q494">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                            </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>gttcagcttctgttagccactga</INSDSeq_sequence>
    </INSDSeq>

```

```

</SequenceData>
<SequenceData sequenceIDNumber="254">
  <INSDSeq>
    <INSDSeq_length>24</INSDSeq_length>
    <INSDSeq_moltype>DNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q495">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
DNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q496">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>tggttcagcttctgttagccactga</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="255">
  <INSDSeq>
    <INSDSeq_length>25</INSDSeq_length>
    <INSDSeq_moltype>DNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>

```

```

        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q497">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                <INSDQualifier_value>other
DNA</INSDQualifier_value>
                </INSDQualifier>
            <INSDQualifier id="q498">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>ctgttcagcttctgttagccactga</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="256">
    <INSDSeq>
        <INSDSeq_length>22</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..22</INSDFeature_location>

```

```

                                <INSDFeature_qual>
                                    <INSDQualifier id="q499">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..22</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q500">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>
<INSDSeq_sequence>gttcagcttctgttagccactg</INSDSeq_sequence>
                                </INSDSeq>
                                </SequenceData>
                                <SequenceData sequenceIDNumber="257">
                                    <INSDSeq>
                                        <INSDSeq_length>23</INSDSeq_length>
                                        <INSDSeq_moltype>DNA</INSDSeq_moltype>
                                        <INSDSeq_division>PAT</INSDSeq_division>
                                        <INSDSeq_feature-table>
                                            <INSDFeature>
<INSDFeature_key>misc_feature</INSDFeature_key>
<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q501">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>

```



```

        </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
      <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
        <INSDQualifier_value>other
DNA</INSDQualifier_value>
        </INSDQualifier>
        <INSDQualifier id="q502">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
        </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
  </INSDSeq_feature-table>

<INSDSeq_sequence>tggtcagcttctgtagccactg</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="258">
  <INSDSeq>
    <INSDSeq_length>24</INSDSeq_length>
    <INSDSeq_moltype>DNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q503">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

```

```

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
DNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q504">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>ctgttcagcttctgttagccactg</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="259">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q505">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other

```

```

DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q506">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>actgttcagcttctgttagccactg</INSDSeq_sequence>
                                </INSDSeq>
                                </SequenceData>
                                <SequenceData sequenceIDNumber="260">
                                    <INSDSeq>
                                        <INSDSeq_length>23</INSDSeq_length>
                                        <INSDSeq_moltype>DNA</INSDSeq_moltype>
                                        <INSDSeq_division>PAT</INSDSeq_division>
                                        <INSDSeq_feature-table>
                                            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q507">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q508">

<INSDQualifier_name>organism</INSDQualifier_name>

```

```

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>ctgttcagcttctgttagccact</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="261">
  <INSDSeq>
    <INSDSeq_length>24</INSDSeq_length>
    <INSDSeq_moltype>DNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q509">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
DNA</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q510">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

```

```

<INSDSeq_sequence>actgttcagcttctgtagccact</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="262">
  <INSDSeq>
    <INSDSeq_length>25</INSDSeq_length>
    <INSDSeq_moltype>DNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q511">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
      <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
DNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q512">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>aactgttcagcttctgtagccact</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="263">
  <INSDSeq>
    <INSDSeq_length>23</INSDSeq_length>

```

```

        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier id="q513">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q514">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                            </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>actgttcagcttctgttagccac</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="264">
        <INSDSeq>
            <INSDSeq_length>24</INSDSeq_length>
            <INSDSeq_moltype>DNA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

```

```

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q515">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
DNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q516">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>aactgttcagcttctgttagccac</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="265">
    <INSDSeq>
        <INSDSeq_length>25</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q517">

<INSDQualifier_name>note</INSDQualifier_name>

```

```

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..25</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
      <INSDQualifier_value>other
DNA</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q518">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>catcacccttcagaacctgatcttt</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="266">
  <INSDSeq>
    <INSDSeq_length>24</INSDSeq_length>
    <INSDSeq_moltype>DNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q519">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>

```



```

<INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..24</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
    <INSDQualifier_value>other
DNA</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q520">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>catcacccttcagaacctgatctt</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="267">
    <INSDSeq>
        <INSDSeq_length>23</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

<INSDFeature_key>misc_feature</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q521">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..23</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

```

```

<INSDQualifier_name>mol_type</INSDQualifier_name>
                                <INSDQualifier_value>other
DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q522">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>catcacccttcagaacctgatct</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="268">
    <INSDSeq>
        <INSDSeq_length>60</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..60</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q690">

<INSDQualifier_name>organism</INSDQualifier_name>
                                <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>agttaacaaaatgtacaaggaccgacaagggttaggtaacacatatatTTTTTcttgatact</IN
SDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="269">
    <INSDSeq>

```

```

        <INSDSeq_length>70465</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..70465</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q691">

<INSDQualifier_name>organism</INSDQualifier_name>
                                <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
        </INSDSeq_feature-table>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="270">
    <INSDSeq>
        <INSDSeq_length>50</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..50</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q692">

<INSDQualifier_name>organism</INSDQualifier_name>
                                <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
        </INSDSeq_feature-table>
    </INSDSeq>
</SequenceData>

```

```

        </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>gtaggtaacacatatatcttcttgatacttcagaaatgatttgttttc</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="271">
    <INSDSeq>
        <INSDSeq_length>250</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>
            </INSDFeature>
        </INSDSeq_feature-table>
    </INSDSeq>
</SequenceData>
</INSDSeq>
<INSDFeature_location>1..250</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>
            <INSDQualifier_name>mol_type</INSDQualifier_name>
            <INSDQualifier_value>genomic DNA</INSDQualifier_value>
            </INSDQualifier>
            <INSDQualifier id="q693">
                <INSDQualifier_name>organism</INSDQualifier_name>
                <INSDQualifier_value>Homo sapiens</INSDQualifier_value>
            </INSDQualifier>
        </INSDFeature_qual>
    </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>ttttaaagggaataatgcaaccttcattttaaatacagcttttatattgagtatcttttttaaa
atgttggtgtacatgctaggtgtgtatattaattttttattgttacttgaaactaaactctgcaaatgcaggaaactatca
gagtgatatctttgtcagtataacaaaaaatatacgtatatctctataatctgttttacataatccatctatctttcttg
atccatgcttttacctgcag</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="272">
    <INSDSeq>
        <INSDSeq_length>60</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>
            </INSDFeature>
        </INSDSeq_feature-table>
    </INSDSeq>
</SequenceData>
</INSDSeq>

```

```

<INSDFeature_location>1..60</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q694">

<INSDQualifier_name>organism</INSDQualifier_name>
      <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>ttttcttgatccatatgcttttacctgcaggcgatttgacagatctgttgagaaatggcg</IN
SDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="273">
  <INSDSeq>
    <INSDSeq_length>148</INSDSeq_length>
    <INSDSeq_moltype>DNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..148</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q695">

<INSDQualifier_name>organism</INSDQualifier_name>
      <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>gcgatttgacagatctgttgagaaatggcggcggttttcattatgatataaagatatttaacag

```

```

tggctaacagaagctgaacagtttctcagaaagacacaaattcctgagaattgggaacatgctaaatacaaattggtatctta
ag</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="274">
    <INSDSeq>
        <INSDSeq_length>55</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..55</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>genomic DNA</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q696">

<INSDQualifier_name>organism</INSDQualifier_name>
                    <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>gcgatttgacagatctgttgagaaatggcggcggttttcattatgatataaagata</INSDSeq
_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="275">
    <INSDSeq>
        <INSDSeq_length>49</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..49</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

```

```

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q697">

<INSDQualifier_name>organism</INSDQualifier_name>
                                <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>aaagatatttaatcagtggctaacagaagctgaacagtttctcagaaag</INSDSeq_seque
nce>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="276">
    <INSDSeq>
        <INSDSeq_length>60</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..60</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q703">

<INSDQualifier_name>organism</INSDQualifier_name>
                                <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>gaacatgctaaatacaaatggtatcttaaggttaagtctttgatttgtttttcgaaattg</IN
SDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="277">
    <INSDSeq>
        <INSDSeq_length>248401</INSDSeq_length>

```

```

        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..248401</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q704">

<INSDQualifier_name>organism</INSDQualifier_name>
                    <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="278">
    <INSDSeq>
        <INSDSeq_length>45</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..45</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q705">

<INSDQualifier_name>organism</INSDQualifier_name>
                    <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
    </INSDSeq>
</SequenceData>

```



```

        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>ttaacttcttaaagatcagggttctgaagggtgatggaaattactt</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="279">
    <INSDSeq>
        <INSDSeq_length>60</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..60</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q706">

<INSDQualifier_name>organism</INSDQualifier_name>
                    <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>tttttgtttgccttttgggtatcttacaggaactccaggatggcattgggcagcggcaa</IN
SDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="280">
    <INSDSeq>
        <INSDSeq_length>176</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..176</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

```

```
<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q707">

<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>gaactccaggatggcattgggcagcggcaaactgttgtcagaaacattgaatgcaactggggaag
aaataattcagcaatcctcaaaaacagatgccagtattctacaggaaaaattgggaagcctgaatctgcggtggcaggaggt
ctgcaaacagctgtcagacagaaaaaagag</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="281">
  <INSDSeq>
    <INSDSeq_length>50</INSDSeq_length>
    <INSDSeq_moltype>DNA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..50</INSDFeature_location>
<INSDFeature_qual>
  <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
</INSDQualifier>
<INSDQualifier id="q710">

<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>Homo
sapiens</INSDQualifier_value>
</INSDQualifier>
</INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>gaactccaggatggcattgggcagcggcaaactgttgtcagaaacattgaa</INSDSeq_sequ
ence>
</INSDSeq>
</SequenceData>
```

```
<SequenceData sequenceIDNumber="282">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="283">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="284">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="285">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="286">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="287">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="288">
  <INSDSeq>
```

```

        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="289">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="290">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="291">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="292">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="293">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="294">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>

```

```

        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="295">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="296">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="297">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="298">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="299">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="300">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>

```

```

        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="301">
        <INSDSeq>
            <INSDSeq_length/>
            <INSDSeq_moltype/>
            <INSDSeq_division/>
            <INSDSeq_sequence>000</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="302">
        <INSDSeq>
            <INSDSeq_length/>
            <INSDSeq_moltype/>
            <INSDSeq_division/>
            <INSDSeq_sequence>000</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="303">
        <INSDSeq>
            <INSDSeq_length/>
            <INSDSeq_moltype/>
            <INSDSeq_division/>
            <INSDSeq_sequence>000</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="304">
        <INSDSeq>
            <INSDSeq_length/>
            <INSDSeq_moltype/>
            <INSDSeq_division/>
            <INSDSeq_sequence>000</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="305">
        <INSDSeq>
            <INSDSeq_length/>
            <INSDSeq_moltype/>
            <INSDSeq_division/>
            <INSDSeq_sequence>000</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="306">
        <INSDSeq>
            <INSDSeq_length/>
            <INSDSeq_moltype/>
            <INSDSeq_division/>
            <INSDSeq_sequence>000</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>

```

```
<SequenceData sequenceIDNumber="307">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="308">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="309">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="310">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="311">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="312">
  <INSDSeq>
    <INSDSeq_length/>
    <INSDSeq_moltype/>
    <INSDSeq_division/>
    <INSDSeq_sequence>000</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="313">
  <INSDSeq>
```

```

        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="314">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="315">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="316">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="317">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="318">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="319">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>

```



```

        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="320">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="321">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="322">
    <INSDSeq>
        <INSDSeq_length/>
        <INSDSeq_moltype/>
        <INSDSeq_division/>
        <INSDSeq_sequence>000</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="323">
    <INSDSeq>
        <INSDSeq_length>250</INSDSeq_length>
        <INSDSeq_moltype>DNA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..250</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>genomic DNA</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q711">

<INSDQualifier_name>organism</INSDQualifier_name>
                    <INSDQualifier_value>Homo
sapiens</INSDQualifier_value>

```

```

                                </INSDQualifier>
                            </INSDFeature_qual>
                        </INSDFeature>
                    </INSDSeq_feature-table>

<INSDSeq_sequence>tgacaagcttacaaaaataaaaactggagctaaccgagagggtgcttttttcctgacacataa
aagggtgtctttctgtcttgtatcctttggatatgggcatgtcagtttcatagggaaattttcacatggagcttttgtatttc
tttctttgccagtacaactgcatgtggttagcacactgtttaatcttttctcaaataaaaagacatggggcttcatttttgtt
ttgcctttttggtatcttacag</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="324">
    <INSDSeq>
        <INSDSeq_length>7</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q620">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
        <INSDFeature_qual>
            <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
            </INSDQualifier>
        </INSDFeature_qual>
    </INSDSeq_feature-table>

```

```

        <INSDSeq_sequence>ASSLNIA</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="325">
    <INSDSeq>
        <INSDSeq_length>12</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..12</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q622">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..12</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q623">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>SKTFNTHPQSTP</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="326">
    <INSDSeq>
        <INSDSeq_length>12</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>

```

```

        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..12</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q624">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..12</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q625">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>TARGEHKEEELI</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="327">
    <INSDSeq>
        <INSDSeq_length>9</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q626">

```

```

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q627">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>CQAQGQLVC</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="328">
  <INSDSeq>
    <INSDSeq_length>9</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q628">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

```

```

<INSDFeature_location>1..9</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q629">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
  </INSDSeq_feature-table>
  <INSDSeq_sequence>CSERSMNFC</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="329">
  <INSDSeq>
    <INSDSeq_length>9</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q630">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
      </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
      <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>

```

```

        </INSDQualifier>
        <INSDQualifier id="q631">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
        </INSDQualifier>
        </INSDFeature_qual>
        </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>CPKTRRVPC</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="330">
    <INSDSeq>
        <INSDSeq_length>20</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..20</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q632">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..20</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q633">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
    </INSDSeq>
</SequenceData>

```

```

        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>WLSEAGPVVTVRALRGTGSW</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="331">
    <INSDSeq>
        <INSDSeq_length>9</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q634">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q635">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>CMQHSMRVC</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="332">
    <INSDSeq>
        <INSDSeq_length>7</INSDSeq_length>

```



```

        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q636">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q637">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>DDTRHWG</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="333">
    <INSDSeq>
        <INSDSeq_length>10</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..10</INSDFeature_location>
                <INSDFeature_qual>

```

```

<INSDQualifier id="q638">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..10</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q639">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>GYTFTNYWMH</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="334">
  <INSDSeq>
    <INSDSeq_length>17</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q640">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>

```

```

        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
                <INSDQualifier id="q641">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>EINPINGRSNYGERFKT</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="335">
    <INSDSeq>
        <INSDSeq_length>7</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q642">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

```

```

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q643">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>
                                <INSDSeq_sequence>GTRAMHY</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="336">
  <INSDSeq>
    <INSDSeq_length>11</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier id="q644">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
                                <INSDFeature_qual>
                                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q645">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>

```

```

                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>RTSENIYNNLA</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="337">
    <INSDSeq>
        <INSDSeq_length>7</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q646">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
            <INSDQualifier id="q647">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>AATNLAD</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="338">

```

```

        <INSDSeq>
            <INSDSeq_length>10</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>
<INSDFeature_location>1..10</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q648">
<INSDQualifier_name>note</INSDQualifier_name>
<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>
<INSDFeature_location>1..10</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>
<INSDQualifier_name>mol_type</INSDQualifier_name>
<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q649">
<INSDQualifier_name>organism</INSDQualifier_name>
<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            </INSDSeq_feature-table>
            <INSDSeq_sequence>QHFWGTP LTF</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="339">
        <INSDSeq>
            <INSDSeq_length>116</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

```

```

<INSDFeature_location>1..116</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q650">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q651">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>QVQLQQPGAELVKPGASVKLSCKASGYTFTNYWMHWVKQRPQGLEWIGEINPINGRSNYGERF
KTKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAMHYWGQTSVTVSS</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="340">
    <INSDSeq>
        <INSDSeq_length>107</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q652">

<INSDQualifier_name>note</INSDQualifier_name>

```

```

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
      <INSDQualifier id="q653">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPASLSVSVGETVTITCRTSENIYNNLAWYQQKQGKSPQLLVYAATNLADGVPSRFSG
SGSGTQYSLKINSLQSEDFGNYCQHFWGTPITFGAGTKLELK</INSDSeq_sequence>
      </INSDSeq>
    </SequenceData>
    <SequenceData sequenceIDNumber="341">
      <INSDSeq>
        <INSDSeq_length>9</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
          <INSDFeature>
            <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..9</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q654">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
  <INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

```



```

<INSDFeature_location>1..9</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q655">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>YTFTNYWMH</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="342">
    <INSDSeq>
        <INSDSeq_length>17</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q656">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
    </INSDFeature>
    <INSDFeature>
        <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>

```

```

        </INSDQualifier>
        <INSDQualifier id="q657">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
        </INSDQualifier>
        </INSDFeature_qual>
        </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>EINPINGRSNYAQKFQG</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="343">
    <INSDSeq>
        <INSDSeq_length>17</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q658">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
                <INSDFeature>
                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                        </INSDQualifier>
                        <INSDQualifier id="q659">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>

```

```

        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>EINPINGRSNYAEKFQG</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="344">
    <INSDSeq>
        <INSDSeq_length>17</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q660">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..17</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q661">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>EINPIQGRSNYAEKFQG</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="345">
    <INSDSeq>
        <INSDSeq_length>7</INSDSeq_length>

```

```

        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q662">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q663">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDSeq_sequence>AATNLAE</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="346">
    <INSDSeq>
        <INSDSeq_length>11</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
                <INSDFeature_qual>

```

```

<INSDQualifier id="q664">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..11</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q665">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>
<INSDSeq_sequence>RTSENIYSNLA</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="347">
    <INSDSeq>
        <INSDSeq_length>7</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
    <INSDFeature_qual>
        <INSDQualifier id="q666">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
    </INSDFeature_qual>
</INSDFeature>

```

```

        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..7</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
                <INSDQualifier id="q667">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>
    <INSDSeq_sequence>AGTNLAD</INSDSeq_sequence>
</INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="348">
    <INSDSeq>
        <INSDSeq_length>116</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q668">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

```

```

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q669">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGASVKVSCASGYTFTNYWMHWVRQAPGQGLEWMGEINPINGRSNYAQKF
QGRVTLTVDTISISTAYMELSLRSDDTAVYYCARGTRAMHYWGQGLTVTVSS</INSDSeq_sequence>
                                </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="349">
    <INSDSeq>
        <INSDSeq_length>116</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier id="q670">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                                </INSDQualifier>
                                </INSDFeature_qual>
                                </INSDFeature>
                                <INSDFeature>
                                    <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
                                <INSDFeature_qual>
                                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                                </INSDQualifier>
                                <INSDQualifier id="q671">

<INSDQualifier_name>organism</INSDQualifier_name>

```

```

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWRQAPGGLEWIGEINPINGRSNYAEKF
QGRVTLTVDTSSSTAYMELSRLSDDTAVYYCARGTRAMHYWGQGLTVTVSS</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="350">
  <INSDSeq>
    <INSDSeq_length>116</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
      <INSDFeature_qual>
        <INSDQualifier id="q672">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q673">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

```



```

<INSDSeq_sequence>QVQLVQSGAEVKKPGASVKVSCKASGYFTFTNYWMHWVRQAPGQGLEWMGEINPIQGRSNYAEKF
QGRVTLTVDTSSSTAYMELSSLRSEDATYYCARGTRAMHYWGQGT LVTVSS</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="351">
    <INSDSeq>
        <INSDSeq_length>116</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier id="q674">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..116</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                    <INSDQualifier id="q675">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>QVQLVQSGAEVKKPGASVKVSCKASGYFTFTNYWMHWVRQAPGQGLEWMGEINPINGRSNYAEKF
QGRVTLTVDTSSSTAYMELSSLRSEDATYYCARGTRAMHYWGQGT LVTVSS</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="352">

```

```

        <INSDSeq>
            <INSDSeq_length>107</INSDSeq_length>
            <INSDSeq_moltype>AA</INSDSeq_moltype>
            <INSDSeq_division>PAT</INSDSeq_division>
            <INSDSeq_feature-table>
                <INSDFeature>
                    <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
                    <INSDFeature_qual>
                        <INSDQualifier id="q676">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
                        </INSDQualifier>
                    </INSDFeature_qual>
                </INSDFeature>
            <INSDFeature>
                <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
                <INSDFeature_qual>
                    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                    </INSDQualifier>
                <INSDQualifier id="q677">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                    </INSDQualifier>
                </INSDFeature_qual>
            </INSDFeature>
        </INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKSPKLLIYAATNLADGVPSRFSG
SGSGTDYTLTISSLQPEDFATYYCQHFWGTP LTFGGGTKVEIK</INSDSeq_sequence>
    </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="353">
    <INSDSeq>
        <INSDSeq_length>107</INSDSeq_length>
        <INSDSeq_moltype>AA</INSDSeq_moltype>
        <INSDSeq_division>PAT</INSDSeq_division>
        <INSDSeq_feature-table>
            <INSDFeature>

```

```

<INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q678">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
    </INSDQualifier>
    <INSDQualifier id="q679">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
    </INSDQualifier>
  </INSDFeature_qual>
</INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPSSLSASVGDRVTITCRTSENIYNNLAWYQQKPGKAPKLLIYAATNLADGVPSRFSG
SGSGTDYTLTISSLQPEDFATYYCQHWGTPITFGGGTKVEIK</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="354">
  <INSDSeq>
    <INSDSeq_length>107</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q680">

```

```

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
<INSDFeature>
  <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
      </INSDQualifier>
    <INSDQualifier id="q681">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>
</INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPSSLASVGRVTITCRTSENIYNNLAWYQQKPGKAPKLLIYAATNLAEGVPSRFSG
SGSGTDYTLTISSLQPEDFATYYCQHWGTPITFGGGTKVEIK</INSDSeq_sequence>
  </INSDSeq>
</SequenceData>
<SequenceData sequenceIDNumber="355">
  <INSDSeq>
    <INSDSeq_length>107</INSDSeq_length>
    <INSDSeq_moltype>AA</INSDSeq_moltype>
    <INSDSeq_division>PAT</INSDSeq_division>
    <INSDSeq_feature-table>
      <INSDFeature>
        <INSDFeature_key>REGION</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
  <INSDFeature_qual>
    <INSDQualifier id="q682">

<INSDQualifier_name>note</INSDQualifier_name>

<INSDQualifier_value>Synthetic</INSDQualifier_value>
      </INSDQualifier>
    </INSDFeature_qual>
  </INSDFeature>

```

```

        <INSDFeature>
            <INSDFeature_key>source</INSDFeature_key>

<INSDFeature_location>1..107</INSDFeature_location>
            <INSDFeature_qual>
                <INSDQualifier>

<INSDQualifier_name>mol_type</INSDQualifier_name>

<INSDQualifier_value>protein</INSDQualifier_value>
                </INSDQualifier>
                <INSDQualifier id="q683">

<INSDQualifier_name>organism</INSDQualifier_name>

<INSDQualifier_value>synthetic construct</INSDQualifier_value>
                </INSDQualifier>
            </INSDFeature_qual>
        </INSDFeature>
    </INSDSeq_feature-table>

<INSDSeq_sequence>DIQMTQSPSSLSASVGDRVTITCRTSENIYSNLAWYQKPGKAPKLLIYAGTNLADGVPSRFSG
SGSGTDYTLTISSLQPEDFANYCQHFWGTPITFGGGTKVEIK</INSDSeq_sequence>
        </INSDSeq>
    </SequenceData>
</ST26SequenceListing>

```